"","study ID","first author","study design","publication date","primary series vaccine","historyofCOVID ","dose_number","dose","timing_of_dose_days","outcome_detail","outcome_category","country","population_detail","population_category","VE","LCL","UCL","variant_sequenced","variant_context","max duration follow-up","dose interval","notes","country_clean","iso3c","Study_id_f","Country.Code","GNI_per_c_WB","year_GNI","Economy","Region","Income group","q_GNI_per_c_WB","continent","owid_vac_intro","owid_vac_F40","owid_vac_F70","who_vac_intro","min_vac_intro","diff_owid_who_intro","diff_min_vac_intro_8Dec2020","diff_intro_F40","diff_intro_F70","owid_who","diff_min_vac_intro_8Dec2020_clean","V1_date_group","V1_group","V40_date_group","V40_group","V1_dummy","V40_dummy","V70_dummy","publication_date","outcome_final","semester","clean_vaccine","vac_type","variant_clean","earliest_date","min_pub_date"
"1",1,"Amit","Prospective cohort","18Feb2021","BNT162b2 (Pfizer BioNTech)","excluded","1+","1+","15-28 including some up to day 7 post dose 2","infection ","infection","Israel","HCW","HCW",75,"72",84,NA,"original & alpha",NA,NA,NA,"Israel","ISR",1,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-02-18,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-02-18
"2",1,"Amit","Prospective cohort","18Feb2021","BNT162b2 (Pfizer BioNTech)","excluded","1+","1+","15-28 including some up to day 7 post dose 2","symptomatic disease","symptomatic","Israel","HCW","HCW",85,"71",92,NA,"original & alpha",NA,NA,NA,"Israel","ISR",1,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-02-18,"symptomatic","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-02-18
"3",2,"Immunisation and Countermeasures Division, National Infection Service, PHE","Screening method","22Feb2021","BNT162b2 (Pfizer BioNTech)","included","1","1",">28","symptomatic disease","symptomatic","UK","> 80 years","> 80 years",57,"48",63,NA,"alpha",NA,NA,NA,"UK","GBR",2,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-02-22,"symptomatic","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-02-22
"4",2,"Immunisation and Countermeasures Division, National Infection Service, PHE","Screening method","22Feb2021","BNT162b2 (Pfizer BioNTech)","included","2","final","7","symptomatic disease","symptomatic","UK","> 80 years","> 80 years",88,"84",90,NA,"alpha",NA,NA,NA,"UK","GBR",2,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-02-22,"symptomatic","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-02-22
"5",3,"Dagan","Retrospective cohort","24Feb2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14-21","infection ","infection","Israel","general pop","general pop",46,"40",51,NA,"original & alpha",NA,NA,NA,"Israel","ISR",3,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-02-24,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-02-24
"6",3,"Dagan","Retrospective cohort","24Feb2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">7","infection ","infection","Israel","general pop","general pop",92,"88",95,NA,"original & alpha",NA,NA,NA,"Israel","ISR",3,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-02-24,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-02-24
"7",3,"Dagan","Retrospective cohort","24Feb2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14-21","symptomatic disease","symptomatic","Israel","general pop","general pop",57,"50",63,NA,"original & alpha",NA,NA,NA,"Israel","ISR",3,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-02-24,"symptomatic","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-02-24
"8",3,"Dagan","Retrospective cohort","24Feb2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">7","symptomatic disease","symptomatic","Israel","general pop","general pop",94,"87",98,NA,"original & alpha",NA,NA,NA,"Israel","ISR",3,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-02-24,"symptomatic","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-02-24
"9",3,"Dagan","Retrospective cohort","24Feb2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14-21","hospitalization","severe","Israel","general pop","general pop",74,"56",86,NA,"original & alpha",NA,NA,NA,"Israel","ISR",3,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-02-24,"severe","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-02-24
"10",3,"Dagan","Retrospective cohort","24Feb2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">7","hospitalization","severe","Israel","general pop","general pop",87,"55",100,NA,"original & alpha",NA,NA,NA,"Israel","ISR",3,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-02-24,"severe","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-02-24
"11",3,"Dagan","Retrospective cohort","24Feb2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14-21","severe disease","severe","Israel","general pop","general pop",62,"39",80,NA,"original & alpha",NA,NA,NA,"Israel","ISR",3,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-02-24,"severe","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-02-24
"12",3,"Dagan","Retrospective cohort","24Feb2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">7","severe disease","severe","Israel","general pop","general pop",92,"75",100,NA,"original & alpha",NA,NA,NA,"Israel","ISR",3,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-02-24,"severe","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-02-24
"13",4,"Hyams","Test-negative case-control","01Nov2021","BNT162b2 (Pfizer BioNTech)","included","1","1",">14","hospitalization","severe","UK"," > 80 years"," > 80 years",79,"47",93,NA,"alpha",NA,NA,NA,"UK","GBR",4,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-11-01,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-11-01
"14",4,"Hyams","Test-negative case-control","01Nov2021","AZD1222 (AstraZeneca)","included","1","1",">14","hospitalization","severe","UK"," > 80 years"," > 80 years",80,"36",95,NA,"alpha",NA,NA,NA,"UK","GBR",4,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-11-01,"severe","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2021-11-01
"15",5,"Mousten-Helms","Retrospective cohort","09Mar2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1",">14","infection ","infection","Denmark","LTCF residents","LTCF residents",21,"-11",44,NA,"original & alpha",NA,NA,NA,"Denmark","DNK",5,"DNK",61830,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,8,212,261,"who",8,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-03-09,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-03-09
"16",5,"Mousten-Helms","Retrospective cohort","09Mar2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">7","infection ","infection","Denmark","LTCF residents","LTCF residents",64,"14",84,NA,"original & alpha",NA,NA,NA,"Denmark","DNK",5,"DNK",61830,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,8,212,261,"who",8,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-03-09,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-03-09
"17",5,"Mousten-Helms","Retrospective cohort","09Mar2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1",">14","infection ","infection","Denmark","LTCF staff","LTCF staff",17,"4",28,NA,"original & alpha",NA,NA,NA,"Denmark","DNK",5,"DNK",61830,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,8,212,261,"who",8,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-03-09,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-03-09
"18",5,"Mousten-Helms","Retrospective cohort","09Mar2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">7","infection ","infection","Denmark","LTCF staff","LTCF staff",90,"82",95,NA,"original & alpha",NA,NA,NA,"Denmark","DNK",5,"DNK",61830,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,8,212,261,"who",8,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-03-09,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-03-09
"19",6,"Tande","Retrospective cohort","11Mar2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","1+","1+",">10 including some with dose 2","asymptomatic infection","asymptomatic","USA","pre-surgical hospital patients","pre-surgical hospital patients",79,"63",88,NA,"original",NA,NA,NA,"USA","USA",6,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-03-11,"infection","2021 (Jan-Jun)","Multiple or heterologous RNA","mRNA","original",NA,2021-03-11
"20",6,"Tande","Retrospective cohort","11Mar2021","BNT162b2 (Pfizer BioNTech)","included","2","final",">0","asymptomatic infection","asymptomatic","USA","pre-surgical hospital patients","pre-surgical hospital patients",80,"56",91,NA,"original",NA,NA,NA,"USA","USA",6,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-03-11,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","original",NA,2021-03-11
"21",6,"Tande","Retrospective cohort","11Mar2021","BNT162b2 (Pfizer BioNTech)","included","1","1",">10","asymptomatic infection","asymptomatic","USA","pre-surgical hospital patients","pre-surgical hospital patients",79,"62",89,NA,"original",NA,NA,NA,"USA","USA",6,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-03-11,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","original",NA,2021-03-11
"22",6,"Tande","Retrospective cohort","11Mar2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final",">0","asymptomatic infection","asymptomatic","USA","pre-surgical hospital patients","pre-surgical hospital patients",80,"56",91,NA,"original",NA,NA,NA,"USA","USA",6,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-03-11,"infection","2021 (Jan-Jun)","Multiple or heterologous RNA","mRNA","original",NA,2021-03-11
"23",7,"Britton","Retrospective cohort","15Mar2021","BNT162b2 (Pfizer BioNTech)","stratified","1+","1+",">14 including some up to day 7 post dose 2","infection ","infection","USA","LTCF residents","LTCF residents",63,"33",79,NA,"original",NA,NA,NA,"USA","USA",7,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-03-15,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","original",NA,2021-03-15
"24",7,"Britton","Retrospective cohort","15Mar2021","BNT162b2 (Pfizer BioNTech)","stratified","1+","1+",">14 including some up to day 7 post dose 2","infection ","infection","USA","LTCF residents","LTCF residents",60,"30",77,NA,"original",NA,NA,NA,"USA","USA",7,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-03-15,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","original",NA,2021-03-15
"25",8,"Yelin","Retrospective cohort","17Mar2021","BNT162b2 (Pfizer BioNTech)","excluded","1+","1+",">35, most with dose 2","infection ","infection","Israel","general pop","general pop",91,"89",93,NA,"alpha",NA,NA,NA,"Israel","ISR",8,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-03-17,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-03-17
"26",8,"Yelin","Retrospective cohort","17Mar2021","BNT162b2 (Pfizer BioNTech)","excluded","1+","1+",">35, most with dose 2","symptomatic disease","symptomatic","Israel","general pop","general pop",99,"95",99,NA,"alpha",NA,NA,NA,"Israel","ISR",8,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-03-17,"symptomatic","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-03-17
"27",9,"Public Health England","Test-negative case-control","17Mar2021","BNT162b2 (Pfizer BioNTech)","unknown","1","1",">28","symptomatic disease","symptomatic","UK","> 70 years","> 70 years",58,"49",65,NA,"alpha",NA,NA,NA,"UK","GBR",9,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-03-17,"symptomatic","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-03-17
"28",9,"Public Health England","Test-negative case-control","17Mar2021","AZD1222 (AstraZeneca)","unknown","1","1",">35","symptomatic disease","symptomatic","UK","> 70 years","> 70 years",58,"38",72,NA,"alpha",NA,NA,NA,"UK","GBR",9,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-03-17,"symptomatic","2021 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2021-03-17
"29",9,"Public Health England","Retrospective cohort","17Mar2021","BNT162b2 (Pfizer BioNTech)","included","1","1",">14","hospitalization","severe","UK","> 70 years","> 70 years",42,"32",51,NA,"alpha",NA,NA,NA,"UK","GBR",9,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-03-17,"severe","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-03-17
"30",9,"Public Health England","Retrospective cohort","17Mar2021","BNT162b2 (Pfizer BioNTech)","included","1","1",">14","death","death","UK","> 70 years","> 70 years",54,"41",64,NA,"alpha",NA,NA,NA,"UK","GBR",9,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-03-17,"death","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-03-17
"31",9,"Public Health England","Retrospective cohort","17Mar2021","AZD1222 (AstraZeneca)","included","1","1","14-21","hospitalization","severe","UK","> 70 years","> 70 years",35,"4",56,NA,"alpha",NA,NA,NA,"UK","GBR",9,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-03-17,"severe","2021 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2021-03-17
"32",10,"Shrotri","Prospective cohort","23Jun2021","BNT162b2 (Pfizer BioNTech)","stratified","1","1","35-48","infection ","infection","UK","LTCF residents","LTCF residents",65,"29",83,NA,"original & alpha",NA,NA,NA,"UK","GBR",10,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-06-23,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-06-23
"33",10,"Shrotri","Prospective cohort","23Jun2021","AZD1222 (AstraZeneca)","stratified","1","1","35-48","infection ","infection","UK","LTCF residents","LTCF residents",68,"34",85,NA,"original & alpha",NA,NA,NA,"UK","GBR",10,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-06-23,"infection","2021 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2021-06-23
"34",11,"Thompson","Prospective cohort","29Mar2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1",">14","infection ","infection","USA","HCW","HCW",80,"59",90,NA,"original",NA,NA,NA,"USA","USA",11,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-03-29,"infection","2021 (Jan-Jun)","Multiple or heterologous RNA","mRNA","original",NA,2021-03-29
"35",11,"Thompson","Prospective cohort","29Mar2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final",">14","infection ","infection","USA","HCW","HCW",90,"68",97,NA,"original",NA,NA,NA,"USA","USA",11,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-03-29,"infection","2021 (Jan-Jun)","Multiple or heterologous RNA","mRNA","original",NA,2021-03-29
"36",12,"Bouton","Prospective cohort","30Mar2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","1+","1+",">14 including some with dose 2","infection ","infection","USA","HCW","HCW",82,"68",90,NA,"original",NA,NA,NA,"USA","USA",12,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-03-30,"infection","2021 (Jan-Jun)","Multiple or heterologous RNA","mRNA","original",NA,2021-03-30
"37",13,"Regev-Yochay","Prospective cohort","07Jul2021","BNT162b2 (Pfizer BioNTech)","included","2","final",">11","asymptomatic infection","asymptomatic","Israel","HCW","HCW",65,"45",79,NA,"alpha",NA,NA,NA,"Israel","ISR",13,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-07-07,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","09/04/2021",2021-04-09
"38",13,"Regev-Yochay","Prospective cohort","07Jul2021","BNT162b2 (Pfizer BioNTech)","included","2","final",">11","asymptomatic infection (presumed infectious ct<30)","asymptomatic","Israel","HCW","HCW",70,"43",84,NA,"alpha",NA,NA,NA,"Israel","ISR",13,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-07-07,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","09/04/2021",2021-04-09
"39",13,"Regev-Yochay","Prospective cohort","07Jul2021","BNT162b2 (Pfizer BioNTech)","included","2","final",">11","symptomatic disease","symptomatic","Israel","HCW","HCW",90,"84",94,NA,"alpha",NA,NA,NA,"Israel","ISR",13,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-07-07,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","09/04/2021",2021-04-09
"40",13,"Regev-Yochay","Prospective cohort","07Jul2021","BNT162b2 (Pfizer BioNTech)","included","2","final",">11","symptomatic disease  (presumed infectious ct<30)","symptomatic","Israel","HCW","HCW",88,"80",94,NA,"alpha",NA,NA,NA,"Israel","ISR",13,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-07-07,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","09/04/2021",2021-04-09
"41",14,"Andrejko","Test-negative case-control","20Jul2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1",">=15","infection ","infection","USA","general pop","general pop",66.9,"28.7",84.6,NA,"B.1.427/ B.1.429 & alpha",NA,NA,NA,"USA","USA",14,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-07-20,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","25/05/2021",2021-05-25
"42",14,"Andrejko","Test-negative case-control","20Jul2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final",">=15","infection ","infection","USA","general pop","general pop",87.4,"77.2",93.1,NA,"B.1.427/ B.1.429 & alpha",NA,NA,NA,"USA","USA",14,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-07-20,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","25/05/2021",2021-05-25
"43",14,"Andrejko","Test-negative case-control","20Jul2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final",">=15","asymptomatic infection","asymptomatic","USA","general pop","general pop",68.3,"27.9",85.7,NA,"B.1.427/ B.1.429 & alpha",NA,NA,NA,"USA","USA",14,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-07-20,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","25/05/2021",2021-05-25
"44",14,"Andrejko","Test-negative case-control","20Jul2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final",">=15","symptomatic disease","symptomatic","USA","general pop","general pop",91.3,"79.3",96.3,NA,"B.1.427/ B.1.429 & alpha",NA,NA,NA,"USA","USA",14,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-07-20,"symptomatic","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","25/05/2021",2021-05-25
"45",14,"Andrejko","Test-negative case-control","20Jul2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final",">=15","hospitalization","severe","USA","general pop","general pop",100,NA,NA,NA,"B.1.427/ B.1.429 & alpha",NA,NA,NA,"USA","USA",14,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-07-20,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","25/05/2021",2021-05-25
"46",14,"Andrejko","Test-negative case-control","20Jul2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">=15","infection ","infection","USA","general pop","general pop",87,"68.6",94.6,NA,"B.1.427/ B.1.429 & alpha",NA,NA,NA,"USA","USA",14,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-07-20,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","25/05/2021",2021-05-25
"47",14,"Andrejko","Test-negative case-control","20Jul2021","mRNA-1273 (Moderna)","excluded","2","final",">=15","infection ","infection","USA","general pop","general pop",86.2,"68.4",93.9,NA,"B.1.427/ B.1.429 & alpha",NA,NA,NA,"USA","USA",14,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-07-20,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","25/05/2021",2021-05-25
"48",15,"Glampson","Retrospective cohort","17Sept2021","BNT162b2 (Pfizer BioNTech)","unknown","1","1","22-28","infection ","infection","UK",">= 16 years","general pop",78,"73",82,NA,"alpha",NA,NA,NA,"UK","GBR",15,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-09-17,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-09-17
"49",15,"Glampson","Retrospective cohort","17Sept2021","AZD1222 (AstraZeneca)","unknown","1","1","22-28","infection ","infection","UK",">= 16 years","general pop",74,"65",81,NA,"alpha",NA,NA,NA,"UK","GBR",15,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-09-17,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2021-09-17
"50",16,"Bjork","Retrospective cohort","29Sept2021","BNT162b2 (Pfizer BioNTech)","unknown","1","1",">14","infection ","infection","Sweden","general pop","general pop",42,"14",63,NA,"original & alpha",NA,NA,NA,"Sweden","SWE",16,"SWE",58060,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,15,228,396,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-29,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","21/04/2021",2021-04-21
"51",16,"Bjork","Retrospective cohort","29Sept2021","BNT162b2 (Pfizer BioNTech)","unknown","2","final",">7","infection ","infection","Sweden","general pop","general pop",86,"72",94,NA,"original & alpha",NA,NA,NA,"Sweden","SWE",16,"SWE",58060,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,15,228,396,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-29,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","21/04/2021",2021-04-21
"52",17,"Mason","Case-control","18Oct2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","21-27","infection ","infection","UK","80-83 years","80-83 years",55,"40",66,NA,"alpha",NA,NA,NA,"UK","GBR",17,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-10-18,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","22/04/2021",2021-04-22
"53",17,"Mason","Case-control","18Oct2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","35-41","infection ","infection","UK","80-83 years","80-83 years",70,"55",80,NA,"alpha",NA,NA,NA,"UK","GBR",17,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-10-18,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","22/04/2021",2021-04-22
"54",17,"Mason","Case-control","18Oct2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","21-27","hospitalization","severe","UK","80-83 years","80-83 years",50,"19",69,NA,"alpha",NA,NA,NA,"UK","GBR",17,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-10-18,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","22/04/2021",2021-04-22
"55",17,"Mason","Case-control","18Oct2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","35-41","hospitalization","severe","UK","80-83 years","80-83 years",75,"52",87,NA,"alpha",NA,NA,NA,"UK","GBR",17,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-10-18,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","22/04/2021",2021-04-22
"56",17,"Mason","Case-control","18Oct2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","35-41","ED or UC visit","symptomatic","UK","80-83 years","80-83 years",58,"31",74,NA,"alpha",NA,NA,NA,"UK","GBR",17,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-10-18,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","22/04/2021",2021-04-22
"57",17,"Mason","Case-control","18Oct2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","35-41","ED or UC visit","symptomatic","UK","80-83 years","80-83 years",79,"60",90,NA,"alpha",NA,NA,NA,"UK","GBR",17,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-10-18,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","22/04/2021",2021-04-22
"58",18,"Hall","Prospective cohort","23Apr2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1",">21","infection ","infection","UK","HCW","HCW",72,"58",86,NA,"alpha",NA,NA,NA,"UK","GBR",18,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-04-23,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","21/02/2021",2021-02-21
"59",18,"Hall","Prospective cohort","23Apr2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">7","infection ","infection","UK","HCW","HCW",86,"76",97,NA,"alpha",NA,NA,NA,"UK","GBR",18,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-04-23,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","21/02/2021",2021-02-21
"60",19,"Vasileiou","Prospective cohort","23Apr2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","28-34","hospitalization","severe","UK","general pop","general pop",91,"85",94,NA,"original & alpha",NA,NA,NA,"UK","GBR",19,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-04-23,"severe","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-04-23
"61",19,"Vasileiou","Prospective cohort","23Apr2021","AZD1222 (AstraZeneca)","excluded","1","1","28-34","hospitalization","severe","UK","general pop","general pop",88,"75",94,NA,"original & alpha",NA,NA,NA,"UK","GBR",19,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-04-23,"severe","2021 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2021-04-23
"62",20,"Pritchard","Prospective cohort","09Jun2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1",">21","infection ","infection","UK",">= 16 years","general pop",66,"60",71,NA,"original & alpha",NA,NA,NA,"UK","GBR",20,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-06-09,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/04/2021",2021-04-23
"63",20,"Pritchard","Prospective cohort","09Jun2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">0","infection ","infection","UK",">= 16 years","general pop",80,"74",85,NA,"original & alpha",NA,NA,NA,"UK","GBR",20,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-06-09,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/04/2021",2021-04-23
"64",20,"Pritchard","Prospective cohort","09Jun2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1",">21","symptomatic disease","symptomatic","UK",">= 16 years","general pop",78,"72",83,NA,"original & alpha",NA,NA,NA,"UK","GBR",20,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-06-09,"symptomatic","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/04/2021",2021-04-23
"65",20,"Pritchard","Prospective cohort","09Jun2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">0","symptomatic disease","symptomatic","UK",">= 16 years","general pop",95,"91",98,NA,"original & alpha",NA,NA,NA,"UK","GBR",20,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-06-09,"symptomatic","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/04/2021",2021-04-23
"66",20,"Pritchard","Prospective cohort","09Jun2021","AZD1222 (AstraZeneca)","excluded","1","1",">21","infection ","infection","UK",">= 16 years","general pop",61,"54",68,NA,"original & alpha",NA,NA,NA,"UK","GBR",20,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-06-09,"infection","2021 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","23/04/2021",2021-04-23
"67",20,"Pritchard","Prospective cohort","09Jun2021","AZD1222 (AstraZeneca)","excluded","2","final",">0","infection ","infection","UK",">= 16 years","general pop",79,"65",88,NA,"original & alpha",NA,NA,NA,"UK","GBR",20,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-06-09,"infection","2021 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","23/04/2021",2021-04-23
"68",20,"Pritchard","Prospective cohort","09Jun2021","AZD1222 (AstraZeneca)","excluded","1","1",">21","symptomatic disease","symptomatic","UK",">= 16 years","general pop",71,"62",78,NA,"original & alpha",NA,NA,NA,"UK","GBR",20,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-06-09,"symptomatic","2021 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","23/04/2021",2021-04-23
"69",20,"Pritchard","Prospective cohort","09Jun2021","AZD1222 (AstraZeneca)","excluded","2","final",">0","symptomatic disease","symptomatic","UK","general pop","general pop",92,"78",97,NA,"original & alpha",NA,NA,NA,"UK","GBR",20,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-06-09,"symptomatic","2021 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","23/04/2021",2021-04-23
"70",21,"Goldberg","Prospective cohort","30Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","1+","1+",">14 days post dose 1 to <14 days post dose 2","infection ","infection","Israel",">= 16 years","general pop",65.9,"65.4",66.4,NA,"alpha",NA,NA,NA,"Israel","ISR",21,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-30,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","24/04/2021",2021-04-24
"71",21,"Goldberg","Prospective cohort","30Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection ","infection","Israel",">= 16 years","general pop",94.5,"94.3",94.7,NA,"alpha","~8 weeks",NA,NA,"Israel","ISR",21,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-30,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","24/04/2021",2021-04-24
"72",21,"Goldberg","Prospective cohort","30Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","1+","1+",">14 days post dose 1 to <14 days post dose 2","hospitalization","severe","Israel",">= 16 years","general pop",74.9,"73.5",76.3,NA,"alpha",NA,NA,NA,"Israel","ISR",21,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-30,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","24/04/2021",2021-04-24
"73",21,"Goldberg","Prospective cohort","30Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization","severe","Israel",">= 16 years","general pop",95.8,"95.2",96.2,NA,"alpha","~8 weeks",NA,NA,"Israel","ISR",21,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-30,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","24/04/2021",2021-04-24
"74",21,"Goldberg","Prospective cohort","30Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","1+","1+",">14 days post dose 1 to <14 days post dose 2","severe disease","severe","Israel",">= 16 years","general pop",72.1,"69.9",74.1,NA,"alpha",NA,NA,NA,"Israel","ISR",21,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-30,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","24/04/2021",2021-04-24
"75",21,"Goldberg","Prospective cohort","30Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","severe disease","severe","Israel",">= 16 years","general pop",96.3,"95.7",96.9,NA,"alpha","~8 weeks",NA,NA,"Israel","ISR",21,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-30,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","24/04/2021",2021-04-24
"76",21,"Goldberg","Prospective cohort","30Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","1+","1+",">14 days post dose 1 to <14 days post dose 2","death","death","Israel",">= 16 years","general pop",69.1,"65.5",72.3,NA,"alpha",NA,NA,NA,"Israel","ISR",21,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-30,"death","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","24/04/2021",2021-04-24
"77",21,"Goldberg","Prospective cohort","30Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","death","death","Israel",">= 16 years","general pop",96,"94.9",96.9,NA,"alpha","~8 weeks",NA,NA,"Israel","ISR",21,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-30,"death","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","24/04/2021",2021-04-24
"78",22,"Tenforde","Test-negative case-control","28Apr2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","unknown","1+","1+",">14 days post dose 1 to 14 days post dose 2","hospitalization","severe","USA","hospital patients >= 65 years",">= 65 years",64,"28",82,NA,"original & alpha",NA,NA,NA,"USA","USA",22,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-04-28,"severe","2021 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-04-28
"79",22,"Tenforde","Test-negative case-control","28Apr2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","unknown","2","final",">14","hospitalization","severe","USA","hospital patients >= 65 years",">= 65 years",94,"49",99,NA,"original & alpha",NA,NA,NA,"USA","USA",22,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-04-28,"severe","2021 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-04-28
"80",23,"Gras-Valenti","Case-control","29Apr2021","BNT162b2 (Pfizer BioNTech)","included","1","1",">12","infection ","infection","Spain","HCW","HCW",53,"1",77,NA,"original & alpha",NA,NA,NA,"Spain","ESP",23,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-04-29,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-04-29
"81",24,"Fabiani","Retrospective cohort","29Apr2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14-21","infection ","infection","Italy","HCW","HCW",84,"40",96,NA,"unknown",NA,NA,NA,"Italy","ITA",24,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-04-29,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","unknown",NA,2021-04-29
"82",24,"Fabiani","Retrospective cohort","29Apr2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">7","infection ","infection","Italy","HCW","HCW",95,"62",99,NA,"unknown",NA,NA,NA,"Italy","ITA",24,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-04-29,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","unknown",NA,2021-04-29
"83",24,"Fabiani","Retrospective cohort","29Apr2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14-21","symptomatic disease","symptomatic","Italy","HCW","HCW",83,"15",97,NA,"unknown",NA,NA,NA,"Italy","ITA",24,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-04-29,"symptomatic","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","unknown",NA,2021-04-29
"84",24,"Fabiani","Retrospective cohort","29Apr2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">7","symptomatic disease","symptomatic","Italy","HCW","HCW",94,"51",99,NA,"unknown",NA,NA,NA,"Italy","ITA",24,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-04-29,"symptomatic","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","unknown",NA,2021-04-29
"85",25,"Corchado-Garcia ","Retrospective cohort","02Nov2021","Ad26.COV2.S (Janssen)","excluded","1","final",">15","infection ","infection","USA","general pop","general pop",74.2,"64.9",81.6,NA,"original & alpha",NA,NA,NA,"USA","USA",25,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-11-02,"infection","2021 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations","30/04/2021",2021-04-30
"86",26,"Haas","Retrospective cohort","05May2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">7","infection ","infection","Israel","general pop","general pop",95.3,"94.9",95.7,NA,"alpha",NA,NA,NA,"Israel","ISR",26,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-05-05,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","24/03/2021",2021-03-24
"87",26,"Haas","Retrospective cohort","05May2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">7","asymptomatic infection","asymptomatic","Israel","general pop","general pop",91.5,"90.7",92.2,NA,"alpha",NA,NA,NA,"Israel","ISR",26,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-05-05,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","24/03/2021",2021-03-24
"88",26,"Haas","Retrospective cohort","05May2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">7","symptomatic disease","symptomatic","Israel","general pop","general pop",97,"96.7",97.2,NA,"alpha",NA,NA,NA,"Israel","ISR",26,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-05-05,"symptomatic","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","24/03/2021",2021-03-24
"89",26,"Haas","Retrospective cohort","05May2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">7","hospitalization","severe","Israel","general pop","general pop",97.2,"96.8",97.5,NA,"alpha",NA,NA,NA,"Israel","ISR",26,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-05-05,"severe","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","24/03/2021",2021-03-24
"90",26,"Haas","Retrospective cohort","05May2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">7","severe/critical hospitalization","severe","Israel","general pop","general pop",97.5,"97.1",97.8,NA,"alpha",NA,NA,NA,"Israel","ISR",26,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-05-05,"severe","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","24/03/2021",2021-03-24
"91",26,"Haas","Retrospective cohort","05May2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">7","death","death","Israel","general pop","general pop",96.7,"96",97.3,NA,"alpha",NA,NA,NA,"Israel","ISR",26,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-05-05,"death","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","24/03/2021",2021-03-24
"92",27,"Abu-Raddad","Test-negative case-control","08Jul2021","BNT162b2 (Pfizer BioNTech)","unknown","1","1","15-21","infection ","infection","Qatar","general pop","general pop",65.5,"58.2",71.5,"alpha","alpha",NA,NA,NA,"Qatar","QAT",27,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-07-08,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-07-08
"93",27,"Abu-Raddad","Test-negative case-control","08Jul2021","BNT162b2 (Pfizer BioNTech)","unknown","2","final",">14","infection ","infection","Qatar","general pop","general pop",90,"86",92,"alpha","alpha",NA,NA,NA,"Qatar","QAT",27,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-07-08,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-07-08
"94",27,"Abu-Raddad","Test-negative case-control","08Jul2021","BNT162b2 (Pfizer BioNTech)","unknown","1","1","15-21","severe/fatal infection","severe","Qatar","general pop","general pop",72,"32",90,"alpha","alpha",NA,NA,NA,"Qatar","QAT",27,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-07-08,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-07-08
"95",27,"Abu-Raddad","Test-negative case-control","08Jul2021","BNT162b2 (Pfizer BioNTech)","unknown","2","final",">14","severe/fatal infection","severe","Qatar","general pop","general pop",100,"82",100,"alpha","alpha",NA,NA,NA,"Qatar","QAT",27,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-07-08,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-07-08
"96",27,"Abu-Raddad","Test-negative case-control","08Jul2021","BNT162b2 (Pfizer BioNTech)","unknown","1","1","15-21","infection ","infection","Qatar","general pop","general pop",46.5,"38.7",53.3,"beta","beta",NA,NA,NA,"Qatar","QAT",27,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-07-08,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","beta",NA,2021-07-08
"97",27,"Abu-Raddad","Test-negative case-control","08Jul2021","BNT162b2 (Pfizer BioNTech)","unknown","2","final",">14","infection ","infection","Qatar","general pop","general pop",75,"71",79,"beta","beta",NA,NA,NA,"Qatar","QAT",27,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-07-08,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","beta",NA,2021-07-08
"98",27,"Abu-Raddad","Test-negative case-control","08Jul2021","BNT162b2 (Pfizer BioNTech)","unknown","1","1","15-21","severe/fatal infection","severe","Qatar","general pop","general pop",56.5,"0",82.8,"beta","beta",NA,NA,NA,"Qatar","QAT",27,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-07-08,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","beta",NA,2021-07-08
"99",27,"Abu-Raddad","Test-negative case-control","08Jul2021","BNT162b2 (Pfizer BioNTech)","unknown","2","final",">14","severe/fatal infection","severe","Qatar","general pop","general pop",100,"74",100,"beta","beta",NA,NA,NA,"Qatar","QAT",27,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-07-08,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","beta",NA,2021-07-08
"100",27,"Abu-Raddad","Retrospective cohort","08Jul2021","BNT162b2 (Pfizer BioNTech)","unknown","2","final",">14","infection ","infection","Qatar","general pop","general pop",87,"82",91,"alpha","alpha",NA,NA,NA,"Qatar","QAT",27,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-07-08,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-07-08
"101",27,"Abu-Raddad","Retrospective cohort","08Jul2021","BNT162b2 (Pfizer BioNTech)","unknown","2","final",">14","infection ","infection","Qatar","general pop","general pop",72,"66",77,"beta","beta",NA,NA,NA,"Qatar","QAT",27,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-07-08,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","beta",NA,2021-07-08
"102",28,"Angel","Retrospective cohort","06May2021","BNT162b2 (Pfizer BioNTech)","excluded","1+","1+",">7 days post dose 1 to 7 days post dose 2","symptomatic disease","symptomatic","Israel","HCW","HCW",89,"83",94,NA,"alpha",NA,NA,NA,"Israel","ISR",28,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-05-06,"symptomatic","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-05-06
"103",28,"Angel","Retrospective cohort","06May2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">7","symptomatic disease","symptomatic","Israel","HCW","HCW",97,"94",99,NA,"alpha",NA,NA,NA,"Israel","ISR",28,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-05-06,"symptomatic","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-05-06
"104",28,"Angel","Retrospective cohort","06May2021","BNT162b2 (Pfizer BioNTech)","excluded","1+","1+",">7 days post dose 1 to 7 days post dose 2","asymptomatic infection","asymptomatic","Israel","HCW","HCW",36,"-51",69,NA,"alpha",NA,NA,NA,"Israel","ISR",28,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-05-06,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-05-06
"105",28,"Angel","Retrospective cohort","06May2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">7","asymptomatic infection","asymptomatic","Israel","HCW","HCW",86,"69",97,NA,"alpha",NA,NA,NA,"Israel","ISR",28,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-05-06,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-05-06
"106",29,"Lopez-Bernal","Test-negative case-control","13May2021","BNT162b2 (Pfizer BioNTech)","included","2","final",">=7","symptomatic disease","symptomatic","UK","> 80 years","> 80 years",79,"68",86,NA,"alpha",NA,NA,NA,"UK","GBR",29,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-05-13,"symptomatic","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","01/03/2021",2021-03-01
"107",29,"Lopez-Bernal","Test-negative case-control","13May2021","BNT162b2 (Pfizer BioNTech)","included","1+","1+","28-34 (includes some with dose 2)","symptomatic disease","symptomatic","UK","> 70 years","> 70 years",61,"51",69,NA,"alpha",NA,NA,NA,"UK","GBR",29,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-05-13,"symptomatic","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","01/03/2021",2021-03-01
"108",29,"Lopez-Bernal","Test-negative case-control","13May2021","AZD1222 (AstraZeneca)","included","1+","1+","28-34 (includes some with dose 2)","symptomatic disease","symptomatic","UK","> 70 years","> 70 years",60,"41",73,NA,"alpha",NA,NA,NA,"UK","GBR",29,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-05-13,"symptomatic","2021 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","01/03/2021",2021-03-01
"109",30,"Pilishvili ","Test-negative case-control","14May2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1+","1+",">14 up to 6 days post dose 2","symptomatic disease","symptomatic","USA","HCW","HCW",82,"74",87,NA,"unknown",NA,NA,NA,"USA","USA",30,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-05-14,"symptomatic","2021 (Jan-Jun)","Multiple or heterologous RNA","mRNA","unknown",NA,2021-05-14
"110",30,"Pilishvili ","Test-negative case-control","14May2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final",">7","symptomatic disease","symptomatic","USA","HCW","HCW",94,"87",97,NA,"unknown",NA,NA,NA,"USA","USA",30,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-05-14,"symptomatic","2021 (Jan-Jun)","Multiple or heterologous RNA","mRNA","unknown",NA,2021-05-14
"111",31,"Ismail","Screening method","12May2021","AZD1222 (AstraZeneca)","included","1","1","28+","hospitalization","severe","UK","70-79 years","70-79 years",84,"74",89,NA,"alpha",NA,NA,NA,"UK","GBR",31,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-05-12,"severe","2021 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2021-05-12
"112",31,"Ismail","Screening method","12May2021","AZD1222 (AstraZeneca)","included","1","1","28+","hospitalization","severe","UK",">= 80 years",">= 80 years",73,"60",81,NA,"alpha",NA,NA,NA,"UK","GBR",31,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-05-12,"severe","2021 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2021-05-12
"113",31,"Ismail","Screening method","12May2021","BNT162b2 (Pfizer BioNTech)","included","1","1","28+","hospitalization","severe","UK","70-79 years","70-79 years",81,"73",87,NA,"alpha",NA,NA,NA,"UK","GBR",31,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-05-12,"severe","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-05-12
"114",31,"Ismail","Screening method","12May2021","BNT162b2 (Pfizer BioNTech)","included","1","1","28+","hospitalization","severe","UK",">= 80 years",">= 80 years",81,"76",85,NA,"alpha",NA,NA,NA,"UK","GBR",31,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-05-12,"severe","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-05-12
"115",31,"Ismail","Screening method","12May2021","BNT162b2 (Pfizer BioNTech)","included","2","final",">14","hospitalization","severe","UK",">= 80 years",">= 80 years",93,"89",95,NA,"alpha",NA,NA,NA,"UK","GBR",31,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-05-12,"severe","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-05-12
"116",32,"Ranzani","Test-negative case-control","20Aug2021","CoronaVac (Sinovac)","included","1","1",">14","symptomatic disease","symptomatic","Brazil",">= 70 years",">= 70 years",12.5,"3.7",20.6,NA,"gamma",NA,NA,NA,"Brazil","BRA",32,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2021-08-20,"symptomatic","2021 (Jul-Dec)","Sinovac CoronaVac","Inactivated","gamma","21/07/2021",2021-07-21
"117",32,"Ranzani","Test-negative case-control","20Aug2021","CoronaVac (Sinovac)","included","2","final",">14","symptomatic disease","symptomatic","Brazil",">= 70 years",">= 70 years",46.8,"38.7",53.8,NA,"gamma",NA,NA,NA,"Brazil","BRA",32,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2021-08-20,"symptomatic","2021 (Jul-Dec)","Sinovac CoronaVac","Inactivated","gamma","21/07/2021",2021-07-21
"118",32,"Ranzani","Test-negative case-control","20Aug2021","CoronaVac (Sinovac)","included","1","1",">14","hospitalization","severe","Brazil",">= 70 years",">= 70 years",16.9,"5.7",26.8,NA,"gamma",NA,NA,NA,"Brazil","BRA",32,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2021-08-20,"severe","2021 (Jul-Dec)","Sinovac CoronaVac","Inactivated","gamma","21/07/2021",2021-07-21
"119",32,"Ranzani","Test-negative case-control","20Aug2021","CoronaVac (Sinovac)","included","2","final",">14","hospitalization","severe","Brazil",">= 70 years",">= 70 years",55.5,"46.5",62.9,NA,"gamma",NA,NA,NA,"Brazil","BRA",32,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2021-08-20,"severe","2021 (Jul-Dec)","Sinovac CoronaVac","Inactivated","gamma","21/07/2021",2021-07-21
"120",32,"Ranzani","Test-negative case-control","20Aug2021","CoronaVac (Sinovac)","included","1","1",">14","death","death","Brazil",">= 70 years",">= 70 years",31.2,"17.6",42.5,NA,"gamma",NA,NA,NA,"Brazil","BRA",32,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2021-08-20,"death","2021 (Jul-Dec)","Sinovac CoronaVac","Inactivated","gamma","21/07/2021",2021-07-21
"121",32,"Ranzani","Test-negative case-control","20Aug2021","CoronaVac (Sinovac)","included","2","final",">14","death","death","Brazil",">= 70 years",">= 70 years",61.2,"48.9",70.5,NA,"gamma",NA,NA,NA,"Brazil","BRA",32,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2021-08-20,"death","2021 (Jul-Dec)","Sinovac CoronaVac","Inactivated","gamma","21/07/2021",2021-07-21
"122",33,"PHE","Test-negative case-control","20May2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","28+","symptomatic disease","symptomatic","UK",">= 65 years",">= 65 years",54,"50",58,NA,"alpha",NA,NA,NA,"UK","GBR",33,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-05-20,"symptomatic","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-05-20
"123",33,"PHE","Test-negative case-control","20May2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">14","symptomatic disease","symptomatic","UK",">= 65 years",">= 65 years",90,"82",95,NA,"alpha",NA,NA,NA,"UK","GBR",33,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-05-20,"symptomatic","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-05-20
"124",33,"PHE","Test-negative case-control","20May2021","AZD1222 (AstraZeneca)","excluded","1","1","28+","symptomatic disease","symptomatic","UK",">= 65 years",">= 65 years",53,"49",57,NA,"alpha",NA,NA,NA,"UK","GBR",33,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-05-20,"symptomatic","2021 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2021-05-20
"125",33,"PHE","Test-negative case-control","20May2021","AZD1222 (AstraZeneca)","excluded","2","final",">14","symptomatic disease","symptomatic","UK",">= 65 years",">= 65 years",89,"78",94,NA,"alpha",NA,NA,NA,"UK","GBR",33,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-05-20,"symptomatic","2021 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2021-05-20
"126",34,"Chung","Test-negative case-control","20Aug2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",59,"55",62,NA,"alpha, beta & gamma",NA,NA,NA,"Canada","CAN",34,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-08-20,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","26/07/2021",2021-07-26
"127",34,"Chung","Test-negative case-control","20Aug2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7+","symptomatic disease","symptomatic","Canada","general pop","general pop",91,"88",93,NA,"alpha, beta & gamma","15 weeks",NA,NA,"Canada","CAN",34,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-08-20,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","26/07/2021",2021-07-26
"128",34,"Chung","Test-negative case-control","20Aug2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14+","hospitalization or death","severe","Canada","general pop","general pop",69,"59",77,NA,"alpha, beta & gamma",NA,NA,NA,"Canada","CAN",34,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-08-20,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","26/07/2021",2021-07-26
"129",34,"Chung","Test-negative case-control","20Aug2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","0+","hospitalization or death","severe","Canada","general pop","general pop",96,"82",99,NA,"alpha, beta & gamma","15 weeks",NA,NA,"Canada","CAN",34,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-08-20,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","26/07/2021",2021-07-26
"130",34,"Chung","Test-negative case-control","20Aug2021","mRNA-1273 (Moderna)","excluded","1","1","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",72,"63",80,NA,"alpha, beta & gamma",NA,NA,NA,"Canada","CAN",34,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-08-20,"symptomatic","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","26/07/2021",2021-07-26
"131",34,"Chung","Test-negative case-control","20Aug2021","mRNA-1273 (Moderna)","excluded","2","final","7+","symptomatic disease","symptomatic","Canada","general pop","general pop",94,"86",97,NA,"alpha, beta & gamma","15 weeks",NA,NA,"Canada","CAN",34,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-08-20,"symptomatic","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","26/07/2021",2021-07-26
"132",34,"Chung","Test-negative case-control","20Aug2021","mRNA-1273 (Moderna)","excluded","1","1","14+","hospitalization or death","severe","Canada","general pop","general pop",73,"42",87,NA,"alpha, beta & gamma",NA,NA,NA,"Canada","CAN",34,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-08-20,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","26/07/2021",2021-07-26
"133",34,"Chung","Test-negative case-control","20Aug2021","mRNA-1273 (Moderna)","excluded","2","final","0+","hospitalization or death","severe","Canada","general pop","general pop",96,"74",100,NA,"alpha, beta & gamma","15 weeks",NA,NA,"Canada","CAN",34,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-08-20,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","26/07/2021",2021-07-26
"134",34,"Chung","Test-negative case-control","20Aug2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",61,"56",66,"alpha","alpha",NA,NA,NA,"Canada","CAN",34,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-08-20,"symptomatic","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha","26/07/2021",2021-07-26
"135",34,"Chung","Test-negative case-control","20Aug2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","symptomatic disease","symptomatic","Canada","general pop","general pop",90,"85",94,"alpha","alpha","15 weeks",NA,NA,"Canada","CAN",34,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-08-20,"symptomatic","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha","26/07/2021",2021-07-26
"136",34,"Chung","Test-negative case-control","20Aug2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","14+","hospitalization or death","severe","Canada","general pop","general pop",59,"39",73,"alpha","alpha",NA,NA,NA,"Canada","CAN",34,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-08-20,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha","26/07/2021",2021-07-26
"137",34,"Chung","Test-negative case-control","20Aug2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","0+","hospitalization or death","severe","Canada","general pop","general pop",94,"59",99,"alpha","alpha","15 weeks",NA,NA,"Canada","CAN",34,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-08-20,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha","26/07/2021",2021-07-26
"138",34,"Chung","Test-negative case-control","20Aug2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",43,"22",59,"beta & gamma","beta & gamma",NA,NA,NA,"Canada","CAN",34,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-08-20,"symptomatic","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","26/07/2021",2021-07-26
"139",34,"Chung","Test-negative case-control","20Aug2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","symptomatic disease","symptomatic","Canada","general pop","general pop",88,"61",96,"beta & gamma","beta & gamma","15 weeks",NA,NA,"Canada","CAN",34,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-08-20,"symptomatic","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","26/07/2021",2021-07-26
"140",34,"Chung","Test-negative case-control","20Aug2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","14+","hospitalization or death","severe","Canada","general pop","general pop",56,"-9",82,"   ","beta & gamma",NA,"15 weeks",NA,"Canada","CAN",34,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-08-20,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","26/07/2021",2021-07-26
"141",34,"Chung","Test-negative case-control","20Aug2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","hospitalization or death","severe","Canada","general pop","general pop",100,NA,NA,"   ","beta & gamma","beta & gamma","15 weeks",NA,"Canada","CAN",34,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-08-20,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","26/07/2021",2021-07-26
"142",35,"Martinez-Bas","Prospective cohort","27May2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14+","infection ","infection","Spain","close contacts","close contacts",21,"3",36,NA,"alpha",NA,NA,NA,"Spain","ESP",35,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-05-27,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-05-27
"143",35,"Martinez-Bas","Prospective cohort","27May2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection ","infection","Spain","close contacts","close contacts",65,"56",73,NA,"alpha","12 weeks",NA,NA,"Spain","ESP",35,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-05-27,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-05-27
"144",35,"Martinez-Bas","Prospective cohort","27May2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14+","symptomatic disease","symptomatic","Spain","close contacts","close contacts",30,"10",45,NA,"alpha",NA,NA,NA,"Spain","ESP",35,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-05-27,"symptomatic","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-05-27
"145",35,"Martinez-Bas","Prospective cohort","27May2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease","symptomatic","Spain","close contacts","close contacts",82,"73",88,NA,"alpha","12 weeks",NA,NA,"Spain","ESP",35,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-05-27,"symptomatic","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-05-27
"146",35,"Martinez-Bas","Prospective cohort","27May2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14+","hospitalization","severe","Spain","close contacts","close contacts",65,"25",83,NA,"alpha",NA,NA,NA,"Spain","ESP",35,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-05-27,"severe","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-05-27
"147",35,"Martinez-Bas","Prospective cohort","27May2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization","severe","Spain","close contacts","close contacts",94,"60",99,NA,"alpha","12 weeks",NA,NA,"Spain","ESP",35,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-05-27,"severe","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-05-27
"148",35,"Martinez-Bas","Prospective cohort","27May2021","AZD1222 (AstraZeneca)","excluded","1","1","14+","infection ","infection","Spain","close contacts","close contacts",44,"31",54,NA,"alpha",NA,NA,NA,"Spain","ESP",35,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-05-27,"infection","2021 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2021-05-27
"149",35,"Martinez-Bas","Prospective cohort","27May2021","AZD1222 (AstraZeneca)","excluded","1","1","14+","symptomatic disease","symptomatic","Spain","close contacts","close contacts",50,"37",61,NA,"alpha",NA,NA,NA,"Spain","ESP",35,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-05-27,"symptomatic","2021 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2021-05-27
"150",35,"Martinez-Bas","Prospective cohort","27May2021","AZD1222 (AstraZeneca)","excluded","1","1","14+","hospitalization","severe","Spain","close contacts","close contacts",92,"46",99,NA,"alpha",NA,NA,NA,"Spain","ESP",35,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-05-27,"severe","2021 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2021-05-27
"151",36,"Khan","Retrospective cohort","31May2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","1+","1+","14+ up to 7 days post dose 2","infection ","infection","USA","hospital patients","general pop",-1,"-50",32,NA,"unknown",NA,NA,NA,"USA","USA",36,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-05-31,"infection","2021 (Jan-Jun)","Multiple or heterologous RNA","mRNA","unknown",NA,2021-05-31
"152",36,"Khan","Retrospective cohort","31May2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","7+","infection ","infection","USA","hospital patients","general pop",69,"44",83,NA,"unknown","14 weeks",NA,NA,"USA","USA",36,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-05-31,"infection","2021 (Jan-Jun)","Multiple or heterologous RNA","mRNA","unknown",NA,2021-05-31
"153",36,"Khan","Retrospective cohort","31May2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","1+","1+","14+ up to 7 days post dose 2","hospitalization or death","severe","USA","hospital patients","general pop",9,"-114",61,NA,"unknown",NA,NA,NA,"USA","USA",36,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-05-31,"severe","2021 (Jan-Jun)","Multiple or heterologous RNA","mRNA","unknown",NA,2021-05-31
"154",36,"Khan","Retrospective cohort","31May2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","7+","hospitalization or death","severe","USA","hospital patients","general pop",49,"-36",81,NA,"unknown","14 weeks",NA,NA,"USA","USA",36,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-05-31,"severe","2021 (Jan-Jun)","Multiple or heterologous RNA","mRNA","unknown",NA,2021-05-31
"155",37,"Salo","Retrospective cohort","04Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","4 weeks","infection ","infection","Finland","HCW","HCW",44.4,"30.4",55.6,NA,"alpha",NA,NA,NA,"Finland","FIN",37,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-04,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","alpha",NA,2022-03-04
"156",37,"Salo","Retrospective cohort","04Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1+","1+","12 weeks (inlcudes 2 dose recipients)","infection ","infection","Finland","HCW","HCW",63,"56.3",68.7,NA,"alpha",NA,NA,NA,"Finland","FIN",37,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-04,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","alpha",NA,2022-03-04
"157",38,"Thompson","Cohort","30June2021","BNT162b2 (Pfizer BioNTech)","excluded","1+","1+",">14 up to 13 days post dose 2","infection ","infection","USA","HCW","HCW",80,"60",90,NA,"original",NA,NA,NA,"USA","USA",38,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-06-30,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","original","30/06/2021",2021-06-30
"158",38,"Thompson","Cohort","30June2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">14","infection ","infection","USA","HCW","HCW",93,"78",98,NA,"original","13 weeks",NA,NA,"USA","USA",38,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-06-30,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","original","30/06/2021",2021-06-30
"159",38,"Thompson","Cohort","30June2021","mRNA-1273 (Moderna)","excluded","1+","1+",">14 up to 13 days post dose 2","infection ","infection","USA","HCW","HCW",83,"40",95,NA,"original",NA,NA,NA,"USA","USA",38,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-06-30,"infection","2021 (Jan-Jun)","Moderna mRNA-1273","mRNA","original","30/06/2021",2021-06-30
"160",38,"Thompson","Cohort","30June2021","mRNA-1273 (Moderna)","excluded","2","final",">14","infection ","infection","USA","HCW","HCW",82,"20",96,NA,"original",NA,NA,NA,"USA","USA",38,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-06-30,"infection","2021 (Jan-Jun)","Moderna mRNA-1273","mRNA","original","30/06/2021",2021-06-30
"161",39,"Emborg","Cohort","30June2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1",">14","infection ","infection","Denmark","priority groups","priority groups",7,"-1",15,NA,"original & alpha",NA,NA,NA,"Denmark","DNK",39,"DNK",61830,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,8,212,261,"who",8,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-06-30,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-06-30
"162",39,"Emborg","Cohort","30June2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">7","infection ","infection","Denmark","priority groups","priority groups",82,"79",84,NA,"original & alpha","10 weeks",NA,NA,"Denmark","DNK",39,"DNK",61830,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,8,212,261,"who",8,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-06-30,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-06-30
"163",39,"Emborg","Cohort","30June2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1",">14","hospitalization","severe","Denmark","priority groups","priority groups",35,"18",49,NA,"original & alpha",NA,NA,NA,"Denmark","DNK",39,"DNK",61830,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,8,212,261,"who",8,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-06-30,"severe","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-06-30
"164",39,"Emborg","Cohort","30June2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">7","hospitalization","severe","Denmark","priority groups","priority groups",93,"89",96,NA,"original & alpha","10 weeks",NA,NA,"Denmark","DNK",39,"DNK",61830,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,8,212,261,"who",8,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-06-30,"severe","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-06-30
"165",39,"Emborg","Cohort","30June2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1",">14","death","death","Denmark","priority groups","priority groups",7,"-15",25,NA,"original & alpha",NA,NA,NA,"Denmark","DNK",39,"DNK",61830,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,8,212,261,"who",8,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-06-30,"death","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-06-30
"166",39,"Emborg","Cohort","30June2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">7","death","death","Denmark","priority groups","priority groups",94,"90",96,NA,"original & alpha","10 weeks",NA,NA,"Denmark","DNK",39,"DNK",61830,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,8,212,261,"who",8,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-06-30,"death","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-06-30
"167",40,"Skowornski","Test-negative case-control","09Jul2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","1","1","21+","infection ","infection","Canada","> 70 years","> 70 years",67,"57",75,"alpha","alpha",NA,NA,NA,"Canada","CAN",40,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-07-09,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha",NA,2021-07-09
"168",40,"Skowornski","Test-negative case-control","09Jul2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","1","1","21+","infection ","infection","Canada","> 70 years","> 70 years",61,"45",72,"gamma","gamma",NA,NA,NA,"Canada","CAN",40,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-07-09,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","gamma",NA,2021-07-09
"169",40,"Skowornski","Test-negative case-control","09Jul2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","1","1","21+","infection ","infection","Canada","> 70 years","> 70 years",72,"58",81,"non-VOC","non-VOC",NA,NA,NA,"Canada","CAN",40,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-07-09,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","original",NA,2021-07-09
"170",40,"Skowornski","Test-negative case-control","09Jul2021","BNT162b2 (Pfizer BioNTech)","included","1","1","21+","infection ","infection","Canada","> 70 years","> 70 years",64,"57",71,NA,"alpha & gamma",NA,NA,NA,"Canada","CAN",40,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-07-09,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-07-09
"171",40,"Skowornski","Test-negative case-control","09Jul2021","mRNA-1273 (Moderna)","included","1","1","21+","infection ","infection","Canada","> 70 years","> 70 years",71,"56",81,NA,"alpha & gamma",NA,NA,NA,"Canada","CAN",40,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-07-09,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-07-09
"172",41,"Flacco","Retrospective cohort","10June2021","BNT162b2 (Pfizer BioNTech)","unknown","1","1","14+","infection ","infection","Italy","general pop","general pop",55,"40",66,NA,"original & alpha",NA,NA,NA,"Italy","ITA",41,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-06-10,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-06-10
"173",41,"Flacco","Retrospective cohort","10June2021","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","infection ","infection","Italy","general pop","general pop",98,"97",99,NA,"original & alpha","~14 weeks",NA,NA,"Italy","ITA",41,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-06-10,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-06-10
"174",41,"Flacco","Retrospective cohort","10June2021","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","hospitalization","severe","Italy","general pop","general pop",99,"96",100,NA,"original & alpha","~14 weeks",NA,NA,"Italy","ITA",41,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-06-10,"severe","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-06-10
"175",41,"Flacco","Retrospective cohort","10June2021","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","death","death","Italy","general pop","general pop",98,"87",100,NA,"original & alpha","~14 weeks",NA,NA,"Italy","ITA",41,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-06-10,"death","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-06-10
"176",41,"Flacco","Retrospective cohort","10June2021","mRNA-1273 (Moderna)","unknown","1","1","14+","infection ","infection","Italy","general pop","general pop",93,"74",98,NA,"original & alpha",NA,NA,NA,"Italy","ITA",41,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-06-10,"infection","2021 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-06-10
"177",41,"Flacco","Retrospective cohort","10June2021","AZD1222 (AstraZeneca)","unknown","1","1","21+","infection ","infection","Italy","general pop","general pop",95,"92",97,NA,"original & alpha",NA,NA,NA,"Italy","ITA",41,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-06-10,"infection","2021 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2021-06-10
"178",42,"Sheikh","Test-negative case-control","14June2021","BNT162b2 (Pfizer BioNTech)","unknown","1","1","28+","infection ","infection","Scotland","general pop","general pop",38,"29",45,"alpha","alpha",NA,NA,NA,"UK","GBR",42,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-06-14,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-06-14
"179",42,"Sheikh","Test-negative case-control","14June2021","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","infection ","infection","Scotland","general pop","general pop",92,"90",93,"alpha","alpha","~20 weeks",NA,NA,"UK","GBR",42,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-06-14,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-06-14
"180",42,"Sheikh","Test-negative case-control","14June2021","AZD1222 (AstraZeneca)","unknown","1","1","28+","infection ","infection","Scotland","general pop","general pop",37,"32",42,"alpha","alpha",NA,NA,NA,"UK","GBR",42,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-06-14,"infection","2021 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2021-06-14
"181",42,"Sheikh","Test-negative case-control","14June2021","AZD1222 (AstraZeneca)","unknown","2","final","14+","infection ","infection","Scotland","general pop","general pop",73,"66",78,"alpha","alpha","~20 weeks",NA,NA,"UK","GBR",42,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-06-14,"infection","2021 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2021-06-14
"182",42,"Sheikh","Test-negative case-control","14June2021","BNT162b2 (Pfizer BioNTech)","unknown","1","1","28+","infection ","infection","Scotland","general pop","general pop",30,"17",41,"delta","delta",NA,NA,NA,"UK","GBR",42,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-06-14,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2021-06-14
"183",42,"Sheikh","Test-negative case-control","14June2021","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","infection ","infection","Scotland","general pop","general pop",79,"75",82,"delta","delta","~20 weeks",NA,NA,"UK","GBR",42,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-06-14,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2021-06-14
"184",42,"Sheikh","Test-negative case-control","14June2021","AZD1222 (AstraZeneca)","unknown","1","1","28+","infection ","infection","Scotland","general pop","general pop",18,"9",25,"delta","delta",NA,NA,NA,"UK","GBR",42,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-06-14,"infection","2021 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2021-06-14
"185",42,"Sheikh","Test-negative case-control","14June2021","AZD1222 (AstraZeneca)","unknown","2","final","14+","infection ","infection","Scotland","general pop","general pop",60,"53",66,"delta","delta","~20 weeks",NA,NA,"UK","GBR",42,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-06-14,"infection","2021 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2021-06-14
"186",43,"Stowe","Test-negative case-control","14June2021","BNT162b2 (Pfizer BioNTech)","included","1","1","21+","hospitalization","severe","UK","hospital patients","general pop",83,"62",93,"alpha","alpha",NA,NA,NA,"UK","GBR",43,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-06-14,"severe","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-06-14
"187",43,"Stowe","Test-negative case-control","14June2021","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","hospitalization","severe","UK","hospital patients","general pop",95,"78",99,"alpha","alpha","~20 weeks",NA,NA,"UK","GBR",43,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-06-14,"severe","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-06-14
"188",43,"Stowe","Test-negative case-control","14June2021","AZD1222 (AstraZeneca)","included","1","1","21+","hospitalization","severe","UK","hospital patients","general pop",76,"61",85,"alpha","alpha",NA,NA,NA,"UK","GBR",43,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-06-14,"severe","2021 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2021-06-14
"189",43,"Stowe","Test-negative case-control","14June2021","AZD1222 (AstraZeneca)","included","2","final","14+","hospitalization","severe","UK","hospital patients","general pop",86,"53",96,"alpha","alpha","~20 weeks",NA,NA,"UK","GBR",43,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-06-14,"severe","2021 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2021-06-14
"190",43,"Stowe","Test-negative case-control","14June2021","BNT162b2 (Pfizer BioNTech)","included","1","1","21+","hospitalization","severe","UK","hospital patients","general pop",94,"46",99,"delta","delta",NA,NA,NA,"UK","GBR",43,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-06-14,"severe","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2021-06-14
"191",43,"Stowe","Test-negative case-control","14June2021","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","hospitalization","severe","UK","hospital patients","general pop",96,"86",99,"delta","delta","~20 weeks",NA,NA,"UK","GBR",43,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-06-14,"severe","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2021-06-14
"192",43,"Stowe","Test-negative case-control","14June2021","AZD1222 (AstraZeneca)","included","1","1","21+","hospitalization","severe","UK","hospital patients","general pop",71,"51",83,"delta","delta",NA,NA,NA,"UK","GBR",43,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-06-14,"severe","2021 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2021-06-14
"193",43,"Stowe","Test-negative case-control","14June2021","AZD1222 (AstraZeneca)","included","2","final","14+","hospitalization","severe","UK","hospital patients","general pop",92,"75",97,"delta","delta","~20 weeks",NA,NA,"UK","GBR",43,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-06-14,"severe","2021 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2021-06-14
"194",44,"Azamgarhi","Retrospective cohort","17June2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1",">14","infection ","infection","UK","HCW","HCW",70,"6",91,NA,"original & alpha",NA,NA,NA,"UK","GBR",44,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-06-17,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-06-17
"195",45,"Young-Xu","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","7+","infection ","infection","USA","general pop","general pop",58,"54",62,NA,"original & alpha",NA,NA,NA,"USA","USA",45,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-10-06,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","14/07/2021",2021-07-14
"196",45,"Young-Xu","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","infection ","infection","USA","general pop","general pop",94,"92",95,NA,"original & alpha","~8 weeks",NA,NA,"USA","USA",45,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-10-06,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","14/07/2021",2021-07-14
"197",45,"Young-Xu","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","7+","hospitalization","severe","USA","general pop","general pop",40,"27",50,NA,"original & alpha",NA,NA,NA,"USA","USA",45,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-10-06,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","14/07/2021",2021-07-14
"198",45,"Young-Xu","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","hospitalization","severe","USA","general pop","general pop",89,"81",93,NA,"original & alpha","~8 weeks",NA,NA,"USA","USA",45,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-10-06,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","14/07/2021",2021-07-14
"199",45,"Young-Xu","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","7+","death","death","USA","general pop","general pop",55,"21",74,NA,"original & alpha",NA,NA,NA,"USA","USA",45,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-10-06,"death","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","14/07/2021",2021-07-14
"200",45,"Young-Xu","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","death","death","USA","general pop","general pop",98.5,"86.6",99.8,NA,"original & alpha","~8 weeks",NA,NA,"USA","USA",45,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-10-06,"death","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","14/07/2021",2021-07-14
"201",45,"Young-Xu","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","7+","asymptomatic infection","asymptomatic","USA","general pop","general pop",58,"41.7",69.7,NA,"original & alpha",NA,NA,NA,"USA","USA",45,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-10-06,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","14/07/2021",2021-07-14
"202",45,"Young-Xu","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","asymptomatic infection","asymptomatic","USA","general pop","general pop",69.7,"47.7",82.5,NA,"original & alpha","~8 weeks",NA,NA,"USA","USA",45,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-10-06,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","14/07/2021",2021-07-14
"203",45,"Young-Xu","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","7+","hospitalization","severe","USA","general pop","general pop",53,"25.7",70.3,NA,"original & alpha",NA,NA,NA,"USA","USA",45,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-10-06,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","14/07/2021",2021-07-14
"204",45,"Young-Xu","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","hospitalization","severe","USA","general pop","general pop",88.4,"74.9",94.7,NA,"original & alpha","~8 weeks",NA,NA,"USA","USA",45,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-10-06,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","14/07/2021",2021-07-14
"205",45,"Young-Xu","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","7+","death","death","USA","general pop","general pop",55.6,"26.6",73.2,NA,"original & alpha",NA,NA,NA,"USA","USA",45,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-10-06,"death","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","14/07/2021",2021-07-14
"206",45,"Young-Xu","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","death","death","USA","general pop","general pop",97,"91.7",98.9,NA,"original & alpha","~8 weeks",NA,NA,"USA","USA",45,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-10-06,"death","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","14/07/2021",2021-07-14
"207",46,"Pawlowski","Retrospective cohort","17Jun2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1",">14","infection ","infection","USA","general pop","general pop",61,"50.8",69.2,NA,"original & alpha",NA,NA,NA,"USA","USA",46,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-06-17,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","18/02/2021",2021-02-18
"208",46,"Pawlowski","Retrospective cohort","17Jun2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">14","infection ","infection","USA","general pop","general pop",88,"84.2",91,NA,"original & alpha","~17 weeks",NA,NA,"USA","USA",46,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-06-17,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","18/02/2021",2021-02-18
"209",46,"Pawlowski","Retrospective cohort","17Jun2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">14","hospitalization","severe","USA","general pop","general pop",88.3,"72.6",95.9,NA,"original & alpha","~17 weeks",NA,NA,"USA","USA",46,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-06-17,"severe","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","18/02/2021",2021-02-18
"210",46,"Pawlowski","Retrospective cohort","17Jun2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">14","ICU admission","severe","USA","general pop","general pop",100,"18.7",100,NA,"original & alpha","~17 weeks",NA,NA,"USA","USA",46,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-06-17,"severe","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","18/02/2021",2021-02-18
"211",46,"Pawlowski","Retrospective cohort","17Jun2021","mRNA-1273 (Moderna)","excluded","1","1",">14","infection ","infection","USA","general pop","general pop",66.6,"51.9",77.3,NA,"original & alpha",NA,NA,NA,"USA","USA",46,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-06-17,"infection","2021 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","18/02/2021",2021-02-18
"212",46,"Pawlowski","Retrospective cohort","17Jun2021","mRNA-1273 (Moderna)","excluded","2","final",">14","infection ","infection","USA","general pop","general pop",92.3,"82.4",97.3,NA,"original & alpha","~17 weeks",NA,NA,"USA","USA",46,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-06-17,"infection","2021 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","18/02/2021",2021-02-18
"213",46,"Pawlowski","Retrospective cohort","17Jun2021","mRNA-1273 (Moderna)","excluded","2","final",">14","hospitalization","severe","USA","general pop","general pop",90.6,"76.5",97.1,NA,"original & alpha","~17 weeks",NA,NA,"USA","USA",46,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-06-17,"severe","2021 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","18/02/2021",2021-02-18
"214",46,"Pawlowski","Retrospective cohort","17Jun2021","mRNA-1273 (Moderna)","excluded","2","final",">14","ICU admission","severe","USA","general pop","general pop",100,"17.9",100,NA,"original & alpha","~17 weeks",NA,NA,"USA","USA",46,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-06-17,"severe","2021 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","18/02/2021",2021-02-18
"215",47,"Saciuk","Retrospective cohort","30Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7+","infection ","infection","Israel","general pop","general pop",93,"92.6",93.4,NA,"original & alpha","14 weeks",NA,NA,"Israel","ISR",47,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-12-30,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","27/06/2021",2021-06-27
"216",47,"Saciuk","Retrospective cohort","30Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7+","hospitalization","severe","Israel","general pop","general pop",93.4,"91.9",94.7,NA,"original & alpha","14 weeks",NA,NA,"Israel","ISR",47,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-12-30,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","27/06/2021",2021-06-27
"217",47,"Saciuk","Retrospective cohort","30Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7+","death","death","Israel","general pop","general pop",91.1,"86.5",94.1,NA,"original & alpha","14 weeks",NA,NA,"Israel","ISR",47,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-12-30,"death","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","27/06/2021",2021-06-27
"218",48,"Baum","Prospective cohort","18Nov2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","21+","infection ","infection","Finland",">= 70 years",">= 70 years",45,"36",53,NA,"original & alpha",NA,NA,NA,"Finland","FIN",48,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-11-18,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","28/06/2021",2021-06-28
"219",48,"Baum","Prospective cohort","18Nov2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","infection ","infection","Finland",">= 70 years",">= 70 years",75,"65",82,NA,"original & alpha","16 weeks",NA,NA,"Finland","FIN",48,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-11-18,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","28/06/2021",2021-06-28
"220",48,"Baum","Prospective cohort","18Nov2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","21+","hospitalization","severe","Finland",">= 70 years",">= 70 years",63,"49",74,NA,"original & alpha",NA,NA,NA,"Finland","FIN",48,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-11-18,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","28/06/2021",2021-06-28
"221",48,"Baum","Prospective cohort","18Nov2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","hospitalization","severe","Finland",">= 70 years",">= 70 years",93,"70",98,NA,"original & alpha","16 weeks",NA,NA,"Finland","FIN",48,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-11-18,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","28/06/2021",2021-06-28
"222",48,"Baum","Prospective cohort","18Nov2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","21+","infection ","infection","Finland","chronically ill","chronically ill",40,"26",51,NA,"original & alpha",NA,NA,NA,"Finland","FIN",48,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-11-18,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","28/06/2021",2021-06-28
"223",48,"Baum","Prospective cohort","18Nov2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","infection ","infection","Finland","chronically ill","chronically ill",77,"65",85,NA,"original & alpha","16 weeks",NA,NA,"Finland","FIN",48,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-11-18,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","28/06/2021",2021-06-28
"224",48,"Baum","Prospective cohort","18Nov2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","21+","hospitalization","severe","Finland","chronically ill","chronically ill",82,"56",93,NA,"original & alpha",NA,NA,NA,"Finland","FIN",48,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-11-18,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","28/06/2021",2021-06-28
"225",48,"Baum","Prospective cohort","18Nov2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","hospitalization","severe","Finland","chronically ill","chronically ill",90,"29",99,NA,"original & alpha","16 weeks",NA,NA,"Finland","FIN",48,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-11-18,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","28/06/2021",2021-06-28
"226",48,"Baum","Prospective cohort","18Nov2021","AZD1222 (AstraZeneca)","excluded","1","1","21+","infection ","infection","Finland","chronically ill","chronically ill",42,"32",50,NA,"original & alpha",NA,NA,NA,"Finland","FIN",48,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-11-18,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","28/06/2021",2021-06-28
"227",48,"Baum","Prospective cohort","18Nov2021","AZD1222 (AstraZeneca)","excluded","1","1","21+","hospitalization","severe","Finland","chronically ill","chronically ill",62,"42",75,NA,"original & alpha",NA,NA,NA,"Finland","FIN",48,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-11-18,"severe","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","28/06/2021",2021-06-28
"228",49,"Nasreen","Test-negative case-control","07Feb2022","BNT162b2 (Pfizer BioNTech)","unknown","1","1","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",63,"56",68,"non-VOC","non-VOC",NA,NA,NA,"Canada","CAN",49,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","original","30/09/2021",2021-09-30
"229",49,"Nasreen","Test-negative case-control","07Feb2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",92,"87",95,"non-VOC","non-VOC","18 weeks",NA,NA,"Canada","CAN",49,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","original","30/09/2021",2021-09-30
"230",49,"Nasreen","Test-negative case-control","07Feb2022","BNT162b2 (Pfizer BioNTech)","unknown","1","1","14+","hospitalization or death","severe","Canada","general pop","general pop",77,"67",84,"non-VOC","non-VOC",NA,NA,NA,"Canada","CAN",49,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","original","30/09/2021",2021-09-30
"231",49,"Nasreen","Test-negative case-control","07Feb2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","hospitalization or death","severe","Canada","general pop","general pop",97,"88",99,"non-VOC","non-VOC","18 weeks",NA,NA,"Canada","CAN",49,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","original","30/09/2021",2021-09-30
"232",49,"Nasreen","Test-negative case-control","07Feb2022","mRNA-1273 (Moderna)","unknown","1","1","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",63,"47",74,"non-VOC","non-VOC",NA,NA,NA,"Canada","CAN",49,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","original","30/09/2021",2021-09-30
"233",49,"Nasreen","Test-negative case-control","07Feb2022","mRNA-1273 (Moderna)","unknown","2","final","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",98,"83",100,"non-VOC","non-VOC","18 weeks",NA,NA,"Canada","CAN",49,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","original","30/09/2021",2021-09-30
"234",49,"Nasreen","Test-negative case-control","07Feb2022","mRNA-1273 (Moderna)","unknown","1","1","14+","hospitalization or death","severe","Canada","general pop","general pop",66,"43",80,"non-VOC","non-VOC",NA,NA,NA,"Canada","CAN",49,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","original","30/09/2021",2021-09-30
"235",49,"Nasreen","Test-negative case-control","07Feb2022","mRNA-1273 (Moderna)","unknown","2","final","14+","hospitalization or death","severe","Canada","general pop","general pop",100,NA,NA,"non-VOC","non-VOC","18 weeks",NA,NA,"Canada","CAN",49,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","original","30/09/2021",2021-09-30
"236",49,"Nasreen","Test-negative case-control","07Feb2022","AZD1222 (AstraZeneca)","unknown","1","1","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",67,"44",81,"non-VOC","non-VOC",NA,NA,NA,"Canada","CAN",49,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","original","30/09/2021",2021-09-30
"237",49,"Nasreen","Test-negative case-control","07Feb2022","AZD1222 (AstraZeneca)","unknown","2","final","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",100,NA,NA,"non-VOC","non-VOC","~3 weeks",NA,NA,"Canada","CAN",49,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","original","30/09/2021",2021-09-30
"238",49,"Nasreen","Test-negative case-control","07Feb2022","AZD1222 (AstraZeneca)","unknown","1","1","14+","hospitalization or death","severe","Canada","general pop","general pop",92,"45",99,"non-VOC","non-VOC",NA,NA,NA,"Canada","CAN",49,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","original","30/09/2021",2021-09-30
"239",49,"Nasreen","Test-negative case-control","07Feb2022","AZD1222 (AstraZeneca)","unknown","2","final","14+","hospitalization or death","severe","Canada","general pop","general pop",100,NA,NA,"non-VOC","non-VOC","~3 weeks",NA,NA,"Canada","CAN",49,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","original","30/09/2021",2021-09-30
"240",49,"Nasreen","Test-negative case-control","07Feb2022","BNT162b2 (Pfizer BioNTech)","unknown","1","1","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",67,"65",68,"alpha","alpha",NA,NA,NA,"Canada","CAN",49,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","30/09/2021",2021-09-30
"241",49,"Nasreen","Test-negative case-control","07Feb2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",88,"86",90,"alpha","alpha","~28 weeks",NA,NA,"Canada","CAN",49,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","30/09/2021",2021-09-30
"242",49,"Nasreen","Test-negative case-control","07Feb2022","BNT162b2 (Pfizer BioNTech)","unknown","1","1","14+","hospitalization or death","severe","Canada","general pop","general pop",82,"81",84,"alpha","alpha",NA,NA,NA,"Canada","CAN",49,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","30/09/2021",2021-09-30
"243",49,"Nasreen","Test-negative case-control","07Feb2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","hospitalization or death","severe","Canada","general pop","general pop",96,"94",97,"alpha","alpha","~28 weeks",NA,NA,"Canada","CAN",49,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","30/09/2021",2021-09-30
"244",49,"Nasreen","Test-negative case-control","07Feb2022","mRNA-1273 (Moderna)","unknown","1","1","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",82,"80",84,"alpha","alpha",NA,NA,NA,"Canada","CAN",49,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","alpha","30/09/2021",2021-09-30
"245",49,"Nasreen","Test-negative case-control","07Feb2022","mRNA-1273 (Moderna)","unknown","2","final","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",92,"87",95,"alpha","alpha","~25 weeks",NA,NA,"Canada","CAN",49,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","alpha","30/09/2021",2021-09-30
"246",49,"Nasreen","Test-negative case-control","07Feb2022","mRNA-1273 (Moderna)","unknown","1","1","14+","hospitalization or death","severe","Canada","general pop","general pop",80,"76",84,"alpha","alpha",NA,NA,NA,"Canada","CAN",49,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","alpha","30/09/2021",2021-09-30
"247",49,"Nasreen","Test-negative case-control","07Feb2022","mRNA-1273 (Moderna)","unknown","2","final","14+","hospitalization or death","severe","Canada","general pop","general pop",95,"92",97,"alpha","alpha","~25 weeks",NA,NA,"Canada","CAN",49,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","alpha","30/09/2021",2021-09-30
"248",49,"Nasreen","Test-negative case-control","07Feb2022","AZD1222 (AstraZeneca)","unknown","1","1","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",63,"59",66,"alpha","alpha",NA,NA,NA,"Canada","CAN",49,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","30/09/2021",2021-09-30
"249",49,"Nasreen","Test-negative case-control","07Feb2022","AZD1222 (AstraZeneca)","unknown","2","final","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",87,"47",97,"alpha","alpha","~3 weeks",NA,NA,"Canada","CAN",49,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","30/09/2021",2021-09-30
"250",49,"Nasreen","Test-negative case-control","07Feb2022","AZD1222 (AstraZeneca)","unknown","1","1","14+","hospitalization or death","severe","Canada","general pop","general pop",87,"83",90,"alpha","alpha",NA,NA,NA,"Canada","CAN",49,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","30/09/2021",2021-09-30
"251",49,"Nasreen","Test-negative case-control","07Feb2022","AZD1222 (AstraZeneca)","unknown","2","final","14+","hospitalization or death","severe","Canada","general pop","general pop",92,"41",99,"alpha","alpha","~3 weeks",NA,NA,"Canada","CAN",49,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","30/09/2021",2021-09-30
"252",49,"Nasreen","Test-negative case-control","07Feb2022","BNT162b2 (Pfizer BioNTech)","unknown","1","1","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",50,"15",70,"beta","beta",NA,NA,NA,"Canada","CAN",49,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","beta","30/09/2021",2021-09-30
"253",49,"Nasreen","Test-negative case-control","07Feb2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",86,"0",98,"beta","beta","~28 weeks",NA,NA,"Canada","CAN",49,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","beta","30/09/2021",2021-09-30
"254",49,"Nasreen","Test-negative case-control","07Feb2022","BNT162b2 (Pfizer BioNTech)","unknown","1","1","14+","hospitalization or death","severe","Canada","general pop","general pop",64,"31",82,"beta","beta",NA,NA,NA,"Canada","CAN",49,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","beta","30/09/2021",2021-09-30
"255",49,"Nasreen","Test-negative case-control","07Feb2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","hospitalization or death","severe","Canada","general pop","general pop",92,"39",99,"beta","beta","~28 weeks",NA,NA,"Canada","CAN",49,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","beta","30/09/2021",2021-09-30
"256",49,"Nasreen","Test-negative case-control","07Feb2022","mRNA-1273 (Moderna)","unknown","2","final","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",100,NA,NA,"beta","beta","~25 weeks",NA,NA,"Canada","CAN",49,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","beta","30/09/2021",2021-09-30
"257",49,"Nasreen","Test-negative case-control","07Feb2022","mRNA-1273 (Moderna)","unknown","1","1","14+","hospitalization or death","severe","Canada","general pop","general pop",59,"-77",90,"beta","beta",NA,NA,NA,"Canada","CAN",49,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","beta","30/09/2021",2021-09-30
"258",49,"Nasreen","Test-negative case-control","07Feb2022","mRNA-1273 (Moderna)","unknown","2","final","14+","hospitalization or death","severe","Canada","general pop","general pop",100,NA,NA,"beta","beta","~25 weeks",NA,NA,"Canada","CAN",49,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","beta","30/09/2021",2021-09-30
"259",49,"Nasreen","Test-negative case-control","07Feb2022","AZD1222 (AstraZeneca)","unknown","1","1","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",84,"-13",98,"beta","beta",NA,NA,NA,"Canada","CAN",49,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","beta","30/09/2021",2021-09-30
"260",49,"Nasreen","Test-negative case-control","07Feb2022","AZD1222 (AstraZeneca)","unknown","2","final","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",100,NA,NA,"beta","beta","~3 weeks",NA,NA,"Canada","CAN",49,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","beta","30/09/2021",2021-09-30
"261",49,"Nasreen","Test-negative case-control","07Feb2022","AZD1222 (AstraZeneca)","unknown","1","1","14+","hospitalization or death","severe","Canada","general pop","general pop",61,"-64",91,"beta","beta",NA,NA,NA,"Canada","CAN",49,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","beta","30/09/2021",2021-09-30
"262",49,"Nasreen","Test-negative case-control","07Feb2022","BNT162b2 (Pfizer BioNTech)","unknown","1","1","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",63,"54",70,"gamma","gamma",NA,NA,NA,"Canada","CAN",49,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","gamma","30/09/2021",2021-09-30
"263",49,"Nasreen","Test-negative case-control","07Feb2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",90,"76",96,"gamma","gamma","~28 weeks",NA,NA,"Canada","CAN",49,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","gamma","30/09/2021",2021-09-30
"264",49,"Nasreen","Test-negative case-control","07Feb2022","BNT162b2 (Pfizer BioNTech)","unknown","1","1","14+","hospitalization or death","severe","Canada","general pop","general pop",80,"70",87,"gamma","gamma",NA,NA,NA,"Canada","CAN",49,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","gamma","30/09/2021",2021-09-30
"265",49,"Nasreen","Test-negative case-control","07Feb2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","hospitalization or death","severe","Canada","general pop","general pop",94,"59",99,"gamma","gamma","~28 weeks",NA,NA,"Canada","CAN",49,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","gamma","30/09/2021",2021-09-30
"266",49,"Nasreen","Test-negative case-control","07Feb2022","mRNA-1273 (Moderna)","unknown","1","1","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",89,"76",95,"gamma","gamma",NA,NA,NA,"Canada","CAN",49,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","gamma","30/09/2021",2021-09-30
"267",49,"Nasreen","Test-negative case-control","07Feb2022","mRNA-1273 (Moderna)","unknown","2","final","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",100,NA,NA,"gamma","gamma","~25 weeks",NA,NA,"Canada","CAN",49,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","gamma","30/09/2021",2021-09-30
"268",49,"Nasreen","Test-negative case-control","07Feb2022","mRNA-1273 (Moderna)","unknown","1","1","14+","hospitalization or death","severe","Canada","general pop","general pop",88,"63",96,"gamma","gamma",NA,NA,NA,"Canada","CAN",49,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","gamma","30/09/2021",2021-09-30
"269",49,"Nasreen","Test-negative case-control","07Feb2022","mRNA-1273 (Moderna)","unknown","2","final","14+","hospitalization or death","severe","Canada","general pop","general pop",100,NA,NA,"gamma","gamma","~25 weeks",NA,NA,"Canada","CAN",49,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","gamma","30/09/2021",2021-09-30
"270",49,"Nasreen","Test-negative case-control","07Feb2022","AZD1222 (AstraZeneca)","unknown","1","1","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",41,"12",60,"gamma","gamma",NA,NA,NA,"Canada","CAN",49,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","gamma","30/09/2021",2021-09-30
"271",49,"Nasreen","Test-negative case-control","07Feb2022","AZD1222 (AstraZeneca)","unknown","2","final","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",100,NA,NA,"gamma","gamma","~3 weeks",NA,NA,"Canada","CAN",49,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","gamma","30/09/2021",2021-09-30
"272",49,"Nasreen","Test-negative case-control","07Feb2022","AZD1222 (AstraZeneca)","unknown","1","1","14+","hospitalization or death","severe","Canada","general pop","general pop",76,"40",90,"gamma","gamma",NA,NA,NA,"Canada","CAN",49,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","gamma","30/09/2021",2021-09-30
"273",49,"Nasreen","Test-negative case-control","07Feb2022","AZD1222 (AstraZeneca)","unknown","2","final","14+","hospitalization or death","severe","Canada","general pop","general pop",100,NA,NA,"gamma","gamma","~3 weeks",NA,NA,"Canada","CAN",49,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","gamma","30/09/2021",2021-09-30
"274",49,"Nasreen","Test-negative case-control","07Feb2022","BNT162b2 (Pfizer BioNTech)","unknown","1","1","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",57,"53",61,"delta","delta",NA,NA,NA,"Canada","CAN",49,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","30/09/2021",2021-09-30
"275",49,"Nasreen","Test-negative case-control","07Feb2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",92,"89",94,"delta","delta","~28 weeks",NA,NA,"Canada","CAN",49,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","30/09/2021",2021-09-30
"276",49,"Nasreen","Test-negative case-control","07Feb2022","BNT162b2 (Pfizer BioNTech)","unknown","1","1","14+","hospitalization or death","severe","Canada","general pop","general pop",81,"76",85,"delta","delta",NA,NA,NA,"Canada","CAN",49,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","30/09/2021",2021-09-30
"277",49,"Nasreen","Test-negative case-control","07Feb2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","hospitalization or death","severe","Canada","general pop","general pop",98,"96",99,"delta","delta","~28 weeks",NA,NA,"Canada","CAN",49,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","30/09/2021",2021-09-30
"278",49,"Nasreen","Test-negative case-control","07Feb2022","mRNA-1273 (Moderna)","unknown","1","1","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",70,"64",76,"delta","delta",NA,NA,NA,"Canada","CAN",49,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","30/09/2021",2021-09-30
"279",49,"Nasreen","Test-negative case-control","07Feb2022","mRNA-1273 (Moderna)","unknown","2","final","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",94,"90",97,"delta","delta","~25 weeks",NA,NA,"Canada","CAN",49,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","30/09/2021",2021-09-30
"280",49,"Nasreen","Test-negative case-control","07Feb2022","mRNA-1273 (Moderna)","unknown","1","1","14+","hospitalization or death","severe","Canada","general pop","general pop",90,"82",94,"delta","delta",NA,NA,NA,"Canada","CAN",49,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","30/09/2021",2021-09-30
"281",49,"Nasreen","Test-negative case-control","07Feb2022","mRNA-1273 (Moderna)","unknown","2","final","14+","hospitalization or death","severe","Canada","general pop","general pop",98,"93",100,"delta","delta","~25 weeks",NA,NA,"Canada","CAN",49,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","30/09/2021",2021-09-30
"282",49,"Nasreen","Test-negative case-control","07Feb2022","AZD1222 (AstraZeneca)","unknown","1","1","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",68,"57",76,"delta","delta",NA,NA,NA,"Canada","CAN",49,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","30/09/2021",2021-09-30
"283",49,"Nasreen","Test-negative case-control","07Feb2022","AZD1222 (AstraZeneca)","unknown","2","final","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",88,"68",96,"delta","delta","~ 3 weeks",NA,NA,"Canada","CAN",49,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","30/09/2021",2021-09-30
"284",49,"Nasreen","Test-negative case-control","07Feb2022","AZD1222 (AstraZeneca)","unknown","1","1","14+","hospitalization or death","severe","Canada","general pop","general pop",91,"82",96,"delta","delta",NA,NA,NA,"Canada","CAN",49,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","30/09/2021",2021-09-30
"285",49,"Nasreen","Test-negative case-control","07Feb2022","AZD1222 (AstraZeneca)","unknown","2","final","14+","hospitalization or death","severe","Canada","general pop","general pop",90,"67",97,"delta","delta","~3 weeks",NA,NA,"Canada","CAN",49,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","30/09/2021",2021-09-30
"286",50,"Jara","Prospective cohort","07Jul2021","CoronaVac (Sinovac)","excluded","1","1","14+","infection ","infection","Chile","general pop","general pop",15.5,"14.2",16.8,NA,"alpha & gamma",NA,NA,NA,"Chile","CHL",50,"CHL",24650,2019,"Chile","Latin America & Caribbean","High income",3,"South America",2020-12-25,2021-05-25,2021-09-02,2020-12-21,2020-12-21,4,13,155,255,"who",13,"before jan/2021","<30","before Jun/2021","<180","yes","yes","yes",2021-07-07,"infection","2021 (Jul-Dec)","Sinovac CoronaVac","Inactivated","other combinations",NA,2021-07-07
"287",50,"Jara","Prospective cohort","07Jul2021","CoronaVac (Sinovac)","excluded","2","final","14+","infection ","infection","Chile","general pop","general pop",65.9,"65.2",66.6,NA,"alpha & gamma","8 weeks",NA,NA,"Chile","CHL",50,"CHL",24650,2019,"Chile","Latin America & Caribbean","High income",3,"South America",2020-12-25,2021-05-25,2021-09-02,2020-12-21,2020-12-21,4,13,155,255,"who",13,"before jan/2021","<30","before Jun/2021","<180","yes","yes","yes",2021-07-07,"infection","2021 (Jul-Dec)","Sinovac CoronaVac","Inactivated","other combinations",NA,2021-07-07
"288",50,"Jara","Prospective cohort","07Jul2021","CoronaVac (Sinovac)","excluded","1","1","14+","hospitalization","severe","Chile","general pop","general pop",37.4,"34.9",39.9,NA,"alpha & gamma",NA,NA,NA,"Chile","CHL",50,"CHL",24650,2019,"Chile","Latin America & Caribbean","High income",3,"South America",2020-12-25,2021-05-25,2021-09-02,2020-12-21,2020-12-21,4,13,155,255,"who",13,"before jan/2021","<30","before Jun/2021","<180","yes","yes","yes",2021-07-07,"severe","2021 (Jul-Dec)","Sinovac CoronaVac","Inactivated","other combinations",NA,2021-07-07
"289",50,"Jara","Prospective cohort","07Jul2021","CoronaVac (Sinovac)","excluded","2","final","14+","hospitalization","severe","Chile","general pop","general pop",87.5,"86.7",88.2,NA,"alpha & gamma","8 weeks",NA,NA,"Chile","CHL",50,"CHL",24650,2019,"Chile","Latin America & Caribbean","High income",3,"South America",2020-12-25,2021-05-25,2021-09-02,2020-12-21,2020-12-21,4,13,155,255,"who",13,"before jan/2021","<30","before Jun/2021","<180","yes","yes","yes",2021-07-07,"severe","2021 (Jul-Dec)","Sinovac CoronaVac","Inactivated","other combinations",NA,2021-07-07
"290",50,"Jara","Prospective cohort","07Jul2021","CoronaVac (Sinovac)","excluded","1","1","14+","ICU admission","severe","Chile","general pop","general pop",44.7,"40.8",48.3,NA,"alpha & gamma",NA,NA,NA,"Chile","CHL",50,"CHL",24650,2019,"Chile","Latin America & Caribbean","High income",3,"South America",2020-12-25,2021-05-25,2021-09-02,2020-12-21,2020-12-21,4,13,155,255,"who",13,"before jan/2021","<30","before Jun/2021","<180","yes","yes","yes",2021-07-07,"severe","2021 (Jul-Dec)","Sinovac CoronaVac","Inactivated","other combinations",NA,2021-07-07
"291",50,"Jara","Prospective cohort","07Jul2021","CoronaVac (Sinovac)","excluded","2","final","14+","ICU admission","severe","Chile","general pop","general pop",90.3,"89.1",91.4,NA,"alpha & gamma","8 weeks",NA,NA,"Chile","CHL",50,"CHL",24650,2019,"Chile","Latin America & Caribbean","High income",3,"South America",2020-12-25,2021-05-25,2021-09-02,2020-12-21,2020-12-21,4,13,155,255,"who",13,"before jan/2021","<30","before Jun/2021","<180","yes","yes","yes",2021-07-07,"severe","2021 (Jul-Dec)","Sinovac CoronaVac","Inactivated","other combinations",NA,2021-07-07
"292",50,"Jara","Prospective cohort","07Jul2021","CoronaVac (Sinovac)","excluded","1","1","14+","death","death","Chile","general pop","general pop",45.7,"40.9",50.2,NA,"alpha & gamma",NA,NA,NA,"Chile","CHL",50,"CHL",24650,2019,"Chile","Latin America & Caribbean","High income",3,"South America",2020-12-25,2021-05-25,2021-09-02,2020-12-21,2020-12-21,4,13,155,255,"who",13,"before jan/2021","<30","before Jun/2021","<180","yes","yes","yes",2021-07-07,"death","2021 (Jul-Dec)","Sinovac CoronaVac","Inactivated","other combinations",NA,2021-07-07
"293",50,"Jara","Prospective cohort","07Jul2021","CoronaVac (Sinovac)","excluded","2","final","14+","death","death","Chile","general pop","general pop",86.3,"84.5",87.9,NA,"alpha & gamma","8 weeks",NA,NA,"Chile","CHL",50,"CHL",24650,2019,"Chile","Latin America & Caribbean","High income",3,"South America",2020-12-25,2021-05-25,2021-09-02,2020-12-21,2020-12-21,4,13,155,255,"who",13,"before jan/2021","<30","before Jun/2021","<180","yes","yes","yes",2021-07-07,"death","2021 (Jul-Dec)","Sinovac CoronaVac","Inactivated","other combinations",NA,2021-07-07
"294",51,"Tenforde","Test-negative case-control","06Aug2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","1+","1+","14+ up to 14 days post dose 2","hospitalization","severe","USA","hospital patients","general pop",75.4,"60.4",84.7,NA,"original & alpha",NA,NA,NA,"USA","USA",51,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-08-06,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","08/07/2021",2021-07-08
"295",51,"Tenforde","Test-negative case-control","06Aug2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","hospital patients","general pop",86.6,"79",91.4,NA,"original & alpha","~2 weeks",NA,NA,"USA","USA",51,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-08-06,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","08/07/2021",2021-07-08
"296",51,"Tenforde","Test-negative case-control","06Aug2021","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","hospitalization","severe","USA","hospital patients","general pop",84.7,"74.1",91,NA,"original & alpha","~2 weeks",NA,NA,"USA","USA",51,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-08-06,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","08/07/2021",2021-07-08
"297",51,"Tenforde","Test-negative case-control","06Aug2021","mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","hospital patients","general pop",88.9,"78.7",94,NA,"original & alpha","~2 weeks",NA,NA,"USA","USA",51,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-08-06,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","08/07/2021",2021-07-08
"298",51,"Tenforde","Test-negative case-control","06Aug2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","hospital patients","general pop",92.1,"82.3",96.5,"alpha","alpha","~2 weeks",NA,NA,"USA","USA",51,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-08-06,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha","08/07/2021",2021-07-08
"299",52,"Chemaitelly","Test-negative case-control","09Jul2021","mRNA-1273 (Moderna)","unknown","1","1","14+","infection ","infection","Qatar","general pop","general pop",88.2,"83.8",91.4,"alpha","alpha",NA,NA,NA,"Qatar","QAT",52,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-07-09,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","alpha",NA,2021-07-09
"300",52,"Chemaitelly","Test-negative case-control","09Jul2021","mRNA-1273 (Moderna)","unknown","2","final","14+","infection ","infection","Qatar","general pop","general pop",100,NA,NA,"alpha","alpha","13 weeks",NA,NA,"Qatar","QAT",52,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-07-09,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","alpha",NA,2021-07-09
"301",52,"Chemaitelly","Test-negative case-control","09Jul2021","mRNA-1273 (Moderna)","unknown","1","1","14+","infection ","infection","Qatar","general pop","general pop",68.2,"64.3",71.7,"beta","beta",NA,NA,NA,"Qatar","QAT",52,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-07-09,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","beta",NA,2021-07-09
"302",52,"Chemaitelly","Test-negative case-control","09Jul2021","mRNA-1273 (Moderna)","unknown","2","final","14+","infection ","infection","Qatar","general pop","general pop",96,"90.9",98.2,"beta","beta","13 weeks",NA,NA,"Qatar","QAT",52,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-07-09,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","beta",NA,2021-07-09
"303",52,"Chemaitelly","Test-negative case-control","09Jul2021","mRNA-1273 (Moderna)","unknown","1","1","14+","severe/fatal infection","severe","Qatar","general pop","general pop",83.7,"74.1",89.7,NA,"alpha & beta",NA,NA,NA,"Qatar","QAT",52,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-07-09,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-07-09
"304",52,"Chemaitelly","Test-negative case-control","09Jul2021","mRNA-1273 (Moderna)","unknown","2","final","14+","severe/fatal infection","severe","Qatar","general pop","general pop",89.5,"18.8",98.7,NA,"alpha & beta","13 weeks",NA,NA,"Qatar","QAT",52,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-07-09,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-07-09
"305",52,"Chemaitelly","Test-negative case-control","09Jul2021","mRNA-1273 (Moderna)","unknown","1","1","14+","symptomatic disease","symptomatic","Qatar","general pop","general pop",66,"60.6",70.7,NA,"alpha & beta",NA,NA,NA,"Qatar","QAT",52,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-07-09,"symptomatic","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-07-09
"306",52,"Chemaitelly","Test-negative case-control","09Jul2021","mRNA-1273 (Moderna)","unknown","2","final","14+","symptomatic disease","symptomatic","Qatar","general pop","general pop",98.6,"92",100,NA,"alpha & beta","13 weeks",NA,NA,"Qatar","QAT",52,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-07-09,"symptomatic","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-07-09
"307",52,"Chemaitelly","Test-negative case-control","09Jul2021","mRNA-1273 (Moderna)","unknown","1","1","14+","asymptomatic infection","asymptomatic","Qatar","general pop","general pop",47.3,"37.6",55.5,NA,"alpha & beta",NA,NA,NA,"Qatar","QAT",52,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-07-09,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-07-09
"308",52,"Chemaitelly","Test-negative case-control","09Jul2021","mRNA-1273 (Moderna)","unknown","2","final","14+","asymptomatic infection","asymptomatic","Qatar","general pop","general pop",92.5,"84.8",96.9,NA,"alpha & beta","13 weeks",NA,NA,"Qatar","QAT",52,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-07-09,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-07-09
"309",52,"Chemaitelly","Retrospective cohort","09Jul2021","mRNA-1273 (Moderna)","excluded","2","final","14+","infection ","infection","Qatar","general pop","general pop",100,"82.5",100,"alpha","alpha","13 weeks",NA,NA,"Qatar","QAT",52,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-07-09,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","alpha",NA,2021-07-09
"310",52,"Chemaitelly","Retrospective cohort","09Jul2021","mRNA-1273 (Moderna)","excluded","2","final","14+","infection ","infection","Qatar","general pop","general pop",87.8,"73.4",95.5,"beta","beta","13 weeks",NA,NA,"Qatar","QAT",52,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-07-09,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","beta",NA,2021-07-09
"311",53,"Goldshtein","Retrospective cohort","12Jul2021","BNT162b2 (Pfizer BioNTech)","excluded","1+","1+","11-27 including some with dose 2","infection ","infection","Israel","pregnant women","pregnant persons",54,"33",69,NA,"original & alpha",NA,NA,NA,"Israel","ISR",53,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-07-12,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-07-12
"312",53,"Goldshtein","Retrospective cohort","12Jul2021","BNT162b2 (Pfizer BioNTech)","excluded","1+","1+","28+ including some with dose 2","infection ","infection","Israel","pregnant women","pregnant persons",78,"57",89,NA,"original & alpha",NA,NA,NA,"Israel","ISR",53,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-07-12,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-07-12
"313",54,"Bertollini","Prospective cohort","13Jul2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","infection ","infection","Qatar","general pop","general pop",78,"72",83,NA,"original, alpha & beta","~4 weeks",NA,NA,"Qatar","QAT",54,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-07-13,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-07-13
"314",55,"John","Retrospective cohort","13Jul2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1+","1+","28+ including some with dose 2","infection ","infection","USA","patients with cirrhosis","patients with cirrhosis",64.8,"10.9",86.1,NA,"original & alpha",NA,NA,NA,"USA","USA",55,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-07-13,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-07-13
"315",55,"John","Retrospective cohort","13Jul2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","infection ","infection","USA","patients with cirrhosis","patients with cirrhosis",78.6,"25.5",93.8,NA,"original & alpha","~10 weeks",NA,NA,"USA","USA",55,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-07-13,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-07-13
"316",55,"John","Retrospective cohort","13Jul2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1+","1+","28+ including some with dose 2","hospitalization","severe","USA","patients with cirrhosis","patients with cirrhosis",100,"99.3",100,NA,"original & alpha",NA,NA,NA,"USA","USA",55,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-07-13,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-07-13
"317",55,"John","Retrospective cohort","13Jul2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","hospitalization","severe","USA","patients with cirrhosis","patients with cirrhosis",100,"99",100,NA,"original & alpha","~10 weeks",NA,NA,"USA","USA",55,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-07-13,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-07-13
"318",55,"John","Retrospective cohort","13Jul2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1+","1+","28+ including some with dose 2","death","death","USA","patients with cirrhosis","patients with cirrhosis",100,"99.3",100,NA,"original & alpha",NA,NA,NA,"USA","USA",55,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-07-13,"death","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-07-13
"319",55,"John","Retrospective cohort","13Jul2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","death","death","USA","patients with cirrhosis","patients with cirrhosis",100,"99",100,NA,"original & alpha","~10 weeks",NA,NA,"USA","USA",55,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-07-13,"death","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-07-13
"320",56,"Whitaker","Prospective cohort","02Jan2022","BNT162b2 (Pfizer BioNTech)","included","1","1","28-90","symptomatic disease","symptomatic","UK","16-64 years","16-64 years",64.1,"50.1",74.1,NA,"original & alpha",NA,NA,NA,"UK","GBR",56,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-02,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","09/07/2021",2021-07-09
"321",56,"Whitaker","Prospective cohort","02Jan2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","symptomatic disease","symptomatic","UK","16-64 years","16-64 years",48.6,"-61.5",83.7,NA,"original & alpha","~20 weeks",NA,NA,"UK","GBR",56,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-02,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","09/07/2021",2021-07-09
"322",56,"Whitaker","Prospective cohort","02Jan2022","BNT162b2 (Pfizer BioNTech)","included","1","1","28-90","symptomatic disease","symptomatic","UK",">= 65 years",">= 65 years",57.7,"49.7",64.3,NA,"original & alpha",NA,NA,NA,"UK","GBR",56,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-02,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","09/07/2021",2021-07-09
"323",56,"Whitaker","Prospective cohort","02Jan2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","symptomatic disease","symptomatic","UK",">= 65 years",">= 65 years",84.7,"77.7",89.5,NA,"original & alpha","~20 weeks",NA,NA,"UK","GBR",56,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-02,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","09/07/2021",2021-07-09
"324",56,"Whitaker","Prospective cohort","02Jan2022","BNT162b2 (Pfizer BioNTech)","included","1","1","28-90","symptomatic disease","symptomatic","UK","immunosuprressed","immunocompromised, >= 16 years",24.3,"-5.9",46,NA,"alpha",NA,NA,NA,"UK","GBR",56,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-02,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","09/07/2021",2021-07-09
"325",56,"Whitaker","Prospective cohort","02Jan2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","symptomatic disease","symptomatic","UK","immunosuprressed","immunocompromised, >= 16 years",59.6,"-35.5",86.3,NA,"alpha","~8 weeks",NA,NA,"UK","GBR",56,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-02,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","09/07/2021",2021-07-09
"326",56,"Whitaker","Prospective cohort","02Jan2022","AZD1222 (AstraZeneca)","included","1","1","28-90","symptomatic disease","symptomatic","UK","16-64 years","16-64 years",65.3,"56.2",72.5,NA,"alpha",NA,NA,NA,"UK","GBR",56,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-02,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","09/07/2021",2021-07-09
"327",56,"Whitaker","Prospective cohort","02Jan2022","AZD1222 (AstraZeneca)","included","2","final","14+","symptomatic disease","symptomatic","UK","16-64 years","16-64 years",67.9,"-1.1",89.8,NA,"alpha","~8 weeks",NA,NA,"UK","GBR",56,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-02,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","09/07/2021",2021-07-09
"328",56,"Whitaker","Prospective cohort","02Jan2022","AZD1222 (AstraZeneca)","included","1","1","28-90","symptomatic disease","symptomatic","UK",">= 65 years",">= 65 years",59.8,"49.2",68.2,NA,"alpha",NA,NA,NA,"UK","GBR",56,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-02,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","09/07/2021",2021-07-09
"329",56,"Whitaker","Prospective cohort","02Jan2022","AZD1222 (AstraZeneca)","included","2","final","14+","symptomatic disease","symptomatic","UK",">= 65 years",">= 65 years",81.7,"59.6",91.7,NA,"alpha","~8 weeks",NA,NA,"UK","GBR",56,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-02,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","09/07/2021",2021-07-09
"330",56,"Whitaker","Prospective cohort","02Jan2022","AZD1222 (AstraZeneca)","included","1","1","28-90","symptomatic disease","symptomatic","UK","immunosuprressed","immunocompromised, >= 16 years",22.5,"-15.2",47.9,NA,"alpha",NA,NA,NA,"UK","GBR",56,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-02,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","09/07/2021",2021-07-09
"331",56,"Whitaker","Prospective cohort","02Jan2022","AZD1222 (AstraZeneca)","included","2","final","14+","symptomatic disease","symptomatic","UK","immunosuprressed","immunocompromised, >= 16 years",60,"-63.6",90.2,NA,"alpha","~8 weeks",NA,NA,"UK","GBR",56,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-02,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","09/07/2021",2021-07-09
"332",57,"Prunas","Retrospective cohort","27Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","1+","1+","10+ including <10 days post dose 2","infection ","infection","Israel","HHC of cases","HHC of cases",62.7,"61.5",63.8,NA,"original & alpha",NA,NA,NA,"Israel","ISR",57,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-01-27,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","16/07/2021",2021-07-16
"333",57,"Prunas","Retrospective cohort","27Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","10-90","infection ","infection","Israel","HHC of cases","HHC of cases",89.4,"88.7",90,NA,"original & alpha","~11 weeks",NA,NA,"Israel","ISR",57,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-01-27,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","16/07/2021",2021-07-16
"334",57,"Prunas","Retrospective cohort","27Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","90+","infection ","infection","Israel","HHC of cases","HHC of cases",58.3,"45.8",67.9,NA,"original & alpha","~26.5 weeks",NA,NA,"Israel","ISR",57,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-01-27,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","16/07/2021",2021-07-16
"335",57,"Prunas","Retrospective cohort","27Jan2022","BNT162b2 (Pfizer BioNTech)","1+","1+","1+","10+ including <10 days post dose 2","infection ","infection","Israel","HHC of cases","HHC of cases",72.1,"66.7",75.6,NA,"delta",NA,NA,NA,"Israel","ISR",57,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-01-27,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","16/07/2021",2021-07-16
"336",57,"Prunas","Retrospective cohort","27Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","10-90","infection ","infection","Israel","HHC of cases","HHC of cases",72,"65.9",77,NA,"delta","~11 weeks",NA,NA,"Israel","ISR",57,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-01-27,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","16/07/2021",2021-07-16
"337",57,"Prunas","Retrospective cohort","27Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","90+","infection ","infection","Israel","HHC of cases","HHC of cases",40.2,"37.6",42.6,NA,"delta","~26.5 weeks",NA,NA,"Israel","ISR",57,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-01-27,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","16/07/2021",2021-07-16
"338",58,"Butt","Retrospective cohort","07Oct2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection ","infection","Qatar","pregnant women","pregnant persons",87.7,"43.5",97.3,NA,"alpha & beta","~17 weeks",NA,NA,"Qatar","QAT",58,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-10-07,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","22/06/2021",2021-06-22
"339",58,"Butt","Retrospective cohort","07Oct2021","mRNA-1273 (Moderna)","excluded","2","final","14+","infection ","infection","Qatar","pregnant women","pregnant persons",100,"0",100,NA,"alpha & beta","~17 weeks",NA,NA,"Qatar","QAT",58,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-10-07,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","22/06/2021",2021-06-22
"340",59,"Balicer","Prospective cohort","07Sept2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14-20","infection ","infection","Israel","pregnant women","pregnant persons",67,"40",84,NA,"original & alpha",NA,NA,NA,"Israel","ISR",59,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-07,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","12/07/2021",2021-07-12
"341",59,"Balicer","Prospective cohort","07Sept2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7-56","infection ","infection","Israel","pregnant women","pregnant persons",96,"89",100,NA,"original & alpha","~18 weeks",NA,NA,"Israel","ISR",59,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-07,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","12/07/2021",2021-07-12
"342",59,"Balicer","Prospective cohort","07Sept2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","21-27","infection ","infection","Israel","pregnant women","pregnant persons",71,"33",94,NA,"original & alpha",NA,NA,NA,"Israel","ISR",59,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-07,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","12/07/2021",2021-07-12
"343",59,"Balicer","Prospective cohort","07Sept2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14-20","symptomatic disease","symptomatic","Israel","pregnant women","pregnant persons",66,"32",86,NA,"original & alpha",NA,NA,NA,"Israel","ISR",59,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-07,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","12/07/2021",2021-07-12
"344",59,"Balicer","Prospective cohort","07Sept2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7-56","symptomatic disease","symptomatic","Israel","pregnant women","pregnant persons",97,"91",100,NA,"original & alpha","~18 weeks",NA,NA,"Israel","ISR",59,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-07,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","12/07/2021",2021-07-12
"345",59,"Balicer","Prospective cohort","07Sept2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","21-27","symptomatic disease","symptomatic","Israel","pregnant women","pregnant persons",76,"30",100,NA,"original & alpha",NA,NA,NA,"Israel","ISR",59,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-07,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","12/07/2021",2021-07-12
"346",59,"Balicer","Prospective cohort","07Sept2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7-56","hospitalization","severe","Israel","pregnant women","pregnant persons",89,"43",100,NA,"original & alpha","~18 weeks",NA,NA,"Israel","ISR",59,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-07,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","12/07/2021",2021-07-12
"347",60,"Layan","Prospective cohort","03Mar2022","BNT162b2 (Pfizer BioNTech)","included","2","final","7+","infection ","infection","Israel","HHC of cases","HHC of cases",79,"56",92,NA,"original & alpha","~12 weeks",NA,NA,"Israel","ISR",60,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-03,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","16/07/2021",2021-07-16
"348",61,"Butt","Test-negative case-control","20Jul2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","0+","infection ","infection","USA","general pop","general pop",85,"84.2",85.8,NA,"original & alpha",NA,NA,NA,"USA","USA",61,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-07-20,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-07-20
"349",61,"Butt","Test-negative case-control","20Jul2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","infection ","infection","USA","general pop","general pop",97.1,"96.6",97.5,NA,"original & alpha","~6.5 weeks",NA,NA,"USA","USA",61,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-07-20,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-07-20
"350",61,"Butt","Test-negative case-control","20Jul2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","0+","infection ","infection","USA","general pop","general pop",84,"82.7",85.1,NA,"original & alpha",NA,NA,NA,"USA","USA",61,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-07-20,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-07-20
"351",61,"Butt","Test-negative case-control","20Jul2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7+","infection ","infection","USA","general pop","general pop",96.2,"95.5",96.9,NA,"original & alpha","~6.5 weeks",NA,NA,"USA","USA",61,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-07-20,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-07-20
"352",61,"Butt","Test-negative case-control","20Jul2021","mRNA-1273 (Moderna)","excluded","1","1","0+","infection ","infection","USA","general pop","general pop",85.7,"84.6",86.8,NA,"original & alpha",NA,NA,NA,"USA","USA",61,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-07-20,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-07-20
"353",61,"Butt","Test-negative case-control","20Jul2021","mRNA-1273 (Moderna)","excluded","2","final","7+","infection ","infection","USA","general pop","general pop",98.2,"97.5",98.6,NA,"original & alpha","~6.5 weeks",NA,NA,"USA","USA",61,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-07-20,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-07-20
"354",62,"Lopez Bernal","Test-negative case-control","21Jul2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","21+","symptomatic disease","symptomatic","UK","general pop","general pop",47.5,"41.6",52.8,"alpha","alpha",NA,NA,NA,"UK","GBR",62,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-07-21,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-07-21
"355",62,"Lopez Bernal","Test-negative case-control","21Jul2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease","symptomatic","UK","general pop","general pop",93.7,"91.6",95.3,"alpha","alpha","~17 weeks",NA,NA,"UK","GBR",62,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-07-21,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-07-21
"356",62,"Lopez Bernal","Test-negative case-control","21Jul2021","AZD1222 (AstraZeneca)","excluded","1","1","21+","symptomatic disease","symptomatic","UK","general pop","general pop",48.7,"45.2",51.9,"alpha","alpha",NA,NA,NA,"UK","GBR",62,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-07-21,"symptomatic","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2021-07-21
"357",62,"Lopez Bernal","Test-negative case-control","21Jul2021","AZD1222 (AstraZeneca)","excluded","2","final","14+","symptomatic disease","symptomatic","UK","general pop","general pop",74.5,"68.4",79.4,"alpha","alpha","~17 weeks",NA,NA,"UK","GBR",62,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-07-21,"symptomatic","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2021-07-21
"358",62,"Lopez Bernal","Test-negative case-control","21Jul2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","21+","symptomatic disease","symptomatic","UK","general pop","general pop",35.6,"22.7",46.4,"delta","delta",NA,NA,NA,"UK","GBR",62,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-07-21,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2021-07-21
"359",62,"Lopez Bernal","Test-negative case-control","21Jul2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease","symptomatic","UK","general pop","general pop",88,"85.3",90.1,"delta","delta","~17 weeks",NA,NA,"UK","GBR",62,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-07-21,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2021-07-21
"360",62,"Lopez Bernal","Test-negative case-control","21Jul2021","AZD1222 (AstraZeneca)","excluded","1","1","21+","symptomatic disease","symptomatic","UK","general pop","general pop",30,"24.3",35.3,"delta","delta",NA,NA,NA,"UK","GBR",62,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-07-21,"symptomatic","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2021-07-21
"361",62,"Lopez Bernal","Test-negative case-control","21Jul2021","AZD1222 (AstraZeneca)","excluded","2","final","14+","symptomatic disease","symptomatic","UK","general pop","general pop",67,"61.3",71.8,"delta","delta","~17 weeks",NA,NA,"UK","GBR",62,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-07-21,"symptomatic","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2021-07-21
"362",63,"Kim","Test-negative case-control","08Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","unknown","1+","1+","14+ up to <14 days post dose 2","symptomatic disease","symptomatic","USA","general pop","general pop",75,"55",87,NA,"non-VOC & alpha",NA,NA,NA,"USA","USA",63,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-08,"symptomatic","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","22/07/2021",2021-07-22
"363",63,"Kim","Test-negative case-control","08Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","unknown","2","final","14+","symptomatic disease","symptomatic","USA","general pop","general pop",91,"83",95,NA,"non-VOC & alpha","~18.5 weeks",NA,NA,"USA","USA",63,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-08,"symptomatic","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","22/07/2021",2021-07-22
"364",64,"Hitchings","Test-negative case-control","28Oct2021","AZD1222 (AstraZeneca)","included","1","1","28+","symptomatic disease","symptomatic","Brazil","> 60 years","> 60 years",33.4,"26.4",39.7,NA,"gamma",NA,NA,NA,"Brazil","BRA",64,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2021-10-28,"symptomatic","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","gamma","22/07/2021",2021-07-22
"365",64,"Hitchings","Test-negative case-control","28Oct2021","AZD1222 (AstraZeneca)","included","2","final","14+","symptomatic disease","symptomatic","Brazil","> 60 years","> 60 years",77.9,"69.2",84.2,NA,"gamma","~9.5 weeks",NA,NA,"Brazil","BRA",64,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2021-10-28,"symptomatic","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","gamma","22/07/2021",2021-07-22
"366",64,"Hitchings","Test-negative case-control","28Oct2021","AZD1222 (AstraZeneca)","included","1","1","28+","hospitalization","severe","Brazil","> 60 years","> 60 years",55.1,"46.6",62.2,NA,"gamma",NA,NA,NA,"Brazil","BRA",64,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2021-10-28,"severe","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","gamma","22/07/2021",2021-07-22
"367",64,"Hitchings","Test-negative case-control","28Oct2021","AZD1222 (AstraZeneca)","included","2","final","14+","hospitalization","severe","Brazil","> 60 years","> 60 years",87.6,"78.2",92.9,NA,"gamma","~9.5 weeks",NA,NA,"Brazil","BRA",64,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2021-10-28,"severe","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","gamma","22/07/2021",2021-07-22
"368",64,"Hitchings","Test-negative case-control","28Oct2021","AZD1222 (AstraZeneca)","included","1","1","28+","death","death","Brazil","> 60 years","> 60 years",61.8,"48.9",71.4,NA,"gamma",NA,NA,NA,"Brazil","BRA",64,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2021-10-28,"death","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","gamma","22/07/2021",2021-07-22
"369",64,"Hitchings","Test-negative case-control","28Oct2021","AZD1222 (AstraZeneca)","included","2","final","14+","death","death","Brazil","> 60 years","> 60 years",93.6,"81.9",97.7,NA,"gamma","~9.5 weeks",NA,NA,"Brazil","BRA",64,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2021-10-28,"death","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","gamma","22/07/2021",2021-07-22
"370",65,"Carazo","Test-negative case-control","30Aug2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14+","infection ","infection","Canada","HCW","HCW",70.3,"68.1",72.4,NA,"non-VOC & alpha",NA,NA,NA,"Canada","CAN",65,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-08-30,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","22/07/2021",2021-07-22
"371",65,"Carazo","Test-negative case-control","30Aug2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7+","infection ","infection","Canada","HCW","HCW",85.5,"80.4",89.3,NA,"non-VOC & alpha","~20 weeks",NA,NA,"Canada","CAN",65,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-08-30,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","22/07/2021",2021-07-22
"372",65,"Carazo","Test-negative case-control","30Aug2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14+","symptomatic disease","symptomatic","Canada","HCW","HCW",72.8,"70.5",74.9,NA,"non-VOC & alpha",NA,NA,NA,"Canada","CAN",65,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-08-30,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","22/07/2021",2021-07-22
"373",65,"Carazo","Test-negative case-control","30Aug2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7+","symptomatic disease","symptomatic","Canada","HCW","HCW",92.2,"87.8",95.1,NA,"non-VOC & alpha","~20 weeks",NA,NA,"Canada","CAN",65,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-08-30,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","22/07/2021",2021-07-22
"374",65,"Carazo","Test-negative case-control","30Aug2021","mRNA-1273 (Moderna)","excluded","1","1","14+","infection ","infection","Canada","HCW","HCW",68.7,"59.5",75.9,NA,"non-VOC & alpha",NA,NA,NA,"Canada","CAN",65,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-08-30,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","22/07/2021",2021-07-22
"375",65,"Carazo","Test-negative case-control","30Aug2021","mRNA-1273 (Moderna)","excluded","2","final","7+","infection ","infection","Canada","HCW","HCW",84.1,"34.9",96.1,NA,"non-VOC & alpha","~20 weeks",NA,NA,"Canada","CAN",65,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-08-30,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","22/07/2021",2021-07-22
"376",65,"Carazo","Test-negative case-control","30Aug2021","mRNA-1273 (Moderna)","excluded","1","1","14+","symptomatic disease","symptomatic","Canada","HCW","HCW",80.9,"74.3",85.8,NA,"non-VOC & alpha",NA,NA,NA,"Canada","CAN",65,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-08-30,"symptomatic","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","22/07/2021",2021-07-22
"377",65,"Carazo","Test-negative case-control","30Aug2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","14+","hospitalization","severe","Canada","HCW","HCW",97.2,"92.3",99,NA,"non-VOC & alpha",NA,NA,NA,"Canada","CAN",65,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-08-30,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","22/07/2021",2021-07-22
"378",65,"Carazo","Test-negative case-control","30Aug2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","14+","infection ","infection","Canada","HCW","HCW",60,"53.6",65.5,"alpha","alpha",NA,NA,NA,"Canada","CAN",65,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-08-30,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha","22/07/2021",2021-07-22
"379",65,"Carazo","Test-negative case-control","30Aug2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","infection ","infection","Canada","HCW","HCW",92.6,"87.1",95.8,"alpha","alpha","~20 weeks",NA,NA,"Canada","CAN",65,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-08-30,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha","22/07/2021",2021-07-22
"380",65,"Carazo","Test-negative case-control","30Aug2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","14+","infection ","infection","Canada","HCW","HCW",77,"72.6",80.7,"non-VOC","non-VOC",NA,NA,NA,"Canada","CAN",65,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-08-30,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","original","22/07/2021",2021-07-22
"381",65,"Carazo","Test-negative case-control","30Aug2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","infection ","infection","Canada","HCW","HCW",86.5,"56.8",95.8,"non-VOC","non-VOC","~20 weeks",NA,NA,"Canada","CAN",65,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-08-30,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","original","22/07/2021",2021-07-22
"382",67,"Amirthalingam","Test-negative case-control","10Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","28+","infection ","infection","UK","> 80 years","> 80 years",42,"31",52,NA,"alpha",NA,NA,NA,"UK","GBR",67,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-12-10,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","28/07/2021",2021-07-28
"383",67,"Amirthalingam","Test-negative case-control","10Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection ","infection","UK","> 80 years","> 80 years",77,"56",88,NA,"alpha","~16 weeks","19-29 days",NA,"UK","GBR",67,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-12-10,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","28/07/2021",2021-07-28
"384",67,"Amirthalingam","Test-negative case-control","10Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","2","1","14+","infection ","infection","UK","> 80 years","> 80 years",90,"83",94,NA,"alpha",NA,"65-84 days",NA,"UK","GBR",67,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-12-10,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","28/07/2021",2021-07-28
"385",67,"Amirthalingam","Test-negative case-control","10Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","1","final","28+","infection ","infection","UK","65-79 years","65-79 years",53,"48",58,NA,"alpha","~16 weeks",NA,NA,"UK","GBR",67,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-12-10,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","28/07/2021",2021-07-28
"386",67,"Amirthalingam","Test-negative case-control","10Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection ","infection","UK","65-79 years","65-79 years",77,"66",85,NA,"alpha","~16 weeks","19-29 days",NA,"UK","GBR",67,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-12-10,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","28/07/2021",2021-07-28
"387",67,"Amirthalingam","Test-negative case-control","10Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection ","infection","UK","65-79 years","65-79 years",89,"86",92,NA,"alpha","~16 weeks","65-84 days",NA,"UK","GBR",67,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-12-10,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","28/07/2021",2021-07-28
"388",67,"Amirthalingam","Test-negative case-control","10Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","28+","infection ","infection","UK","50-64 years","50-64 years",51,"47",55,NA,"alpha",NA,NA,NA,"UK","GBR",67,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-12-10,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","28/07/2021",2021-07-28
"389",67,"Amirthalingam","Test-negative case-control","10Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection ","infection","UK","50-64 years","50-64 years",88,"67",96,NA,"alpha","~16 weeks","19-29 days",NA,"UK","GBR",67,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-12-10,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","28/07/2021",2021-07-28
"390",67,"Amirthalingam","Test-negative case-control","10Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection ","infection","UK","50-64 years","50-64 years",92,"91",94,NA,"alpha","~16 weeks","65-84 days",NA,"UK","GBR",67,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-12-10,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","28/07/2021",2021-07-28
"391",67,"Amirthalingam","Test-negative case-control","10Dec2021","AZD1222 (AstraZeneca)","excluded","1","1","28+","infection ","infection","UK","> 80 years","> 80 years",42,"29",53,NA,"alpha",NA,NA,NA,"UK","GBR",67,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-12-10,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","28/07/2021",2021-07-28
"392",67,"Amirthalingam","Test-negative case-control","10Dec2021","AZD1222 (AstraZeneca)","excluded","2","final","14+","infection ","infection","UK","> 80 years","> 80 years",96,"68",99,NA,"alpha","~16 weeks","45-64 days",NA,"UK","GBR",67,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-12-10,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","28/07/2021",2021-07-28
"393",67,"Amirthalingam","Test-negative case-control","10Dec2021","AZD1222 (AstraZeneca)","excluded","2","final","14+","infection ","infection","UK","> 80 years","> 80 years",82,"68",89,NA,"alpha","~16 weeks","65-84 days",NA,"UK","GBR",67,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-12-10,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","28/07/2021",2021-07-28
"394",67,"Amirthalingam","Test-negative case-control","10Dec2021","AZD1222 (AstraZeneca)","excluded","1","1","28+","infection ","infection","UK","65-79 years","65-79 years",52,"46",56,NA,"alpha",NA,NA,NA,"UK","GBR",67,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-12-10,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","28/07/2021",2021-07-28
"395",67,"Amirthalingam","Test-negative case-control","10Dec2021","AZD1222 (AstraZeneca)","excluded","2","final","14+","infection ","infection","UK","65-79 years","65-79 years",73,"25",90,NA,"alpha","~16 weeks","30-44 days",NA,"UK","GBR",67,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-12-10,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","28/07/2021",2021-07-28
"396",67,"Amirthalingam","Test-negative case-control","10Dec2021","AZD1222 (AstraZeneca)","excluded","2","final","14+","infection ","infection","UK","65-79 years","65-79 years",74,"69",79,NA,"alpha","~16 weeks","65-84 days",NA,"UK","GBR",67,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-12-10,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","28/07/2021",2021-07-28
"397",67,"Amirthalingam","Test-negative case-control","10Dec2021","AZD1222 (AstraZeneca)","excluded","1","1","28+","infection ","infection","UK","50-64 years","50-64 years",42,"39",46,NA,"alpha",NA,NA,NA,"UK","GBR",67,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-12-10,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","28/07/2021",2021-07-28
"398",67,"Amirthalingam","Test-negative case-control","10Dec2021","AZD1222 (AstraZeneca)","excluded","2","final","14+","infection ","infection","UK","50-64 years","50-64 years",55,"34",69,NA,"alpha","~16 weeks","30-44 days",NA,"UK","GBR",67,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-12-10,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","28/07/2021",2021-07-28
"399",67,"Amirthalingam","Test-negative case-control","10Dec2021","AZD1222 (AstraZeneca)","excluded","2","final","14+","infection ","infection","UK","50-64 years","50-64 years",77,"74",79,NA,"alpha","~16 weeks","65-84 days",NA,"UK","GBR",67,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-12-10,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","28/07/2021",2021-07-28
"400",68,"Gram","Retrospective cohort","17Dec2021","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","1","1","14-20","infection ","infection","Denmark","general pop","general pop",39,"23",52,NA,"alpha",NA,NA,NA,"Denmark","DNK",68,"DNK",61830,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,8,212,261,"who",8,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-12-17,"infection","2021 (Jul-Dec)","Heterologous platforms","Multiple","alpha","28/07/2021",2021-07-28
"401",68,"Gram","Retrospective cohort","17Dec2021","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","14+","infection ","infection","Denmark","general pop","general pop",88,"83",92,NA,"alpha","~20 weeks",NA,NA,"Denmark","DNK",68,"DNK",61830,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,8,212,261,"who",8,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-12-17,"infection","2021 (Jul-Dec)","Heterologous platforms","Multiple","alpha","28/07/2021",2021-07-28
"402",68,"Gram","Retrospective cohort","17Dec2021","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","1","1","105+","infection ","infection","Denmark","general pop","general pop",-47,"-208",30,NA,"alpha",NA,NA,NA,"Denmark","DNK",68,"DNK",61830,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,8,212,261,"who",8,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-12-17,"infection","2021 (Jul-Dec)","Heterologous platforms","Multiple","alpha","28/07/2021",2021-07-28
"403",68,"Gram","Retrospective cohort","17Dec2021","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","1","1","14+","hospitalization","severe","Denmark","general pop","general pop",93,"80",98,NA,"alpha",NA,NA,NA,"Denmark","DNK",68,"DNK",61830,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,8,212,261,"who",8,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-12-17,"severe","2021 (Jul-Dec)","Heterologous platforms","Multiple","alpha","28/07/2021",2021-07-28
"404",69,"Alali","Retrospective cohort","29Jul2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14+","infection ","infection","Kuwait","HCW","HCW",91.4,"65.1",97.9,NA,"alpha",NA,NA,NA,"Kuwait","KWT",69,"KWT",55930,2019,"Kuwait","Middle East & North Africa","High income",4,"Asia",2020-12-28,2021-11-30,2021-11-30,2020-12-28,2020-12-28,0,20,337,337,"equal",20,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","yes",2021-07-29,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-07-29
"405",69,"Alali","Retrospective cohort","29Jul2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7+","infection ","infection","Kuwait","HCW","HCW",94.5,"89.4",97.2,NA,"alpha","~18 weeks",NA,NA,"Kuwait","KWT",69,"KWT",55930,2019,"Kuwait","Middle East & North Africa","High income",4,"Asia",2020-12-28,2021-11-30,2021-11-30,2020-12-28,2020-12-28,0,20,337,337,"equal",20,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","yes",2021-07-29,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-07-29
"406",69,"Alali","Retrospective cohort","29Jul2021","AZD1222 (AstraZeneca)","excluded","1","1","28+","infection ","infection","Kuwait","HCW","HCW",75.4,"67.2",81.6,NA,"alpha",NA,NA,NA,"Kuwait","KWT",69,"KWT",55930,2019,"Kuwait","Middle East & North Africa","High income",4,"Asia",2020-12-28,2021-11-30,2021-11-30,2020-12-28,2020-12-28,0,20,337,337,"equal",20,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","yes",2021-07-29,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2021-07-29
"407",70,"Lefèvre","Retrospective cohort","31Jul2021","BNT162b2 (Pfizer BioNTech)","included","1+","1+","14+ up to t days after 2nd dose","infection ","infection","France","LTCF residents","LTCF residents",55,"13",76,"beta","beta",NA,NA,NA,"France","FRA",70,"FRA",51580,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,15,204,345,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-07-31,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","beta",NA,2021-07-31
"408",70,"Lefèvre","Retrospective cohort","31Jul2021","BNT162b2 (Pfizer BioNTech)","included","2","final","7+","infection ","infection","France","LTCF residents","LTCF residents",49,"14",69,"beta","beta","~16 weeks",NA,NA,"France","FRA",70,"FRA",51580,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,15,204,345,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-07-31,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","beta",NA,2021-07-31
"409",70,"Lefèvre","Retrospective cohort","31Jul2021","BNT162b2 (Pfizer BioNTech)","included","1+","1+","14+ up to t days after 2nd dose","hospitalization or death","severe","France","LTCF residents","LTCF residents",86,"32",97,"beta","beta",NA,NA,NA,"France","FRA",70,"FRA",51580,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,15,204,345,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-07-31,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","beta",NA,2021-07-31
"410",70,"Lefèvre","Retrospective cohort","31Jul2021","BNT162b2 (Pfizer BioNTech)","included","2","final","7+","hospitalization or death","severe","France","LTCF residents","LTCF residents",86,"67",94,"beta","beta","~16 weeks",NA,NA,"France","FRA",70,"FRA",51580,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,15,204,345,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-07-31,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","beta",NA,2021-07-31
"411",71,"de Gier","Retrospective cohort","05Aug2021","AZD1222 (AstraZeneca)","unknown","1","1","14+","infection ","infection","Netherlands","HHC of cases","HHC of cases",2,"-11",14,NA,"alpha",NA,NA,NA,"Netherlands","NLD",71,"NLD",60460,2019,"Netherlands","Europe & Central Asia","High income",4,"Europe",2021-01-08,2021-07-16,NA,2020-12-30,2020-12-30,9,22,198,NA,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2021-08-05,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2021-08-05
"412",71,"de Gier","Retrospective cohort","05Aug2021","AZD1222 (AstraZeneca)","unknown","2","final","7+","infection ","infection","Netherlands","HHC of cases","HHC of cases",87,"77",93,NA,"alpha","~15 weeks",NA,NA,"Netherlands","NLD",71,"NLD",60460,2019,"Netherlands","Europe & Central Asia","High income",4,"Europe",2021-01-08,2021-07-16,NA,2020-12-30,2020-12-30,9,22,198,NA,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2021-08-05,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2021-08-05
"413",71,"de Gier","Retrospective cohort","05Aug2021","BNT162b2 (Pfizer BioNTech)","unknown","1","1","14+","infection ","infection","Netherlands","HHC of cases","HHC of cases",-18,"-43",2,NA,"alpha",NA,NA,NA,"Netherlands","NLD",71,"NLD",60460,2019,"Netherlands","Europe & Central Asia","High income",4,"Europe",2021-01-08,2021-07-16,NA,2020-12-30,2020-12-30,9,22,198,NA,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2021-08-05,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-08-05
"414",71,"de Gier","Retrospective cohort","05Aug2021","BNT162b2 (Pfizer BioNTech)","unknown","2","final","7+","infection ","infection","Netherlands","HHC of cases","HHC of cases",65,"60",70,NA,"alpha","~15 weeks",NA,NA,"Netherlands","NLD",71,"NLD",60460,2019,"Netherlands","Europe & Central Asia","High income",4,"Europe",2021-01-08,2021-07-16,NA,2020-12-30,2020-12-30,9,22,198,NA,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2021-08-05,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-08-05
"415",71,"de Gier","Retrospective cohort","05Aug2021","mRNA-1273 (Moderna)","unknown","1","1","14+","infection ","infection","Netherlands","HHC of cases","HHC of cases",33,"-27",64,NA,"alpha",NA,NA,NA,"Netherlands","NLD",71,"NLD",60460,2019,"Netherlands","Europe & Central Asia","High income",4,"Europe",2021-01-08,2021-07-16,NA,2020-12-30,2020-12-30,9,22,198,NA,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2021-08-05,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","alpha",NA,2021-08-05
"416",71,"de Gier","Retrospective cohort","05Aug2021","mRNA-1273 (Moderna)","unknown","2","final","7+","infection ","infection","Netherlands","HHC of cases","HHC of cases",91,"79",97,NA,"alpha","~15 weeks",NA,NA,"Netherlands","NLD",71,"NLD",60460,2019,"Netherlands","Europe & Central Asia","High income",4,"Europe",2021-01-08,2021-07-16,NA,2020-12-30,2020-12-30,9,22,198,NA,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2021-08-05,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","alpha",NA,2021-08-05
"417",71,"de Gier","Retrospective cohort","05Aug2021","Ad26.COV2.S (Janssen)","unknown","1","final","14+","infection ","infection","Netherlands","HHC of cases","HHC of cases",12,"-71",54,NA,"alpha","~15 weeks",NA,NA,"Netherlands","NLD",71,"NLD",60460,2019,"Netherlands","Europe & Central Asia","High income",4,"Europe",2021-01-08,2021-07-16,NA,2020-12-30,2020-12-30,9,22,198,NA,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2021-08-05,"infection","2021 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","alpha",NA,2021-08-05
"418",72,"Puranik","Retrospective cohort","09Aug2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","1-7","infection ","infection","USA","general pop","general pop",16,"-20",42,NA,"alpha & delta",NA,NA,NA,"USA","USA",72,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-08-09,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-08-09
"419",72,"Puranik","Retrospective cohort","09Aug2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection ","infection","USA","general pop","general pop",76,"69",81,NA,"alpha & delta","~26 weeks",NA,NA,"USA","USA",72,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-08-09,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-08-09
"420",72,"Puranik","Retrospective cohort","09Aug2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","1-7","hospitalization","severe","USA","general pop","general pop",75,"-30",97.4,NA,"alpha & delta",NA,NA,NA,"USA","USA",72,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-08-09,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-08-09
"421",72,"Puranik","Retrospective cohort","09Aug2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization","severe","USA","general pop","general pop",85,"73",93,NA,"alpha & delta","~26 weeks",NA,NA,"USA","USA",72,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-08-09,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-08-09
"422",72,"Puranik","Retrospective cohort","09Aug2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","1-7","ICU admission","severe","USA","general pop","general pop",100,"-430",100,NA,"alpha & delta",NA,NA,NA,"USA","USA",72,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-08-09,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-08-09
"423",72,"Puranik","Retrospective cohort","09Aug2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","ICU admission","severe","USA","general pop","general pop",87,"46",98.6,NA,"alpha & delta","~26 weeks",NA,NA,"USA","USA",72,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-08-09,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-08-09
"424",72,"Puranik","Retrospective cohort","09Aug2021","mRNA-1273 (Moderna)","excluded","1","1","1-7","infection ","infection","USA","general pop","general pop",-10,"-50",24,NA,"alpha & delta",NA,NA,NA,"USA","USA",72,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-08-09,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-08-09
"425",72,"Puranik","Retrospective cohort","09Aug2021","mRNA-1273 (Moderna)","excluded","2","final","14+","infection ","infection","USA","general pop","general pop",86,"81",90.6,NA,"alpha & delta","~26 weeks",NA,NA,"USA","USA",72,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-08-09,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-08-09
"426",72,"Puranik","Retrospective cohort","09Aug2021","mRNA-1273 (Moderna)","excluded","1","1","1-7","hospitalization","severe","USA","general pop","general pop",25,"-150",79,NA,"alpha & delta",NA,NA,NA,"USA","USA",72,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-08-09,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-08-09
"427",72,"Puranik","Retrospective cohort","09Aug2021","mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization","severe","USA","general pop","general pop",91.6,"81",97,NA,"alpha & delta","~26 weeks",NA,NA,"USA","USA",72,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-08-09,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-08-09
"428",72,"Puranik","Retrospective cohort","09Aug2021","mRNA-1273 (Moderna)","excluded","1","1","1-7","ICU admission","severe","USA","general pop","general pop",100,"-430",100,NA,"alpha & delta",NA,NA,NA,"USA","USA",72,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-08-09,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-08-09
"429",72,"Puranik","Retrospective cohort","09Aug2021","mRNA-1273 (Moderna)","excluded","2","final","14+","ICU admission","severe","USA","general pop","general pop",93.3,"57",99.8,NA,"alpha & delta","~26 weeks",NA,NA,"USA","USA",72,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-08-09,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-08-09
"430",73,"Chemaitelly","Retrospective cohort","09Aug2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","infection ","infection","Qatar","transplant patients","transplant patients",46.6,"0",73.7,NA,"alpha & beta","~17 weeks",NA,NA,"Qatar","QAT",73,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-08-09,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-08-09
"431",73,"Chemaitelly","Retrospective cohort","09Aug2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","42+","infection ","infection","Qatar","transplant patients","transplant patients",66,"21.3",85.3,NA,"alpha & beta","~17 weeks",NA,NA,"Qatar","QAT",73,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-08-09,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-08-09
"432",73,"Chemaitelly","Retrospective cohort","09Aug2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","56+","infection ","infection","Qatar","transplant patients","transplant patients",73.9,"33",89.9,NA,"alpha & beta","~17 weeks",NA,NA,"Qatar","QAT",73,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-08-09,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-08-09
"433",73,"Chemaitelly","Retrospective cohort","09Aug2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","severe infection","severe","Qatar","transplant patients","transplant patients",72.3,"0",90.9,NA,"alpha & beta","~17 weeks",NA,NA,"Qatar","QAT",73,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-08-09,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-08-09
"434",73,"Chemaitelly","Retrospective cohort","09Aug2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","42+","severe infection","severe","Qatar","transplant patients","transplant patients",85,"35.7",96.5,NA,"alpha & beta","~17 weeks",NA,NA,"Qatar","QAT",73,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-08-09,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-08-09
"435",73,"Chemaitelly","Retrospective cohort","09Aug2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","56+","severe infection","severe","Qatar","transplant patients","transplant patients",83.8,"31.3",96.2,NA,"alpha & beta","~17 weeks",NA,NA,"Qatar","QAT",73,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-08-09,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-08-09
"436",74,"Tang","Test-negative case-control","02Nov2021","BNT162b2 (Pfizer BioNTech)","included","1","1","14+","infection ","infection","Qatar","general pop","general pop",42.8,"18.2",60.1,"delta","delta",NA,NA,NA,"Qatar","QAT",74,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-11-02,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","11/08/2021",2021-08-11
"437",74,"Tang","Test-negative case-control","02Nov2021","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection ","infection","Qatar","general pop","general pop",50.6,"45.4",55.3,"delta","delta","~25 weeks",NA,NA,"Qatar","QAT",74,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-11-02,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","11/08/2021",2021-08-11
"438",74,"Tang","Test-negative case-control","02Nov2021","mRNA-1273 (Moderna)","included","1","1","14+","infection ","infection","Qatar","general pop","general pop",73.2,"57.3",83.2,"delta","delta",NA,NA,NA,"Qatar","QAT",74,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-11-02,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","11/08/2021",2021-08-11
"439",74,"Tang","Test-negative case-control","02Nov2021","mRNA-1273 (Moderna)","included","2","final","14+","infection ","infection","Qatar","general pop","general pop",72,"66.1",76.9,"delta","delta","~25 weeks",NA,NA,"Qatar","QAT",74,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-11-02,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","11/08/2021",2021-08-11
"440",74,"Tang","Test-negative case-control","02Nov2021","BNT162b2 (Pfizer BioNTech)","included","1","1","14+","severe, critical, fatal disease","severe","Qatar","general pop","general pop",84.5,"-25.2",98.1,"delta","delta",NA,NA,NA,"Qatar","QAT",74,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-11-02,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","11/08/2021",2021-08-11
"441",74,"Tang","Test-negative case-control","02Nov2021","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","severe, critical, fatal disease","severe","Qatar","general pop","general pop",94.1,"85.9",97.6,"delta","delta","~25 weeks",NA,NA,"Qatar","QAT",74,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-11-02,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","11/08/2021",2021-08-11
"442",74,"Tang","Test-negative case-control","02Nov2021","mRNA-1273 (Moderna)","included","1","1","14+","severe, critical, fatal disease","severe","Qatar","general pop","general pop",87.5,"23.4",95.8,"delta","delta",NA,NA,NA,"Qatar","QAT",74,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-11-02,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","11/08/2021",2021-08-11
"443",74,"Tang","Test-negative case-control","02Nov2021","mRNA-1273 (Moderna)","included","2","final","14+","severe, critical, fatal disease","severe","Qatar","general pop","general pop",96.1,"71.4",99.5,"delta","delta","~25 weeks",NA,NA,"Qatar","QAT",74,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-11-02,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","11/08/2021",2021-08-11
"444",74,"Tang","Test-negative case-control","02Nov2021","BNT162b2 (Pfizer BioNTech)","included","1","1","14+","symptomatic disease","symptomatic","Qatar","general pop","general pop",56.2,"30.6",72.4,"delta","delta",NA,NA,NA,"Qatar","QAT",74,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-11-02,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","11/08/2021",2021-08-11
"445",74,"Tang","Test-negative case-control","02Nov2021","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","symptomatic disease","symptomatic","Qatar","general pop","general pop",44.4,"37",50.9,"delta","delta","~25 weeks",NA,NA,"Qatar","QAT",74,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-11-02,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","11/08/2021",2021-08-11
"446",74,"Tang","Test-negative case-control","02Nov2021","mRNA-1273 (Moderna)","included","1","1","14+","symptomatic disease","symptomatic","Qatar","general pop","general pop",82.5,"65.2",91.2,"delta","delta",NA,NA,NA,"Qatar","QAT",74,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-11-02,"symptomatic","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","11/08/2021",2021-08-11
"447",74,"Tang","Test-negative case-control","02Nov2021","mRNA-1273 (Moderna)","included","2","final","14+","symptomatic disease","symptomatic","Qatar","general pop","general pop",73.9,"65.9",79.9,"delta","delta","~25 weeks",NA,NA,"Qatar","QAT",74,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-11-02,"symptomatic","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","11/08/2021",2021-08-11
"448",74,"Tang","Test-negative case-control","02Nov2021","BNT162b2 (Pfizer BioNTech)","included","1","1","14+","asymptomatic infection","asymptomatic","Qatar","general pop","general pop",46.7,"-56.2",81.8,"delta","delta",NA,NA,NA,"Qatar","QAT",74,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-11-02,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","11/08/2021",2021-08-11
"449",74,"Tang","Test-negative case-control","02Nov2021","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","asymptomatic infection","asymptomatic","Qatar","general pop","general pop",46,"32.3",56.9,"delta","delta","~25 weeks",NA,NA,"Qatar","QAT",74,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-11-02,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","11/08/2021",2021-08-11
"450",74,"Tang","Test-negative case-control","02Nov2021","mRNA-1273 (Moderna)","included","1","1","14+","asymptomatic infection","asymptomatic","Qatar","general pop","general pop",61.8,"-9.6",86.7,"delta","delta",NA,NA,NA,"Qatar","QAT",74,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-11-02,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","11/08/2021",2021-08-11
"451",74,"Tang","Test-negative case-control","02Nov2021","mRNA-1273 (Moderna)","included","2","final","14+","asymptomatic infection","asymptomatic","Qatar","general pop","general pop",53.6,"33.4",67.6,"delta","delta","~25 weeks",NA,NA,"Qatar","QAT",74,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-11-02,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","11/08/2021",2021-08-11
"452",74,"Tang","Test-negative case-control","02Nov2021","BNT162b2 (Pfizer BioNTech)","included","1","1","14+","infection ","infection","Qatar","general pop","general pop",18.9,"-1.8",35.4,"beta","beta",NA,NA,NA,"Qatar","QAT",74,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-11-02,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","beta","11/08/2021",2021-08-11
"453",74,"Tang","Test-negative case-control","02Nov2021","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection ","infection","Qatar","general pop","general pop",74.3,"70.3",77.7,"beta","beta","~25 weeks",NA,NA,"Qatar","QAT",74,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-11-02,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","beta","11/08/2021",2021-08-11
"454",74,"Tang","Test-negative case-control","02Nov2021","mRNA-1273 (Moderna)","included","1","1","14+","infection ","infection","Qatar","general pop","general pop",66.3,"55.8",74.2,"beta","beta",NA,NA,NA,"Qatar","QAT",74,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-11-02,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","beta","11/08/2021",2021-08-11
"455",74,"Tang","Test-negative case-control","02Nov2021","mRNA-1273 (Moderna)","included","2","final","14+","infection ","infection","Qatar","general pop","general pop",80.8,"69",88.2,"beta","beta","~25 weeks",NA,NA,"Qatar","QAT",74,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-11-02,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","beta","11/08/2021",2021-08-11
"456",74,"Tang","Test-negative case-control","02Nov2021","BNT162b2 (Pfizer BioNTech)","included","1","1","14+","severe, critical, fatal disease","severe","Qatar","general pop","general pop",74.8,"-7.6",94.1,"beta","beta",NA,NA,NA,"Qatar","QAT",74,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-11-02,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","beta","11/08/2021",2021-08-11
"457",74,"Tang","Test-negative case-control","02Nov2021","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","severe, critical, fatal disease","severe","Qatar","general pop","general pop",92.7,"81.5",97.1,"beta","beta","~25 weeks",NA,NA,"Qatar","QAT",74,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-11-02,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","beta","11/08/2021",2021-08-11
"458",74,"Tang","Test-negative case-control","02Nov2021","mRNA-1273 (Moderna)","included","1","1","14+","severe, critical, fatal disease","severe","Qatar","general pop","general pop",72.5,"7.7",91.8,"beta","beta",NA,NA,NA,"Qatar","QAT",74,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-11-02,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","beta","11/08/2021",2021-08-11
"459",74,"Tang","Test-negative case-control","02Nov2021","mRNA-1273 (Moderna)","included","2","final","14+","severe, critical, fatal disease","severe","Qatar","general pop","general pop",100,NA,NA,"beta","beta","~25 weeks",NA,NA,"Qatar","QAT",74,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-11-02,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","beta","11/08/2021",2021-08-11
"460",75,"Nanduri","Retrospective cohort","18Aug2021","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","infection ","infection","USA","SNF residents","SNF residents",74.2,"69",78.7,NA,"non-VOC & alpha","~16 weeks",NA,NA,"USA","USA",75,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-08-18,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-08-18
"461",75,"Nanduri","Retrospective cohort","18Aug2021","mRNA-1273 (Moderna)","unknown","2","final","14+","infection ","infection","USA","SNF residents","SNF residents",74.7,"66.2",81.1,NA,"non-VOC & alpha","~16 weeks",NA,NA,"USA","USA",75,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-08-18,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-08-18
"462",75,"Nanduri","Retrospective cohort","18Aug2021","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","infection ","infection","USA","SNF residents","SNF residents",66.5,"58.3",73.1,NA,"alpha","~22 weeks",NA,NA,"USA","USA",75,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-08-18,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-08-18
"463",75,"Nanduri","Retrospective cohort","18Aug2021","mRNA-1273 (Moderna)","unknown","2","final","14+","infection ","infection","USA","SNF residents","SNF residents",70.4,"60.1",78,NA,"alpha","~22 weeks",NA,NA,"USA","USA",75,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-08-18,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","alpha",NA,2021-08-18
"464",75,"Nanduri","Retrospective cohort","18Aug2021","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","infection ","infection","USA","SNF residents","SNF residents",52.4,"48",56.4,NA,"delta","~25 weeks",NA,NA,"USA","USA",75,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-08-18,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2021-08-18
"465",75,"Nanduri","Retrospective cohort","18Aug2021","mRNA-1273 (Moderna)","unknown","2","final","14+","infection ","infection","USA","SNF residents","SNF residents",50.6,"45",55.7,NA,"delta","~25 weeks",NA,NA,"USA","USA",75,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-08-18,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2021-08-18
"466",76,"Chin","Retrospective cohort","27Jan2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","14+","infection ","infection","USA","incarcerated persons","incarcerated persons",74,"64",82,NA,"non-VOC",NA,NA,NA,"USA","USA",76,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-01-27,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","original","18/08/2021",2021-08-18
"467",76,"Chin","Retrospective cohort","27Jan2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","infection ","infection","USA","incarcerated persons","incarcerated persons",97,"88",99,NA,"non-VOC","~5 weeks",NA,NA,"USA","USA",76,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-01-27,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","original","18/08/2021",2021-08-18
"468",76,"Chin","Retrospective cohort","27Jan2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","14+","infection ","infection","USA","incarcerated persons, moderate/high risk for severe disease","incarcerated persons, moderate/high risk for severe disease",74,"62",82,NA,"non-VOC",NA,NA,NA,"USA","USA",76,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-01-27,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","original","18/08/2021",2021-08-18
"469",76,"Chin","Retrospective cohort","27Jan2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","infection ","infection","USA","incarcerated persons, moderate/high risk for severe disease","incarcerated persons, moderate/high risk for severe disease",92,"74",98,NA,"non-VOC","~5 weeks",NA,NA,"USA","USA",76,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-01-27,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","original","18/08/2021",2021-08-18
"470",76,"Chin","Retrospective cohort","27Jan2022","mRNA-1273 (Moderna)","excluded","1","1","14+","infection ","infection","USA","incarcerated persons","incarcerated persons",71,"58",80,NA,"non-VOC",NA,NA,NA,"USA","USA",76,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-01-27,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","original","18/08/2021",2021-08-18
"471",76,"Chin","Retrospective cohort","27Jan2022","mRNA-1273 (Moderna)","excluded","2","final","14+","infection ","infection","USA","incarcerated persons","incarcerated persons",96,"67",99,NA,"non-VOC","~5 weeks",NA,NA,"USA","USA",76,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-01-27,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","original","18/08/2021",2021-08-18
"472",77,"Tenforde","Case-control","04Nov2021","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","hospitalization","severe","USA","general pop","general pop",81,"77",84,NA,"alpha & delta","~30 weeks",NA,NA,"USA","USA",77,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-11-04,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","18/08/2021",2021-08-18
"473",77,"Tenforde","Case-control","04Nov2021","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14-120","hospitalization","severe","USA","general pop","general pop",85,"82",88,NA,"alpha & delta",NA,NA,NA,"USA","USA",77,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-11-04,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","18/08/2021",2021-08-18
"474",77,"Tenforde","Case-control","04Nov2021","BNT162b2 (Pfizer BioNTech)","unknown","2","final","120+","hospitalization","severe","USA","general pop","general pop",64,"51",73,NA,"alpha & delta","~30 weeks",NA,NA,"USA","USA",77,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-11-04,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","18/08/2021",2021-08-18
"475",77,"Tenforde","Case-control","04Nov2021","mRNA-1273 (Moderna)","unknown","2","final","14+","hospitalization","severe","USA","general pop","general pop",89,"86",92,NA,"alpha & delta","~30 weeks",NA,NA,"USA","USA",77,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-11-04,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","18/08/2021",2021-08-18
"476",77,"Tenforde","Case-control","04Nov2021","mRNA-1273 (Moderna)","unknown","2","final","14-120","hospitalization","severe","USA","general pop","general pop",91,"87",93,NA,"alpha & delta",NA,NA,NA,"USA","USA",77,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-11-04,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","18/08/2021",2021-08-18
"477",77,"Tenforde","Case-control","04Nov2021","mRNA-1273 (Moderna)","unknown","2","final","120+","hospitalization","severe","USA","general pop","general pop",85,"77",91,NA,"alpha & delta","~30 weeks",NA,NA,"USA","USA",77,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-11-04,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","18/08/2021",2021-08-18
"478",77,"Tenforde","Case-control","04Nov2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","unknown","2","final","14+","hospitalization","severe","USA","immunocompetent adults","immunocompetent adults",90,"87",91,NA,"alpha & delta","~30 weeks",NA,NA,"USA","USA",77,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-11-04,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","18/08/2021",2021-08-18
"479",77,"Tenforde","Case-control","04Nov2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","unknown","2","final","14+","hospitalization","severe","USA","immucompromised","immunocompromised, >= 16 years",51,"31",65,NA,"alpha & delta","~30 weeks",NA,NA,"USA","USA",77,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-11-04,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","18/08/2021",2021-08-18
"480",77,"Tenforde","Case-control","04Nov2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","unknown","2","final","14+","hospitalization","severe","USA","general pop","general pop",90,"84",94,"alpha","alpha","~30 weeks",NA,NA,"USA","USA",77,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-11-04,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha","18/08/2021",2021-08-18
"481",77,"Tenforde","Case-control","04Nov2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","unknown","2","final","14+","hospitalization","severe","USA","general pop","general pop",86,"79",90,"delta","delta","~30 weeks",NA,NA,"USA","USA",77,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-11-04,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta","18/08/2021",2021-08-18
"482",78,"Pouwels","Prospective cohort","14Oct2021","BNT162b2 (Pfizer BioNTech)","included","1","1","21+","infection ","infection","UK","general pop","general pop",59,"52",95,NA,"alpha",NA,NA,NA,"UK","GBR",78,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-10-14,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","18/08/2021",2021-08-18
"483",78,"Pouwels","Prospective cohort","14Oct2021","BNT162b2 (Pfizer BioNTech)","included","1","1","21+","infection, ct<30","infection","UK","general pop","general pop",70,"65",74,NA,"alpha",NA,NA,NA,"UK","GBR",78,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-10-14,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","18/08/2021",2021-08-18
"484",78,"Pouwels","Prospective cohort","14Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection ","infection","UK","general pop","general pop",78,"68",84,NA,"alpha","~28 weeks",NA,NA,"UK","GBR",78,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-10-14,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","18/08/2021",2021-08-18
"485",78,"Pouwels","Prospective cohort","14Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection, ct<30","infection","UK","general pop","general pop",94,"94",96,NA,"alpha","~28 weeks",NA,NA,"UK","GBR",78,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-10-14,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","18/08/2021",2021-08-18
"486",78,"Pouwels","Prospective cohort","14Oct2021","AZD1222 (AstraZeneca)","included","1","1","21+","infection ","infection","UK","general pop","general pop",63,"55",69,NA,"alpha",NA,NA,NA,"UK","GBR",78,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-10-14,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","18/08/2021",2021-08-18
"487",78,"Pouwels","Prospective cohort","14Oct2021","AZD1222 (AstraZeneca)","included","1","1","21+","infection, ct<30","infection","UK","general pop","general pop",74,"69",79,NA,"alpha",NA,NA,NA,"UK","GBR",78,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-10-14,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","18/08/2021",2021-08-18
"488",78,"Pouwels","Prospective cohort","14Oct2021","AZD1222 (AstraZeneca)","included","2","final","14+","infection ","infection","UK","general pop","general pop",79,"56",90,NA,"alpha","~28 weeks",NA,NA,"UK","GBR",78,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-10-14,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","18/08/2021",2021-08-18
"489",78,"Pouwels","Prospective cohort","14Oct2021","AZD1222 (AstraZeneca)","included","2","final","14+","infection, ct<30","infection","UK","general pop","general pop",86,"71",93,NA,"alpha","~28 weeks",NA,NA,"UK","GBR",78,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-10-14,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","18/08/2021",2021-08-18
"490",78,"Pouwels","Prospective cohort","14Oct2021","BNT162b2 (Pfizer BioNTech)","included","1","1","21+","infection ","infection","UK","general pop","general pop",57,"50",63,NA,"delta",NA,NA,NA,"UK","GBR",78,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-10-14,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","18/08/2021",2021-08-18
"491",78,"Pouwels","Prospective cohort","14Oct2021","BNT162b2 (Pfizer BioNTech)","included","1","1","21+","infection, ct<30","infection","UK","general pop","general pop",62,"56",68,NA,"delta",NA,NA,NA,"UK","GBR",78,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-10-14,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","18/08/2021",2021-08-18
"492",78,"Pouwels","Prospective cohort","14Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection ","infection","UK","general pop","general pop",80,"77",83,NA,"delta","~28 weeks",NA,NA,"UK","GBR",78,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-10-14,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","18/08/2021",2021-08-18
"493",78,"Pouwels","Prospective cohort","14Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection, ct<30","infection","UK","general pop","general pop",84,"82",86,NA,"delta","~28 weeks",NA,NA,"UK","GBR",78,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-10-14,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","18/08/2021",2021-08-18
"494",78,"Pouwels","Prospective cohort","14Oct2021","AZD1222 (AstraZeneca)","included","1","1","21+","infection ","infection","UK","general pop","general pop",46,"35",55,NA,"delta",NA,NA,NA,"UK","GBR",78,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-10-14,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","18/08/2021",2021-08-18
"495",78,"Pouwels","Prospective cohort","14Oct2021","AZD1222 (AstraZeneca)","included","1","1","21+","infection, ct<30","infection","UK","general pop","general pop",50,"41",59,NA,"delta",NA,NA,NA,"UK","GBR",78,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-10-14,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","18/08/2021",2021-08-18
"496",78,"Pouwels","Prospective cohort","14Oct2021","AZD1222 (AstraZeneca)","included","2","final","14+","infection ","infection","UK","general pop","general pop",67,"62",71,NA,"delta","~28 weeks",NA,NA,"UK","GBR",78,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-10-14,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","18/08/2021",2021-08-18
"497",78,"Pouwels","Prospective cohort","14Oct2021","AZD1222 (AstraZeneca)","included","2","final","14+","infection, ct<30","infection","UK","general pop","general pop",70,"65",73,NA,"delta","~28 weeks",NA,NA,"UK","GBR",78,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-10-14,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","18/08/2021",2021-08-18
"498",79,"Prasad","Retrospective cohort","19Aug2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","post-operative infection","infection","USA","surgery patients","surgery patients",91,"56",99,NA,"non-VOC","~8 weeks",NA,NA,"USA","USA",79,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-08-19,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","original",NA,2021-08-19
"499",80,"Tartof","Retrospective cohort","16Oct2021","BNT162b2 (Pfizer BioNTech)","included","1","1","14+","infection","infection","USA",">= 12 years","general pop",58,"54",61,NA,"epsilon & alpha & delta",NA,NA,NA,"USA","USA",80,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-10-16,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/08/2021",2021-08-23
"500",80,"Tartof","Retrospective cohort","16Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","7+","infection ","infection","USA",">= 12 years","general pop",73,"72",74,NA,"epsilon & alpha & delta","~29 weeks",NA,NA,"USA","USA",80,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-10-16,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/08/2021",2021-08-23
"501",80,"Tartof","Retrospective cohort","16Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","7-36","infection","infection","USA",">= 12 years","general pop",88,"86",89,NA,"epsilon & alpha & delta","~3 weeks",NA,NA,"USA","USA",80,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-10-16,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/08/2021",2021-08-23
"502",80,"Tartof","Retrospective cohort","16Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","157+","infection","infection","USA",">= 12 years","general pop",47,"43",51,NA,"epsilon & alpha & delta","~29 weeks",NA,NA,"USA","USA",80,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-10-16,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/08/2021",2021-08-23
"503",80,"Tartof","Retrospective cohort","16Oct2021","BNT162b2 (Pfizer BioNTech)","included","1","1","14+","hospitalization","severe","USA",">= 12 years","general pop",54,"43",63,NA,"epsilon & alpha & delta",NA,NA,NA,"USA","USA",80,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-10-16,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/08/2021",2021-08-23
"504",80,"Tartof","Retrospective cohort","16Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","7+","hospitalization","severe","USA",">= 12 years","general pop",90,"89",92,NA,"epsilon & alpha & delta","~29 weeks",NA,NA,"USA","USA",80,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-10-16,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/08/2021",2021-08-23
"505",80,"Tartof","Retrospective cohort","16Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","7-36","hospitalization","severe","USA",">= 12 years","general pop",87,"82",91,NA,"epsilon & alpha & delta","~3 weeks",NA,NA,"USA","USA",80,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-10-16,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/08/2021",2021-08-23
"506",80,"Tartof","Retrospective cohort","16Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","157+","hospitalization","severe","USA",">= 12 years","general pop",88,"82",92,NA,"epsilon & alpha & delta","~29 weeks",NA,NA,"USA","USA",80,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-10-16,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/08/2021",2021-08-23
"507",80,"Tartof","Retrospective cohort","16Oct2021","BNT162b2 (Pfizer BioNTech)","included","1","1","14+","infection ","infection","USA",">= 12 years","general pop",74,"55",85,"delta","delta",NA,NA,NA,"USA","USA",80,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-10-16,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","23/08/2021",2021-08-23
"508",80,"Tartof","Retrospective cohort","16Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","7+","infection ","infection","USA",">= 12 years","general pop",75,"71",78,"delta","delta","~29 weeks",NA,NA,"USA","USA",80,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-10-16,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","23/08/2021",2021-08-23
"509",80,"Tartof","Retrospective cohort","16Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","7-36","infection","infection","USA",">= 12 years","general pop",93,"85",97,"delta","delta","~3 weeks",NA,NA,"USA","USA",80,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-10-16,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","23/08/2021",2021-08-23
"510",80,"Tartof","Retrospective cohort","16Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","127+","infection","infection","USA",">= 12 years","general pop",53,"39",65,"delta","delta","~29 weeks",NA,NA,"USA","USA",80,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-10-16,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","23/08/2021",2021-08-23
"511",80,"Tartof","Retrospective cohort","16Oct2021","BNT162b2 (Pfizer BioNTech)","included","1","1","14+","hospitalization","severe","USA",">= 12 years","general pop",79,"-49",97,"delta","delta",NA,NA,NA,"USA","USA",80,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-10-16,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","23/08/2021",2021-08-23
"512",80,"Tartof","Retrospective cohort","16Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","7+","hospitalization","severe","USA",">= 12 years","general pop",93,"84",96,"delta","delta","~29 weeks",NA,NA,"USA","USA",80,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-10-16,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","23/08/2021",2021-08-23
"513",80,"Tartof","Retrospective cohort","16Oct2021","BNT162b2 (Pfizer BioNTech)","included","1","1","14+","infection ","infection","USA",">= 12 years","general pop",74,"64",81,"non-delta","non-delta",NA,NA,NA,"USA","USA",80,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-10-16,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/08/2021",2021-08-23
"514",80,"Tartof","Retrospective cohort","16Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","7+","infection ","infection","USA",">= 12 years","general pop",91,"88",92,"non-delta","non-delta","~29 weeks",NA,NA,"USA","USA",80,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-10-16,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/08/2021",2021-08-23
"515",80,"Tartof","Retrospective cohort","16Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","7-36","infection","infection","USA",">= 12 years","general pop",97,"95",99,"non-delta","non-delta","~3 weeks",NA,NA,"USA","USA",80,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-10-16,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/08/2021",2021-08-23
"516",80,"Tartof","Retrospective cohort","16Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","127+","infection","infection","USA",">= 12 years","general pop",67,"45",80,"non-delta","non-delta","~29 weeks",NA,NA,"USA","USA",80,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-10-16,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/08/2021",2021-08-23
"517",80,"Tartof","Retrospective cohort","16Oct2021","BNT162b2 (Pfizer BioNTech)","included","1","1","14+","hospitalization","severe","USA",">= 12 years","general pop",75,"21",92,"non-delta","non-delta",NA,NA,NA,"USA","USA",80,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-10-16,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/08/2021",2021-08-23
"518",80,"Tartof","Retrospective cohort","16Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","7+","hospitalization","severe","USA",">= 12 years","general pop",95,"90",98,"non-delta","non-delta","~29 weeks",NA,NA,"USA","USA",80,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-10-16,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/08/2021",2021-08-23
"519",81,"Golberg","Retrospective cohort","27Oct2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","168-203","infection","infection","Israel","16-39 years","16-39 years",55,"50",60,NA,"delta","28 weeks",NA,NA,"Israel","ISR",81,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-10-27,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","25/08/2021",2021-08-25
"520",81,"Golberg","Retrospective cohort","27Oct2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","55-98","infection","infection","Israel","16-39 years","16-39 years",80,"75",84,NA,"delta","13 weeks",NA,NA,"Israel","ISR",81,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-10-27,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","25/08/2021",2021-08-25
"521",81,"Golberg","Retrospective cohort","27Oct2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","168-203","infection","infection","Israel","40-59 years","40-59 years",57,"53",61,NA,"delta","28 weeks",NA,NA,"Israel","ISR",81,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-10-27,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","25/08/2021",2021-08-25
"522",81,"Golberg","Retrospective cohort","27Oct2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","55-98","infection","infection","Israel","40-59 years","40-59 years",83,"75",88,NA,"delta","13 weeks",NA,NA,"Israel","ISR",81,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-10-27,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","25/08/2021",2021-08-25
"523",81,"Golberg","Retrospective cohort","27Oct2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","168-203","infection","infection","Israel",">= 60 years",">= 60 years",57,"52",62,NA,"delta","28 weeks",NA,NA,"Israel","ISR",81,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-10-27,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","25/08/2021",2021-08-25
"524",81,"Golberg","Retrospective cohort","27Oct2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","55-98","infection","infection","Israel",">= 60 years",">= 60 years",82,"70",89,NA,"delta","13 weeks",NA,NA,"Israel","ISR",81,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-10-27,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","25/08/2021",2021-08-25
"525",81,"Golberg","Retrospective cohort","27Oct2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","168-203","severe disease","severe","Israel","40-59 years","40-59 years",98,"94",99,NA,"delta","28 weeks",NA,NA,"Israel","ISR",81,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-10-27,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","25/08/2021",2021-08-25
"526",81,"Golberg","Retrospective cohort","27Oct2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","168-203","severe disease","severe","Israel",">= 60 years",">= 60 years",93,"86",97,NA,"delta","13 weeks",NA,NA,"Israel","ISR",81,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-10-27,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","25/08/2021",2021-08-25
"527",81,"Golberg","Retrospective cohort","27Oct2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","109-159","severe disease","severe","Israel","40-59 years","40-59 years",92,"87",95,NA,"delta","22 weeks",NA,NA,"Israel","ISR",81,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-10-27,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","25/08/2021",2021-08-25
"528",81,"Golberg","Retrospective cohort","27Oct2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","109-159","severe disease","severe","Israel",">= 60 years",">= 60 years",85,"81",88,NA,"delta","22 weeks",NA,NA,"Israel","ISR",81,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-10-27,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","25/08/2021",2021-08-25
"529",82,"Chemaitelly ","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech)","included","1","1","14+","infection","infection","Qatar",">= 12 years","general pop",36.8,"33.2",40.2,NA,"alpha, beta & delta",NA,NA,NA,"Qatar","QAT",82,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-10-06,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","27/08/2021",2021-08-27
"530",82,"Chemaitelly ","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","28-63","infection ","infection","Qatar",">= 12 years","general pop",73.2,"71.3",75,NA,"alpha, beta & delta","7 weeks",NA,NA,"Qatar","QAT",82,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-10-06,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","27/08/2021",2021-08-27
"531",82,"Chemaitelly ","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","175+","infection ","infection","Qatar",">= 12 years","general pop",22.3,"-1.7",40.7,NA,"alpha, beta & delta","~32 weeks",NA,NA,"Qatar","QAT",82,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-10-06,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","27/08/2021",2021-08-27
"532",82,"Chemaitelly ","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech)","included","1","1","14+","symptomatic disease","symptomatic","Qatar",">= 12 years","general pop",47.9,"43.6",51.9,NA,"alpha, beta & delta",NA,NA,NA,"Qatar","QAT",82,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-10-06,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","27/08/2021",2021-08-27
"533",82,"Chemaitelly ","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","28-63","symptomatic disease","symptomatic","Qatar",">= 12 years","general pop",72.5,"69.6",75.1,NA,"alpha, beta & delta","7 weeks",NA,NA,"Qatar","QAT",82,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-10-06,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","27/08/2021",2021-08-27
"534",82,"Chemaitelly ","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","175+","symptomatic disease","symptomatic","Qatar",">= 12 years","general pop",27.8,"-1.4",48.7,NA,"alpha, beta & delta","~32 weeks",NA,NA,"Qatar","QAT",82,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-10-06,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","27/08/2021",2021-08-27
"535",82,"Chemaitelly ","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech)","included","1","1","14+","asymptomatic infection","asymptomatic","Qatar",">= 12 years","general pop",22.2,"12.1",31.2,NA,"alpha, beta & delta",NA,NA,NA,"Qatar","QAT",82,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-10-06,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","27/08/2021",2021-08-27
"536",82,"Chemaitelly ","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","28-63","asymptomatic infection","asymptomatic","Qatar",">= 12 years","general pop",66.9,"61.9",71.3,NA,"alpha, beta & delta","7 weeks",NA,NA,"Qatar","QAT",82,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-10-06,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","27/08/2021",2021-08-27
"537",82,"Chemaitelly ","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","175+","asymptomatic infection","asymptomatic","Qatar",">= 12 years","general pop",-33.3,"-181.8",36.9,NA,"alpha, beta & delta","~29 weeks",NA,NA,"Qatar","QAT",82,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-10-06,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","27/08/2021",2021-08-27
"538",82,"Chemaitelly ","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech)","included","1","1","14+","severe, critical, fatal disease","severe","Qatar",">= 12 years","general pop",66.1,"56.8",73.5,NA,"alpha, beta & delta",NA,NA,NA,"Qatar","QAT",82,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-10-06,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","27/08/2021",2021-08-27
"539",82,"Chemaitelly ","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","28-63","severe, critical, fatal disease","severe","Qatar",">= 12 years","general pop",96.8,"93.9",98.3,NA,"alpha, beta & delta","7 weeks",NA,NA,"Qatar","QAT",82,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-10-06,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","27/08/2021",2021-08-27
"540",82,"Chemaitelly ","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","175+","severe, critical, fatal disease","severe","Qatar",">= 12 years","general pop",55.6,"-44.3",86.3,NA,"alpha, beta & delta","~32 weeks",NA,NA,"Qatar","QAT",82,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-10-06,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","27/08/2021",2021-08-27
"541",82,"Chemaitelly ","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech)","included","1","1","14+","infection","infection","Qatar",">= 12 years","general pop",47.9,"15.5",67.9,"alpha","alpha",NA,NA,NA,"Qatar","QAT",82,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-10-06,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","27/08/2021",2021-08-27
"542",82,"Chemaitelly ","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","28-63","infection","infection","Qatar",">= 12 years","general pop",88.6,"79.2",93.7,"alpha","alpha","7 weeks",NA,NA,"Qatar","QAT",82,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-10-06,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","27/08/2021",2021-08-27
"543",82,"Chemaitelly ","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","147+","infection","infection","Qatar",">= 12 years","general pop",80,"-71.2",97.7,"alpha","alpha","~29 weeks",NA,NA,"Qatar","QAT",82,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-10-06,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","27/08/2021",2021-08-27
"544",82,"Chemaitelly ","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech)","included","1","1","14+","infection","infection","Qatar",">= 12 years","general pop",25.8,"-2",46.1,"beta","beta",NA,NA,NA,"Qatar","QAT",82,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-10-06,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","beta","27/08/2021",2021-08-27
"545",82,"Chemaitelly ","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","28-63","infection","infection","Qatar",">= 12 years","general pop",63.9,"52.6",72.5,"beta","beta","7 weeks",NA,NA,"Qatar","QAT",82,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-10-06,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","beta","27/08/2021",2021-08-27
"546",82,"Chemaitelly ","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","147+","infection ","infection","Qatar",">= 12 years","general pop",40,"-151.1",85.7,"beta","beta","~29 weeks",NA,NA,"Qatar","QAT",82,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-10-06,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","beta","27/08/2021",2021-08-27
"547",82,"Chemaitelly ","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech)","included","1","1","14+","infection","infection","Qatar",">= 12 years","general pop",63.4,"42.6",76.6,"delta","delta",NA,NA,NA,"Qatar","QAT",82,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-10-06,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","27/08/2021",2021-08-27
"548",82,"Chemaitelly ","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","28-63","infection","infection","Qatar",">= 12 years","general pop",73.3,"63.6",80.4,"delta","delta","7 weeks",NA,NA,"Qatar","QAT",82,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-10-06,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","27/08/2021",2021-08-27
"549",82,"Chemaitelly ","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","147+","infection","infection","Qatar",">= 12 years","general pop",17.9,"-12.9",40.3,"delta","delta","~29 weeks",NA,NA,"Qatar","QAT",82,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2021-10-06,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","27/08/2021",2021-08-27
"550",83,"Nunes","Retrospective cohort","23Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","14+ up to <14 post 2nd dose","hospitalization","severe","Portugal","65-79 years","65-79 years",78,"61",87,NA,"alpha & delta",NA,NA,NA,"Portugal","PRT",83,"PRT",36330,2019,"Portugal","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-09,2021-08-27,2020-12-23,2020-12-23,9,15,198,247,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-23,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-09-23
"551",83,"Nunes","Retrospective cohort","23Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization","severe","Portugal","65-79 years","65-79 years",94,"88",97,NA,"alpha & delta","~14.5 weeks",NA,NA,"Portugal","PRT",83,"PRT",36330,2019,"Portugal","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-09,2021-08-27,2020-12-23,2020-12-23,9,15,198,247,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-23,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-09-23
"552",83,"Nunes","Retrospective cohort","23Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","14+ up to <14 post 2nd dose","death","death","Portugal","65-79 years","65-79 years",77,"56",88,NA,"alpha & delta",NA,NA,NA,"Portugal","PRT",83,"PRT",36330,2019,"Portugal","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-09,2021-08-27,2020-12-23,2020-12-23,9,15,198,247,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-23,"death","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-09-23
"553",83,"Nunes","Retrospective cohort","23Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","death","death","Portugal","65-79 years","65-79 years",96,"92",98,NA,"alpha & delta","~14.5 weeks",NA,NA,"Portugal","PRT",83,"PRT",36330,2019,"Portugal","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-09,2021-08-27,2020-12-23,2020-12-23,9,15,198,247,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-23,"death","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-09-23
"554",83,"Nunes","Retrospective cohort","23Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","14+ up to <14 post 2nd dose","hospitalization","severe","Portugal",">= 80 years",">= 80 years",55,"36",69,NA,"alpha & delta",NA,NA,NA,"Portugal","PRT",83,"PRT",36330,2019,"Portugal","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-09,2021-08-27,2020-12-23,2020-12-23,9,15,198,247,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-23,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-09-23
"555",83,"Nunes","Retrospective cohort","23Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization","severe","Portugal",">= 80 years",">= 80 years",82,"72",89,NA,"alpha & delta","~22.5 weeks",NA,NA,"Portugal","PRT",83,"PRT",36330,2019,"Portugal","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-09,2021-08-27,2020-12-23,2020-12-23,9,15,198,247,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-23,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-09-23
"556",83,"Nunes","Retrospective cohort","23Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","14+ up to <14 post 2nd dose","death","death","Portugal",">= 80 years",">= 80 years",56,"35",70,NA,"alpha & delta",NA,NA,NA,"Portugal","PRT",83,"PRT",36330,2019,"Portugal","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-09,2021-08-27,2020-12-23,2020-12-23,9,15,198,247,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-23,"death","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-09-23
"557",83,"Nunes","Retrospective cohort","23Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","death","death","Portugal",">= 80 years",">= 80 years",81,"74",87,NA,"alpha & delta","~22.5 weeks",NA,NA,"Portugal","PRT",83,"PRT",36330,2019,"Portugal","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-09,2021-08-27,2020-12-23,2020-12-23,9,15,198,247,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-23,"death","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-09-23
"558",84,"Katz","Prospective cohort","10Dec2021","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection","infection","Israel","HCW","HCW",94.5,"82.5",98.2,NA,"alpha","~18 weeks",NA,NA,"Israel","ISR",84,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-12-10,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","02/09/2021",2021-09-02
"559",84,"Katz","Prospective cohort","10Dec2021","BNT162b2 (Pfizer BioNTech)","included","2","final","7+","symptomatic disease","symptomatic","Israel","HCW","HCW",97,"72",99.7,NA,"alpha","~18 weeks",NA,NA,"Israel","ISR",84,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-12-10,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","02/09/2021",2021-09-02
"560",85,"Giansante","Retrospective cohort","02Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","14+","infection","infection","Italy","HCW and staff","HCW and staff",85.5,"75.9",91.3,NA,"alpha & delta",NA,NA,NA,"Italy","ITA",85,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-02,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-09-02
"561",85,"Giansante","Retrospective cohort","02Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","Italy","HCW and staff","HCW and staff",84.8,"73.2",91.4,NA,"alpha & delta","~16 weeks",NA,NA,"Italy","ITA",85,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-02,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-09-02
"562",85,"Giansante","Retrospective cohort","02Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","14+","symptomatic disease","symptomatic","Italy","HCW and staff","HCW and staff",81.7,"62.7",91,NA,"alpha & delta",NA,NA,NA,"Italy","ITA",85,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-02,"symptomatic","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-09-02
"563",85,"Giansante","Retrospective cohort","02Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","symptomatic disease","symptomatic","Italy","HCW and staff","HCW and staff",87.1,"69.3",94.6,NA,"alpha & delta","~16 weeks",NA,NA,"Italy","ITA",85,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-02,"symptomatic","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-09-02
"564",85,"Giansante","Retrospective cohort","02Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","14+","infection","infection","Italy","HCW","HCW",87.8,"76.5",93.7,NA,"alpha & delta",NA,NA,NA,"Italy","ITA",85,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-02,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-09-02
"565",85,"Giansante","Retrospective cohort","02Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","Italy","HCW","HCW",84.4,"69.7",92,NA,"alpha & delta","~16 weeks",NA,NA,"Italy","ITA",85,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-02,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-09-02
"566",85,"Giansante","Retrospective cohort","02Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","14+","symptomatic disease","symptomatic","Italy","HCW","HCW",83.1,"60",92.9,NA,"alpha & delta",NA,NA,NA,"Italy","ITA",85,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-02,"symptomatic","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-09-02
"567",85,"Giansante","Retrospective cohort","02Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","symptomatic disease","symptomatic","Italy","HCW","HCW",86.5,"62.9",95.1,NA,"alpha & delta","~16 weeks",NA,NA,"Italy","ITA",85,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-02,"symptomatic","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-09-02
"568",86,"Bruxvoort","Matched prospective cohort","24Nov2021","mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","USA","adults","general pop",87.4,"85.6",89.1,NA,"alpha & delta","~20 weeks",NA,NA,"USA","USA",86,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-11-24,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","02/09/2021",2021-09-02
"569",86,"Bruxvoort","Matched prospective cohort","24Nov2021","mRNA-1273 (Moderna)","included","2","final","14+","asymptomatic infection","asymptomatic","USA","adults","general pop",72.7,"57.6",82.4,NA,"alpha & delta","~20 weeks",NA,NA,"USA","USA",86,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-11-24,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","02/09/2021",2021-09-02
"570",86,"Bruxvoort","Matched prospective cohort","24Nov2021","mRNA-1273 (Moderna)","included","2","final","14+","symptomatic disease","symptomatic","USA","adults","general pop",88.3,"86.5",89.9,NA,"alpha & delta","~20 weeks",NA,NA,"USA","USA",86,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-11-24,"symptomatic","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","02/09/2021",2021-09-02
"571",86,"Bruxvoort","Matched prospective cohort","24Nov2021","mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","adults","general pop",95.8,"92.5",97.6,NA,"alpha & delta","~20 weeks",NA,NA,"USA","USA",86,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-11-24,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","02/09/2021",2021-09-02
"572",86,"Bruxvoort","Matched prospective cohort","24Nov2021","mRNA-1273 (Moderna)","included","2","final","14+","death","death","USA","adults","general pop",97.9,"84.5",99.7,NA,"alpha & delta","~20 weeks",NA,NA,"USA","USA",86,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-11-24,"death","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","02/09/2021",2021-09-02
"573",87,"Barlow","Test-negative case-control","03Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","USA",">= 15 years","general pop",74,"65",82,NA,"delta","~4 weeks",NA,NA,"USA","USA",87,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-03,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2021-09-03
"574",87,"Barlow","Test-negative case-control","03Sept2021","Ad26.COV2.S (Janssen)","excluded","1","final","14+","infection","infection","USA",">= 15 years","general pop",51,"-2",76,NA,"delta","~4 weeks",NA,NA,"USA","USA",87,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-03,"infection","2021 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta",NA,2021-09-03
"575",88,"Tande","Retrospective cohort","06Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","1","1","20+","asymptomatic infection (January-March)","asymptomatic","USA","surgery patients","surgery patients",44,"-6",71,NA,"non-VOC",NA,NA,NA,"USA","USA",88,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-06,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","original",NA,2021-09-06
"576",88,"Tande","Retrospective cohort","06Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","asymptomatic infection (January-March)","asymptomatic","USA","surgery patients","surgery patients",91,"72",98,NA,"non-VOC","~10 weeks",NA,NA,"USA","USA",88,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-06,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","original",NA,2021-09-06
"577",88,"Tande","Retrospective cohort","06Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","1","1","20+","asymptomatic infection (April-May)","asymptomatic","USA","surgery patients","surgery patients",46,"53",83,NA,"alpha",NA,NA,NA,"USA","USA",88,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-06,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha",NA,2021-09-06
"578",88,"Tande","Retrospective cohort","06Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","asymptomatic infection (April-May)","asymptomatic","USA","surgery patients","surgery patients",71,"53",83,NA,"alpha","~19 weeks",NA,NA,"USA","USA",88,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-06,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha",NA,2021-09-06
"579",88,"Tande","Retrospective cohort","06Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","1","1","20+","asymptomatic infection (June-August)","asymptomatic","USA","surgery patients","surgery patients",63,"44",76,NA,"delta",NA,NA,NA,"USA","USA",88,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-06,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2021-09-06
"580",88,"Tande","Retrospective cohort","06Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","asymptomatic infection (June-August)","asymptomatic","USA","surgery patients","surgery patients",63,"44",76,NA,"delta","~32 weeks",NA,NA,"USA","USA",88,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-06,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2021-09-06
"581",89,"Iliaki","Retrospective cohort","18Oct2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","14+","infection","infection","USA","HCW","HCW",80.2,"57.5",90.8,NA,"alpha",NA,NA,NA,"USA","USA",89,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-10-18,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha","06/09/2021",2021-09-06
"582",89,"Iliaki","Retrospective cohort","18Oct2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","USA","HCW","HCW",95.2,"80",98.8,NA,"alpha","~10 weeks",NA,NA,"USA","USA",89,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-10-18,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha","06/09/2021",2021-09-06
"583",90,"Thompson","Test-negative case-control","08Sept2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14+","hospitalization","severe","USA",">= 50 years",">= 50 years",33,"18",46,NA,"non-VOC & alpha",NA,NA,NA,"USA","USA",90,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-08,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-09-08
"584",90,"Thompson","Test-negative case-control","08Sept2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization","severe","USA",">= 50 years",">= 50 years",87,"85",90,NA,"non-VOC & alpha","~22 weeks",NA,NA,"USA","USA",90,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-08,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-09-08
"585",90,"Thompson","Test-negative case-control","08Sept2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14+","ED or UC visit","symptomatic","USA",">= 50 years",">= 50 years",58,"46",68,NA,"non-VOC & alpha",NA,NA,NA,"USA","USA",90,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-08,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-09-08
"586",90,"Thompson","Test-negative case-control","08Sept2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","ED or UC visit","symptomatic","USA",">= 50 years",">= 50 years",89,"85",91,NA,"non-VOC & alpha","~22 weeks",NA,NA,"USA","USA",90,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-08,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-09-08
"587",90,"Thompson","Test-negative case-control","08Sept2021","mRNA-1273 (Moderna)","excluded","1","1","14+","hospitalization","severe","USA",">= 50 years",">= 50 years",68,"59",75,NA,"non-VOC & alpha",NA,NA,NA,"USA","USA",90,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-08,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-09-08
"588",90,"Thompson","Test-negative case-control","08Sept2021","mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization","severe","USA",">= 50 years",">= 50 years",91,"89",93,NA,"non-VOC & alpha","20 weeks",NA,NA,"USA","USA",90,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-08,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-09-08
"589",90,"Thompson","Test-negative case-control","08Sept2021","mRNA-1273 (Moderna)","excluded","1","1","14+","ED or UC visit","symptomatic","USA",">= 50 years",">= 50 years",73,"64",79,NA,"non-VOC & alpha",NA,NA,NA,"USA","USA",90,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-08,"symptomatic","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-09-08
"590",90,"Thompson","Test-negative case-control","08Sept2021","mRNA-1273 (Moderna)","excluded","2","final","14+","ED or UC visit","symptomatic","USA",">= 50 years",">= 50 years",92,"89",94,NA,"non-VOC & alpha","20 weeks",NA,NA,"USA","USA",90,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-08,"symptomatic","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-09-08
"591",90,"Thompson","Test-negative case-control","08Sept2021","Ad26.COV2.S (Janssen)","excluded","1","final","14+","hospitalization","severe","USA",">= 50 years",">= 50 years",68,"50",79,NA,"non-VOC & alpha","14 weeks",NA,NA,"USA","USA",90,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-08,"severe","2021 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2021-09-08
"592",90,"Thompson","Test-negative case-control","08Sept2021","Ad26.COV2.S (Janssen)","excluded","1","final","14+","ED or UC visit","symptomatic","USA",">= 50 years",">= 50 years",73,"59",82,NA,"non-VOC & alpha","14 weeks",NA,NA,"USA","USA",90,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-08,"symptomatic","2021 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2021-09-08
"593",90,"Thompson","Test-negative case-control","08Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","14+","hospitalization","severe","USA",">= 50 years with >= 1 chronic respiratory condition",">= 50 years with >= 1 chronic respiratory condition",56,"47",64,NA,"non-VOC & alpha",NA,NA,NA,"USA","USA",90,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-08,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-09-08
"594",90,"Thompson","Test-negative case-control","08Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization","severe","USA",">= 50 years with >= 1 chronic respiratory condition",">= 50 years with >= 1 chronic respiratory condition",90,"88",92,NA,"non-VOC & alpha","~22 weeks",NA,NA,"USA","USA",90,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-08,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-09-08
"595",90,"Thompson","Test-negative case-control","08Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","14+","hospitalization","severe","USA",">= 50 years with >= 1 chronic non-respiratory condition",">= 50 years with >= 1 chronic non-respiratory condition",54,"45",61,NA,"non-VOC & alpha",NA,NA,NA,"USA","USA",90,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-08,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-09-08
"596",90,"Thompson","Test-negative case-control","08Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization","severe","USA",">= 50 years with >= 1 chronic non-respiratory condition",">= 50 years with >= 1 chronic non-respiratory condition",88,"86",90,NA,"non-VOC & alpha","~22 weeks",NA,NA,"USA","USA",90,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-08,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-09-08
"597",90,"Thompson","Test-negative case-control","08Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-27","hospitalization","severe","USA",">= 50 years",">= 50 years",88,"84",92,NA,"non-VOC & alpha","~2 weeks",NA,NA,"USA","USA",90,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-08,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-09-08
"598",90,"Thompson","Test-negative case-control","08Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","112+","hospitalization","severe","USA",">= 50 years",">= 50 years",86,"74",93,NA,"non-VOC & alpha","~22 weeks",NA,NA,"USA","USA",90,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-08,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-09-08
"599",90,"Thompson","Test-negative case-control","08Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-27","ED or UC visit","symptomatic","USA",">= 50 years",">= 50 years",92,"88",95,NA,"non-VOC & alpha","~2 weeks",NA,NA,"USA","USA",90,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-08,"symptomatic","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-09-08
"600",90,"Thompson","Test-negative case-control","08Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","112+","ED or UC visit","symptomatic","USA",">= 50 years",">= 50 years",86,"74",93,NA,"non-VOC & alpha","~22 weeks",NA,NA,"USA","USA",90,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-08,"symptomatic","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-09-08
"601",91,"Dagan","Prospective cohort","07Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","21-27","infection","infection","Israel","pregnant women","pregnant persons",71,"33",94,NA,"alpha",NA,NA,NA,"Israel","ISR",91,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-07,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha",NA,2021-09-07
"602",91,"Dagan","Prospective cohort","07Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7-56","infection ","infection","Israel","pregnant women","pregnant persons",96,"89",100,NA,"alpha","~11 weeks",NA,NA,"Israel","ISR",91,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-07,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha",NA,2021-09-07
"603",91,"Dagan","Prospective cohort","07Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","21-27","symptomatic disease","symptomatic","Israel","pregnant women","pregnant persons",76,"30",100,NA,"alpha",NA,NA,NA,"Israel","ISR",91,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-07,"symptomatic","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha",NA,2021-09-07
"604",91,"Dagan","Prospective cohort","07Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7-56","symptomatic disease","symptomatic","Israel","pregnant women","pregnant persons",97,"91",100,NA,"alpha","~11 weeks",NA,NA,"Israel","ISR",91,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-07,"symptomatic","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha",NA,2021-09-07
"605",91,"Dagan","Prospective cohort","07Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7-56","hospitalization","severe","Israel","pregnant women","pregnant persons",89,"43",100,NA,"alpha","~11 weeks",NA,NA,"Israel","ISR",91,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-07,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha",NA,2021-09-07
"606",92,"Grannis","Test-negative case-control","10Sept2021","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","hospitalization","severe","USA",">= 18 years","general pop",80,"73",85,NA,"delta","4 weeks",NA,NA,"USA","USA",92,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-10,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2021-09-10
"607",92,"Grannis","Test-negative case-control","10Sept2021","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","ED or UC visit","symptomatic","USA",">= 18 years","general pop",77,"74",80,NA,"delta","4 weeks",NA,NA,"USA","USA",92,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-10,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2021-09-10
"608",92,"Grannis","Test-negative case-control","10Sept2021","mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA",">= 18 years","general pop",95,"92",97,NA,"delta","4 weeks",NA,NA,"USA","USA",92,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-10,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2021-09-10
"609",92,"Grannis","Test-negative case-control","10Sept2021","mRNA-1273 (Moderna)","included","2","final","14+","ED or UC visit","symptomatic","USA",">= 18 years","general pop",92,"89",93,NA,"delta","4 weeks",NA,NA,"USA","USA",92,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-10,"symptomatic","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2021-09-10
"610",92,"Grannis","Test-negative case-control","10Sept2021","Ad26.COV2.S (Janssen)","included","1","final","14+","hospitalization","severe","USA",">= 18 years","general pop",60,"31",77,NA,"delta","4 weeks",NA,NA,"USA","USA",92,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-10,"severe","2021 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta",NA,2021-09-10
"611",92,"Grannis","Test-negative case-control","10Sept2021","Ad26.COV2.S (Janssen)","included","1","final","14+","ED or UC visit","symptomatic","USA",">= 18 years","general pop",65,"56",72,NA,"delta","4 weeks",NA,NA,"USA","USA",92,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-10,"symptomatic","2021 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta",NA,2021-09-10
"612",93,"Polinski","Retrospective cohort","17Mar2022","Ad26.COV2.S (Janssen)","excluded","1","final","14+","infection","infection","USA",">= 18 years","general pop",76,"75",77,NA,"alpha","~14 weeks",NA,NA,"USA","USA",93,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-17,"infection","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","alpha","10/09/2021",2021-09-10
"613",93,"Polinski","Retrospective cohort","17Mar2022","Ad26.COV2.S (Janssen)","excluded","1","final","14+","hospitalization","severe","USA",">= 18 years","general pop",81,"78",82,NA,"alpha","~14 weeks",NA,NA,"USA","USA",93,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-17,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","alpha","10/09/2021",2021-09-10
"614",93,"Polinski","Retrospective cohort","17Mar2022","Ad26.COV2.S (Janssen)","excluded","1","final","14+","infection","infection","USA","immunocompromised, >= 18 years","immunocompromised adults",64,"59",68,NA,"alpha","~14 weeks",NA,NA,"USA","USA",93,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-17,"infection","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","alpha","10/09/2021",2021-09-10
"615",93,"Polinski","Retrospective cohort","17Mar2022","Ad26.COV2.S (Janssen)","excluded","1","final","14+","hospitalization","severe","USA","immunocompromised, >= 18 years","immunocompromised adults",67,"57",74,NA,"alpha","~14 weeks",NA,NA,"USA","USA",93,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-17,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","alpha","10/09/2021",2021-09-10
"616",93,"Polinski","Retrospective cohort","17Mar2022","Ad26.COV2.S (Janssen)","excluded","1","final","14+","infection (June-July)","infection","USA",">= 18 years","general pop",74,"71",77,NA,"delta","~14 weeks",NA,NA,"USA","USA",93,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-17,"infection","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta","10/09/2021",2021-09-10
"617",93,"Polinski","Retrospective cohort","17Mar2022","Ad26.COV2.S (Janssen)","excluded","1","final","14+","hospitalization (June-July)","severe","USA",">= 18 years","general pop",81,"75",86,NA,"delta","~14 weeks",NA,NA,"USA","USA",93,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-17,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta","10/09/2021",2021-09-10
"618",94,"Bajema","Test-negative case-control","10Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","<104 days","hospitalization","severe","USA","hospitalized veterans","hospitalized veterans",86.1,"76.5",91.8,NA,"alpha, delta, non-VOC","~13 weeks",NA,NA,"USA","USA",94,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-10,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-09-10
"619",94,"Bajema","Test-negative case-control","10Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final",">104 days","hospitalization","severe","USA","hospitalized veterans","hospitalized veterans",87.2,"78.2",92.5,NA,"alpha, delta, non-VOC","~28.5 weeks",NA,NA,"USA","USA",94,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-10,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-09-10
"620",94,"Bajema","Test-negative case-control","10Sept2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization","severe","USA","hospitalized veterans","hospitalized veterans",83.4,"74",89.4,NA,"alpha, delta, non-VOC","~28.5 weeks",NA,NA,"USA","USA",94,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-10,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-09-10
"621",94,"Bajema","Test-negative case-control","10Sept2021","mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization","severe","USA","hospitalized veterans","hospitalized veterans",91.6,"83.5",95.7,NA,"alpha, delta, non-VOC","~26.5 weeks",NA,NA,"USA","USA",94,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-10,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-09-10
"622",94,"Bajema","Test-negative case-control","10Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization (February-June)","severe","USA","hospitalized veterans","hospitalized veterans",84.1,"74.1",90.2,NA,"alpha","~23 weeks",NA,NA,"USA","USA",94,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-10,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha",NA,2021-09-10
"623",94,"Bajema","Test-negative case-control","10Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization (July-August)","severe","USA","hospitalized veterans","hospitalized veterans",89.3,"80.1",94.3,NA,"delta","~28.5 weeks",NA,NA,"USA","USA",94,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-10,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2021-09-10
"624",95,"Andrews","Test-negative case-control","12Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","28+","symptomatic disease","symptomatic","UK",">= 16 years","general pop",45.9,"44.2",47.6,"alpha","alpha",NA,NA,NA,"UK","GBR",95,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","14/09/2021",2021-09-14
"625",95,"Andrews","Test-negative case-control","12Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease","symptomatic","UK",">= 16 years","general pop",94.9,"93.6",95.9,"alpha","alpha","~33.5 weeks",NA,NA,"UK","GBR",95,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","14/09/2021",2021-09-14
"626",95,"Andrews","Test-negative case-control","12Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","70+","symptomatic disease","symptomatic","UK",">= 16 years","general pop",94.8,"88.4",97.7,"alpha","alpha","~8 weeks",NA,NA,"UK","GBR",95,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","14/09/2021",2021-09-14
"627",95,"Andrews","Test-negative case-control","12Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","28+","hospitalization","severe","UK",">= 16 years","general pop",85.2,"81.6",88.1,"alpha","alpha",NA,NA,NA,"UK","GBR",95,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","14/09/2021",2021-09-14
"628",95,"Andrews","Test-negative case-control","12Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-63","hospitalization","severe","UK",">= 16 years","general pop",97.7,"90.8",99.4,"alpha","alpha","~33.5 weeks",NA,NA,"UK","GBR",95,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","14/09/2021",2021-09-14
"629",95,"Andrews","Test-negative case-control","12Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","28+","death","death","UK",">= 16 years","general pop",73.1,"65",79.3,"alpha","alpha",NA,NA,NA,"UK","GBR",95,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"death","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","14/09/2021",2021-09-14
"630",95,"Andrews","Test-negative case-control","12Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","death","death","UK",">= 16 years","general pop",96.6,"94.4",96.5,"alpha","alpha","~33.5 weeks",NA,NA,"UK","GBR",95,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"death","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","14/09/2021",2021-09-14
"631",95,"Andrews","Test-negative case-control","12Jan2022","AZD1222 (AstraZeneca)","excluded","1","1","28+","symptomatic disease","symptomatic","UK",">= 16 years","general pop",45.1,"43.3",46.7,"alpha","alpha",NA,NA,NA,"UK","GBR",95,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","14/09/2021",2021-09-14
"632",95,"Andrews","Test-negative case-control","12Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","14+","symptomatic disease","symptomatic","UK",">= 16 years","general pop",82.1,"79.4",84.5,"alpha","alpha","~20.5 weeks",NA,NA,"UK","GBR",95,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","14/09/2021",2021-09-14
"633",95,"Andrews","Test-negative case-control","12Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","14-63","symptomatic disease","symptomatic","UK",">= 16 years","general pop",82.4,"79.6",84.7,"alpha","alpha","~8 weeks",NA,NA,"UK","GBR",95,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","14/09/2021",2021-09-14
"634",95,"Andrews","Test-negative case-control","12Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","70+","symptomatic disease","symptomatic","UK",">= 16 years","general pop",76.2,"49.8",88.7,"alpha","alpha","~20.5 weeks",NA,NA,"UK","GBR",95,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","14/09/2021",2021-09-14
"635",95,"Andrews","Test-negative case-control","12Jan2022","AZD1222 (AstraZeneca)","excluded","1","1","28+","hospitalization","severe","UK",">= 16 years","general pop",82.5,"78.7",85.7,"alpha","alpha",NA,NA,NA,"UK","GBR",95,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","14/09/2021",2021-09-14
"636",95,"Andrews","Test-negative case-control","12Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","14-63","hospitalization","severe","UK",">= 16 years","general pop",95.1,"86.7",98.2,"alpha","alpha","~20.5 weeks",NA,NA,"UK","GBR",95,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","14/09/2021",2021-09-14
"637",95,"Andrews","Test-negative case-control","12Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","70+","hospitalization","severe","UK",">= 16 years","general pop",100,NA,NA,"alpha","alpha","~20.5 weeks",NA,NA,"UK","GBR",95,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","14/09/2021",2021-09-14
"638",95,"Andrews","Test-negative case-control","12Jan2022","AZD1222 (AstraZeneca)","excluded","1","1","28+","death","death","UK",">= 16 years","general pop",79.1,"68.8",86,"alpha","alpha",NA,NA,NA,"UK","GBR",95,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"death","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","14/09/2021",2021-09-14
"639",95,"Andrews","Test-negative case-control","12Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","14+","death","death","UK",">= 16 years","general pop",100,NA,NA,"alpha","alpha","~20.5 weeks",NA,NA,"UK","GBR",95,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"death","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","14/09/2021",2021-09-14
"640",95,"Andrews","Test-negative case-control","12Jan2022","mRNA-1273 (Moderna)","excluded","1","1","28+","symptomatic disease","symptomatic","UK",">= 16 years","general pop",58.1,"11.7",80.1,"alpha","alpha",NA,NA,NA,"UK","GBR",95,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","alpha","14/09/2021",2021-09-14
"641",95,"Andrews","Test-negative case-control","12Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","28+","symptomatic disease","symptomatic","UK",">= 16 years","general pop",51.2,"50.7",51.7,"delta","delta",NA,NA,NA,"UK","GBR",95,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","14/09/2021",2021-09-14
"642",95,"Andrews","Test-negative case-control","12Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease","symptomatic","UK",">= 16 years","general pop",83.3,"83.1",83.5,"delta","delta","~33.5 weeks",NA,NA,"UK","GBR",95,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","14/09/2021",2021-09-14
"643",95,"Andrews","Test-negative case-control","12Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-69","symptomatic disease","symptomatic","UK",">= 16 years","general pop",89.8,"89.6",90,"delta","delta","~8 weeks",NA,NA,"UK","GBR",95,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","14/09/2021",2021-09-14
"644",95,"Andrews","Test-negative case-control","12Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","140+","symptomatic disease","symptomatic","UK",">= 16 years","general pop",69.7,"68.7",70.5,"delta","delta","~33.5 weeks",NA,NA,"UK","GBR",95,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","14/09/2021",2021-09-14
"645",95,"Andrews","Test-negative case-control","12Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","28+","hospitalization","severe","UK",">= 16 years","general pop",91.1,"89.7",92.3,"delta","delta",NA,NA,NA,"UK","GBR",95,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","14/09/2021",2021-09-14
"646",95,"Andrews","Test-negative case-control","12Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization","severe","UK",">= 16 years","general pop",96.6,"96.2",96.9,"delta","delta","~33.5 weeks",NA,NA,"UK","GBR",95,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","14/09/2021",2021-09-14
"647",95,"Andrews","Test-negative case-control","12Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-69","hospitalization","severe","UK",">= 16 years","general pop",98.4,"97.9",98.8,"delta","delta","~8 weeks",NA,NA,"UK","GBR",95,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","14/09/2021",2021-09-14
"648",95,"Andrews","Test-negative case-control","12Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","140+","hospitalization","severe","UK",">= 16 years","general pop",92.7,"90.3",94.6,"delta","delta","~33.5 weeks",NA,NA,"UK","GBR",95,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","14/09/2021",2021-09-14
"649",95,"Andrews","Test-negative case-control","12Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","28+","death","death","UK",">= 16 years","general pop",88.6,"78.8",93.9,"delta","delta",NA,NA,NA,"UK","GBR",95,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"death","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","14/09/2021",2021-09-14
"650",95,"Andrews","Test-negative case-control","12Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","death","death","UK",">= 16 years","general pop",95.6,"94.4",96.6,"delta","delta","~33.5 weeks",NA,NA,"UK","GBR",95,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"death","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","14/09/2021",2021-09-14
"651",95,"Andrews","Test-negative case-control","12Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-69","death","death","UK",">= 16 years","general pop",98.2,"95.9",99.2,"delta","delta","~8 weeks",NA,NA,"UK","GBR",95,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"death","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","14/09/2021",2021-09-14
"652",95,"Andrews","Test-negative case-control","12Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","140+","death","death","UK",">= 16 years","general pop",90.4,"85.1",93.8,"delta","delta","~33.5 weeks",NA,NA,"UK","GBR",95,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"death","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","14/09/2021",2021-09-14
"653",95,"Andrews","Test-negative case-control","12Jan2022","AZD1222 (AstraZeneca)","excluded","1","1","28+","symptomatic disease","symptomatic","UK",">= 16 years","general pop",45.1,"43.4",46.7,"delta","delta",NA,NA,NA,"UK","GBR",95,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","14/09/2021",2021-09-14
"654",95,"Andrews","Test-negative case-control","12Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","14+","symptomatic disease","symptomatic","UK",">= 16 years","general pop",64.2,"63.9",64.5,"delta","delta","~20.5 weeks",NA,NA,"UK","GBR",95,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","14/09/2021",2021-09-14
"655",95,"Andrews","Test-negative case-control","12Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","14-69","symptomatic disease","symptomatic","UK",">= 16 years","general pop",66.7,"66.3",67,"delta","delta","~8 weeks",NA,NA,"UK","GBR",95,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","14/09/2021",2021-09-14
"656",95,"Andrews","Test-negative case-control","12Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","140+","symptomatic disease","symptomatic","UK",">= 16 years","general pop",47.3,"45",49.6,"delta","delta","~20.5 weeks",NA,NA,"UK","GBR",95,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","14/09/2021",2021-09-14
"657",95,"Andrews","Test-negative case-control","12Jan2022","AZD1222 (AstraZeneca)","excluded","1","1","28+","hospitalization","severe","UK",">= 16 years","general pop",80.7,"78",83,"delta","delta",NA,NA,NA,"UK","GBR",95,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","14/09/2021",2021-09-14
"658",95,"Andrews","Test-negative case-control","12Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","14+","hospitalization","severe","UK",">= 16 years","general pop",92.5,"92",93,"delta","delta","~20.5 weeks",NA,NA,"UK","GBR",95,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","14/09/2021",2021-09-14
"659",95,"Andrews","Test-negative case-control","12Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","14-69","hospitalization","severe","UK",">= 16 years","general pop",95.2,"94.6",95.6,"delta","delta","~8 weeks",NA,NA,"UK","GBR",95,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","14/09/2021",2021-09-14
"660",95,"Andrews","Test-negative case-control","12Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","140+","hospitalization","severe","UK",">= 16 years","general pop",77,"70.3",82.3,"delta","delta","~20.5 weeks",NA,NA,"UK","GBR",95,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","14/09/2021",2021-09-14
"661",95,"Andrews","Test-negative case-control","12Jan2022","AZD1222 (AstraZeneca)","excluded","1","1","28+","death","death","UK",">= 16 years","general pop",86.9,"77.5",92.4,"delta","delta",NA,NA,NA,"UK","GBR",95,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"death","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","14/09/2021",2021-09-14
"662",95,"Andrews","Test-negative case-control","12Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","14+","death","death","UK",">= 16 years","general pop",93.2,"91.7",94.5,"delta","delta","~20.5 weeks",NA,NA,"UK","GBR",95,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"death","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","14/09/2021",2021-09-14
"663",95,"Andrews","Test-negative case-control","12Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","14-69","death","death","UK",">= 16 years","general pop",94.1,"91.8",95.8,"delta","delta","~8 weeks",NA,NA,"UK","GBR",95,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"death","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","14/09/2021",2021-09-14
"664",95,"Andrews","Test-negative case-control","12Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","140+","death","death","UK",">= 16 years","general pop",78.7,"52.7",90.4,"delta","delta","~20.5 weeks",NA,NA,"UK","GBR",95,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"death","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","14/09/2021",2021-09-14
"665",95,"Andrews","Test-negative case-control","12Jan2022","mRNA-1273 (Moderna)","excluded","1","1","28+","symptomatic disease","symptomatic","UK",">= 16 years","general pop",64.9,"64",65.7,"delta","delta",NA,NA,NA,"UK","GBR",95,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","14/09/2021",2021-09-14
"666",95,"Andrews","Test-negative case-control","12Jan2022","mRNA-1273 (Moderna)","excluded","2","final","14+","symptomatic disease","symptomatic","UK",">= 16 years","general pop",94.8,"94.4",95.2,"delta","delta","~7 weeks",NA,NA,"UK","GBR",95,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","14/09/2021",2021-09-14
"667",95,"Andrews","Test-negative case-control","12Jan2022","mRNA-1273 (Moderna)","excluded","2","final","14-63","symptomatic disease","symptomatic","UK",">= 16 years","general pop",93.8,"93.4",94.1,"delta","delta","~7 weeks",NA,NA,"UK","GBR",95,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","14/09/2021",2021-09-14
"668",95,"Andrews","Test-negative case-control","12Jan2022","mRNA-1273 (Moderna)","excluded","2","final","70-104","symptomatic disease","symptomatic","UK",">= 16 years","general pop",85.6,"83.8",87.2,"delta","delta","~7 weeks",NA,NA,"UK","GBR",95,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","14/09/2021",2021-09-14
"669",95,"Andrews","Test-negative case-control","12Jan2022","mRNA-1273 (Moderna)","excluded","1","1","28+","hospitalization","severe","UK",">= 16 years","general pop",93.7,"89.9",96,"delta","delta",NA,NA,NA,"UK","GBR",95,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","14/09/2021",2021-09-14
"670",95,"Andrews","Test-negative case-control","12Jan2022","mRNA-1273 (Moderna)","excluded","2","final","14-69","hospitalization","severe","UK",">= 16 years","general pop",100,NA,NA,"delta","delta","~7 weeks",NA,NA,"UK","GBR",95,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","14/09/2021",2021-09-14
"671",96,"Glatman-Freedman","Retrospective cohort","16Sept2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14-20","infection","infection","Israel",">= 16 years","general pop",54.3,"50.6",57.8,NA,"alpha",NA,NA,NA,"Israel","ISR",96,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-16,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-09-16
"672",96,"Glatman-Freedman","Retrospective cohort","16Sept2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","22-28","infection","infection","Israel",">= 16 years","general pop",97.3,"96.7",97.8,NA,"alpha","2 weeks",NA,NA,"Israel","ISR",96,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-16,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-09-16
"673",96,"Glatman-Freedman","Retrospective cohort","16Sept2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14-20","symptomatic disease","symptomatic","Israel",">= 16 years","general pop",58.3,"54.7",61.6,NA,"alpha",NA,NA,NA,"Israel","ISR",96,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-16,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-09-16
"674",96,"Glatman-Freedman","Retrospective cohort","16Sept2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","22-28","symptomatic disease","symptomatic","Israel",">= 16 years","general pop",97.9,"97.4",98.3,NA,"alpha","2 weeks",NA,NA,"Israel","ISR",96,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-16,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-09-16
"675",96,"Glatman-Freedman","Retrospective cohort","16Sept2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14-20","hospitalization","severe","Israel",">= 16 years","general pop",74.5,"69.1",79,NA,"alpha",NA,NA,NA,"Israel","ISR",96,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-16,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-09-16
"676",96,"Glatman-Freedman","Retrospective cohort","16Sept2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","22-28","hospitalization","severe","Israel",">= 16 years","general pop",99,"98.4",99.3,NA,"alpha","2 weeks",NA,NA,"Israel","ISR",96,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-16,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-09-16
"677",96,"Glatman-Freedman","Retrospective cohort","16Sept2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14-20","severe/critical disease","severe","Israel",">= 16 years","general pop",77.3,"71.2",82.1,NA,"alpha",NA,NA,NA,"Israel","ISR",96,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-16,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-09-16
"678",96,"Glatman-Freedman","Retrospective cohort","16Sept2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","22-28","severe/critical disease","severe","Israel",">= 16 years","general pop",99.2,"98.6",99.5,NA,"alpha","2 weeks",NA,NA,"Israel","ISR",96,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-16,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-09-16
"679",96,"Glatman-Freedman","Retrospective cohort","16Sept2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14-20","death","death","Israel",">= 16 years","general pop",71.7,"64.1",77.7,NA,"alpha",NA,NA,NA,"Israel","ISR",96,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-16,"death","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-09-16
"680",96,"Glatman-Freedman","Retrospective cohort","16Sept2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","22-28","death","death","Israel",">= 16 years","general pop",98.6,"97",99.3,NA,"alpha","2 weeks",NA,NA,"Israel","ISR",96,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-16,"death","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-09-16
"681",97,"Self","Test-negative case-control","17Sept2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization","severe","USA",">= 18 years","general pop",88,"85",91,NA,"alpha & delta","~20 weeks",NA,NA,"USA","USA",97,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-17,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-09-17
"682",97,"Self","Test-negative case-control","17Sept2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-120","hospitalization","severe","USA",">= 18 years","general pop",91,"88",93,NA,"alpha & delta","~20 weeks",NA,NA,"USA","USA",97,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-17,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-09-17
"683",97,"Self","Test-negative case-control","17Sept2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">120","hospitalization","severe","USA",">= 18 years","general pop",77,"67",84,NA,"alpha & delta","~20 weeks",NA,NA,"USA","USA",97,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-17,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-09-17
"684",97,"Self","Test-negative case-control","17Sept2021","mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization","severe","USA",">= 18 years","general pop",93,"91",95,NA,"alpha & delta","~20 weeks",NA,NA,"USA","USA",97,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-17,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-09-17
"685",97,"Self","Test-negative case-control","17Sept2021","mRNA-1273 (Moderna)","excluded","2","final","14-120","hospitalization","severe","USA",">= 18 years","general pop",93,"90",95,NA,"alpha & delta","~20 weeks",NA,NA,"USA","USA",97,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-17,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-09-17
"686",97,"Self","Test-negative case-control","17Sept2021","mRNA-1273 (Moderna)","excluded","2","final",">120","hospitalization","severe","USA",">= 18 years","general pop",92,"87",96,NA,"alpha & delta","~20 weeks",NA,NA,"USA","USA",97,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-17,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-09-17
"687",97,"Self","Test-negative case-control","17Sept2021","Ad26.COV2.S (Janssen)","excluded","1","final","14+","hospitalization","severe","USA",">= 18 years","general pop",71,"56",81,NA,"alpha & delta","~20 weeks",NA,NA,"USA","USA",97,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-17,"severe","2021 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2021-09-17
"688",97,"Self","Test-negative case-control","17Sept2021","Ad26.COV2.S (Janssen)","excluded","1","final",">28","hospitalization","severe","USA",">= 18 years","general pop",68,"49",80,NA,"alpha & delta","~20 weeks",NA,NA,"USA","USA",97,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-17,"severe","2021 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2021-09-17
"689",98,"Skowronski","Test-negative case-control","27Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","21+","infection","infection","Canada","50-69 years","50-69 years",70,"68",72,NA,"alpha, gamma & delta",NA,NA,NA,"Canada","CAN",98,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-01-27
"690",98,"Skowronski","Test-negative case-control","27Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14-20","infection","infection","Canada","50-69 years","50-69 years",55,"48",61,NA,"alpha, gamma & delta",NA,NA,NA,"Canada","CAN",98,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-01-27
"691",98,"Skowronski","Test-negative case-control","27Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","98+","infection","infection","Canada","50-69 years","50-69 years",65,"57",71,NA,"alpha, gamma & delta",NA,NA,NA,"Canada","CAN",98,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-01-27
"692",98,"Skowronski","Test-negative case-control","27Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","21+","hospitalization","severe","Canada","50-69 years","50-69 years",81,"75",85,NA,"alpha, gamma & delta",NA,NA,NA,"Canada","CAN",98,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-01-27
"693",98,"Skowronski","Test-negative case-control","27Jan2022","mRNA-1273 (Moderna)","excluded","1","1","21+","infection","infection","Canada","50-69 years","50-69 years",75,"71",78,NA,"alpha, gamma & delta",NA,NA,NA,"Canada","CAN",98,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-01-27
"694",98,"Skowronski","Test-negative case-control","27Jan2022","mRNA-1273 (Moderna)","excluded","1","1","14-20","infection","infection","Canada","50-69 years","50-69 years",67,"57",75,NA,"alpha, gamma & delta",NA,NA,NA,"Canada","CAN",98,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-01-27
"695",98,"Skowronski","Test-negative case-control","27Jan2022","mRNA-1273 (Moderna)","excluded","1","1","98+","infection","infection","Canada","50-69 years","50-69 years",54,"38",66,NA,"alpha, gamma & delta",NA,NA,NA,"Canada","CAN",98,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-01-27
"696",98,"Skowronski","Test-negative case-control","27Jan2022","mRNA-1273 (Moderna)","excluded","1","1","21+","hospitalization","severe","Canada","50-69 years","50-69 years",85,"76",91,NA,"alpha, gamma & delta",NA,NA,NA,"Canada","CAN",98,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-01-27
"697",98,"Skowronski","Test-negative case-control","27Jan2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","14-20","hospitalization","severe","Canada","50-69 years","50-69 years",74,"60",83,NA,"alpha, gamma & delta",NA,NA,NA,"Canada","CAN",98,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-01-27
"698",98,"Skowronski","Test-negative case-control","27Jan2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","98+","hospitalization","severe","Canada","50-69 years","50-69 years",65,"47",77,NA,"alpha, gamma & delta",NA,NA,NA,"Canada","CAN",98,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-01-27
"699",98,"Skowronski","Test-negative case-control","27Jan2022","AZD1222 (AstraZeneca)","excluded","1","1","21+","infection","infection","Canada","50-69 years","50-69 years",60,"54",65,NA,"alpha, gamma & delta",NA,NA,NA,"Canada","CAN",98,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-01-27
"700",98,"Skowronski","Test-negative case-control","27Jan2022","AZD1222 (AstraZeneca)","excluded","1","1","14-20","infection","infection","Canada","50-69 years","50-69 years",25,"10",37,NA,"alpha, gamma & delta",NA,NA,NA,"Canada","CAN",98,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-01-27
"701",98,"Skowronski","Test-negative case-control","27Jan2022","AZD1222 (AstraZeneca)","excluded","1","1","98+","infection","infection","Canada","50-69 years","50-69 years",62,"36",77,NA,"alpha, gamma & delta",NA,NA,NA,"Canada","CAN",98,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-01-27
"702",98,"Skowronski","Test-negative case-control","27Jan2022","AZD1222 (AstraZeneca)","excluded","1","1","21+","hospitalization","severe","Canada","50-69 years","50-69 years",93,"85",97,NA,"alpha, gamma & delta",NA,NA,NA,"Canada","CAN",98,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-01-27
"703",98,"Skowronski","Test-negative case-control","27Jan2022","AZD1222 (AstraZeneca)","excluded","1","1","14-20","hospitalization","severe","Canada","50-69 years","50-69 years",67,"30",84,NA,"alpha, gamma & delta",NA,NA,NA,"Canada","CAN",98,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-01-27
"704",98,"Skowronski","Test-negative case-control","27Jan2022","AZD1222 (AstraZeneca)","excluded","1","1","84+","hospitalization","severe","Canada","50-69 years","50-69 years",74,"-4",94,NA,"alpha, gamma & delta",NA,NA,NA,"Canada","CAN",98,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-01-27
"705",98,"Skowronski","Test-negative case-control","27Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","21+","infection","infection","Canada","50-69 years","50-69 years",77,"73",80,"alpha","alpha",NA,NA,NA,"Canada","CAN",98,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2022-01-27
"706",98,"Skowronski","Test-negative case-control","27Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","21+","hospitalization","severe","Canada","50-69 years","50-69 years",85,"72",92,"alpha","alpha",NA,NA,NA,"Canada","CAN",98,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2022-01-27
"707",98,"Skowronski","Test-negative case-control","27Jan2022","mRNA-1273 (Moderna)","excluded","1","1","21+","infection","infection","Canada","50-69 years","50-69 years",84,"77",89,"alpha","alpha",NA,NA,NA,"Canada","CAN",98,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","alpha",NA,2022-01-27
"708",98,"Skowronski","Test-negative case-control","27Jan2022","mRNA-1273 (Moderna)","excluded","1","1","21+","hospitalization","severe","Canada","50-69 years","50-69 years",78,"44",91,"alpha","alpha",NA,NA,NA,"Canada","CAN",98,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","alpha",NA,2022-01-27
"709",98,"Skowronski","Test-negative case-control","27Jan2022","AZD1222 (AstraZeneca)","excluded","1","1","21+","infection ","infection","Canada","50-69 years","50-69 years",69,"61",75,"alpha","alpha",NA,NA,NA,"Canada","CAN",98,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2022-01-27
"710",98,"Skowronski","Test-negative case-control","27Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","21+","infection ","infection","Canada","50-69 years","50-69 years",77,"72",81,"gamma","gamma",NA,NA,NA,"Canada","CAN",98,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","gamma",NA,2022-01-27
"711",98,"Skowronski","Test-negative case-control","27Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","21+","hospitalization","severe","Canada","50-69 years","50-69 years",89,"79",94,"gamma","gamma",NA,NA,NA,"Canada","CAN",98,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","gamma",NA,2022-01-27
"712",98,"Skowronski","Test-negative case-control","27Jan2022","mRNA-1273 (Moderna)","excluded","1","1","21+","infection","infection","Canada","50-69 years","50-69 years",85,"76",90,"gamma","gamma",NA,NA,NA,"Canada","CAN",98,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","gamma",NA,2022-01-27
"713",98,"Skowronski","Test-negative case-control","27Jan2022","mRNA-1273 (Moderna)","excluded","1","1","21+","hospitalization","severe","Canada","50-69 years","50-69 years",96,"71",99,"gamma","gamma",NA,NA,NA,"Canada","CAN",98,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","gamma",NA,2022-01-27
"714",98,"Skowronski","Test-negative case-control","27Jan2022","AZD1222 (AstraZeneca)","excluded","1","1","21+","infection","infection","Canada","50-69 years","50-69 years",67,"58",74,"gamma","gamma",NA,NA,NA,"Canada","CAN",98,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","gamma",NA,2022-01-27
"715",98,"Skowronski","Test-negative case-control","27Jan2022","AZD1222 (AstraZeneca)","excluded","1","1","21+","hospitalization","severe","Canada","50-69 years","50-69 years",93,"78",98,"gamma","gamma",NA,NA,NA,"Canada","CAN",98,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","gamma",NA,2022-01-27
"716",98,"Skowronski","Test-negative case-control","27Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","21+","infection","infection","Canada","50-69 years","50-69 years",58,"52",63,"delta","delta",NA,NA,NA,"Canada","CAN",98,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-01-27
"717",98,"Skowronski","Test-negative case-control","27Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","21+","hospitalization","severe","Canada","50-69 years","50-69 years",73,"60",82,"delta","delta",NA,NA,NA,"Canada","CAN",98,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-01-27
"718",98,"Skowronski","Test-negative case-control","27Jan2022","mRNA-1273 (Moderna)","excluded","1","1","21+","infection","infection","Canada","50-69 years","50-69 years",70,"64",76,"delta","delta",NA,NA,NA,"Canada","CAN",98,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta",NA,2022-01-27
"719",98,"Skowronski","Test-negative case-control","27Jan2022","mRNA-1273 (Moderna)","excluded","1","1","21+","hospitalization","severe","Canada","50-69 years","50-69 years",86,"72",93,"delta","delta",NA,NA,NA,"Canada","CAN",98,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta",NA,2022-01-27
"720",98,"Skowronski","Test-negative case-control","27Jan2022","AZD1222 (AstraZeneca)","excluded","1","1","21+","infection","infection","Canada","50-69 years","50-69 years",41,"15",59,"delta","delta",NA,NA,NA,"Canada","CAN",98,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2022-01-27
"721",98,"Skowronski","Test-negative case-control","27Jan2022","AZD1222 (AstraZeneca)","excluded","1","1","21+","hospitalization","severe","Canada","50-69 years","50-69 years",61,"-8",86,"delta","delta",NA,NA,NA,"Canada","CAN",98,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2022-01-27
"722",98,"Skowronski","Test-negative case-control","27Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","21+","infection","infection","Canada","50-69 years","50-69 years",88,"75",95,"non-VOC","non-VOC",NA,NA,NA,"Canada","CAN",98,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","original",NA,2022-01-27
"723",98,"Skowronski","Test-negative case-control","27Jan2022","mRNA-1273 (Moderna)","excluded","1","1","21+","infection","infection","Canada","50-69 years","50-69 years",78,"31",93,"non-VOC","non-VOC",NA,NA,NA,"Canada","CAN",98,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","original",NA,2022-01-27
"724",98,"Skowronski","Test-negative case-control","27Jan2022","AZD1222 (AstraZeneca)","excluded","1","1","21+","infection","infection","Canada","50-69 years","50-69 years",93,"70",98,"non-VOC","non-VOC",NA,NA,NA,"Canada","CAN",98,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","original",NA,2022-01-27
"725",99,"Pilishvili","Test-negative case-control","22Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","symptomatic disease","symptomatic","USA","HCW","HCW",88.9,"84.7",92,NA,"alpha","~14 weeks",NA,NA,"USA","USA",99,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-22,"symptomatic","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha",NA,2021-09-22
"726",99,"Pilishvili","Test-negative case-control","22Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","15-28","symptomatic disease","symptomatic","USA","HCW","HCW",96.3,"92.5",98.2,NA,"alpha","~14 weeks",NA,NA,"USA","USA",99,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-22,"symptomatic","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha",NA,2021-09-22
"727",99,"Pilishvili","Test-negative case-control","22Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","85-98","symptomatic disease","symptomatic","USA","HCW","HCW",80.7,"61",90.4,NA,"alpha","~14 weeks",NA,NA,"USA","USA",99,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-22,"symptomatic","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha",NA,2021-09-22
"728",99,"Pilishvili","Test-negative case-control","22Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","14+ through dose 2 or later (at least one dose)","symptomatic disease","symptomatic","USA","immunocompromised HCW","immunocompromised HCW",39.1,"-45",74.4,NA,"alpha",NA,NA,NA,"USA","USA",99,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-22,"symptomatic","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha",NA,2021-09-22
"729",99,"Pilishvili","Test-negative case-control","22Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","14+ through dose 2 or later (at least one dose)","symptomatic disease","symptomatic","USA","pregnant HCW","pregnant HCW",77.1,"32.2",92.2,NA,"alpha",NA,NA,NA,"USA","USA",99,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-22,"symptomatic","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha",NA,2021-09-22
"730",99,"Pilishvili","Test-negative case-control","22Sept2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14+ up to <7 days post 2nd dose","symptomatic disease","symptomatic","USA","HCW","HCW",77.6,"70.9",82.7,NA,"alpha",NA,NA,NA,"USA","USA",99,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-22,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-09-22
"731",99,"Pilishvili","Test-negative case-control","22Sept2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7+","symptomatic disease","symptomatic","USA","HCW","HCW",88.8,"84.6",91.8,NA,"alpha","~14 weeks",NA,NA,"USA","USA",99,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-22,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-09-22
"732",99,"Pilishvili","Test-negative case-control","22Sept2021","mRNA-1273 (Moderna)","excluded","1","1","14+ up to <7 days post 2nd dose","symptomatic disease","symptomatic","USA","HCW","HCW",88.9,"78.7",94.2,NA,"alpha",NA,NA,NA,"USA","USA",99,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-22,"symptomatic","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","alpha",NA,2021-09-22
"733",99,"Pilishvili","Test-negative case-control","22Sept2021","mRNA-1273 (Moderna)","excluded","2","final","7+","symptomatic disease","symptomatic","USA","HCW","HCW",96.3,"91.3",98.4,NA,"alpha","~14 weeks",NA,NA,"USA","USA",99,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-22,"symptomatic","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","alpha",NA,2021-09-22
"734",100,"Meyer","Retrospective cohort","09Sept2021","BNT162b2 (Pfizer BioNTech)","unknown","2","final","7+","infection","infection","Germany","LTCF residents and staff","LTCF residents and staff",56,"15",77,NA,"alpha","~11 weeks",NA,NA,"Germany","DEU",100,"DEU",59260,2019,"Germany","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-06,2021-12-18,2020-12-23,2020-12-23,4,15,195,360,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-09,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","23/09/2021",2021-09-09
"735",101,"Glatman-Freedman","Retrospective cohort","27Sep2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","8-28","infection","infection","Israel","12-15 years","12-15 years",91.5,"88.2",93.9,NA,"delta","2 weeks",NA,NA,"Israel","ISR",101,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-09-27,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2021-09-27
"736",102,"Eyre","Retrospective cohort","05Jan2022","BNT162b2 (Pfizer BioNTech)","included","1","1","0+ up to 13 days post dose 2","infection","infection","UK","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",15,"12",18,"alpha","alpha",NA,NA,NA,"UK","GBR",102,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-05,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","29/09/2021",2021-09-29
"737",102,"Eyre","Retrospective cohort","05Jan2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection","infection","UK","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",85,"79",89,"alpha","alpha","~20.5 weeks",NA,NA,"UK","GBR",102,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-05,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","29/09/2021",2021-09-29
"738",102,"Eyre","Retrospective cohort","05Jan2022","AZD1222 (AstraZeneca)","included","1","1","0+ up to 13 days post dose 2","infection","infection","UK","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",6,"2",9,"alpha","alpha",NA,NA,NA,"UK","GBR",102,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-05,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","29/09/2021",2021-09-29
"739",102,"Eyre","Retrospective cohort","05Jan2022","AZD1222 (AstraZeneca)","included","2","final","14+","infection","infection","UK","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",60,"41",73,"alpha","alpha","~8 weeks",NA,NA,"UK","GBR",102,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-05,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","29/09/2021",2021-09-29
"740",102,"Eyre","Retrospective cohort","05Jan2022","BNT162b2 (Pfizer BioNTech)","included","1","1","0+ up to 13 days post dose 2","infection","infection","UK","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",33,"31",35,"delta","delta",NA,NA,NA,"UK","GBR",102,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-05,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","29/09/2021",2021-09-29
"741",102,"Eyre","Retrospective cohort","05Jan2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection","infection","UK","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",81,"77",84,"delta","delta","~29 weeks",NA,NA,"UK","GBR",102,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-05,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","29/09/2021",2021-09-29
"742",102,"Eyre","Retrospective cohort","05Jan2022","AZD1222 (AstraZeneca)","included","1","1","0+ up to 13 days post dose 2","infection","infection","UK","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",31,"28",34,"delta","delta",NA,NA,NA,"UK","GBR",102,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-05,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","29/09/2021",2021-09-29
"743",102,"Eyre","Retrospective cohort","05Jan2022","AZD1222 (AstraZeneca)","included","2","final","14+","infection","infection","UK","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",58,"55",62,"delta","delta","~16 weeks",NA,NA,"UK","GBR",102,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-05,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","29/09/2021",2021-09-29
"744",103,"Martinez-Baz","Prospective cohort","30Sep2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14+","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",57,"52",61,NA,"non-VOC, alpha, & delta",NA,NA,NA,"Spain","ESP",103,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-09-30
"745",103,"Martinez-Baz","Prospective cohort","30Sep2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",69,"66",72,NA,"non-VOC, alpha, & delta","~31 weeks",NA,NA,"Spain","ESP",103,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-09-30
"746",103,"Martinez-Baz","Prospective cohort","30Sep2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","<90","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",57,"51",61,NA,"non-VOC, alpha, & delta",NA,NA,NA,"Spain","ESP",103,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-09-30
"747",103,"Martinez-Baz","Prospective cohort","30Sep2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","<90","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",70,"67",73,NA,"non-VOC, alpha, & delta","~11 weeks",NA,NA,"Spain","ESP",103,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-09-30
"748",103,"Martinez-Baz","Prospective cohort","30Sep2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","90+","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",63,"58",68,NA,"non-VOC, alpha, & delta","~18 weeks",NA,NA,"Spain","ESP",103,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-09-30
"749",103,"Martinez-Baz","Prospective cohort","30Sep2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14+","symptomatic disease","symptomatic","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",66,"60",71,NA,"non-VOC, alpha, & delta",NA,NA,NA,"Spain","ESP",103,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-09-30
"750",103,"Martinez-Baz","Prospective cohort","30Sep2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease","symptomatic","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",72,"69",75,NA,"non-VOC, alpha, & delta","~31 weeks",NA,NA,"Spain","ESP",103,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-09-30
"751",103,"Martinez-Baz","Prospective cohort","30Sep2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14+","hospitalization","severe","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",86,"69",94,NA,"non-VOC, alpha, & delta",NA,NA,NA,"Spain","ESP",103,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-09-30
"752",103,"Martinez-Baz","Prospective cohort","30Sep2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization","severe","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",93,"88",96,NA,"non-VOC, alpha, & delta","~31 weeks",NA,NA,"Spain","ESP",103,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-09-30
"753",103,"Martinez-Baz","Prospective cohort","30Sep2021","mRNA-1273 (Moderna)","excluded","1","1","14+","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",66,"56",73,NA,"non-VOC, alpha, & delta",NA,NA,NA,"Spain","ESP",103,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-09-30
"754",103,"Martinez-Baz","Prospective cohort","30Sep2021","mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",82,"78",86,NA,"non-VOC, alpha, & delta","~28 weeks",NA,NA,"Spain","ESP",103,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-09-30
"755",103,"Martinez-Baz","Prospective cohort","30Sep2021","mRNA-1273 (Moderna)","excluded","1","1","<90","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",65,"56",73,NA,"non-VOC, alpha, & delta",NA,NA,NA,"Spain","ESP",103,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-09-30
"756",103,"Martinez-Baz","Prospective cohort","30Sep2021","mRNA-1273 (Moderna)","excluded","2","final","90+","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",67,"50",78,NA,"non-VOC, alpha, & delta","~15 weeks",NA,NA,"Spain","ESP",103,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-09-30
"757",103,"Martinez-Baz","Prospective cohort","30Sep2021","mRNA-1273 (Moderna)","excluded","1","1","14+","symptomatic disease","symptomatic","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",71,"61",79,NA,"non-VOC, alpha, & delta",NA,NA,NA,"Spain","ESP",103,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"symptomatic","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-09-30
"758",103,"Martinez-Baz","Prospective cohort","30Sep2021","mRNA-1273 (Moderna)","excluded","2","final","14+","symptomatic disease","symptomatic","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",85,"80",89,NA,"non-VOC, alpha, & delta","~28 weeks",NA,NA,"Spain","ESP",103,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"symptomatic","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-09-30
"759",103,"Martinez-Baz","Prospective cohort","30Sep2021","mRNA-1273 (Moderna)","excluded","1","1","14+","hospitalization","severe","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",73,"-10",93,NA,"non-VOC, alpha, & delta",NA,NA,NA,"Spain","ESP",103,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-09-30
"760",103,"Martinez-Baz","Prospective cohort","30Sep2021","mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization","severe","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",98,"82",100,NA,"non-VOC, alpha, & delta","~28 weeks",NA,NA,"Spain","ESP",103,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-09-30
"761",103,"Martinez-Baz","Prospective cohort","30Sep2021","AZD1222 (AstraZeneca)","excluded","1","1","14+","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",41,"34",48,NA,"non-VOC, alpha, & delta",NA,NA,NA,"Spain","ESP",103,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2021-09-30
"762",103,"Martinez-Baz","Prospective cohort","30Sep2021","AZD1222 (AstraZeneca)","excluded","2","final","14+","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",54,"48",60,NA,"non-VOC, alpha, & delta","~16 weeks",NA,NA,"Spain","ESP",103,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2021-09-30
"763",103,"Martinez-Baz","Prospective cohort","30Sep2021","AZD1222 (AstraZeneca)","excluded","1","1","<90","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",40,"31",47,NA,"non-VOC, alpha, & delta",NA,NA,NA,"Spain","ESP",103,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2021-09-30
"764",103,"Martinez-Baz","Prospective cohort","30Sep2021","AZD1222 (AstraZeneca)","excluded","2","final","<90","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",54,"47",60,NA,"non-VOC, alpha, & delta","~11 weeks",NA,NA,"Spain","ESP",103,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2021-09-30
"765",103,"Martinez-Baz","Prospective cohort","30Sep2021","AZD1222 (AstraZeneca)","excluded","1","1","90+","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",52,"37",64,NA,"non-VOC, alpha, & delta",NA,NA,NA,"Spain","ESP",103,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2021-09-30
"766",103,"Martinez-Baz","Prospective cohort","30Sep2021","AZD1222 (AstraZeneca)","excluded","1","1","14+","symptomatic disease","symptomatic","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",46,"37",54,NA,"non-VOC, alpha, & delta",NA,NA,NA,"Spain","ESP",103,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"symptomatic","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2021-09-30
"767",103,"Martinez-Baz","Prospective cohort","30Sep2021","AZD1222 (AstraZeneca)","excluded","2","final","14+","symptomatic disease","symptomatic","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",56,"48",63,NA,"non-VOC, alpha, & delta","~16 weeks",NA,NA,"Spain","ESP",103,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"symptomatic","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2021-09-30
"768",103,"Martinez-Baz","Prospective cohort","30Sep2021","AZD1222 (AstraZeneca)","excluded","1","1","14+","hospitalization","severe","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",78,"54",89,NA,"non-VOC, alpha, & delta",NA,NA,NA,"Spain","ESP",103,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"severe","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2021-09-30
"769",103,"Martinez-Baz","Prospective cohort","30Sep2021","AZD1222 (AstraZeneca)","excluded","2","final","14+","hospitalization","severe","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",95,"79",99,NA,"non-VOC, alpha, & delta","~16 weeks",NA,NA,"Spain","ESP",103,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"severe","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2021-09-30
"770",103,"Martinez-Baz","Prospective cohort","30Sep2021","Ad26.COV2.S (Janssen)","excluded","1","final","14+","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",50,"42",57,NA,"non-VOC, alpha, & delta","~23 weeks",NA,NA,"Spain","ESP",103,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2021-09-30
"771",103,"Martinez-Baz","Prospective cohort","30Sep2021","Ad26.COV2.S (Janssen)","excluded","1","final","<90","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",52,"44",59,NA,"non-VOC, alpha, & delta","~11 weeks",NA,NA,"Spain","ESP",103,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2021-09-30
"772",103,"Martinez-Baz","Prospective cohort","30Sep2021","Ad26.COV2.S (Janssen)","excluded","1","final","90+","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",28,"-8",53,NA,"non-VOC, alpha, & delta","~10 weeks",NA,NA,"Spain","ESP",103,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2021-09-30
"773",103,"Martinez-Baz","Prospective cohort","30Sep2021","Ad26.COV2.S (Janssen)","excluded","1","final","14+","symptomatic disease","symptomatic","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",54,"45",62,NA,"non-VOC, alpha, & delta","~23 weeks",NA,NA,"Spain","ESP",103,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"symptomatic","2021 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2021-09-30
"774",103,"Martinez-Baz","Prospective cohort","30Sep2021","Ad26.COV2.S (Janssen)","excluded","1","final","14+","hospitalization","severe","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",74,"43",88,NA,"non-VOC, alpha, & delta","~23 weeks",NA,NA,"Spain","ESP",103,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"severe","2021 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2021-09-30
"775",103,"Martinez-Baz","Prospective cohort","30Sep2021","AZD1222 (AstraZeneca) & BNT162b2 (Pfizer BioNTech) - heterologous","excluded","2","final","14+","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",86,"70",93,NA,"non-VOC, alpha, & delta","~21 weeks",NA,NA,"Spain","ESP",103,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","Heterologous platforms","Multiple","other combinations",NA,2021-09-30
"776",103,"Martinez-Baz","Prospective cohort","30Sep2021","AZD1222 (AstraZeneca) & BNT162b2 (Pfizer BioNTech) - heterologous","excluded","2","final","<90","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",85,"69",93,NA,"non-VOC, alpha, & delta","~11 weeks",NA,NA,"Spain","ESP",103,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","Heterologous platforms","Multiple","other combinations",NA,2021-09-30
"777",103,"Martinez-Baz","Prospective cohort","30Sep2021","AZD1222 (AstraZeneca) & BNT162b2 (Pfizer BioNTech) - heterologous","excluded","2","final","14+","symptomatic disease","symptomatic","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",91,"71",97,NA,"non-VOC, alpha, & delta","~21 weeks",NA,NA,"Spain","ESP",103,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"symptomatic","2021 (Jul-Dec)","Heterologous platforms","Multiple","other combinations",NA,2021-09-30
"778",103,"Martinez-Baz","Prospective cohort","30Sep2021","AZD1222 (AstraZeneca) & BNT162b2 (Pfizer BioNTech) - heterologous","excluded","2","final","14+","hospitalization","severe","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",95,"79",99,NA,"non-VOC, alpha, & delta","~21 weeks",NA,NA,"Spain","ESP",103,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"severe","2021 (Jul-Dec)","Heterologous platforms","Multiple","other combinations",NA,2021-09-30
"779",103,"Martinez-Baz","Prospective cohort","30Sep2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14+","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",54,"37",67,"alpha","alpha",NA,NA,NA,"Spain","ESP",103,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-09-30
"780",103,"Martinez-Baz","Prospective cohort","30Sep2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",71,"61",78,"alpha","alpha","~31 weeks",NA,NA,"Spain","ESP",103,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-09-30
"781",103,"Martinez-Baz","Prospective cohort","30Sep2021","mRNA-1273 (Moderna)","excluded","1","1","14+","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",60,"14",81,"alpha","alpha",NA,NA,NA,"Spain","ESP",103,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","alpha",NA,2021-09-30
"782",103,"Martinez-Baz","Prospective cohort","30Sep2021","mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",86,"56",95,"alpha","alpha","~28 weeks",NA,NA,"Spain","ESP",103,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","alpha",NA,2021-09-30
"783",103,"Martinez-Baz","Prospective cohort","30Sep2021","AZD1222 (AstraZeneca)","excluded","1","1","14+","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",37,"21",50,"alpha","alpha",NA,NA,NA,"Spain","ESP",103,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2021-09-30
"784",103,"Martinez-Baz","Prospective cohort","30Sep2021","AZD1222 (AstraZeneca)","excluded","2","final","14+","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",38,"-42",73,"alpha","alpha","~16 weeks",NA,NA,"Spain","ESP",103,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2021-09-30
"785",103,"Martinez-Baz","Prospective cohort","30Sep2021","Ad26.COV2.S (Janssen)","excluded","1","final","14+","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",77,"27",92,"alpha","alpha",NA,NA,NA,"Spain","ESP",103,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","alpha",NA,2021-09-30
"786",103,"Martinez-Baz","Prospective cohort","30Sep2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14+","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",63,"51",73,"delta","delta",NA,NA,NA,"Spain","ESP",103,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2021-09-30
"787",103,"Martinez-Baz","Prospective cohort","30Sep2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",67,"59",74,"delta","delta","~31 weeks",NA,NA,"Spain","ESP",103,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2021-09-30
"788",103,"Martinez-Baz","Prospective cohort","30Sep2021","mRNA-1273 (Moderna)","excluded","1","1","14+","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",72,"51",84,"delta","delta",NA,NA,NA,"Spain","ESP",103,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2021-09-30
"789",103,"Martinez-Baz","Prospective cohort","30Sep2021","mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",77,"64",85,"delta","delta","~28 weeks",NA,NA,"Spain","ESP",103,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2021-09-30
"790",103,"Martinez-Baz","Prospective cohort","30Sep2021","AZD1222 (AstraZeneca)","excluded","1","1","14+","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",53,"26",70,"delta","delta",NA,NA,NA,"Spain","ESP",103,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2021-09-30
"791",103,"Martinez-Baz","Prospective cohort","30Sep2021","AZD1222 (AstraZeneca)","excluded","2","final","14+","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",55,"39",67,"delta","delta","~16 weeks",NA,NA,"Spain","ESP",103,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2021-09-30
"792",103,"Martinez-Baz","Prospective cohort","30Sep2021","Ad26.COV2.S (Janssen)","excluded","1","final","14+","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",42,"18",53,"delta","delta",NA,NA,NA,"Spain","ESP",103,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta",NA,2021-09-30
"793",103,"Martinez-Baz","Prospective cohort","30Sep2021","AZD1222 (AstraZeneca) & BNT162b2 (Pfizer BioNTech) - heterologous","excluded","2","final","14+","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",86,"45",97,"delta","delta","~21 weeks",NA,NA,"Spain","ESP",103,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","Heterologous platforms","Multiple","delta",NA,2021-09-30
"794",104,"Bruxvoort","Test-negative case-control","15Dec2021","mRNA-1273 (Moderna)","excluded","1","1","14+","infection","infection","USA",">= 18 years","general pop",77,"60.7",86.5,"delta","delta",NA,NA,NA,"USA","USA",104,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-12-15,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","01/10/2021",2021-10-01
"795",104,"Bruxvoort","Test-negative case-control","15Dec2021","mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","USA",">= 18 years","general pop",86.7,"84.3",88.7,"delta","delta","~25 weeks",NA,NA,"USA","USA",104,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-12-15,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","01/10/2021",2021-10-01
"796",104,"Bruxvoort","Test-negative case-control","15Dec2021","mRNA-1273 (Moderna)","excluded","2","final","14-60","infection","infection","USA",">= 18 years","general pop",94.1,"90.5",96.3,"delta","delta","~6.5 weeks",NA,NA,"USA","USA",104,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-12-15,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","01/10/2021",2021-10-01
"797",104,"Bruxvoort","Test-negative case-control","15Dec2021","mRNA-1273 (Moderna)","excluded","2","final","151-180","infection","infection","USA",">= 18 years","general pop",80,"70.2",86.6,"delta","delta","~23.5 weeks",NA,NA,"USA","USA",104,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-12-15,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","01/10/2021",2021-10-01
"798",104,"Bruxvoort","Test-negative case-control","15Dec2021","mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization","severe","USA",">= 18 years","general pop",97.5,"92.7",99.2,"delta","delta","~25 weeks",NA,NA,"USA","USA",104,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-12-15,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","01/10/2021",2021-10-01
"799",104,"Bruxvoort","Test-negative case-control","15Dec2021","mRNA-1273 (Moderna)","excluded","2","final","14-60","infection","infection","USA",">= 18 years","general pop",98.6,"97.3",99.3,"non-delta","non-delta","~6.5 weeks",NA,NA,"USA","USA",104,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-12-15,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","01/10/2021",2021-10-01
"800",104,"Bruxvoort","Test-negative case-control","15Dec2021","mRNA-1273 (Moderna)","excluded","2","final","121-150","infection","infection","USA",">= 18 years","general pop",88.7,"73.2",95.2,"non-delta","non-delta","~19.5 weeks",NA,NA,"USA","USA",104,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-12-15,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","01/10/2021",2021-10-01
"801",104,"Bruxvoort","Test-negative case-control","15Dec2021","mRNA-1273 (Moderna)","excluded","1","1","14+","infection","infection","USA",">= 18 years","general pop",90.1,"82.9",94.2,"alpha","alpha",NA,NA,NA,"USA","USA",104,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-12-15,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","alpha","01/10/2021",2021-10-01
"802",104,"Bruxvoort","Test-negative case-control","15Dec2021","mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","USA",">= 18 years","general pop",98.4,"96.9",99.1,"alpha","alpha","~25 weeks",NA,NA,"USA","USA",104,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-12-15,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","alpha","01/10/2021",2021-10-01
"803",104,"Bruxvoort","Test-negative case-control","15Dec2021","mRNA-1273 (Moderna)","excluded","1","1","14+","infection","infection","USA",">= 18 years","general pop",74.2,"43.8",88.1,"gamma","gamma",NA,NA,NA,"USA","USA",104,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-12-15,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","gamma","01/10/2021",2021-10-01
"804",104,"Bruxvoort","Test-negative case-control","15Dec2021","mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","USA",">= 18 years","general pop",95.5,"90.9",97.8,"gamma","gamma","~25 weeks",NA,NA,"USA","USA",104,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-12-15,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","gamma","01/10/2021",2021-10-01
"805",105,"Liu","Test-negative case-control","24May2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","USA",">= 18 years","general pop",59,"52",65,NA,"alpha & delta","~35 weeks",NA,NA,"USA","USA",105,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-05-24,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations","07/10/2021",2021-10-07
"806",105,"Liu","Test-negative case-control","24May2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","USA","immunocompromised, >= 18 years","immunocompromised adults",57,"45",66,NA,"alpha & delta","~35 weeks",NA,NA,"USA","USA",105,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-05-24,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations","07/10/2021",2021-10-07
"807",106,"Ranzani","Test-negative case-control","18Oct2021","Ad26.COV2.S (Janssen)","excluded","1","final","28+","symptomatic disease","symptomatic","Brazil",">= 18 years","general pop",50.9,"35.5",63,NA,"gamma","~10 weeks",NA,NA,"Brazil","BRA",106,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2021-10-18,"symptomatic","2021 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","gamma",NA,2021-10-18
"808",106,"Ranzani","Test-negative case-control","18Oct2021","Ad26.COV2.S (Janssen)","excluded","1","final","28+","hospitalization","severe","Brazil",">= 18 years","general pop",72.9,"35.1",91.1,NA,"gamma","~10 weeks",NA,NA,"Brazil","BRA",106,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2021-10-18,"severe","2021 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","gamma",NA,2021-10-18
"809",106,"Ranzani","Test-negative case-control","18Oct2021","Ad26.COV2.S (Janssen)","excluded","1","final","28+","ICU admission","severe","Brazil",">= 18 years","general pop",92.5,"54.9",99.6,NA,"gamma","~10 weeks",NA,NA,"Brazil","BRA",106,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2021-10-18,"severe","2021 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","gamma",NA,2021-10-18
"810",106,"Ranzani","Test-negative case-control","18Oct2021","Ad26.COV2.S (Janssen)","excluded","1","final","28+","death","death","Brazil",">= 18 years","general pop",90.5,"31.5",99.6,NA,"gamma","~10 weeks",NA,NA,"Brazil","BRA",106,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2021-10-18,"death","2021 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","gamma",NA,2021-10-18
"811",107,"Arregoces","Matched-pair cohort","19Oct2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization","severe","Colombia",">= 60 years",">= 60 years",90.3,"87.1",92.7,NA,"mu","~9 weeks",NA,NA,"Colombia","COL",107,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2021-10-19,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","mu",NA,2021-10-19
"812",107,"Arregoces","Matched-pair cohort","19Oct2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","post-hospitalization death","death","Colombia",">= 60 years",">= 60 years",98.5,"97.8",98.9,NA,"mu","~9 weeks",NA,NA,"Colombia","COL",107,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2021-10-19,"death","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","mu",NA,2021-10-19
"813",107,"Arregoces","Matched-pair cohort","19Oct2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","death without prior hospitalization","death","Colombia",">= 60 years",">= 60 years",89.2,"85.6",91.9,NA,"mu","~9 weeks",NA,NA,"Colombia","COL",107,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2021-10-19,"death","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","mu",NA,2021-10-19
"814",107,"Arregoces","Matched-pair cohort","19Oct2021","CoronaVac (Sinovac)","excluded","2","final","14+","hospitalization","severe","Colombia",">= 60 years",">= 60 years",67.2,"63.7",70.4,NA,"mu","~11 weeks",NA,NA,"Colombia","COL",107,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2021-10-19,"severe","2021 (Jul-Dec)","Sinovac CoronaVac","Inactivated","mu",NA,2021-10-19
"815",107,"Arregoces","Matched-pair cohort","19Oct2021","CoronaVac (Sinovac)","excluded","2","final","14+","post-hospitalization death","death","Colombia",">= 60 years",">= 60 years",77.1,"75.5",78.6,NA,"mu","~11 weeks",NA,NA,"Colombia","COL",107,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2021-10-19,"death","2021 (Jul-Dec)","Sinovac CoronaVac","Inactivated","mu",NA,2021-10-19
"816",107,"Arregoces","Matched-pair cohort","19Oct2021","CoronaVac (Sinovac)","excluded","2","final","14+","death without prior hospitalization","death","Colombia",">= 60 years",">= 60 years",69.8,"66.7",72.6,NA,"mu","~11 weeks",NA,NA,"Colombia","COL",107,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2021-10-19,"death","2021 (Jul-Dec)","Sinovac CoronaVac","Inactivated","mu",NA,2021-10-19
"817",107,"Arregoces","Matched-pair cohort","19Oct2021","AZD1222 (AstraZeneca)","excluded","2","final","14+","hospitalization","severe","Colombia",">= 60 years",">= 60 years",75.4,"48.2",88.3,NA,"mu","~7 weeks",NA,NA,"Colombia","COL",107,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2021-10-19,"severe","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","mu",NA,2021-10-19
"818",107,"Arregoces","Matched-pair cohort","19Oct2021","AZD1222 (AstraZeneca)","excluded","2","final","14+","post-hospitalization death","death","Colombia",">= 60 years",">= 60 years",96.3,"88.4",98.8,NA,"mu","~7 weeks",NA,NA,"Colombia","COL",107,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2021-10-19,"death","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","mu",NA,2021-10-19
"819",107,"Arregoces","Matched-pair cohort","19Oct2021","AZD1222 (AstraZeneca)","excluded","2","final","14+","death without prior hospitalization","death","Colombia",">= 60 years",">= 60 years",88.7,"64.8",96.4,NA,"mu","~7 weeks",NA,NA,"Colombia","COL",107,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2021-10-19,"death","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","mu",NA,2021-10-19
"820",107,"Arregoces","Matched-pair cohort","19Oct2021","Ad26.COV2.S (Janssen)","excluded","1","final","14+","hospitalization","severe","Colombia",">= 60 years",">= 60 years",80,"19.9",95,NA,"mu","~4 weeks",NA,NA,"Colombia","COL",107,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2021-10-19,"severe","2021 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","mu",NA,2021-10-19
"821",107,"Arregoces","Matched-pair cohort","19Oct2021","Ad26.COV2.S (Janssen)","excluded","1","final","14+","death without prior hospitalization","death","Colombia",">= 60 years",">= 60 years",75,"0",93.8,NA,"mu","~4 weeks",NA,NA,"Colombia","COL",107,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2021-10-19,"death","2021 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","mu",NA,2021-10-19
"822",108,"Olson","Test-negative case-control","19Oct2021","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","hospitalization","severe","USA","12-15 years","12-15 years",91,"74",97,NA,"delta","~12 weeks",NA,NA,"USA","USA",108,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-10-19,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2021-10-19
"823",108,"Olson","Test-negative case-control","19Oct2021","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","hospitalization","severe","USA","16-18 years","16-18 years",94,"78",99,NA,"delta","~12 weeks",NA,NA,"USA","USA",108,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-10-19,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2021-10-19
"824",110,"Chin","Retrospective cohort","20Oct2021","mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","USA","incarcerated men","incarcerated men",56.6,"42",67.5,NA,"delta","~27 weeks",NA,NA,"USA","USA",110,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-10-20,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2021-10-20
"825",110,"Chin","Retrospective cohort","20Oct2021","mRNA-1273 (Moderna)","included","2","final","14+","symptomatic disease","symptomatic","USA","incarcerated men","incarcerated men",84.2,"56.4",94.3,NA,"delta","~27 weeks",NA,NA,"USA","USA",110,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-10-20,"symptomatic","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2021-10-20
"826",110,"Chin","Retrospective cohort","20Oct2021","mRNA-1273 (Moderna)","previously infected only","2","final","14+","infection","infection","USA","incarcerated men","incarcerated men",80.5,"52.8",92,NA,"delta","~27 weeks",NA,NA,"USA","USA",110,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-10-20,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2021-10-20
"827",110,"Chin","Retrospective cohort","20Oct2021","mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","USA","incarcerated men","incarcerated men",49.5,"31.5",62.7,NA,"delta","~27 weeks",NA,NA,"USA","USA",110,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-10-20,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2021-10-20
"828",111,"Ranzani","Test-negative case-control","09Feb2022","AZD1222 (AstraZeneca)","excluded","1","1",">21","infection","infection","Brazil",">= 18 years","general pop",31,"12.7",45.5,NA,"gamma & delta",NA,NA,NA,"Brazil","BRA",111,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-02-09,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","20/10/2021",2021-10-20
"829",111,"Ranzani","Test-negative case-control","09Feb2022","AZD1222 (AstraZeneca)","excluded","2","final","14+","infection","infection","Brazil",">= 18 years","general pop",59,"33.1",74.8,NA,"gamma & delta","~31 weeks",NA,NA,"Brazil","BRA",111,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-02-09,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","20/10/2021",2021-10-20
"830",111,"Ranzani","Test-negative case-control","09Feb2022","AZD1222 (AstraZeneca)","excluded","1","1",">21","symptomatic disease","symptomatic","Brazil",">= 18 years","general pop",31.6,"12",46.8,NA,"gamma & delta",NA,NA,NA,"Brazil","BRA",111,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-02-09,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","20/10/2021",2021-10-20
"831",111,"Ranzani","Test-negative case-control","09Feb2022","AZD1222 (AstraZeneca)","excluded","2","final","14+","symptomatic disease","symptomatic","Brazil",">= 18 years","general pop",65.1,"40.9",79.4,NA,"gamma & delta","~31 weeks",NA,NA,"Brazil","BRA",111,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-02-09,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","20/10/2021",2021-10-20
"832",111,"Ranzani","Test-negative case-control","09Feb2022","AZD1222 (AstraZeneca)","excluded","1","1",">21","asymptomatic infection","asymptomatic","Brazil",">= 18 years","general pop",26.6,"-53.8",65,NA,"gamma & delta",NA,NA,NA,"Brazil","BRA",111,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-02-09,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","20/10/2021",2021-10-20
"833",112,"Nordstrom","Retrospective cohort","04Feb2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","15-30","symptomatic disease","symptomatic","Sweden",">= 18 years","general pop",92,"92",93,NA,"delta","~30 weeks",NA,NA,"Sweden","SWE",112,"SWE",58060,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,15,228,396,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-04,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","25/10/2021",2021-10-25
"834",112,"Nordstrom","Retrospective cohort","04Feb2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","210+","symptomatic disease","symptomatic","Sweden",">= 18 years","general pop",23,"-2",41,NA,"delta","~30 weeks",NA,NA,"Sweden","SWE",112,"SWE",58060,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,15,228,396,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-04,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","25/10/2021",2021-10-25
"835",112,"Nordstrom","Retrospective cohort","04Feb2022","mRNA-1273 (Moderna)","excluded","2","final","15-30","symptomatic disease","symptomatic","Sweden",">= 18 years","general pop",96,"94",97,NA,"delta","~30 weeks",NA,NA,"Sweden","SWE",112,"SWE",58060,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,15,228,396,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-04,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","25/10/2021",2021-10-25
"836",112,"Nordstrom","Retrospective cohort","04Feb2022","mRNA-1273 (Moderna)","excluded","2","final","210+","symptomatic disease","symptomatic","Sweden",">= 18 years","general pop",59,"18",79,NA,"delta","~30 weeks",NA,NA,"Sweden","SWE",112,"SWE",58060,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,15,228,396,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-04,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","25/10/2021",2021-10-25
"837",112,"Nordstrom","Retrospective cohort","04Feb2022","AZD1222 (AstraZeneca)","excluded","2","final","15-30","symptomatic disease","symptomatic","Sweden",">= 18 years","general pop",68,"52",79,NA,"delta","~30 weeks",NA,NA,"Sweden","SWE",112,"SWE",58060,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,15,228,396,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-04,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","25/10/2021",2021-10-25
"838",112,"Nordstrom","Retrospective cohort","04Feb2022","AZD1222 (AstraZeneca)","excluded","2","final","210+","symptomatic disease","symptomatic","Sweden",">= 18 years","general pop",-19,"-97",28,NA,"delta","~30 weeks",NA,NA,"Sweden","SWE",112,"SWE",58060,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,15,228,396,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-04,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","25/10/2021",2021-10-25
"839",112,"Nordstrom","Retrospective cohort","04Feb2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","15-30","symptomatic disease","symptomatic","Sweden",">= 18 years","general pop",89,"79",94,NA,"delta","~30 weeks",NA,NA,"Sweden","SWE",112,"SWE",58060,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,15,228,396,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-04,"symptomatic","2022 (Jan-Jun)","Heterologous platforms","Multiple","delta","25/10/2021",2021-10-25
"840",112,"Nordstrom","Retrospective cohort","04Feb2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","210+","symptomatic disease","symptomatic","Sweden",">= 18 years","general pop",66,"41",80,NA,"delta","~30 weeks",NA,NA,"Sweden","SWE",112,"SWE",58060,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,15,228,396,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-04,"symptomatic","2022 (Jan-Jun)","Heterologous platforms","Multiple","delta","25/10/2021",2021-10-25
"841",113,"Lin","Retrospective cohort","10Mar2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","1.25 months","symptomatic disease","symptomatic","USA",">= 18 years","general pop",94.5,"94.1",94.9,NA,"alpha & delta","~27 weeks",NA,NA,"USA","USA",113,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-10,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","26/10/2021",2021-10-26
"842",113,"Lin","Retrospective cohort","10Mar2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","7.25 months","symptomatic disease","symptomatic","USA",">= 18 years","general pop",67.8,"65.9",69.7,NA,"alpha & delta","~27 weeks",NA,NA,"USA","USA",113,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-10,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","26/10/2021",2021-10-26
"843",113,"Lin","Retrospective cohort","10Mar2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","1.25 months","hospitalization","severe","USA",">= 18 years","general pop",96.4,"95.1",97.4,NA,"alpha & delta","~27 weeks",NA,NA,"USA","USA",113,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-10,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","26/10/2021",2021-10-26
"844",113,"Lin","Retrospective cohort","10Mar2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","7.25 months","hospitalization","severe","USA",">= 18 years","general pop",92.4,"89.7",94.4,NA,"alpha & delta","~27 weeks",NA,NA,"USA","USA",113,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-10,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","26/10/2021",2021-10-26
"845",113,"Lin","Retrospective cohort","10Mar2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","1.25 months","death","death","USA",">= 18 years","general pop",98,"95.5",99.1,NA,"alpha & delta","~27 weeks",NA,NA,"USA","USA",113,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-10,"death","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","26/10/2021",2021-10-26
"846",113,"Lin","Retrospective cohort","10Mar2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","7.25 months","death","death","USA",">= 18 years","general pop",95.5,"92.2",97.4,NA,"alpha & delta","~32 weeks",NA,NA,"USA","USA",113,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-10,"death","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","26/10/2021",2021-10-26
"847",113,"Lin","Retrospective cohort","10Mar2022","mRNA-1273 (Moderna)","unknown","2","final","1 month","symptomatic disease","symptomatic","USA",">= 18 years","general pop",95.9,"95.5",96.2,NA,"alpha & delta","~32 weeks",NA,NA,"USA","USA",113,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-10,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","26/10/2021",2021-10-26
"848",113,"Lin","Retrospective cohort","10Mar2022","mRNA-1273 (Moderna)","unknown","2","final","7 months","symptomatic disease","symptomatic","USA",">= 18 years","general pop",77.8,"75.9",79.6,NA,"alpha & delta","~32 weeks",NA,NA,"USA","USA",113,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-10,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","26/10/2021",2021-10-26
"849",113,"Lin","Retrospective cohort","10Mar2022","mRNA-1273 (Moderna)","unknown","2","final","1 month","hospitalization","severe","USA",">= 18 years","general pop",97.2,"96.1",98,NA,"alpha & delta","~32 weeks",NA,NA,"USA","USA",113,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-10,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","26/10/2021",2021-10-26
"850",113,"Lin","Retrospective cohort","10Mar2022","mRNA-1273 (Moderna)","unknown","2","final","7 months","hospitalization","severe","USA",">= 18 years","general pop",94.9,"92.4",96.6,NA,"alpha & delta","~32 weeks",NA,NA,"USA","USA",113,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-10,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","26/10/2021",2021-10-26
"851",113,"Lin","Retrospective cohort","10Mar2022","mRNA-1273 (Moderna)","unknown","2","final","1 month","death","death","USA",">= 18 years","general pop",98.6,"97.3",99.3,NA,"alpha & delta","~32 weeks",NA,NA,"USA","USA",113,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-10,"death","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","26/10/2021",2021-10-26
"852",113,"Lin","Retrospective cohort","10Mar2022","mRNA-1273 (Moderna)","unknown","2","final","7 months","death","death","USA",">= 18 years","general pop",96,"92.8",97.8,NA,"alpha & delta","~22 weeks",NA,NA,"USA","USA",113,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-10,"death","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","26/10/2021",2021-10-26
"853",113,"Lin","Retrospective cohort","10Mar2022","Ad26.COV2.S (Janssen)","unknown","1","final","2 months","symptomatic disease","symptomatic","USA",">= 18 years","general pop",71.4,"68.3",74.2,NA,"alpha & delta","~22 weeks",NA,NA,"USA","USA",113,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-10,"symptomatic","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations","26/10/2021",2021-10-26
"854",113,"Lin","Retrospective cohort","10Mar2022","Ad26.COV2.S (Janssen)","unknown","1","final","6 months","symptomatic disease","symptomatic","USA",">= 18 years","general pop",64,"60.3",67.4,NA,"alpha & delta","~22 weeks",NA,NA,"USA","USA",113,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-10,"symptomatic","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations","26/10/2021",2021-10-26
"855",113,"Lin","Retrospective cohort","10Mar2022","Ad26.COV2.S (Janssen)","unknown","1","final","2 months","hospitalization","severe","USA",">= 18 years","general pop",85.8,"74.9",91.9,NA,"alpha & delta","~22 weeks",NA,NA,"USA","USA",113,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-10,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations","26/10/2021",2021-10-26
"856",113,"Lin","Retrospective cohort","10Mar2022","Ad26.COV2.S (Janssen)","unknown","1","final","6 months","hospitalization","severe","USA",">= 18 years","general pop",81.7,"68.6",89.3,NA,"alpha & delta","~22 weeks",NA,NA,"USA","USA",113,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-10,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations","26/10/2021",2021-10-26
"857",113,"Lin","Retrospective cohort","10Mar2022","Ad26.COV2.S (Janssen)","unknown","1","final","2 months","death","death","USA",">= 18 years","general pop",82.2,"46.3",94.1,NA,"alpha & delta","~22 weeks",NA,NA,"USA","USA",113,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-10,"death","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations","26/10/2021",2021-10-26
"858",113,"Lin","Retrospective cohort","10Mar2022","Ad26.COV2.S (Janssen)","unknown","1","final","6 months","death","death","USA",">= 18 years","general pop",71.2,"40.8",86,NA,"alpha & delta","~22 weeks",NA,NA,"USA","USA",113,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-10,"death","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations","26/10/2021",2021-10-26
"859",114,"Skowronski","Test-negative case-control","19Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","Infection","infection","Canada",">= 18 years","general pop",89,"89",89,NA,"non-VOC, alpha, gamma & delta","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","26/10/2021",2021-10-26
"860",114,"Skowronski","Test-negative case-control","19Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-27","Infection","infection","Canada",">= 18 years","general pop",93,"92",94,NA,"non-VOC, alpha, gamma & delta","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","26/10/2021",2021-10-26
"861",114,"Skowronski","Test-negative case-control","19Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","252-279","Infection","infection","Canada",">= 18 years","general pop",80,"75",83,NA,"non-VOC, alpha, gamma & delta","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","26/10/2021",2021-10-26
"862",114,"Skowronski","Test-negative case-control","19Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","Hospitalization","severe","Canada",">= 18 years","general pop",97,"97",98,NA,"non-VOC, alpha, gamma & delta","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","26/10/2021",2021-10-26
"863",114,"Skowronski","Test-negative case-control","19Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-27","Hospitalization","severe","Canada",">= 18 years","general pop",98,"96",99,NA,"non-VOC, alpha, gamma & delta","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","26/10/2021",2021-10-26
"864",114,"Skowronski","Test-negative case-control","19Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","252-279","Hospitalization","severe","Canada",">= 18 years","general pop",96,"86",99,NA,"non-VOC, alpha, gamma & delta","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","26/10/2021",2021-10-26
"865",114,"Skowronski","Test-negative case-control","19Apr2022","mRNA-1273 (Moderna)","excluded","2","final","14+","Infection","infection","Canada",">= 18 years","general pop",90,"89",90,NA,"non-VOC, alpha, gamma & delta","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","26/10/2021",2021-10-26
"866",114,"Skowronski","Test-negative case-control","19Apr2022","mRNA-1273 (Moderna)","excluded","2","final","14-27","Infection","infection","Canada",">= 18 years","general pop",95,"94",96,NA,"non-VOC, alpha, gamma & delta","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","26/10/2021",2021-10-26
"867",114,"Skowronski","Test-negative case-control","19Apr2022","mRNA-1273 (Moderna)","excluded","2","final","252-279","Infection","infection","Canada",">= 18 years","general pop",55,"40",66,NA,"non-VOC, alpha, gamma & delta","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","26/10/2021",2021-10-26
"868",114,"Skowronski","Test-negative case-control","19Apr2022","mRNA-1273 (Moderna)","excluded","2","final","14+","Hospitalization","severe","Canada",">= 18 years","general pop",97,"97",98,NA,"non-VOC, alpha, gamma & delta","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","26/10/2021",2021-10-26
"869",114,"Skowronski","Test-negative case-control","19Apr2022","mRNA-1273 (Moderna)","excluded","2","final","14-27","Hospitalization","severe","Canada",">= 18 years","general pop",99,"95",100,NA,"non-VOC, alpha, gamma & delta","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","26/10/2021",2021-10-26
"870",114,"Skowronski","Test-negative case-control","19Apr2022","mRNA-1273 (Moderna)","excluded","2","final","252-279","Hospitalization","severe","Canada",">= 18 years","general pop",95,"65",99,NA,"non-VOC, alpha, gamma & delta","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","26/10/2021",2021-10-26
"871",114,"Skowronski","Test-negative case-control","19Apr2022","AZD1222 (AstraZeneca)","excluded","2","final","14+","Infection","infection","Canada",">= 18 years","general pop",74,"72",76,NA,"non-VOC, alpha, gamma & delta","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","26/10/2021",2021-10-26
"872",114,"Skowronski","Test-negative case-control","19Apr2022","AZD1222 (AstraZeneca)","excluded","2","final","14-27","Infection","infection","Canada",">= 18 years","general pop",77,"57",87,NA,"non-VOC, alpha, gamma & delta","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","26/10/2021",2021-10-26
"873",114,"Skowronski","Test-negative case-control","19Apr2022","AZD1222 (AstraZeneca)","excluded","2","final","168-195","Infection","infection","Canada",">= 18 years","general pop",67,"48",80,NA,"non-VOC, alpha, gamma & delta","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","26/10/2021",2021-10-26
"874",114,"Skowronski","Test-negative case-control","19Apr2022","AZD1222 (AstraZeneca)","excluded","2","final","14+","Hospitalization","severe","Canada",">= 18 years","general pop",95,"94",97,NA,"non-VOC, alpha, gamma & delta","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","26/10/2021",2021-10-26
"875",114,"Skowronski","Test-negative case-control","19Apr2022","AZD1222 (AstraZeneca)","excluded","2","final","28-55","Hospitalization","severe","Canada",">= 18 years","general pop",97,"71",97,NA,"non-VOC, alpha, gamma & delta","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","26/10/2021",2021-10-26
"876",114,"Skowronski","Test-negative case-control","19Apr2022","AZD1222 (AstraZeneca)","excluded","2","final","168-195","Hospitalization","severe","Canada",">= 18 years","general pop",91,"35",99,NA,"non-VOC, alpha, gamma & delta","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","26/10/2021",2021-10-26
"877",114,"Skowronski","Test-negative case-control","19Apr2022","Any mRNA - heterologous","excluded","2","final","14+","Infection","infection","Canada",">= 18 years","general pop",90,"89",90,NA,"non-VOC, alpha, gamma & delta","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations","26/10/2021",2021-10-26
"878",114,"Skowronski","Test-negative case-control","19Apr2022","Any mRNA - heterologous","excluded","2","final","14-27","Infection","infection","Canada",">= 18 years","general pop",95,"91",97,NA,"non-VOC, alpha, gamma & delta","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations","26/10/2021",2021-10-26
"879",114,"Skowronski","Test-negative case-control","19Apr2022","Any mRNA - heterologous","excluded","2","final","168-195","Infection","infection","Canada",">= 18 years","general pop",96,"73",99,NA,"non-VOC, alpha, gamma & delta","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations","26/10/2021",2021-10-26
"880",114,"Skowronski","Test-negative case-control","19Apr2022","Any mRNA - heterologous","excluded","2","final","14+","Hospitalization","severe","Canada",">= 18 years","general pop",98,"97",98,NA,"non-VOC, alpha, gamma & delta","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations","26/10/2021",2021-10-26
"881",114,"Skowronski","Test-negative case-control","19Apr2022","Any mRNA - heterologous","excluded","2","final","14-27","Hospitalization","severe","Canada",">= 18 years","general pop",96,"75",100,NA,"non-VOC, alpha, gamma & delta","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations","26/10/2021",2021-10-26
"882",114,"Skowronski","Test-negative case-control","19Apr2022","Any mRNA - heterologous","excluded","2","final","140-167","Hospitalization","severe","Canada",">= 18 years","general pop",96,"92",98,NA,"non-VOC, alpha, gamma & delta","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations","26/10/2021",2021-10-26
"883",114,"Skowronski","Test-negative case-control","19Apr2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","14+","Infection","infection","Canada",">= 18 years","general pop",89,"88",89,NA,"non-VOC, alpha, gamma & delta","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Heterologous platforms","Multiple","other combinations","26/10/2021",2021-10-26
"884",114,"Skowronski","Test-negative case-control","19Apr2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","14-27","Infection","infection","Canada",">= 18 years","general pop",94,"89",97,NA,"non-VOC, alpha, gamma & delta","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Heterologous platforms","Multiple","other combinations","26/10/2021",2021-10-26
"885",114,"Skowronski","Test-negative case-control","19Apr2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","140-167","Infection","infection","Canada",">= 18 years","general pop",82,"78",85,NA,"non-VOC, alpha, gamma & delta","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Heterologous platforms","Multiple","other combinations","26/10/2021",2021-10-26
"886",114,"Skowronski","Test-negative case-control","19Apr2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","14+","Hospitalization","severe","Canada",">= 18 years","general pop",99,"99",100,NA,"non-VOC, alpha, gamma & delta","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Heterologous platforms","Multiple","other combinations","26/10/2021",2021-10-26
"887",114,"Skowronski","Test-negative case-control","19Apr2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","14-27","Hospitalization","severe","Canada",">= 18 years","general pop",93,"48",99,NA,"non-VOC, alpha, gamma & delta","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Heterologous platforms","Multiple","other combinations","26/10/2021",2021-10-26
"888",114,"Skowronski","Test-negative case-control","19Apr2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","140-167","hospitalization","severe","Canada",">= 18 years","general pop",98,"91",99,NA,"non-VOC, alpha, gamma & delta","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Heterologous platforms","Multiple","other combinations","26/10/2021",2021-10-26
"889",114,"Skowronski","Test-negative case-control","19Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","Infection","infection","Canada",">= 18 years","general pop",89,"89",89,"delta","delta","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","26/10/2021",2021-10-26
"890",114,"Skowronski","Test-negative case-control","19Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-27","Infection","infection","Canada",">= 18 years","general pop",93,"93",94,"delta","delta","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","26/10/2021",2021-10-26
"891",114,"Skowronski","Test-negative case-control","19Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","252-279","Infection","infection","Canada",">= 18 years","general pop",79,"75",83,"delta","delta","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","26/10/2021",2021-10-26
"892",114,"Skowronski","Test-negative case-control","19Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization","severe","Canada",">= 18 years","general pop",98,"97",98,"delta","delta","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","26/10/2021",2021-10-26
"893",114,"Skowronski","Test-negative case-control","19Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-27","hospitalization","severe","Canada",">= 18 years","general pop",98,"95",99,"delta","delta","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","26/10/2021",2021-10-26
"894",114,"Skowronski","Test-negative case-control","19Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","196-223","hospitalization","severe","Canada",">= 18 years","general pop",94,"87",97,"delta","delta","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","26/10/2021",2021-10-26
"895",114,"Skowronski","Test-negative case-control","19Apr2022","mRNA-1273 (Moderna)","excluded","2","final","14+","Infection","infection","Canada",">= 18 years","general pop",90,"89",90,"delta","delta","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","26/10/2021",2021-10-26
"896",114,"Skowronski","Test-negative case-control","19Apr2022","mRNA-1273 (Moderna)","excluded","2","final","14-27","Infection","infection","Canada",">= 18 years","general pop",95,"94",96,"delta","delta","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","26/10/2021",2021-10-26
"897",114,"Skowronski","Test-negative case-control","19Apr2022","mRNA-1273 (Moderna)","excluded","2","final","196-223","Infection","infection","Canada",">= 18 years","general pop",55,"41",66,"delta","delta","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","26/10/2021",2021-10-26
"898",114,"Skowronski","Test-negative case-control","19Apr2022","mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization","severe","Canada",">= 18 years","general pop",97,"97",98,"delta","delta","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","26/10/2021",2021-10-26
"899",114,"Skowronski","Test-negative case-control","19Apr2022","mRNA-1273 (Moderna)","excluded","2","final","14-27","hospitalization","severe","Canada",">= 18 years","general pop",98,"94",100,"delta","delta","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","26/10/2021",2021-10-26
"900",114,"Skowronski","Test-negative case-control","19Apr2022","mRNA-1273 (Moderna)","excluded","2","final","196-223","hospitalization","severe","Canada",">= 18 years","general pop",95,"80",99,"delta","delta","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","26/10/2021",2021-10-26
"901",114,"Skowronski","Test-negative case-control","19Apr2022","AZD1222 (AstraZeneca)","excluded","2","final","14+","Infection","infection","Canada",">= 18 years","general pop",73,"72",75,"delta","delta","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","26/10/2021",2021-10-26
"902",114,"Skowronski","Test-negative case-control","19Apr2022","AZD1222 (AstraZeneca)","excluded","2","final","14-27","Infection","infection","Canada",">= 18 years","general pop",70,"39",86,"delta","delta","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","26/10/2021",2021-10-26
"903",114,"Skowronski","Test-negative case-control","19Apr2022","AZD1222 (AstraZeneca)","excluded","2","final","168-195","Infection","infection","Canada",">= 18 years","general pop",67,"48",80,"delta","delta","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","26/10/2021",2021-10-26
"904",114,"Skowronski","Test-negative case-control","19Apr2022","AZD1222 (AstraZeneca)","excluded","2","final","14+","Hospitalization","severe","Canada",">= 18 years","general pop",95,"93",97,"delta","delta","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","26/10/2021",2021-10-26
"905",114,"Skowronski","Test-negative case-control","19Apr2022","AZD1222 (AstraZeneca)","excluded","2","final","28-55","Hospitalization","severe","Canada",">= 18 years","general pop",89,"67",97,"delta","delta","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","26/10/2021",2021-10-26
"906",114,"Skowronski","Test-negative case-control","19Apr2022","AZD1222 (AstraZeneca)","excluded","2","final","168-195","Hospitalization","severe","Canada",">= 18 years","general pop",91,"34",99,"delta","delta","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","26/10/2021",2021-10-26
"907",114,"Skowronski","Test-negative case-control","19Apr2022","Any mRNA - heterologous","excluded","2","final","14+","Infection","infection","Canada",">= 18 years","general pop",90,"89",90,"delta","delta","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta","26/10/2021",2021-10-26
"908",114,"Skowronski","Test-negative case-control","19Apr2022","Any mRNA - heterologous","excluded","2","final","14-27","Infection","infection","Canada",">= 18 years","general pop",94,"90",97,"delta","delta","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta","26/10/2021",2021-10-26
"909",114,"Skowronski","Test-negative case-control","19Apr2022","Any mRNA - heterologous","excluded","2","final","168-195","Infection","infection","Canada",">= 18 years","general pop",96,"73",99,"delta","delta","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta","26/10/2021",2021-10-26
"910",114,"Skowronski","Test-negative case-control","19Apr2022","Any mRNA - heterologous","excluded","2","final","14+","Hospitalization","severe","Canada",">= 18 years","general pop",98,"97",98,"delta","delta","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta","26/10/2021",2021-10-26
"911",114,"Skowronski","Test-negative case-control","19Apr2022","Any mRNA - heterologous","excluded","2","final","28-55","Hospitalization","severe","Canada",">= 18 years","general pop",97,"93",99,"delta","delta","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta","26/10/2021",2021-10-26
"912",114,"Skowronski","Test-negative case-control","19Apr2022","Any mRNA - heterologous","excluded","2","final","140-167","Hospitalization","severe","Canada",">= 18 years","general pop",96,"92",98,"delta","delta","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta","26/10/2021",2021-10-26
"913",114,"Skowronski","Test-negative case-control","19Apr2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","14+","Infection","infection","Canada",">= 18 years","general pop",88,"88",89,"delta","delta","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Heterologous platforms","Multiple","delta","26/10/2021",2021-10-26
"914",114,"Skowronski","Test-negative case-control","19Apr2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","14-27","Infection","infection","Canada",">= 18 years","general pop",94,"88",97,"delta","delta","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Heterologous platforms","Multiple","delta","26/10/2021",2021-10-26
"915",114,"Skowronski","Test-negative case-control","19Apr2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","140-167","Infection","infection","Canada",">= 18 years","general pop",82,"77",85,"delta","delta","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Heterologous platforms","Multiple","delta","26/10/2021",2021-10-26
"916",114,"Skowronski","Test-negative case-control","19Apr2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","14+","Hospitalization","severe","Canada",">= 18 years","general pop",99,"99",100,"delta","delta","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Heterologous platforms","Multiple","delta","26/10/2021",2021-10-26
"917",114,"Skowronski","Test-negative case-control","19Apr2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","14-27","Hospitalization","severe","Canada",">= 18 years","general pop",91,"33",99,"delta","delta","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Heterologous platforms","Multiple","delta","26/10/2021",2021-10-26
"918",114,"Skowronski","Test-negative case-control","19Apr2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","140-167","Hospitalization","severe","Canada",">= 18 years","general pop",98,"91",99,"delta","delta","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Heterologous platforms","Multiple","delta","26/10/2021",2021-10-26
"919",114,"Skowronski","Test-negative case-control","19Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","Infection","infection","Canada",">= 18 years","general pop",96,"92",98,"alpha","alpha","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","26/10/2021",2021-10-26
"920",114,"Skowronski","Test-negative case-control","19Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","Hospitalization","severe","Canada",">= 18 years","general pop",96,"83",99,"alpha","alpha","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","26/10/2021",2021-10-26
"921",114,"Skowronski","Test-negative case-control","19Apr2022","mRNA-1273 (Moderna)","excluded","2","final","14+","Infection","infection","Canada",">= 18 years","general pop",95,"84",98,"alpha","alpha","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","alpha","26/10/2021",2021-10-26
"922",114,"Skowronski","Test-negative case-control","19Apr2022","AZD1222 (AstraZeneca)","excluded","2","final","14+","Infection","infection","Canada",">= 18 years","general pop",75,"33",91,"alpha","alpha","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","26/10/2021",2021-10-26
"923",114,"Skowronski","Test-negative case-control","19Apr2022","Any mRNA - heterologous","excluded","2","final","14+","Infection","infection","Canada",">= 18 years","general pop",96,"73",99,"alpha","alpha","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","alpha","26/10/2021",2021-10-26
"924",114,"Skowronski","Test-negative case-control","19Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","Infection","infection","Canada",">= 18 years","general pop",92,"88",95,"gamma","gamma","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","gamma","26/10/2021",2021-10-26
"925",114,"Skowronski","Test-negative case-control","19Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","Hospitalization","severe","Canada",">= 18 years","general pop",95,"82",98,"gamma","gamma","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","gamma","26/10/2021",2021-10-26
"926",114,"Skowronski","Test-negative case-control","19Apr2022","mRNA-1273 (Moderna)","excluded","2","final","14+","Infection","infection","Canada",">= 18 years","general pop",95,"85",98,"gamma","gamma","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","gamma","26/10/2021",2021-10-26
"927",114,"Skowronski","Test-negative case-control","19Apr2022","AZD1222 (AstraZeneca)","excluded","2","final","14+","Infection","infection","Canada",">= 18 years","general pop",91,"63",98,"gamma","gamma","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","gamma","26/10/2021",2021-10-26
"928",114,"Skowronski","Test-negative case-control","19Apr2022","Any mRNA - heterologous","excluded","2","final","14+","Infection","infection","Canada",">= 18 years","general pop",94,"76",99,"gamma","gamma","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","gamma","26/10/2021",2021-10-26
"929",114,"Skowronski","Test-negative case-control","19Apr2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","14+","Infection","infection","Canada",">= 18 years","general pop",96,"69",99,"gamma","gamma","~38 weeks",NA,NA,"Canada","CAN",114,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Heterologous platforms","Multiple","gamma","26/10/2021",2021-10-26
"930",115,"Nordstrom","Retrospective cohort","18Oct2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease","symptomatic","Sweden",">= 18 years","general pop",78,"78",79,NA,"delta","~11 weeks",NA,NA,"Sweden","SWE",115,"SWE",58060,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,15,228,396,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-10-18,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2021-10-18
"931",115,"Nordstrom","Retrospective cohort","18Oct2021","mRNA-1273 (Moderna)","excluded","2","final","14+","symptomatic disease","symptomatic","Sweden",">= 18 years","general pop",87,"84",88,NA,"delta","~11 weeks",NA,NA,"Sweden","SWE",115,"SWE",58060,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,15,228,396,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-10-18,"symptomatic","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2021-10-18
"932",115,"Nordstrom","Retrospective cohort","18Oct2021","AZD1222 (AstraZeneca)","excluded","2","final","14+","symptomatic disease","symptomatic","Sweden",">= 18 years","general pop",50,"41",58,NA,"delta","~11 weeks",NA,NA,"Sweden","SWE",115,"SWE",58060,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,15,228,396,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-10-18,"symptomatic","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2021-10-18
"933",115,"Nordstrom","Retrospective cohort","18Oct2021","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","14+","symptomatic disease","symptomatic","Sweden",">= 18 years","general pop",67,"59",73,NA,"delta","~11 weeks",NA,NA,"Sweden","SWE",115,"SWE",58060,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,15,228,396,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-10-18,"symptomatic","2021 (Jul-Dec)","Heterologous platforms","Multiple","delta",NA,2021-10-18
"934",115,"Nordstrom","Retrospective cohort","18Oct2021","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","14+","symptomatic disease","symptomatic","Sweden",">= 18 years","general pop",79,"62",88,NA,"delta","~11 weeks",NA,NA,"Sweden","SWE",115,"SWE",58060,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,15,228,396,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-10-18,"symptomatic","2021 (Jul-Dec)","Heterologous platforms","Multiple","delta",NA,2021-10-18
"935",116,"Reis","Retrospective cohort","20Oct2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14-20","infection","infection","Israel","12-18 years","12-18 years",59,"52",65,NA,"delta",NA,NA,NA,"Israel","ISR",116,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-10-20,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2021-10-20
"936",116,"Reis","Retrospective cohort","20Oct2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7-21","infection","infection","Israel","12-18 years","12-18 years",90,"88",92,NA,"delta","~12 weeks",NA,NA,"Israel","ISR",116,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-10-20,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2021-10-20
"937",116,"Reis","Retrospective cohort","20Oct2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","21-27","infection","infection","Israel","12-18 years","12-18 years",66,"59",72,NA,"delta",NA,NA,NA,"Israel","ISR",116,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-10-20,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2021-10-20
"938",116,"Reis","Retrospective cohort","20Oct2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14-20","symptomatic disease","symptomatic","Israel","12-18 years","12-18 years",57,"39",71,NA,"delta",NA,NA,NA,"Israel","ISR",116,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-10-20,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2021-10-20
"939",116,"Reis","Retrospective cohort","20Oct2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7-21","symptomatic disease","symptomatic","Israel","12-18 years","12-18 years",93,"88",97,NA,"delta","~12 weeks",NA,NA,"Israel","ISR",116,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-10-20,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2021-10-20
"940",116,"Reis","Retrospective cohort","20Oct2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","21-27","symptomatic disease","symptomatic","Israel","12-18 years","12-18 years",82,"73",91,NA,"delta",NA,NA,NA,"Israel","ISR",116,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-10-20,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2021-10-20
"941",117,"Sheikh","Retrospective cohort","20Oct2021","BNT162b2 (Pfizer BioNTech)","unknown","1","1","14+","death","death","Scotland","40-59 years","40-59 years",100,NA,NA,NA,"alpha & delta",NA,NA,NA,"UK","GBR",117,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-10-20,"death","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-10-20
"942",117,"Sheikh","Retrospective cohort","20Oct2021","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","death","death","Scotland","40-59 years","40-59 years",95,"79",99,NA,"alpha & delta","~25 weeks",NA,NA,"UK","GBR",117,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-10-20,"death","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-10-20
"943",117,"Sheikh","Retrospective cohort","20Oct2021","BNT162b2 (Pfizer BioNTech)","unknown","1","1","14+","death","death","Scotland",">= 60 years","60+ years",75,"26",91,NA,"alpha & delta",NA,NA,NA,"UK","GBR",117,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-10-20,"death","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-10-20
"944",117,"Sheikh","Retrospective cohort","20Oct2021","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","death","death","Scotland",">= 60 years","60+ years",87,"77",93,NA,"alpha & delta","~25 weeks",NA,NA,"UK","GBR",117,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-10-20,"death","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-10-20
"945",117,"Sheikh","Retrospective cohort","20Oct2021","AZD1222 (AstraZeneca)","unknown","1","1","14+","death","death","Scotland","40-59 years","40-59 years",96,"85",99,NA,"alpha & delta",NA,NA,NA,"UK","GBR",117,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-10-20,"death","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2021-10-20
"946",117,"Sheikh","Retrospective cohort","20Oct2021","AZD1222 (AstraZeneca)","unknown","2","final","14+","death","death","Scotland","40-59 years","40-59 years",88,"76",93,NA,"alpha & delta","~25 weeks",NA,NA,"UK","GBR",117,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-10-20,"death","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2021-10-20
"947",117,"Sheikh","Retrospective cohort","20Oct2021","AZD1222 (AstraZeneca)","unknown","1","1","14+","death","death","Scotland",">= 60 years","60+ years",97,"86",99,NA,"alpha & delta",NA,NA,NA,"UK","GBR",117,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-10-20,"death","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2021-10-20
"948",117,"Sheikh","Retrospective cohort","20Oct2021","AZD1222 (AstraZeneca)","unknown","2","final","14+","death","death","Scotland",">= 60 years","60+ years",90,"84",94,NA,"alpha & delta","~25 weeks",NA,NA,"UK","GBR",117,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-10-20,"death","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2021-10-20
"949",117,"Sheikh","Retrospective cohort","20Oct2021","BNT162b2 (Pfizer BioNTech)","unknown","1","1","14+","death","death","Scotland",">= 18 years","general pop",92,"66",98,"delta","delta",NA,NA,NA,"UK","GBR",117,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-10-20,"death","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2021-10-20
"950",117,"Sheikh","Retrospective cohort","20Oct2021","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","death","death","Scotland",">= 18 years","general pop",90,"83",94,"delta","delta","~25 weeks",NA,NA,"UK","GBR",117,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-10-20,"death","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2021-10-20
"951",117,"Sheikh","Retrospective cohort","20Oct2021","AZD1222 (AstraZeneca)","unknown","1","1","14+","death","death","Scotland",">= 18 years","general pop",96,"89",99,"delta","delta",NA,NA,NA,"UK","GBR",117,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-10-20,"death","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2021-10-20
"952",117,"Sheikh","Retrospective cohort","20Oct2021","AZD1222 (AstraZeneca)","unknown","2","final","14+","death","death","Scotland",">= 18 years","general pop",91,"86",94,"delta","delta","~25 weeks",NA,NA,"UK","GBR",117,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-10-20,"death","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2021-10-20
"953",118,"Embi","Test-negative case-control","30Dec2021","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","hospitalization","severe","USA","immunocompromised, >= 18 years","immunocompromised adults",71,"65",76,NA,"non-VOC, alpha, & delta","~33 weeks",NA,NA,"USA","USA",118,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-12-30,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","05/11/2021",2021-11-05
"954",118,"Embi","Test-negative case-control","30Dec2021","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","hospitalization","severe","USA",">= 18 years","general pop",88,"86",89,NA,"non-VOC, alpha, & delta","~33 weeks",NA,NA,"USA","USA",118,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-12-30,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","05/11/2021",2021-11-05
"955",118,"Embi","Test-negative case-control","30Dec2021","mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","immunocompromised, >= 18 years","immunocompromised adults",81,"76",85,NA,"non-VOC, alpha, & delta","~33 weeks",NA,NA,"USA","USA",118,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-12-30,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","05/11/2021",2021-11-05
"956",118,"Embi","Test-negative case-control","30Dec2021","mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA",">= 18 years","general pop",93,"92",94,NA,"non-VOC, alpha, & delta","~33 weeks",NA,NA,"USA","USA",118,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-12-30,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","05/11/2021",2021-11-05
"957",118,"Embi","Test-negative case-control","30Dec2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","immunocompromised, >= 18 years","immunocompromised adults",76,"69",81,NA,"non-VOC & alpha","~33 weeks",NA,NA,"USA","USA",118,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-12-30,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","05/11/2021",2021-11-05
"958",118,"Embi","Test-negative case-control","30Dec2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA",">= 18 years","general pop",91,"90",93,NA,"non-VOC & alpha","~33 weeks",NA,NA,"USA","USA",118,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-12-30,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","05/11/2021",2021-11-05
"959",118,"Embi","Test-negative case-control","30Dec2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","immunocompromised, >= 18 years","immunocompromised adults",79,"74",83,NA,"delta","~33 weeks",NA,NA,"USA","USA",118,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-12-30,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta","05/11/2021",2021-11-05
"960",118,"Embi","Test-negative case-control","30Dec2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA",">= 18 years","general pop",90,"89",91,NA,"delta","~33 weeks",NA,NA,"USA","USA",118,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-12-30,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta","05/11/2021",2021-11-05
"961",119,"Poukka","Retrospective cohort","31Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","42+","Infection","infection","Finland","HCW","HCW aged 16-69 years",40,"33",46,NA,"non-VOC, alpha, & delta",NA,NA,NA,"Finland","FIN",119,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","08/11/2021",2021-11-08
"962",119,"Poukka","Retrospective cohort","31Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-90","Infection","infection","Finland","HCW","HCW aged 16-69 years",83,"80",85,NA,"non-VOC, alpha, & delta","~11 weeks",NA,NA,"Finland","FIN",119,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","08/11/2021",2021-11-08
"963",119,"Poukka","Retrospective cohort","31Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","181+","Infection","infection","Finland","HCW","HCW aged 16-69 years",55,"45",64,NA,"non-VOC, alpha, & delta","~29.5 weeks",NA,NA,"Finland","FIN",119,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","08/11/2021",2021-11-08
"964",119,"Poukka","Retrospective cohort","31Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","42+","Hospitalization","severe","Finland","HCW","HCW aged 16-69 years",82,"68",90,NA,"non-VOC, alpha, & delta",NA,NA,NA,"Finland","FIN",119,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","08/11/2021",2021-11-08
"965",119,"Poukka","Retrospective cohort","31Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-90","Hospitalization","severe","Finland","HCW","HCW aged 16-69 years",99,"97",100,NA,"non-VOC, alpha, & delta","~11 weeks",NA,NA,"Finland","FIN",119,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","08/11/2021",2021-11-08
"966",119,"Poukka","Retrospective cohort","31Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","181+","Hospitalization","severe","Finland","HCW","HCW aged 16-69 years",98,"89",100,NA,"non-VOC, alpha, & delta","~38 weeks",NA,NA,"Finland","FIN",119,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","08/11/2021",2021-11-08
"967",119,"Poukka","Retrospective cohort","31Jan2022","mRNA-1273 (Moderna)","excluded","1","1","42+","Infection","infection","Finland","HCW","HCW aged 16-69 years",61,"45",72,NA,"non-VOC, alpha, & delta",NA,NA,NA,"Finland","FIN",119,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","08/11/2021",2021-11-08
"968",119,"Poukka","Retrospective cohort","31Jan2022","mRNA-1273 (Moderna)","excluded","2","final","14-90","Infection","infection","Finland","HCW","HCW aged 16-69 years",84,"68",92,NA,"non-VOC, alpha, & delta","~11 weeks",NA,NA,"Finland","FIN",119,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","08/11/2021",2021-11-08
"969",119,"Poukka","Retrospective cohort","31Jan2022","mRNA-1273 (Moderna)","excluded","2","final","91-180","Infection","infection","Finland","HCW","HCW aged 16-69 years",69,"-124",96,NA,"non-VOC, alpha, & delta","~24 weeks",NA,NA,"Finland","FIN",119,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","08/11/2021",2021-11-08
"970",119,"Poukka","Retrospective cohort","31Jan2022","mRNA-1273 (Moderna)","excluded","1","1","42+","Hospitalization","severe","Finland","HCW","HCW aged 16-69 years",89,"22",98,NA,"non-VOC, alpha, & delta",NA,NA,NA,"Finland","FIN",119,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","08/11/2021",2021-11-08
"971",119,"Poukka","Retrospective cohort","31Jan2022","mRNA-1273 (Moderna)","excluded","2","final","14-90","Hospitalization","severe","Finland","HCW","HCW aged 16-69 years",100,NA,NA,NA,"non-VOC, alpha, & delta","~11 weeks",NA,NA,"Finland","FIN",119,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","08/11/2021",2021-11-08
"972",119,"Poukka","Retrospective cohort","31Jan2022","mRNA-1273 (Moderna)","excluded","2","final","181+","Hospitalization","severe","Finland","HCW","HCW aged 16-69 years",100,NA,NA,NA,"non-VOC, alpha, & delta","~34 weeks",NA,NA,"Finland","FIN",119,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","08/11/2021",2021-11-08
"973",119,"Poukka","Retrospective cohort","31Jan2022","Any mRNA - heterologous","excluded","2","final","14-90","Infection","infection","Finland","HCW","HCW aged 16-69 years",100,NA,NA,NA,"non-VOC, alpha, & delta","~11 weeks",NA,NA,"Finland","FIN",119,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations","08/11/2021",2021-11-08
"974",119,"Poukka","Retrospective cohort","31Jan2022","Any mRNA - heterologous","excluded","2","final","181+","Infection","infection","Finland","HCW","HCW aged 16-69 years",100,NA,NA,NA,"non-VOC, alpha, & delta","~29.5 weeks",NA,NA,"Finland","FIN",119,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations","08/11/2021",2021-11-08
"975",119,"Poukka","Retrospective cohort","31Jan2022","Any mRNA - heterologous","excluded","2","final","14-90","Hospitalization","severe","Finland","HCW","HCW aged 16-69 years",100,NA,NA,NA,"non-VOC, alpha, & delta","~11 weeks",NA,NA,"Finland","FIN",119,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations","08/11/2021",2021-11-08
"976",119,"Poukka","Retrospective cohort","31Jan2022","Any mRNA - heterologous","excluded","2","final","181+","Hospitalization","severe","Finland","HCW","HCW aged 16-69 years",100,NA,NA,NA,"non-VOC, alpha, & delta","~38 weeks",NA,NA,"Finland","FIN",119,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations","08/11/2021",2021-11-08
"977",119,"Poukka","Retrospective cohort","31Jan2022","AZD1222 (AstraZeneca)","excluded","1","1","42+","Infection","infection","Finland","HCW","HCW aged 16-69 years",22,"-3",42,NA,"non-VOC, alpha, & delta",NA,NA,NA,"Finland","FIN",119,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","08/11/2021",2021-11-08
"978",119,"Poukka","Retrospective cohort","31Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","14-90","Infection","infection","Finland","HCW","HCW aged 16-69 years",89,"73",95,NA,"non-VOC, alpha, & delta","~11 weeks",NA,NA,"Finland","FIN",119,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","08/11/2021",2021-11-08
"979",119,"Poukka","Retrospective cohort","31Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","91-180","Infection","infection","Finland","HCW","HCW aged 16-69 years",63,"-166",95,NA,"non-VOC, alpha, & delta","~24 weeks",NA,NA,"Finland","FIN",119,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","08/11/2021",2021-11-08
"980",119,"Poukka","Retrospective cohort","31Jan2022","AZD1222 (AstraZeneca)","excluded","1","1","42+","Hospitalization","severe","Finland","HCW","HCW aged 16-69 years",88,"10",98,NA,"non-VOC, alpha, & delta",NA,NA,NA,"Finland","FIN",119,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","08/11/2021",2021-11-08
"981",119,"Poukka","Retrospective cohort","31Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","14-90","Hospitalization","severe","Finland","HCW","HCW aged 16-69 years",100,NA,NA,NA,"non-VOC, alpha, & delta","~11 weeks",NA,NA,"Finland","FIN",119,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","08/11/2021",2021-11-08
"982",119,"Poukka","Retrospective cohort","31Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","181+","Hospitalization","severe","Finland","HCW","HCW aged 16-69 years",100,NA,NA,NA,"non-VOC, alpha, & delta","~25 weeks",NA,NA,"Finland","FIN",119,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","08/11/2021",2021-11-08
"983",119,"Poukka","Retrospective cohort","31Jan2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","14-90","Infection","infection","Finland","HCW","HCW aged 16-69 years",80,"72",86,NA,"non-VOC, alpha, & delta","~11 weeks",NA,NA,"Finland","FIN",119,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"infection","2022 (Jan-Jun)","Heterologous platforms","Multiple","other combinations","08/11/2021",2021-11-08
"984",119,"Poukka","Retrospective cohort","31Jan2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","91-180","Infection","infection","Finland","HCW","HCW aged 16-69 years",62,"30",79,NA,"non-VOC, alpha, & delta","~24 weeks",NA,NA,"Finland","FIN",119,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"infection","2022 (Jan-Jun)","Heterologous platforms","Multiple","other combinations","08/11/2021",2021-11-08
"985",119,"Poukka","Retrospective cohort","31Jan2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","14-90","Hospitalization","severe","Finland","HCW","HCW aged 16-69 years",100,NA,NA,NA,"non-VOC, alpha, & delta","~11 weeks",NA,NA,"Finland","FIN",119,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"severe","2022 (Jan-Jun)","Heterologous platforms","Multiple","other combinations","08/11/2021",2021-11-08
"986",119,"Poukka","Retrospective cohort","31Jan2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","181+","Hospitalization","severe","Finland","HCW","HCW aged 16-69 years",100,NA,NA,NA,"non-VOC, alpha, & delta","~25 weeks",NA,NA,"Finland","FIN",119,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"severe","2022 (Jan-Jun)","Heterologous platforms","Multiple","other combinations","08/11/2021",2021-11-08
"987",119,"Poukka","Retrospective cohort","31Jan2022","Any mRNA - homologous or heterologous","excluded","1","1","42+","Infection","infection","Finland","HCW","HCW aged 16-69 years",38,"23",50,NA,"non-VOC & alpha",NA,NA,NA,"Finland","FIN",119,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations","08/11/2021",2021-11-08
"988",119,"Poukka","Retrospective cohort","31Jan2022","Any mRNA - homologous or heterologous","excluded","2","final","14-90","Infection","infection","Finland","HCW","HCW aged 16-69 years",77,"71",82,NA,"non-VOC & alpha","~11 weeks",NA,NA,"Finland","FIN",119,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations","08/11/2021",2021-11-08
"989",119,"Poukka","Retrospective cohort","31Jan2022","Any mRNA - homologous or heterologous","excluded","2","final","91-180","Infection","infection","Finland","HCW","HCW aged 16-69 years",55,"34",69,NA,"non-VOC & alpha","~24 weeks",NA,NA,"Finland","FIN",119,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations","08/11/2021",2021-11-08
"990",119,"Poukka","Retrospective cohort","31Jan2022","Any mRNA - homologous or heterologous","excluded","1","1","42+","hospitalization","severe","Finland","HCW","HCW aged 16-69 years",90,"27",99,NA,"non-VOC & alpha",NA,NA,NA,"Finland","FIN",119,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations","08/11/2021",2021-11-08
"991",119,"Poukka","Retrospective cohort","31Jan2022","Any mRNA - homologous or heterologous","excluded","2","final","14-90","hospitalization","severe","Finland","HCW","HCW aged 16-69 years",95,"64",99,NA,"non-VOC & alpha","~11 weeks",NA,NA,"Finland","FIN",119,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations","08/11/2021",2021-11-08
"992",119,"Poukka","Retrospective cohort","31Jan2022","Any mRNA - homologous or heterologous","excluded","2","final","91-180","hospitalization","severe","Finland","HCW","HCW aged 16-69 years",100,NA,NA,NA,"non-VOC & alpha","~24 weeks",NA,NA,"Finland","FIN",119,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations","08/11/2021",2021-11-08
"993",119,"Poukka","Retrospective cohort","31Jan2022","AZD1222 (AstraZeneca)","excluded","1","1","42+","Infection","infection","Finland","HCW","HCW aged 16-69 years",15,"-15",37,NA,"non-VOC & alpha",NA,NA,NA,"Finland","FIN",119,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","08/11/2021",2021-11-08
"994",119,"Poukka","Retrospective cohort","31Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","14-90","Infection","infection","Finland","HCW","HCW aged 16-69 years",100,NA,NA,NA,"non-VOC & alpha","~11 weeks",NA,NA,"Finland","FIN",119,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","08/11/2021",2021-11-08
"995",119,"Poukka","Retrospective cohort","31Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","91-180","Infection","infection","Finland","HCW","HCW aged 16-69 years",100,NA,NA,NA,"non-VOC & alpha","~24 weeks",NA,NA,"Finland","FIN",119,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","08/11/2021",2021-11-08
"996",119,"Poukka","Retrospective cohort","31Jan2022","AZD1222 (AstraZeneca)","excluded","1","1","42+","hospitalization","severe","Finland","HCW","HCW aged 16-69 years",100,"-inf",100,NA,"non-VOC & alpha",NA,NA,NA,"Finland","FIN",119,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","08/11/2021",2021-11-08
"997",119,"Poukka","Retrospective cohort","31Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","14-90","hospitalization","severe","Finland","HCW","HCW aged 16-69 years",100,NA,NA,NA,"non-VOC & alpha","~11 weeks",NA,NA,"Finland","FIN",119,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","08/11/2021",2021-11-08
"998",119,"Poukka","Retrospective cohort","31Jan2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","14-90","Infection","infection","Finland","HCW","HCW aged 16-69 years",100,NA,NA,NA,"non-VOC & alpha","~11 weeks",NA,NA,"Finland","FIN",119,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"infection","2022 (Jan-Jun)","Heterologous platforms","Multiple","other combinations","08/11/2021",2021-11-08
"999",119,"Poukka","Retrospective cohort","31Jan2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","91-180","Infection","infection","Finland","HCW","HCW aged 16-69 years",100,NA,NA,NA,"non-VOC & alpha","~24 weeks",NA,NA,"Finland","FIN",119,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"infection","2022 (Jan-Jun)","Heterologous platforms","Multiple","other combinations","08/11/2021",2021-11-08
"1000",119,"Poukka","Retrospective cohort","31Jan2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","14-90","Hospitalization","severe","Finland","HCW","HCW aged 16-69 years",100,NA,NA,NA,"non-VOC & alpha","~11 weeks",NA,NA,"Finland","FIN",119,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"severe","2022 (Jan-Jun)","Heterologous platforms","Multiple","other combinations","08/11/2021",2021-11-08
"1001",119,"Poukka","Retrospective cohort","31Jan2022","Any mRNA - homologous or heterologous","excluded","1","1","42+","Infection","infection","Finland","HCW","HCW aged 16-69 years",45,"37",51,NA,"delta",NA,NA,NA,"Finland","FIN",119,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta","08/11/2021",2021-11-08
"1002",119,"Poukka","Retrospective cohort","31Jan2022","Any mRNA - homologous or heterologous","excluded","2","final","14-90","Infection","infection","Finland","HCW","HCW aged 16-69 years",85,"81",88,NA,"delta","~11 weeks",NA,NA,"Finland","FIN",119,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta","08/11/2021",2021-11-08
"1003",119,"Poukka","Retrospective cohort","31Jan2022","Any mRNA - homologous or heterologous","excluded","2","final","181+","Infection","infection","Finland","HCW","HCW aged 16-69 years",56,"46",65,NA,"delta","~29.5 weeks",NA,NA,"Finland","FIN",119,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta","08/11/2021",2021-11-08
"1004",119,"Poukka","Retrospective cohort","31Jan2022","Any mRNA - homologous or heterologous","excluded","1","1","42+","Hospitalization","severe","Finland","HCW","HCW aged 16-69 years",83,"68",91,NA,"delta",NA,NA,NA,"Finland","FIN",119,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta","08/11/2021",2021-11-08
"1005",119,"Poukka","Retrospective cohort","31Jan2022","Any mRNA - homologous or heterologous","excluded","2","final","14-90","Hospitalization","severe","Finland","HCW","HCW aged 16-69 years",100,"97",100,NA,"delta","~11 weeks",NA,NA,"Finland","FIN",119,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta","08/11/2021",2021-11-08
"1006",119,"Poukka","Retrospective cohort","31Jan2022","Any mRNA - homologous or heterologous","excluded","2","final","181+","Hospitalization","severe","Finland","HCW","HCW aged 16-69 years",98,"88",100,NA,"delta","~38 weeks",NA,NA,"Finland","FIN",119,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta","08/11/2021",2021-11-08
"1007",119,"Poukka","Retrospective cohort","31Jan2022","AZD1222 (AstraZeneca)","excluded","1","1","42+","Infection","infection","Finland","HCW","HCW aged 16-69 years",49,"-16",77,NA,"delta",NA,NA,NA,"Finland","FIN",119,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","08/11/2021",2021-11-08
"1008",119,"Poukka","Retrospective cohort","31Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","14-90","Infection","infection","Finland","HCW","HCW aged 16-69 years",88,"71",95,NA,"delta","~11 weeks",NA,NA,"Finland","FIN",119,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","08/11/2021",2021-11-08
"1009",119,"Poukka","Retrospective cohort","31Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","91-180","Infection","infection","Finland","HCW","HCW aged 16-69 years",62,"-177",95,NA,"delta","~24 weeks",NA,NA,"Finland","FIN",119,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","08/11/2021",2021-11-08
"1010",119,"Poukka","Retrospective cohort","31Jan2022","AZD1222 (AstraZeneca)","excluded","1","1","42+","Hospitalization","severe","Finland","HCW","HCW aged 16-69 years",42,"-330",92,NA,"delta",NA,NA,NA,"Finland","FIN",119,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","08/11/2021",2021-11-08
"1011",119,"Poukka","Retrospective cohort","31Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","14-90","Hospitalization","severe","Finland","HCW","HCW aged 16-69 years",100,NA,NA,NA,"delta","~11 weeks",NA,NA,"Finland","FIN",119,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","08/11/2021",2021-11-08
"1012",119,"Poukka","Retrospective cohort","31Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","181+","Hospitalization","severe","Finland","HCW","HCW aged 16-69 years",100,NA,NA,NA,"delta","~25 weeks",NA,NA,"Finland","FIN",119,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","08/11/2021",2021-11-08
"1013",119,"Poukka","Retrospective cohort","31Jan2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","14-90","Infection","infection","Finland","HCW","HCW aged 16-69 years",80,"72",86,NA,"delta","~11 weeks",NA,NA,"Finland","FIN",119,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"infection","2022 (Jan-Jun)","Heterologous platforms","Multiple","delta","08/11/2021",2021-11-08
"1014",119,"Poukka","Retrospective cohort","31Jan2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","91-180","Infection","infection","Finland","HCW","HCW aged 16-69 years",63,"33",80,NA,"delta","~24 weeks",NA,NA,"Finland","FIN",119,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"infection","2022 (Jan-Jun)","Heterologous platforms","Multiple","delta","08/11/2021",2021-11-08
"1015",119,"Poukka","Retrospective cohort","31Jan2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","14-90","Hospitalization","severe","Finland","HCW","HCW aged 16-69 years",100,NA,NA,NA,"delta","~11 weeks",NA,NA,"Finland","FIN",119,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"severe","2022 (Jan-Jun)","Heterologous platforms","Multiple","delta","08/11/2021",2021-11-08
"1016",119,"Poukka","Retrospective cohort","31Jan2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","181+","Hospitalization","severe","Finland","HCW","HCW aged 16-69 years",100,NA,NA,NA,"delta","~25 weeks",NA,NA,"Finland","FIN",119,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"severe","2022 (Jan-Jun)","Heterologous platforms","Multiple","delta","08/11/2021",2021-11-08
"1017",120,"Al Hosani","Retrospective cohort","18Mar2022","BBIBP-CorV (Beijing CNBG)","included","1","1","14+","Hospitalization","severe","United Arab Emirates",">= 15 years",">= 15 years",-20,"-28.6",11.8,NA,"non-VOC & alpha",NA,NA,NA,"United Arab Emirates","ARE",120,"ARE",75180,2019,"United Arab Emirates","Middle East & North Africa","High income",4,"Asia",2021-01-05,2021-04-20,2021-07-15,NA,2021-01-05,NA,28,105,191,"owid",28,"jan/2021","<30","before Jun/2021","<180","yes","yes","yes",2022-03-18,"severe","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","other combinations","27/10/2021",2021-10-27
"1018",120,"Al Hosani","Retrospective cohort","18Mar2022","BBIBP-CorV (Beijing CNBG)","included","2","final","14+","Hospitalization","severe","United Arab Emirates",">= 15 years",">= 15 years",79.8,"78",81.4,NA,"non-VOC & alpha","~34 weeks",NA,NA,"United Arab Emirates","ARE",120,"ARE",75180,2019,"United Arab Emirates","Middle East & North Africa","High income",4,"Asia",2021-01-05,2021-04-20,2021-07-15,NA,2021-01-05,NA,28,105,191,"owid",28,"jan/2021","<30","before Jun/2021","<180","yes","yes","yes",2022-03-18,"severe","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","other combinations","27/10/2021",2021-10-27
"1019",120,"Al Hosani","Retrospective cohort","18Mar2022","BBIBP-CorV (Beijing CNBG)","included","1","1","14+","ICU admission","severe","United Arab Emirates",">= 15 years",">= 15 years",3.7,"-12.8",18.1,NA,"non-VOC & alpha",NA,NA,NA,"United Arab Emirates","ARE",120,"ARE",75180,2019,"United Arab Emirates","Middle East & North Africa","High income",4,"Asia",2021-01-05,2021-04-20,2021-07-15,NA,2021-01-05,NA,28,105,191,"owid",28,"jan/2021","<30","before Jun/2021","<180","yes","yes","yes",2022-03-18,"severe","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","other combinations","27/10/2021",2021-10-27
"1020",120,"Al Hosani","Retrospective cohort","18Mar2022","BBIBP-CorV (Beijing CNBG)","included","2","final","14+","ICU admission","severe","United Arab Emirates",">= 15 years",">= 15 years",92.2,"89.7",94.1,NA,"non-VOC & alpha","~34 weeks",NA,NA,"United Arab Emirates","ARE",120,"ARE",75180,2019,"United Arab Emirates","Middle East & North Africa","High income",4,"Asia",2021-01-05,2021-04-20,2021-07-15,NA,2021-01-05,NA,28,105,191,"owid",28,"jan/2021","<30","before Jun/2021","<180","yes","yes","yes",2022-03-18,"severe","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","other combinations","27/10/2021",2021-10-27
"1021",120,"Al Hosani","Retrospective cohort","18Mar2022","BBIBP-CorV (Beijing CNBG)","included","1","1","14+","death","death","United Arab Emirates",">= 15 years",">= 15 years",27.9,"-61",72.6,NA,"non-VOC & alpha",NA,NA,NA,"United Arab Emirates","ARE",120,"ARE",75180,2019,"United Arab Emirates","Middle East & North Africa","High income",4,"Asia",2021-01-05,2021-04-20,2021-07-15,NA,2021-01-05,NA,28,105,191,"owid",28,"jan/2021","<30","before Jun/2021","<180","yes","yes","yes",2022-03-18,"death","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","other combinations","27/10/2021",2021-10-27
"1022",120,"Al Hosani","Retrospective cohort","18Mar2022","BBIBP-CorV (Beijing CNBG)","included","2","final","14+","death","death","United Arab Emirates",">= 15 years",">= 15 years",97.1,"83",99.9,NA,"non-VOC & alpha","~34 weeks",NA,NA,"United Arab Emirates","ARE",120,"ARE",75180,2019,"United Arab Emirates","Middle East & North Africa","High income",4,"Asia",2021-01-05,2021-04-20,2021-07-15,NA,2021-01-05,NA,28,105,191,"owid",28,"jan/2021","<30","before Jun/2021","<180","yes","yes","yes",2022-03-18,"death","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","other combinations","27/10/2021",2021-10-27
"1023",121,"Ng","Retrospective cohort","01Nov2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","unknown","2","final","15+","Infection","infection","Singapore","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",61.6,"37.5",80.4,"delta","delta","~16.5 weeks",NA,NA,"Singapore","SGP",121,"SGP",89630,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,22,192,227,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-11-01,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2021-11-01
"1024",121,"Ng","Retrospective cohort","01Nov2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","unknown","2","final","15+","symptomatic disease","symptomatic","Singapore","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",67.9,"41.3",87.8,"delta","delta","~16.5 weeks",NA,NA,"Singapore","SGP",121,"SGP",89630,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,22,192,227,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-11-01,"symptomatic","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2021-11-01
"1025",121,"Ng","Retrospective cohort","01Nov2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","unknown","2","final","15+","severe disease","severe","Singapore","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",100,NA,NA,"delta","delta","~16.5 weeks",NA,NA,"Singapore","SGP",121,"SGP",89630,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,22,192,227,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-11-01,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2021-11-01
"1026",122,"Paixao","Test-negative case-control","05Apr2022","CoronaVac (Sinovac)","excluded","1","1","14+","symptomatic disease","symptomatic","Brazil","pregnant women","pregnant persons",5,"-18.2",23.7,NA,"gamma & delta",NA,NA,NA,"Brazil","BRA",122,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-04-05,"symptomatic","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations","12/11/2021",2021-11-12
"1027",122,"Paixao","Test-negative case-control","05Apr2022","CoronaVac (Sinovac)","excluded","2","final","14+","symptomatic disease","symptomatic","Brazil","pregnant women","pregnant persons",41,"27",52.2,NA,"gamma & delta","~25 weeks",NA,NA,"Brazil","BRA",122,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-04-05,"symptomatic","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations","12/11/2021",2021-11-12
"1028",122,"Paixao","Test-negative case-control","05Apr2022","CoronaVac (Sinovac)","excluded","1","1","14+","severe disease","severe","Brazil","pregnant women","pregnant persons",67.7,"20",87,NA,"gamma & delta",NA,NA,NA,"Brazil","BRA",122,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-04-05,"severe","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations","12/11/2021",2021-11-12
"1029",122,"Paixao","Test-negative case-control","05Apr2022","CoronaVac (Sinovac)","excluded","2","final","14+","severe disease","severe","Brazil","pregnant women","pregnant persons",85.4,"59.4",94.8,NA,"gamma & delta","~25 weeks",NA,NA,"Brazil","BRA",122,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-04-05,"severe","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations","12/11/2021",2021-11-12
"1030",123,"Desai","Test-negative case-control","23Nov2021","BBV152 (Bharat)","included","1","1","21+","symptomatic disease","symptomatic","India","HCW","HCW",-1,"-51",33,NA,"delta",NA,NA,NA,"India","IND",123,"IND",6820,2019,"India","South Asia","Lower middle income",2,"Asia",2021-01-16,2021-12-24,NA,2021-01-16,2021-01-16,0,39,342,NA,"equal",39,"jan/2021","30-59","Dec/2021 +","270-359","yes","yes","no",2021-11-23,"symptomatic","2021 (Jul-Dec)","Bharat Covaxin/BBV152","Inactivated","delta",NA,2021-11-23
"1031",123,"Desai","Test-negative case-control","23Nov2021","BBV152 (Bharat)","included","2","final","14+","symptomatic disease","symptomatic","India","HCW","HCW",50,"33",62,NA,"delta","~4 weeks",NA,NA,"India","IND",123,"IND",6820,2019,"India","South Asia","Lower middle income",2,"Asia",2021-01-16,2021-12-24,NA,2021-01-16,2021-01-16,0,39,342,NA,"equal",39,"jan/2021","30-59","Dec/2021 +","270-359","yes","yes","no",2021-11-23,"symptomatic","2021 (Jul-Dec)","Bharat Covaxin/BBV152","Inactivated","delta",NA,2021-11-23
"1032",123,"Desai","Test-negative case-control","23Nov2021","BBV152 (Bharat)","included","2","final","28+","symptomatic disease","symptomatic","India","HCW","HCW",46,"22",62,NA,"delta","~4 weeks",NA,NA,"India","IND",123,"IND",6820,2019,"India","South Asia","Lower middle income",2,"Asia",2021-01-16,2021-12-24,NA,2021-01-16,2021-01-16,0,39,342,NA,"equal",39,"jan/2021","30-59","Dec/2021 +","270-359","yes","yes","no",2021-11-23,"symptomatic","2021 (Jul-Dec)","Bharat Covaxin/BBV152","Inactivated","delta",NA,2021-11-23
"1033",123,"Desai","Test-negative case-control","23Nov2021","BBV152 (Bharat)","included","2","final","42+","symptomatic disease","symptomatic","India","HCW","HCW",57,"21",76,NA,"delta","~4 weeks",NA,NA,"India","IND",123,"IND",6820,2019,"India","South Asia","Lower middle income",2,"Asia",2021-01-16,2021-12-24,NA,2021-01-16,2021-01-16,0,39,342,NA,"equal",39,"jan/2021","30-59","Dec/2021 +","270-359","yes","yes","no",2021-11-23,"symptomatic","2021 (Jul-Dec)","Bharat Covaxin/BBV152","Inactivated","delta",NA,2021-11-23
"1034",123,"Desai","Test-negative case-control","23Nov2021","BBV152 (Bharat)","excluded","2","final","14+","symptomatic disease","symptomatic","India","HCW","HCW",47,"29",61,NA,"delta","~4 weeks",NA,NA,"India","IND",123,"IND",6820,2019,"India","South Asia","Lower middle income",2,"Asia",2021-01-16,2021-12-24,NA,2021-01-16,2021-01-16,0,39,342,NA,"equal",39,"jan/2021","30-59","Dec/2021 +","270-359","yes","yes","no",2021-11-23,"symptomatic","2021 (Jul-Dec)","Bharat Covaxin/BBV152","Inactivated","delta",NA,2021-11-23
"1035",124,"Thiruvengadam","Test-negative case-control","25Nov2021","AZD1222 (AstraZeneca)","excluded","1","1","21+","infection","infection","India",">= 18 years","general pop",46.2,"31.6",57.7,NA,"delta",NA,NA,NA,"India","IND",124,"IND",6820,2019,"India","South Asia","Lower middle income",2,"Asia",2021-01-16,2021-12-24,NA,2021-01-16,2021-01-16,0,39,342,NA,"equal",39,"jan/2021","30-59","Dec/2021 +","270-359","yes","yes","no",2021-11-25,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2021-11-25
"1036",124,"Thiruvengadam","Test-negative case-control","25Nov2021","AZD1222 (AstraZeneca)","excluded","2","final","14+","infection","infection","India",">= 18 years","general pop",63.1,"51.5",72.1,NA,"delta","~10 weeks",NA,NA,"India","IND",124,"IND",6820,2019,"India","South Asia","Lower middle income",2,"Asia",2021-01-16,2021-12-24,NA,2021-01-16,2021-01-16,0,39,342,NA,"equal",39,"jan/2021","30-59","Dec/2021 +","270-359","yes","yes","no",2021-11-25,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2021-11-25
"1037",125,"Hall","Prospective cohort","16Feb2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","21-27","Infection","infection","UK","HCW","HCW",59,"42",71,NA,"non-VOC, alpha, & delta",NA,NA,NA,"UK","GBR",125,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-02-16,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","01/12/2021",2021-12-01
"1038",125,"Hall","Prospective cohort","16Feb2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-73","Infection","infection","UK","HCW","HCW",89,"78",94,NA,"non-VOC, alpha, & delta","~8 weeks","<6 weeks",NA,"UK","GBR",125,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-02-16,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","01/12/2021",2021-12-01
"1039",125,"Hall","Prospective cohort","16Feb2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","194-265","Infection","infection","UK","HCW","HCW",53,"28",69,NA,"non-VOC, alpha, & delta","36 weeks","<6 weeks",NA,"UK","GBR",125,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-02-16,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","01/12/2021",2021-12-01
"1040",125,"Hall","Prospective cohort","16Feb2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","56-280","Infection","infection","UK","HCW","HCW",63,"46",75,NA,"non-VOC, alpha, & delta",NA,NA,NA,"UK","GBR",125,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-02-16,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","01/12/2021",2021-12-01
"1041",125,"Hall","Prospective cohort","16Feb2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-73","Infection","infection","UK","HCW","HCW",85,"72",92,NA,"non-VOC, alpha, & delta","~8 weeks","6+ weeks",NA,"UK","GBR",125,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-02-16,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","01/12/2021",2021-12-01
"1042",125,"Hall","Prospective cohort","16Feb2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","194-239","Infection","infection","UK","HCW","HCW",51,"22",69,NA,"non-VOC, alpha, & delta","~32 weeks","6+ weeks",NA,"UK","GBR",125,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-02-16,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","01/12/2021",2021-12-01
"1043",125,"Hall","Prospective cohort","16Feb2022","AZD1222 (AstraZeneca)","excluded","1","1","21-27","Infection","infection","UK","HCW","HCW",63,"-80",92,NA,"non-VOC, alpha, & delta",NA,NA,NA,"UK","GBR",125,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-02-16,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","01/12/2021",2021-12-01
"1044",125,"Hall","Prospective cohort","16Feb2022","AZD1222 (AstraZeneca)","excluded","2","final","14-73","Infection","infection","UK","HCW","HCW",58,"23",77,NA,"non-VOC, alpha, & delta","~8 weeks",NA,NA,"UK","GBR",125,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-02-16,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","01/12/2021",2021-12-01
"1045",125,"Hall","Prospective cohort","16Feb2022","AZD1222 (AstraZeneca)","excluded","1","1","56-249","Infection","infection","UK","HCW","HCW",9,"-87",55,NA,"non-VOC, alpha, & delta",NA,NA,NA,"UK","GBR",125,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-02-16,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","01/12/2021",2021-12-01
"1046",125,"Hall","Prospective cohort","16Feb2022","AZD1222 (AstraZeneca)","excluded","2","final","134-220","Infection","infection","UK","HCW","HCW",72,"39",87,NA,"non-VOC, alpha, & delta","~29 weeks",NA,NA,"UK","GBR",125,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-02-16,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","01/12/2021",2021-12-01
"1047",126,"Voko","Retrospective cohort","24Nov2021","BNT162b2 (Pfizer BioNTech)","included","1","1+","0+","Infection","infection","Hungary",">= 16 years","general pop",41,"39.5",42.4,NA,"alpha",NA,NA,NA,"Hungary","HUN",126,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2021-11-24,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-11-24
"1048",126,"Voko","Retrospective cohort","24Nov2021","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","Infection","infection","Hungary",">= 16 years","general pop",84,"83.3",84.7,NA,"alpha","~19 weeks",NA,NA,"Hungary","HUN",126,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2021-11-24,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-11-24
"1049",126,"Voko","Retrospective cohort","24Nov2021","BNT162b2 (Pfizer BioNTech)","included","1","1+","0+","death","death","Hungary",">= 16 years","general pop",64.3,"61.8",66.6,NA,"alpha",NA,NA,NA,"Hungary","HUN",126,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2021-11-24,"death","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-11-24
"1050",126,"Voko","Retrospective cohort","24Nov2021","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","death","death","Hungary",">= 16 years","general pop",90.3,"88.9",91.5,NA,"alpha","~19 weeks",NA,NA,"Hungary","HUN",126,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2021-11-24,"death","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-11-24
"1051",126,"Voko","Retrospective cohort","24Nov2021","BBIBP-CorV (Beijing CNBG)","included","1","1+","0+","Infection","infection","Hungary",">= 16 years","general pop",34,"31.8",36.1,NA,"alpha",NA,NA,NA,"Hungary","HUN",126,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2021-11-24,"infection","2021 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","alpha",NA,2021-11-24
"1052",126,"Voko","Retrospective cohort","24Nov2021","BBIBP-CorV (Beijing CNBG)","included","2","final","14+","Infection","infection","Hungary",">= 16 years","general pop",72.8,"71.2",74.4,NA,"alpha","~10.5 weeks",NA,NA,"Hungary","HUN",126,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2021-11-24,"infection","2021 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","alpha",NA,2021-11-24
"1053",126,"Voko","Retrospective cohort","24Nov2021","BBIBP-CorV (Beijing CNBG)","included","1","1+","0+","death","death","Hungary",">= 16 years","general pop",39.4,"34.1",44.3,NA,"alpha",NA,NA,NA,"Hungary","HUN",126,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2021-11-24,"death","2021 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","alpha",NA,2021-11-24
"1054",126,"Voko","Retrospective cohort","24Nov2021","BBIBP-CorV (Beijing CNBG)","included","2","final","14+","death","death","Hungary",">= 16 years","general pop",86,"83.7",87.9,NA,"alpha","~10.5 weeks",NA,NA,"Hungary","HUN",126,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2021-11-24,"death","2021 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","alpha",NA,2021-11-24
"1055",126,"Voko","Retrospective cohort","24Nov2021","Gam-COVID-Vac (Gamaleya)","included","1","1+","0+","Infection","infection","Hungary",">= 16 years","general pop",48.7,"47.1",50.2,NA,"alpha",NA,NA,NA,"Hungary","HUN",126,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2021-11-24,"infection","2021 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","alpha",NA,2021-11-24
"1056",126,"Voko","Retrospective cohort","24Nov2021","Gam-COVID-Vac (Gamaleya)","included","2","final","14+","Infection","infection","Hungary",">= 16 years","general pop",88.1,"86.5",89.4,NA,"alpha","~11 weeks",NA,NA,"Hungary","HUN",126,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2021-11-24,"infection","2021 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","alpha",NA,2021-11-24
"1057",126,"Voko","Retrospective cohort","24Nov2021","Gam-COVID-Vac (Gamaleya)","included","1","1+","0+","death","death","Hungary",">= 16 years","general pop",78,"74.3",81.2,NA,"alpha",NA,NA,NA,"Hungary","HUN",126,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2021-11-24,"death","2021 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","alpha",NA,2021-11-24
"1058",126,"Voko","Retrospective cohort","24Nov2021","Gam-COVID-Vac (Gamaleya)","included","2","final","14+","death","death","Hungary",">= 16 years","general pop",97.8,"95.5",98.9,NA,"alpha","~11 weeks",NA,NA,"Hungary","HUN",126,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2021-11-24,"death","2021 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","alpha",NA,2021-11-24
"1059",126,"Voko","Retrospective cohort","24Nov2021","AZD1222 (AstraZeneca)","included","1","1+","0+","Infection","infection","Hungary",">= 16 years","general pop",49.2,"47.7",50.6,NA,"alpha",NA,NA,NA,"Hungary","HUN",126,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2021-11-24,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2021-11-24
"1060",126,"Voko","Retrospective cohort","24Nov2021","AZD1222 (AstraZeneca)","included","2","final","14+","Infection","infection","Hungary",">= 16 years","general pop",73.3,"71.1",76,NA,"alpha","~11.5 weeks",NA,NA,"Hungary","HUN",126,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2021-11-24,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2021-11-24
"1061",126,"Voko","Retrospective cohort","24Nov2021","AZD1222 (AstraZeneca)","included","1","1+","0+","death","death","Hungary",">= 16 years","general pop",71.3,"67.9",74.4,NA,"alpha",NA,NA,NA,"Hungary","HUN",126,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2021-11-24,"death","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2021-11-24
"1062",126,"Voko","Retrospective cohort","24Nov2021","AZD1222 (AstraZeneca)","included","2","final","14+","death","death","Hungary",">= 16 years","general pop",85.8,"73.5",92.4,NA,"alpha","~11.5 weeks",NA,NA,"Hungary","HUN",126,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2021-11-24,"death","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2021-11-24
"1063",126,"Voko","Retrospective cohort","24Nov2021","mRNA-1273 (Moderna)","included","1","1+","0+","Infection","infection","Hungary",">= 16 years","general pop",60.8,"58.6",63,NA,"alpha",NA,NA,NA,"Hungary","HUN",126,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2021-11-24,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","alpha",NA,2021-11-24
"1064",126,"Voko","Retrospective cohort","24Nov2021","mRNA-1273 (Moderna)","included","2","final","14+","Infection","infection","Hungary",">= 16 years","general pop",88.2,"85.8",90.3,NA,"alpha","~15 weeks",NA,NA,"Hungary","HUN",126,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2021-11-24,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","alpha",NA,2021-11-24
"1065",126,"Voko","Retrospective cohort","24Nov2021","mRNA-1273 (Moderna)","included","1","1+","0+","death","death","Hungary",">= 16 years","general pop",68.7,"62.5",73.8,NA,"alpha",NA,NA,NA,"Hungary","HUN",126,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2021-11-24,"death","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","alpha",NA,2021-11-24
"1066",126,"Voko","Retrospective cohort","24Nov2021","mRNA-1273 (Moderna)","included","2","final","14+","death","death","Hungary",">= 16 years","general pop",93.8,"90.3",96.1,NA,"alpha","~15 weeks",NA,NA,"Hungary","HUN",126,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2021-11-24,"death","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","alpha",NA,2021-11-24
"1067",127,"Wu","Retrospective cohort","02Dec2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","14+","Infection","infection","USA","cancer patients","immunocompromised adults",45,"8",66,NA,"non-VOC & alpha",NA,NA,NA,"USA","USA",127,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-12-02,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-12-02
"1068",127,"Wu","Retrospective cohort","02Dec2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","Infection","infection","USA","cancer patients","immunocompromised adults",58,"39",73,NA,"non-VOC & alpha","15 weeks",NA,NA,"USA","USA",127,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-12-02,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-12-02
"1069",128,"Muhsen","Prospective cohort","28Oct2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","Infection","infection","Israel","HCW","HCW",89,"83",93,NA,"alpha","~11 weeks",NA,NA,"Israel","ISR",128,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-10-28,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-10-28
"1070",129,"Yassi","Retrospective cohort","06Dec2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","unknown","2","final","7+","Infection","infection","Canada","HCW","HCW",74.1,"62.5",82.1,NA,"non-VOC, alpha, & delta","~40.5 weeks",NA,NA,"Canada","CAN",129,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-12-06,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-12-06
"1071",129,"Yassi","Test-negative case-control","06Dec2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","unknown","2","final","7+","Infection","infection","Canada","HCW","HCW",82.8,"74",88.6,NA,"non-VOC, alpha, & delta","~40.5 weeks",NA,NA,"Canada","CAN",129,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-12-06,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-12-06
"1072",130,"UKHSA","Test-negative case-control","27Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","2-4 weeks","symptomatic disease","symptomatic","UK",">= 18 years","general pop",65.8,"64.4",67.2,"omicron","omicron","~32 weeks",NA,NA,"UK","GBR",130,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-27,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","14/01/2022",2022-01-14
"1073",130,"UKHSA","Test-negative case-control","27Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","25+ weeks","symptomatic disease","symptomatic","UK",">= 18 years","general pop",9.4,"7.8",11.1,"omicron","omicron","~32 weeks",NA,NA,"UK","GBR",130,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-27,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","14/01/2022",2022-01-14
"1074",130,"UKHSA","Test-negative case-control","27Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","2-4 weeks","symptomatic disease","symptomatic","UK",">= 18 years","general pop",49.8,"40.7",57.5,"omicron","omicron","~32 weeks",NA,NA,"UK","GBR",130,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-27,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","14/01/2022",2022-01-14
"1075",130,"UKHSA","Test-negative case-control","27Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","25+ weeks","symptomatic disease","symptomatic","UK",">= 18 years","general pop",-1,"-2.4",0.3,"omicron","omicron","~32 weeks",NA,NA,"UK","GBR",130,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-27,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","14/01/2022",2022-01-14
"1076",130,"UKHSA","Test-negative case-control","27Jan2022","mRNA-1273 (Moderna)","excluded","2","final","2-4 weeks","symptomatic disease","symptomatic","UK",">= 18 years","general pop",76,"72",79,"omicron","omicron","~32 weeks",NA,NA,"UK","GBR",130,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-27,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","14/01/2022",2022-01-14
"1077",130,"UKHSA","Test-negative case-control","27Jan2022","mRNA-1273 (Moderna)","excluded","2","final","25+ weeks","symptomatic disease","symptomatic","UK",">= 18 years","general pop",13,"3",22,"omicron","omicron","~32 weeks",NA,NA,"UK","GBR",130,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-27,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","14/01/2022",2022-01-14
"1078",130,"UKHSA","Test-negative case-control","27Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","2-4 weeks","symptomatic disease","symptomatic","UK",">= 18 years","general pop",90.9,"89.6",92,"delta","delta","~32 weeks",NA,NA,"UK","GBR",130,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-27,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","14/01/2022",2022-01-14
"1079",130,"UKHSA","Test-negative case-control","27Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","25+ weeks","symptomatic disease","symptomatic","UK",">= 18 years","general pop",62.7,"61.6",63.7,"delta","delta","~32 weeks",NA,NA,"UK","GBR",130,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-27,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","14/01/2022",2022-01-14
"1080",130,"UKHSA","Test-negative case-control","27Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","2-4 weeks","symptomatic disease","symptomatic","UK",">= 18 years","general pop",82.8,"74.5",88.4,"delta","delta","~32 weeks",NA,NA,"UK","GBR",130,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-27,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","14/01/2022",2022-01-14
"1081",130,"UKHSA","Test-negative case-control","27Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","25+ weeks","symptomatic disease","symptomatic","UK",">= 18 years","general pop",43.5,"42.4",44.5,"delta","delta","~32 weeks",NA,NA,"UK","GBR",130,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-27,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","14/01/2022",2022-01-14
"1082",130,"UKHSA","Test-negative case-control","27Jan2022","mRNA-1273 (Moderna)","excluded","2","final","2-4 weeks","symptomatic disease","symptomatic","UK",">= 18 years","general pop",94.5,"90.5",96.9,"delta","delta","~32 weeks",NA,NA,"UK","GBR",130,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-27,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","14/01/2022",2022-01-14
"1083",130,"UKHSA","Test-negative case-control","27Jan2022","mRNA-1273 (Moderna)","excluded","2","final","25+ weeks","symptomatic disease","symptomatic","UK",">= 18 years","general pop",80.4,"67.3",88.2,"delta","delta","~32 weeks",NA,NA,"UK","GBR",130,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-27,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","14/01/2022",2022-01-14
"1084",130,"UKHSA","Test-negative case-control","27Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","2-4 weeks","symptomatic disease","symptomatic","UK",">= 18 years","general pop",73.6,"40.7",88.3,"omicron","omicron","~32 weeks",NA,NA,"UK","GBR",130,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-27,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","14/01/2022",2022-01-14
"1085",130,"UKHSA","Test-negative case-control","27Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","25+ weeks","symptomatic disease","symptomatic","UK",">= 18 years","general pop",34.9,"17.7",48.4,"omicron","omicron","~32 weeks",NA,NA,"UK","GBR",130,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-27,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","14/01/2022",2022-01-14
"1086",130,"UKHSA","Test-negative case-control","27Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","20-24 weeks","symptomatic disease","symptomatic","UK",">= 18 years","general pop",55.8,"34.1",70.3,"omicron","omicron","~32 weeks",NA,NA,"UK","GBR",130,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-27,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","14/01/2022",2022-01-14
"1087",130,"UKHSA","Test-negative case-control","27Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","25+ weeks","symptomatic disease","symptomatic","UK",">= 18 years","general pop",32.7,"19.7",43.6,"omicron","omicron","~32 weeks",NA,NA,"UK","GBR",130,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-27,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","14/01/2022",2022-01-14
"1088",130,"UKHSA","Test-negative case-control","27Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","2-4 weeks","symptomatic disease","symptomatic","UK",">= 18 years","general pop",94.1,"81.6",98.1,"delta","delta","~32 weeks",NA,NA,"UK","GBR",130,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-27,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","14/01/2022",2022-01-14
"1089",130,"UKHSA","Test-negative case-control","27Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","25+ weeks","symptomatic disease","symptomatic","UK",">= 18 years","general pop",95.3,"93.9",96.5,"delta","delta","~32 weeks",NA,NA,"UK","GBR",130,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-27,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","14/01/2022",2022-01-14
"1090",130,"UKHSA","Test-negative case-control","27Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","20-24 weeks","symptomatic disease","symptomatic","UK",">= 18 years","general pop",92.9,"91.3",94.2,"delta","delta","~32 weeks",NA,NA,"UK","GBR",130,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-27,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","14/01/2022",2022-01-14
"1091",130,"UKHSA","Test-negative case-control","27Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","25+ weeks","symptomatic disease","symptomatic","UK",">= 18 years","general pop",90.6,"89.3",91.8,"delta","delta","~32 weeks",NA,NA,"UK","GBR",130,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-27,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","14/01/2022",2022-01-14
"1092",131,"Bajema","Test-negative case-control","10Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-119","Hospitalization","severe","USA",">= 18 years","general pop",86,"77.6",91.3,NA,"non-VOC, alpha, & delta","~36 weeks",NA,NA,"USA","USA",131,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-12-10,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","10/09/2021",2021-09-10
"1093",131,"Bajema","Test-negative case-control","10Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","120+","Hospitalization","severe","USA",">= 18 years","general pop",75.1,"64.6",82.4,NA,"non-VOC, alpha, & delta","~36 weeks",NA,NA,"USA","USA",131,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-12-10,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","10/09/2021",2021-09-10
"1094",131,"Bajema","Test-negative case-control","10Dec2021","mRNA-1273 (Moderna)","excluded","2","final","14-119","Hospitalization","severe","USA",">= 18 years","general pop",89.6,"80.1",94.5,NA,"non-VOC, alpha, & delta","~36 weeks",NA,NA,"USA","USA",131,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-12-10,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","10/09/2021",2021-09-10
"1095",131,"Bajema","Test-negative case-control","10Dec2021","mRNA-1273 (Moderna)","excluded","2","final","120+","Hospitalization","severe","USA",">= 18 years","general pop",86.1,"77.7",91.3,NA,"non-VOC, alpha, & delta","~36 weeks",NA,NA,"USA","USA",131,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-12-10,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","10/09/2021",2021-09-10
"1096",132,"Powell","Test-negative case-control","21Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14-20","symptomatic disease","symptomatic","UK","12-15 years","12-15 years",49.6,"43.9",54.8,"omicron","omicron",NA,NA,NA,"UK","GBR",132,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-21,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","18/02/2022",2022-02-18
"1097",132,"Powell","Test-negative case-control","21Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease","symptomatic","UK","12-15 years","12-15 years",73,"66.4",78.3,"omicron","omicron","~33 weeks",NA,NA,"UK","GBR",132,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-21,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","18/02/2022",2022-02-18
"1098",132,"Powell","Test-negative case-control","21Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","84+","symptomatic disease","symptomatic","UK","12-15 years","12-15 years",17.2,"12",22.1,"omicron","omicron",NA,NA,NA,"UK","GBR",132,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-21,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","18/02/2022",2022-02-18
"1099",132,"Powell","Test-negative case-control","21Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14-20","symptomatic disease","symptomatic","UK","16-17 years","16-17 years",51.4,"42.7",58.8,"omicron","omicron",NA,NA,NA,"UK","GBR",132,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-21,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","18/02/2022",2022-02-18
"1100",132,"Powell","Test-negative case-control","21Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-34","symptomatic disease","symptomatic","UK","16-17 years","16-17 years",71.3,"69.3",73.1,"omicron","omicron","~33 weeks",NA,NA,"UK","GBR",132,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-21,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","18/02/2022",2022-02-18
"1101",132,"Powell","Test-negative case-control","21Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","105+","symptomatic disease","symptomatic","UK","16-17 years","16-17 years",12.5,"6.9",17.8,"omicron","omicron",NA,NA,NA,"UK","GBR",132,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-21,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","18/02/2022",2022-02-18
"1102",132,"Powell","Test-negative case-control","21Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","70+","symptomatic disease","symptomatic","UK","16-17 years","16-17 years",22.6,"14.5",29.9,"omicron","omicron","~33 weeks",NA,NA,"UK","GBR",132,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-21,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","18/02/2022",2022-02-18
"1103",132,"Powell","Test-negative case-control","21Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14-20","symptomatic disease","symptomatic","UK","12-15 years","12-15 years",74.5,"73.2",75.6,"delta","delta",NA,NA,NA,"UK","GBR",132,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-21,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","18/02/2022",2022-02-18
"1104",132,"Powell","Test-negative case-control","21Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease","symptomatic","UK","12-15 years","12-15 years",87.2,"73.7",93.8,"delta","delta","~33 weeks",NA,NA,"UK","GBR",132,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-21,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","18/02/2022",2022-02-18
"1105",132,"Powell","Test-negative case-control","21Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","84+","symptomatic disease","symptomatic","UK","12-15 years","12-15 years",53.1,"41.6",62.4,"delta","delta",NA,NA,NA,"UK","GBR",132,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-21,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","18/02/2022",2022-02-18
"1106",132,"Powell","Test-negative case-control","21Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14-20","symptomatic disease","symptomatic","UK","16-17 years","16-17 years",75.9,"74.3",77.3,"delta","delta",NA,NA,NA,"UK","GBR",132,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-21,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","18/02/2022",2022-02-18
"1107",132,"Powell","Test-negative case-control","21Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-34","symptomatic disease","symptomatic","UK","16-17 years","16-17 years",93.1,"91.6",94.4,"delta","delta","~33 weeks",NA,NA,"UK","GBR",132,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-21,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","18/02/2022",2022-02-18
"1108",132,"Powell","Test-negative case-control","21Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","105+","symptomatic disease","symptomatic","UK","16-17 years","16-17 years",30.9,"25.4",36,"delta","delta",NA,NA,NA,"UK","GBR",132,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-21,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","18/02/2022",2022-02-18
"1109",132,"Powell","Test-negative case-control","21Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","70+","symptomatic disease","symptomatic","UK","16-17 years","16-17 years",83.7,"72",90.5,"delta","delta","~33 weeks",NA,NA,"UK","GBR",132,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-21,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","18/02/2022",2022-02-18
"1110",132,"Powell","Test-negative case-control","21Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","28+","hospitalization","severe","UK","12-15 years","12-15 years",83.4,"54",94,"delta","delta",NA,NA,NA,"UK","GBR",132,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-21,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","18/02/2022",2022-02-18
"1111",132,"Powell","Test-negative case-control","21Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","28+","hospitalization","severe","UK","16-17 years","16-17 years",76.3,"61.1",85.6,"delta","delta",NA,NA,NA,"UK","GBR",132,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-21,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","18/02/2022",2022-02-18
"1112",133,"Berec","Retrospective cohort","08Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final","0-2 months","Infection","infection","Czech Republic",">= 18 years","general pop",87,"86",87,NA,"alpha & delta","~35 weeks",NA,NA,"Czech Republic","CZE",133,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-07-08,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","12/12/2021",2021-12-12
"1113",133,"Berec","Retrospective cohort","08Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final","7-8 months","Infection","infection","Czech Republic",">= 18 years","general pop",53,"52",54,NA,"alpha & delta","~35 weeks",NA,NA,"Czech Republic","CZE",133,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-07-08,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","12/12/2021",2021-12-12
"1114",133,"Berec","Retrospective cohort","08Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final","0-2 months","Hospitalization","severe","Czech Republic",">= 18 years","general pop",90,"89",91,NA,"alpha & delta","~35 weeks",NA,NA,"Czech Republic","CZE",133,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-07-08,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","12/12/2021",2021-12-12
"1115",133,"Berec","Retrospective cohort","08Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final","7-8 months","Hospitalization","severe","Czech Republic",">= 18 years","general pop",75,"73",76,NA,"alpha & delta","~35 weeks",NA,NA,"Czech Republic","CZE",133,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-07-08,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","12/12/2021",2021-12-12
"1116",133,"Berec","Retrospective cohort","08Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final","0-2 months","death","death","Czech Republic",">= 18 years","general pop",92,"90",93,NA,"alpha & delta","~35 weeks",NA,NA,"Czech Republic","CZE",133,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-07-08,"death","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","12/12/2021",2021-12-12
"1117",133,"Berec","Retrospective cohort","08Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final","7-8 months","death","death","Czech Republic",">= 18 years","general pop",83,"81",86,NA,"alpha & delta","~35 weeks",NA,NA,"Czech Republic","CZE",133,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-07-08,"death","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","12/12/2021",2021-12-12
"1118",133,"Berec","Retrospective cohort","08Jul2022","mRNA-1273 (Moderna)","included","2","final","0-2 months","Infection","infection","Czech Republic",">= 18 years","general pop",90,"89",91,NA,"alpha & delta","~35 weeks",NA,NA,"Czech Republic","CZE",133,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-07-08,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","12/12/2021",2021-12-12
"1119",133,"Berec","Retrospective cohort","08Jul2022","mRNA-1273 (Moderna)","included","2","final","7-8 months","Infection","infection","Czech Republic",">= 18 years","general pop",65,"63",67,NA,"alpha & delta","~35 weeks",NA,NA,"Czech Republic","CZE",133,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-07-08,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","12/12/2021",2021-12-12
"1120",133,"Berec","Retrospective cohort","08Jul2022","mRNA-1273 (Moderna)","included","2","final","0-2 months","Hospitalization","severe","Czech Republic",">= 18 years","general pop",94,"92",96,NA,"alpha & delta","~35 weeks",NA,NA,"Czech Republic","CZE",133,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-07-08,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","12/12/2021",2021-12-12
"1121",133,"Berec","Retrospective cohort","08Jul2022","mRNA-1273 (Moderna)","included","2","final","7-8 months","Hospitalization","severe","Czech Republic",">= 18 years","general pop",81,"78",84,NA,"alpha & delta","~35 weeks",NA,NA,"Czech Republic","CZE",133,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-07-08,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","12/12/2021",2021-12-12
"1122",133,"Berec","Retrospective cohort","08Jul2022","mRNA-1273 (Moderna)","included","2","final","0-2 months","death","death","Czech Republic",">= 18 years","general pop",96,"91",98,NA,"alpha & delta","~35 weeks",NA,NA,"Czech Republic","CZE",133,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-07-08,"death","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","12/12/2021",2021-12-12
"1123",133,"Berec","Retrospective cohort","08Jul2022","mRNA-1273 (Moderna)","included","2","final","7-8 months","death","death","Czech Republic",">= 18 years","general pop",88,"82",92,NA,"alpha & delta","~35 weeks",NA,NA,"Czech Republic","CZE",133,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-07-08,"death","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","12/12/2021",2021-12-12
"1124",133,"Berec","Retrospective cohort","08Jul2022","AZD1222 (AstraZeneca)","included","2","final","0-2 months","Infection","infection","Czech Republic",">= 18 years","general pop",83,"80",85,NA,"alpha & delta","~35 weeks",NA,NA,"Czech Republic","CZE",133,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-07-08,"infection","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","12/12/2021",2021-12-12
"1125",133,"Berec","Retrospective cohort","08Jul2022","AZD1222 (AstraZeneca)","included","2","final","5-6 months","Infection","infection","Czech Republic",">= 18 years","general pop",55,"54",56,NA,"alpha & delta","~35 weeks",NA,NA,"Czech Republic","CZE",133,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-07-08,"infection","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","12/12/2021",2021-12-12
"1126",133,"Berec","Retrospective cohort","08Jul2022","AZD1222 (AstraZeneca)","included","2","final","0-2 months","Hospitalization","severe","Czech Republic",">= 18 years","general pop",87,"81",91,NA,"alpha & delta","~35 weeks",NA,NA,"Czech Republic","CZE",133,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-07-08,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","12/12/2021",2021-12-12
"1127",133,"Berec","Retrospective cohort","08Jul2022","AZD1222 (AstraZeneca)","included","2","final","5-6 months","Hospitalization","severe","Czech Republic",">= 18 years","general pop",70,"68",72,NA,"alpha & delta","~35 weeks",NA,NA,"Czech Republic","CZE",133,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-07-08,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","12/12/2021",2021-12-12
"1128",133,"Berec","Retrospective cohort","08Jul2022","AZD1222 (AstraZeneca)","included","2","final","0-2 months","death","death","Czech Republic",">= 18 years","general pop",93,"77",98,NA,"alpha & delta","~35 weeks",NA,NA,"Czech Republic","CZE",133,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-07-08,"death","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","12/12/2021",2021-12-12
"1129",133,"Berec","Retrospective cohort","08Jul2022","AZD1222 (AstraZeneca)","included","2","final","5-6 months","death","death","Czech Republic",">= 18 years","general pop",82,"78",85,NA,"alpha & delta","~35 weeks",NA,NA,"Czech Republic","CZE",133,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-07-08,"death","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","12/12/2021",2021-12-12
"1130",133,"Berec","Retrospective cohort","08Jul2022","Ad26.COV2.S (Janssen)","included","2","final","0-2 months","Infection","infection","Czech Republic",">= 18 years","general pop",68,"66",70,NA,"alpha & delta","~35 weeks",NA,NA,"Czech Republic","CZE",133,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-07-08,"infection","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations","12/12/2021",2021-12-12
"1131",133,"Berec","Retrospective cohort","08Jul2022","Ad26.COV2.S (Janssen)","included","2","final","5-6 months","Infection","infection","Czech Republic",">= 18 years","general pop",67,"65",69,NA,"alpha & delta","~35 weeks",NA,NA,"Czech Republic","CZE",133,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-07-08,"infection","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations","12/12/2021",2021-12-12
"1132",133,"Berec","Retrospective cohort","08Jul2022","Ad26.COV2.S (Janssen)","included","2","final","2 months","Hospitalization","severe","Czech Republic",">= 18 years","general pop",68,"60",75,NA,"alpha & delta","~35 weeks",NA,NA,"Czech Republic","CZE",133,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-07-08,"severe","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations","12/12/2021",2021-12-12
"1133",133,"Berec","Retrospective cohort","08Jul2022","Ad26.COV2.S (Janssen)","included","2","final","5-6 months","Hospitalization","severe","Czech Republic",">= 18 years","general pop",67,"62",72,NA,"alpha & delta","~35 weeks",NA,NA,"Czech Republic","CZE",133,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-07-08,"severe","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations","12/12/2021",2021-12-12
"1134",133,"Berec","Retrospective cohort","08Jul2022","Ad26.COV2.S (Janssen)","included","2","final","2 months","death","death","Czech Republic",">= 18 years","general pop",68,"42",82,NA,"alpha & delta","~35 weeks",NA,NA,"Czech Republic","CZE",133,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-07-08,"death","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations","12/12/2021",2021-12-12
"1135",133,"Berec","Retrospective cohort","08Jul2022","Ad26.COV2.S (Janssen)","included","2","final","5-6 months","death","death","Czech Republic",">= 18 years","general pop",68,"53",78,NA,"alpha & delta","~35 weeks",NA,NA,"Czech Republic","CZE",133,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-07-08,"death","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations","12/12/2021",2021-12-12
"1136",134,"Machado","Retrospective cohort","13Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-41","symptomatic disease","symptomatic","Portugal","65-79 years","65-79 years",79,"76",83,NA,"alpha & delta","~29 weeks",NA,NA,"Portugal","PRT",134,"PRT",36330,2019,"Portugal","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-09,2021-08-27,2020-12-23,2020-12-23,9,15,198,247,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-13,"symptomatic","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","14/12/2021",2021-09-13
"1137",134,"Machado","Retrospective cohort","13Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","98+","symptomatic disease","symptomatic","Portugal","65-79 years","65-79 years",39,"29",48,NA,"alpha & delta","~29 weeks",NA,NA,"Portugal","PRT",134,"PRT",36330,2019,"Portugal","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-09,2021-08-27,2020-12-23,2020-12-23,9,15,198,247,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-13,"symptomatic","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","14/12/2021",2021-09-13
"1138",134,"Machado","Retrospective cohort","13Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-41","symptomatic disease","symptomatic","Portugal",">= 80 years",">= 80 years",72,"61",79,NA,"alpha & delta","~29 weeks",NA,NA,"Portugal","PRT",134,"PRT",36330,2019,"Portugal","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-09,2021-08-27,2020-12-23,2020-12-23,9,15,198,247,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-13,"symptomatic","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","14/12/2021",2021-09-13
"1139",134,"Machado","Retrospective cohort","13Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","124+","symptomatic disease","symptomatic","Portugal",">= 80 years",">= 80 years",34,"29",48,NA,"alpha & delta","~29 weeks",NA,NA,"Portugal","PRT",134,"PRT",36330,2019,"Portugal","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-09,2021-08-27,2020-12-23,2020-12-23,9,15,198,247,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-13,"symptomatic","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","14/12/2021",2021-09-13
"1140",134,"Machado","Retrospective cohort","13Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-41","Hospitalization","severe","Portugal","65-79 years","65-79 years",95,"90",97,NA,"alpha & delta","~29 weeks",NA,NA,"Portugal","PRT",134,"PRT",36330,2019,"Portugal","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-09,2021-08-27,2020-12-23,2020-12-23,9,15,198,247,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-13,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","14/12/2021",2021-09-13
"1141",134,"Machado","Retrospective cohort","13Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","70+","Hospitalization","severe","Portugal","65-79 years","65-79 years",93,"86",96,NA,"alpha & delta","~29 weeks",NA,NA,"Portugal","PRT",134,"PRT",36330,2019,"Portugal","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-09,2021-08-27,2020-12-23,2020-12-23,9,15,198,247,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-13,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","14/12/2021",2021-09-13
"1142",134,"Machado","Retrospective cohort","13Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-41","Hospitalization","severe","Portugal",">= 80 years",">= 80 years",83,"68",91,NA,"alpha & delta","~29 weeks",NA,NA,"Portugal","PRT",134,"PRT",36330,2019,"Portugal","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-09,2021-08-27,2020-12-23,2020-12-23,9,15,198,247,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-13,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","14/12/2021",2021-09-13
"1143",134,"Machado","Retrospective cohort","13Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","124+","Hospitalization","severe","Portugal",">= 80 years",">= 80 years",63,"37",78,NA,"alpha & delta","~29 weeks",NA,NA,"Portugal","PRT",134,"PRT",36330,2019,"Portugal","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-09,2021-08-27,2020-12-23,2020-12-23,9,15,198,247,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-13,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","14/12/2021",2021-09-13
"1144",134,"Machado","Retrospective cohort","13Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-41","death","death","Portugal","65-79 years","65-79 years",95,"88",98,NA,"alpha & delta","~29 weeks",NA,NA,"Portugal","PRT",134,"PRT",36330,2019,"Portugal","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-09,2021-08-27,2020-12-23,2020-12-23,9,15,198,247,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-13,"death","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","14/12/2021",2021-09-13
"1145",134,"Machado","Retrospective cohort","13Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","70+","death","death","Portugal","65-79 years","65-79 years",93,"87",96,NA,"alpha & delta","~29 weeks",NA,NA,"Portugal","PRT",134,"PRT",36330,2019,"Portugal","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-09,2021-08-27,2020-12-23,2020-12-23,9,15,198,247,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-13,"death","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","14/12/2021",2021-09-13
"1146",134,"Machado","Retrospective cohort","13Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-41","death","death","Portugal",">= 80 years",">= 80 years",87,"71",93,NA,"alpha & delta","~29 weeks",NA,NA,"Portugal","PRT",134,"PRT",36330,2019,"Portugal","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-09,2021-08-27,2020-12-23,2020-12-23,9,15,198,247,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-13,"death","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","14/12/2021",2021-09-13
"1147",134,"Machado","Retrospective cohort","13Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","124+","death","death","Portugal",">= 80 years",">= 80 years",75,"64",82,NA,"alpha & delta","~29 weeks",NA,NA,"Portugal","PRT",134,"PRT",36330,2019,"Portugal","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-09,2021-08-27,2020-12-23,2020-12-23,9,15,198,247,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-13,"death","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","14/12/2021",2021-09-13
"1148",134,"Machado","Retrospective cohort","13Sept2021","AZD1222 (AstraZeneca)","excluded","2","final","14-41","symptomatic disease","symptomatic","Portugal","65-79 years","65-79 years",95,"90",97,NA,"alpha & delta","~29 weeks",NA,NA,"Portugal","PRT",134,"PRT",36330,2019,"Portugal","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-09,2021-08-27,2020-12-23,2020-12-23,9,15,198,247,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-13,"symptomatic","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","14/12/2021",2021-09-13
"1149",134,"Machado","Retrospective cohort","13Sept2021","AZD1222 (AstraZeneca)","excluded","2","final","70+","symptomatic disease","symptomatic","Portugal","65-79 years","65-79 years",93,"86",96,NA,"alpha & delta","~29 weeks",NA,NA,"Portugal","PRT",134,"PRT",36330,2019,"Portugal","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-09,2021-08-27,2020-12-23,2020-12-23,9,15,198,247,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-13,"symptomatic","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","14/12/2021",2021-09-13
"1150",134,"Machado","Retrospective cohort","13Sept2021","AZD1222 (AstraZeneca)","excluded","2","final","14+","Hospitalization","severe","Portugal","65-79 years","65-79 years",89,"52",94,NA,"alpha & delta","~29 weeks",NA,NA,"Portugal","PRT",134,"PRT",36330,2019,"Portugal","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-09,2021-08-27,2020-12-23,2020-12-23,9,15,198,247,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-13,"severe","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","14/12/2021",2021-09-13
"1151",134,"Machado","Retrospective cohort","13Sept2021","AZD1222 (AstraZeneca)","excluded","2","final","14+","death","death","Portugal","65-79 years","65-79 years",95,"90",97,NA,"alpha & delta","~29 weeks",NA,NA,"Portugal","PRT",134,"PRT",36330,2019,"Portugal","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-09,2021-08-27,2020-12-23,2020-12-23,9,15,198,247,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-13,"death","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","14/12/2021",2021-09-13
"1152",135,"Florea","Prospective cohort","28Apr2022","mRNA-1273 (Moderna)","included","2","final","14+","Infection","infection","USA",">= 18 years","general pop",82.8,"82.2",83.3,NA,"non-VOC, alpha, & delta","~35 weeks",NA,NA,"USA","USA",135,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-28,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","24/11/2021",2021-11-24
"1153",135,"Florea","Prospective cohort","28Apr2022","mRNA-1273 (Moderna)","included","2","final","14-60","Infection","infection","USA",">= 18 years","general pop",88,"86.8",89.1,NA,"non-VOC, alpha, & delta","~6.5 weeks",NA,NA,"USA","USA",135,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-28,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","24/11/2021",2021-11-24
"1154",135,"Florea","Prospective cohort","28Apr2022","mRNA-1273 (Moderna)","included","2","final","180-240","Infection","infection","USA",">= 18 years","general pop",75.5,"70.4",79.7,NA,"non-VOC, alpha, & delta","~35 weeks",NA,NA,"USA","USA",135,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-28,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","24/11/2021",2021-11-24
"1155",135,"Florea","Prospective cohort","28Apr2022","mRNA-1273 (Moderna)","included","2","final","14+","Hospitalization","severe","USA",">= 18 years","general pop",96.1,"95.5",96.6,NA,"non-VOC, alpha, & delta","~35 weeks",NA,NA,"USA","USA",135,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-28,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","24/11/2021",2021-11-24
"1156",135,"Florea","Prospective cohort","28Apr2022","mRNA-1273 (Moderna)","included","2","final","14-60","Hospitalization","severe","USA",">= 18 years","general pop",95.9,"93.5",97.4,NA,"non-VOC, alpha, & delta","~6.5 weeks",NA,NA,"USA","USA",135,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-28,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","24/11/2021",2021-11-24
"1157",135,"Florea","Prospective cohort","28Apr2022","mRNA-1273 (Moderna)","included","2","final","180-240","Hospitalization","severe","USA",">= 18 years","general pop",94.5,"90.9",96.7,NA,"non-VOC, alpha, & delta","~35 weeks",NA,NA,"USA","USA",135,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-28,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","24/11/2021",2021-11-24
"1158",135,"Florea","Prospective cohort","28Apr2022","mRNA-1273 (Moderna)","included","2","final","14+","death","death","USA",">= 18 years","general pop",97.2,"94.8",98.4,NA,"non-VOC, alpha, & delta","~35 weeks",NA,NA,"USA","USA",135,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-28,"death","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","24/11/2021",2021-11-24
"1159",135,"Florea","Prospective cohort","28Apr2022","mRNA-1273 (Moderna)","included","2","final","14+","Infection","infection","USA",">= 18 years","general pop",86.5,"84.8",88,NA,"delta","~15 weeks",NA,NA,"USA","USA",135,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-28,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","24/11/2021",2021-11-24
"1160",136,"Young-Xu","Test-negative case-control","15Dec2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-43","Infection","infection","USA","males 65+","males 65+",94.5,"90.7",96.7,NA,"non-VOC & alpha","4 weeks",NA,NA,"USA","USA",136,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-12-15,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","06/10/2021",2021-10-06
"1161",136,"Young-Xu","Test-negative case-control","15Dec2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","74-103","Infection","infection","USA","males 65+","males 65+",87.9,"85.9",89.5,NA,"non-VOC & alpha","12 weeks",NA,NA,"USA","USA",136,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-12-15,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","06/10/2021",2021-10-06
"1162",136,"Young-Xu","Test-negative case-control","15Dec2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-43","Infection","infection","USA","males 65+","males 65+",92.1,"87.2",95.1,NA,"alpha & delta","4 weeks",NA,NA,"USA","USA",136,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-12-15,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","06/10/2021",2021-10-06
"1163",136,"Young-Xu","Test-negative case-control","15Dec2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","134-163","Infection","infection","USA","males 65+","males 65+",67.3,"63.2",70.9,NA,"alpha & delta","20 weeks",NA,NA,"USA","USA",136,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-12-15,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","06/10/2021",2021-10-06
"1164",136,"Young-Xu","Test-negative case-control","15Dec2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-43","Infection","infection","USA","males 65+","males 65+",62,"45.6",73.5,NA,"delta","4 weeks",NA,NA,"USA","USA",136,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-12-15,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta","06/10/2021",2021-10-06
"1165",136,"Young-Xu","Test-negative case-control","15Dec2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","224-253","Infection","infection","USA","males 65+","males 65+",24.8,"18.8",30.4,NA,"delta","32 weeks",NA,NA,"USA","USA",136,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-12-15,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta","06/10/2021",2021-10-06
"1166",137,"Castillo-Arregoces","Retrospective matched cohort","16Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization","severe","Colombia",">= 60 years","60+ years",83,"78.4",86.6,NA,"mu","32 weeks",NA,NA,"Colombia","COL",137,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2021-12-16,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","mu",NA,2021-12-16
"1167",137,"Castillo-Arregoces","Retrospective matched cohort","16Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","post-hospitalization death","death","Colombia",">= 60 years","60+ years",94.8,"93.3",96,NA,"mu","32 weeks",NA,NA,"Colombia","COL",137,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2021-12-16,"death","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","mu",NA,2021-12-16
"1168",137,"Castillo-Arregoces","Retrospective matched cohort","16Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","death","death","Colombia",">= 60 years","60+ years",88.3,"84.1",91.4,NA,"mu","32 weeks",NA,NA,"Colombia","COL",137,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2021-12-16,"death","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","mu",NA,2021-12-16
"1169",137,"Castillo-Arregoces","Retrospective matched cohort","16Dec2021","AZD1222 (AstraZeneca)","excluded","2","final","14+","hospitalization","severe","Colombia",">= 60 years","60+ years",90.8,"85.5",94.2,NA,"mu","32 weeks",NA,NA,"Colombia","COL",137,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2021-12-16,"severe","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","mu",NA,2021-12-16
"1170",137,"Castillo-Arregoces","Retrospective matched cohort","16Dec2021","AZD1222 (AstraZeneca)","excluded","2","final","14+","post-hospitalization death","death","Colombia",">= 60 years","60+ years",97.5,"95.8",98.5,NA,"mu","32 weeks",NA,NA,"Colombia","COL",137,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2021-12-16,"death","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","mu",NA,2021-12-16
"1171",137,"Castillo-Arregoces","Retrospective matched cohort","16Dec2021","AZD1222 (AstraZeneca)","excluded","2","final","14+","death","death","Colombia",">= 60 years","60+ years",93.9,"89.3",96.6,NA,"mu","32 weeks",NA,NA,"Colombia","COL",137,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2021-12-16,"death","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","mu",NA,2021-12-16
"1172",137,"Castillo-Arregoces","Retrospective matched cohort","16Dec2021","Ad26.COV2.S (Janssen)","excluded","1","final","14+","hospitalization","severe","Colombia",">= 60 years","60+ years",60.9,"36.8",75.8,NA,"mu","32 weeks",NA,NA,"Colombia","COL",137,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2021-12-16,"severe","2021 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","mu",NA,2021-12-16
"1173",137,"Castillo-Arregoces","Retrospective matched cohort","16Dec2021","Ad26.COV2.S (Janssen)","excluded","1","final","14+","post-hospitalization death","death","Colombia",">= 60 years","60+ years",85.8,"77.1",91.2,NA,"mu","32 weeks",NA,NA,"Colombia","COL",137,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2021-12-16,"death","2021 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","mu",NA,2021-12-16
"1174",137,"Castillo-Arregoces","Retrospective matched cohort","16Dec2021","Ad26.COV2.S (Janssen)","excluded","1","final","14+","death","death","Colombia",">= 60 years","60+ years",95.5,"82",98.9,NA,"mu","32 weeks",NA,NA,"Colombia","COL",137,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2021-12-16,"death","2021 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","mu",NA,2021-12-16
"1175",137,"Castillo-Arregoces","Retrospective matched cohort","16Dec2021","CoronaVac (Sinovac)","excluded","2","final","14+","hospitalization","severe","Colombia",">= 60 years",">= 60 years",47.3,"41.9",52.3,NA,"mu","32 weeks",NA,NA,"Colombia","COL",137,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2021-12-16,"severe","2021 (Jul-Dec)","Sinovac CoronaVac","Inactivated","mu",NA,2021-12-16
"1176",137,"Castillo-Arregoces","Retrospective matched cohort","16Dec2021","CoronaVac (Sinovac)","excluded","2","final","14+","post-hospitalization death","death","Colombia",">= 60 years","60+ years",72.1,"70.1",73.9,NA,"mu","32 weeks",NA,NA,"Colombia","COL",137,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2021-12-16,"death","2021 (Jul-Dec)","Sinovac CoronaVac","Inactivated","mu",NA,2021-12-16
"1177",137,"Castillo-Arregoces","Retrospective matched cohort","16Dec2021","CoronaVac (Sinovac)","excluded","2","final","14+","death","death","Colombia",">= 60 years","60+ years",64.9,"61.2",68.9,NA,"mu","32 weeks",NA,NA,"Colombia","COL",137,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2021-12-16,"death","2021 (Jul-Dec)","Sinovac CoronaVac","Inactivated","mu",NA,2021-12-16
"1178",138,"McLean","Prospective cohort","18Feb2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection","infection","USA",">= 12 years","general pop",50,"21",69,NA,"non-VOC, alpha, & delta","~52 weeks",NA,NA,"USA","USA",138,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-02-18,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","16/12/2021",2021-12-16
"1179",138,"McLean","Prospective cohort","18Feb2022","mRNA-1273 (Moderna)","included","2","final","14+","Infection","infection","USA",">= 12 years","general pop",65,"37",81,NA,"non-VOC, alpha, & delta","~52 weeks",NA,NA,"USA","USA",138,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-02-18,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","16/12/2021",2021-12-16
"1180",138,"McLean","Prospective cohort","18Feb2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","symptomatic disease","symptomatic","USA",">= 12 years","general pop",54,"26",71,NA,"non-VOC, alpha, & delta","~52 weeks",NA,NA,"USA","USA",138,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-02-18,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","16/12/2021",2021-12-16
"1181",138,"McLean","Prospective cohort","18Feb2022","mRNA-1273 (Moderna)","included","2","final","14+","symptomatic disease","symptomatic","USA",">= 12 years","general pop",65,"38",81,NA,"non-VOC, alpha, & delta","~52 weeks",NA,NA,"USA","USA",138,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-02-18,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","16/12/2021",2021-12-16
"1182",138,"McLean","Prospective cohort","18Feb2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","Infection","infection","USA",">= 12 years","general pop",51,"22",70,NA,"non-VOC, alpha, & delta","~52 weeks",NA,NA,"USA","USA",138,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-02-18,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","16/12/2021",2021-12-16
"1183",138,"McLean","Prospective cohort","18Feb2022","mRNA-1273 (Moderna)","excluded","2","final","14+","Infection","infection","USA",">= 12 years","general pop",66,"38",82,NA,"non-VOC, alpha, & delta","~52 weeks",NA,NA,"USA","USA",138,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-02-18,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","16/12/2021",2021-12-16
"1184",138,"McLean","Prospective cohort","18Feb2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","Infection","infection","USA",">= 12 years","general pop",52,"20",71,"delta","delta","~52 weeks",NA,NA,"USA","USA",138,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-02-18,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","16/12/2021",2021-12-16
"1185",138,"McLean","Prospective cohort","18Feb2022","mRNA-1273 (Moderna)","excluded","2","final","14+","Infection","infection","USA",">= 12 years","general pop",59,"24",78,"delta","delta","~52 weeks",NA,NA,"USA","USA",138,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-02-18,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","16/12/2021",2021-12-16
"1186",139,"Abu-Raddad","Test-negative case-control","21Jan2022","mRNA-1273 (Moderna)","excluded","1","1","14+","Infection","infection","Qatar",">= 18 years","general pop",60.3,"57",63.3,NA,"beta & delta",NA,NA,NA,"Qatar","QAT",139,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2022-01-21,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","16/12/2021",2021-12-16
"1187",139,"Abu-Raddad","Test-negative case-control","21Jan2022","mRNA-1273 (Moderna)","excluded","2","final","30+","Infection","infection","Qatar",">= 18 years","general pop",85.3,"83.5",86.9,NA,"beta & delta","~35 weeks",NA,NA,"Qatar","QAT",139,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2022-01-21,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","16/12/2021",2021-12-16
"1188",139,"Abu-Raddad","Test-negative case-control","21Jan2022","mRNA-1273 (Moderna)","excluded","2","final","240+","Infection","infection","Qatar",">= 18 years","general pop",-29.5,"-84",8.8,NA,"beta & delta","~35 weeks",NA,NA,"Qatar","QAT",139,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2022-01-21,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","16/12/2021",2021-12-16
"1189",139,"Abu-Raddad","Test-negative case-control","21Jan2022","mRNA-1273 (Moderna)","excluded","1","1","14+","symptomatic disease","symptomatic","Qatar",">= 18 years","general pop",78.3,"75.2",81.1,NA,"beta & delta",NA,NA,NA,"Qatar","QAT",139,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2022-01-21,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","16/12/2021",2021-12-16
"1190",139,"Abu-Raddad","Test-negative case-control","21Jan2022","mRNA-1273 (Moderna)","excluded","2","final","30+","symptomatic disease","symptomatic","Qatar",">= 18 years","general pop",94.4,"92.8",95.6,NA,"beta & delta","~35 weeks",NA,NA,"Qatar","QAT",139,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2022-01-21,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","16/12/2021",2021-12-16
"1191",139,"Abu-Raddad","Test-negative case-control","21Jan2022","mRNA-1273 (Moderna)","excluded","2","final","240+","symptomatic disease","symptomatic","Qatar",">= 18 years","general pop",20,"-29",59.3,NA,"beta & delta","~35 weeks",NA,NA,"Qatar","QAT",139,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2022-01-21,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","16/12/2021",2021-12-16
"1192",139,"Abu-Raddad","Test-negative case-control","21Jan2022","mRNA-1273 (Moderna)","excluded","1","1","14+","asymptomatic infection","asymptomatic","Qatar",">= 18 years","general pop",54.6,"47.7",60.6,NA,"beta & delta",NA,NA,NA,"Qatar","QAT",139,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2022-01-21,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","16/12/2021",2021-12-16
"1193",139,"Abu-Raddad","Test-negative case-control","21Jan2022","mRNA-1273 (Moderna)","excluded","2","final","30+","asymptomatic infection","asymptomatic","Qatar",">= 18 years","general pop",79.9,"75.5",83.4,NA,"beta & delta","~35 weeks",NA,NA,"Qatar","QAT",139,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2022-01-21,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","16/12/2021",2021-12-16
"1194",139,"Abu-Raddad","Test-negative case-control","21Jan2022","mRNA-1273 (Moderna)","excluded","2","final","240+","asymptomatic infection","asymptomatic","Qatar",">= 18 years","general pop",-28.4,"-129.3",28.1,NA,"beta & delta","~35 weeks",NA,NA,"Qatar","QAT",139,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2022-01-21,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","16/12/2021",2021-12-16
"1195",139,"Abu-Raddad","Test-negative case-control","21Jan2022","mRNA-1273 (Moderna)","excluded","1","1","14+","hospitalization or death","severe","Qatar",">= 18 years","general pop",82.1,"73.1",88.1,NA,"beta & delta",NA,NA,NA,"Qatar","QAT",139,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2022-01-21,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","16/12/2021",2021-12-16
"1196",139,"Abu-Raddad","Test-negative case-control","21Jan2022","mRNA-1273 (Moderna)","excluded","2","final","30+","hospitalization or death","severe","Qatar",">= 18 years","general pop",97.2,"92.4",99,NA,"beta & delta","~35 weeks",NA,NA,"Qatar","QAT",139,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2022-01-21,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","16/12/2021",2021-12-16
"1197",139,"Abu-Raddad","Test-negative case-control","21Jan2022","mRNA-1273 (Moderna)","excluded","2","final","180+","hospitalization or death","severe","Qatar",">= 18 years","general pop",61,"-225.5",95.3,NA,"beta & delta","~35 weeks",NA,NA,"Qatar","QAT",139,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2022-01-21,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","16/12/2021",2021-12-16
"1198",140,"Bekker","Retrospective matched cohort","19Mar2022","Ad26.COV2.S (Janssen)","included","1","final","28+","hospitalization","severe","South Africa","HCW","HCW",67,"62",71,NA,"beta, delta, & kappa","12 weeks",NA,NA,"South Africa","ZAF",140,"ZAF",14080,2019,"South Africa","Sub-Saharan Africa","Upper middle income",2,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,71,NA,NA,"who",71,"feb/2021","60-89","not reached","not reached","yes","no","no",2022-03-19,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations","20/12/2021",2021-12-20
"1199",140,"Bekker","Retrospective matched cohort","19Mar2022","Ad26.COV2.S (Janssen)","included","1","final","28+","ICU admission","severe","South Africa","HCW","HCW",75,"69",82,NA,"beta, delta, & kappa","12 weeks",NA,NA,"South Africa","ZAF",140,"ZAF",14080,2019,"South Africa","Sub-Saharan Africa","Upper middle income",2,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,71,NA,NA,"who",71,"feb/2021","60-89","not reached","not reached","yes","no","no",2022-03-19,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations","20/12/2021",2021-12-20
"1200",140,"Bekker","Retrospective matched cohort","19Mar2022","Ad26.COV2.S (Janssen)","included","1","final","28+","death","death","South Africa","HCW","HCW",83,"75",89,NA,"beta, delta, & kappa","12 weeks",NA,NA,"South Africa","ZAF",140,"ZAF",14080,2019,"South Africa","Sub-Saharan Africa","Upper middle income",2,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,71,NA,NA,"who",71,"feb/2021","60-89","not reached","not reached","yes","no","no",2022-03-19,"death","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations","20/12/2021",2021-12-20
"1201",140,"Bekker","Retrospective matched cohort","19Mar2022","Ad26.COV2.S (Janssen)","included","1","final","28+","hospitalization","severe","South Africa","HCW","HCW",62,"42",76,"beta","beta","12 weeks",NA,NA,"South Africa","ZAF",140,"ZAF",14080,2019,"South Africa","Sub-Saharan Africa","Upper middle income",2,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,71,NA,NA,"who",71,"feb/2021","60-89","not reached","not reached","yes","no","no",2022-03-19,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","beta","20/12/2021",2021-12-20
"1202",140,"Bekker","Retrospective matched cohort","19Mar2022","Ad26.COV2.S (Janssen)","included","1","final","28+","ICU admission","severe","South Africa","HCW","HCW",49,"8",77,"beta","beta","12 weeks",NA,NA,"South Africa","ZAF",140,"ZAF",14080,2019,"South Africa","Sub-Saharan Africa","Upper middle income",2,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,71,NA,NA,"who",71,"feb/2021","60-89","not reached","not reached","yes","no","no",2022-03-19,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","beta","20/12/2021",2021-12-20
"1203",140,"Bekker","Retrospective matched cohort","19Mar2022","Ad26.COV2.S (Janssen)","included","1","final","28+","death","death","South Africa","HCW","HCW",86,"57",100,"beta","beta","12 weeks",NA,NA,"South Africa","ZAF",140,"ZAF",14080,2019,"South Africa","Sub-Saharan Africa","Upper middle income",2,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,71,NA,NA,"who",71,"feb/2021","60-89","not reached","not reached","yes","no","no",2022-03-19,"death","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","beta","20/12/2021",2021-12-20
"1204",140,"Bekker","Retrospective matched cohort","19Mar2022","Ad26.COV2.S (Janssen)","included","1","final","28+","hospitalization","severe","South Africa","HCW","HCW",67,"62",71,"delta","delta","12 weeks",NA,NA,"South Africa","ZAF",140,"ZAF",14080,2019,"South Africa","Sub-Saharan Africa","Upper middle income",2,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,71,NA,NA,"who",71,"feb/2021","60-89","not reached","not reached","yes","no","no",2022-03-19,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta","20/12/2021",2021-12-20
"1205",140,"Bekker","Retrospective matched cohort","19Mar2022","Ad26.COV2.S (Janssen)","included","1","final","28+","ICU admission","severe","South Africa","HCW","HCW",78,"71",88,"delta","delta","12 weeks",NA,NA,"South Africa","ZAF",140,"ZAF",14080,2019,"South Africa","Sub-Saharan Africa","Upper middle income",2,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,71,NA,NA,"who",71,"feb/2021","60-89","not reached","not reached","yes","no","no",2022-03-19,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta","20/12/2021",2021-12-20
"1206",140,"Bekker","Retrospective matched cohort","19Mar2022","Ad26.COV2.S (Janssen)","included","1","final","28+","death","death","South Africa","HCW","HCW",82,"74",89,"delta","delta","12 weeks",NA,NA,"South Africa","ZAF",140,"ZAF",14080,2019,"South Africa","Sub-Saharan Africa","Upper middle income",2,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,71,NA,NA,"who",71,"feb/2021","60-89","not reached","not reached","yes","no","no",2022-03-19,"death","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta","20/12/2021",2021-12-20
"1207",141,"Tartof","Retrospective matched cohort","14Feb2022","BNT162b2 (Pfizer BioNTech)","included","2","final","7-36","Infection","infection","USA",">= 18 years","general pop",85,"83",86,NA,"non-VOC, alpha, & delta","~48 weeks",NA,NA,"USA","USA",141,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-02-14,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","21/12/2021",2021-12-21
"1208",141,"Tartof","Retrospective matched cohort","14Feb2022","BNT162b2 (Pfizer BioNTech)","included","2","final","217+","Infection","infection","USA",">= 18 years","general pop",49,"46",51,NA,"non-VOC, alpha, & delta","~48 weeks",NA,NA,"USA","USA",141,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-02-14,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","21/12/2021",2021-12-21
"1209",141,"Tartof","Retrospective matched cohort","14Feb2022","BNT162b2 (Pfizer BioNTech)","included","2","final","7-36","hospitalization","severe","USA",">= 18 years","general pop",90,"86",92,NA,"non-VOC, alpha, & delta","~48 weeks",NA,NA,"USA","USA",141,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-02-14,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","21/12/2021",2021-12-21
"1210",141,"Tartof","Retrospective matched cohort","14Feb2022","BNT162b2 (Pfizer BioNTech)","included","2","final","217+","hospitalization","severe","USA",">= 18 years","general pop",88,"85",90,NA,"non-VOC, alpha, & delta","~48 weeks",NA,NA,"USA","USA",141,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-02-14,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","21/12/2021",2021-12-21
"1211",142,"Lewis","Test-negative case-control","21Dec2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA",">= 18 years","general pop",96,"93",98,NA,"alpha & delta","~30 weeks",NA,NA,"USA","USA",142,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-12-21,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-12-21
"1212",142,"Lewis","Test-negative case-control","21Dec2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA",">= 18 years","general pop",93,"89",95,NA,"alpha & delta","~30 weeks",NA,NA,"USA","USA",142,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-12-21,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-12-21
"1213",142,"Lewis","Test-negative case-control","21Dec2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA",">= 18 years","general pop",87,"82",91,NA,"alpha & delta","~30 weeks",NA,NA,"USA","USA",142,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-12-21,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-12-21
"1214",142,"Lewis","Test-negative case-control","21Dec2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA",">= 18 years","general pop",83,"72",88,NA,"alpha & delta","~30 weeks",NA,NA,"USA","USA",142,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-12-21,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-12-21
"1215",143,"Ioannou","Target trial emulation","21Dec2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","14+","infection (March 31 2021)","infection","USA",">= 18 years","general pop",31,"26",35,NA,"non-VOC & alpha",NA,NA,NA,"USA","USA",143,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-12-21,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-12-21
"1216",143,"Ioannou","Target trial emulation","21Dec2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","infection (March 31 2021)","infection","USA",">= 18 years","general pop",65,"63",68,NA,"non-VOC & alpha","~28 weeks",NA,NA,"USA","USA",143,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-12-21,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-12-21
"1217",143,"Ioannou","Target trial emulation","21Dec2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","infection (June 30 2021)","infection","USA",">= 18 years","general pop",69,"67",70,NA,"non-VOC & alpha","~28 weeks",NA,NA,"USA","USA",143,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-12-21,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-12-21
"1218",143,"Ioannou","Target trial emulation","21Dec2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","14+","death (March 31 2021)","death","USA",">= 18 years","general pop",55,"42",64,NA,"non-VOC & alpha",NA,NA,NA,"USA","USA",143,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-12-21,"death","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-12-21
"1219",143,"Ioannou","Target trial emulation","21Dec2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","death (March 31 2021)","death","USA",">= 18 years","general pop",89,"84",92,NA,"non-VOC & alpha","~28 weeks",NA,NA,"USA","USA",143,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-12-21,"death","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-12-21
"1220",143,"Ioannou","Target trial emulation","21Dec2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","death (June 30 2021)","death","USA",">= 18 years","general pop",86,"82",89,NA,"non-VOC & alpha","~28 weeks",NA,NA,"USA","USA",143,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-12-21,"death","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-12-21
"1221",144,"Hansen","Retrospective cohort","23Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","15-44","Infection","infection","Denmark",">= 12 years","general pop",55.2,"23.5",73.7,"omicron","omicron","21 weeks",NA,NA,"Denmark","DNK",144,"DNK",61830,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,8,212,261,"who",8,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-12-23,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2021-12-23
"1222",144,"Hansen","Retrospective cohort","23Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","105-164","Infection","infection","Denmark",">= 12 years","general pop",-76.5,"-95.3",-59.5,"omicron","omicron","22 weeks",NA,NA,"Denmark","DNK",144,"DNK",61830,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,8,212,261,"who",8,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-12-23,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2021-12-23
"1223",144,"Hansen","Retrospective cohort","23Dec2021","mRNA-1273 (Moderna)","excluded","2","final","15-44","Infection","infection","Denmark",">= 12 years","general pop",36.7,"-69.9",76.4,"omicron","omicron","23 weeks",NA,NA,"Denmark","DNK",144,"DNK",61830,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,8,212,261,"who",8,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-12-23,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron",NA,2021-12-23
"1224",144,"Hansen","Retrospective cohort","23Dec2021","mRNA-1273 (Moderna)","excluded","2","final","105-164","Infection","infection","Denmark",">= 12 years","general pop",-39.3,"-61.6",-20,"omicron","omicron","24 weeks",NA,NA,"Denmark","DNK",144,"DNK",61830,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,8,212,261,"who",8,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-12-23,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron",NA,2021-12-23
"1225",144,"Hansen","Retrospective cohort","23Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","15-44","Infection","infection","Denmark",">= 12 years","general pop",86.7,"84.6",88.6,"delta","delta","25 weeks",NA,NA,"Denmark","DNK",144,"DNK",61830,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,8,212,261,"who",8,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-12-23,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2021-12-23
"1226",144,"Hansen","Retrospective cohort","23Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","105-164","Infection","infection","Denmark",">= 12 years","general pop",53.8,"52.9",54.6,"delta","delta","26 weeks",NA,NA,"Denmark","DNK",144,"DNK",61830,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,8,212,261,"who",8,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-12-23,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2021-12-23
"1227",144,"Hansen","Retrospective cohort","23Dec2021","mRNA-1273 (Moderna)","excluded","2","final","15-44","Infection","infection","Denmark",">= 12 years","general pop",88.2,"83.1",91.8,"delta","delta","27 weeks",NA,NA,"Denmark","DNK",144,"DNK",61830,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,8,212,261,"who",8,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-12-23,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2021-12-23
"1228",144,"Hansen","Retrospective cohort","23Dec2021","mRNA-1273 (Moderna)","excluded","2","final","105-164","Infection","infection","Denmark",">= 12 years","general pop",65,"63.6",66.3,"delta","delta","28 weeks",NA,NA,"Denmark","DNK",144,"DNK",61830,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,8,212,261,"who",8,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-12-23,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2021-12-23
"1229",146,"Katikireddi","Retrospective cohort","20Dec2021","AZD1222 (AstraZeneca)","excluded","2","final","14-27","severe disease","severe","Scotland",">= 18 years","general pop",83.7,"79.7",87,NA,"delta","~20 weeks",NA,NA,"UK","GBR",146,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-12-20,"severe","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2021-12-20
"1230",146,"Katikireddi","Retrospective cohort","20Dec2021","AZD1222 (AstraZeneca)","excluded","2","final","140-153","severe disease","severe","Scotland",">= 18 years","general pop",53.6,"48.4",58.3,NA,"delta","~20 weeks",NA,NA,"UK","GBR",146,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2021-12-20,"severe","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2021-12-20
"1231",147,"Amir","Quasi-experimental","21Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-60","Infection","infection","Israel","12-14 years","12-14 years",92,"91.1",92.8,NA,"delta","~6.5 weeks",NA,NA,"Israel","ISR",147,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-12-21,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2021-12-21
"1232",147,"Amir","Quasi-experimental","21Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-60","Infection","infection","Israel","16-18 years","16-18 years",89.8,"80",93.8,NA,"delta","~6.5 weeks",NA,NA,"Israel","ISR",147,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-12-21,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2021-12-21
"1233",148,"Ostropolets","Retrospective cohort","23Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","Infection","infection","USA",">= 18 years","general pop",94,"91",95,NA,"non-VOC, alpha, & delta","52 weeks",NA,NA,"USA","USA",148,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-08-23,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","25/12/2021",2021-12-25
"1234",148,"Ostropolets","Retrospective cohort","23Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","Hospitalization","severe","USA",">= 18 years","general pop",95,"92",97,NA,"non-VOC, alpha, & delta","52 weeks",NA,NA,"USA","USA",148,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-08-23,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","25/12/2021",2021-12-25
"1235",148,"Ostropolets","Retrospective cohort","23Aug2022","mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","USA",">= 18 years","general pop",97,"94",98,NA,"non-VOC, alpha, & delta","52 weeks",NA,NA,"USA","USA",148,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-08-23,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","25/12/2021",2021-12-25
"1236",148,"Ostropolets","Retrospective cohort","23Aug2022","mRNA-1273 (Moderna)","excluded","2","final","14+","Hospitalization","severe","USA",">= 18 years","general pop",96,"92",99,NA,"non-VOC, alpha, & delta","52 weeks",NA,NA,"USA","USA",148,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-08-23,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","25/12/2021",2021-12-25
"1237",148,"Ostropolets","Retrospective cohort","23Aug2022","Ad26.COV2.S (Janssen)","excluded","1","final","14+","Infection","infection","USA",">= 18 years","general pop",81,"50",94,NA,"non-VOC, alpha, & delta","52 weeks",NA,NA,"USA","USA",148,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-08-23,"infection","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations","25/12/2021",2021-12-25
"1238",148,"Ostropolets","Retrospective cohort","23Aug2022","Ad26.COV2.S (Janssen)","excluded","1","final","14+","hospitalization","severe","USA",">= 18 years","general pop",92,"58",100,NA,"non-VOC, alpha, & delta","52 weeks",NA,NA,"USA","USA",148,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-08-23,"severe","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations","25/12/2021",2021-12-25
"1239",149,"Alali","Retrospective cohort","07Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14+","symptomatic disease","symptomatic","Kuwait","HCW","HCW",91.4,"65.1",97.9,NA,"alpha",NA,NA,NA,"Kuwait","KWT",149,"KWT",55930,2019,"Kuwait","Middle East & North Africa","High income",4,"Asia",2020-12-28,2021-11-30,2021-11-30,2020-12-28,2020-12-28,0,20,337,337,"equal",20,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","yes",2021-12-07,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-12-07
"1240",149,"Alali","Retrospective cohort","07Dec2021","AZD1222 (AstraZeneca)","excluded","1","1","28+","symptomatic disease","symptomatic","Kuwait","HCW","HCW",75.4,"67.2",81.6,NA,"alpha",NA,NA,NA,"Kuwait","KWT",149,"KWT",55930,2019,"Kuwait","Middle East & North Africa","High income",4,"Asia",2020-12-28,2021-11-30,2021-11-30,2020-12-28,2020-12-28,0,20,337,337,"equal",20,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","yes",2021-12-07,"symptomatic","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2021-12-07
"1241",149,"Alali","Retrospective cohort","07Dec2021","AZD1222 (AstraZeneca)","excluded","2","final","14+","symptomatic disease","symptomatic","Kuwait","HCW","HCW",94.5,"89.4",97.2,NA,"alpha","~20 weeks",NA,NA,"Kuwait","KWT",149,"KWT",55930,2019,"Kuwait","Middle East & North Africa","High income",4,"Asia",2020-12-28,2021-11-30,2021-11-30,2020-12-28,2020-12-28,0,20,337,337,"equal",20,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","yes",2021-12-07,"symptomatic","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2021-12-07
"1242",150,"Mendola","Retrospective cohort","23Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","8-98","infection","infection","Italy","HCW","HCW",89,"78",95,NA,"alpha","~12 weeks",NA,NA,"Italy","ITA",150,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2021-12-23,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-12-23
"1243",151,"Collie","Test-negative case-control","29Dec2021","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","Hospitalization","severe","South Africa",">= 18 years","general pop",70,"62",76,NA,"omicron","~24 weeks",NA,NA,"South Africa","ZAF",151,"ZAF",14080,2019,"South Africa","Sub-Saharan Africa","Upper middle income",2,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,71,NA,NA,"who",71,"feb/2021","60-89","not reached","not reached","yes","no","no",2021-12-29,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2021-12-29
"1244",151,"Collie","Test-negative case-control","29Dec2021","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","Hospitalization","severe","South Africa",">= 18 years","general pop",93,"90",94,NA,"delta","~19 weeks",NA,NA,"South Africa","ZAF",151,"ZAF",14080,2019,"South Africa","Sub-Saharan Africa","Upper middle income",2,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,71,NA,NA,"who",71,"feb/2021","60-89","not reached","not reached","yes","no","no",2021-12-29,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2021-12-29
"1245",152,"Lutrick","Prospective cohort","31Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","USA","12-17 years","12-17 years",92,"79",97,NA,"delta","~17 weeks",NA,NA,"USA","USA",152,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-12-31,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2021-12-31
"1246",153,"Chung","Test-negative case-control","01Jan2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","symptomatic disease","symptomatic","USA",">= 12 years","general pop",66,"56",73,NA,"non-VOC, alpha, & delta","~34 weeks",NA,NA,"USA","USA",153,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-01-01,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-01-01
"1247",153,"Chung","Test-negative case-control","01Jan2022","mRNA-1273 (Moderna)","included","2","final","14+","symptomatic disease","symptomatic","USA",">= 12 years","general pop",81,"73",86,NA,"non-VOC, alpha, & delta","~34 weeks",NA,NA,"USA","USA",153,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-01-01,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-01-01
"1248",155,"Cerqueira-Silva ","Test-negative case-control","31Mar2022","CoronaVac (Sinovac)","confirmed prior infection","1","1","14+","symptomatic reinfection","symptomatic","Brazil",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection",18.8,"10.7",26.1,NA,"non-VOC, gamma, & delta",NA,NA,NA,"Brazil","BRA",155,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-31,"symptomatic","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations","27/12/2021",2021-12-27
"1249",155,"Cerqueira-Silva ","Test-negative case-control","31Mar2022","CoronaVac (Sinovac)","confirmed prior infection","2","final","14+","symptomatic reinfection","symptomatic","Brazil",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection",39.4,"36.1",42.6,NA,"non-VOC, gamma, & delta","~37 weeks",NA,NA,"Brazil","BRA",155,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-31,"symptomatic","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations","27/12/2021",2021-12-27
"1250",155,"Cerqueira-Silva ","Test-negative case-control","31Mar2022","CoronaVac (Sinovac)","confirmed prior infection","2","final","14-90","symptomatic reinfection","symptomatic","Brazil",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection",40.5,"36.4",44.3,NA,"non-VOC, gamma, & delta","~11 weeks",NA,NA,"Brazil","BRA",155,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-31,"symptomatic","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations","27/12/2021",2021-12-27
"1251",155,"Cerqueira-Silva ","Test-negative case-control","31Mar2022","CoronaVac (Sinovac)","confirmed prior infection","2","final","90+","symptomatic reinfection","symptomatic","Brazil",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection",38,"33.1",42.5,NA,"non-VOC, gamma, & delta","~37 weeks",NA,NA,"Brazil","BRA",155,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-31,"symptomatic","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations","27/12/2021",2021-12-27
"1252",155,"Cerqueira-Silva ","Test-negative case-control","31Mar2022","CoronaVac (Sinovac)","confirmed prior infection","1","1","14+","hospitalization or death","severe","Brazil",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection",35.3,"7.9",54.5,NA,"non-VOC, gamma, & delta",NA,NA,NA,"Brazil","BRA",155,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-31,"severe","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations","27/12/2021",2021-12-27
"1253",155,"Cerqueira-Silva ","Test-negative case-control","31Mar2022","CoronaVac (Sinovac)","confirmed prior infection","2","final","14+","hospitalization or death","severe","Brazil",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection",81.3,"75.3",85.8,NA,"non-VOC, gamma, & delta","~37 weeks",NA,NA,"Brazil","BRA",155,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-31,"severe","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations","27/12/2021",2021-12-27
"1254",155,"Cerqueira-Silva ","Test-negative case-control","31Mar2022","CoronaVac (Sinovac)","confirmed prior infection","2","final","14-90","hospitalization or death","severe","Brazil",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection",86.6,"79.8",90.3,NA,"non-VOC, gamma, & delta","~11 weeks",NA,NA,"Brazil","BRA",155,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-31,"severe","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations","27/12/2021",2021-12-27
"1255",155,"Cerqueira-Silva ","Test-negative case-control","31Mar2022","CoronaVac (Sinovac)","confirmed prior infection","2","final","90+","hospitalization or death","severe","Brazil",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection",74.4,"63.3",82.2,NA,"non-VOC, gamma, & delta","~37 weeks",NA,NA,"Brazil","BRA",155,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-31,"severe","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations","27/12/2021",2021-12-27
"1256",155,"Cerqueira-Silva ","Test-negative case-control","31Mar2022","AZD1222 (AstraZeneca)","confirmed prior infection","1","1","14+","symptomatic reinfection","symptomatic","Brazil",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection",34.2,"30.1",38.1,NA,"non-VOC, gamma, & delta",NA,NA,NA,"Brazil","BRA",155,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-31,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","27/12/2021",2021-12-27
"1257",155,"Cerqueira-Silva ","Test-negative case-control","31Mar2022","AZD1222 (AstraZeneca)","confirmed prior infection","2","final","14+","symptomatic reinfection","symptomatic","Brazil",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection",56,"51.4",60.2,NA,"non-VOC, gamma, & delta","~37 weeks",NA,NA,"Brazil","BRA",155,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-31,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","27/12/2021",2021-12-27
"1258",155,"Cerqueira-Silva ","Test-negative case-control","31Mar2022","AZD1222 (AstraZeneca)","confirmed prior infection","2","final","14-90","symptomatic reinfection","symptomatic","Brazil",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection",55.5,"50.5",60.1,NA,"non-VOC, gamma, & delta","~11 weeks",NA,NA,"Brazil","BRA",155,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-31,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","27/12/2021",2021-12-27
"1259",155,"Cerqueira-Silva ","Test-negative case-control","31Mar2022","AZD1222 (AstraZeneca)","confirmed prior infection","2","final","90+","symptomatic reinfection","symptomatic","Brazil",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection",56.8,"46.6",65.1,NA,"non-VOC, gamma, & delta","~37 weeks",NA,NA,"Brazil","BRA",155,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-31,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","27/12/2021",2021-12-27
"1260",155,"Cerqueira-Silva ","Test-negative case-control","31Mar2022","AZD1222 (AstraZeneca)","confirmed prior infection","1","1","14+","hospitalization or death","severe","Brazil",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection",56.9,"45.2",66.1,NA,"non-VOC, gamma, & delta",NA,NA,NA,"Brazil","BRA",155,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-31,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","27/12/2021",2021-12-27
"1261",155,"Cerqueira-Silva ","Test-negative case-control","31Mar2022","AZD1222 (AstraZeneca)","confirmed prior infection","2","final","14+","hospitalization or death","severe","Brazil",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection",89.9,"83.5",93.8,NA,"non-VOC, gamma, & delta","~37 weeks",NA,NA,"Brazil","BRA",155,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-31,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","27/12/2021",2021-12-27
"1262",155,"Cerqueira-Silva ","Test-negative case-control","31Mar2022","AZD1222 (AstraZeneca)","confirmed prior infection","2","final","14-90","hospitalization or death","severe","Brazil",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection",86.6,"77.6",92,NA,"non-VOC, gamma, & delta","~11 weeks",NA,NA,"Brazil","BRA",155,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-31,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","27/12/2021",2021-12-27
"1263",155,"Cerqueira-Silva ","Test-negative case-control","31Mar2022","AZD1222 (AstraZeneca)","confirmed prior infection","2","final","90+","hospitalization or death","severe","Brazil",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection",95.1,"84.8",98.4,NA,"non-VOC, gamma, & delta","~37 weeks",NA,NA,"Brazil","BRA",155,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-31,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","27/12/2021",2021-12-27
"1264",155,"Cerqueira-Silva ","Test-negative case-control","31Mar2022","BNT162b2 (Pfizer BioNTech)","confirmed prior infection","1","1","14+","symptomatic reinfection","symptomatic","Brazil",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection",45,"39.7",49.9,NA,"non-VOC, gamma, & delta",NA,NA,NA,"Brazil","BRA",155,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-31,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","27/12/2021",2021-12-27
"1265",155,"Cerqueira-Silva ","Test-negative case-control","31Mar2022","BNT162b2 (Pfizer BioNTech)","confirmed prior infection","2","final","14+","symptomatic reinfection","symptomatic","Brazil",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection",64.8,"54.9",72.4,NA,"non-VOC, gamma, & delta","~37 weeks",NA,NA,"Brazil","BRA",155,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-31,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","27/12/2021",2021-12-27
"1266",155,"Cerqueira-Silva ","Test-negative case-control","31Mar2022","BNT162b2 (Pfizer BioNTech)","confirmed prior infection","2","final","14-90","symptomatic reinfection","symptomatic","Brazil",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection",64.2,"54.2",72,NA,"non-VOC, gamma, & delta","~11 weeks",NA,NA,"Brazil","BRA",155,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-31,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","27/12/2021",2021-12-27
"1267",155,"Cerqueira-Silva ","Test-negative case-control","31Mar2022","BNT162b2 (Pfizer BioNTech)","confirmed prior infection","2","final","90+","symptomatic reinfection","symptomatic","Brazil",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection",100,NA,NA,NA,"non-VOC, gamma, & delta","~37 weeks",NA,NA,"Brazil","BRA",155,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-31,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","27/12/2021",2021-12-27
"1268",155,"Cerqueira-Silva ","Test-negative case-control","31Mar2022","BNT162b2 (Pfizer BioNTech)","confirmed prior infection","1","1","14+","hospitalization or death","severe","Brazil",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection",61.8,"40.8",75.3,NA,"non-VOC, gamma, & delta",NA,NA,NA,"Brazil","BRA",155,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-31,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","27/12/2021",2021-12-27
"1269",155,"Cerqueira-Silva ","Test-negative case-control","31Mar2022","BNT162b2 (Pfizer BioNTech)","confirmed prior infection","2","final","14+","hospitalization or death","severe","Brazil",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection",89.7,"54.3",97.7,NA,"non-VOC, gamma, & delta","~37 weeks",NA,NA,"Brazil","BRA",155,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-31,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","27/12/2021",2021-12-27
"1270",155,"Cerqueira-Silva ","Test-negative case-control","31Mar2022","BNT162b2 (Pfizer BioNTech)","confirmed prior infection","2","final","14-90","hospitalization or death","severe","Brazil",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection",88.8,"50",97.5,NA,"non-VOC, gamma, & delta","~11 weeks",NA,NA,"Brazil","BRA",155,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-31,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","27/12/2021",2021-12-27
"1271",155,"Cerqueira-Silva ","Test-negative case-control","31Mar2022","BNT162b2 (Pfizer BioNTech)","confirmed prior infection","2","final","90+","hospitalization or death","severe","Brazil",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection",100,NA,NA,NA,"non-VOC, gamma, & delta","~37 weeks",NA,NA,"Brazil","BRA",155,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-31,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","27/12/2021",2021-12-27
"1272",155,"Cerqueira-Silva ","Test-negative case-control","31Mar2022","Ad26.COV2.S (Janssen)","confirmed prior infection","1","final","14+","symptomatic reinfection","symptomatic","Brazil",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection",44,"31.5",54.2,NA,"non-VOC, gamma, & delta","~37 weeks",NA,NA,"Brazil","BRA",155,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-31,"symptomatic","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations","27/12/2021",2021-12-27
"1273",155,"Cerqueira-Silva ","Test-negative case-control","31Mar2022","Ad26.COV2.S (Janssen)","confirmed prior infection","1","final","14-90","symptomatic reinfection","symptomatic","Brazil",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection",46.1,"32.7",56.7,NA,"non-VOC, gamma, & delta","~11 weeks",NA,NA,"Brazil","BRA",155,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-31,"symptomatic","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations","27/12/2021",2021-12-27
"1274",155,"Cerqueira-Silva ","Test-negative case-control","31Mar2022","Ad26.COV2.S (Janssen)","confirmed prior infection","1","final","90+","symptomatic reinfection","symptomatic","Brazil",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection",30.6,"-12.4",57.1,NA,"non-VOC, gamma, & delta","~37 weeks",NA,NA,"Brazil","BRA",155,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-31,"symptomatic","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations","27/12/2021",2021-12-27
"1275",155,"Cerqueira-Silva ","Test-negative case-control","31Mar2022","Ad26.COV2.S (Janssen)","confirmed prior infection","1","final","14+","hospitalization or death","severe","Brazil",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection",57.7,"-2.6",82.5,NA,"non-VOC, gamma, & delta","~37 weeks",NA,NA,"Brazil","BRA",155,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-31,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations","27/12/2021",2021-12-27
"1276",155,"Cerqueira-Silva ","Test-negative case-control","31Mar2022","Ad26.COV2.S (Janssen)","confirmed prior infection","1","final","14-90","hospitalization or death","severe","Brazil",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection",60.2,"-10.8",85.7,NA,"non-VOC, gamma, & delta","~11 weeks",NA,NA,"Brazil","BRA",155,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-31,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations","27/12/2021",2021-12-27
"1277",155,"Cerqueira-Silva ","Test-negative case-control","31Mar2022","Ad26.COV2.S (Janssen)","confirmed prior infection","1","final","90+","hospitalization or death","severe","Brazil",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection",41,"-240.9",89.9,NA,"non-VOC, gamma, & delta","~37 weeks",NA,NA,"Brazil","BRA",155,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-31,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations","27/12/2021",2021-12-27
"1278",156,"Petraš","Retrospective cohort","22Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14+","infection","infection","Czech Republic","HCW","HCW",47.7,"19.2",66.2,NA,"alpha & delta",NA,NA,NA,"Czech Republic","CZE",156,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2021-12-22,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-12-22
"1279",156,"Petraš","Retrospective cohort","22Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","Infection","infection","Czech Republic","HCW","HCW",88.3,"83.2",91.8,NA,"alpha & delta","~30 weeks",NA,NA,"Czech Republic","CZE",156,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2021-12-22,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-12-22
"1280",156,"Petraš","Retrospective cohort","22Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14+","symptomatic disease","symptomatic","Czech Republic","HCW","HCW",76.4,"46",89.7,NA,"alpha & delta",NA,NA,NA,"Czech Republic","CZE",156,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2021-12-22,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-12-22
"1281",156,"Petraš","Retrospective cohort","22Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease","symptomatic","Czech Republic","HCW","HCW",91.7,"85.7",95.2,NA,"alpha & delta","~30 weeks",NA,NA,"Czech Republic","CZE",156,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2021-12-22,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-12-22
"1282",156,"Petraš","Retrospective cohort","22Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection (February 2021)","infection","Czech Republic","HCW","HCW",96.2,"91.6",98.7,NA,"alpha & delta","4 weeks",NA,NA,"Czech Republic","CZE",156,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2021-12-22,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-12-22
"1283",156,"Petraš","Retrospective cohort","22Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection (June-August 2021)","infection","Czech Republic","HCW","HCW",65,"<0",96.6,NA,"alpha & delta","~30 weeks",NA,NA,"Czech Republic","CZE",156,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2021-12-22,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-12-22
"1284",157,"Prunas","Matched case-control","09Dec2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-89","Infection","infection","Israel","12-16 years","12-16 years",85,"84",86,NA,"delta","~25 weeks",NA,NA,"Israel","ISR",157,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-12-09,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","05/01/2022",2022-01-05
"1285",157,"Prunas","Matched case-control","09Dec2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","150-180","Infection","infection","Israel","12-16 years","12-16 years",53,"46",60,NA,"delta","~25 weeks",NA,NA,"Israel","ISR",157,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-12-09,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","05/01/2022",2022-01-05
"1286",157,"Prunas","Matched case-control","09Dec2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-89","symptomatic disease","symptomatic","Israel","12-16 years","12-16 years",90,"89",91,NA,"delta","~25 weeks",NA,NA,"Israel","ISR",157,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-12-09,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","05/01/2022",2022-01-05
"1287",157,"Prunas","Matched case-control","09Dec2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","150-180","symptomatic disease","symptomatic","Israel","12-16 years","12-16 years",66,"59",72,NA,"delta","~25 weeks",NA,NA,"Israel","ISR",157,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-12-09,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","05/01/2022",2022-01-05
"1288",157,"Prunas","Test-negative case-control","09Dec2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-89","Infection","infection","Israel","12-16 years","12-16 years",84,"82",85,NA,"delta","~25 weeks",NA,NA,"Israel","ISR",157,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-12-09,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","05/01/2022",2022-01-05
"1289",157,"Prunas","Test-negative case-control","09Dec2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","150-180","Infection","infection","Israel","12-16 years","12-16 years",50,"43",57,NA,"delta","~25 weeks",NA,NA,"Israel","ISR",157,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-12-09,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","05/01/2022",2022-01-05
"1290",158,"Zambrano","Test-negative case-control","07Jan2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","MIS-C","MIS-C","USA","12-18 years","12-18 years",86,"70",93,NA,"delta","~23 weeks",NA,NA,"USA","USA",158,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-01-07,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-01-07
"1291",158,"Zambrano","Test-negative case-control","07Jan2022","BNT162b2 (Pfizer BioNTech)","included","2","final","28+","MIS-C","MIS-C","USA","12-18 years","12-18 years",91,"78",97,NA,"delta","~23 weeks",NA,NA,"USA","USA",158,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-01-07,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-01-07
"1292",158,"Zambrano","Test-negative case-control","07Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","28+","MIS-C","MIS-C","USA","12-18 years","12-18 years",90,"75",96,NA,"delta","~23 weeks",NA,NA,"USA","USA",158,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-01-07,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-01-07
"1293",159,"Tseng","Test-negative case-control","21Feb2022","mRNA-1273 (Moderna)","included","1","1","14+","Infection","infection","USA",">= 18 years","general pop",20.4,"9.5",30,"omicron","omicron",NA,NA,NA,"USA","USA",159,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-02-21,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","21/01/2022",2022-01-21
"1294",159,"Tseng","Test-negative case-control","21Feb2022","mRNA-1273 (Moderna)","included","2","final","14+","Infection","infection","USA",">= 18 years","general pop",13.9,"10.5",17.1,"omicron","omicron","~47.5 weeks",NA,NA,"USA","USA",159,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-02-21,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","21/01/2022",2022-01-21
"1295",159,"Tseng","Test-negative case-control","21Feb2022","mRNA-1273 (Moderna)","included","2","final","14-90","Infection","infection","USA",">= 18 years","general pop",44,"35.1",51.6,"omicron","omicron","~11 weeks",NA,NA,"USA","USA",159,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-02-21,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","21/01/2022",2022-01-21
"1296",159,"Tseng","Test-negative case-control","21Feb2022","mRNA-1273 (Moderna)","included","2","final","270+","Infection","infection","USA",">= 18 years","general pop",5.9,"0.4",11,"omicron","omicron","~47.5 weeks",NA,NA,"USA","USA",159,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-02-21,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","21/01/2022",2022-01-21
"1297",159,"Tseng","Test-negative case-control","21Feb2022","mRNA-1273 (Moderna)","included","2","final","14+","Hospitalization","severe","USA",">= 18 years","general pop",84.5,"23",96.9,"omicron","omicron","~47.5 weeks",NA,NA,"USA","USA",159,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-02-21,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","21/01/2022",2022-01-21
"1298",159,"Tseng","Test-negative case-control","21Feb2022","mRNA-1273 (Moderna)","included","1","1","14+","Infection","infection","USA",">= 18 years","general pop",56.7,"40.7",68.4,"delta","delta",NA,NA,NA,"USA","USA",159,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-02-21,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","21/01/2022",2022-01-21
"1299",159,"Tseng","Test-negative case-control","21Feb2022","mRNA-1273 (Moderna)","included","2","final","14+","Infection","infection","USA",">= 18 years","general pop",63.6,"59.9",66.9,"delta","delta","~47.5 weeks",NA,NA,"USA","USA",159,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-02-21,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","21/01/2022",2022-01-21
"1300",159,"Tseng","Test-negative case-control","21Feb2022","mRNA-1273 (Moderna)","included","2","final","14-90","Infection","infection","USA",">= 18 years","general pop",80.2,"68.2",87.7,"delta","delta","~11 weeks",NA,NA,"USA","USA",159,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-02-21,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","21/01/2022",2022-01-21
"1301",159,"Tseng","Test-negative case-control","21Feb2022","mRNA-1273 (Moderna)","included","2","final","270+","Infection","infection","USA",">= 18 years","general pop",61.3,"55",66.7,"delta","delta","~47.5 weeks",NA,NA,"USA","USA",159,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-02-21,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","21/01/2022",2022-01-21
"1302",159,"Tseng","Test-negative case-control","21Feb2022","mRNA-1273 (Moderna)","included","1","1","14+","Hospitalization","severe","USA",">= 18 years","general pop",71.2,"-68.7",97.4,"delta","delta",NA,NA,NA,"USA","USA",159,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-02-21,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","21/01/2022",2022-01-21
"1303",159,"Tseng","Test-negative case-control","21Feb2022","mRNA-1273 (Moderna)","included","2","final","14+","Hospitalization","severe","USA",">= 18 years","general pop",99,"93.3",99.9,"delta","delta","~47.5 weeks",NA,NA,"USA","USA",159,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-02-21,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","21/01/2022",2022-01-21
"1304",160,"Chiew","Retrospective cohort","28Sep2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","8+","Infection","infection","Singapore","12-17 years","12-17 years",25,"21",29,NA,"omicron","~44 weeks",NA,NA,"Singapore","SGP",160,"SGP",89630,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,22,192,227,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-28,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","28/09/2022",2022-09-28
"1305",160,"Chiew","Retrospective cohort","28Sep2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","8-59","Infection","infection","Singapore","12-17 years","12-17 years",38,"32",43,NA,"omicron",NA,NA,NA,"Singapore","SGP",160,"SGP",89630,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,22,192,227,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-28,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","28/09/2022",2022-09-28
"1306",160,"Chiew","Retrospective cohort","28Sep2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","240+","Infection","infection","Singapore","12-17 years","12-17 years",40,"34",46,NA,"omicron","~44 weeks",NA,NA,"Singapore","SGP",160,"SGP",89630,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,22,192,227,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-28,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","28/09/2022",2022-09-28
"1307",160,"Chiew","Retrospective cohort","28Sep2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","8+","Hospitalization","severe","Singapore","12-17 years","12-17 years",75,"56",86,NA,"omicron","~44 weeks",NA,NA,"Singapore","SGP",160,"SGP",89630,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,22,192,227,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-28,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","28/09/2022",2022-09-28
"1308",160,"Chiew","Retrospective cohort","28Sep2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","8-59","Hospitalization","severe","Singapore","12-17 years","12-17 years",74,"26",91,NA,"omicron",NA,NA,NA,"Singapore","SGP",160,"SGP",89630,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,22,192,227,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-28,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","28/09/2022",2022-09-28
"1309",160,"Chiew","Retrospective cohort","28Sep2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","240+","Hospitalization","severe","Singapore","12-17 years","12-17 years",77,"54",89,NA,"omicron","~44 weeks",NA,NA,"Singapore","SGP",160,"SGP",89630,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,22,192,227,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-28,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","28/09/2022",2022-09-28
"1310",160,"Chiew","Retrospective cohort","28Sep2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","8+","Infection","infection","Singapore","12-17 years","12-17 years",66,"63",69,NA,"delta","~24 weeks",NA,NA,"Singapore","SGP",160,"SGP",89630,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,22,192,227,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-28,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","28/09/2022",2022-09-28
"1311",160,"Chiew","Retrospective cohort","28Sep2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","8-59","Infection","infection","Singapore","12-17 years","12-17 years",71,"67",74,NA,"delta",NA,NA,NA,"Singapore","SGP",160,"SGP",89630,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,22,192,227,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-28,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","28/09/2022",2022-09-28
"1312",160,"Chiew","Retrospective cohort","28Sep2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","240+","Infection","infection","Singapore","12-17 years","12-17 years",57,"27",75,NA,"delta","~24 weeks",NA,NA,"Singapore","SGP",160,"SGP",89630,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,22,192,227,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-28,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","28/09/2022",2022-09-28
"1313",160,"Chiew","Retrospective cohort","28Sep2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","8+","Hospitalization","severe","Singapore","12-17 years","12-17 years",83,"74",89,NA,"delta","~24 weeks",NA,NA,"Singapore","SGP",160,"SGP",89630,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,22,192,227,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-28,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","28/09/2022",2022-09-28
"1314",160,"Chiew","Retrospective cohort","28Sep2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","8-59","Hospitalization","severe","Singapore","12-17 years","12-17 years",76,"62",85,NA,"delta",NA,NA,NA,"Singapore","SGP",160,"SGP",89630,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,22,192,227,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-28,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","28/09/2022",2022-09-28
"1315",160,"Chiew","Retrospective cohort","28Sep2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","240+","Hospitalization","severe","Singapore","12-17 years","12-17 years",89,"64",94,NA,"delta","~24 weeks",NA,NA,"Singapore","SGP",160,"SGP",89630,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,22,192,227,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-28,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","28/09/2022",2022-09-28
"1316",161,"Olson","Case-control","12Jan2022","BNT162b2 (Pfizer BioNTech)","unknown","1","1","14+","Hospitalization","severe","USA","12-18 years","12-18 years",97,"86",100,NA,"delta",NA,NA,NA,"USA","USA",161,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-01-12,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-01-12
"1317",161,"Olson","Case-control","12Jan2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","Hospitalization","severe","USA","12-18 years","12-18 years",94,"90",96,NA,"delta","~18 weeks",NA,NA,"USA","USA",161,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-01-12,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-01-12
"1318",161,"Olson","Case-control","12Jan2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","ICU admission","severe","USA","12-18 years","12-18 years",98,"93",99,NA,"delta","~18 weeks",NA,NA,"USA","USA",161,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-01-12,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-01-12
"1319",161,"Olson","Case-control","12Jan2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","life support","severe","USA","12-18 years","12-18 years",98,"92",100,NA,"delta","~18 weeks",NA,NA,"USA","USA",161,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-01-12,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-01-12
"1320",161,"Olson","Test-negative case-control","12Jan2022","BNT162b2 (Pfizer BioNTech)","unknown","1","1","14+","hospitalization","severe","USA","12-18 years","12-18 years",98,"88",100,NA,"delta",NA,NA,NA,"USA","USA",161,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-01-12,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-01-12
"1321",161,"Olson","Test-negative case-control","12Jan2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","hospitalization","severe","USA","12-18 years","12-18 years",95,"91",97,NA,"delta","~18 weeks",NA,NA,"USA","USA",161,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-01-12,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-01-12
"1322",161,"Olson","Test-negative case-control","12Jan2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","ICU admission","severe","USA","12-18 years","12-18 years",98,"94",100,NA,"delta","~18 weeks",NA,NA,"USA","USA",161,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-01-12,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-01-12
"1323",161,"Olson","Test-negative case-control","12Jan2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","life support","severe","USA","12-18 years","12-18 years",99,"93",100,NA,"delta","~18 weeks",NA,NA,"USA","USA",161,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-01-12,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-01-12
"1324",162,"Gazit","Retrospective cohort","24Nov2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7+","infection","infection","Israel","adult contacts of SARS-CoV-2 index cases","contacts of index cases",80.3,"73.5",85.4,NA,"alpha","~7.5 weeks",NA,NA,"Israel","ISR",162,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2021-11-24,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-11-24
"1325",163,"Suah","Retrospective cohort","21Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","9-26 weeks","infection (vaccinated April to June)","infection","Malaysia",">= 15 years","general pop",79.3,"76.1",82.1,NA,"delta","~26 weeks",NA,NA,"Malaysia","MYS",163,"MYS",28090,2019,"Malaysia","East Asia & Pacific","Upper middle income",3,"Asia",2021-02-26,2021-08-24,2021-10-21,2021-02-24,2021-02-24,2,78,181,239,"who",78,"feb/2021","60-89","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-21,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","16/01/2022",2022-01-16
"1326",163,"Suah","Retrospective cohort","21Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","2-13 weeks","infection (vaccinated July to August)","infection","Malaysia",">= 15 years","general pop",90.8,"89.4",92.1,NA,"delta","~26 weeks",NA,NA,"Malaysia","MYS",163,"MYS",28090,2019,"Malaysia","East Asia & Pacific","Upper middle income",3,"Asia",2021-02-26,2021-08-24,2021-10-21,2021-02-24,2021-02-24,2,78,181,239,"who",78,"feb/2021","60-89","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-21,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","16/01/2022",2022-01-16
"1327",163,"Suah","Retrospective cohort","21Mar2022","CoronaVac (Sinovac)","excluded","2","final","9-26 weeks","infection (vaccinated April to June)","infection","Malaysia",">= 15 years","general pop",30.4,"18.8",40.3,NA,"delta","~26 weeks",NA,NA,"Malaysia","MYS",163,"MYS",28090,2019,"Malaysia","East Asia & Pacific","Upper middle income",3,"Asia",2021-02-26,2021-08-24,2021-10-21,2021-02-24,2021-02-24,2,78,181,239,"who",78,"feb/2021","60-89","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-21,"infection","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","delta","16/01/2022",2022-01-16
"1328",163,"Suah","Retrospective cohort","21Mar2022","CoronaVac (Sinovac)","excluded","2","final","2-13 weeks","infection (vaccinated July to August)","infection","Malaysia",">= 15 years","general pop",74.5,"70.6",78,NA,"delta","~26 weeks",NA,NA,"Malaysia","MYS",163,"MYS",28090,2019,"Malaysia","East Asia & Pacific","Upper middle income",3,"Asia",2021-02-26,2021-08-24,2021-10-21,2021-02-24,2021-02-24,2,78,181,239,"who",78,"feb/2021","60-89","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-21,"infection","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","delta","16/01/2022",2022-01-16
"1329",164,"Young-Xu","Matched test-negative case-control","03Aug2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","USA","veterans 18+ years","veterans 18+ years",12,"10",15,"omicron","omicron","~48 weeks",NA,NA,"USA","USA",164,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-08-03,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","13/03/2022",2022-03-13
"1330",164,"Young-Xu","Matched test-negative case-control","03Aug2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization","severe","USA","veterans 18+ years","veterans 18+ years",63,"58",67,"omicron","omicron","~48 weeks",NA,NA,"USA","USA",164,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-08-03,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","13/03/2022",2022-03-13
"1331",164,"Young-Xu","Matched test-negative case-control","03Aug2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","death","death","USA","veterans 18+ years","veterans 18+ years",77,"67",83,"omicron","omicron","~48 weeks",NA,NA,"USA","USA",164,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-08-03,"death","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","13/03/2022",2022-03-13
"1332",164,"Young-Xu","Matched test-negative case-control","03Aug2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","USA","veterans 18+ years","veterans 18+ years",54,"50",57,"delta","delta","~48 weeks",NA,NA,"USA","USA",164,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-08-03,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta","13/03/2022",2022-03-13
"1333",164,"Young-Xu","Matched test-negative case-control","03Aug2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization","severe","USA","veterans 18+ years","veterans 18+ years",75,"69",80,"delta","delta","~48 weeks",NA,NA,"USA","USA",164,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-08-03,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta","13/03/2022",2022-03-13
"1334",164,"Young-Xu","Matched test-negative case-control","03Aug2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","death","death","USA","veterans 18+ years","veterans 18+ years",92,"83",96,"delta","delta","~48 weeks",NA,NA,"USA","USA",164,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-08-03,"death","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta","13/03/2022",2022-03-13
"1335",165,"Tartof","Test-negative case-control","22Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7+","ED visits","symptomatic","USA","hospital admissions","general pop",47,"40",54,"omicron","omicron","~47 weeks",NA,NA,"USA","USA",165,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-22,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","18/01/2022",2022-01-18
"1336",165,"Tartof","Test-negative case-control","22Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7 to <3 months","ED visits","symptomatic","USA","hospital admissions","general pop",64,"51",73,"omicron","omicron","~47 weeks",NA,NA,"USA","USA",165,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-22,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","18/01/2022",2022-01-18
"1337",165,"Tartof","Test-negative case-control","22Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">=9 months","ED visits","symptomatic","USA","hospital admissions","general pop",31,"16",43,"omicron","omicron","~47 weeks",NA,NA,"USA","USA",165,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-22,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","18/01/2022",2022-01-18
"1338",165,"Tartof","Test-negative case-control","22Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7+","hospitalization","severe","USA","hospital admissions","general pop",62,"53",69,"omicron","omicron","~47 weeks",NA,NA,"USA","USA",165,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-22,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","18/01/2022",2022-01-18
"1339",165,"Tartof","Test-negative case-control","22Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7 to <3 months","hospitalization","severe","USA","hospital admissions","general pop",68,"48",80,"omicron","omicron","~47 weeks",NA,NA,"USA","USA",165,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-22,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","18/01/2022",2022-01-18
"1340",165,"Tartof","Test-negative case-control","22Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">=9 months","Hospitalization","severe","USA","hospital admissions","general pop",41,"21",55,"omicron","omicron","~47 weeks",NA,NA,"USA","USA",165,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-22,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","18/01/2022",2022-01-18
"1341",165,"Tartof","Test-negative case-control","22Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7+","ED visits","symptomatic","USA","hospital admissions","general pop",61,"55",66,"delta","delta","~47 weeks",NA,NA,"USA","USA",165,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-22,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","18/01/2022",2022-01-18
"1342",165,"Tartof","Test-negative case-control","22Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7 to <3 months","ED visits","symptomatic","USA","hospital admissions","general pop",78,"69",85,"delta","delta","~47 weeks",NA,NA,"USA","USA",165,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-22,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","18/01/2022",2022-01-18
"1343",165,"Tartof","Test-negative case-control","22Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">=9 months","ED visits","symptomatic","USA","hospital admissions","general pop",57,"45",66,"delta","delta","~47 weeks",NA,NA,"USA","USA",165,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-22,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","18/01/2022",2022-01-18
"1344",165,"Tartof","Test-negative case-control","22Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7+","hospitalization","severe","USA","hospital admissions","general pop",76,"69",82,"delta","delta","~47 weeks",NA,NA,"USA","USA",165,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-22,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","18/01/2022",2022-01-18
"1345",166,"Tartof","Test-negative case-control","22Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7 to <3 months","hospitalization","severe","USA","hospital admissions","general pop",78,"55",89,"delta","delta","~47 weeks",NA,NA,"USA","USA",165,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-22,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","18/01/2022",2022-01-18
"1346",167,"Tartof","Test-negative case-control","22Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">=9 months","hospitalization","severe","USA","hospital admissions","general pop",73,"58",83,"delta","delta","~47 weeks",NA,NA,"USA","USA",165,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-22,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","18/01/2022",2022-01-18
"1347",166,"Amodio","Retrospective cohort","11Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","2 months","Infection","infection","Italy",">= 18 years","general pop",81.3,"80.3",82.3,NA,"alpha & delta","~37 weeks",NA,NA,"Italy","ITA",166,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-11,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations","13/01/2022",2022-01-13
"1348",166,"Amodio","Retrospective cohort","11Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","8 months","infection","infection","Italy",">= 18 years","general pop",57.8,"55.4",60.2,NA,"alpha & delta","~37 weeks",NA,NA,"Italy","ITA",166,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-11,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations","13/01/2022",2022-01-13
"1349",166,"Amodio","Retrospective cohort","11Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","2 months","severe disease","severe","Italy",">= 18 years","general pop",96.1,"94.5",97.7,NA,"alpha & delta","~37 weeks",NA,NA,"Italy","ITA",166,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-11,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations","13/01/2022",2022-01-13
"1350",166,"Amodio","Retrospective cohort","11Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","8 months","severe disease","severe","Italy",">= 18 years","general pop",90.3,"86.2",94.4,NA,"alpha & delta","~37 weeks",NA,NA,"Italy","ITA",166,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-11,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations","13/01/2022",2022-01-13
"1351",166,"Amodio","Retrospective cohort","11Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","2 months","death or intubation","severe","Italy",">= 18 years","general pop",93.4,"91.2",95.6,NA,"alpha & delta","~37 weeks",NA,NA,"Italy","ITA",166,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-11,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations","13/01/2022",2022-01-13
"1352",166,"Amodio","Retrospective cohort","11Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","8 months","death or intubation","severe","Italy",">= 18 years","general pop",83.7,"75.1",92.3,NA,"alpha & delta","~37 weeks",NA,NA,"Italy","ITA",166,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-11,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations","13/01/2022",2022-01-13
"1353",167,"Thompson","Test-negative case-control","21Jan2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","unknown","2","final","14-179","ED or UC visit","symptomatic","USA","ED encounters and hospital admissions","general pop",52,"46",58,NA,"omicron","~50 weeks",NA,NA,"USA","USA",167,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-01-21,"symptomatic","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-01-21
"1354",167,"Thompson","Test-negative case-control","21Jan2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","unknown","2","final","180+","ED or UC visit","symptomatic","USA","ED encounters and hospital admissions","general pop",38,"32",43,NA,"omicron","~50 weeks",NA,NA,"USA","USA",167,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-01-21,"symptomatic","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-01-21
"1355",167,"Thompson","Test-negative case-control","21Jan2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","unknown","2","final","14-179","hospitalization","severe","USA","ED encounters and hospital admissions","general pop",81,"65",90,NA,"omicron","~50 weeks",NA,NA,"USA","USA",167,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-01-21,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-01-21
"1356",167,"Thompson","Test-negative case-control","21Jan2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","unknown","2","final","180+","hospitalization","severe","USA","ED encounters and hospital admissions","general pop",57,"39",70,NA,"omicron","~50 weeks",NA,NA,"USA","USA",167,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-01-21,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-01-21
"1357",167,"Thompson","Test-negative case-control","21Jan2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","unknown","2","final","14-179","ED or UC visit","symptomatic","USA","ED encounters and hospital admissions","general pop",86,"85",87,NA,"delta","~32 weeks",NA,NA,"USA","USA",167,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-01-21,"symptomatic","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2022-01-21
"1358",167,"Thompson","Test-negative case-control","21Jan2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","unknown","2","final","180+","ED or UC visit","symptomatic","USA","ED encounters and hospital admissions","general pop",76,"75",77,NA,"delta","~32 weeks",NA,NA,"USA","USA",167,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-01-21,"symptomatic","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2022-01-21
"1359",167,"Thompson","Test-negative case-control","21Jan2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","unknown","2","final","14-179","hospitalization","severe","USA","ED encounters and hospital admissions","general pop",90,"89",90,NA,"delta","~32 weeks",NA,NA,"USA","USA",167,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-01-21,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2022-01-21
"1360",167,"Thompson","Test-negative case-control","21Jan2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","unknown","2","final","180+","hospitalization","severe","USA","ED encounters and hospital admissions","general pop",81,"80",82,NA,"delta","~32 weeks",NA,NA,"USA","USA",167,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-01-21,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2022-01-21
"1361",168,"Bedston","Prospective cohort","21Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","3-6 weeks","infection","infection","UK","HCW","HCW",52,"45",58,NA,"alpha",NA,NA,NA,"UK","GBR",168,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-21,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2022-01-21
"1362",168,"Bedston","Prospective cohort","21Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","2-5 weeks","infection","infection","UK","HCW","HCW",86,"74",91,NA,"alpha","~37 weeks",NA,NA,"UK","GBR",168,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-21,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2022-01-21
"1363",168,"Bedston","Prospective cohort","21Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","7+ weeks","infection","infection","UK","HCW","HCW",39,"24",50,NA,"alpha",NA,NA,NA,"UK","GBR",168,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-21,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2022-01-21
"1364",168,"Bedston","Prospective cohort","21Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","26+ weeks","infection","infection","UK","HCW","HCW",45,"39",51,NA,"alpha","~37 weeks",NA,NA,"UK","GBR",168,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-21,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2022-01-21
"1365",169,"Botton","Retrospective cohort","24Jan2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","unknown","1","1","14+","hospitalization","severe","France",">= 75 years",">= 75 years",34,"28",40,NA,"non-VOC & alpha",NA,NA,NA,"France","FRA",169,"FRA",51580,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,15,204,345,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-24,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-01-24
"1366",169,"Botton","Retrospective cohort","24Jan2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","unknown","2","final","7+","hospitalization","severe","France",">= 75 years",">= 75 years",86,"83",89,NA,"non-VOC & alpha","~7 weeks",NA,NA,"France","FRA",169,"FRA",51580,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,15,204,345,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-24,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-01-24
"1367",170,"Spensley","Prospective cohort","26Jan2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection","infection","UK","end stage kidney disease patients","end stage kidney disease patients",17,"-62",57,"omicron","omicron","~52.5 weeks",NA,NA,"UK","GBR",170,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-26,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-01-26
"1368",170,"Spensley","Prospective cohort","26Jan2022","AZD1222 (AstraZeneca)","included","2","final","14+","infection","infection","UK","end stage kidney disease patients","end stage kidney disease patients",-4,"-97",43,"omicron","omicron","~52.5 weeks",NA,NA,"UK","GBR",170,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-26,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron",NA,2022-01-26
"1369",171,"Willet","Test-negative case-control","26Jan2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection","infection","Scotland",">= 18 years","general pop",26,"13.9",36.4,"omicron","omicron","~11 weeks",NA,NA,"UK","GBR",171,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-26,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-01-26
"1370",171,"Willet","Test-negative case-control","26Jan2022","mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","Scotland",">= 18 years","general pop",23.7,"4.4",39.4,"omicron","omicron","~11 weeks",NA,NA,"UK","GBR",171,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-26,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron",NA,2022-01-26
"1371",171,"Willet","Test-negative case-control","26Jan2022","AZD1222 (AstraZeneca)","included","2","final","14+","infection","infection","Scotland",">= 18 years","general pop",11.4,"-18.8",34.6,"omicron","omicron","~11 weeks",NA,NA,"UK","GBR",171,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-26,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron",NA,2022-01-26
"1372",171,"Willet","Test-negative case-control","26Jan2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection","infection","Scotland",">= 18 years","general pop",83.5,"78.6",87.3,"delta","delta","~11 weeks",NA,NA,"UK","GBR",171,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-26,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-01-26
"1373",171,"Willet","Test-negative case-control","26Jan2022","mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","Scotland",">= 18 years","general pop",87.8,"79.8",92.7,"delta","delta","~11 weeks",NA,NA,"UK","GBR",171,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-26,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta",NA,2022-01-26
"1374",171,"Willet","Test-negative case-control","26Jan2022","AZD1222 (AstraZeneca)","included","2","final","14+","infection","infection","Scotland",">= 18 years","general pop",78.9,"66.6",86.7,"delta","delta","~11 weeks",NA,NA,"UK","GBR",171,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-01-26,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2022-01-26
"1375",172,"Belayachi","Test-negative case-control","07Dec2022","BBIBP-CorV (Beijing CNBG)","included","2","final","1-273","severe hospitalization","severe","Morocco","hospital patients","general pop",73,"71",76,NA,"non-VOC, alpha, & delta","~39 weeks",NA,NA,"Morocco","MAR",172,"MAR",8440,2019,"Morocco","Middle East & North Africa","Lower middle income",2,"Africa",2021-01-30,2021-08-31,NA,2021-01-28,2021-01-28,2,51,215,NA,"who",51,"jan/2021","30-59","Jun-Aug/2021","180-269","yes","yes","no",2022-12-07,"severe","2022 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","other combinations","27/01/2022",2022-01-27
"1376",172,"Belayachi","Test-negative case-control","07Dec2022","BBIBP-CorV (Beijing CNBG)","included","2","final","1-30","severe hospitalization","severe","Morocco","hospital patients","general pop",88,"84",91,NA,"non-VOC, alpha, & delta","~39 weeks",NA,NA,"Morocco","MAR",172,"MAR",8440,2019,"Morocco","Middle East & North Africa","Lower middle income",2,"Africa",2021-01-30,2021-08-31,NA,2021-01-28,2021-01-28,2,51,215,NA,"who",51,"jan/2021","30-59","Jun-Aug/2021","180-269","yes","yes","no",2022-12-07,"severe","2022 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","other combinations","27/01/2022",2022-01-27
"1377",172,"Belayachi","Test-negative case-control","07Dec2022","BBIBP-CorV (Beijing CNBG)","included","2","final","150+","severe hospitalization","severe","Morocco","hospital patients","general pop",64,"59",69,NA,"non-VOC, alpha, & delta","~39 weeks",NA,NA,"Morocco","MAR",172,"MAR",8440,2019,"Morocco","Middle East & North Africa","Lower middle income",2,"Africa",2021-01-30,2021-08-31,NA,2021-01-28,2021-01-28,2,51,215,NA,"who",51,"jan/2021","30-59","Jun-Aug/2021","180-269","yes","yes","no",2022-12-07,"severe","2022 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","other combinations","27/01/2022",2022-01-27
"1378",173,"Tenforde","Test-negative case-control","28Jan2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","hospital patients 18+ years","general pop",69,"57",78,NA,"delta","~47 weeks",NA,NA,"USA","USA",173,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-01-28,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2022-01-28
"1379",173,"Tenforde","Test-negative case-control","28Jan2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","hospital patients 18+ years","general pop",82,"77",86,NA,"delta","~47 weeks",NA,NA,"USA","USA",173,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-01-28,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2022-01-28
"1380",174,"Lytras","Retrospective cohort","14Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","intubation","severe","Greece","15-59 years","15-59 years",98.1,"97.5",98.6,NA,"delta","~48 weeks",NA,NA,"Greece","GRC",174,"GRC",30860,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,15,198,397,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","29/01/2022",2022-01-29
"1381",174,"Lytras","Retrospective cohort","14Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final","6 months","intubation","severe","Greece","15-59 years","15-59 years",95.5,"94.3",96.5,NA,"delta","~48 weeks",NA,NA,"Greece","GRC",174,"GRC",30860,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,15,198,397,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","29/01/2022",2022-01-29
"1382",174,"Lytras","Retrospective cohort","14Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","intubation","severe","Greece","60-79 years","60-79 years",96.7,"95.9",97.4,NA,"delta","~48 weeks",NA,NA,"Greece","GRC",174,"GRC",30860,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,15,198,397,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","29/01/2022",2022-01-29
"1383",174,"Lytras","Retrospective cohort","14Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final","6 months","intubation","severe","Greece","60-79 years","60-79 years",92,"91",92.9,NA,"delta","~48 weeks",NA,NA,"Greece","GRC",174,"GRC",30860,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,15,198,397,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","29/01/2022",2022-01-29
"1384",174,"Lytras","Retrospective cohort","14Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","intubation","severe","Greece",">= 80 years",">= 80 years",94.2,"92",95.7,NA,"delta","~48 weeks",NA,NA,"Greece","GRC",174,"GRC",30860,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,15,198,397,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","29/01/2022",2022-01-29
"1385",174,"Lytras","Retrospective cohort","14Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final","6 months","intubation","severe","Greece",">= 80 years",">= 80 years",85.9,"83.5",88,NA,"delta","~48 weeks",NA,NA,"Greece","GRC",174,"GRC",30860,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,15,198,397,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","29/01/2022",2022-01-29
"1386",174,"Lytras","Retrospective cohort","14Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","death","death","Greece","15-59 years","15-59 years",96.5,"94.8",97.6,NA,"delta","~48 weeks",NA,NA,"Greece","GRC",174,"GRC",30860,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,15,198,397,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"death","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","29/01/2022",2022-01-29
"1387",174,"Lytras","Retrospective cohort","14Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final","6 months","death","death","Greece","15-59 years","15-59 years",93.8,"91",95.7,NA,"delta","~48 weeks",NA,NA,"Greece","GRC",174,"GRC",30860,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,15,198,397,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"death","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","29/01/2022",2022-01-29
"1388",174,"Lytras","Retrospective cohort","14Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","death","death","Greece","60-79 years","60-79 years",94.1,"92.7",95.2,NA,"delta","~48 weeks",NA,NA,"Greece","GRC",174,"GRC",30860,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,15,198,397,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"death","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","29/01/2022",2022-01-29
"1389",174,"Lytras","Retrospective cohort","14Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final","6 months","death","death","Greece","60-79 years","60-79 years",89.4,"87.9",90.8,NA,"delta","~48 weeks",NA,NA,"Greece","GRC",174,"GRC",30860,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,15,198,397,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"death","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","29/01/2022",2022-01-29
"1390",174,"Lytras","Retrospective cohort","14Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","death","death","Greece",">= 80 years",">= 80 years",91,"88.4",93,NA,"delta","~48 weeks",NA,NA,"Greece","GRC",174,"GRC",30860,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,15,198,397,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"death","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","29/01/2022",2022-01-29
"1391",174,"Lytras","Retrospective cohort","14Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final","6 months","death","death","Greece",">= 80 years",">= 80 years",84,"82.2",85.6,NA,"delta","~48 weeks",NA,NA,"Greece","GRC",174,"GRC",30860,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,15,198,397,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"death","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","29/01/2022",2022-01-29
"1392",174,"Lytras","Retrospective cohort","14Jun2022","mRNA-1273 (Moderna)","included","2","final","14+","intubation","severe","Greece","15-59 years","15-59 years",99.4,"98.2",99.8,NA,"delta","~48 weeks",NA,NA,"Greece","GRC",174,"GRC",30860,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,15,198,397,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","29/01/2022",2022-01-29
"1393",174,"Lytras","Retrospective cohort","14Jun2022","mRNA-1273 (Moderna)","included","2","final","6 months","intubation","severe","Greece","15-59 years","15-59 years",97.3,"93.1",98.9,NA,"delta","~48 weeks",NA,NA,"Greece","GRC",174,"GRC",30860,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,15,198,397,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","29/01/2022",2022-01-29
"1394",174,"Lytras","Retrospective cohort","14Jun2022","mRNA-1273 (Moderna)","included","2","final","14+","intubation","severe","Greece","60-79 years","60-79 years",98.9,"97.3",99.5,NA,"delta","~48 weeks",NA,NA,"Greece","GRC",174,"GRC",30860,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,15,198,397,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","29/01/2022",2022-01-29
"1395",174,"Lytras","Retrospective cohort","14Jun2022","mRNA-1273 (Moderna)","included","2","final","6 months","intubation","severe","Greece","60-79 years","60-79 years",95.1,"93",96.5,NA,"delta","~48 weeks",NA,NA,"Greece","GRC",174,"GRC",30860,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,15,198,397,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","29/01/2022",2022-01-29
"1396",174,"Lytras","Retrospective cohort","14Jun2022","mRNA-1273 (Moderna)","included","2","final","14+","intubation","severe","Greece",">= 80 years",">= 80 years",97.9,"90.2",99.5,NA,"delta","~48 weeks",NA,NA,"Greece","GRC",174,"GRC",30860,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,15,198,397,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","29/01/2022",2022-01-29
"1397",174,"Lytras","Retrospective cohort","14Jun2022","mRNA-1273 (Moderna)","included","2","final","6 months","intubation","severe","Greece",">= 80 years",">= 80 years",90.6,"67",97.3,NA,"delta","~48 weeks",NA,NA,"Greece","GRC",174,"GRC",30860,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,15,198,397,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","29/01/2022",2022-01-29
"1398",174,"Lytras","Retrospective cohort","14Jun2022","mRNA-1273 (Moderna)","included","2","final","14+","death","death","Greece","15-59 years","15-59 years",99.3,"94.7",99.9,NA,"delta","~48 weeks",NA,NA,"Greece","GRC",174,"GRC",30860,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,15,198,397,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"death","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","29/01/2022",2022-01-29
"1399",174,"Lytras","Retrospective cohort","14Jun2022","mRNA-1273 (Moderna)","included","2","final","6 months","death","death","Greece","15-59 years","15-59 years",98.3,"88.3",99.8,NA,"delta","~48 weeks",NA,NA,"Greece","GRC",174,"GRC",30860,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,15,198,397,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"death","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","29/01/2022",2022-01-29
"1400",174,"Lytras","Retrospective cohort","14Jun2022","mRNA-1273 (Moderna)","included","2","final","14+","death","death","Greece","60-79 years","60-79 years",98.4,"95.5",99.5,NA,"delta","~48 weeks",NA,NA,"Greece","GRC",174,"GRC",30860,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,15,198,397,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"death","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","29/01/2022",2022-01-29
"1401",174,"Lytras","Retrospective cohort","14Jun2022","mRNA-1273 (Moderna)","included","2","final","6 months","death","death","Greece","60-79 years","60-79 years",96.2,"93.6",97.7,NA,"delta","~48 weeks",NA,NA,"Greece","GRC",174,"GRC",30860,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,15,198,397,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"death","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","29/01/2022",2022-01-29
"1402",174,"Lytras","Retrospective cohort","14Jun2022","mRNA-1273 (Moderna)","included","2","final","14+","death","death","Greece",">= 80 years",">= 80 years",96.7,"87.9",99.1,NA,"delta","~48 weeks",NA,NA,"Greece","GRC",174,"GRC",30860,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,15,198,397,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"death","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","29/01/2022",2022-01-29
"1403",174,"Lytras","Retrospective cohort","14Jun2022","mRNA-1273 (Moderna)","included","2","final","6 months","death","death","Greece",">= 80 years",">= 80 years",92,"80",96.8,NA,"delta","~48 weeks",NA,NA,"Greece","GRC",174,"GRC",30860,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,15,198,397,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"death","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","29/01/2022",2022-01-29
"1404",174,"Lytras","Retrospective cohort","14Jun2022","AZD1222 (AstraZeneca)","included","2","final","14+","intubation","severe","Greece","15-59 years","15-59 years",97.8,"95.3",99,NA,"delta","~48 weeks",NA,NA,"Greece","GRC",174,"GRC",30860,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,15,198,397,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","29/01/2022",2022-01-29
"1405",174,"Lytras","Retrospective cohort","14Jun2022","AZD1222 (AstraZeneca)","included","2","final","6 months","intubation","severe","Greece","15-59 years","15-59 years",92.4,"84",96.4,NA,"delta","~48 weeks",NA,NA,"Greece","GRC",174,"GRC",30860,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,15,198,397,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","29/01/2022",2022-01-29
"1406",174,"Lytras","Retrospective cohort","14Jun2022","AZD1222 (AstraZeneca)","included","2","final","14+","intubation","severe","Greece","60-79 years","60-79 years",97.2,"95.3",98.3,NA,"delta","~48 weeks",NA,NA,"Greece","GRC",174,"GRC",30860,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,15,198,397,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","29/01/2022",2022-01-29
"1407",174,"Lytras","Retrospective cohort","14Jun2022","AZD1222 (AstraZeneca)","included","2","final","6 months","intubation","severe","Greece","60-79 years","60-79 years",90.3,"87.4",92.5,NA,"delta","~48 weeks",NA,NA,"Greece","GRC",174,"GRC",30860,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,15,198,397,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","29/01/2022",2022-01-29
"1408",174,"Lytras","Retrospective cohort","14Jun2022","AZD1222 (AstraZeneca)","included","2","final","14+","intubation","severe","Greece",">= 80 years",">= 80 years",97.8,"91.7",99.4,NA,"delta","~48 weeks",NA,NA,"Greece","GRC",174,"GRC",30860,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,15,198,397,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","29/01/2022",2022-01-29
"1409",174,"Lytras","Retrospective cohort","14Jun2022","AZD1222 (AstraZeneca)","included","2","final","6 months","intubation","severe","Greece",">= 80 years",">= 80 years",92.4,"72.7",97.9,NA,"delta","~48 weeks",NA,NA,"Greece","GRC",174,"GRC",30860,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,15,198,397,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","29/01/2022",2022-01-29
"1410",174,"Lytras","Retrospective cohort","14Jun2022","AZD1222 (AstraZeneca)","included","2","final","14+","death","death","Greece","15-59 years","15-59 years",97.5,"89.7",99.4,NA,"delta","~48 weeks",NA,NA,"Greece","GRC",174,"GRC",30860,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,15,198,397,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"death","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","29/01/2022",2022-01-29
"1411",174,"Lytras","Retrospective cohort","14Jun2022","AZD1222 (AstraZeneca)","included","2","final","6 months","death","death","Greece","15-59 years","15-59 years",94.5,"77.2",98.7,NA,"delta","~48 weeks",NA,NA,"Greece","GRC",174,"GRC",30860,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,15,198,397,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"death","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","29/01/2022",2022-01-29
"1412",174,"Lytras","Retrospective cohort","14Jun2022","AZD1222 (AstraZeneca)","included","2","final","14+","death","death","Greece","60-79 years","60-79 years",95.4,"91.2",97.6,NA,"delta","~48 weeks",NA,NA,"Greece","GRC",174,"GRC",30860,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,15,198,397,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"death","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","29/01/2022",2022-01-29
"1413",174,"Lytras","Retrospective cohort","14Jun2022","AZD1222 (AstraZeneca)","included","2","final","6 months","death","death","Greece","60-79 years","60-79 years",89.8,"85.2",93,NA,"delta","~48 weeks",NA,NA,"Greece","GRC",174,"GRC",30860,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,15,198,397,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"death","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","29/01/2022",2022-01-29
"1414",174,"Lytras","Retrospective cohort","14Jun2022","AZD1222 (AstraZeneca)","included","2","final","14+","death","death","Greece",">= 80 years",">= 80 years",92.6,"84.2",96.5,NA,"delta","~48 weeks",NA,NA,"Greece","GRC",174,"GRC",30860,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,15,198,397,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"death","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","29/01/2022",2022-01-29
"1415",174,"Lytras","Retrospective cohort","14Jun2022","AZD1222 (AstraZeneca)","included","2","final","6 months","death","death","Greece",">= 80 years",">= 80 years",83.4,"69.6",90.9,NA,"delta","~48 weeks",NA,NA,"Greece","GRC",174,"GRC",30860,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,15,198,397,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"death","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","29/01/2022",2022-01-29
"1416",174,"Lytras","Retrospective cohort","14Jun2022","Ad26.COV2.S (Janssen)","included","1","final","14+","intubation","severe","Greece","15-59 years","15-59 years",85,"73.9",91.4,NA,"delta","~48 weeks",NA,NA,"Greece","GRC",174,"GRC",30860,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,15,198,397,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta","29/01/2022",2022-01-29
"1417",174,"Lytras","Retrospective cohort","14Jun2022","Ad26.COV2.S (Janssen)","included","1","final","6 months","intubation","severe","Greece","15-59 years","15-59 years",91.7,"84.4",95.6,NA,"delta","~48 weeks",NA,NA,"Greece","GRC",174,"GRC",30860,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,15,198,397,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta","29/01/2022",2022-01-29
"1418",174,"Lytras","Retrospective cohort","14Jun2022","Ad26.COV2.S (Janssen)","included","1","final","14+","intubation","severe","Greece","60-79 years","60-79 years",79.6,"65.2",88,NA,"delta","~48 weeks",NA,NA,"Greece","GRC",174,"GRC",30860,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,15,198,397,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta","29/01/2022",2022-01-29
"1419",174,"Lytras","Retrospective cohort","14Jun2022","Ad26.COV2.S (Janssen)","included","1","final","6 months","intubation","severe","Greece","60-79 years","60-79 years",88.7,"78.7",94,NA,"delta","~48 weeks",NA,NA,"Greece","GRC",174,"GRC",30860,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,15,198,397,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta","29/01/2022",2022-01-29
"1420",174,"Lytras","Retrospective cohort","14Jun2022","Ad26.COV2.S (Janssen)","included","1","final","14+","intubation","severe","Greece",">= 80 years",">= 80 years",85,"62.3",94,NA,"delta","~48 weeks",NA,NA,"Greece","GRC",174,"GRC",30860,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,15,198,397,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta","29/01/2022",2022-01-29
"1421",174,"Lytras","Retrospective cohort","14Jun2022","Ad26.COV2.S (Janssen)","included","1","final","6 months","intubation","severe","Greece",">= 80 years",">= 80 years",91.7,"75.5",97.2,NA,"delta","~48 weeks",NA,NA,"Greece","GRC",174,"GRC",30860,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,15,198,397,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta","29/01/2022",2022-01-29
"1422",174,"Lytras","Retrospective cohort","14Jun2022","Ad26.COV2.S (Janssen)","included","1","final","14+","death","death","Greece","15-59 years","15-59 years",81.7,"57.5",92.1,NA,"delta","~48 weeks",NA,NA,"Greece","GRC",174,"GRC",30860,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,15,198,397,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"death","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta","29/01/2022",2022-01-29
"1423",174,"Lytras","Retrospective cohort","14Jun2022","Ad26.COV2.S (Janssen)","included","1","final","6 months","death","death","Greece","15-59 years","15-59 years",90.7,"77.2",96.2,NA,"delta","~48 weeks",NA,NA,"Greece","GRC",174,"GRC",30860,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,15,198,397,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"death","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta","29/01/2022",2022-01-29
"1424",174,"Lytras","Retrospective cohort","14Jun2022","Ad26.COV2.S (Janssen)","included","1","final","14+","death","death","Greece","60-79 years","60-79 years",69.1,"43.2",83.2,NA,"delta","~48 weeks",NA,NA,"Greece","GRC",174,"GRC",30860,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,15,198,397,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"death","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta","29/01/2022",2022-01-29
"1425",174,"Lytras","Retrospective cohort","14Jun2022","Ad26.COV2.S (Janssen)","included","1","final","6 months","death","death","Greece","60-79 years","60-79 years",84.3,"67.9",92.3,NA,"delta","~48 weeks",NA,NA,"Greece","GRC",174,"GRC",30860,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,15,198,397,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"death","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta","29/01/2022",2022-01-29
"1426",174,"Lytras","Retrospective cohort","14Jun2022","Ad26.COV2.S (Janssen)","included","1","final","14+","death","death","Greece",">= 80 years",">= 80 years",61.9,"43.2",74.4,NA,"delta","~48 weeks",NA,NA,"Greece","GRC",174,"GRC",30860,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,15,198,397,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"death","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta","29/01/2022",2022-01-29
"1427",174,"Lytras","Retrospective cohort","14Jun2022","Ad26.COV2.S (Janssen)","included","1","final","6 months","death","death","Greece",">= 80 years",">= 80 years",80.6,"59.7",90.7,NA,"delta","~48 weeks",NA,NA,"Greece","GRC",174,"GRC",30860,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,15,198,397,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"death","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta","29/01/2022",2022-01-29
"1428",175,"Roberts","Test-negative case-control","26Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final","<3 months","infection","infection","USA",">= 18 years","general pop",83,"81",84,NA,"non-VOC, alpha, & delta","~48 weeks",NA,NA,"USA","USA",175,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-07-26,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","31/01/2022",2022-01-31
"1429",175,"Roberts","Test-negative case-control","26Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final",">=3 months","infection","infection","USA",">= 18 years","general pop",60,"58",62,NA,"non-VOC, alpha, & delta","~48 weeks",NA,NA,"USA","USA",175,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-07-26,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","31/01/2022",2022-01-31
"1430",175,"Roberts","Test-negative case-control","26Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final","<3 months","infection (Jan-March)","infection","USA",">= 18 years","general pop",80,"74",85,NA,"non-VOC, alpha, & delta","~48 weeks",NA,NA,"USA","USA",175,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-07-26,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","31/01/2022",2022-01-31
"1431",175,"Roberts","Test-negative case-control","26Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final",">=3 months","infection (Jan-March)","infection","USA",">= 18 years","general pop",80.5,"74",86,NA,"non-VOC, alpha, & delta","~48 weeks",NA,NA,"USA","USA",175,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-07-26,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","31/01/2022",2022-01-31
"1432",175,"Roberts","Test-negative case-control","26Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final","<3 months","infection (Oct-Dec)","infection","USA",">= 18 years","general pop",75,"64",81,NA,"non-VOC, alpha, & delta","~48 weeks",NA,NA,"USA","USA",175,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-07-26,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","31/01/2022",2022-01-31
"1433",175,"Roberts","Test-negative case-control","26Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final",">=3 months","infection (Oct-Dec)","infection","USA",">= 18 years","general pop",60,"55",62,NA,"non-VOC, alpha, & delta","~48 weeks",NA,NA,"USA","USA",175,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-07-26,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","31/01/2022",2022-01-31
"1434",175,"Roberts","Test-negative case-control","26Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final","<3 months","severe disease","severe","USA",">= 18 years","general pop",88,"80",91,NA,"non-VOC, alpha, & delta","~48 weeks",NA,NA,"USA","USA",175,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-07-26,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","31/01/2022",2022-01-31
"1435",175,"Roberts","Test-negative case-control","26Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final",">=3 months","severe disease","severe","USA",">= 18 years","general pop",75,"70",80,NA,"non-VOC, alpha, & delta","~48 weeks",NA,NA,"USA","USA",175,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-07-26,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","31/01/2022",2022-01-31
"1436",175,"Roberts","Test-negative case-control","26Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final","<3 months","severe disease (Jan-March)","severe","USA",">= 18 years","general pop",90,"49",99,NA,"non-VOC, alpha, & delta","~48 weeks",NA,NA,"USA","USA",175,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-07-26,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","31/01/2022",2022-01-31
"1437",175,"Roberts","Test-negative case-control","26Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final",">=3 months","severe disease (Jan-March)","severe","USA",">= 18 years","general pop",90,"50",99,NA,"non-VOC, alpha, & delta","~48 weeks",NA,NA,"USA","USA",175,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-07-26,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","31/01/2022",2022-01-31
"1438",175,"Roberts","Test-negative case-control","26Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final","<3 months","severe disease (Oct-Dec)","severe","USA",">= 18 years","general pop",69,"22",88,NA,"non-VOC, alpha, & delta","~48 weeks",NA,NA,"USA","USA",175,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-07-26,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","31/01/2022",2022-01-31
"1439",175,"Roberts","Test-negative case-control","26Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final",">=3 months","severe disease (Oct-Dec)","severe","USA",">= 18 years","general pop",78,"70",82,NA,"non-VOC, alpha, & delta","~48 weeks",NA,NA,"USA","USA",175,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-07-26,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","31/01/2022",2022-01-31
"1440",175,"Roberts","Test-negative case-control","26Jul2022","mRNA-1273 (Moderna)","included","2","final","<3 months","infection","infection","USA",">= 18 years","general pop",88,"85",90,NA,"non-VOC, alpha, & delta","~48 weeks",NA,NA,"USA","USA",175,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-07-26,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","31/01/2022",2022-01-31
"1441",175,"Roberts","Test-negative case-control","26Jul2022","mRNA-1273 (Moderna)","included","2","final",">=3 months","infection","infection","USA",">= 18 years","general pop",65,"62",68,NA,"non-VOC, alpha, & delta","~48 weeks",NA,NA,"USA","USA",175,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-07-26,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","31/01/2022",2022-01-31
"1442",175,"Roberts","Test-negative case-control","26Jul2022","mRNA-1273 (Moderna)","included","2","final","<3 months","infection (Jan-March)","infection","USA",">= 18 years","general pop",89,"73",95,NA,"non-VOC, alpha, & delta","~48 weeks",NA,NA,"USA","USA",175,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-07-26,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","31/01/2022",2022-01-31
"1443",175,"Roberts","Test-negative case-control","26Jul2022","mRNA-1273 (Moderna)","included","2","final",">=3 months","infection (Jan-March)","infection","USA",">= 18 years","general pop",89,"74",93,NA,"non-VOC, alpha, & delta","~48 weeks",NA,NA,"USA","USA",175,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-07-26,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","31/01/2022",2022-01-31
"1444",175,"Roberts","Test-negative case-control","26Jul2022","mRNA-1273 (Moderna)","included","2","final","<3 months","infection (Oct-Dec)","infection","USA",">= 18 years","general pop",82,"69",91,NA,"non-VOC, alpha, & delta","~48 weeks",NA,NA,"USA","USA",175,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-07-26,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","31/01/2022",2022-01-31
"1445",175,"Roberts","Test-negative case-control","26Jul2022","mRNA-1273 (Moderna)","included","2","final",">=3 months","infection (Oct-Dec)","infection","USA",">= 18 years","general pop",68,"64",69,NA,"non-VOC, alpha, & delta","~48 weeks",NA,NA,"USA","USA",175,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-07-26,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","31/01/2022",2022-01-31
"1446",175,"Roberts","Test-negative case-control","26Jul2022","mRNA-1273 (Moderna)","included","2","final","<3 months","severe disease","severe","USA",">= 18 years","general pop",85,"75",90,NA,"non-VOC, alpha, & delta","~48 weeks",NA,NA,"USA","USA",175,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-07-26,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","31/01/2022",2022-01-31
"1447",175,"Roberts","Test-negative case-control","26Jul2022","mRNA-1273 (Moderna)","included","2","final",">=3 months","severe disease","severe","USA",">= 18 years","general pop",72,"65",78,NA,"non-VOC, alpha, & delta","~48 weeks",NA,NA,"USA","USA",175,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-07-26,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","31/01/2022",2022-01-31
"1448",175,"Roberts","Test-negative case-control","26Jul2022","mRNA-1273 (Moderna)","included","2","final","<3 months","severe disease (Jan-March)","severe","USA",">= 18 years","general pop",70,"0",95,NA,"non-VOC, alpha, & delta","~48 weeks",NA,NA,"USA","USA",175,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-07-26,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","31/01/2022",2022-01-31
"1449",175,"Roberts","Test-negative case-control","26Jul2022","mRNA-1273 (Moderna)","included","2","final",">=3 months","severe disease (Jan-March)","severe","USA",">= 18 years","general pop",70,"0",93,NA,"non-VOC, alpha, & delta","~48 weeks",NA,NA,"USA","USA",175,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-07-26,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","31/01/2022",2022-01-31
"1450",175,"Roberts","Test-negative case-control","26Jul2022","mRNA-1273 (Moderna)","included","2","final","<3 months","severe disease (Oct-Dec)","severe","USA",">= 18 years","general pop",91,"5",99,NA,"non-VOC, alpha, & delta","~48 weeks",NA,NA,"USA","USA",175,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-07-26,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","31/01/2022",2022-01-31
"1451",175,"Roberts","Test-negative case-control","26Jul2022","mRNA-1273 (Moderna)","included","2","final",">=3 months","severe disease (Oct-Dec)","severe","USA",">= 18 years","general pop",80,"72",88,NA,"non-VOC, alpha, & delta","~48 weeks",NA,NA,"USA","USA",175,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-07-26,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","31/01/2022",2022-01-31
"1452",176,"Sritipsukho","Test-negative case-control","03Feb2022","AZD1222 (AstraZeneca)","excluded","1","1","21+","Infection","infection","Thailand",">= 18 years","general pop",49,"36",58,NA,"delta",NA,NA,NA,"Thailand","THA",176,"THA",18070,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,82,240,395,"who",82,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","yes",2022-02-03,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2022-02-03
"1453",176,"Sritipsukho","Test-negative case-control","03Feb2022","AZD1222 (AstraZeneca)","excluded","2","final","14+","Infection","infection","Thailand",">= 18 years","general pop",83,"70",90,NA,"delta","~13 weeks",NA,NA,"Thailand","THA",176,"THA",18070,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,82,240,395,"who",82,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","yes",2022-02-03,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2022-02-03
"1454",176,"Sritipsukho","Test-negative case-control","03Feb2022","CoronaVac (Sinovac)","excluded","1","1","21+","Infection","infection","Thailand",">= 18 years","general pop",-15,"-45",15,NA,"delta",NA,NA,NA,"Thailand","THA",176,"THA",18070,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,82,240,395,"who",82,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","yes",2022-02-03,"infection","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","delta",NA,2022-02-03
"1455",176,"Sritipsukho","Test-negative case-control","03Feb2022","CoronaVac (Sinovac)","excluded","2","final","14+","Infection","infection","Thailand",">= 18 years","general pop",60,"49",69,NA,"delta","~13 weeks",NA,NA,"Thailand","THA",176,"THA",18070,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,82,240,395,"who",82,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","yes",2022-02-03,"infection","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","delta",NA,2022-02-03
"1456",176,"Sritipsukho","Test-negative case-control","03Feb2022","CoronaVac (Sinovac) & AZD1222 (AstraZeneca) - heterologous","excluded","2","final","14+","Infection","infection","Thailand",">= 18 years","general pop",74,"43",88,NA,"delta","~13 weeks",NA,NA,"Thailand","THA",176,"THA",18070,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,82,240,395,"who",82,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","yes",2022-02-03,"infection","2022 (Jan-Jun)","Heterologous platforms","Multiple","delta",NA,2022-02-03
"1457",177,"Suryatma","Test-negative case-control","04Feb2022","CoronaVac (Sinovac)","excluded","1","1","14+","infection","infection","Indonesia",">= 18 years","general pop",10.5,"-12",28.6,NA,"non-VOC & alpha",NA,NA,NA,"Indonesia","IDN",177,"IDN",11980,2019,"Indonesia","East Asia & Pacific","Upper middle income",2,"Asia",2021-01-22,2021-12-25,NA,2021-01-13,2021-01-13,9,36,346,NA,"who",36,"jan/2021","30-59","Dec/2021 +","270-359","yes","yes","no",2022-02-04,"infection","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations","03/02/2022",2022-02-03
"1458",177,"Suryatma","Test-negative case-control","04Feb2022","CoronaVac (Sinovac)","excluded","2","final","14+","infection","infection","Indonesia",">= 18 years","general pop",66.7,"58.1",73.5,NA,"non-VOC & alpha","~24 weeks",NA,NA,"Indonesia","IDN",177,"IDN",11980,2019,"Indonesia","East Asia & Pacific","Upper middle income",2,"Asia",2021-01-22,2021-12-25,NA,2021-01-13,2021-01-13,9,36,346,NA,"who",36,"jan/2021","30-59","Dec/2021 +","270-359","yes","yes","no",2022-02-04,"infection","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations","03/02/2022",2022-02-03
"1459",177,"Suryatma","Test-negative case-control","04Feb2022","CoronaVac (Sinovac)","excluded","1","1","14+","hospitalization","severe","Indonesia",">= 18 years","general pop",34.1,"16.4",48.1,NA,"non-VOC & alpha",NA,NA,NA,"Indonesia","IDN",177,"IDN",11980,2019,"Indonesia","East Asia & Pacific","Upper middle income",2,"Asia",2021-01-22,2021-12-25,NA,2021-01-13,2021-01-13,9,36,346,NA,"who",36,"jan/2021","30-59","Dec/2021 +","270-359","yes","yes","no",2022-02-04,"severe","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations","03/02/2022",2022-02-03
"1460",177,"Suryatma","Test-negative case-control","04Feb2022","CoronaVac (Sinovac)","excluded","2","final","14+","hospitalization","severe","Indonesia",">= 18 years","general pop",71.1,"62.9",77.6,NA,"non-VOC & alpha","~24 weeks",NA,NA,"Indonesia","IDN",177,"IDN",11980,2019,"Indonesia","East Asia & Pacific","Upper middle income",2,"Asia",2021-01-22,2021-12-25,NA,2021-01-13,2021-01-13,9,36,346,NA,"who",36,"jan/2021","30-59","Dec/2021 +","270-359","yes","yes","no",2022-02-04,"severe","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations","03/02/2022",2022-02-03
"1461",177,"Suryatma","Test-negative case-control","04Feb2022","CoronaVac (Sinovac)","excluded","1","1","14+","death","death","Indonesia",">= 18 years","general pop",58.6,"28.3",76.1,NA,"non-VOC & alpha",NA,NA,NA,"Indonesia","IDN",177,"IDN",11980,2019,"Indonesia","East Asia & Pacific","Upper middle income",2,"Asia",2021-01-22,2021-12-25,NA,2021-01-13,2021-01-13,9,36,346,NA,"who",36,"jan/2021","30-59","Dec/2021 +","270-359","yes","yes","no",2022-02-04,"death","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations","03/02/2022",2022-02-03
"1462",177,"Suryatma","Test-negative case-control","04Feb2022","CoronaVac (Sinovac)","excluded","2","final","14+","death","death","Indonesia",">= 18 years","general pop",87.4,"65.1",95.4,NA,"non-VOC & alpha","~24 weeks",NA,NA,"Indonesia","IDN",177,"IDN",11980,2019,"Indonesia","East Asia & Pacific","Upper middle income",2,"Asia",2021-01-22,2021-12-25,NA,2021-01-13,2021-01-13,9,36,346,NA,"who",36,"jan/2021","30-59","Dec/2021 +","270-359","yes","yes","no",2022-02-04,"death","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations","03/02/2022",2022-02-03
"1463",178,"Lauring","Test-negative case-control","09Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization","severe","USA",">= 18 years","general pop",65,"51",75,"omicron","omicron","~3 weeks",NA,NA,"USA","USA",178,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-09,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","07/02/2022",2022-02-07
"1464",178,"Lauring","Test-negative case-control","09Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","150+","hospitalization","severe","USA",">= 18 years","general pop",85,"83",87,"delta","delta","~27 weeks",NA,NA,"USA","USA",178,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-09,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta","07/02/2022",2022-02-07
"1465",178,"Lauring","Test-negative case-control","09Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final",">150","hospitalization","severe","USA",">= 18 years","general pop",90,"85",93,"delta","delta","~27 weeks",NA,NA,"USA","USA",178,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-09,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta","07/02/2022",2022-02-07
"1466",178,"Lauring","Test-negative case-control","09Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization","severe","USA",">= 18 years","general pop",82,"80",84,"delta","delta","~27 weeks",NA,NA,"USA","USA",178,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-09,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","07/02/2022",2022-02-07
"1467",178,"Lauring","Test-negative case-control","09Mar2022","mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization","severe","USA",">= 18 years","general pop",88,"86",90,"delta","delta","~27 weeks",NA,NA,"USA","USA",178,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-09,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","07/02/2022",2022-02-07
"1468",178,"Lauring","Test-negative case-control","09Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization","severe","USA",">= 18 years","general pop",82,"77",86,"alpha","alpha","~44 weeks",NA,NA,"USA","USA",178,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-09,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","07/02/2022",2022-02-07
"1469",178,"Lauring","Test-negative case-control","09Mar2022","mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization","severe","USA",">= 18 years","general pop",90,"85",93,"alpha","alpha","~44 weeks",NA,NA,"USA","USA",178,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-09,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","alpha","07/02/2022",2022-02-07
"1470",178,"Lauring","Test-negative case-control","09Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","14+","hospitalization","severe","USA",">= 18 years","general pop",77,"71",81,NA,"alpha, delta, & omicron",NA,NA,NA,"USA","USA",178,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-09,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations","07/02/2022",2022-02-07
"1471",179,"Chemaitelly","Test-negative case-control","02Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final","1-3 months","symptomatic disease","symptomatic","Qatar",">= 18 years","general pop",46.6,"33.4",57.2,"omicron BA.1","omicron BA.1","~58 weeks",NA,NA,"Qatar","QAT",179,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2022-06-02,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","13/03/2022",2022-03-13
"1472",179,"Chemaitelly","Test-negative case-control","02Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final","7+ months","symptomatic disease","symptomatic","Qatar",">= 18 years","general pop",-17.8,"-28.2",-8.2,"omicron BA.1","omicron BA.1","~58 weeks",NA,NA,"Qatar","QAT",179,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2022-06-02,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","13/03/2022",2022-03-13
"1473",179,"Chemaitelly","Test-negative case-control","02Jun2022","mRNA-1273 (Moderna)","included","2","final","1-3 months","symptomatic disease","symptomatic","Qatar",">= 18 years","general pop",71,"24",89,"omicron BA.1","omicron BA.1","~58 weeks",NA,NA,"Qatar","QAT",179,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2022-06-02,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","13/03/2022",2022-03-13
"1474",179,"Chemaitelly","Test-negative case-control","02Jun2022","mRNA-1273 (Moderna)","included","2","final","7+ months","symptomatic disease","symptomatic","Qatar",">= 18 years","general pop",-10.2,"-23.1",1.3,"omicron BA.1","omicron BA.1","~58 weeks",NA,NA,"Qatar","QAT",179,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2022-06-02,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","13/03/2022",2022-03-13
"1475",179,"Chemaitelly","Test-negative case-control","02Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final","1-3 months","symptomatic disease","symptomatic","Qatar",">= 18 years","general pop",51.7,"43.2",58.9,"omicron BA.2","omicron BA.2","~58 weeks",NA,NA,"Qatar","QAT",179,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2022-06-02,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","13/03/2022",2022-03-13
"1476",179,"Chemaitelly","Test-negative case-control","02Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final","7+ months","symptomatic disease","symptomatic","Qatar",">= 18 years","general pop",-12.1,"-19.1",5.5,"omicron BA.2","omicron BA.2","~58 weeks",NA,NA,"Qatar","QAT",179,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2022-06-02,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","13/03/2022",2022-03-13
"1477",179,"Chemaitelly","Test-negative case-control","02Jun2022","mRNA-1273 (Moderna)","included","2","final","1-3 months","symptomatic disease","symptomatic","Qatar",">= 18 years","general pop",35.9,"-5.9",61.2,"omicron BA.2","omicron BA.2","~58 weeks",NA,NA,"Qatar","QAT",179,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2022-06-02,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","13/03/2022",2022-03-13
"1478",179,"Chemaitelly","Test-negative case-control","02Jun2022","mRNA-1273 (Moderna)","included","2","final","7+ months","symptomatic disease","symptomatic","Qatar",">= 18 years","general pop",-20.4,"-30.2",1.2,"omicron BA.2","omicron BA.2","~58 weeks",NA,NA,"Qatar","QAT",179,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2022-06-02,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","13/03/2022",2022-03-13
"1479",179,"Chemaitelly","Test-negative case-control","02Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final","1-3 months","symptomatic disease","symptomatic","Qatar",">= 18 years","general pop",51.7,"43.2",58.9,"omicron","omicron","~58 weeks",NA,NA,"Qatar","QAT",179,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2022-06-02,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","13/03/2022",2022-03-13
"1480",179,"Chemaitelly","Test-negative case-control","02Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final","7+ months","symptomatic disease","symptomatic","Qatar",">= 18 years","general pop",-9,"-14.5",-3.7,"omicron","omicron","~58 weeks",NA,NA,"Qatar","QAT",179,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2022-06-02,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","13/03/2022",2022-03-13
"1481",179,"Chemaitelly","Test-negative case-control","02Jun2022","mRNA-1273 (Moderna)","included","2","final","1-3 months","symptomatic disease","symptomatic","Qatar",">= 18 years","general pop",43.2,"15",62.1,"omicron","omicron","~58 weeks",NA,NA,"Qatar","QAT",179,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2022-06-02,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","13/03/2022",2022-03-13
"1482",179,"Chemaitelly","Test-negative case-control","02Jun2022","mRNA-1273 (Moderna)","included","2","final","7+ months","symptomatic disease","symptomatic","Qatar",">= 18 years","general pop",-13.7,"-21.3",-6.6,"omicron","omicron","~58 weeks",NA,NA,"Qatar","QAT",179,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2022-06-02,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","13/03/2022",2022-03-13
"1483",179,"Chemaitelly","Test-negative case-control","02Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final","1-6 months","severe, critical or fatal disease","severe","Qatar",">= 18 years","general pop",70.4,"45",85,"omicron","omicron","~58 weeks",NA,NA,"Qatar","QAT",179,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2022-06-02,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","13/03/2022",2022-03-13
"1484",179,"Chemaitelly","Test-negative case-control","02Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final",">=7 months","severe, critical or fatal disease","severe","Qatar",">= 18 years","general pop",77.5,"67.8",84.3,"omicron","omicron","~58 weeks",NA,NA,"Qatar","QAT",179,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2022-06-02,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","13/03/2022",2022-03-13
"1485",179,"Chemaitelly","Test-negative case-control","02Jun2022","mRNA-1273 (Moderna)","included","2","final","1-6 months","severe, critical or fatal disease","severe","Qatar",">= 18 years","general pop",87.1,"40.2",97.2,"omicron","omicron","~58 weeks",NA,NA,"Qatar","QAT",179,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2022-06-02,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","13/03/2022",2022-03-13
"1486",179,"Chemaitelly","Test-negative case-control","02Jun2022","mRNA-1273 (Moderna)","included","2","final",">=7 months","severe, critical or fatal disease","severe","Qatar",">= 18 years","general pop",68.4,"46.1",81.5,"omicron","omicron","~58 weeks",NA,NA,"Qatar","QAT",179,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2022-06-02,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","13/03/2022",2022-03-13
"1487",180,"Cerqueira-Silva","Test-negative case-control","09Feb2022","CoronaVac (Sinovac)","excluded","2","final","14-30","infection","infection","Brazil",">= 18 years","general pop",55,"54.3",55.7,NA,"gamma & delta","~30 weeks",NA,NA,"Brazil","BRA",180,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-02-09,"infection","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations",NA,2022-02-09
"1488",180,"Cerqueira-Silva","Test-negative case-control","09Feb2022","CoronaVac (Sinovac)","excluded","2","final","180+","infection","infection","Brazil",">= 18 years","general pop",34.7,"33.1",36.3,NA,"gamma & delta","~30 weeks",NA,NA,"Brazil","BRA",180,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-02-09,"infection","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations",NA,2022-02-09
"1489",180,"Cerqueira-Silva","Test-negative case-control","09Feb2022","CoronaVac (Sinovac)","excluded","2","final","14-30","severe disease","severe","Brazil",">= 18 years","general pop",82.1,"81.4",82.8,NA,"gamma & delta","~30 weeks",NA,NA,"Brazil","BRA",180,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-02-09,"severe","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations",NA,2022-02-09
"1490",180,"Cerqueira-Silva","Test-negative case-control","09Feb2022","CoronaVac (Sinovac)","excluded","2","final","180+","severe disease","severe","Brazil",">= 18 years","general pop",72.6,"71",74.2,NA,"gamma & delta","~30 weeks",NA,NA,"Brazil","BRA",180,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-02-09,"severe","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations",NA,2022-02-09
"1491",180,"Cerqueira-Silva","Test-negative case-control","09Feb2022","CoronaVac (Sinovac)","excluded","2","final","14-30","hospitalization","severe","Brazil",">= 18 years","general pop",82.1,"81.4",82.8,NA,"gamma & delta","~30 weeks",NA,NA,"Brazil","BRA",180,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-02-09,"severe","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations",NA,2022-02-09
"1492",180,"Cerqueira-Silva","Test-negative case-control","09Feb2022","CoronaVac (Sinovac)","excluded","2","final","180+","hospitalization","severe","Brazil",">= 18 years","general pop",72.4,"70.7",73.9,NA,"gamma & delta","~30 weeks",NA,NA,"Brazil","BRA",180,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-02-09,"severe","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations",NA,2022-02-09
"1493",180,"Cerqueira-Silva","Test-negative case-control","09Feb2022","CoronaVac (Sinovac)","excluded","2","final","14-30","death","death","Brazil",">= 18 years","general pop",82.7,"81.7",83.6,NA,"gamma & delta","~30 weeks",NA,NA,"Brazil","BRA",180,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-02-09,"death","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations",NA,2022-02-09
"1494",180,"Cerqueira-Silva","Test-negative case-control","09Feb2022","CoronaVac (Sinovac)","excluded","2","final","180+","death","death","Brazil",">= 18 years","general pop",74.8,"72.2",77.2,NA,"gamma & delta","~30 weeks",NA,NA,"Brazil","BRA",180,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-02-09,"death","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations",NA,2022-02-09
"1495",181,"Butt","Test-negative case-control","09Feb2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14+","infection","infection","USA","haemodialysis patients","haemodialysis patients",60.6,"25.5",79.2,NA,"delta",NA,NA,NA,"USA","USA",181,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-02-09,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-02-09
"1496",181,"Butt","Test-negative case-control","09Feb2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","USA","haemodialysis patients","haemodialysis patients",68.9,"61.9",74.7,NA,"delta","~31 weeks",NA,NA,"USA","USA",181,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-02-09,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-02-09
"1497",181,"Butt","Test-negative case-control","09Feb2022","mRNA-1273 (Moderna)","excluded","1","1","14+","infection","infection","USA","haemodialysis patients","haemodialysis patients",37.2,"27.1",69,NA,"delta",NA,NA,NA,"USA","USA",181,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-02-09,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta",NA,2022-02-09
"1498",181,"Butt","Test-negative case-control","09Feb2022","mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","USA","haemodialysis patients","haemodialysis patients",66.7,"58.9",73,NA,"delta","~31 weeks",NA,NA,"USA","USA",181,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-02-09,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta",NA,2022-02-09
"1499",183,"Hayek","Retrospective cohort","27Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7+","infection","infection","Israel","households with children","households with children",94.4,"93.2",95.4,NA,"alpha","~12 weeks",NA,NA,"Israel","ISR",183,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-01-27,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2022-01-27
"1500",184,"Goldin","Retrospective cohort","08Feb2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","10+","infection","infection","Israel","LTCF residents","LTCF residents",61.8,"58.2",65.1,NA,"non-VOC & alpha",NA,NA,NA,"Israel","ISR",184,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-02-08,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-02-08
"1501",184,"Goldin","Retrospective cohort","08Feb2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7+","infection","infection","Israel","LTCF residents","LTCF residents",81.2,"78.6",83.5,NA,"non-VOC & alpha","~16.5 weeks",NA,NA,"Israel","ISR",184,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-02-08,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-02-08
"1502",184,"Goldin","Retrospective cohort","08Feb2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","10+","death","death","Israel","LTCF residents","LTCF residents",72.3,"66.9",76.8,NA,"non-VOC & alpha",NA,NA,NA,"Israel","ISR",184,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-02-08,"death","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-02-08
"1503",184,"Goldin","Retrospective cohort","08Feb2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7+","death","death","Israel","LTCF residents","LTCF residents",85.3,"80.4",88.9,NA,"non-VOC & alpha","~16.5 weeks",NA,NA,"Israel","ISR",184,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-02-08,"death","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-02-08
"1504",185,"Ferdinands","Test-negative case-control","11Feb2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","<2 months","ED or UC visit","symptomatic","USA","ED encounters and hospital admissions","general pop",69,"62",75,NA,"omicron","~53 weeks",NA,NA,"USA","USA",185,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-02-11,"symptomatic","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-02-11
"1505",185,"Ferdinands","Test-negative case-control","11Feb2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final",">=5 months","ED or UC visit","symptomatic","USA","ED encounters and hospital admissions","general pop",37,"34",40,NA,"omicron","~53 weeks",NA,NA,"USA","USA",185,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-02-11,"symptomatic","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-02-11
"1506",185,"Ferdinands","Test-negative case-control","11Feb2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","<2 months","hospitalization","severe","USA","ED encounters and hospital admissions","general pop",71,"51",83,NA,"omicron","~53 weeks",NA,NA,"USA","USA",185,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-02-11,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-02-11
"1507",185,"Ferdinands","Test-negative case-control","11Feb2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final",">=5 months","hospitalization","severe","USA","ED encounters and hospital admissions","general pop",54,"48",59,NA,"omicron","~53 weeks",NA,NA,"USA","USA",185,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-02-11,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-02-11
"1508",185,"Ferdinands","Test-negative case-control","11Feb2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","<2 months","ED or UC visit","symptomatic","USA","ED encounters and hospital admissions","general pop",92,"91",94,NA,"delta","~25 weeks",NA,NA,"USA","USA",185,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-02-11,"symptomatic","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2022-02-11
"1509",185,"Ferdinands","Test-negative case-control","11Feb2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final",">=5 months","ED or UC visit","symptomatic","USA","ED encounters and hospital admissions","general pop",77,"76",78,NA,"delta","~25 weeks",NA,NA,"USA","USA",185,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-02-11,"symptomatic","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2022-02-11
"1510",185,"Ferdinands","Test-negative case-control","11Feb2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","<2 months","hospitalization","severe","USA","ED encounters and hospital admissions","general pop",94,"92",96,NA,"delta","~25 weeks",NA,NA,"USA","USA",185,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-02-11,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2022-02-11
"1511",185,"Ferdinands","Test-negative case-control","11Feb2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final",">=5 months","hospitalization","severe","USA","ED encounters and hospital admissions","general pop",82,"82",83,NA,"delta","~25 weeks",NA,NA,"USA","USA",185,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-02-11,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2022-02-11
"1512",186,"Jara","Prospective cohort","20Apr2023","CoronaVac (Sinovac)","excluded","2","final","14+","infection","infection","Chile","6-16 years","6-16 years",74.8,"74.1",75.5,NA,"delta","~28 weeks",NA,NA,"Chile","CHL",186,"CHL",24650,2019,"Chile","Latin America & Caribbean","High income",3,"South America",2020-12-25,2021-05-25,2021-09-02,2020-12-21,2020-12-21,4,13,155,255,"who",13,"before jan/2021","<30","before Jun/2021","<180","yes","yes","yes",2023-04-20,"infection","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","delta","15/02/2022",2022-02-15
"1513",186,"Jara","Prospective cohort","20Apr2023","CoronaVac (Sinovac)","excluded","2","final","14+","hospitalization","severe","Chile","6-16 years","6-16 years",91.3,"88.1",93.6,NA,"delta","~28 weeks",NA,NA,"Chile","CHL",186,"CHL",24650,2019,"Chile","Latin America & Caribbean","High income",3,"South America",2020-12-25,2021-05-25,2021-09-02,2020-12-21,2020-12-21,4,13,155,255,"who",13,"before jan/2021","<30","before Jun/2021","<180","yes","yes","yes",2023-04-20,"severe","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","delta","15/02/2022",2022-02-15
"1514",186,"Jara","Prospective cohort","20Apr2023","CoronaVac (Sinovac)","excluded","2","final","14+","ICU admission","severe","Chile","6-16 years","6-16 years",93.8,"85.7",97.3,NA,"delta","~28 weeks",NA,NA,"Chile","CHL",186,"CHL",24650,2019,"Chile","Latin America & Caribbean","High income",3,"South America",2020-12-25,2021-05-25,2021-09-02,2020-12-21,2020-12-21,4,13,155,255,"who",13,"before jan/2021","<30","before Jun/2021","<180","yes","yes","yes",2023-04-20,"severe","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","delta","15/02/2022",2022-02-15
"1515",186,"Jara","Prospective cohort","20Apr2023","CoronaVac (Sinovac)","excluded","2","final","14+","infection","infection","Chile","6-11 years","6-11 years",75.8,"74.8",76.8,NA,"delta","~28 weeks",NA,NA,"Chile","CHL",186,"CHL",24650,2019,"Chile","Latin America & Caribbean","High income",3,"South America",2020-12-25,2021-05-25,2021-09-02,2020-12-21,2020-12-21,4,13,155,255,"who",13,"before jan/2021","<30","before Jun/2021","<180","yes","yes","yes",2023-04-20,"infection","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","delta","15/02/2022",2022-02-15
"1516",186,"Jara","Prospective cohort","20Apr2023","CoronaVac (Sinovac)","excluded","2","final","14+","hospitalization","severe","Chile","6-11 years","6-11 years",78.5,"62.8",87.6,NA,"delta","~28 weeks",NA,NA,"Chile","CHL",186,"CHL",24650,2019,"Chile","Latin America & Caribbean","High income",3,"South America",2020-12-25,2021-05-25,2021-09-02,2020-12-21,2020-12-21,4,13,155,255,"who",13,"before jan/2021","<30","before Jun/2021","<180","yes","yes","yes",2023-04-20,"severe","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","delta","15/02/2022",2022-02-15
"1517",186,"Jara","Prospective cohort","20Apr2023","CoronaVac (Sinovac)","excluded","2","final","14+","infection","infection","Chile","12-16 years","12-16 years",73.6,"72.5",74.6,NA,"delta","~28 weeks",NA,NA,"Chile","CHL",186,"CHL",24650,2019,"Chile","Latin America & Caribbean","High income",3,"South America",2020-12-25,2021-05-25,2021-09-02,2020-12-21,2020-12-21,4,13,155,255,"who",13,"before jan/2021","<30","before Jun/2021","<180","yes","yes","yes",2023-04-20,"infection","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","delta","15/02/2022",2022-02-15
"1518",186,"Jara","Prospective cohort","20Apr2023","CoronaVac (Sinovac)","excluded","2","final","14+","hospitalization","severe","Chile","12-16 years","12-16 years",93.4,"90.4",95.5,NA,"delta","~28 weeks",NA,NA,"Chile","CHL",186,"CHL",24650,2019,"Chile","Latin America & Caribbean","High income",3,"South America",2020-12-25,2021-05-25,2021-09-02,2020-12-21,2020-12-21,4,13,155,255,"who",13,"before jan/2021","<30","before Jun/2021","<180","yes","yes","yes",2023-04-20,"severe","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","delta","15/02/2022",2022-02-15
"1519",186,"Jara","Prospective cohort","20Apr2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","Chile","12-16 years","12-16 years",84.4,"83.7",85,NA,"delta","~30 weeks",NA,NA,"Chile","CHL",186,"CHL",24650,2019,"Chile","Latin America & Caribbean","High income",3,"South America",2020-12-25,2021-05-25,2021-09-02,2020-12-21,2020-12-21,4,13,155,255,"who",13,"before jan/2021","<30","before Jun/2021","<180","yes","yes","yes",2023-04-20,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","15/02/2022",2022-02-15
"1520",186,"Jara","Prospective cohort","20Apr2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization","severe","Chile","12-16 years","12-16 years",93.5,"90.4",95.6,NA,"delta","~30 weeks",NA,NA,"Chile","CHL",186,"CHL",24650,2019,"Chile","Latin America & Caribbean","High income",3,"South America",2020-12-25,2021-05-25,2021-09-02,2020-12-21,2020-12-21,4,13,155,255,"who",13,"before jan/2021","<30","before Jun/2021","<180","yes","yes","yes",2023-04-20,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","15/02/2022",2022-02-15
"1521",186,"Jara","Prospective cohort","20Apr2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","ICU admission","severe","Chile","12-16 years","12-16 years",98,"89.9",99.6,NA,"delta","~30 weeks",NA,NA,"Chile","CHL",186,"CHL",24650,2019,"Chile","Latin America & Caribbean","High income",3,"South America",2020-12-25,2021-05-25,2021-09-02,2020-12-21,2020-12-21,4,13,155,255,"who",13,"before jan/2021","<30","before Jun/2021","<180","yes","yes","yes",2023-04-20,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","15/02/2022",2022-02-15
"1522",187,"Halasa","Test-negative case-control","22Jun2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","infants <6 months when timing of maternal vaccination was anytime up to 14 days before delivery","infants <6 months when timing of maternal vaccination was anytime up to 14 days before delivery",52,"33",65,NA,"delta & omicron","~33 weeks",NA,NA,"USA","USA",187,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta/omicron","15/02/2022",2022-02-15
"1523",187,"Halasa","Test-negative case-control","22Jun2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","infants <6 months when timing of maternal vaccination was in first 20 weeks","infants <6 months when timing of maternal vaccination was in first 20 weeks",38,"3",60,NA,"delta & omicron","~33 weeks",NA,NA,"USA","USA",187,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta/omicron","15/02/2022",2022-02-15
"1524",187,"Halasa","Test-negative case-control","22Jun2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","infants <6 months when timing of maternal vaccination was from 21 weeks' gestation up to 14 days before delivery","infants <6 months when timing of maternal vaccination was from 21 weeks' gestation up to 14 days before delivery",69,"50",80,NA,"delta & omicron","~33 weeks",NA,NA,"USA","USA",187,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta/omicron","15/02/2022",2022-02-15
"1525",187,"Halasa","Test-negative case-control","22Jun2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","infants <6 months when timing of maternal vaccination was anytime up to 14 days before delivery","infants <6 months when timing of maternal vaccination was anytime up to 14 days before delivery",38,"8",58,NA,"omicron","~33 weeks",NA,NA,"USA","USA",187,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","15/02/2022",2022-02-15
"1526",187,"Halasa","Test-negative case-control","22Jun2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","infants <6 months when timing of maternal vaccination was in first 20 weeks","infants <6 months when timing of maternal vaccination was in first 20 weeks",25,"-26",56,NA,"omicron","~33 weeks",NA,NA,"USA","USA",187,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","15/02/2022",2022-02-15
"1527",187,"Halasa","Test-negative case-control","22Jun2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","infants <6 months when timing of maternal vaccination was from 21 weeks' gestation up to 14 days before delivery","infants <6 months when timing of maternal vaccination was from 21 weeks' gestation up to 14 days before delivery",57,"25",75,NA,"omicron","~33 weeks",NA,NA,"USA","USA",187,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","15/02/2022",2022-02-15
"1528",187,"Halasa","Test-negative case-control","22Jun2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","infants <6 months when timing of maternal vaccination was anytime up to 14 days before delivery","infants <6 months when timing of maternal vaccination was anytime up to 14 days before delivery",80,"60",90,NA,"delta","~33 weeks",NA,NA,"USA","USA",187,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta","15/02/2022",2022-02-15
"1529",187,"Halasa","Test-negative case-control","22Jun2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","infants <6 months when timing of maternal vaccination was in first 20 weeks","infants <6 months when timing of maternal vaccination was in first 20 weeks",68,"19",87,NA,"delta","~33 weeks",NA,NA,"USA","USA",187,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta","15/02/2022",2022-02-15
"1530",187,"Halasa","Test-negative case-control","22Jun2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","infants <6 months when timing of maternal vaccination was from 21 weeks' gestation up to 14 days before delivery","infants <6 months when timing of maternal vaccination was from 21 weeks' gestation up to 14 days before delivery",88,"68",96,NA,"delta","~33 weeks",NA,NA,"USA","USA",187,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta","15/02/2022",2022-02-15
"1531",188,"Gazit","Retrospective cohort","15Feb2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection","infection","Israel",">= 18 years","general pop",82,"80",85,NA,"alpha & delta","~40 weeks",NA,NA,"Israel","ISR",188,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-02-15,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-02-15
"1532",188,"Gazit","Retrospective cohort","15Feb2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","symptomatic disease","symptomatic","Israel",">= 18 years","general pop",76,"71",80,NA,"alpha & delta","~40 weeks",NA,NA,"Israel","ISR",188,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-02-15,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-02-15
"1533",189,"Filon","Retrospective cohort","15Feb2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection (March)","infection","Italy","HCW","HCW",95,"92",98,NA,"non-VOC & alpha","~16 weeks",NA,NA,"Italy","ITA",189,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-15,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-02-15
"1534",189,"Filon","Retrospective cohort","15Feb2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection (April)","infection","Italy","HCW","HCW",95,"92",98,NA,"non-VOC & alpha","~16 weeks",NA,NA,"Italy","ITA",189,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-15,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-02-15
"1535",189,"Filon","Retrospective cohort","15Feb2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection (May)","infection","Italy","HCW","HCW",80,"70",84,NA,"non-VOC & alpha","~16 weeks",NA,NA,"Italy","ITA",189,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-15,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-02-15
"1536",190,"Wu","Retrospective cohort","10Jan2022","BBIBP-CorV (Beijing CNBG)","excluded","1+","1+","14+","symptomatic disease","symptomatic","China","close contacts","Contacts of index cases",24.7,"-98.8",71.4,NA,"delta",NA,NA,NA,"China","CHN",190,"CHN",16610,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,-139,386,420,"who",0,"before jan/2021","<30","Jun-Aug/2021","360+","yes","yes","yes",2022-01-10,"symptomatic","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta",NA,2022-01-10
"1537",190,"Wu","Retrospective cohort","10Jan2022","BBIBP-CorV (Beijing CNBG)","excluded","2","final","14+","symptomatic disease","symptomatic","China","close contacts","Contacts of index cases",50.5,"3.8",74.6,NA,"delta","~24 weeks",NA,NA,"China","CHN",190,"CHN",16610,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,-139,386,420,"who",0,"before jan/2021","<30","Jun-Aug/2021","360+","yes","yes","yes",2022-01-10,"symptomatic","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta",NA,2022-01-10
"1538",190,"Wu","Retrospective cohort","10Jan2022","BBIBP-CorV (Beijing CNBG)","excluded","2","final",">=3 months","symptomatic disease","symptomatic","China","close contacts","Contacts of index cases",39.3,"-20.4",69.4,NA,"delta","~24 weeks",NA,NA,"China","CHN",190,"CHN",16610,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,-139,386,420,"who",0,"before jan/2021","<30","Jun-Aug/2021","360+","yes","yes","yes",2022-01-10,"symptomatic","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta",NA,2022-01-10
"1539",190,"Wu","Retrospective cohort","10Jan2022","BBIBP-CorV (Beijing CNBG)","excluded","2","final","4-6 months","symptomatic disease","symptomatic","China","close contacts","Contacts of index cases",82,"-25.7",97.4,NA,"delta","~24 weeks",NA,NA,"China","CHN",190,"CHN",16610,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,-139,386,420,"who",0,"before jan/2021","<30","Jun-Aug/2021","360+","yes","yes","yes",2022-01-10,"symptomatic","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta",NA,2022-01-10
"1540",190,"Wu","Retrospective cohort","10Jan2022","BBIBP-CorV (Beijing CNBG)","excluded","1+","1+","14+","pneumonia","severe","China","close contacts","Contacts of index cases",16.3,"-164.3",73.2,NA,"delta",NA,NA,NA,"China","CHN",190,"CHN",16610,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,-139,386,420,"who",0,"before jan/2021","<30","Jun-Aug/2021","360+","yes","yes","yes",2022-01-10,"severe","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta",NA,2022-01-10
"1541",190,"Wu","Retrospective cohort","10Jan2022","BBIBP-CorV (Beijing CNBG)","excluded","2","final","14+","pneumonia","severe","China","close contacts","Contacts of index cases",54.7,"-3.4",80.2,NA,"delta","~24 weeks",NA,NA,"China","CHN",190,"CHN",16610,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,-139,386,420,"who",0,"before jan/2021","<30","Jun-Aug/2021","360+","yes","yes","yes",2022-01-10,"severe","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta",NA,2022-01-10
"1542",190,"Wu","Retrospective cohort","10Jan2022","BBIBP-CorV (Beijing CNBG)","excluded","2","final",">=3 months","pneumonia","severe","China","close contacts","Contacts of index cases",39.6,"-35.4",73.1,NA,"delta","~24 weeks",NA,NA,"China","CHN",190,"CHN",16610,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,-139,386,420,"who",0,"before jan/2021","<30","Jun-Aug/2021","360+","yes","yes","yes",2022-01-10,"severe","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta",NA,2022-01-10
"1543",190,"Wu","Retrospective cohort","10Jan2022","BBIBP-CorV (Beijing CNBG)","excluded","1+","1+","14+","severe disease","severe","China","close contacts","Contacts of index cases",7.5,"-655.6",88.7,NA,"delta",NA,NA,NA,"China","CHN",190,"CHN",16610,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,-139,386,420,"who",0,"before jan/2021","<30","Jun-Aug/2021","360+","yes","yes","yes",2022-01-10,"severe","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta",NA,2022-01-10
"1544",190,"Wu","Retrospective cohort","10Jan2022","CoronaVac (Sinovac)","excluded","1+","1+","14+","symptomatic disease","symptomatic","China","close contacts","Contacts of index cases",29.9,"-44.3",66,NA,"delta",NA,NA,NA,"China","CHN",190,"CHN",16610,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,-139,386,420,"who",0,"before jan/2021","<30","Jun-Aug/2021","360+","yes","yes","yes",2022-01-10,"symptomatic","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","delta",NA,2022-01-10
"1545",190,"Wu","Retrospective cohort","10Jan2022","CoronaVac (Sinovac)","excluded","2","final","14+","symptomatic disease","symptomatic","China","close contacts","Contacts of index cases",39.1,"-0.9",63.3,NA,"delta","~24 weeks",NA,NA,"China","CHN",190,"CHN",16610,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,-139,386,420,"who",0,"before jan/2021","<30","Jun-Aug/2021","360+","yes","yes","yes",2022-01-10,"symptomatic","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","delta",NA,2022-01-10
"1546",190,"Wu","Retrospective cohort","10Jan2022","CoronaVac (Sinovac)","excluded","2","final",">=3 months","symptomatic disease","symptomatic","China","close contacts","Contacts of index cases",45.5,"-5.9",71.9,NA,"delta","~24 weeks",NA,NA,"China","CHN",190,"CHN",16610,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,-139,386,420,"who",0,"before jan/2021","<30","Jun-Aug/2021","360+","yes","yes","yes",2022-01-10,"symptomatic","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","delta",NA,2022-01-10
"1547",190,"Wu","Retrospective cohort","10Jan2022","CoronaVac (Sinovac)","excluded","2","final","4-6 months","symptomatic disease","symptomatic","China","close contacts","Contacts of index cases",29.8,"-41.1",65.1,NA,"delta","~24 weeks",NA,NA,"China","CHN",190,"CHN",16610,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,-139,386,420,"who",0,"before jan/2021","<30","Jun-Aug/2021","360+","yes","yes","yes",2022-01-10,"symptomatic","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","delta",NA,2022-01-10
"1548",190,"Wu","Retrospective cohort","10Jan2022","CoronaVac (Sinovac)","excluded","1","1","14+","pneumonia","severe","China","close contacts","Contacts of index cases",52.6,"-25.2",82.1,NA,"delta",NA,NA,NA,"China","CHN",190,"CHN",16610,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,-139,386,420,"who",0,"before jan/2021","<30","Jun-Aug/2021","360+","yes","yes","yes",2022-01-10,"severe","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","delta",NA,2022-01-10
"1549",190,"Wu","Retrospective cohort","10Jan2022","CoronaVac (Sinovac)","excluded","2","final","14+","pneumonia","severe","China","close contacts","Contacts of index cases",64.9,"22.8",84,NA,"delta","~24 weeks",NA,NA,"China","CHN",190,"CHN",16610,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,-139,386,420,"who",0,"before jan/2021","<30","Jun-Aug/2021","360+","yes","yes","yes",2022-01-10,"severe","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","delta",NA,2022-01-10
"1550",190,"Wu","Retrospective cohort","10Jan2022","CoronaVac (Sinovac)","excluded","2","final",">=3 months","pneumonia","severe","China","close contacts","Contacts of index cases",73.8,"17.9",91.6,NA,"delta","~24 weeks",NA,NA,"China","CHN",190,"CHN",16610,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,-139,386,420,"who",0,"before jan/2021","<30","Jun-Aug/2021","360+","yes","yes","yes",2022-01-10,"severe","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","delta",NA,2022-01-10
"1551",190,"Wu","Retrospective cohort","10Jan2022","CoronaVac (Sinovac)","excluded","2","final","4-6 months","pneumonia","severe","China","close contacts","Contacts of index cases",47.4,"-44.3",80.8,NA,"delta","~24 weeks",NA,NA,"China","CHN",190,"CHN",16610,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,-139,386,420,"who",0,"before jan/2021","<30","Jun-Aug/2021","360+","yes","yes","yes",2022-01-10,"severe","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","delta",NA,2022-01-10
"1552",190,"Wu","Retrospective cohort","10Jan2022","CoronaVac (Sinovac)","excluded","1","1","14+","severe disease","severe","China","close contacts","Contacts of index cases",59.7,"-209.9",94.7,NA,"delta",NA,NA,NA,"China","CHN",190,"CHN",16610,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,-139,386,420,"who",0,"before jan/2021","<30","Jun-Aug/2021","360+","yes","yes","yes",2022-01-10,"severe","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","delta",NA,2022-01-10
"1553",191,"Mallow","Test-negative case-control","09Feb2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","ED visits","symptomatic","USA","ED patients (aged 18+)","general pop",73.9,"66.3",79.8,NA,"non-VOC, alpha, & delta","~31 weeks",NA,NA,"USA","USA",191,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-02-09,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-02-09
"1554",191,"Mallow","Test-negative case-control","09Feb2022","mRNA-1273 (Moderna)","unknown","2","final","14+","ED visits","symptomatic","USA","ED patients (aged 18+)","general pop",78,"68.1",84.9,NA,"non-VOC, alpha, & delta","~31 weeks",NA,NA,"USA","USA",191,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-02-09,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-02-09
"1555",192,"Shen","Retrospective cohort","23Feb2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","Infection","infection","USA","immunocompromised","immunocompromised adults",41,"9",62,NA,"non-VOC, alpha, & delta","~36 weeks",NA,NA,"USA","USA",192,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-02-23,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-02-23
"1556",192,"Shen","Retrospective cohort","23Feb2022","mRNA-1273 (Moderna)","excluded","2","final","14+","Infection","infection","USA","immunocompromised","immunocompromised adults",48,"18",67,NA,"non-VOC, alpha, & delta","~36 weeks",NA,NA,"USA","USA",192,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-02-23,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-02-23
"1557",192,"Shen","Retrospective cohort","23Feb2022","Ad26.COV2.S (Janssen)","excluded","1","final","14+","Infection","infection","USA","immunocompromised","immunocompromised adults",66,"-30",91,NA,"non-VOC, alpha, & delta","~36 weeks",NA,NA,"USA","USA",192,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-02-23,"infection","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-02-23
"1558",193,"Cura-Bilbao","Prospective cohort","02Feb2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","12+","Infection","infection","Spain",">= 18 years","general pop",20.8,"11.6",29,NA,"non-VOC & alpha",NA,NA,NA,"Spain","ESP",193,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-02,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-02-02
"1559",193,"Cura-Bilbao","Prospective cohort","02Feb2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7+","Infection","infection","Spain",">= 18 years","general pop",70,"65.3",74.1,NA,"non-VOC & alpha","~16 weeks",NA,NA,"Spain","ESP",193,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-02,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-02-02
"1560",193,"Cura-Bilbao","Prospective cohort","02Feb2022","mRNA-1273 (Moderna)","excluded","1","1","14+","Infection","infection","Spain",">= 18 years","general pop",52.8,"30.7",67.8,NA,"non-VOC & alpha",NA,NA,NA,"Spain","ESP",193,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-02,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-02-02
"1561",193,"Cura-Bilbao","Prospective cohort","02Feb2022","mRNA-1273 (Moderna)","excluded","2","final","14+","Infection","infection","Spain",">= 18 years","general pop",70.3,"52.2",81.5,NA,"non-VOC & alpha","~16 weeks",NA,NA,"Spain","ESP",193,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-02,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-02-02
"1562",193,"Cura-Bilbao","Prospective cohort","02Feb2022","AZD1222 (AstraZeneca)","excluded","1","1","21+","Infection","infection","Spain",">= 18 years","general pop",40.3,"31.8",47.7,NA,"non-VOC & alpha",NA,NA,NA,"Spain","ESP",193,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-02,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-02-02
"1563",194,"Smid","Retrospective cohort","15Oct2022","BNT162b2 (Pfizer BioNTech)","included","1","1","14-74","Infection","infection","Czech Republic","all ages","general pop",31,"28",34,NA,"omicron",NA,NA,NA,"Czech Republic","CZE",194,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","25/02/2022",2022-02-25
"1564",194,"Smid","Retrospective cohort","15Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14-74","Infection","infection","Czech Republic","all ages","general pop",49,"48",50,NA,"omicron","~54 weeks",NA,NA,"Czech Republic","CZE",194,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","25/02/2022",2022-02-25
"1565",194,"Smid","Retrospective cohort","15Oct2022","BNT162b2 (Pfizer BioNTech)","included","1","1","75+","Infection","infection","Czech Republic","all ages","general pop",53,"46",59,NA,"omicron",NA,NA,NA,"Czech Republic","CZE",194,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","25/02/2022",2022-02-25
"1566",194,"Smid","Retrospective cohort","15Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final","135+","Infection","infection","Czech Republic","all ages","general pop",11,"10",12,NA,"omicron","~54 weeks",NA,NA,"Czech Republic","CZE",194,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","25/02/2022",2022-02-25
"1567",194,"Smid","Retrospective cohort","15Oct2022","BNT162b2 (Pfizer BioNTech)","included","1","1","14-74","hospitalization","severe","Czech Republic","all ages","general pop",41,"-3",66,NA,"omicron",NA,NA,NA,"Czech Republic","CZE",194,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","25/02/2022",2022-02-25
"1568",194,"Smid","Retrospective cohort","15Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14-74","hospitalization","severe","Czech Republic","all ages","general pop",46,"28",60,NA,"omicron","~54 weeks",NA,NA,"Czech Republic","CZE",194,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","25/02/2022",2022-02-25
"1569",194,"Smid","Retrospective cohort","15Oct2022","BNT162b2 (Pfizer BioNTech)","included","1","1","75+","hospitalization","severe","Czech Republic","all ages","general pop",4,"-287",76,NA,"omicron",NA,NA,NA,"Czech Republic","CZE",194,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","25/02/2022",2022-02-25
"1570",194,"Smid","Retrospective cohort","15Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final","135+","hospitalization","severe","Czech Republic","all ages","general pop",34,"24",42,NA,"omicron","~54 weeks",NA,NA,"Czech Republic","CZE",194,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","25/02/2022",2022-02-25
"1571",194,"Smid","Retrospective cohort","15Oct2022","mRNA-1273 (Moderna)","included","1","1","14-74","Infection","infection","Czech Republic","all ages","general pop",49,"42",55,NA,"omicron",NA,NA,NA,"Czech Republic","CZE",194,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron","25/02/2022",2022-02-25
"1572",194,"Smid","Retrospective cohort","15Oct2022","mRNA-1273 (Moderna)","included","2","final","14-74","Infection","infection","Czech Republic","all ages","general pop",48,"44",52,NA,"omicron","~54 weeks",NA,NA,"Czech Republic","CZE",194,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron","25/02/2022",2022-02-25
"1573",194,"Smid","Retrospective cohort","15Oct2022","mRNA-1273 (Moderna)","included","1","1","75+","Infection","infection","Czech Republic","all ages","general pop",60,"36",75,NA,"omicron",NA,NA,NA,"Czech Republic","CZE",194,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron","25/02/2022",2022-02-25
"1574",194,"Smid","Retrospective cohort","15Oct2022","mRNA-1273 (Moderna)","included","2","final","135+","Infection","infection","Czech Republic","all ages","general pop",20,"17",22,NA,"omicron","~54 weeks",NA,NA,"Czech Republic","CZE",194,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron","25/02/2022",2022-02-25
"1575",194,"Smid","Retrospective cohort","15Oct2022","mRNA-1273 (Moderna)","included","1","1","14-74","hospitalization","severe","Czech Republic","all ages","general pop",56,"-78",89,NA,"omicron",NA,NA,NA,"Czech Republic","CZE",194,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron","25/02/2022",2022-02-25
"1576",194,"Smid","Retrospective cohort","15Oct2022","mRNA-1273 (Moderna)","included","2","final","14-74","hospitalization","severe","Czech Republic","all ages","general pop",51,"-20",80,NA,"omicron","~54 weeks",NA,NA,"Czech Republic","CZE",194,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron","25/02/2022",2022-02-25
"1577",194,"Smid","Retrospective cohort","15Oct2022","mRNA-1273 (Moderna)","included","1","1","75+","hospitalization","severe","Czech Republic","all ages","general pop",-160,"-1743",64,NA,"omicron",NA,NA,NA,"Czech Republic","CZE",194,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron","25/02/2022",2022-02-25
"1578",194,"Smid","Retrospective cohort","15Oct2022","mRNA-1273 (Moderna)","included","2","final","135+","hospitalization","severe","Czech Republic","all ages","general pop",31,"9",49,NA,"omicron","~54 weeks",NA,NA,"Czech Republic","CZE",194,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron","25/02/2022",2022-02-25
"1579",194,"Smid","Retrospective cohort","15Oct2022","AZD1222 (AstraZeneca)","included","2","final","75-135","Infection","infection","Czech Republic","all ages","general pop",51,"23",69,NA,"omicron","~54 weeks",NA,NA,"Czech Republic","CZE",194,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"infection","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","25/02/2022",2022-02-25
"1580",194,"Smid","Retrospective cohort","15Oct2022","AZD1222 (AstraZeneca)","included","2","final","135+","Infection","infection","Czech Republic","all ages","general pop",5,"1",9,NA,"omicron","~54 weeks",NA,NA,"Czech Republic","CZE",194,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"infection","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","25/02/2022",2022-02-25
"1581",194,"Smid","Retrospective cohort","15Oct2022","AZD1222 (AstraZeneca)","included","2","final","75-135","hospitalization","severe","Czech Republic","all ages","general pop",-139,"-861",41,NA,"omicron","~54 weeks",NA,NA,"Czech Republic","CZE",194,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","25/02/2022",2022-02-25
"1582",194,"Smid","Retrospective cohort","15Oct2022","AZD1222 (AstraZeneca)","included","2","final","135+","hospitalization","severe","Czech Republic","all ages","general pop",13,"-8",30,NA,"omicron","~54 weeks",NA,NA,"Czech Republic","CZE",194,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","25/02/2022",2022-02-25
"1583",194,"Smid","Retrospective cohort","15Oct2022","Ad26.COV2.S (Janssen)","included","1","final","14-74","Infection","infection","Czech Republic","all ages","general pop",47,"45",49,NA,"omicron","~54 weeks",NA,NA,"Czech Republic","CZE",194,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"infection","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","omicron","25/02/2022",2022-02-25
"1584",194,"Smid","Retrospective cohort","15Oct2022","Ad26.COV2.S (Janssen)","included","1","final","135+","Infection","infection","Czech Republic","all ages","general pop",35,"33",38,NA,"omicron","~54 weeks",NA,NA,"Czech Republic","CZE",194,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"infection","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","omicron","25/02/2022",2022-02-25
"1585",194,"Smid","Retrospective cohort","15Oct2022","Ad26.COV2.S (Janssen)","included","1","final","14-74","hospitalization","severe","Czech Republic","all ages","general pop",28,"-22",57,NA,"omicron","~54 weeks",NA,NA,"Czech Republic","CZE",194,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"severe","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","omicron","25/02/2022",2022-02-25
"1586",194,"Smid","Retrospective cohort","15Oct2022","Ad26.COV2.S (Janssen)","included","1","final","135+","hospitalization","severe","Czech Republic","all ages","general pop",38,"8",58,NA,"omicron","~54 weeks",NA,NA,"Czech Republic","CZE",194,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"severe","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","omicron","25/02/2022",2022-02-25
"1587",194,"Smid","Retrospective cohort","15Oct2022","BNT162b2 (Pfizer BioNTech)","included","1","1","14-74","Infection","infection","Czech Republic","all ages","general pop",67,"65",69,NA,"delta",NA,NA,NA,"Czech Republic","CZE",194,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","25/02/2022",2022-02-25
"1588",194,"Smid","Retrospective cohort","15Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14-74","Infection","infection","Czech Republic","all ages","general pop",82,"81",83,NA,"delta","~54 weeks",NA,NA,"Czech Republic","CZE",194,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","25/02/2022",2022-02-25
"1589",194,"Smid","Retrospective cohort","15Oct2022","BNT162b2 (Pfizer BioNTech)","included","1","1","75+","Infection","infection","Czech Republic","all ages","general pop",61,"51",69,NA,"delta",NA,NA,NA,"Czech Republic","CZE",194,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","25/02/2022",2022-02-25
"1590",194,"Smid","Retrospective cohort","15Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final","135+","Infection","infection","Czech Republic","all ages","general pop",54,"53",55,NA,"delta","~54 weeks",NA,NA,"Czech Republic","CZE",194,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","25/02/2022",2022-02-25
"1591",194,"Smid","Retrospective cohort","15Oct2022","BNT162b2 (Pfizer BioNTech)","included","1","1","14-74","hospitalization","severe","Czech Republic","all ages","general pop",53,"40",63,NA,"delta",NA,NA,NA,"Czech Republic","CZE",194,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","25/02/2022",2022-02-25
"1592",194,"Smid","Retrospective cohort","15Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14-74","hospitalization","severe","Czech Republic","all ages","general pop",80,"72",85,NA,"delta","~54 weeks",NA,NA,"Czech Republic","CZE",194,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","25/02/2022",2022-02-25
"1593",194,"Smid","Retrospective cohort","15Oct2022","BNT162b2 (Pfizer BioNTech)","included","1","1","75+","hospitalization","severe","Czech Republic","all ages","general pop",61,"-20",87,NA,"delta",NA,NA,NA,"Czech Republic","CZE",194,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","25/02/2022",2022-02-25
"1594",194,"Smid","Retrospective cohort","15Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final","135+","hospitalization","severe","Czech Republic","all ages","general pop",82,"77",86,NA,"delta","~54 weeks",NA,NA,"Czech Republic","CZE",194,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","25/02/2022",2022-02-25
"1595",194,"Smid","Retrospective cohort","15Oct2022","mRNA-1273 (Moderna)","included","1","1","14-74","Infection","infection","Czech Republic","all ages","general pop",68,"61",74,NA,"delta",NA,NA,NA,"Czech Republic","CZE",194,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","25/02/2022",2022-02-25
"1596",194,"Smid","Retrospective cohort","15Oct2022","mRNA-1273 (Moderna)","included","2","final","14-74","Infection","infection","Czech Republic","all ages","general pop",71,"65",76,NA,"delta","~54 weeks",NA,NA,"Czech Republic","CZE",194,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","25/02/2022",2022-02-25
"1597",194,"Smid","Retrospective cohort","15Oct2022","mRNA-1273 (Moderna)","included","1","1","75+","Infection","infection","Czech Republic","all ages","general pop",67,"34",84,NA,"delta",NA,NA,NA,"Czech Republic","CZE",194,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","25/02/2022",2022-02-25
"1598",194,"Smid","Retrospective cohort","15Oct2022","mRNA-1273 (Moderna)","included","2","final","135+","Infection","infection","Czech Republic","all ages","general pop",68,"66",69,NA,"delta","~54 weeks",NA,NA,"Czech Republic","CZE",194,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","25/02/2022",2022-02-25
"1599",194,"Smid","Retrospective cohort","15Oct2022","mRNA-1273 (Moderna)","included","1","1","14-74","hospitalization","severe","Czech Republic","all ages","general pop",49,"13",71,NA,"delta",NA,NA,NA,"Czech Republic","CZE",194,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","25/02/2022",2022-02-25
"1600",194,"Smid","Retrospective cohort","15Oct2022","mRNA-1273 (Moderna)","included","2","final","14-74","hospitalization","severe","Czech Republic","all ages","general pop",100,NA,NA,NA,"delta","~54 weeks",NA,NA,"Czech Republic","CZE",194,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","25/02/2022",2022-02-25
"1601",194,"Smid","Retrospective cohort","15Oct2022","mRNA-1273 (Moderna)","included","1","1","75+","hospitalization","severe","Czech Republic","all ages","general pop",100,NA,NA,NA,"delta",NA,NA,NA,"Czech Republic","CZE",194,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","25/02/2022",2022-02-25
"1602",194,"Smid","Retrospective cohort","15Oct2022","mRNA-1273 (Moderna)","included","2","final","135+","hospitalization","severe","Czech Republic","all ages","general pop",82,"78",85,NA,"delta","~54 weeks",NA,NA,"Czech Republic","CZE",194,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","25/02/2022",2022-02-25
"1603",194,"Smid","Retrospective cohort","15Oct2022","AZD1222 (AstraZeneca)","included","2","final","75-135","Infection","infection","Czech Republic","all ages","general pop",65,"57",72,NA,"delta","~54 weeks",NA,NA,"Czech Republic","CZE",194,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"infection","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","25/02/2022",2022-02-25
"1604",194,"Smid","Retrospective cohort","15Oct2022","AZD1222 (AstraZeneca)","included","2","final","135+","Infection","infection","Czech Republic","all ages","general pop",45,"43",48,NA,"delta","~54 weeks",NA,NA,"Czech Republic","CZE",194,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"infection","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","25/02/2022",2022-02-25
"1605",194,"Smid","Retrospective cohort","15Oct2022","AZD1222 (AstraZeneca)","included","2","final","75-135","hospitalization","severe","Czech Republic","all ages","general pop",80,"62",89,NA,"delta","~54 weeks",NA,NA,"Czech Republic","CZE",194,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","25/02/2022",2022-02-25
"1606",194,"Smid","Retrospective cohort","15Oct2022","AZD1222 (AstraZeneca)","included","2","final","135+","hospitalization","severe","Czech Republic","all ages","general pop",68,"64",71,NA,"delta","~54 weeks",NA,NA,"Czech Republic","CZE",194,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","25/02/2022",2022-02-25
"1607",194,"Smid","Retrospective cohort","15Oct2022","Ad26.COV2.S (Janssen)","included","1","final","14-74","Infection","infection","Czech Republic","all ages","general pop",60,"57",63,NA,"delta","~54 weeks",NA,NA,"Czech Republic","CZE",194,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"infection","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta","25/02/2022",2022-02-25
"1608",194,"Smid","Retrospective cohort","15Oct2022","Ad26.COV2.S (Janssen)","included","1","final","135+","Infection","infection","Czech Republic","all ages","general pop",54,"50",57,NA,"delta","~54 weeks",NA,NA,"Czech Republic","CZE",194,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"infection","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta","25/02/2022",2022-02-25
"1609",194,"Smid","Retrospective cohort","15Oct2022","Ad26.COV2.S (Janssen)","included","1","final","14-74","hospitalization","severe","Czech Republic","all ages","general pop",54,"39",65,NA,"delta","~54 weeks",NA,NA,"Czech Republic","CZE",194,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"severe","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta","25/02/2022",2022-02-25
"1610",194,"Smid","Retrospective cohort","15Oct2022","Ad26.COV2.S (Janssen)","included","1","final","135+","hospitalization","severe","Czech Republic","all ages","general pop",61,"51",69,NA,"delta","~54 weeks",NA,NA,"Czech Republic","CZE",194,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"severe","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta","25/02/2022",2022-02-25
"1611",195,"Klein","Test-negative case-control","01Mar2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14-67","ED or UC visit","symptomatic","USA","5-11 years","5-11 years",51,"30",65,NA,"omicron","~33 weeks",NA,NA,"USA","USA",195,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-01,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-03-01
"1612",195,"Klein","Test-negative case-control","01Mar2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14-149","ED or UC visit","symptomatic","USA","12-15 years","12-15 years",45,"30",57,NA,"omicron","~33 weeks",NA,NA,"USA","USA",195,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-01,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-03-01
"1613",195,"Klein","Test-negative case-control","01Mar2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","150+","ED or UC visit","symptomatic","USA","12-15 years","12-15 years",-2,"-25",17,NA,"omicron","~33 weeks",NA,NA,"USA","USA",195,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-01,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-03-01
"1614",195,"Klein","Test-negative case-control","01Mar2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14-149","ED or UC visit","symptomatic","USA","16-17 years","16-17 years",34,"8",53,NA,"omicron","~33 weeks",NA,NA,"USA","USA",195,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-01,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-03-01
"1615",195,"Klein","Test-negative case-control","01Mar2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","150+","ED or UC visit","symptomatic","USA","16-17 years","16-17 years",-3,"-30",18,NA,"omicron","~33 weeks",NA,NA,"USA","USA",195,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-01,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-03-01
"1616",195,"Klein","Test-negative case-control","01Mar2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14-149","ED or UC visit","symptomatic","USA","12-15 years","12-15 years",92,"89",94,NA,"delta","~33 weeks",NA,NA,"USA","USA",195,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-01,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-03-01
"1617",195,"Klein","Test-negative case-control","01Mar2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","150+","ED or UC visit","symptomatic","USA","12-15 years","12-15 years",79,"68",86,NA,"delta","~33 weeks",NA,NA,"USA","USA",195,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-01,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-03-01
"1618",195,"Klein","Test-negative case-control","01Mar2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14-149","ED or UC visit","symptomatic","USA","16-17 years","16-17 years",85,"81",89,NA,"delta","~33 weeks",NA,NA,"USA","USA",195,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-01,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-03-01
"1619",195,"Klein","Test-negative case-control","01Mar2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","150+","ED or UC visit","symptomatic","USA","16-17 years","16-17 years",77,"67",84,NA,"delta","~33 weeks",NA,NA,"USA","USA",195,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-01,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-03-01
"1620",195,"Klein","Test-negative case-control","01Mar2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14-67","hospitalization","severe","USA","5-11 years","5-11 years",74,"-35",95,NA,"omicron or delta","~33 weeks",NA,NA,"USA","USA",195,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-01,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta/omicron",NA,2022-03-01
"1621",195,"Klein","Test-negative case-control","01Mar2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14-149","hospitalization","severe","USA","12-15 years","12-15 years",92,"79",97,NA,"omicron or delta","~33 weeks",NA,NA,"USA","USA",195,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-01,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta/omicron",NA,2022-03-01
"1622",195,"Klein","Test-negative case-control","01Mar2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","150+","hospitalization","severe","USA","12-15 years","12-15 years",73,"43",88,NA,"omicron or delta","~33 weeks",NA,NA,"USA","USA",195,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-01,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta/omicron",NA,2022-03-01
"1623",195,"Klein","Test-negative case-control","01Mar2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14-149","hospitalization","severe","USA","16-17 years","16-17 years",94,"87",97,NA,"omicron or delta","~33 weeks",NA,NA,"USA","USA",195,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-01,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta/omicron",NA,2022-03-01
"1624",195,"Klein","Test-negative case-control","01Mar2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","150+","hospitalization","severe","USA","16-17 years","16-17 years",88,"72",95,NA,"omicron or delta","~33 weeks",NA,NA,"USA","USA",195,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-01,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta/omicron",NA,2022-03-01
"1625",196,"Wright","Case-control","25Feb2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","severe disease","severe","USA",">= 18 years","general pop",87.9,"86.7",89,NA,"alpha & delta","~40 weeks",NA,NA,"USA","USA",196,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-02-25,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-02-25
"1626",196,"Wright","Case-control","25Feb2022","mRNA-1273 (Moderna)","included","2","final","14+","severe disease","severe","USA",">= 18 years","general pop",92.9,"92",93.7,NA,"alpha & delta","~40 weeks",NA,NA,"USA","USA",196,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-02-25,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-02-25
"1627",196,"Wright","Case-control","25Feb2022","Ad26.COV2.S (Janssen)","included","1","final","14+","severe disease","severe","USA",">= 18 years","general pop",73,"68.8",76.6,NA,"alpha & delta","~40 weeks",NA,NA,"USA","USA",196,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-02-25,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-02-25
"1628",197,"Perry","Retrospective cohort","03Mar2022","BNT162b2 (Pfizer BioNTech)","included","1","1","14-20","infection","infection","UK",">= 50 years",">= 50 years",19,"9",28,NA,"alpha & delta",NA,NA,NA,"UK","GBR",197,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-03,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-03-03
"1629",197,"Perry","Retrospective cohort","03Mar2022","BNT162b2 (Pfizer BioNTech)","included","1","1",">27","infection","infection","UK",">= 50 years",">= 50 years",16,"8",24,NA,"alpha & delta",NA,NA,NA,"UK","GBR",197,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-03,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-03-03
"1630",197,"Perry","Retrospective cohort","03Mar2022","BNT162b2 (Pfizer BioNTech)","included","2","final",">6","infection","infection","UK",">= 50 years",">= 50 years",50,"44",55,NA,"alpha & delta","~26.5 weeks",NA,NA,"UK","GBR",197,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-03,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-03-03
"1631",197,"Perry","Retrospective cohort","03Mar2022","BNT162b2 (Pfizer BioNTech)","included","1","1","14-20","hospitalization","severe","UK",">= 50 years",">= 50 years",69,"43",83,NA,"alpha & delta",NA,NA,NA,"UK","GBR",197,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-03,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-03-03
"1632",197,"Perry","Retrospective cohort","03Mar2022","BNT162b2 (Pfizer BioNTech)","included","1","1",">27","hospitalization","severe","UK",">= 50 years",">= 50 years",75,"56",85,NA,"alpha & delta",NA,NA,NA,"UK","GBR",197,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-03,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-03-03
"1633",197,"Perry","Retrospective cohort","03Mar2022","BNT162b2 (Pfizer BioNTech)","included","2","final",">6","hospitalization","severe","UK",">= 50 years",">= 50 years",88,"81",93,NA,"alpha & delta","~26.5 weeks",NA,NA,"UK","GBR",197,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-03,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-03-03
"1634",197,"Perry","Retrospective cohort","03Mar2022","AZD1222 (AstraZeneca)","included","1","1","14-20","infection","infection","UK",">= 50 years",">= 50 years",7,"-5",19,NA,"alpha & delta",NA,NA,NA,"UK","GBR",197,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-03,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-03-03
"1635",197,"Perry","Retrospective cohort","03Mar2022","AZD1222 (AstraZeneca)","included","1","1",">27","infection","infection","UK",">= 50 years",">= 50 years",17,"9",25,NA,"alpha & delta",NA,NA,NA,"UK","GBR",197,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-03,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-03-03
"1636",197,"Perry","Retrospective cohort","03Mar2022","AZD1222 (AstraZeneca)","included","2","final",">6","infection","infection","UK",">= 50 years",">= 50 years",25,"15",33,NA,"alpha & delta","~18 weeks",NA,NA,"UK","GBR",197,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-03,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-03-03
"1637",197,"Perry","Retrospective cohort","03Mar2022","AZD1222 (AstraZeneca)","included","1","1","14-20","hospitalization","severe","UK",">= 50 years",">= 50 years",48,"26",64,NA,"alpha & delta",NA,NA,NA,"UK","GBR",197,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-03,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-03-03
"1638",197,"Perry","Retrospective cohort","03Mar2022","AZD1222 (AstraZeneca)","included","1","1",">27","hospitalization","severe","UK",">= 50 years",">= 50 years",72,"62",80,NA,"alpha & delta",NA,NA,NA,"UK","GBR",197,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-03,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-03-03
"1639",197,"Perry","Retrospective cohort","03Mar2022","AZD1222 (AstraZeneca)","included","2","final",">6","hospitalization","severe","UK",">= 50 years",">= 50 years",81,"71",88,NA,"alpha & delta","~18 weeks",NA,NA,"UK","GBR",197,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-03,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-03-03
"1640",198,"Oliver","Retrospective cohort","09Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","1","1","14+","infection","infection","Canada","hemodialysis patients","hemodialysis patients",41,"24",54,NA,"alpha",NA,NA,NA,"Canada","CAN",198,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-09,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","alpha",NA,2022-03-09
"1641",198,"Oliver","Retrospective cohort","09Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","7+","infection","infection","Canada","hemodialysis patients","hemodialysis patients",69,"58",78,NA,"alpha","~22 weeks",NA,NA,"Canada","CAN",198,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-09,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","alpha",NA,2022-03-09
"1642",198,"Oliver","Retrospective cohort","09Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","1","1","14+","severe disease","severe","Canada","hemodialysis patients","hemodialysis patients",46,"23",63,NA,"alpha",NA,NA,NA,"Canada","CAN",198,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-09,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","alpha",NA,2022-03-09
"1643",198,"Oliver","Retrospective cohort","09Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","7+","severe disease","severe","Canada","hemodialysis patients","hemodialysis patients",83,"70",90,NA,"alpha","~22 weeks",NA,NA,"Canada","CAN",198,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-09,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","alpha",NA,2022-03-09
"1644",198,"Oliver","Retrospective cohort","09Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","1","1","14+","hospitalization","severe","Canada","hemodialysis patients","hemodialysis patients",40,"13",58,NA,"alpha",NA,NA,NA,"Canada","CAN",198,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-09,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","alpha",NA,2022-03-09
"1645",198,"Oliver","Retrospective cohort","09Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","7+","hospitalization","severe","Canada","hemodialysis patients","hemodialysis patients",82,"69",90,NA,"alpha","~22 weeks",NA,NA,"Canada","CAN",198,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-09,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","alpha",NA,2022-03-09
"1646",198,"Oliver","Retrospective cohort","09Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","1","1","14+","death","death","Canada","hemodialysis patients","hemodialysis patients",71,"40",86,NA,"alpha",NA,NA,NA,"Canada","CAN",198,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-09,"death","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","alpha",NA,2022-03-09
"1647",198,"Oliver","Retrospective cohort","09Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","7+","death","death","Canada","hemodialysis patients","hemodialysis patients",85,"59",95,NA,"alpha","~22 weeks",NA,NA,"Canada","CAN",198,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-09,"death","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","alpha",NA,2022-03-09
"1648",199,"Oliveira","Matched case-control","03Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14+","infection","infection","USA","12-18 years","12-18 years",74,"18",92,NA,"delta",NA,NA,NA,"USA","USA",199,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-03,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-03-03
"1649",199,"Oliveira","Matched case-control","03Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","1-4 weeks","infection","infection","USA","12-18 years","12-18 years",91,"33",99,NA,"delta","~11 weeks",NA,NA,"USA","USA",199,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-03,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-03-03
"1650",199,"Oliveira","Matched case-control","03Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","13-17 weeks","infection","infection","USA","12-18 years","12-18 years",83,"34",95,NA,"delta","~11 weeks",NA,NA,"USA","USA",199,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-03,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-03-03
"1651",199,"Oliveira","Matched case-control","03Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease","symptomatic","USA","12-18 years","12-18 years",93,"81",97,NA,"delta","~11 weeks",NA,NA,"USA","USA",199,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-03,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-03-03
"1652",199,"Oliveira","Matched case-control","03Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","asymptomatic infection","asymptomatic","USA","12-18 years","12-18 years",85,"57",95,NA,"delta","~11 weeks",NA,NA,"USA","USA",199,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-03,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-03-03
"1653",200,"Ashmawy","Ambispective cohort","24Apr2023","BBIBP-CorV (Beijing CNBG)","included","2","final","14+","symptomatic disease","symptomatic","Egypt","HCW","HCW",67,"43",80,NA,"delta","~29 weeks",NA,NA,"Egypt","EGY",200,"EGY",11230,2019,"Egypt, Arab Rep.","Middle East & North Africa","Lower middle income",2,"Africa",2021-03-27,NA,NA,2021-01-24,2021-01-24,62,47,NA,NA,"who",47,"jan/2021","30-59","not reached","not reached","yes","no","no",2023-04-24,"symptomatic","2023 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta","11/03/2022",2022-03-11
"1654",200,"Ashmawy","Ambispective cohort","24Apr2023","BBIBP-CorV (Beijing CNBG)","included","2","final","14+","infection","infection","Egypt","HCW","HCW",46,"24",62,NA,"delta","~29 weeks",NA,NA,"Egypt","EGY",200,"EGY",11230,2019,"Egypt, Arab Rep.","Middle East & North Africa","Lower middle income",2,"Africa",2021-03-27,NA,NA,2021-01-24,2021-01-24,62,47,NA,NA,"who",47,"jan/2021","30-59","not reached","not reached","yes","no","no",2023-04-24,"infection","2023 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta","11/03/2022",2022-03-11
"1655",200,"Ashmawy","Ambispective cohort","24Apr2023","BBIBP-CorV (Beijing CNBG)","included","2","final","14+","hospitalization","severe","Egypt","HCW","HCW",65,"-8",88,NA,"delta","~29 weeks",NA,NA,"Egypt","EGY",200,"EGY",11230,2019,"Egypt, Arab Rep.","Middle East & North Africa","Lower middle income",2,"Africa",2021-03-27,NA,NA,2021-01-24,2021-01-24,62,47,NA,NA,"who",47,"jan/2021","30-59","not reached","not reached","yes","no","no",2023-04-24,"severe","2023 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta","11/03/2022",2022-03-11
"1656",201,"Fowlkes","Prospective cohort","11Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-82","infection","infection","USA","5-11 years","5-11 years",31,"9",48,"omicron","omicron","~29 weeks",NA,NA,"USA","USA",201,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-11,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-03-11
"1657",201,"Fowlkes","Prospective cohort","11Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","USA","12-15 years","12-15 years",59,"24",78,"omicron","omicron","~29 weeks",NA,NA,"USA","USA",201,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-11,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-03-11
"1658",201,"Fowlkes","Prospective cohort","11Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-149","infection","infection","USA","12-15 years","12-15 years",59,"22",79,"omicron","omicron",NA,NA,NA,"USA","USA",201,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-11,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-03-11
"1659",201,"Fowlkes","Prospective cohort","11Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","150+","infection","infection","USA","12-15 years","12-15 years",62,"-28",29,"omicron","omicron","~29 weeks",NA,NA,"USA","USA",201,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-11,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-03-11
"1660",201,"Fowlkes","Prospective cohort","11Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","USA","12-15 years","12-15 years",81,"51",93,"delta","delta","~29 weeks",NA,NA,"USA","USA",201,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-11,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-03-11
"1661",201,"Fowlkes","Prospective cohort","11Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-149","infection","infection","USA","12-15 years","12-15 years",87,"49",97,"delta","delta",NA,NA,NA,"USA","USA",201,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-11,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-03-11
"1662",201,"Fowlkes","Prospective cohort","11Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","150+","infection","infection","USA","12-15 years","12-15 years",60,"-35",88,"delta","delta","~29 weeks",NA,NA,"USA","USA",201,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-11,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-03-11
"1663",202,"Shrotri","Prospective cohort","12Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","28+","infection","infection","UK","LTCF residents","LTCF residents",31.7,"-14.2",59.1,NA,"alpha & delta",NA,NA,NA,"UK","GBR",202,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-03-12
"1664",202,"Shrotri","Prospective cohort","12Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-83","Infection","infection","UK","LTCF residents","LTCF residents",25.5,"-57.5",64.7,NA,"alpha & delta","45 weeks",NA,NA,"UK","GBR",202,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-03-12
"1665",202,"Shrotri","Prospective cohort","12Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","84+","Infection","infection","UK","LTCF residents","LTCF residents",26.3,"-21.7",55.4,NA,"alpha & delta","45 weeks",NA,NA,"UK","GBR",202,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-03-12
"1666",202,"Shrotri","Prospective cohort","12Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","28+","hospitalization","severe","UK","LTCF residents","LTCF residents",40.8,"-16",69.7,NA,"alpha & delta",NA,NA,NA,"UK","GBR",202,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-03-12
"1667",202,"Shrotri","Prospective cohort","12Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-83","hospitalization","severe","UK","LTCF residents","LTCF residents",88.8,"16.8",98.5,NA,"alpha & delta","45 weeks",NA,NA,"UK","GBR",202,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-03-12
"1668",202,"Shrotri","Prospective cohort","12Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","84+","hospitalization","severe","UK","LTCF residents","LTCF residents",65.1,"33.6",81.6,NA,"alpha & delta","45 weeks",NA,NA,"UK","GBR",202,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-03-12
"1669",202,"Shrotri","Prospective cohort","12Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","28+","death","death","UK","LTCF residents","LTCF residents",58.6,"25.3",77,NA,"alpha & delta",NA,NA,NA,"UK","GBR",202,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"death","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-03-12
"1670",202,"Shrotri","Prospective cohort","12Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-83","death","death","UK","LTCF residents","LTCF residents",100,NA,NA,NA,"alpha & delta","45 weeks",NA,NA,"UK","GBR",202,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"death","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-03-12
"1671",202,"Shrotri","Prospective cohort","12Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","84+","death","death","UK","LTCF residents","LTCF residents",66.1,"26",84.4,NA,"alpha & delta","45 weeks",NA,NA,"UK","GBR",202,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"death","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-03-12
"1672",202,"Shrotri","Prospective cohort","12Mar2022","AZD1222 (AstraZeneca)","excluded","1","1","28+","Infection","infection","UK","LTCF residents","LTCF residents",41.3,"8.8",62.2,NA,"alpha & delta",NA,NA,NA,"UK","GBR",202,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-03-12
"1673",202,"Shrotri","Prospective cohort","12Mar2022","AZD1222 (AstraZeneca)","excluded","2","final","14-83","Infection","infection","UK","LTCF residents","LTCF residents",62.1,"12.1",83.6,NA,"alpha & delta","45 weeks",NA,NA,"UK","GBR",202,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-03-12
"1674",202,"Shrotri","Prospective cohort","12Mar2022","AZD1222 (AstraZeneca)","excluded","2","final","84+","Infection","infection","UK","LTCF residents","LTCF residents",13.6,"-33.2",43.9,NA,"alpha & delta","45 weeks",NA,NA,"UK","GBR",202,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-03-12
"1675",202,"Shrotri","Prospective cohort","12Mar2022","AZD1222 (AstraZeneca)","excluded","1","1","28+","hospitalization","severe","UK","LTCF residents","LTCF residents",44.9,"7.9",67.1,NA,"alpha & delta",NA,NA,NA,"UK","GBR",202,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-03-12
"1676",202,"Shrotri","Prospective cohort","12Mar2022","AZD1222 (AstraZeneca)","excluded","2","final","14-83","hospitalization","severe","UK","LTCF residents","LTCF residents",82.7,"46.4",94.4,NA,"alpha & delta","45 weeks",NA,NA,"UK","GBR",202,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-03-12
"1677",202,"Shrotri","Prospective cohort","12Mar2022","AZD1222 (AstraZeneca)","excluded","2","final","84+","hospitalization","severe","UK","LTCF residents","LTCF residents",48.7,"12.5",70,NA,"alpha & delta","45 weeks",NA,NA,"UK","GBR",202,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-03-12
"1678",202,"Shrotri","Prospective cohort","12Mar2022","AZD1222 (AstraZeneca)","excluded","1","1","28+","death","death","UK","LTCF residents","LTCF residents",52.7,"16.4",73.2,NA,"alpha & delta",NA,NA,NA,"UK","GBR",202,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"death","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-03-12
"1679",202,"Shrotri","Prospective cohort","12Mar2022","AZD1222 (AstraZeneca)","excluded","2","final","14-83","death","death","UK","LTCF residents","LTCF residents",91.7,"65.1",98,NA,"alpha & delta","45 weeks",NA,NA,"UK","GBR",202,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"death","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-03-12
"1680",202,"Shrotri","Prospective cohort","12Mar2022","AZD1222 (AstraZeneca)","excluded","2","final","84+","death","death","UK","LTCF residents","LTCF residents",61.1,"26.2",79.5,NA,"alpha & delta","45 weeks",NA,NA,"UK","GBR",202,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"death","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-03-12
"1681",202,"Shrotri","Prospective cohort","12Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","28+","Infection","infection","UK","LTCF staff","LTCF staff",27,"4.4",44.3,NA,"alpha & delta",NA,NA,NA,"UK","GBR",202,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-03-12
"1682",202,"Shrotri","Prospective cohort","12Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-83","infection","infection","UK","LTCF staff","LTCF staff",60.7,"44.2",72.4,NA,"alpha & delta","45 weeks",NA,NA,"UK","GBR",202,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-03-12
"1683",202,"Shrotri","Prospective cohort","12Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","84+","Infection","infection","UK","LTCF staff","LTCF staff",45.1,"31.3",56.2,NA,"alpha & delta","45 weeks",NA,NA,"UK","GBR",202,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-03-12
"1684",202,"Shrotri","Prospective cohort","12Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","28+","hospitalization","severe","UK","LTCF staff","LTCF staff",100,NA,NA,NA,"alpha & delta",NA,NA,NA,"UK","GBR",202,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-03-12
"1685",202,"Shrotri","Prospective cohort","12Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-83","hospitalization","severe","UK","LTCF staff","LTCF staff",100,NA,NA,NA,"alpha & delta","45 weeks",NA,NA,"UK","GBR",202,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-03-12
"1686",202,"Shrotri","Prospective cohort","12Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","84+","hospitalization","severe","UK","LTCF staff","LTCF staff",92.1,"69.3",97.9,NA,"alpha & delta","45 weeks",NA,NA,"UK","GBR",202,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-03-12
"1687",202,"Shrotri","Prospective cohort","12Mar2022","AZD1222 (AstraZeneca)","excluded","1","1","28+","Infection","infection","UK","LTCF staff","LTCF staff",19.6,"-10.7",41.6,NA,"alpha & delta",NA,NA,NA,"UK","GBR",202,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-03-12
"1688",202,"Shrotri","Prospective cohort","12Mar2022","AZD1222 (AstraZeneca)","excluded","2","final","14-83","Infection","infection","UK","LTCF staff","LTCF staff",29,"-10.3",54.3,NA,"alpha & delta","45 weeks",NA,NA,"UK","GBR",202,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-03-12
"1689",202,"Shrotri","Prospective cohort","12Mar2022","AZD1222 (AstraZeneca)","excluded","2","final","84+","Infection","infection","UK","LTCF staff","LTCF staff",36.9,"20.6",49.9,NA,"alpha & delta","45 weeks",NA,NA,"UK","GBR",202,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-03-12
"1690",202,"Shrotri","Prospective cohort","12Mar2022","AZD1222 (AstraZeneca)","excluded","1","1","28+","hospitalization","severe","UK","LTCF staff","LTCF staff",19.6,"-121.6",70.8,NA,"alpha & delta",NA,NA,NA,"UK","GBR",202,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-03-12
"1691",202,"Shrotri","Prospective cohort","12Mar2022","AZD1222 (AstraZeneca)","excluded","2","final","14-83","hospitalization","severe","UK","LTCF staff","LTCF staff",100,NA,NA,NA,"alpha & delta","45 weeks",NA,NA,"UK","GBR",202,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-03-12
"1692",202,"Shrotri","Prospective cohort","12Mar2022","AZD1222 (AstraZeneca)","excluded","2","final","84+","hospitalization","severe","UK","LTCF staff","LTCF staff",89.6,"64.4",96.9,NA,"alpha & delta","45 weeks",NA,NA,"UK","GBR",202,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-03-12
"1693",203,"Baum","Retrospective cohort","05Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","21-83","hospitalization","severe","Finland",">= 70 years",">= 70 years",61,"49",71,NA,"non-VOC, alpha, delta, & omicron",NA,NA,NA,"Finland","FIN",203,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","06/07/2022",2022-07-06
"1694",203,"Baum","Retrospective cohort","05Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","84+","hospitalization","severe","Finland",">= 70 years",">= 70 years",64,"49",75,NA,"non-VOC, alpha, delta, & omicron",NA,NA,NA,"Finland","FIN",203,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","06/07/2022",2022-07-06
"1695",203,"Baum","Retrospective cohort","05Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-90","hospitalization","severe","Finland",">= 70 years",">= 70 years",93,"89",95,NA,"non-VOC, alpha, delta, & omicron",NA,NA,NA,"Finland","FIN",203,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","06/07/2022",2022-07-06
"1696",203,"Baum","Retrospective cohort","05Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","181+","hospitalization","severe","Finland",">= 70 years",">= 70 years",69,"63",74,NA,"non-VOC, alpha, delta, & omicron","~56 weeks",NA,NA,"Finland","FIN",203,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","06/07/2022",2022-07-06
"1697",203,"Baum","Retrospective cohort","05Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","21-83","ICU admission","severe","Finland",">= 70 years",">= 70 years",84,"63",93,NA,"non-VOC, alpha, delta, & omicron",NA,NA,NA,"Finland","FIN",203,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","06/07/2022",2022-07-06
"1698",203,"Baum","Retrospective cohort","05Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","84+","ICU admission","severe","Finland",">= 70 years",">= 70 years",69,"15",89,NA,"non-VOC, alpha, delta, & omicron",NA,NA,NA,"Finland","FIN",203,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","06/07/2022",2022-07-06
"1699",203,"Baum","Retrospective cohort","05Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-90","ICU admission","severe","Finland",">= 70 years",">= 70 years",98,"92",99,NA,"non-VOC, alpha, delta, & omicron",NA,NA,NA,"Finland","FIN",203,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","06/07/2022",2022-07-06
"1700",203,"Baum","Retrospective cohort","05Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","181+","ICU admission","severe","Finland",">= 70 years",">= 70 years",79,"65",87,NA,"non-VOC, alpha, delta, & omicron","~56 weeks",NA,NA,"Finland","FIN",203,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","06/07/2022",2022-07-06
"1701",203,"Baum","Retrospective cohort","05Nov2022","mRNA-1273 (Moderna)","excluded","1","1","21-83","hospitalization","severe","Finland",">= 70 years",">= 70 years",70,"43",84,NA,"non-VOC, alpha, delta, & omicron",NA,NA,NA,"Finland","FIN",203,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","06/07/2022",2022-07-06
"1702",203,"Baum","Retrospective cohort","05Nov2022","mRNA-1273 (Moderna)","excluded","1","1","84+","hospitalization","severe","Finland",">= 70 years",">= 70 years",63,"26",82,NA,"non-VOC, alpha, delta, & omicron",NA,NA,NA,"Finland","FIN",203,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","06/07/2022",2022-07-06
"1703",203,"Baum","Retrospective cohort","05Nov2022","mRNA-1273 (Moderna)","excluded","2","final","14-90","hospitalization","severe","Finland",">= 70 years",">= 70 years",93,"82",97,NA,"non-VOC, alpha, delta, & omicron","~56 weeks",NA,NA,"Finland","FIN",203,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","06/07/2022",2022-07-06
"1704",203,"Baum","Retrospective cohort","05Nov2022","mRNA-1273 (Moderna)","excluded","2","final","181+","hospitalization","severe","Finland",">= 70 years",">= 70 years",73,"59",83,NA,"non-VOC, alpha, delta, & omicron","~56 weeks",NA,NA,"Finland","FIN",203,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","06/07/2022",2022-07-06
"1705",203,"Baum","Retrospective cohort","05Nov2022","mRNA-1273 (Moderna)","excluded","1","1","21-83","ICU admission","severe","Finland",">= 70 years",">= 70 years",70,"-29",93,NA,"non-VOC, alpha, delta, & omicron",NA,NA,NA,"Finland","FIN",203,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","06/07/2022",2022-07-06
"1706",203,"Baum","Retrospective cohort","05Nov2022","mRNA-1273 (Moderna)","excluded","1","1","84+","ICU admission","severe","Finland",">= 70 years",">= 70 years",100,NA,NA,NA,"non-VOC, alpha, delta, & omicron",NA,NA,NA,"Finland","FIN",203,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","06/07/2022",2022-07-06
"1707",203,"Baum","Retrospective cohort","05Nov2022","mRNA-1273 (Moderna)","excluded","2","final","14-90","ICU admission","severe","Finland",">= 70 years",">= 70 years",100,NA,NA,NA,"non-VOC, alpha, delta, & omicron","~56 weeks",NA,NA,"Finland","FIN",203,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","06/07/2022",2022-07-06
"1708",203,"Baum","Retrospective cohort","05Nov2022","mRNA-1273 (Moderna)","excluded","2","final","181+","ICU admission","severe","Finland",">= 70 years",">= 70 years",93,"46",99,NA,"non-VOC, alpha, delta, & omicron","~56 weeks",NA,NA,"Finland","FIN",203,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","06/07/2022",2022-07-06
"1709",203,"Baum","Retrospective cohort","05Nov2022","AZD1222 (AstraZeneca)","excluded","1","1","21-83","hospitalization","severe","Finland",">= 70 years",">= 70 years",68,"-3",90,NA,"non-VOC, alpha, delta, & omicron",NA,NA,NA,"Finland","FIN",203,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","06/07/2022",2022-07-06
"1710",203,"Baum","Retrospective cohort","05Nov2022","AZD1222 (AstraZeneca)","excluded","1","1","84+","hospitalization","severe","Finland",">= 70 years",">= 70 years",37,"-95",80,NA,"non-VOC, alpha, delta, & omicron",NA,NA,NA,"Finland","FIN",203,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","06/07/2022",2022-07-06
"1711",203,"Baum","Retrospective cohort","05Nov2022","AZD1222 (AstraZeneca)","excluded","2","final","14-90","hospitalization","severe","Finland",">= 70 years",">= 70 years",81,"49",93,NA,"non-VOC, alpha, delta, & omicron","~56 weeks",NA,NA,"Finland","FIN",203,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","06/07/2022",2022-07-06
"1712",203,"Baum","Retrospective cohort","05Nov2022","AZD1222 (AstraZeneca)","excluded","2","final","181+","hospitalization","severe","Finland",">= 70 years",">= 70 years",48,"17",68,NA,"non-VOC, alpha, delta, & omicron","~56 weeks",NA,NA,"Finland","FIN",203,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","06/07/2022",2022-07-06
"1713",203,"Baum","Retrospective cohort","05Nov2022","AZD1222 (AstraZeneca)","excluded","1","1","21-83","ICU admission","severe","Finland",">= 70 years",">= 70 years",68,"-151",96,NA,"non-VOC, alpha, delta, & omicron",NA,NA,NA,"Finland","FIN",203,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","06/07/2022",2022-07-06
"1714",203,"Baum","Retrospective cohort","05Nov2022","AZD1222 (AstraZeneca)","excluded","1","1","84+","ICU admission","severe","Finland",">= 70 years",">= 70 years",100,NA,NA,NA,"non-VOC, alpha, delta, & omicron",NA,NA,NA,"Finland","FIN",203,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","06/07/2022",2022-07-06
"1715",203,"Baum","Retrospective cohort","05Nov2022","AZD1222 (AstraZeneca)","excluded","2","final","14-90","ICU admission","severe","Finland",">= 70 years",">= 70 years",78,"2",95,NA,"non-VOC, alpha, delta, & omicron","~56 weeks",NA,NA,"Finland","FIN",203,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","06/07/2022",2022-07-06
"1716",203,"Baum","Retrospective cohort","05Nov2022","AZD1222 (AstraZeneca)","excluded","2","final","181+","ICU admission","severe","Finland",">= 70 years",">= 70 years",64,"-14",89,NA,"non-VOC, alpha, delta, & omicron","~56 weeks",NA,NA,"Finland","FIN",203,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","06/07/2022",2022-07-06
"1717",203,"Baum","Retrospective cohort","05Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","21-83","hospitalization","severe","Finland",">= 70 years",">= 70 years",53,"-16",81,NA,"delta",NA,NA,NA,"Finland","FIN",203,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","06/07/2022",2022-07-06
"1718",203,"Baum","Retrospective cohort","05Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","84+","hospitalization","severe","Finland",">= 70 years",">= 70 years",68,"45",81,NA,"delta",NA,NA,NA,"Finland","FIN",203,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","06/07/2022",2022-07-06
"1719",203,"Baum","Retrospective cohort","05Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-90","hospitalization","severe","Finland",">= 70 years",">= 70 years",90,"78",96,NA,"delta","~48.5 weeks",NA,NA,"Finland","FIN",203,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","06/07/2022",2022-07-06
"1720",203,"Baum","Retrospective cohort","05Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","181+","hospitalization","severe","Finland",">= 70 years",">= 70 years",79,"71",84,NA,"delta","~48.5 weeks",NA,NA,"Finland","FIN",203,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","06/07/2022",2022-07-06
"1721",203,"Baum","Retrospective cohort","05Nov2022","mRNA-1273 (Moderna)","excluded","1","1","21-83","hospitalization","severe","Finland",">= 70 years",">= 70 years",60,"-189",94,NA,"delta",NA,NA,NA,"Finland","FIN",203,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","06/07/2022",2022-07-06
"1722",203,"Baum","Retrospective cohort","05Nov2022","mRNA-1273 (Moderna)","excluded","1","1","84+","hospitalization","severe","Finland",">= 70 years",">= 70 years",91,"35",99,NA,"delta",NA,NA,NA,"Finland","FIN",203,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","06/07/2022",2022-07-06
"1723",203,"Baum","Retrospective cohort","05Nov2022","mRNA-1273 (Moderna)","excluded","2","final","14-90","hospitalization","severe","Finland",">= 70 years",">= 70 years",92,"42",99,NA,"delta","~48.5 weeks",NA,NA,"Finland","FIN",203,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","06/07/2022",2022-07-06
"1724",203,"Baum","Retrospective cohort","05Nov2022","mRNA-1273 (Moderna)","excluded","2","final","181+","hospitalization","severe","Finland",">= 70 years",">= 70 years",87,"70",94,NA,"delta","~48.5 weeks",NA,NA,"Finland","FIN",203,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","06/07/2022",2022-07-06
"1725",203,"Baum","Retrospective cohort","05Nov2022","AZD1222 (AstraZeneca)","excluded","1","1","84+","hospitalization","severe","Finland",">= 70 years",">= 70 years",62,"-171",95,NA,"delta",NA,NA,NA,"Finland","FIN",203,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","06/07/2022",2022-07-06
"1726",203,"Baum","Retrospective cohort","05Nov2022","AZD1222 (AstraZeneca)","excluded","2","final","91-180","hospitalization","severe","Finland",">= 70 years",">= 70 years",79,"67",87,NA,"delta","~48.5 weeks",NA,NA,"Finland","FIN",203,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","06/07/2022",2022-07-06
"1727",203,"Baum","Retrospective cohort","05Nov2022","AZD1222 (AstraZeneca)","excluded","2","final","181+","hospitalization","severe","Finland",">= 70 years",">= 70 years",23,"-76",67,NA,"delta","~48.5 weeks",NA,NA,"Finland","FIN",203,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","06/07/2022",2022-07-06
"1728",203,"Baum","Retrospective cohort","05Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","21-83","hospitalization","severe","Finland",">= 70 years",">= 70 years",22,"-38",56,NA,"omicron",NA,NA,NA,"Finland","FIN",203,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","06/07/2022",2022-07-06
"1729",203,"Baum","Retrospective cohort","05Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","84+","hospitalization","severe","Finland",">= 70 years",">= 70 years",61,"34",77,NA,"omicron",NA,NA,NA,"Finland","FIN",203,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","06/07/2022",2022-07-06
"1730",203,"Baum","Retrospective cohort","05Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-90","hospitalization","severe","Finland",">= 70 years",">= 70 years",91,"83",95,NA,"omicron","~56 weeks",NA,NA,"Finland","FIN",203,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","06/07/2022",2022-07-06
"1731",203,"Baum","Retrospective cohort","05Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","181+","hospitalization","severe","Finland",">= 70 years",">= 70 years",58,"48",66,NA,"omicron","~56 weeks",NA,NA,"Finland","FIN",203,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","06/07/2022",2022-07-06
"1732",203,"Baum","Retrospective cohort","05Nov2022","mRNA-1273 (Moderna)","excluded","1","1","21-83","hospitalization","severe","Finland",">= 70 years",">= 70 years",81,"-33",97,NA,"omicron",NA,NA,NA,"Finland","FIN",203,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron","06/07/2022",2022-07-06
"1733",203,"Baum","Retrospective cohort","05Nov2022","mRNA-1273 (Moderna)","excluded","1","1","84+","hospitalization","severe","Finland",">= 70 years",">= 70 years",23,"-63",64,NA,"omicron",NA,NA,NA,"Finland","FIN",203,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron","06/07/2022",2022-07-06
"1734",203,"Baum","Retrospective cohort","05Nov2022","mRNA-1273 (Moderna)","excluded","2","final","14-90","hospitalization","severe","Finland",">= 70 years",">= 70 years",79,"43",92,NA,"omicron","~56 weeks",NA,NA,"Finland","FIN",203,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron","06/07/2022",2022-07-06
"1735",203,"Baum","Retrospective cohort","05Nov2022","mRNA-1273 (Moderna)","excluded","2","final","181+","hospitalization","severe","Finland",">= 70 years",">= 70 years",60,"34",75,NA,"omicron","~56 weeks",NA,NA,"Finland","FIN",203,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron","06/07/2022",2022-07-06
"1736",203,"Baum","Retrospective cohort","05Nov2022","AZD1222 (AstraZeneca)","excluded","1","1","84+","hospitalization","severe","Finland",">= 70 years",">= 70 years",100,NA,NA,NA,"omicron",NA,NA,NA,"Finland","FIN",203,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","06/07/2022",2022-07-06
"1737",203,"Baum","Retrospective cohort","05Nov2022","AZD1222 (AstraZeneca)","excluded","2","final","91-180","hospitalization","severe","Finland",">= 70 years",">= 70 years",37,"-154",85,NA,"omicron",NA,NA,NA,"Finland","FIN",203,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","06/07/2022",2022-07-06
"1738",203,"Baum","Retrospective cohort","05Nov2022","AZD1222 (AstraZeneca)","excluded","2","final","181+","hospitalization","severe","Finland",">= 70 years",">= 70 years",51,"12",73,NA,"omicron","~56 weeks",NA,NA,"Finland","FIN",203,"FIN",52070,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,15,235,312,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","06/07/2022",2022-07-06
"1739",204,"Jara","Retrospective cohort","23May2022","CoronaVac (Sinovac)","excluded","2","final","14+","infection","infection","Chile","3-5 years","3-5 years",37.9,"36.1",39.6,"omicron","omicron","~12 weeks",NA,NA,"Chile","CHL",204,"CHL",24650,2019,"Chile","Latin America & Caribbean","High income",3,"South America",2020-12-25,2021-05-25,2021-09-02,2020-12-21,2020-12-21,4,13,155,255,"who",13,"before jan/2021","<30","before Jun/2021","<180","yes","yes","yes",2022-05-23,"infection","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","omicron","15/03/2022",2022-03-15
"1740",204,"Jara","Retrospective cohort","23May2022","CoronaVac (Sinovac)","excluded","2","final","14+","hospitalization","severe","Chile","3-5 years","3-5 years",65.2,"50.4",75.6,"omicron","omicron","~12 weeks",NA,NA,"Chile","CHL",204,"CHL",24650,2019,"Chile","Latin America & Caribbean","High income",3,"South America",2020-12-25,2021-05-25,2021-09-02,2020-12-21,2020-12-21,4,13,155,255,"who",13,"before jan/2021","<30","before Jun/2021","<180","yes","yes","yes",2022-05-23,"severe","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","omicron","15/03/2022",2022-03-15
"1741",204,"Jara","Retrospective cohort","23May2022","CoronaVac (Sinovac)","excluded","2","final","14+","ICU admission","severe","Chile","3-5 years","3-5 years",68.8,"18",88.1,"omicron","omicron","~12 weeks",NA,NA,"Chile","CHL",204,"CHL",24650,2019,"Chile","Latin America & Caribbean","High income",3,"South America",2020-12-25,2021-05-25,2021-09-02,2020-12-21,2020-12-21,4,13,155,255,"who",13,"before jan/2021","<30","before Jun/2021","<180","yes","yes","yes",2022-05-23,"severe","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","omicron","15/03/2022",2022-03-15
"1742",205,"Rearte","Test-negative case-control","15Mar2022","AZD1222 (AstraZeneca)","excluded","1","1","21+","infection","infection","Argentina",">= 18 years","general pop",39.9,"39",41,NA,"alpha, gamma, & delta",NA,NA,NA,"Argentina","ARG",205,"ARG",22100,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,21,263,381,"equal",21,"before jan/2021","<30","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-15,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-03-15
"1743",205,"Rearte","Test-negative case-control","15Mar2022","AZD1222 (AstraZeneca)","excluded","2","final","21+","infection","infection","Argentina",">= 18 years","general pop",68.5,"67",69,NA,"alpha, gamma, & delta","~26 weeks",NA,NA,"Argentina","ARG",205,"ARG",22100,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,21,263,381,"equal",21,"before jan/2021","<30","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-15,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-03-15
"1744",205,"Rearte","Test-negative case-control","15Mar2022","AZD1222 (AstraZeneca)","excluded","1","1","21+","death","death","Argentina",">= 18 years","general pop",83.1,"82.3",83.9,NA,"alpha, gamma, & delta",NA,NA,NA,"Argentina","ARG",205,"ARG",22100,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,21,263,381,"equal",21,"before jan/2021","<30","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-15,"death","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-03-15
"1745",205,"Rearte","Test-negative case-control","15Mar2022","AZD1222 (AstraZeneca)","excluded","2","final","21+","death","death","Argentina",">= 18 years","general pop",93.7,"93.2",94.3,NA,"alpha, gamma, & delta","~26 weeks",NA,NA,"Argentina","ARG",205,"ARG",22100,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,21,263,381,"equal",21,"before jan/2021","<30","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-15,"death","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-03-15
"1746",205,"Rearte","Test-negative case-control","15Mar2022","BBIBP-CorV (Beijing CNBG)","excluded","1","1","21+","infection","infection","Argentina",">= 18 years","general pop",22.6,"20",25,NA,"alpha, gamma, & delta",NA,NA,NA,"Argentina","ARG",205,"ARG",22100,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,21,263,381,"equal",21,"before jan/2021","<30","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-15,"infection","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","other combinations",NA,2022-03-15
"1747",205,"Rearte","Test-negative case-control","15Mar2022","BBIBP-CorV (Beijing CNBG)","excluded","2","final","21+","infection","infection","Argentina",">= 18 years","general pop",43.6,"42",45,NA,"alpha, gamma, & delta","~26 weeks",NA,NA,"Argentina","ARG",205,"ARG",22100,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,21,263,381,"equal",21,"before jan/2021","<30","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-15,"infection","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","other combinations",NA,2022-03-15
"1748",205,"Rearte","Test-negative case-control","15Mar2022","BBIBP-CorV (Beijing CNBG)","excluded","1","1","21+","death","death","Argentina",">= 18 years","general pop",70.4,"68.1",72.8,NA,"alpha, gamma, & delta",NA,NA,NA,"Argentina","ARG",205,"ARG",22100,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,21,263,381,"equal",21,"before jan/2021","<30","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-15,"death","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","other combinations",NA,2022-03-15
"1749",205,"Rearte","Test-negative case-control","15Mar2022","BBIBP-CorV (Beijing CNBG)","excluded","2","final","21+","death","death","Argentina",">= 18 years","general pop",85,"84",86,NA,"alpha, gamma, & delta","~26 weeks",NA,NA,"Argentina","ARG",205,"ARG",22100,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,21,263,381,"equal",21,"before jan/2021","<30","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-15,"death","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","other combinations",NA,2022-03-15
"1750",205,"Rearte","Test-negative case-control","15Mar2022","Gam-COVID-Vac (Gamaleya)","excluded","1","1","21+","infection","infection","Argentina",">= 18 years","general pop",39.5,"39",40,NA,"alpha, gamma, & delta",NA,NA,NA,"Argentina","ARG",205,"ARG",22100,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,21,263,381,"equal",21,"before jan/2021","<30","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-15,"infection","2022 (Jan-Jun)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","other combinations",NA,2022-03-15
"1751",205,"Rearte","Test-negative case-control","15Mar2022","Gam-COVID-Vac (Gamaleya)","excluded","2","final","21+","infection","infection","Argentina",">= 18 years","general pop",64,"63",65,NA,"alpha, gamma, & delta","~26 weeks",NA,NA,"Argentina","ARG",205,"ARG",22100,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,21,263,381,"equal",21,"before jan/2021","<30","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-15,"infection","2022 (Jan-Jun)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","other combinations",NA,2022-03-15
"1752",205,"Rearte","Test-negative case-control","15Mar2022","Gam-COVID-Vac (Gamaleya)","excluded","1","1","21+","death","death","Argentina",">= 18 years","general pop",81.1,"80.5",81.7,NA,"alpha, gamma, & delta",NA,NA,NA,"Argentina","ARG",205,"ARG",22100,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,21,263,381,"equal",21,"before jan/2021","<30","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-15,"death","2022 (Jan-Jun)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","other combinations",NA,2022-03-15
"1753",205,"Rearte","Test-negative case-control","15Mar2022","Gam-COVID-Vac (Gamaleya)","excluded","2","final","21+","death","death","Argentina",">= 18 years","general pop",93.1,"92.6",93.5,NA,"alpha, gamma, & delta","~26 weeks",NA,NA,"Argentina","ARG",205,"ARG",22100,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,21,263,381,"equal",21,"before jan/2021","<30","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-15,"death","2022 (Jan-Jun)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","other combinations",NA,2022-03-15
"1754",206,"Can","Retrospective cohort","19Mar2022","CoronaVac (Sinovac)","excluded","2","final","14+","infection","infection","Turkey","HCW","HCW",39,"20",54,NA,"alpha","13 weeks",NA,NA,"Turkey","TUR",206,"TUR",27240,2019,"Türkiye","Europe & Central Asia","Upper middle income",3,"Asia",2021-01-14,2021-08-19,NA,NA,2021-01-14,NA,37,217,NA,"owid",37,"jan/2021","30-59","Jun-Aug/2021","180-269","yes","yes","no",2022-03-19,"infection","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","alpha",NA,2022-03-19
"1755",207,"Altarawneh","Test-negative case-control","15Jun2022","BNT162b2 (Pfizer BioNTech)","previously infected only","2","final","14+","symptomatic disease","symptomatic","Qatar",">= 18 years","general pop",51.7,"43.5",58.7,"omicron BA.1","omicron BA.1","44 weeks",NA,NA,"Qatar","QAT",207,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2022-06-15,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","31/03/2022",2022-03-31
"1756",207,"Altarawneh","Test-negative case-control","15Jun2022","BNT162b2 (Pfizer BioNTech)","previously infected only","2","final","14+","hospitalization or death","severe","Qatar",">= 18 years","general pop",96.2,"37.7",99.8,"omicron BA.1","omicron BA.1","44 weeks",NA,NA,"Qatar","QAT",207,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2022-06-15,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","31/03/2022",2022-03-31
"1757",207,"Altarawneh","Test-negative case-control","15Jun2022","mRNA-1273 (Moderna)","previously infected only","2","final","14+","symptomatic disease","symptomatic","Qatar",">= 18 years","general pop",44.3,"30.4",55.4,"omicron BA.1","omicron BA.1","44 weeks",NA,NA,"Qatar","QAT",207,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2022-06-15,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","31/03/2022",2022-03-31
"1758",207,"Altarawneh","Test-negative case-control","15Jun2022","mRNA-1273 (Moderna)","previously infected only","2","final","14+","hospitalization or death","severe","Qatar",">= 18 years","general pop",100,"-51.5",100,"omicron BA.1","omicron BA.1","44 weeks",NA,NA,"Qatar","QAT",207,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2022-06-15,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","31/03/2022",2022-03-31
"1759",207,"Altarawneh","Test-negative case-control","15Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease","symptomatic","Qatar",">= 18 years","general pop",-4.9,"-16.4",5.4,"omicron BA.1","omicron BA.1","44 weeks",NA,NA,"Qatar","QAT",207,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2022-06-15,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","31/03/2022",2022-03-31
"1760",207,"Altarawneh","Test-negative case-control","15Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization or death","severe","Qatar",">= 18 years","general pop",96.8,"71.1",99.6,"omicron BA.1","omicron BA.1","44 weeks",NA,NA,"Qatar","QAT",207,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2022-06-15,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","31/03/2022",2022-03-31
"1761",207,"Altarawneh","Test-negative case-control","15Jun2022","mRNA-1273 (Moderna)","excluded","2","final","14+","symptomatic disease","symptomatic","Qatar",">= 18 years","general pop",-2.7,"-16.8",9.7,"omicron BA.1","omicron BA.1","44 weeks",NA,NA,"Qatar","QAT",207,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2022-06-15,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","31/03/2022",2022-03-31
"1762",207,"Altarawneh","Test-negative case-control","15Jun2022","mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization or death","severe","Qatar",">= 18 years","general pop",88.8,"-1.7",98.8,"omicron BA.1","omicron BA.1","44 weeks",NA,NA,"Qatar","QAT",207,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2022-06-15,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","31/03/2022",2022-03-31
"1763",207,"Altarawneh","Test-negative case-control","15Jun2022","BNT162b2 (Pfizer BioNTech)","previously infected only","2","final","14+","symptomatic disease","symptomatic","Qatar",">= 18 years","general pop",55.1,"50.9",58.9,"omicron BA.2","omicron BA.2","44 weeks",NA,NA,"Qatar","QAT",207,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2022-06-15,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","31/03/2022",2022-03-31
"1764",207,"Altarawneh","Test-negative case-control","15Jun2022","BNT162b2 (Pfizer BioNTech)","previously infected only","2","final","14+","hospitalization or death","severe","Qatar",">= 18 years","general pop",97.8,"82.6",99.7,"omicron BA.2","omicron BA.2","44 weeks",NA,NA,"Qatar","QAT",207,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2022-06-15,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","31/03/2022",2022-03-31
"1765",207,"Altarawneh","Test-negative case-control","15Jun2022","mRNA-1273 (Moderna)","previously infected only","2","final","14+","symptomatic disease","symptomatic","Qatar",">= 18 years","general pop",47.9,"40.8",54.1,"omicron BA.2","omicron BA.2","44 weeks",NA,NA,"Qatar","QAT",207,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2022-06-15,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","31/03/2022",2022-03-31
"1766",207,"Altarawneh","Test-negative case-control","15Jun2022","mRNA-1273 (Moderna)","previously infected only","2","final","14+","hospitalization or death","severe","Qatar",">= 18 years","general pop",100,"55.4",100,"omicron BA.2","omicron BA.2","44 weeks",NA,NA,"Qatar","QAT",207,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2022-06-15,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","31/03/2022",2022-03-31
"1767",207,"Altarawneh","Test-negative case-control","15Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease","symptomatic","Qatar",">= 18 years","general pop",-1.1,"-7.1",4.6,"omicron BA.2","omicron BA.2","44 weeks",NA,NA,"Qatar","QAT",207,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2022-06-15,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","31/03/2022",2022-03-31
"1768",207,"Altarawneh","Test-negative case-control","15Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization or death","severe","Qatar",">= 18 years","general pop",76.8,"58",87.1,"omicron BA.2","omicron BA.2","44 weeks",NA,NA,"Qatar","QAT",207,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2022-06-15,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","31/03/2022",2022-03-31
"1769",207,"Altarawneh","Test-negative case-control","15Jun2022","mRNA-1273 (Moderna)","excluded","2","final","14+","symptomatic disease","symptomatic","Qatar",">= 18 years","general pop",-7.3,"-15.6",0.3,"omicron BA.2","omicron BA.2","44 weeks",NA,NA,"Qatar","QAT",207,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2022-06-15,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","31/03/2022",2022-03-31
"1770",207,"Altarawneh","Test-negative case-control","15Jun2022","mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization or death","severe","Qatar",">= 18 years","general pop",84.8,"47.9",95.6,"omicron BA.2","omicron BA.2","44 weeks",NA,NA,"Qatar","QAT",207,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2022-06-15,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","31/03/2022",2022-03-31
"1771",207,"Altarawneh","Test-negative case-control","15Jun2022","BNT162b2 (Pfizer BioNTech)","previously infected only","2","final","14+","symptomatic disease","symptomatic","Qatar",">= 18 years","general pop",55.5,"51.8",59,"omicron","omicron","44 weeks",NA,NA,"Qatar","QAT",207,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2022-06-15,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","31/03/2022",2022-03-31
"1772",207,"Altarawneh","Test-negative case-control","15Jun2022","BNT162b2 (Pfizer BioNTech)","previously infected only","2","final","14+","hospitalization or death","severe","Qatar",">= 18 years","general pop",94.3,"81.3",98.3,"omicron","omicron","44 weeks",NA,NA,"Qatar","QAT",207,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2022-06-15,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","31/03/2022",2022-03-31
"1773",207,"Altarawneh","Test-negative case-control","15Jun2022","mRNA-1273 (Moderna)","previously infected only","2","final","14+","symptomatic disease","symptomatic","Qatar",">= 18 years","general pop",52,"45.8",57.4,"omicron","omicron","44 weeks",NA,NA,"Qatar","QAT",207,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2022-06-15,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","31/03/2022",2022-03-31
"1774",207,"Altarawneh","Test-negative case-control","15Jun2022","mRNA-1273 (Moderna)","previously infected only","2","final","14+","hospitalization or death","severe","Qatar",">= 18 years","general pop",100,NA,NA,"omicron","omicron","44 weeks",NA,NA,"Qatar","QAT",207,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2022-06-15,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","31/03/2022",2022-03-31
"1775",207,"Altarawneh","Test-negative case-control","15Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease","symptomatic","Qatar",">= 18 years","general pop",-0.2,"-5.5",4.9,"omicron","omicron","44 weeks",NA,NA,"Qatar","QAT",207,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2022-06-15,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","31/03/2022",2022-03-31
"1776",207,"Altarawneh","Test-negative case-control","15Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization or death","severe","Qatar",">= 18 years","general pop",73.5,"60.5",82.2,"omicron","omicron","44 weeks",NA,NA,"Qatar","QAT",207,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2022-06-15,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","31/03/2022",2022-03-31
"1777",207,"Altarawneh","Test-negative case-control","15Jun2022","mRNA-1273 (Moderna)","excluded","2","final","14+","symptomatic disease","symptomatic","Qatar",">= 18 years","general pop",2.2,"-4.6",8.5,"omicron","omicron","44 weeks",NA,NA,"Qatar","QAT",207,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2022-06-15,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","31/03/2022",2022-03-31
"1778",207,"Altarawneh","Test-negative case-control","15Jun2022","mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization or death","severe","Qatar",">= 18 years","general pop",66.3,"38.3",81.6,"omicron","omicron","44 weeks",NA,NA,"Qatar","QAT",207,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2022-06-15,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","31/03/2022",2022-03-31
"1779",208,"Kaura","Retrospective cohort","12Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14-84","Infection","infection","UK",">= 16 years","general pop",31,"14",45,NA,"alpha",NA,NA,NA,"UK","GBR",208,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2022-03-12
"1780",208,"Kaura","Retrospective cohort","12Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14-84","hospitalization","severe","UK",">= 16 years","general pop",75,"45",91,NA,"alpha",NA,NA,NA,"UK","GBR",208,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2022-03-12
"1781",208,"Kaura","Retrospective cohort","12Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14-84","death","death","UK",">= 16 years","general pop",86,"42",98,NA,"alpha",NA,NA,NA,"UK","GBR",208,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"death","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2022-03-12
"1782",208,"Kaura","Retrospective cohort","12Mar2022","AZD1222 (AstraZeneca)","excluded","1","1","14-84","Infection","infection","UK",">= 16 years","general pop",15,"-5",31,NA,"alpha",NA,NA,NA,"UK","GBR",208,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2022-03-12
"1783",208,"Kaura","Retrospective cohort","12Mar2022","AZD1222 (AstraZeneca)","excluded","1","1","14-84","hospitalization","severe","UK",">= 16 years","general pop",75,"45",91,NA,"alpha",NA,NA,NA,"UK","GBR",208,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2022-03-12
"1784",208,"Kaura","Retrospective cohort","12Mar2022","AZD1222 (AstraZeneca)","excluded","1","1","14-84","death","death","UK",">= 16 years","general pop",86,"42",98,NA,"alpha",NA,NA,NA,"UK","GBR",208,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"death","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2022-03-12
"1785",209,"Horne","Retrospective cohort","20Jul2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","21-42","infection","infection","UK","18-39 years","18-39 years",76,"75",77,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,"UK","GBR",209,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/03/2022",2022-03-23
"1786",209,"Horne","Retrospective cohort","20Jul2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","161-182","infection","infection","UK","18-39 years","18-39 years",-53,"-118",-7,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,"UK","GBR",209,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/03/2022",2022-03-23
"1787",209,"Horne","Retrospective cohort","20Jul2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","21-42","hospitalization","severe","UK","18-39 years","18-39 years",96,"94",98,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,"UK","GBR",209,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/03/2022",2022-03-23
"1788",209,"Horne","Retrospective cohort","20Jul2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","133-154","hospitalization","severe","UK","18-39 years","18-39 years",82,"71",90,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,"UK","GBR",209,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/03/2022",2022-03-23
"1789",209,"Horne","Retrospective cohort","20Jul2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","21-42","infection","infection","UK","40-64 years","40-64 years",73,"69",77,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,"UK","GBR",209,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/03/2022",2022-03-23
"1790",209,"Horne","Retrospective cohort","20Jul2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","161-182","infection","infection","UK","40-64 years","40-64 years",-3,"-15",7,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,"UK","GBR",209,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/03/2022",2022-03-23
"1791",209,"Horne","Retrospective cohort","20Jul2022","AZD1222 (AstraZeneca)","excluded","2","final","21-42","infection","infection","UK","40-64 years","40-64 years",21,"18",24,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,"UK","GBR",209,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"infection","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","23/03/2022",2022-03-23
"1792",209,"Horne","Retrospective cohort","20Jul2022","AZD1222 (AstraZeneca)","excluded","2","final","161-182","infection","infection","UK","40-64 years","40-64 years",-99,"-105",-94,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,"UK","GBR",209,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"infection","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","23/03/2022",2022-03-23
"1793",209,"Horne","Retrospective cohort","20Jul2022","AZD1222 (AstraZeneca)","excluded","2","final","21-42","hospitalization","severe","UK","40-64 years","40-64 years",95,"93",96,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,"UK","GBR",209,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","23/03/2022",2022-03-23
"1794",209,"Horne","Retrospective cohort","20Jul2022","AZD1222 (AstraZeneca)","excluded","2","final","161-182","hospitalization","severe","UK","40-64 years","40-64 years",86,"83",88,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,"UK","GBR",209,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","23/03/2022",2022-03-23
"1795",209,"Horne","Retrospective cohort","20Jul2022","AZD1222 (AstraZeneca)","excluded","2","final","105-126","death","death","UK","40-64 years","40-64 years",55,"-5",81,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,"UK","GBR",209,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"death","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","23/03/2022",2022-03-23
"1796",209,"Horne","Retrospective cohort","20Jul2022","AZD1222 (AstraZeneca)","excluded","2","final","161-182","death","death","UK","40-64 years","40-64 years",41,"-7",68,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,"UK","GBR",209,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"death","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","23/03/2022",2022-03-23
"1797",209,"Horne","Retrospective cohort","20Jul2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","21-42","infection","infection","UK","clinically vulnerable 16-64 years","clinically vulnerable 16-64 years",34,"30",39,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,"UK","GBR",209,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/03/2022",2022-03-23
"1798",209,"Horne","Retrospective cohort","20Jul2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","161-182","infection","infection","UK","clinically vulnerable 16-64 years","clinically vulnerable 16-64 years",4,"-1",8,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,"UK","GBR",209,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/03/2022",2022-03-23
"1799",209,"Horne","Retrospective cohort","20Jul2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","49-70","hospitalization","severe","UK","clinically vulnerable 16-64 years","clinically vulnerable 16-64 years",95,"94",97,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,"UK","GBR",209,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/03/2022",2022-03-23
"1800",209,"Horne","Retrospective cohort","20Jul2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","161-182","hospitalization","severe","UK","clinically vulnerable 16-64 years","clinically vulnerable 16-64 years",91,"88",93,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,"UK","GBR",209,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/03/2022",2022-03-23
"1801",209,"Horne","Retrospective cohort","20Jul2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","77-98","death","death","UK","clinically vulnerable 16-64 years","clinically vulnerable 16-64 years",96,"91",98,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,"UK","GBR",209,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"death","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/03/2022",2022-03-23
"1802",209,"Horne","Retrospective cohort","20Jul2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","161-182","death","death","UK","clinically vulnerable 16-64 years","clinically vulnerable 16-64 years",92,"86",96,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,"UK","GBR",209,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"death","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/03/2022",2022-03-23
"1803",209,"Horne","Retrospective cohort","20Jul2022","AZD1222 (AstraZeneca)","excluded","2","final","21-42","infection","infection","UK","clinically vulnerable 16-64 years","clinically vulnerable 16-64 years",34,"30",39,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,"UK","GBR",209,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"infection","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","23/03/2022",2022-03-23
"1804",209,"Horne","Retrospective cohort","20Jul2022","AZD1222 (AstraZeneca)","excluded","2","final","161-182","infection","infection","UK","clinically vulnerable 16-64 years","clinically vulnerable 16-64 years",-45,"-50",-40,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,"UK","GBR",209,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"infection","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","23/03/2022",2022-03-23
"1805",209,"Horne","Retrospective cohort","20Jul2022","AZD1222 (AstraZeneca)","excluded","2","final","21-42","hospitalization","severe","UK","clinically vulnerable 16-64 years","clinically vulnerable 16-64 years",92,"88",95,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,"UK","GBR",209,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","23/03/2022",2022-03-23
"1806",209,"Horne","Retrospective cohort","20Jul2022","AZD1222 (AstraZeneca)","excluded","2","final","161-182","hospitalization","severe","UK","clinically vulnerable 16-64 years","clinically vulnerable 16-64 years",75,"71",78,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,"UK","GBR",209,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","23/03/2022",2022-03-23
"1807",209,"Horne","Retrospective cohort","20Jul2022","AZD1222 (AstraZeneca)","excluded","2","final","77-98","death","death","UK","clinically vulnerable 16-64 years","clinically vulnerable 16-64 years",92,"88",95,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,"UK","GBR",209,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"death","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","23/03/2022",2022-03-23
"1808",209,"Horne","Retrospective cohort","20Jul2022","AZD1222 (AstraZeneca)","excluded","2","final","161-182","death","death","UK","clinically vulnerable 16-64 years","clinically vulnerable 16-64 years",87,"81",92,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,"UK","GBR",209,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"death","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","23/03/2022",2022-03-23
"1809",209,"Horne","Retrospective cohort","20Jul2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","21-42","infection","infection","UK",">= 65 years",">= 65 years",81,"74",86,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,"UK","GBR",209,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/03/2022",2022-03-23
"1810",209,"Horne","Retrospective cohort","20Jul2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","161-182","infection","infection","UK",">= 65 years",">= 65 years",15,"8",22,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,"UK","GBR",209,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/03/2022",2022-03-23
"1811",209,"Horne","Retrospective cohort","20Jul2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","21-42","hospitalization","severe","UK",">= 65 years",">= 65 years",91,"86",95,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,"UK","GBR",209,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/03/2022",2022-03-23
"1812",209,"Horne","Retrospective cohort","20Jul2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","161-182","hospitalization","severe","UK",">= 65 years",">= 65 years",80,"76",82,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,"UK","GBR",209,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/03/2022",2022-03-23
"1813",209,"Horne","Retrospective cohort","20Jul2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","21-42","death","death","UK",">= 65 years",">= 65 years",98,"93",99,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,"UK","GBR",209,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"death","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/03/2022",2022-03-23
"1814",209,"Horne","Retrospective cohort","20Jul2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","161-182","death","death","UK",">= 65 years",">= 65 years",88,"84",91,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,"UK","GBR",209,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"death","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/03/2022",2022-03-23
"1815",209,"Horne","Retrospective cohort","20Jul2022","AZD1222 (AstraZeneca)","excluded","2","final","21-42","infection","infection","UK",">= 65 years",">= 65 years",53,"41",62,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,"UK","GBR",209,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"infection","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","23/03/2022",2022-03-23
"1816",209,"Horne","Retrospective cohort","20Jul2022","AZD1222 (AstraZeneca)","excluded","2","final","161-182","infection","infection","UK",">= 65 years",">= 65 years",-21,"-30",-13,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,"UK","GBR",209,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"infection","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","23/03/2022",2022-03-23
"1817",209,"Horne","Retrospective cohort","20Jul2022","AZD1222 (AstraZeneca)","excluded","2","final","21-42","hospitalization","severe","UK",">= 65 years",">= 65 years",88,"85",90,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,"UK","GBR",209,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","23/03/2022",2022-03-23
"1818",209,"Horne","Retrospective cohort","20Jul2022","AZD1222 (AstraZeneca)","excluded","2","final","161-182","hospitalization","severe","UK",">= 65 years",">= 65 years",75,"71",79,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,"UK","GBR",209,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","23/03/2022",2022-03-23
"1819",209,"Horne","Retrospective cohort","20Jul2022","AZD1222 (AstraZeneca)","excluded","2","final","21-42","death","death","UK",">= 65 years",">= 65 years",90,"84",94,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,"UK","GBR",209,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"death","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","23/03/2022",2022-03-23
"1820",209,"Horne","Retrospective cohort","20Jul2022","AZD1222 (AstraZeneca)","excluded","2","final","161-182","death","death","UK",">= 65 years",">= 65 years",83,"77",88,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,"UK","GBR",209,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"death","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","23/03/2022",2022-03-23
"1821",210,"Stowe","Test-negative case-control","30Sep2022","BNT162b2 (Pfizer BioNTech)","included","1","1","28+","hospitalization with ARI","severe","UK","18-64 years","18-64 years",31.7,"-3.1",54.8,NA,"omicron",NA,NA,NA,"UK","GBR",210,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-09-30,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","01/04/2022",2022-04-01
"1822",210,"Stowe","Test-negative case-control","30Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14-174","hospitalization with ARI","severe","UK","18-64 years","18-64 years",73.8,"62.5",81.7,NA,"omicron","~43 weeks",NA,NA,"UK","GBR",210,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-09-30,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","01/04/2022",2022-04-01
"1823",210,"Stowe","Test-negative case-control","30Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","175+","hospitalization with ARI","severe","UK","18-64 years","18-64 years",65.1,"51.3",74.9,NA,"omicron","~43 weeks",NA,NA,"UK","GBR",210,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-09-30,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","01/04/2022",2022-04-01
"1824",210,"Stowe","Test-negative case-control","30Sep2022","BNT162b2 (Pfizer BioNTech)","included","1","1","0-27","hospitalization with ARI","severe","UK",">= 65 years",">= 65 years",54.8,"-25.3",83.7,NA,"omicron",NA,NA,NA,"UK","GBR",210,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-09-30,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","01/04/2022",2022-04-01
"1825",210,"Stowe","Test-negative case-control","30Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14-174","hospitalization with ARI","severe","UK",">= 65 years",">= 65 years",87.6,"79.4",92.5,NA,"omicron","~43 weeks",NA,NA,"UK","GBR",210,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-09-30,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","01/04/2022",2022-04-01
"1826",210,"Stowe","Test-negative case-control","30Sep2022","BNT162b2 (Pfizer BioNTech)","included","1","1","28+","hospitalization with ARI","severe","UK",">= 65 years",">= 65 years",59.5,"35.5",74.6,NA,"omicron",NA,NA,NA,"UK","GBR",210,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-09-30,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","01/04/2022",2022-04-01
"1827",210,"Stowe","Test-negative case-control","30Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","175+","hospitalization with ARI","severe","UK",">= 65 years",">= 65 years",65.4,"56.6",72.5,NA,"omicron","~43 weeks",NA,NA,"UK","GBR",210,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-09-30,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","01/04/2022",2022-04-01
"1828",210,"Stowe","Test-negative case-control","30Sep2022","AZD1222 (AstraZeneca)","included","1","1","28+","hospitalization with ARI","severe","UK","18-64 years","18-64 years",48.5,"25.7",64.3,NA,"omicron",NA,NA,NA,"UK","GBR",210,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-09-30,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","01/04/2022",2022-04-01
"1829",210,"Stowe","Test-negative case-control","30Sep2022","AZD1222 (AstraZeneca)","included","2","final","14-174","hospitalization with ARI","severe","UK","18-64 years","18-64 years",59,"31.9",75.3,NA,"omicron","~43 weeks",NA,NA,"UK","GBR",210,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-09-30,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","01/04/2022",2022-04-01
"1830",210,"Stowe","Test-negative case-control","30Sep2022","AZD1222 (AstraZeneca)","included","2","final","175+","hospitalization with ARI","severe","UK","18-64 years","18-64 years",53,"41.7",62,NA,"omicron","~43 weeks",NA,NA,"UK","GBR",210,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-09-30,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","01/04/2022",2022-04-01
"1831",210,"Stowe","Test-negative case-control","30Sep2022","AZD1222 (AstraZeneca)","included","1","1","28+","hospitalization with ARI","severe","UK",">= 65 years",">= 65 years",48.1,"23.5",64.8,NA,"omicron",NA,NA,NA,"UK","GBR",210,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-09-30,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","01/04/2022",2022-04-01
"1832",210,"Stowe","Test-negative case-control","30Sep2022","AZD1222 (AstraZeneca)","included","2","final","14-174","hospitalization with ARI","severe","UK",">= 65 years",">= 65 years",71.2,"50",83.4,NA,"omicron","~43 weeks",NA,NA,"UK","GBR",210,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-09-30,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","01/04/2022",2022-04-01
"1833",210,"Stowe","Test-negative case-control","30Sep2022","AZD1222 (AstraZeneca)","included","2","final","175+","hospitalization with ARI","severe","UK",">= 65 years",">= 65 years",53.1,"43.4",61.2,NA,"omicron","~43 weeks",NA,NA,"UK","GBR",210,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-09-30,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","01/04/2022",2022-04-01
"1834",211,"Tenforde","Case-control","25Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","invasive mechanical ventilation or in-hospital death","severe","USA","hospitalized patients","general pop",79,"66",87,NA,"omicron","~45 weeks",NA,NA,"USA","USA",211,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-25,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-03-25
"1835",211,"Tenforde","Case-control","25Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","invasive mechanical ventilation or in-hospital death","severe","USA","hospitalized patients","general pop",88,"86",90,NA,"delta","~45 weeks",NA,NA,"USA","USA",211,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-25,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2022-03-25
"1836",211,"Tenforde","Case-control","25Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-150","invasive mechanical ventilation or in-hospital death","severe","USA","hospitalized patients","general pop",92,"90",94,NA,"alpha","~45 weeks",NA,NA,"USA","USA",211,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-25,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","alpha",NA,2022-03-25
"1837",211,"Tenforde","Case-control","25Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final",">150","invasive mechanical ventilation or in-hospital death","severe","USA","hospitalized patients","general pop",84,"80",87,NA,"alpha","~45 weeks",NA,NA,"USA","USA",211,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-25,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","alpha",NA,2022-03-25
"1838",212,"Veneti","Retrospective cohort","07Mar2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7-34","infection","infection","Norway","16-17 years","16-17 years",53.1,"42.6",61.7,NA,"omicron","~12 weeks",NA,NA,"Norway","NOR",212,"NOR",71400,2019,"Norway","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-08-12,2021-11-18,2020-12-23,2020-12-23,5,15,232,330,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-03-07,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","25/03/2022",2022-03-25
"1839",212,"Veneti","Retrospective cohort","07Mar2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","63+","infection","infection","Norway","16-17 years","16-17 years",23.3,"2.7",39.5,NA,"omicron","~12 weeks",NA,NA,"Norway","NOR",212,"NOR",71400,2019,"Norway","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-08-12,2021-11-18,2020-12-23,2020-12-23,5,15,232,330,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-03-07,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","25/03/2022",2022-03-25
"1840",212,"Veneti","Retrospective cohort","07Mar2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7-34","infection","infection","Norway","16-17 years","16-17 years",90.8,"89.1",92.3,NA,"delta","~12 weeks",NA,NA,"Norway","NOR",212,"NOR",71400,2019,"Norway","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-08-12,2021-11-18,2020-12-23,2020-12-23,5,15,232,330,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-03-07,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","25/03/2022",2022-03-25
"1841",212,"Veneti","Retrospective cohort","07Mar2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","63+","infection","infection","Norway","16-17 years","16-17 years",83.7,"75.9",89,NA,"delta","~12 weeks",NA,NA,"Norway","NOR",212,"NOR",71400,2019,"Norway","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-08-12,2021-11-18,2020-12-23,2020-12-23,5,15,232,330,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-03-07,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","25/03/2022",2022-03-25
"1842",213,"Wang","Test-negative case-control","23Nov2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-179","infection","infection","USA","patients","general pop",26,"22",30,NA,"omicron","~23.5 weeks",NA,NA,"USA","USA",213,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-11-23,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","25/03/2022",2022-03-25
"1843",213,"Wang","Test-negative case-control","23Nov2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","180+","infection","infection","USA","patients","general pop",7,"4",10,NA,"omicron","54 weeks",NA,NA,"USA","USA",213,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-11-23,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","25/03/2022",2022-03-25
"1844",213,"Wang","Test-negative case-control","23Nov2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-179","infection","infection","USA","patients","general pop",70,"68",72,NA,"delta","~23.5 weeks",NA,NA,"USA","USA",213,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-11-23,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta","25/03/2022",2022-03-25
"1845",213,"Wang","Test-negative case-control","23Nov2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","180+","infection","infection","USA","patients","general pop",53,"52",55,NA,"delta","54 weeks",NA,NA,"USA","USA",213,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-11-23,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta","25/03/2022",2022-03-25
"1846",214,"Natarajan","Test-negative case-control","29Mar2022","Ad26.COV2.S (Janssen)","included","1","final","14+","ED or UC visit","symptomatic","USA","ED/UC encounters or hospitalization among adults with COVID-19 like illness","ED/UC encounters or hospitalization among adults with COVID-19 like illness",24,"18",29,NA,"omicron","40 weeks",NA,NA,"USA","USA",214,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-29,"symptomatic","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","omicron",NA,2022-03-29
"1847",214,"Natarajan","Test-negative case-control","29Mar2022","Ad26.COV2.S (Janssen)","included","1","final","14+","hospitalization","severe","USA","ED/UC encounters or hospitalization among adults with COVID-19 like illness","ED/UC encounters or hospitalization among adults with COVID-19 like illness",31,"21",40,NA,"omicron","40 weeks",NA,NA,"USA","USA",214,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-29,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","omicron",NA,2022-03-29
"1848",215,"Hansen","Retrospective cohort","30Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-30","infection","infection","Denmark",">= 12 years","general pop",37,"35.6",38.3,NA,"omicron","~2 weeks",NA,NA,"Denmark","DNK",215,"DNK",61830,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,8,212,261,"who",8,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-30,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-03-30
"1849",215,"Hansen","Retrospective cohort","30Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","121+","infection","infection","Denmark",">= 12 years","general pop",9.8,"9.2",10.4,NA,"omicron","~30 weeks",NA,NA,"Denmark","DNK",215,"DNK",61830,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,8,212,261,"who",8,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-30,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-03-30
"1850",215,"Hansen","Retrospective cohort","30Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-30","hospitalization","severe","Denmark",">= 12 years","general pop",50.5,"33.9",63,NA,"omicron","~2 weeks",NA,NA,"Denmark","DNK",215,"DNK",61830,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,8,212,261,"who",8,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-30,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-03-30
"1851",215,"Hansen","Retrospective cohort","30Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","121+","hospitalization","severe","Denmark",">= 12 years","general pop",51.6,"47.2",55.6,NA,"omicron","~30 weeks",NA,NA,"Denmark","DNK",215,"DNK",61830,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,8,212,261,"who",8,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-30,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-03-30
"1852",215,"Hansen","Retrospective cohort","30Mar2022","mRNA-1273 (Moderna)","excluded","2","final","14-30","infection","infection","Denmark",">= 12 years","general pop",37.9,"34.4",41.2,NA,"omicron","~2 weeks",NA,NA,"Denmark","DNK",215,"DNK",61830,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,8,212,261,"who",8,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-30,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron",NA,2022-03-30
"1853",215,"Hansen","Retrospective cohort","30Mar2022","mRNA-1273 (Moderna)","excluded","2","final","121+","infection","infection","Denmark",">= 12 years","general pop",13.2,"12.3",14.2,NA,"omicron","~30 weeks",NA,NA,"Denmark","DNK",215,"DNK",61830,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,8,212,261,"who",8,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-30,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron",NA,2022-03-30
"1854",216,"Price","Test-negative case-control","30Mar2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","hospitalization","severe","USA","12-18 years","12-18 years",40,"9",60,NA,"omicron","~42 weeks",NA,NA,"USA","USA",216,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-30,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-03-30
"1855",216,"Price","Test-negative case-control","30Mar2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14-160","hospitalization","severe","USA","12-18 years","12-18 years",43,"-1",68,NA,"omicron","~20 weeks",NA,NA,"USA","USA",216,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-30,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-03-30
"1856",216,"Price","Test-negative case-control","30Mar2022","BNT162b2 (Pfizer BioNTech)","included","2","final","161-314","hospitalization","severe","USA","12-18 years","12-18 years",38,"-3",62,NA,"omicron","~42 weeks",NA,NA,"USA","USA",216,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-30,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-03-30
"1857",216,"Price","Test-negative case-control","30Mar2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","hospitalization","severe","USA","5-11 years","5-11 years",68,"42",82,NA,"omicron","~11 weeks",NA,NA,"USA","USA",216,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-30,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-03-30
"1858",216,"Price","Test-negative case-control","30Mar2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","hospitalization","severe","USA","12-18 years","12-18 years",92,"89",95,NA,"delta","~42 weeks",NA,NA,"USA","USA",216,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-30,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-03-30
"1859",216,"Price","Test-negative case-control","30Mar2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14-160","hospitalization","severe","USA","12-18 years","12-18 years",93,"89",95,NA,"delta","~20 weeks",NA,NA,"USA","USA",216,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-30,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-03-30
"1860",216,"Price","Test-negative case-control","30Mar2022","BNT162b2 (Pfizer BioNTech)","included","2","final","161-314","hospitalization","severe","USA","12-18 years","12-18 years",92,"80",97,NA,"delta","~42 weeks",NA,NA,"USA","USA",216,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-03-30,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-03-30
"1861",217,"Marra","Retrospective cohort","30Mar2022","CoronaVac (Sinovac)","excluded","2","final","14+","Infection","infection","Brazil","HCW","HCW",51.3,"34.6",63.7,NA,"gamma","~23 weeks",NA,NA,"Brazil","BRA",217,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-30,"infection","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","gamma",NA,2022-03-30
"1862",217,"Marra","Retrospective cohort","30Mar2022","AZD1222 (AstraZeneca)","excluded","2","final","14+","Infection","infection","Brazil","HCW","HCW",88.1,"82.8",91.7,NA,"gamma","~15 weeks",NA,NA,"Brazil","BRA",217,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-30,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","gamma",NA,2022-03-30
"1863",218,"Starrfelt","Retrospective cohort","30Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","21+","Infection","infection","Norway",">= 18 years","general pop",15.5,"12.9",18,NA,"delta",NA,NA,NA,"Norway","NOR",218,"NOR",71400,2019,"Norway","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-08-12,2021-11-18,2020-12-23,2020-12-23,5,15,232,330,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-30,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","30/03/2022",2022-03-30
"1864",218,"Starrfelt","Retrospective cohort","30Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","2-9 weeks","Infection","infection","Norway",">= 18 years","general pop",77.7,"76.8",78.5,NA,"delta","~7 weeks",NA,NA,"Norway","NOR",218,"NOR",71400,2019,"Norway","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-08-12,2021-11-18,2020-12-23,2020-12-23,5,15,232,330,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-30,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","30/03/2022",2022-03-30
"1865",218,"Starrfelt","Retrospective cohort","30Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">33 weeks","Infection","infection","Norway",">= 18 years","general pop",8.2,"3.4",12.8,NA,"delta","~43 weeks",NA,NA,"Norway","NOR",218,"NOR",71400,2019,"Norway","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-08-12,2021-11-18,2020-12-23,2020-12-23,5,15,232,330,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-30,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","30/03/2022",2022-03-30
"1866",218,"Starrfelt","Retrospective cohort","30Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","21+","hospitalization","severe","Norway",">= 18 years","general pop",75.3,"66.4",81.9,NA,"delta",NA,NA,NA,"Norway","NOR",218,"NOR",71400,2019,"Norway","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-08-12,2021-11-18,2020-12-23,2020-12-23,5,15,232,330,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-30,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","30/03/2022",2022-03-30
"1867",218,"Starrfelt","Retrospective cohort","30Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","2-9 weeks","hospitalization","severe","Norway",">= 18 years","general pop",97.5,"95.6",98.6,NA,"delta","~7 weeks",NA,NA,"Norway","NOR",218,"NOR",71400,2019,"Norway","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-08-12,2021-11-18,2020-12-23,2020-12-23,5,15,232,330,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-30,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","30/03/2022",2022-03-30
"1868",218,"Starrfelt","Retrospective cohort","30Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">33 weeks","hospitalization","severe","Norway",">= 18 years","general pop",63.9,"54.3",71.5,NA,"delta","~43 weeks",NA,NA,"Norway","NOR",218,"NOR",71400,2019,"Norway","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-08-12,2021-11-18,2020-12-23,2020-12-23,5,15,232,330,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-30,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","30/03/2022",2022-03-30
"1869",218,"Starrfelt","Retrospective cohort","30Mar2022","mRNA-1273 (Moderna)","excluded","1","1","21+","Infection","infection","Norway",">= 18 years","general pop",38.1,"34.7",41.3,NA,"delta",NA,NA,NA,"Norway","NOR",218,"NOR",71400,2019,"Norway","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-08-12,2021-11-18,2020-12-23,2020-12-23,5,15,232,330,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-30,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","30/03/2022",2022-03-30
"1870",218,"Starrfelt","Retrospective cohort","30Mar2022","mRNA-1273 (Moderna)","excluded","2","final","2-9 weeks","Infection","infection","Norway",">= 18 years","general pop",86.6,"85.6",87.6,NA,"delta","~7 weeks",NA,NA,"Norway","NOR",218,"NOR",71400,2019,"Norway","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-08-12,2021-11-18,2020-12-23,2020-12-23,5,15,232,330,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-30,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","30/03/2022",2022-03-30
"1871",218,"Starrfelt","Retrospective cohort","30Mar2022","mRNA-1273 (Moderna)","excluded","2","final",">33 weeks","Infection","infection","Norway",">= 18 years","general pop",28.6,"9.6",43.6,NA,"delta","~43 weeks",NA,NA,"Norway","NOR",218,"NOR",71400,2019,"Norway","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-08-12,2021-11-18,2020-12-23,2020-12-23,5,15,232,330,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-30,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","30/03/2022",2022-03-30
"1872",218,"Starrfelt","Retrospective cohort","30Mar2022","mRNA-1273 (Moderna)","excluded","1","1","21+","hospitalization","severe","Norway",">= 18 years","general pop",77.1,"58.9",87.3,NA,"delta",NA,NA,NA,"Norway","NOR",218,"NOR",71400,2019,"Norway","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-08-12,2021-11-18,2020-12-23,2020-12-23,5,15,232,330,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-30,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","30/03/2022",2022-03-30
"1873",218,"Starrfelt","Retrospective cohort","30Mar2022","mRNA-1273 (Moderna)","excluded","2","final","18-25 weeks","hospitalization","severe","Norway",">= 18 years","general pop",95.3,"91.5",97.4,NA,"delta","~23 weeks",NA,NA,"Norway","NOR",218,"NOR",71400,2019,"Norway","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-08-12,2021-11-18,2020-12-23,2020-12-23,5,15,232,330,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-30,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","30/03/2022",2022-03-30
"1874",218,"Starrfelt","Retrospective cohort","30Mar2022","mRNA-1273 (Moderna)","excluded","2","final","26-33 weeks","hospitalization","severe","Norway",">= 18 years","general pop",91.1,"84.9",94.8,NA,"delta","~31 weeks",NA,NA,"Norway","NOR",218,"NOR",71400,2019,"Norway","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-08-12,2021-11-18,2020-12-23,2020-12-23,5,15,232,330,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-30,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","30/03/2022",2022-03-30
"1875",218,"Starrfelt","Retrospective cohort","30Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","2-9 weeks","Infection","infection","Norway",">= 18 years","general pop",84.1,"83.2",85,NA,"delta","~7 weeks",NA,NA,"Norway","NOR",218,"NOR",71400,2019,"Norway","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-08-12,2021-11-18,2020-12-23,2020-12-23,5,15,232,330,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-30,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta","30/03/2022",2022-03-30
"1876",218,"Starrfelt","Retrospective cohort","30Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","18-25 weeks","Infection","infection","Norway",">= 18 years","general pop",40.7,"23.9",53.8,NA,"delta","~23 weeks",NA,NA,"Norway","NOR",218,"NOR",71400,2019,"Norway","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-08-12,2021-11-18,2020-12-23,2020-12-23,5,15,232,330,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-30,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta","30/03/2022",2022-03-30
"1877",219,"Pardo-Seco","Test-negative case-control","29Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14-20","Infection","infection","Spain",">= 18 years","general pop",67.7,"64.6",70.6,NA,"non-VOC & alpha",NA,NA,NA,"Spain","ESP",219,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-29,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-03-29
"1878",219,"Pardo-Seco","Test-negative case-control","29Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","Infection","infection","Spain",">= 18 years","general pop",90.8,"88.6",92.7,NA,"non-VOC & alpha","~7.5 weeks",NA,NA,"Spain","ESP",219,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-29,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-03-29
"1879",220,"Nordstrom","Retrospective cohort","31Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","previously infected only","2","final","14+","Infection","infection","Sweden",">= 18 years","general pop",68,"63",72,NA,"non-VOC, alpha, & delta","~38 weeks",NA,NA,"Sweden","SWE",220,"SWE",58060,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,15,228,396,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-31,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-03-31
"1880",220,"Nordstrom","Retrospective cohort","31Mar2022","AZD1222 (AstraZeneca)","previously infected only","2","final","14+","Infection","infection","Sweden",">= 18 years","general pop",25,"-37",59,NA,"non-VOC, alpha, & delta","~38 weeks",NA,NA,"Sweden","SWE",220,"SWE",58060,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,15,228,396,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-31,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-03-31
"1881",221,"Ranzani","Test-negative case-control","16Aug2022","CoronaVac (Sinovac)","included","2","final","14-59","symptomatic disease","symptomatic","Brazil",">= 18 years","general pop",28.1,"26.5",29.6,NA,"omicron","~10 weeks",NA,NA,"Brazil","BRA",221,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-08-16,"symptomatic","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron","16/08/2022",2022-08-16
"1882",221,"Ranzani","Test-negative case-control","16Aug2022","CoronaVac (Sinovac)","included","2","final","180+","symptomatic disease","symptomatic","Brazil",">= 18 years","general pop",6.3,"5.3",7.3,NA,"omicron","~59 weeks",NA,NA,"Brazil","BRA",221,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-08-16,"symptomatic","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron","16/08/2022",2022-08-16
"1883",221,"Ranzani","Test-negative case-control","16Aug2022","CoronaVac (Sinovac)","included","2","final","14-59","hospitalization or death","severe","Brazil",">= 18 years","general pop",56.1,"40.6",67.5,NA,"omicron","~10 weeks",NA,NA,"Brazil","BRA",221,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-08-16,"severe","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron","16/08/2022",2022-08-16
"1884",221,"Ranzani","Test-negative case-control","16Aug2022","CoronaVac (Sinovac)","included","2","final","180+","hospitalization or death","severe","Brazil",">= 18 years","general pop",57.6,"54.4",60.6,NA,"omicron","~59 weeks",NA,NA,"Brazil","BRA",221,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-08-16,"severe","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron","16/08/2022",2022-08-16
"1885",221,"Ranzani","Test-negative case-control","16Aug2022","CoronaVac (Sinovac)","included","2","final","14-59","symptomatic disease","symptomatic","Brazil",">= 18 years","general pop",51.3,"49.9",52.7,NA,"delta","~10 weeks",NA,NA,"Brazil","BRA",221,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-08-16,"symptomatic","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","delta","16/08/2022",2022-08-16
"1886",221,"Ranzani","Test-negative case-control","16Aug2022","CoronaVac (Sinovac)","included","2","final","180+","symptomatic disease","symptomatic","Brazil",">= 18 years","general pop",34,"49.9",52.7,NA,"delta","~59 weeks",NA,NA,"Brazil","BRA",221,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-08-16,"symptomatic","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","delta","16/08/2022",2022-08-16
"1887",221,"Ranzani","Test-negative case-control","16Aug2022","CoronaVac (Sinovac)","included","2","final","14-59","hospitalization or death","severe","Brazil",">= 18 years","general pop",86.5,"83.4",88.9,NA,"delta","~10 weeks",NA,NA,"Brazil","BRA",221,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-08-16,"severe","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","delta","16/08/2022",2022-08-16
"1888",221,"Ranzani","Test-negative case-control","16Aug2022","CoronaVac (Sinovac)","included","2","final","180+","hospitalization or death","severe","Brazil",">= 18 years","general pop",60.9,"57.3",64.2,NA,"delta","~59 weeks",NA,NA,"Brazil","BRA",221,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-08-16,"severe","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","delta","16/08/2022",2022-08-16
"1889",222,"Florentino","Test-negative case-control","08Aug2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14-27","symptomatic disease","symptomatic","Brazil","12-17 years","12-17 years",64.7,"63",66.3,NA,"omicron","2 weeks",NA,NA,"Brazil","BRA",222,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-08-08,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","05/04/2022",2022-04-05
"1890",222,"Florentino","Test-negative case-control","08Aug2022","BNT162b2 (Pfizer BioNTech)","included","2","final","98+","symptomatic disease","symptomatic","Brazil","12-17 years","12-17 years",5.9,"2.2",9.4,NA,"omicron","~21 weeks",NA,NA,"Brazil","BRA",222,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-08-08,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","05/04/2022",2022-04-05
"1891",222,"Florentino","Test-negative case-control","08Aug2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14-27","severe disease","severe","Brazil","12-17 years","12-17 years",75.6,"58.1",85.8,NA,"omicron","2 weeks",NA,NA,"Brazil","BRA",222,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-08-08,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","05/04/2022",2022-04-05
"1892",222,"Florentino","Test-negative case-control","08Aug2022","BNT162b2 (Pfizer BioNTech)","included","2","final","98+","severe disease","severe","Brazil","12-17 years","12-17 years",82.7,"68.8",90.4,NA,"omicron","~21 weeks",NA,NA,"Brazil","BRA",222,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-08-08,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","05/04/2022",2022-04-05
"1893",222,"Florentino","Test-negative case-control","08Aug2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14-27","symptomatic disease","symptomatic","Brazil","12-17 years","12-17 years",80.7,"77.8",83.3,NA,"delta","2 weeks",NA,NA,"Brazil","BRA",222,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-08-08,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","05/04/2022",2022-04-05
"1894",222,"Florentino","Test-negative case-control","08Aug2022","BNT162b2 (Pfizer BioNTech)","included","2","final","56-69","symptomatic disease","symptomatic","Brazil","12-17 years","12-17 years",26.6,"4.1",43.9,NA,"delta","~8 weeks",NA,NA,"Brazil","BRA",222,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-08-08,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","05/04/2022",2022-04-05
"1895",222,"Florentino","Test-negative case-control","08Aug2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14-27","symptomatic disease","symptomatic","Scotland","12-17 years","12-17 years",82.6,"80.6",84.5,NA,"omicron","2 weeks",NA,NA,"UK","GBR",501,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-08-08,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","05/04/2022",2022-04-05
"1896",222,"Florentino","Test-negative case-control","08Aug2022","BNT162b2 (Pfizer BioNTech)","included","2","final","98+","symptomatic disease","symptomatic","Scotland","12-17 years","12-17 years",50.6,"42.7",57.4,NA,"omicron","~15.5 weeks",NA,NA,"UK","GBR",501,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-08-08,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","05/04/2022",2022-04-05
"1897",222,"Florentino","Test-negative case-control","08Aug2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14-27","symptomatic disease","symptomatic","Scotland","12-17 years","12-17 years",92.8,"85.7",96.4,NA,"delta","2 weeks",NA,NA,"UK","GBR",501,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-08-08,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","05/04/2022",2022-04-05
"1898",222,"Florentino","Test-negative case-control","08Aug2022","BNT162b2 (Pfizer BioNTech)","included","2","final","56-69","symptomatic disease","symptomatic","Scotland","12-17 years","12-17 years",86.5,"72.2",93.4,NA,"delta","~8 weeks",NA,NA,"UK","GBR",501,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-08-08,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","05/04/2022",2022-04-05
"1899",223,"Yoon","Prospective cohort","06Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","USA","HCW","HCW",46,"25",61,"omicron","omicron","~21 weeks",NA,NA,"USA","USA",223,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-06,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-04-06
"1900",223,"Yoon","Prospective cohort","06Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","USA","HCW","HCW",65,"49",76,"delta","delta","~21 weeks",NA,NA,"USA","USA",223,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-06,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2022-04-06
"1901",224,"Kwon","Test-negative case-control","06Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","transplant recipients","transplant recipients",29,"-19",58,NA,"alpha & delta","~37 weeks",NA,NA,"USA","USA",224,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-06,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-04-06
"1902",224,"Kwon","Test-negative case-control","06Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","immunocompromised","immunocompromised adults",72,"64",79,NA,"alpha & delta","~37 weeks",NA,NA,"USA","USA",224,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-06,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-04-06
"1903",224,"Kwon","Test-negative case-control","06Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","immunocompetent adults","immunocompetent adults",88,"87",90,NA,"alpha & delta","~37 weeks",NA,NA,"USA","USA",224,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-06,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-04-06
"1904",224,"Kwon","Test-negative case-control","06Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","supplemental oxygen/oxygen support","severe","USA","transplant recipients","transplant recipients",31,"-27",63,NA,"alpha & delta","~37 weeks",NA,NA,"USA","USA",224,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-06,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-04-06
"1905",224,"Kwon","Test-negative case-control","06Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","supplemental oxygen/oxygen support","severe","USA","immunocompromised","immunocompromised adults",73,"64",80,NA,"alpha & delta","~37 weeks",NA,NA,"USA","USA",224,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-06,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-04-06
"1906",224,"Kwon","Test-negative case-control","06Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","supplemental oxygen/oxygen support","severe","USA","immunocompetent adults","immunocompetent adults",90,"89",92,NA,"alpha & delta","~37 weeks",NA,NA,"USA","USA",224,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-06,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-04-06
"1907",225,"Paraguay Ministry of Health and Social Welfare","Test-negative case-control","22Mar2022","BBV152 (Bharat)","excluded","2","final","14+","hospitalization with SARI","severe","Paraguay","patients >=16 years with severe acute respiratory infection","general pop",27.7,"-10.2",52.6,NA,"gamma & delta","~38 weeks",NA,NA,"Paraguay","PRY",225,"PRY",13770,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,76,291,NA,"who",76,"feb/2021","60-89","Dec/2021 +","270-359","yes","yes","no",2022-03-22,"severe","2022 (Jan-Jun)","Bharat Covaxin/BBV152","Inactivated","other combinations",NA,2022-03-22
"1908",225,"Paraguay Ministry of Health and Social Welfare","Test-negative case-control","22Mar2022","AZD1222 (AstraZeneca)","excluded","2","final","14+","hospitalization with SARI","severe","Paraguay","patients >=16 years with severe acute respiratory infection","general pop",85.8,"70.6",93.1,NA,"gamma & delta","~38 weeks",NA,NA,"Paraguay","PRY",225,"PRY",13770,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,76,291,NA,"who",76,"feb/2021","60-89","Dec/2021 +","270-359","yes","yes","no",2022-03-22,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-03-22
"1909",225,"Paraguay Ministry of Health and Social Welfare","Test-negative case-control","22Mar2022","Hayat-Vax (Julphar)","excluded","2","final","14+","hospitalization with SARI","severe","Paraguay","patients >=16 years with severe acute respiratory infection","general pop",56.4,"15.5",77.6,NA,"gamma & delta","~38 weeks",NA,NA,"Paraguay","PRY",225,"PRY",13770,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,76,291,NA,"who",76,"feb/2021","60-89","Dec/2021 +","270-359","yes","yes","no",2022-03-22,"severe","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","other combinations",NA,2022-03-22
"1910",225,"Paraguay Ministry of Health and Social Welfare","Test-negative case-control","22Mar2022","Gam-COVID-Vac (Gamaleya)","excluded","2","final","14+","hospitalization with SARI","severe","Paraguay","patients >=16 years with severe acute respiratory infection","general pop",77,"30.8",92.3,NA,"gamma & delta","~38 weeks",NA,NA,"Paraguay","PRY",225,"PRY",13770,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,76,291,NA,"who",76,"feb/2021","60-89","Dec/2021 +","270-359","yes","yes","no",2022-03-22,"severe","2022 (Jan-Jun)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","other combinations",NA,2022-03-22
"1911",225,"Paraguay Ministry of Health and Social Welfare","Test-negative case-control","22Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization with SARI","severe","Paraguay","patients >=16 years with severe acute respiratory infection","general pop",95.4,"65.7",99.4,NA,"gamma & delta","~38 weeks",NA,NA,"Paraguay","PRY",225,"PRY",13770,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,76,291,NA,"who",76,"feb/2021","60-89","Dec/2021 +","270-359","yes","yes","no",2022-03-22,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-03-22
"1912",226,"Buchan","Test-negative case-control","07Apr2022","BNT162b2 (Pfizer BioNTech)","included","2","final","7-59","symptomatic disease","symptomatic","Canada","12-17 years","12-17 years",51,"38",61,"omicron","omicron","~41 weeks",NA,NA,"Canada","CAN",226,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-07,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-04-07
"1913",226,"Buchan","Test-negative case-control","07Apr2022","BNT162b2 (Pfizer BioNTech)","included","2","final","180+","symptomatic disease","symptomatic","Canada","12-17 years","12-17 years",29,"17",38,"omicron","omicron","~41 weeks",NA,NA,"Canada","CAN",226,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-07,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-04-07
"1914",226,"Buchan","Test-negative case-control","07Apr2022","BNT162b2 (Pfizer BioNTech)","included","2","final","7-59","hospitalization or death","severe","Canada","12-17 years","12-17 years",76,"-10",95,"omicron","omicron","~41 weeks",NA,NA,"Canada","CAN",226,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-07,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-04-07
"1915",226,"Buchan","Test-negative case-control","07Apr2022","BNT162b2 (Pfizer BioNTech)","included","2","final","180+","hospitalization or death","severe","Canada","12-17 years","12-17 years",88,"77",94,"omicron","omicron","~32 weeks",NA,NA,"Canada","CAN",226,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-07,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-04-07
"1916",226,"Buchan","Test-negative case-control","07Apr2022","BNT162b2 (Pfizer BioNTech)","included","2","final","7-59","symptomatic disease","symptomatic","Canada","12-17 years","12-17 years",97,"94",99,"delta","delta","~32 weeks",NA,NA,"Canada","CAN",226,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-07,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-04-07
"1917",226,"Buchan","Test-negative case-control","07Apr2022","BNT162b2 (Pfizer BioNTech)","included","2","final","180+","symptomatic disease","symptomatic","Canada","12-17 years","12-17 years",90,"79",95,"delta","delta","~32 weeks",NA,NA,"Canada","CAN",226,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-07,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-04-07
"1918",227,"Kim","Test-negative case-control","29Jul2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-149","symptomatic disease","symptomatic","USA",">= 18 years","general pop",45,"14",66,"omicron","omicron","~58 weeks",NA,NA,"USA","USA",227,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-07-29,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","10/04/2022",2022-04-10
"1919",227,"Kim","Test-negative case-control","29Jul2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","150+","symptomatic disease","symptomatic","USA",">= 18 years","general pop",11,"-21",35,"omicron","omicron","~58 weeks",NA,NA,"USA","USA",227,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-07-29,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","10/04/2022",2022-04-10
"1920",227,"Kim","Test-negative case-control","29Jul2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-149","symptomatic disease","symptomatic","USA",">= 18 years","general pop",89,"78",94,"delta","delta","~48 weeks",NA,NA,"USA","USA",227,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-07-29,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta","10/04/2022",2022-04-10
"1921",227,"Kim","Test-negative case-control","29Jul2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","150+","symptomatic disease","symptomatic","USA",">= 18 years","general pop",58,"44",68,"delta","delta","~48 weeks",NA,NA,"USA","USA",227,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-07-29,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta","10/04/2022",2022-04-10
"1922",228,"Kildegard","Retrospective cohort","11Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","0-20","infection","infection","Denmark","12-17 years","12-17 years",62,"59",65,NA,"delta",NA,NA,NA,"Denmark","DNK",228,"DNK",61830,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,8,212,261,"who",8,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-11,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-04-11
"1923",228,"Kildegard","Retrospective cohort","11Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","0-59","infection","infection","Denmark","12-17 years","12-17 years",93,"93",94,NA,"delta","~13 weeks",NA,NA,"Denmark","DNK",228,"DNK",61830,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,8,212,261,"who",8,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-11,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-04-11
"1924",229,"Institute of Public Health","Test-negative case-control","12Apr2022","BNT162b2 (Pfizer BioNTech)","included","1","1","14+","hospitalization","severe","Chile",">= 18 years","general pop",53.5,"-27.3",83,NA,"gamma & delta",NA,NA,NA,"Chile","CHL",229,"CHL",24650,2019,"Chile","Latin America & Caribbean","High income",3,"South America",2020-12-25,2021-05-25,2021-09-02,2020-12-21,2020-12-21,4,13,155,255,"who",13,"before jan/2021","<30","before Jun/2021","<180","yes","yes","yes",2022-04-12,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-04-12
"1925",229,"Institute of Public Health","Test-negative case-control","12Apr2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","hospitalization","severe","Chile",">= 18 years","general pop",85.3,"73.5",91.8,NA,"gamma & delta","~53 weeks",NA,NA,"Chile","CHL",229,"CHL",24650,2019,"Chile","Latin America & Caribbean","High income",3,"South America",2020-12-25,2021-05-25,2021-09-02,2020-12-21,2020-12-21,4,13,155,255,"who",13,"before jan/2021","<30","before Jun/2021","<180","yes","yes","yes",2022-04-12,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-04-12
"1926",229,"Institute of Public Health","Test-negative case-control","12Apr2022","CoronaVac (Sinovac)","included","1","1","14+","hospitalization","severe","Chile",">= 18 years","general pop",36.6,"6",57.2,NA,"gamma & delta",NA,NA,NA,"Chile","CHL",229,"CHL",24650,2019,"Chile","Latin America & Caribbean","High income",3,"South America",2020-12-25,2021-05-25,2021-09-02,2020-12-21,2020-12-21,4,13,155,255,"who",13,"before jan/2021","<30","before Jun/2021","<180","yes","yes","yes",2022-04-12,"severe","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations",NA,2022-04-12
"1927",229,"Institute of Public Health","Test-negative case-control","12Apr2022","CoronaVac (Sinovac)","included","2","final","14+","hospitalization","severe","Chile",">= 18 years","general pop",59.5,"49",67.9,NA,"gamma & delta","~53 weeks",NA,NA,"Chile","CHL",229,"CHL",24650,2019,"Chile","Latin America & Caribbean","High income",3,"South America",2020-12-25,2021-05-25,2021-09-02,2020-12-21,2020-12-21,4,13,155,255,"who",13,"before jan/2021","<30","before Jun/2021","<180","yes","yes","yes",2022-04-12,"severe","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations",NA,2022-04-12
"1928",230,"Plumb","Test-negative case-control","12Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","1","1","14+","hospitalization","severe","USA","hospitalized adults","general pop",33,"15",47.2,NA,"omicron",NA,NA,NA,"USA","USA",230,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-12,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-04-12
"1929",230,"Plumb","Test-negative case-control","12Apr2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","hospitalization","severe","USA","hospitalized adults","general pop",37.3,"25.8",46.9,NA,"omicron","~55 weeks",NA,NA,"USA","USA",230,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-12,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-04-12
"1930",230,"Plumb","Test-negative case-control","12Apr2022","mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","hospitalized adults","general pop",35.9,"21.7",47.4,NA,"omicron","~55 weeks",NA,NA,"USA","USA",230,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-12,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron",NA,2022-04-12
"1931",230,"Plumb","Test-negative case-control","12Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","1","1","14+","hospitalization","severe","USA","hospitalized adults","general pop",58.8,"41.3",71.1,NA,"delta",NA,NA,NA,"USA","USA",230,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-12,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2022-04-12
"1932",230,"Plumb","Test-negative case-control","12Apr2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","hospitalization","severe","USA","hospitalized adults","general pop",50,"39",59,NA,"delta","~55 weeks",NA,NA,"USA","USA",230,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-12,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-04-12
"1933",230,"Plumb","Test-negative case-control","12Apr2022","mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","hospitalized adults","general pop",44,"29.9",55.2,NA,"delta","~55 weeks",NA,NA,"USA","USA",230,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-12,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta",NA,2022-04-12
"1934",231,"Dale","Outbreak investigation","12Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","USA",">= 18 years","general pop",51,"-27",81,"delta","delta","~25 weeks",NA,NA,"USA","USA",231,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-12,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2022-04-12
"1935",231,"Dale","Outbreak investigation","12Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","symptomatic disease","symptomatic","USA",">= 18 years","general pop",67,"-7",90,"delta","delta","~25 weeks",NA,NA,"USA","USA",231,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-12,"symptomatic","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2022-04-12
"1936",231,"Dale","Outbreak investigation","12Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization","severe","USA",">= 18 years","general pop",61,"-59",90,"delta","delta","~25 weeks",NA,NA,"USA","USA",231,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-12,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2022-04-12
"1937",231,"Dale","Outbreak investigation","12Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","death","death","USA",">= 18 years","general pop",80,"-10",96,"delta","delta","~25 weeks",NA,NA,"USA","USA",231,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-12,"death","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2022-04-12
"1938",232,"Cerqueira-Silva","Test-negative case-control","01Jul2022","BNT162b2 (Pfizer BioNTech)","previously infected only","2","final","14-69","symptomatic disease","symptomatic","Brazil",">= 18 years","general pop",51.9,"50",53.8,NA,"omicron","~59 weeks",NA,NA,"Brazil","BRA",232,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-01,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","13/04/2022",2022-04-13
"1939",232,"Cerqueira-Silva","Test-negative case-control","01Jul2022","BNT162b2 (Pfizer BioNTech)","previously infected only","2","final","140+","symptomatic disease","symptomatic","Brazil",">= 18 years","general pop",26.2,"22.8",29.4,NA,"omicron","~59 weeks",NA,NA,"Brazil","BRA",232,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-01,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","13/04/2022",2022-04-13
"1940",232,"Cerqueira-Silva","Test-negative case-control","01Jul2022","BNT162b2 (Pfizer BioNTech)","previously infected only","2","final","14-69","hospitalization or death","severe","Brazil",">= 18 years","general pop",59.6,"36.6",74.2,NA,"omicron","~59 weeks",NA,NA,"Brazil","BRA",232,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-01,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","13/04/2022",2022-04-13
"1941",232,"Cerqueira-Silva","Test-negative case-control","01Jul2022","BNT162b2 (Pfizer BioNTech)","previously infected only","2","final","140+","hospitalization or death","severe","Brazil",">= 18 years","general pop",53.6,"30.2",69.1,NA,"omicron","~59 weeks",NA,NA,"Brazil","BRA",232,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-01,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","13/04/2022",2022-04-13
"1942",232,"Cerqueira-Silva","Test-negative case-control","01Jul2022","AZD1222 (AstraZeneca)","previously infected only","2","final","14-69","symptomatic disease","symptomatic","Brazil",">= 18 years","general pop",25.5,"1",29.7,NA,"omicron","~59 weeks",NA,NA,"Brazil","BRA",232,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-01,"symptomatic","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","13/04/2022",2022-04-13
"1943",232,"Cerqueira-Silva","Test-negative case-control","01Jul2022","AZD1222 (AstraZeneca)","previously infected only","2","final","140+","symptomatic disease","symptomatic","Brazil",">= 18 years","general pop",17,"14.4",19.6,NA,"omicron","~59 weeks",NA,NA,"Brazil","BRA",232,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-01,"symptomatic","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","13/04/2022",2022-04-13
"1944",232,"Cerqueira-Silva","Test-negative case-control","01Jul2022","AZD1222 (AstraZeneca)","previously infected only","2","final","14-69","hospitalization or death","severe","Brazil",">= 18 years","general pop",41,"-8.1",67.8,NA,"omicron","~59 weeks",NA,NA,"Brazil","BRA",232,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-01,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","13/04/2022",2022-04-13
"1945",232,"Cerqueira-Silva","Test-negative case-control","01Jul2022","AZD1222 (AstraZeneca)","previously infected only","2","final","140+","hospitalization or death","severe","Brazil",">= 18 years","general pop",55.4,"44.6",64.1,NA,"omicron","~59 weeks",NA,NA,"Brazil","BRA",232,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-01,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","13/04/2022",2022-04-13
"1946",232,"Cerqueira-Silva","Test-negative case-control","01Jul2022","Ad26.COV2.S (Janssen)","previously infected only","1","final","14+","symptomatic disease","symptomatic","Brazil",">= 18 years","general pop",16.2,"12.4",19.8,NA,"omicron","~59 weeks",NA,NA,"Brazil","BRA",232,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-01,"symptomatic","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","omicron","13/04/2022",2022-04-13
"1947",232,"Cerqueira-Silva","Test-negative case-control","01Jul2022","Ad26.COV2.S (Janssen)","previously infected only","1","final","14+","hospitalization or death","severe","Brazil",">= 18 years","general pop",39.5,"8.3",69,NA,"omicron","~59 weeks",NA,NA,"Brazil","BRA",232,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-01,"severe","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","omicron","13/04/2022",2022-04-13
"1948",232,"Cerqueira-Silva","Test-negative case-control","01Jul2022","CoronaVac (Sinovac)","previously infected only","2","final","14-69","symptomatic disease","symptomatic","Brazil",">= 18 years","general pop",23.4,"18.2",28.3,NA,"omicron","~59 weeks",NA,NA,"Brazil","BRA",232,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-01,"symptomatic","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron","13/04/2022",2022-04-13
"1949",232,"Cerqueira-Silva","Test-negative case-control","01Jul2022","CoronaVac (Sinovac)","previously infected only","2","final","140+","symptomatic disease","symptomatic","Brazil",">= 18 years","general pop",12.3,"9.4",15.1,NA,"omicron","~59 weeks",NA,NA,"Brazil","BRA",232,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-01,"symptomatic","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron","13/04/2022",2022-04-13
"1950",232,"Cerqueira-Silva","Test-negative case-control","01Jul2022","CoronaVac (Sinovac)","previously infected only","2","final","14-69","hospitalization or death","severe","Brazil",">= 18 years","general pop",34.1,"-28.9",66.3,NA,"omicron","~59 weeks",NA,NA,"Brazil","BRA",232,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-01,"severe","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron","13/04/2022",2022-04-13
"1951",232,"Cerqueira-Silva","Test-negative case-control","01Jul2022","CoronaVac (Sinovac)","previously infected only","2","final","140+","hospitalization or death","severe","Brazil",">= 18 years","general pop",34.4,"18.3",47.3,NA,"omicron","~59 weeks",NA,NA,"Brazil","BRA",232,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-01,"severe","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron","13/04/2022",2022-04-13
"1952",232,"Cerqueira-Silva","Matched case-control","01Jul2022","BNT162b2 (Pfizer BioNTech)","previously infected only","2","final","14-69","symptomatic disease","symptomatic","Brazil",">= 18 years","general pop",54.1,"52.1",55.9,NA,"omicron","~59 weeks",NA,NA,"Brazil","BRA",232,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-01,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","13/04/2022",2022-04-13
"1953",232,"Cerqueira-Silva","Matched case-control","01Jul2022","BNT162b2 (Pfizer BioNTech)","previously infected only","2","final","140+","symptomatic disease","symptomatic","Brazil",">= 18 years","general pop",30.6,"27.3",33.7,NA,"omicron","~59 weeks",NA,NA,"Brazil","BRA",232,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-01,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","13/04/2022",2022-04-13
"1954",232,"Cerqueira-Silva","Matched case-control","01Jul2022","BNT162b2 (Pfizer BioNTech)","previously infected only","2","final","14-69","hospitalization or death","severe","Brazil",">= 18 years","general pop",53.6,"-6.4",79.8,NA,"omicron","~59 weeks",NA,NA,"Brazil","BRA",232,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-01,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","13/04/2022",2022-04-13
"1955",232,"Cerqueira-Silva","Matched case-control","01Jul2022","BNT162b2 (Pfizer BioNTech)","previously infected only","2","final","140+","hospitalization or death","severe","Brazil",">= 18 years","general pop",55.1,"-1.9",80.2,NA,"omicron","~59 weeks",NA,NA,"Brazil","BRA",232,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-01,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","13/04/2022",2022-04-13
"1956",232,"Cerqueira-Silva","Matched case-control","01Jul2022","AZD1222 (AstraZeneca)","previously infected only","2","final","14-69","symptomatic disease","symptomatic","Brazil",">= 18 years","general pop",27.2,"22.9",31.3,NA,"omicron","~59 weeks",NA,NA,"Brazil","BRA",232,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-01,"symptomatic","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","13/04/2022",2022-04-13
"1957",232,"Cerqueira-Silva","Matched case-control","01Jul2022","AZD1222 (AstraZeneca)","previously infected only","2","final","140+","symptomatic disease","symptomatic","Brazil",">= 18 years","general pop",15.9,"13.2",18.5,NA,"omicron","~59 weeks",NA,NA,"Brazil","BRA",232,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-01,"symptomatic","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","13/04/2022",2022-04-13
"1958",232,"Cerqueira-Silva","Matched case-control","01Jul2022","AZD1222 (AstraZeneca)","previously infected only","2","final","14-69","hospitalization or death","severe","Brazil",">= 18 years","general pop",67.5,"-7.9",90.2,NA,"omicron","~59 weeks",NA,NA,"Brazil","BRA",232,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-01,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","13/04/2022",2022-04-13
"1959",232,"Cerqueira-Silva","Matched case-control","01Jul2022","AZD1222 (AstraZeneca)","previously infected only","2","final","140+","hospitalization or death","severe","Brazil",">= 18 years","general pop",63.2,"39",77.8,NA,"omicron","~59 weeks",NA,NA,"Brazil","BRA",232,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-01,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","13/04/2022",2022-04-13
"1960",232,"Cerqueira-Silva","Matched case-control","01Jul2022","Ad26.COV2.S (Janssen)","previously infected only","1","final","14+","symptomatic disease","symptomatic","Brazil",">= 18 years","general pop",16.9,"13.2",20.5,NA,"omicron","~59 weeks",NA,NA,"Brazil","BRA",232,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-01,"symptomatic","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","omicron","13/04/2022",2022-04-13
"1961",232,"Cerqueira-Silva","Matched case-control","01Jul2022","Ad26.COV2.S (Janssen)","previously infected only","1","final","14+","hospitalization or death","severe","Brazil",">= 18 years","general pop",45.4,"-19.6",75.1,NA,"omicron","~59 weeks",NA,NA,"Brazil","BRA",232,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-01,"severe","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","omicron","13/04/2022",2022-04-13
"1962",232,"Cerqueira-Silva","Matched case-control","01Jul2022","CoronaVac (Sinovac)","previously infected only","2","final","14-69","symptomatic disease","symptomatic","Brazil",">= 18 years","general pop",27.3,"22.3",31.9,NA,"omicron","~59 weeks",NA,NA,"Brazil","BRA",232,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-01,"symptomatic","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron","13/04/2022",2022-04-13
"1963",232,"Cerqueira-Silva","Matched case-control","01Jul2022","CoronaVac (Sinovac)","previously infected only","2","final","140+","symptomatic disease","symptomatic","Brazil",">= 18 years","general pop",14.3,"11.4",17,NA,"omicron","~59 weeks",NA,NA,"Brazil","BRA",232,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-01,"symptomatic","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron","13/04/2022",2022-04-13
"1964",232,"Cerqueira-Silva","Matched case-control","01Jul2022","CoronaVac (Sinovac)","previously infected only","2","final","14-69","hospitalization or death","severe","Brazil",">= 18 years","general pop",21.4,"-148.4",75.1,NA,"omicron","~59 weeks",NA,NA,"Brazil","BRA",232,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-01,"severe","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron","13/04/2022",2022-04-13
"1965",232,"Cerqueira-Silva","Matched case-control","01Jul2022","CoronaVac (Sinovac)","previously infected only","2","final","140+","hospitalization or death","severe","Brazil",">= 18 years","general pop",66.4,"37.6",81.9,NA,"omicron","~59 weeks",NA,NA,"Brazil","BRA",232,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-01,"severe","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron","13/04/2022",2022-04-13
"1966",233,"Nasreen","Test-negative case-control","17Aug2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7-55","hospitalization or death","severe","Canada",">= 18 years","general pop",98,"95",99,NA,"non-VOC, alpha, beta, gamma, & delta","~32 weeks",NA,NA,"Canada","CAN",233,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-08-17,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","13/04/2022",2022-04-13
"1967",233,"Nasreen","Test-negative case-control","17Aug2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","112+","hospitalization or death","severe","Canada",">= 18 years","general pop",98,"95",99,NA,"non-VOC, alpha, beta, gamma, & delta","~32 weeks",NA,NA,"Canada","CAN",233,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-08-17,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","13/04/2022",2022-04-13
"1968",233,"Nasreen","Test-negative case-control","17Aug2022","AZD1222 (AstraZeneca)","excluded","2","final","7-55","hospitalization or death","severe","Canada",">= 18 years","general pop",96,"88",96,NA,"non-VOC, alpha, beta, gamma, & delta","~7 weeks",NA,NA,"Canada","CAN",233,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-08-17,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","13/04/2022",2022-04-13
"1969",233,"Nasreen","Test-negative case-control","17Aug2022","AZD1222 (AstraZeneca)","excluded","2","final","56+","hospitalization or death","severe","Canada",">= 18 years","general pop",97,"91",99,NA,"non-VOC, alpha, beta, gamma, & delta","~7 weeks",NA,NA,"Canada","CAN",233,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-08-17,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","13/04/2022",2022-04-13
"1970",233,"Nasreen","Test-negative case-control","17Aug2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","14+","hospitalization or death","severe","Canada",">= 18 years","general pop",99,"98",100,NA,"non-VOC, alpha, beta, gamma, & delta","~7 weeks",NA,NA,"Canada","CAN",233,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-08-17,"severe","2022 (Jul-Dec)","Heterologous platforms","Multiple","other combinations","13/04/2022",2022-04-13
"1971",234,"Richardson","Prospective cohort","19Jun2022","Ad5-nCOV (CanSino)","excluded","1","final","14-60","infection","infection","Mexico","childcare workers","childcare workers",48,"32",61,NA,"non-VOC, alpha, gamma, & delta","~33 weeks",NA,NA,"Mexico","MEX",234,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2022-06-19,"infection","2022 (Jan-Jun)","Cansino Ad5-nCoV","Vectored","other combinations","17/04/2022",2022-04-17
"1972",234,"Richardson","Prospective cohort","19Jun2022","Ad5-nCOV (CanSino)","excluded","1","final","120+","infection","infection","Mexico","childcare workers","childcare workers",-3,"-26",16,NA,"non-VOC, alpha, gamma, & delta","~33 weeks",NA,NA,"Mexico","MEX",234,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2022-06-19,"infection","2022 (Jan-Jun)","Cansino Ad5-nCoV","Vectored","other combinations","17/04/2022",2022-04-17
"1973",234,"Richardson","Prospective cohort","19Jun2022","Ad5-nCOV (CanSino)","excluded","1","final","14-60","hospitalization","severe","Mexico","childcare workers","childcare workers",92,"23",99,NA,"non-VOC, alpha, gamma, & delta","~33 weeks",NA,NA,"Mexico","MEX",234,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2022-06-19,"severe","2022 (Jan-Jun)","Cansino Ad5-nCoV","Vectored","other combinations","17/04/2022",2022-04-17
"1974",234,"Richardson","Prospective cohort","19Jun2022","Ad5-nCOV (CanSino)","excluded","1","final","120+","hospitalization","severe","Mexico","childcare workers","childcare workers",24,"-263",84,NA,"non-VOC, alpha, gamma, & delta","~33 weeks",NA,NA,"Mexico","MEX",234,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2022-06-19,"severe","2022 (Jan-Jun)","Cansino Ad5-nCoV","Vectored","other combinations","17/04/2022",2022-04-17
"1975",234,"Richardson","Prospective cohort","19Jun2022","Ad5-nCOV (CanSino)","excluded","1","final","61-120","death","death","Mexico","childcare workers","childcare workers",95,"53",100,NA,"non-VOC, alpha, gamma, & delta","~33 weeks",NA,NA,"Mexico","MEX",234,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2022-06-19,"death","2022 (Jan-Jun)","Cansino Ad5-nCoV","Vectored","other combinations","17/04/2022",2022-04-17
"1976",234,"Richardson","Prospective cohort","19Jun2022","Ad5-nCOV (CanSino)","excluded","1","final","120+","death","death","Mexico","childcare workers","childcare workers",93,"22",99,NA,"non-VOC, alpha, gamma, & delta","~33 weeks",NA,NA,"Mexico","MEX",234,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2022-06-19,"death","2022 (Jan-Jun)","Cansino Ad5-nCoV","Vectored","other combinations","17/04/2022",2022-04-17
"1977",234,"Richardson","Prospective cohort","19Jun2022","Ad5-nCOV (CanSino)","excluded","1","final","14+","infection","infection","Mexico","childcare workers","childcare workers",53,"23",71,NA,"alpha & gamma","~33 weeks",NA,NA,"Mexico","MEX",234,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2022-06-19,"infection","2022 (Jan-Jun)","Cansino Ad5-nCoV","Vectored","other combinations","17/04/2022",2022-04-17
"1978",234,"Richardson","Prospective cohort","19Jun2022","Ad5-nCOV (CanSino)","excluded","1","final","14+","infection","infection","Mexico","childcare workers","childcare workers",18,"8",28,NA,"delta","~33 weeks",NA,NA,"Mexico","MEX",234,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2022-06-19,"infection","2022 (Jan-Jun)","Cansino Ad5-nCoV","Vectored","delta","17/04/2022",2022-04-17
"1979",234,"Richardson","Prospective cohort","19Jun2022","Ad5-nCOV (CanSino)","excluded","1","final","14+","hospitalization","severe","Mexico","childcare workers","childcare workers",74,"38",89,NA,"delta","~33 weeks",NA,NA,"Mexico","MEX",234,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2022-06-19,"severe","2022 (Jan-Jun)","Cansino Ad5-nCoV","Vectored","delta","17/04/2022",2022-04-17
"1980",234,"Richardson","Prospective cohort","19Jun2022","Ad5-nCOV (CanSino)","excluded","1","final","14+","death","death","Mexico","childcare workers","childcare workers",94,"67",99,NA,"delta","~33 weeks",NA,NA,"Mexico","MEX",234,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2022-06-19,"death","2022 (Jan-Jun)","Cansino Ad5-nCoV","Vectored","delta","17/04/2022",2022-04-17
"1981",235,"Voko","Retrospective cohort","22Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14-120","infection","infection","Hungary","18-64 years","18-64 years",70.3,"69.2",71.3,NA,"delta","~47 weeks",NA,NA,"Hungary","HUN",235,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","18/04/2022",2022-04-18
"1982",235,"Voko","Retrospective cohort","22Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final","240+","infection","infection","Hungary","18-64 years","18-64 years",0.6,"-2.3",3.4,NA,"delta","~47 weeks",NA,NA,"Hungary","HUN",235,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","18/04/2022",2022-04-18
"1983",235,"Voko","Retrospective cohort","22Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14-120","hospitalization","severe","Hungary","18-64 years","18-64 years",82.6,"80.1",84.7,NA,"delta","~47 weeks",NA,NA,"Hungary","HUN",235,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","18/04/2022",2022-04-18
"1984",235,"Voko","Retrospective cohort","22Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final","240+","hospitalization","severe","Hungary","18-64 years","18-64 years",69.6,"64.9",73.6,NA,"delta","~47 weeks",NA,NA,"Hungary","HUN",235,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","18/04/2022",2022-04-18
"1985",235,"Voko","Retrospective cohort","22Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14-120","death","death","Hungary","18-64 years","18-64 years",87.4,"81.5",91.5,NA,"delta","~47 weeks",NA,NA,"Hungary","HUN",235,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"death","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","18/04/2022",2022-04-18
"1986",235,"Voko","Retrospective cohort","22Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final","240+","death","death","Hungary","18-64 years","18-64 years",73.6,"61.1",82.1,NA,"delta","~47 weeks",NA,NA,"Hungary","HUN",235,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"death","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","18/04/2022",2022-04-18
"1987",235,"Voko","Retrospective cohort","22Jul2022","mRNA-1273 (Moderna)","included","2","final","14-120","infection","infection","Hungary","18-64 years","18-64 years",76.9,"73.3",80,NA,"delta","~47 weeks",NA,NA,"Hungary","HUN",235,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","18/04/2022",2022-04-18
"1988",235,"Voko","Retrospective cohort","22Jul2022","mRNA-1273 (Moderna)","included","2","final","240+","infection","infection","Hungary","18-64 years","18-64 years",22.6,"6.1",36.2,NA,"delta","~47 weeks",NA,NA,"Hungary","HUN",235,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","18/04/2022",2022-04-18
"1989",235,"Voko","Retrospective cohort","22Jul2022","mRNA-1273 (Moderna)","included","2","final","14-120","hospitalization","severe","Hungary","18-64 years","18-64 years",84.9,"75.4",90.8,NA,"delta","~47 weeks",NA,NA,"Hungary","HUN",235,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","18/04/2022",2022-04-18
"1990",235,"Voko","Retrospective cohort","22Jul2022","mRNA-1273 (Moderna)","included","2","final","240+","hospitalization","severe","Hungary","18-64 years","18-64 years",42.5,"-4",68.2,NA,"delta","~47 weeks",NA,NA,"Hungary","HUN",235,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","18/04/2022",2022-04-18
"1991",235,"Voko","Retrospective cohort","22Jul2022","mRNA-1273 (Moderna)","included","2","final","14-120","death","death","Hungary","18-64 years","18-64 years",77.7,"30.7",92.8,NA,"delta","~47 weeks",NA,NA,"Hungary","HUN",235,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"death","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","18/04/2022",2022-04-18
"1992",235,"Voko","Retrospective cohort","22Jul2022","mRNA-1273 (Moderna)","included","2","final","240+","death","death","Hungary","18-64 years","18-64 years",100,NA,NA,NA,"delta","~47 weeks",NA,NA,"Hungary","HUN",235,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"death","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","18/04/2022",2022-04-18
"1993",235,"Voko","Retrospective cohort","22Jul2022","AZD1222 (AstraZeneca)","included","2","final","14-120","infection","infection","Hungary","18-64 years","18-64 years",39.2,"36.4",41.9,NA,"delta","~47 weeks",NA,NA,"Hungary","HUN",235,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"infection","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","18/04/2022",2022-04-18
"1994",235,"Voko","Retrospective cohort","22Jul2022","AZD1222 (AstraZeneca)","included","2","final","240+","infection","infection","Hungary","18-64 years","18-64 years",-14,"-20.5",-7.9,NA,"delta","~47 weeks",NA,NA,"Hungary","HUN",235,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"infection","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","18/04/2022",2022-04-18
"1995",235,"Voko","Retrospective cohort","22Jul2022","AZD1222 (AstraZeneca)","included","2","final","14-120","hospitalization","severe","Hungary","18-64 years","18-64 years",76.2,"70.6",80.7,NA,"delta","~47 weeks",NA,NA,"Hungary","HUN",235,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","18/04/2022",2022-04-18
"1996",235,"Voko","Retrospective cohort","22Jul2022","AZD1222 (AstraZeneca)","included","2","final","240+","hospitalization","severe","Hungary","18-64 years","18-64 years",48.8,"38.2",57.6,NA,"delta","~47 weeks",NA,NA,"Hungary","HUN",235,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","18/04/2022",2022-04-18
"1997",235,"Voko","Retrospective cohort","22Jul2022","AZD1222 (AstraZeneca)","included","2","final","14-120","death","death","Hungary","18-64 years","18-64 years",90.1,"73.5",96.3,NA,"delta","~47 weeks",NA,NA,"Hungary","HUN",235,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"death","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","18/04/2022",2022-04-18
"1998",235,"Voko","Retrospective cohort","22Jul2022","AZD1222 (AstraZeneca)","included","2","final","240+","death","death","Hungary","18-64 years","18-64 years",57.1,"35.2",71.6,NA,"delta","~47 weeks",NA,NA,"Hungary","HUN",235,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"death","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","18/04/2022",2022-04-18
"1999",235,"Voko","Retrospective cohort","22Jul2022","Gam-COVID-Vac (Gamaleya)","included","2","final","14-120","infection","infection","Hungary","18-64 years","18-64 years",38.3,"31.8",44.3,NA,"delta","~47 weeks",NA,NA,"Hungary","HUN",235,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"infection","2022 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","delta","18/04/2022",2022-04-18
"2000",235,"Voko","Retrospective cohort","22Jul2022","Gam-COVID-Vac (Gamaleya)","included","2","final","240+","infection","infection","Hungary","18-64 years","18-64 years",-4.6,"-12.5",2.9,NA,"delta","~47 weeks",NA,NA,"Hungary","HUN",235,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"infection","2022 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","delta","18/04/2022",2022-04-18
"2001",235,"Voko","Retrospective cohort","22Jul2022","Gam-COVID-Vac (Gamaleya)","included","2","final","14-120","hospitalization","severe","Hungary","18-64 years","18-64 years",90.4,"78.5",95.7,NA,"delta","~47 weeks",NA,NA,"Hungary","HUN",235,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"severe","2022 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","delta","18/04/2022",2022-04-18
"2002",235,"Voko","Retrospective cohort","22Jul2022","Gam-COVID-Vac (Gamaleya)","included","2","final","240+","hospitalization","severe","Hungary","18-64 years","18-64 years",78.7,"69.1",85.4,NA,"delta","~47 weeks",NA,NA,"Hungary","HUN",235,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"severe","2022 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","delta","18/04/2022",2022-04-18
"2003",235,"Voko","Retrospective cohort","22Jul2022","Gam-COVID-Vac (Gamaleya)","included","2","final","121-180","death","death","Hungary","18-64 years","18-64 years",89.3,"79.9",94.3,NA,"delta","~47 weeks",NA,NA,"Hungary","HUN",235,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"death","2022 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","delta","18/04/2022",2022-04-18
"2004",235,"Voko","Retrospective cohort","22Jul2022","Gam-COVID-Vac (Gamaleya)","included","2","final","240+","death","death","Hungary","18-64 years","18-64 years",79.1,"59.8",89.2,NA,"delta","~47 weeks",NA,NA,"Hungary","HUN",235,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"death","2022 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","delta","18/04/2022",2022-04-18
"2005",235,"Voko","Retrospective cohort","22Jul2022","Ad26.COV2.S (Janssen)","included","1","final","14-120","infection","infection","Hungary","18-64 years","18-64 years",39.3,"36.1",42.4,NA,"delta","~47 weeks",NA,NA,"Hungary","HUN",235,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"infection","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta","18/04/2022",2022-04-18
"2006",235,"Voko","Retrospective cohort","22Jul2022","Ad26.COV2.S (Janssen)","included","1","final","181-240","infection","infection","Hungary","18-64 years","18-64 years",35.9,"32.5",39.2,NA,"delta","~47 weeks",NA,NA,"Hungary","HUN",235,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"infection","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta","18/04/2022",2022-04-18
"2007",235,"Voko","Retrospective cohort","22Jul2022","Ad26.COV2.S (Janssen)","included","1","final","14-120","hospitalization","severe","Hungary","18-64 years","18-64 years",43.2,"32.9",52,NA,"delta","~47 weeks",NA,NA,"Hungary","HUN",235,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"severe","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta","18/04/2022",2022-04-18
"2008",235,"Voko","Retrospective cohort","22Jul2022","Ad26.COV2.S (Janssen)","included","1","final","181-240","hospitalization","severe","Hungary","18-64 years","18-64 years",59.4,"50.1",67,NA,"delta","~47 weeks",NA,NA,"Hungary","HUN",235,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"severe","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta","18/04/2022",2022-04-18
"2009",235,"Voko","Retrospective cohort","22Jul2022","Ad26.COV2.S (Janssen)","included","1","final","14-120","death","death","Hungary","18-64 years","18-64 years",59.8,"35.2",75.1,NA,"delta","~47 weeks",NA,NA,"Hungary","HUN",235,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"death","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta","18/04/2022",2022-04-18
"2010",235,"Voko","Retrospective cohort","22Jul2022","Ad26.COV2.S (Janssen)","included","1","final","181-240","death","death","Hungary","18-64 years","18-64 years",76.1,"56.7",86.8,NA,"delta","~47 weeks",NA,NA,"Hungary","HUN",235,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"death","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta","18/04/2022",2022-04-18
"2011",235,"Voko","Retrospective cohort","22Jul2022","BBIBP-CorV (Beijing CNBG)","included","2","final","14-120","infection","infection","Hungary","18-64 years","18-64 years",10.9,"6.7",15,NA,"delta","~47 weeks",NA,NA,"Hungary","HUN",235,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"infection","2022 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta","18/04/2022",2022-04-18
"2012",235,"Voko","Retrospective cohort","22Jul2022","BBIBP-CorV (Beijing CNBG)","included","2","final","240+","infection","infection","Hungary","18-64 years","18-64 years",-19.9,"-31.9",-9,NA,"delta","~47 weeks",NA,NA,"Hungary","HUN",235,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"infection","2022 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta","18/04/2022",2022-04-18
"2013",235,"Voko","Retrospective cohort","22Jul2022","BBIBP-CorV (Beijing CNBG)","included","2","final","14-120","hospitalization","severe","Hungary","18-64 years","18-64 years",53.8,"43.9",61.9,NA,"delta","~47 weeks",NA,NA,"Hungary","HUN",235,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"severe","2022 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta","18/04/2022",2022-04-18
"2014",235,"Voko","Retrospective cohort","22Jul2022","BBIBP-CorV (Beijing CNBG)","included","2","final","240+","hospitalization","severe","Hungary","18-64 years","18-64 years",40.9,"24.4",53.8,NA,"delta","~47 weeks",NA,NA,"Hungary","HUN",235,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"severe","2022 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta","18/04/2022",2022-04-18
"2015",235,"Voko","Retrospective cohort","22Jul2022","BBIBP-CorV (Beijing CNBG)","included","2","final","14-120","death","death","Hungary","18-64 years","18-64 years",67.4,"39.2",82.5,NA,"delta","~47 weeks",NA,NA,"Hungary","HUN",235,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"death","2022 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta","18/04/2022",2022-04-18
"2016",235,"Voko","Retrospective cohort","22Jul2022","BBIBP-CorV (Beijing CNBG)","included","2","final","240+","death","death","Hungary","18-64 years","18-64 years",50.7,"21.4",69.1,NA,"delta","~47 weeks",NA,NA,"Hungary","HUN",235,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"death","2022 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta","18/04/2022",2022-04-18
"2017",236,"Gram","Retrospective cohort","01Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-30","infection","infection","Denmark","12-59 years","12-59 years",40,"38.6",41.3,NA,"omicron","~56 weeks",NA,NA,"Denmark","DNK",236,"DNK",61830,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,8,212,261,"who",8,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-01,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","20/04/2022",2022-04-20
"2018",236,"Gram","Retrospective cohort","01Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","120+","infection","infection","Denmark","12-59 years","12-59 years",12.6,"12",13.3,NA,"omicron","~56 weeks",NA,NA,"Denmark","DNK",236,"DNK",61830,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,8,212,261,"who",8,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-01,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","20/04/2022",2022-04-20
"2019",236,"Gram","Retrospective cohort","01Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-30","hospitalization","severe","Denmark","12-59 years","12-59 years",96.2,"72.9",99.5,NA,"omicron","~56 weeks",NA,NA,"Denmark","DNK",236,"DNK",61830,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,8,212,261,"who",8,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-01,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","20/04/2022",2022-04-20
"2020",236,"Gram","Retrospective cohort","01Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","120+","hospitalization","severe","Denmark","12-59 years","12-59 years",77.6,"72.6",81.6,NA,"omicron","~56 weeks",NA,NA,"Denmark","DNK",236,"DNK",61830,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,8,212,261,"who",8,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-01,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","20/04/2022",2022-04-20
"2021",236,"Gram","Retrospective cohort","01Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-30","infection","infection","Denmark","12-59 years","12-59 years",92.2,"91.8",92.6,NA,"delta","~56 weeks",NA,NA,"Denmark","DNK",236,"DNK",61830,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,8,212,261,"who",8,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-01,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta","20/04/2022",2022-04-20
"2022",236,"Gram","Retrospective cohort","01Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","120+","infection","infection","Denmark","12-59 years","12-59 years",64.8,"64",65.8,NA,"delta","~56 weeks",NA,NA,"Denmark","DNK",236,"DNK",61830,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,8,212,261,"who",8,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-01,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta","20/04/2022",2022-04-20
"2023",236,"Gram","Retrospective cohort","01Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-30","hospitalization","severe","Denmark","12-59 years","12-59 years",99.5,"98.4",99.8,NA,"delta","~56 weeks",NA,NA,"Denmark","DNK",236,"DNK",61830,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,8,212,261,"who",8,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-01,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta","20/04/2022",2022-04-20
"2024",236,"Gram","Retrospective cohort","01Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","120+","hospitalization","severe","Denmark","12-59 years","12-59 years",93.5,"91.6",95,NA,"delta","~56 weeks",NA,NA,"Denmark","DNK",236,"DNK",61830,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,8,212,261,"who",8,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-01,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta","20/04/2022",2022-04-20
"2025",236,"Gram","Retrospective cohort","01Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-30","infection","infection","Denmark",">= 60 years",">= 60 years",39.9,"26.3",50.9,NA,"omicron","~56 weeks",NA,NA,"Denmark","DNK",236,"DNK",61830,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,8,212,261,"who",8,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-01,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","20/04/2022",2022-04-20
"2026",236,"Gram","Retrospective cohort","01Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","120+","infection","infection","Denmark",">= 60 years",">= 60 years",4.4,"-0.1",8.7,NA,"omicron","~56 weeks",NA,NA,"Denmark","DNK",236,"DNK",61830,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,8,212,261,"who",8,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-01,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","20/04/2022",2022-04-20
"2027",236,"Gram","Retrospective cohort","01Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-30","infection","infection","Denmark",">= 60 years",">= 60 years",82.3,"75.5",87.2,NA,"delta","~56 weeks",NA,NA,"Denmark","DNK",236,"DNK",61830,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,8,212,261,"who",8,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-01,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta","20/04/2022",2022-04-20
"2028",236,"Gram","Retrospective cohort","01Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","120+","infection","infection","Denmark",">= 60 years",">= 60 years",50,"46.7",53,NA,"delta","~56 weeks",NA,NA,"Denmark","DNK",236,"DNK",61830,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,8,212,261,"who",8,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-01,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta","20/04/2022",2022-04-20
"2029",236,"Gram","Retrospective cohort","01Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","31-60","hospitalization","severe","Denmark",">= 60 years",">= 60 years",97.7,"94.8",98.8,NA,"delta","~56 weeks",NA,NA,"Denmark","DNK",236,"DNK",61830,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,8,212,261,"who",8,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-01,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta","20/04/2022",2022-04-20
"2030",236,"Gram","Retrospective cohort","01Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","120+","hospitalization","severe","Denmark",">= 60 years",">= 60 years",87.5,"85.6",89.2,NA,"delta","~56 weeks",NA,NA,"Denmark","DNK",236,"DNK",61830,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,8,212,261,"who",8,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-01,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta","20/04/2022",2022-04-20
"2031",236,"Gram","Retrospective cohort","01Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-30","infection","infection","Denmark",">= 60 years",">= 60 years",90.7,"88.2",92.7,NA,"alpha","~56 weeks",NA,NA,"Denmark","DNK",236,"DNK",61830,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,8,212,261,"who",8,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-01,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha","20/04/2022",2022-04-20
"2032",236,"Gram","Retrospective cohort","01Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","120+","infection","infection","Denmark",">= 60 years",">= 60 years",73.2,"57.1",83.3,NA,"alpha","~56 weeks",NA,NA,"Denmark","DNK",236,"DNK",61830,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,8,212,261,"who",8,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-01,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha","20/04/2022",2022-04-20
"2033",236,"Gram","Retrospective cohort","01Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-30","hospitalization","severe","Denmark",">= 60 years",">= 60 years",98.1,"94.7",99.3,NA,"alpha","~56 weeks",NA,NA,"Denmark","DNK",236,"DNK",61830,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,8,212,261,"who",8,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-01,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha","20/04/2022",2022-04-20
"2034",236,"Gram","Retrospective cohort","01Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","120+","hospitalization","severe","Denmark",">= 60 years",">= 60 years",96.5,"73.4",99.5,NA,"alpha","~56 weeks",NA,NA,"Denmark","DNK",236,"DNK",61830,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,8,212,261,"who",8,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-01,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha","20/04/2022",2022-04-20
"2035",237,"Lind","Test-negative case-control","25Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-140","infection","infection","USA",">= 18 years","general pop",28.5,"20",36.2,"omicron","omicron","~67 weeks",NA,NA,"USA","USA",237,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-25,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","25/04/2022",2022-04-25
"2036",237,"Lind","Test-negative case-control","25Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","150+","infection","infection","USA",">= 18 years","general pop",15.3,"10.4",20,"omicron","omicron","~67 weeks",NA,NA,"USA","USA",237,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-25,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","25/04/2022",2022-04-25
"2037",237,"Lind","Test-negative case-control","25Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-140","infection","infection","USA",">= 18 years","general pop",36.1,"7.1",56.1,"omicron","omicron","~67 weeks",NA,NA,"USA","USA",237,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-25,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","25/04/2022",2022-04-25
"2038",237,"Lind","Test-negative case-control","25Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","150+","infection","infection","USA",">= 18 years","general pop",34,"18.5",46.5,"omicron","omicron","~67 weeks",NA,NA,"USA","USA",237,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-25,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","25/04/2022",2022-04-25
"2039",237,"Lind","1:1 Matched case control","25Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-140","infection","infection","USA",">= 18 years","general pop",30.7,"20.6",39.6,"omicron","omicron","~67 weeks",NA,NA,"USA","USA",237,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-25,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","25/04/2022",2022-04-25
"2040",237,"Lind","1:1 Matched case control","25Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","150+","infection","infection","USA",">= 18 years","general pop",20,"14",25.6,"omicron","omicron","~67 weeks",NA,NA,"USA","USA",237,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-25,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","25/04/2022",2022-04-25
"2041",237,"Lind","1:1 Matched case control","25Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-140","infection","infection","USA",">= 18 years","general pop",14.3,"-43.1",48.7,"omicron","omicron","~67 weeks",NA,NA,"USA","USA",237,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-25,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","25/04/2022",2022-04-25
"2042",237,"Lind","1:1 Matched case control","25Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","150+","infection","infection","USA",">= 18 years","general pop",18.8,"-9",39.5,"omicron","omicron","~67 weeks",NA,NA,"USA","USA",237,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-25,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","25/04/2022",2022-04-25
"2043",238,"Sanchez Ruiz","Retrospective cohort","01Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","France","LTCF residents","LTCF residents",11.2,"0",61.1,"delta","delta",NA,NA,NA,"France","FRA",238,"FRA",51580,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,15,204,345,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-01,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-04-01
"2044",238,"Sanchez Ruiz","Retrospective cohort","01Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease","symptomatic","France","LTCF residents","LTCF residents",88.4,"59.9",96.7,"delta","delta",NA,NA,NA,"France","FRA",238,"FRA",51580,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,15,204,345,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-01,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-04-01
"2045",238,"Sanchez Ruiz","Retrospective cohort","01Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","severe disease","severe","France","LTCF residents","LTCF residents",93.5,"67.2",98.7,"delta","delta",NA,NA,NA,"France","FRA",238,"FRA",51580,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,15,204,345,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-01,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-04-01
"2046",239,"Widdifield","Test-negative case-control","14Apr2022","BNT162b2 (Pfizer BioNTech)","included","2","final","7+","infection","infection","Canada","individuals with rheumatoid arthritis","individuals with rheumatoid arthritis",82,"78",85,NA,"alpha & delta","~44 weeks",NA,NA,"Canada","CAN",239,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-14,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-04-14
"2047",239,"Widdifield","Test-negative case-control","14Apr2022","mRNA-1273 (Moderna)","included","2","final","7+","infection","infection","Canada","individuals with rheumatoid arthritis","individuals with rheumatoid arthritis",86,"80",90,NA,"alpha & delta","~44 weeks",NA,NA,"Canada","CAN",239,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-14,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-04-14
"2048",239,"Widdifield","Test-negative case-control","14Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","7+","infection","infection","Canada","individuals with rheumatoid arthritis","individuals with rheumatoid arthritis",83,"80",86,NA,"alpha & delta","~44 weeks",NA,NA,"Canada","CAN",239,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-14,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-04-14
"2049",239,"Widdifield","Test-negative case-control","14Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","7+","severe disease","severe","Canada","individuals with rheumatoid arthritis","individuals with rheumatoid arthritis",92,"88",95,NA,"alpha & delta","~44 weeks",NA,NA,"Canada","CAN",239,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-14,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-04-14
"2050",239,"Widdifield","Test-negative case-control","14Apr2022","BNT162b2 (Pfizer BioNTech)","included","2","final","7+","infection","infection","Canada","individuals with ankylosing spondylitis","individuals with ankylosing spondylitis",88,"82",93,NA,"alpha & delta","~44 weeks",NA,NA,"Canada","CAN",239,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-14,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-04-14
"2051",239,"Widdifield","Test-negative case-control","14Apr2022","mRNA-1273 (Moderna)","included","2","final","7+","infection","infection","Canada","individuals with ankylosing spondylitis","individuals with ankylosing spondylitis",93,"83",97,NA,"alpha & delta","~44 weeks",NA,NA,"Canada","CAN",239,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-14,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-04-14
"2052",239,"Widdifield","Test-negative case-control","14Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","7+","infection","infection","Canada","individuals with ankylosing spondylitis","individuals with ankylosing spondylitis",89,"83",93,NA,"alpha & delta","~44 weeks",NA,NA,"Canada","CAN",239,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-14,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-04-14
"2053",239,"Widdifield","Test-negative case-control","14Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","7+","severe disease","severe","Canada","individuals with ankylosing spondylitis","individuals with ankylosing spondylitis",97,"83",99,NA,"alpha & delta","~44 weeks",NA,NA,"Canada","CAN",239,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-14,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-04-14
"2054",239,"Widdifield","Test-negative case-control","14Apr2022","BNT162b2 (Pfizer BioNTech)","included","2","final","7+","infection","infection","Canada","individuals with psoriasis","individuals with psoriasis",82,"79",85,NA,"alpha & delta","~44 weeks",NA,NA,"Canada","CAN",239,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-14,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-04-14
"2055",239,"Widdifield","Test-negative case-control","14Apr2022","mRNA-1273 (Moderna)","included","2","final","7+","infection","infection","Canada","individuals with psoriasis","individuals with psoriasis",87,"82",91,NA,"alpha & delta","~44 weeks",NA,NA,"Canada","CAN",239,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-14,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-04-14
"2056",239,"Widdifield","Test-negative case-control","14Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","7+","infection","infection","Canada","individuals with psoriasis","individuals with psoriasis",84,"81",86,NA,"alpha & delta","~44 weeks",NA,NA,"Canada","CAN",239,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-14,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-04-14
"2057",239,"Widdifield","Test-negative case-control","14Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","7+","severe disease","severe","Canada","individuals with psoriasis","individuals with psoriasis",92,"86",95,NA,"alpha & delta","~44 weeks",NA,NA,"Canada","CAN",239,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-14,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-04-14
"2058",239,"Widdifield","Test-negative case-control","14Apr2022","BNT162b2 (Pfizer BioNTech)","included","2","final","7+","infection","infection","Canada","individuals with inflammatory bowel disease","individuals with inflammatory bowel disease",82,"79",85,NA,"alpha & delta","~44 weeks",NA,NA,"Canada","CAN",239,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-14,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-04-14
"2059",239,"Widdifield","Test-negative case-control","14Apr2022","mRNA-1273 (Moderna)","included","2","final","7+","infection","infection","Canada","individuals with inflammatory bowel disease","individuals with inflammatory bowel disease",87,"82",91,NA,"alpha & delta","~44 weeks",NA,NA,"Canada","CAN",239,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-14,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-04-14
"2060",239,"Widdifield","Test-negative case-control","14Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","7+","infection","infection","Canada","individuals with inflammatory bowel disease","individuals with inflammatory bowel disease",79,"74",82,NA,"alpha & delta","~44 weeks",NA,NA,"Canada","CAN",239,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-14,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-04-14
"2061",239,"Widdifield","Test-negative case-control","14Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","7+","severe disease","severe","Canada","individuals with inflammatory bowel disease","individuals with inflammatory bowel disease",94,"88",97,NA,"alpha & delta","~44 weeks",NA,NA,"Canada","CAN",239,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-14,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-04-14
"2062",240,"Cerqueira-Silva","Test-negative case-control","11Jan2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14-59","symptomatic disease","symptomatic","Brazil",">= 18 years","general pop",49.2,"48.5",49.9,NA,"omicron","~7 weeks",NA,NA,"Brazil","BRA",240,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2023-01-11,"symptomatic","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","14/04/2022",2022-04-14
"2063",240,"Cerqueira-Silva","Test-negative case-control","11Jan2023","BNT162b2 (Pfizer BioNTech)","included","2","final","150+","symptomatic disease","symptomatic","Brazil",">= 18 years","general pop",9.6,"8.1",11,NA,"omicron","~33 weeks",NA,NA,"Brazil","BRA",240,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2023-01-11,"symptomatic","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","14/04/2022",2022-04-14
"2064",240,"Cerqueira-Silva","Test-negative case-control","11Jan2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14-59","severe disease","severe","Brazil",">= 18 years","general pop",82.9,"80.6",85,NA,"omicron","~7 weeks",NA,NA,"Brazil","BRA",240,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2023-01-11,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","14/04/2022",2022-04-14
"2065",240,"Cerqueira-Silva","Test-negative case-control","11Jan2023","BNT162b2 (Pfizer BioNTech)","included","2","final","150+","severe disease","severe","Brazil",">= 18 years","general pop",82.6,"80.7",84.3,NA,"omicron","~33 weeks",NA,NA,"Brazil","BRA",240,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2023-01-11,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","14/04/2022",2022-04-14
"2066",240,"Cerqueira-Silva","Test-negative case-control","11Jan2023","AZD1222 (AstraZeneca)","included","2","final","14-59","symptomatic disease","symptomatic","Brazil",">= 18 years","general pop",26.7,"25.2",28.2,NA,"omicron","~7 weeks",NA,NA,"Brazil","BRA",240,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2023-01-11,"symptomatic","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","14/04/2022",2022-04-14
"2067",240,"Cerqueira-Silva","Test-negative case-control","11Jan2023","AZD1222 (AstraZeneca)","included","2","final","150+","symptomatic disease","symptomatic","Brazil",">= 18 years","general pop",0.9,"0",1.9,NA,"omicron","~36 weeks",NA,NA,"Brazil","BRA",240,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2023-01-11,"symptomatic","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","14/04/2022",2022-04-14
"2068",240,"Cerqueira-Silva","Test-negative case-control","11Jan2023","AZD1222 (AstraZeneca)","included","2","final","14-59","severe disease","severe","Brazil",">= 18 years","general pop",77.1,"72.9",80.6,NA,"omicron","~7 weeks",NA,NA,"Brazil","BRA",240,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2023-01-11,"severe","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","14/04/2022",2022-04-14
"2069",240,"Cerqueira-Silva","Test-negative case-control","11Jan2023","AZD1222 (AstraZeneca)","included","2","final","150+","severe disease","severe","Brazil",">= 18 years","general pop",67.8,"66.7",69,NA,"omicron","~36 weeks",NA,NA,"Brazil","BRA",240,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2023-01-11,"severe","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","14/04/2022",2022-04-14
"2070",240,"Cerqueira-Silva","Test-negative case-control","11Jan2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14-59","symptomatic disease","symptomatic","Scotland",">= 18 years","general pop",57.7,"54.5",60.6,NA,"omicron","~7 weeks",NA,NA,"UK","GBR",500,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-01-11,"symptomatic","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","14/04/2022",2022-04-14
"2071",240,"Cerqueira-Silva","Test-negative case-control","11Jan2023","BNT162b2 (Pfizer BioNTech)","included","2","final","150+","symptomatic disease","symptomatic","Scotland",">= 18 years","general pop",17.8,"15.1",20.5,NA,"omicron","~38.5 weeks",NA,NA,"UK","GBR",500,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-01-11,"symptomatic","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","14/04/2022",2022-04-14
"2072",240,"Cerqueira-Silva","Test-negative case-control","11Jan2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14-59","severe disease","severe","Scotland",">= 18 years","general pop",90.4,"30.4",98.7,NA,"omicron","~7 weeks",NA,NA,"UK","GBR",500,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-01-11,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","14/04/2022",2022-04-14
"2073",240,"Cerqueira-Silva","Test-negative case-control","11Jan2023","BNT162b2 (Pfizer BioNTech)","included","2","final","150+","severe disease","severe","Scotland",">= 18 years","general pop",72.9,"57.9",82.5,NA,"omicron","~38.5 weeks",NA,NA,"UK","GBR",500,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-01-11,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","14/04/2022",2022-04-14
"2074",240,"Cerqueira-Silva","Test-negative case-control","11Jan2023","AZD1222 (AstraZeneca)","included","2","final","14-59","symptomatic disease","symptomatic","Scotland",">= 18 years","general pop",40.7,"26.6",52.1,NA,"omicron","~7 weeks",NA,NA,"UK","GBR",500,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-01-11,"symptomatic","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","14/04/2022",2022-04-14
"2075",240,"Cerqueira-Silva","Test-negative case-control","11Jan2023","AZD1222 (AstraZeneca)","included","2","final","150+","symptomatic disease","symptomatic","Scotland",">= 18 years","general pop",9.6,"6.3",12.9,NA,"omicron","~35.5 weeks",NA,NA,"UK","GBR",500,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-01-11,"symptomatic","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","14/04/2022",2022-04-14
"2076",240,"Cerqueira-Silva","Test-negative case-control","11Jan2023","AZD1222 (AstraZeneca)","included","2","final","60-149","severe disease","severe","Scotland",">= 18 years","general pop",78.8,"31.8",93.4,NA,"omicron","~19 weeks",NA,NA,"UK","GBR",500,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-01-11,"severe","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","14/04/2022",2022-04-14
"2077",240,"Cerqueira-Silva","Test-negative case-control","11Jan2023","AZD1222 (AstraZeneca)","included","2","final","150+","severe disease","severe","Scotland",">= 18 years","general pop",52.8,"33.3",66.7,NA,"omicron","~35.5 weeks",NA,NA,"UK","GBR",500,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-01-11,"severe","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","14/04/2022",2022-04-14
"2078",241,"Gonzalez","Retrospective cohort","19Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","Argentina","12-17 years","12-17 years",81,"59.9",90.1,NA,"delta & omicron","~17 weeks",NA,NA,"Argentina","ARG",241,"ARG",22100,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,21,263,381,"equal",21,"before jan/2021","<30","Sep-Nov/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta/omicron","19/04/2022",2022-04-19
"2079",241,"Gonzalez","Retrospective cohort","19Apr2022","BBIBP-CorV (Beijing CNBG)","included","2","final","14+","hospitalization","severe","Argentina","3-11 years","3-11 years",83.4,"70.9",90.2,NA,"delta & omicron","~9 weeks",NA,NA,"Argentina","ARG",241,"ARG",22100,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,21,263,381,"equal",21,"before jan/2021","<30","Sep-Nov/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta/omicron","19/04/2022",2022-04-19
"2080",241,"Gonzalez","Retrospective cohort","19Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","Argentina","12-17 years","12-17 years",78.2,"42",90.3,NA,"omicron","~25 weeks",NA,NA,"Argentina","ARG",241,"ARG",22100,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,21,263,381,"equal",21,"before jan/2021","<30","Sep-Nov/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","19/04/2022",2022-04-19
"2081",241,"Gonzalez","Retrospective cohort","19Apr2022","BBIBP-CorV (Beijing CNBG)","included","2","final","14+","hospitalization","severe","Argentina","3-11 years","3-11 years",58.6,"4.1",79.7,NA,"omicron","16 weeks",NA,NA,"Argentina","ARG",241,"ARG",22100,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,21,263,381,"equal",21,"before jan/2021","<30","Sep-Nov/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","omicron","19/04/2022",2022-04-19
"2082",242,"Eick-Cost","Case-control","20Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","USA","military personnel","military personnel",87.6,"86.2",88.9,NA,"pre-delta (non-VOC, alpha)","~19 weeks",NA,NA,"USA","USA",242,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-20,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-04-20
"2083",242,"Eick-Cost","Case-control","20Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","asymptomatic infection","asymptomatic","USA","military personnel","military personnel",80.3,"76.5",83.5,NA,"pre-delta (non-VOC, alpha)","~19 weeks",NA,NA,"USA","USA",242,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-20,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-04-20
"2084",242,"Eick-Cost","Case-control","20Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease","symptomatic","USA","military personnel","military personnel",89.9,"88.4",91.2,NA,"pre-delta (non-VOC, alpha)","~19 weeks",NA,NA,"USA","USA",242,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-20,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-04-20
"2085",242,"Eick-Cost","Case-control","20Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization","severe","USA","military personnel","military personnel",88,"75.4",94.1,NA,"pre-delta (non-VOC, alpha)","~19 weeks",NA,NA,"USA","USA",242,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-20,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-04-20
"2086",242,"Eick-Cost","Case-control","20Apr2022","mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","USA","military personnel","military personnel",93.5,"91.9",94.7,NA,"pre-delta (non-VOC, alpha)","~19 weeks",NA,NA,"USA","USA",242,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-20,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-04-20
"2087",242,"Eick-Cost","Case-control","20Apr2022","mRNA-1273 (Moderna)","excluded","2","final","14+","asymptomatic infection","asymptomatic","USA","military personnel","military personnel",94.7,"91.9",96.6,NA,"pre-delta (non-VOC, alpha)","~19 weeks",NA,NA,"USA","USA",242,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-20,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-04-20
"2088",242,"Eick-Cost","Case-control","20Apr2022","mRNA-1273 (Moderna)","excluded","2","final","14+","symptomatic disease","symptomatic","USA","military personnel","military personnel",93.1,"91.2",94.6,NA,"pre-delta (non-VOC, alpha)","~19 weeks",NA,NA,"USA","USA",242,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-20,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-04-20
"2089",242,"Eick-Cost","Case-control","20Apr2022","mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization","severe","USA","military personnel","military personnel",89.6,"57.5",97.4,NA,"pre-delta (non-VOC, alpha)","~19 weeks",NA,NA,"USA","USA",242,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-20,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-04-20
"2090",242,"Eick-Cost","Case-control","20Apr2022","Ad26.COV2.S (Janssen)","excluded","1","final","14+","infection","infection","USA","military personnel","military personnel",81.8,"74.2",87.1,NA,"pre-delta (non-VOC, alpha)","~19 weeks",NA,NA,"USA","USA",242,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-20,"infection","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-04-20
"2091",242,"Eick-Cost","Case-control","20Apr2022","Ad26.COV2.S (Janssen)","excluded","1","final","14+","asymptomatic infection","asymptomatic","USA","military personnel","military personnel",81.4,"62.6",90.8,NA,"pre-delta (non-VOC, alpha)","~19 weeks",NA,NA,"USA","USA",242,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-20,"infection","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-04-20
"2092",242,"Eick-Cost","Case-control","20Apr2022","Ad26.COV2.S (Janssen)","excluded","1","final","14+","symptomatic disease","symptomatic","USA","military personnel","military personnel",82.4,"73.9",88.2,NA,"pre-delta (non-VOC, alpha)","~19 weeks",NA,NA,"USA","USA",242,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-20,"symptomatic","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-04-20
"2093",242,"Eick-Cost","Case-control","20Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","USA","military personnel","military personnel",69.3,"68.2",70.3,NA,"delta","~35 weeks",NA,NA,"USA","USA",242,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-20,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-04-20
"2094",242,"Eick-Cost","Case-control","20Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","asymptomatic infection","asymptomatic","USA","military personnel","military personnel",66,"64",67.8,NA,"delta","~35 weeks",NA,NA,"USA","USA",242,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-20,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-04-20
"2095",242,"Eick-Cost","Case-control","20Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease","symptomatic","USA","military personnel","military personnel",71,"69.7",72.1,NA,"delta","~35 weeks",NA,NA,"USA","USA",242,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-20,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-04-20
"2096",242,"Eick-Cost","Case-control","20Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization","severe","USA","military personnel","military personnel",88.4,"82.1",92.5,NA,"delta","~35 weeks",NA,NA,"USA","USA",242,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-20,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-04-20
"2097",242,"Eick-Cost","Case-control","20Apr2022","mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","USA","military personnel","military personnel",79.4,"78.3",80.4,NA,"delta","~35 weeks",NA,NA,"USA","USA",242,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-20,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta",NA,2022-04-20
"2098",242,"Eick-Cost","Case-control","20Apr2022","mRNA-1273 (Moderna)","excluded","2","final","14+","asymptomatic infection","asymptomatic","USA","military personnel","military personnel",77,"75.1",78.8,NA,"delta","~35 weeks",NA,NA,"USA","USA",242,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-20,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta",NA,2022-04-20
"2099",242,"Eick-Cost","Case-control","20Apr2022","mRNA-1273 (Moderna)","excluded","2","final","14+","symptomatic disease","symptomatic","USA","military personnel","military personnel",80.6,"79.4",81.8,NA,"delta","~35 weeks",NA,NA,"USA","USA",242,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-20,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta",NA,2022-04-20
"2100",242,"Eick-Cost","Case-control","20Apr2022","mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization","severe","USA","military personnel","military personnel",88.1,"75.7",94.2,NA,"delta","~35 weeks",NA,NA,"USA","USA",242,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-20,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta",NA,2022-04-20
"2101",242,"Eick-Cost","Case-control","20Apr2022","Ad26.COV2.S (Janssen)","excluded","1","final","14+","infection","infection","USA","military personnel","military personnel",38.3,"34.5",41.9,NA,"delta","~35 weeks",NA,NA,"USA","USA",242,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-20,"infection","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta",NA,2022-04-20
"2102",242,"Eick-Cost","Case-control","20Apr2022","Ad26.COV2.S (Janssen)","excluded","1","final","14+","asymptomatic infection","asymptomatic","USA","military personnel","military personnel",19.6,"12.2",26.4,NA,"delta","~35 weeks",NA,NA,"USA","USA",242,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-20,"infection","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta",NA,2022-04-20
"2103",242,"Eick-Cost","Case-control","20Apr2022","Ad26.COV2.S (Janssen)","excluded","1","final","14+","symptomatic disease","symptomatic","USA","military personnel","military personnel",48.9,"45",52.7,NA,"delta","~35 weeks",NA,NA,"USA","USA",242,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-20,"symptomatic","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta",NA,2022-04-20
"2104",242,"Eick-Cost","Case-control","20Apr2022","Ad26.COV2.S (Janssen)","excluded","1","final","14+","hospitalization","severe","USA","military personnel","military personnel",57.7,"2.6",81.6,NA,"delta","~35 weeks",NA,NA,"USA","USA",242,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-20,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta",NA,2022-04-20
"2105",243,"Castillo","Test-negative case-control","21Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","0-30","symptomatic disease","symptomatic","France",">= 18 years","general pop",43,"41",45,"omicron","omicron","~48 weeks",NA,NA,"France","FRA",243,"FRA",51580,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,15,204,345,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-21,"symptomatic","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-04-21
"2106",243,"Castillo","Test-negative case-control","21Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","180+","symptomatic disease","symptomatic","France",">= 18 years","general pop",11,"10",13,"omicron","omicron","~48 weeks",NA,NA,"France","FRA",243,"FRA",51580,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,15,204,345,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-21,"symptomatic","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-04-21
"2107",243,"Castillo","Test-negative case-control","21Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","0-30","hospitalization","severe","France",">= 18 years","general pop",59,"49",70,"omicron","omicron","~48 weeks",NA,NA,"France","FRA",243,"FRA",51580,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,15,204,345,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-21,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-04-21
"2108",243,"Castillo","Test-negative case-control","21Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","180+","hospitalization","severe","France",">= 18 years","general pop",56,"51",62,"omicron","omicron","~48 weeks",NA,NA,"France","FRA",243,"FRA",51580,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,15,204,345,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-21,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-04-21
"2109",243,"Castillo","Test-negative case-control","21Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","0-30","ICU admission","severe","France",">= 18 years","general pop",70,"40",97,"omicron","omicron","~48 weeks",NA,NA,"France","FRA",243,"FRA",51580,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,15,204,345,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-21,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-04-21
"2110",243,"Castillo","Test-negative case-control","21Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","180+","ICU admission","severe","France",">= 18 years","general pop",72,"63",81,"omicron","omicron","~48 weeks",NA,NA,"France","FRA",243,"FRA",51580,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,15,204,345,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-21,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-04-21
"2111",243,"Castillo","Test-negative case-control","21Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","0-30","death","death","France",">= 18 years","general pop",60,"24",92,"omicron","omicron","~48 weeks",NA,NA,"France","FRA",243,"FRA",51580,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,15,204,345,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-21,"death","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-04-21
"2112",243,"Castillo","Test-negative case-control","21Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","180+","death","death","France",">= 18 years","general pop",54,"41",69,"omicron","omicron","~48 weeks",NA,NA,"France","FRA",243,"FRA",51580,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,15,204,345,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-21,"death","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-04-21
"2113",243,"Castillo","Test-negative case-control","21Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","0-30","symptomatic disease","symptomatic","France",">= 18 years","general pop",78,"77",80,"delta","delta","~48 weeks",NA,NA,"France","FRA",243,"FRA",51580,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,15,204,345,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-21,"symptomatic","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2022-04-21
"2114",243,"Castillo","Test-negative case-control","21Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","180+","symptomatic disease","symptomatic","France",">= 18 years","general pop",63,"62",64,"delta","delta","~48 weeks",NA,NA,"France","FRA",243,"FRA",51580,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,15,204,345,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-21,"symptomatic","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2022-04-21
"2115",243,"Castillo","Test-negative case-control","21Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","0-30","hospitalization","severe","France",">= 18 years","general pop",91,"87",95,"delta","delta","~48 weeks",NA,NA,"France","FRA",243,"FRA",51580,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,15,204,345,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-21,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2022-04-21
"2116",243,"Castillo","Test-negative case-control","21Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","180+","hospitalization","severe","France",">= 18 years","general pop",90,"89",91,"delta","delta","~48 weeks",NA,NA,"France","FRA",243,"FRA",51580,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,15,204,345,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-21,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2022-04-21
"2117",243,"Castillo","Test-negative case-control","21Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","0-30","ICU admission","severe","France",">= 18 years","general pop",93,"86",99,"delta","delta","~48 weeks",NA,NA,"France","FRA",243,"FRA",51580,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,15,204,345,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-21,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2022-04-21
"2118",243,"Castillo","Test-negative case-control","21Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","180+","ICU admission","severe","France",">= 18 years","general pop",95,"93",97,"delta","delta","~48 weeks",NA,NA,"France","FRA",243,"FRA",51580,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,15,204,345,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-21,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2022-04-21
"2119",243,"Castillo","Test-negative case-control","21Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","0-30","death","death","France",">= 18 years","general pop",90,"79",100,"delta","delta","~48 weeks",NA,NA,"France","FRA",243,"FRA",51580,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,15,204,345,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-21,"death","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2022-04-21
"2120",243,"Castillo","Test-negative case-control","21Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","180+","death","death","France",">= 18 years","general pop",87,"83",91,"delta","delta","~48 weeks",NA,NA,"France","FRA",243,"FRA",51580,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,15,204,345,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-21,"death","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2022-04-21
"2121",244,"Sharma","Matched case-control","27Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","USA","veterans","veterans",25.3,"21.8",28.7,NA,"omicron","~42 weeks",NA,NA,"USA","USA",244,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-27,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-04-27
"2122",244,"Sharma","Matched case-control","27Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization","severe","USA","veterans","veterans",52.9,"47.8",57.6,NA,"omicron","~42 weeks",NA,NA,"USA","USA",244,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-27,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-04-27
"2123",244,"Sharma","Matched case-control","27Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","death","death","USA","veterans","veterans",50.7,"37.9",61.6,NA,"omicron","~42 weeks",NA,NA,"USA","USA",244,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-27,"death","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-04-27
"2124",244,"Sharma","Matched case-control","27Apr2022","mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","USA","veterans","veterans",39.5,"35.8",43,NA,"omicron","~42 weeks",NA,NA,"USA","USA",244,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-27,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron",NA,2022-04-27
"2125",244,"Sharma","Matched case-control","27Apr2022","mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization","severe","USA","veterans","veterans",66.7,"61.4",71.6,NA,"omicron","~42 weeks",NA,NA,"USA","USA",244,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-27,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron",NA,2022-04-27
"2126",244,"Sharma","Matched case-control","27Apr2022","mRNA-1273 (Moderna)","excluded","2","final","14+","death","death","USA","veterans","veterans",65.6,"52.8",76.3,NA,"omicron","~42 weeks",NA,NA,"USA","USA",244,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-27,"death","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron",NA,2022-04-27
"2127",246,"Florentino","Test-negative case-control","13Aug2022","CoronaVac (Sinovac)","included","2","final","14+","symptomatic disease","symptomatic","Brazil","6-11 years","6-11 years",39.8,"33.7",45.4,NA,"omicron","~12 weeks",NA,NA,"Brazil","BRA",246,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-08-13,"symptomatic","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron","29/04/2022",2022-04-29
"2128",246,"Florentino","Test-negative case-control","13Aug2022","CoronaVac (Sinovac)","included","2","final","14+","hospitalization","severe","Brazil","6-11 years","6-11 years",59.2,"11.3",84.5,NA,"omicron","~12 weeks",NA,NA,"Brazil","BRA",246,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-08-13,"severe","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron","29/04/2022",2022-04-29
"2129",247,"Kirsebom","Test-negative case-control","12Dec2022","AZD1222 (AstraZeneca)","included","2","final","175+","symptomatic disease","symptomatic","UK","40-64 years","40-64 years",8,"6",9.9,"omicron","omicron","~44.5 weeks",NA,NA,"UK","GBR",247,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-12-12,"symptomatic","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","01/05/2022",2022-05-01
"2130",247,"Kirsebom","Test-negative case-control","12Dec2022","AZD1222 (AstraZeneca)","included","2","final","175+","symptomatic disease","symptomatic","UK","40-64 years","40-64 years",19.5,"11.7",26.6,"omicron","omicron","~44.5 weeks",NA,NA,"UK","GBR",247,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-12-12,"symptomatic","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","01/05/2022",2022-05-01
"2131",247,"Kirsebom","Test-negative case-control","12Dec2022","AZD1222 (AstraZeneca)","included","2","final","175+","hospitalization","severe","UK",">= 65 years",">= 65 years",61,"49.8",69.7,"omicron","omicron","~44.5 weeks",NA,NA,"UK","GBR",247,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-12-12,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","01/05/2022",2022-05-01
"2132",247,"Kirsebom","Test-negative case-control","12Dec2022","AZD1222 (AstraZeneca)","included","2","final","175+","hospitalization","severe","UK",">= 65 years",">= 65 years",73.4,"70.4",76.2,"delta","delta","~44.5 weeks",NA,NA,"UK","GBR",247,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-12-12,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","01/05/2022",2022-05-01
"2133",248,"Carazo","Test-negative case-control","14Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","infection","infection","Canada",">= 12 years","general pop",42,"41",44,NA,"omicron","~51 weeks",NA,NA,"Canada","CAN",248,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-10-14,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","03/05/2022",2022-05-03
"2134",248,"Carazo","Test-negative case-control","14Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","hospitalization","severe","Canada",">= 12 years","general pop",76,"74",78,NA,"omicron","~51 weeks",NA,NA,"Canada","CAN",248,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-10-14,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","03/05/2022",2022-05-03
"2135",248,"Carazo","Test-negative case-control","14Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","previously infected only","2","final","7+","infection","infection","Canada",">= 12 years","general pop",23.2,"21.2",27.4,NA,"omicron","~51 weeks",NA,NA,"Canada","CAN",248,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-10-14,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","03/05/2022",2022-05-03
"2136",248,"Carazo","Test-negative case-control","14Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","previously infected only","2","final","7+","hospitalization","severe","Canada",">= 12 years","general pop",68.4,"63.6",73.5,NA,"omicron","~51 weeks",NA,NA,"Canada","CAN",248,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-10-14,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","03/05/2022",2022-05-03
"2137",249,"Ma","Retrospective cohort/Outbreak investigation","03May2022","BBIBP-CorV (Beijing CNBG)","included","2","final","14+","symptomatic disease","symptomatic","China","close contacts","close contacts",75.5,"63",93.6,NA,"delta","~8 weeks",NA,NA,"China","CHN",249,"CHN",16610,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,-139,386,420,"who",0,"before jan/2021","<30","Jun-Aug/2021","360+","yes","yes","yes",2022-05-03,"symptomatic","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta",NA,2022-05-03
"2138",249,"Ma","Retrospective cohort/Outbreak investigation","03May2022","BBIBP-CorV (Beijing CNBG)","included","2","final","14+","pneumonia","severe","China","close contacts","close contacts",56.5,"-95.9",90.4,NA,"delta","~8 weeks",NA,NA,"China","CHN",249,"CHN",16610,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,-139,386,420,"who",0,"before jan/2021","<30","Jun-Aug/2021","360+","yes","yes","yes",2022-05-03,"severe","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta",NA,2022-05-03
"2139",249,"Ma","Retrospective cohort/Outbreak investigation","03May2022","CoronaVac (Sinovac)","included","2","final","14+","symptomatic disease","symptomatic","China","close contacts","close contacts",73,"22.3",96,NA,"delta","~8 weeks",NA,NA,"China","CHN",249,"CHN",16610,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,-139,386,420,"who",0,"before jan/2021","<30","Jun-Aug/2021","360+","yes","yes","yes",2022-05-03,"symptomatic","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","delta",NA,2022-05-03
"2140",249,"Ma","Retrospective cohort/Outbreak investigation","03May2022","CoronaVac (Sinovac)","included","2","final","14+","pneumonia","severe","China","close contacts","close contacts",84.6,"18.8",97.1,NA,"delta","~8 weeks",NA,NA,"China","CHN",249,"CHN",16610,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,-139,386,420,"who",0,"before jan/2021","<30","Jun-Aug/2021","360+","yes","yes","yes",2022-05-03,"severe","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","delta",NA,2022-05-03
"2141",249,"Ma","Retrospective cohort/Outbreak investigation","03May2022","Ad5-nCOV (CanSino)","included","1","final","14+","symptomatic disease","symptomatic","China","close contacts","close contacts",61.5,"9.5",83.6,NA,"delta","~8 weeks",NA,NA,"China","CHN",249,"CHN",16610,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,-139,386,420,"who",0,"before jan/2021","<30","Jun-Aug/2021","360+","yes","yes","yes",2022-05-03,"symptomatic","2022 (Jan-Jun)","Cansino Ad5-nCoV","Vectored","delta",NA,2022-05-03
"2142",249,"Ma","Retrospective cohort/Outbreak investigation","03May2022","Ad5-nCOV (CanSino)","included","1","final","14+","pneumonia","severe","China","close contacts","close contacts",67.9,"1.7",89.9,NA,"delta","~8 weeks",NA,NA,"China","CHN",249,"CHN",16610,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,-139,386,420,"who",0,"before jan/2021","<30","Jun-Aug/2021","360+","yes","yes","yes",2022-05-03,"severe","2022 (Jan-Jun)","Cansino Ad5-nCoV","Vectored","delta",NA,2022-05-03
"2143",249,"Ma","Retrospective cohort/Outbreak investigation","03May2022","Ad5-nCOV (CanSino)","included","1","final","14+","severe disease","severe","China","close contacts","close contacts",100,NA,NA,NA,"delta","~8 weeks",NA,NA,"China","CHN",249,"CHN",16610,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,-139,386,420,"who",0,"before jan/2021","<30","Jun-Aug/2021","360+","yes","yes","yes",2022-05-03,"severe","2022 (Jan-Jun)","Cansino Ad5-nCoV","Vectored","delta",NA,2022-05-03
"2144",250,"Rennert","Propensity matched case control","10Jan2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection","infection","USA","students 18-64 years","students 18-64 years",2.1,"-21.2",21,NA,"omicron","~23 weeks",NA,NA,"USA","USA",250,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-01-10,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","07/05/2022",2022-05-07
"2145",250,"Rennert","Propensity matched case control","10Jan2023","mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","USA","students 18-64 years","students 18-64 years",17.3,"-10.8",38.3,NA,"omicron","~23 weeks",NA,NA,"USA","USA",250,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-01-10,"infection","2023 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","07/05/2022",2022-05-07
"2146",250,"Rennert","Propensity matched case control","10Jan2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection","infection","USA","employees 18-65 years","employees 18-65 years",30.1,"-24.5",60.8,NA,"omicron","~23 weeks",NA,NA,"USA","USA",250,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-01-10,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","07/05/2022",2022-05-07
"2147",250,"Rennert","Propensity matched case control","10Jan2023","mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","USA","employees 18-65 years","employees 18-65 years",14.4,"-64.2",55.4,NA,"omicron","~23 weeks",NA,NA,"USA","USA",250,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-01-10,"infection","2023 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","07/05/2022",2022-05-07
"2148",251,"Simwanza","Case-control","12Sept2022","Ad26.COV2.S (Janssen)","included","1","final","14+","infection","infection","Zambia",">= 18 years in a correctional facility","18+ years in a correctional facility",63.6,"33.6",80.5,NA,"omicron","~13 weeks",NA,NA,"Zambia","ZMB",251,"ZMB",3450,2019,"Zambia","Sub-Saharan Africa","Lower middle income",1,"Africa",2021-04-18,2022-10-27,NA,2021-04-14,2021-04-14,4,127,561,NA,"who",127,"march/2021 +","90+","Dec/2021 +","360+","yes","no","no",2022-09-12,"infection","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","omicron","08/06/2022",2022-06-08
"2149",251,"Simwanza","Case-control","12Sept2022","Ad26.COV2.S (Janssen)","included","1","final","14+","symptomatic disease","symptomatic","Zambia",">= 18 years in a correctional facility","18+ years in a correctional facility",73,"41.6",87.7,NA,"omicron","~13 weeks",NA,NA,"Zambia","ZMB",251,"ZMB",3450,2019,"Zambia","Sub-Saharan Africa","Lower middle income",1,"Africa",2021-04-18,2022-10-27,NA,2021-04-14,2021-04-14,4,127,561,NA,"who",127,"march/2021 +","90+","Dec/2021 +","360+","yes","no","no",2022-09-12,"symptomatic","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","omicron","08/06/2022",2022-06-08
"2150",251,"Simwanza","Case-control","12Sept2022","AZD1222 (AstraZeneca)","included","2","final","14+","infection","infection","Zambia",">= 18 years in a correctional facility","18+ years in a correctional facility",89.4,"59.5",97.8,NA,"omicron","~13 weeks",NA,NA,"Zambia","ZMB",251,"ZMB",3450,2019,"Zambia","Sub-Saharan Africa","Lower middle income",1,"Africa",2021-04-18,2022-10-27,NA,2021-04-14,2021-04-14,4,127,561,NA,"who",127,"march/2021 +","90+","Dec/2021 +","360+","yes","no","no",2022-09-12,"infection","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","08/06/2022",2022-06-08
"2151",251,"Simwanza","Case-control","12Sept2022","AZD1222 (AstraZeneca)","included","2","final","14+","symptomatic disease","symptomatic","Zambia",">= 18 years in a correctional facility","18+ years in a correctional facility",85.1,"19.5",98,NA,"omicron","~13 weeks",NA,NA,"Zambia","ZMB",251,"ZMB",3450,2019,"Zambia","Sub-Saharan Africa","Lower middle income",1,"Africa",2021-04-18,2022-10-27,NA,2021-04-14,2021-04-14,4,127,561,NA,"who",127,"march/2021 +","90+","Dec/2021 +","360+","yes","no","no",2022-09-12,"symptomatic","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","08/06/2022",2022-06-08
"2152",252,"Zahradka","Retrospective cohort","03May2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","Czech Republic","kidney transplant recipients","transplant recipients",45.6,"12.4",67.6,NA,"alpha","~12.5 weeks",NA,NA,"Czech Republic","CZE",252,"CZE",41530,2019,"Czechia","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,15,205,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-05-03,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","alpha",NA,2022-05-03
"2153",253,"Martellucci","Retrospective cohort","22Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","Italy",">= 18 years","general pop",24,"23",25,NA,"alpha, delta, & omicron","~53 weeks",NA,NA,"Italy","ITA",253,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-22,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-04-22
"2154",253,"Martellucci","Retrospective cohort","22Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization","severe","Italy",">= 18 years","general pop",86,"84",88,NA,"alpha, delta, & omicron","~53 weeks",NA,NA,"Italy","ITA",253,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-22,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-04-22
"2155",253,"Martellucci","Retrospective cohort","22Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","death","death","Italy",">= 18 years","general pop",92,"90",94,NA,"alpha, delta, & omicron","~53 weeks",NA,NA,"Italy","ITA",253,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-22,"death","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-04-22
"2156",253,"Martellucci","Retrospective cohort","22Apr2022","mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","Italy",">= 18 years","general pop",32,"31",34,NA,"alpha, delta, & omicron","~53 weeks",NA,NA,"Italy","ITA",253,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-22,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-04-22
"2157",253,"Martellucci","Retrospective cohort","22Apr2022","mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization","severe","Italy",">= 18 years","general pop",90,"86",93,NA,"alpha, delta, & omicron","~53 weeks",NA,NA,"Italy","ITA",253,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-22,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-04-22
"2158",253,"Martellucci","Retrospective cohort","22Apr2022","mRNA-1273 (Moderna)","excluded","2","final","14+","death","death","Italy",">= 18 years","general pop",96,"92",98,NA,"alpha, delta, & omicron","~53 weeks",NA,NA,"Italy","ITA",253,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-22,"death","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-04-22
"2159",253,"Martellucci","Retrospective cohort","22Apr2022","AZD1222 (AstraZeneca)","excluded","2","final","14+","infection","infection","Italy",">= 18 years","general pop",4,"1",6,NA,"alpha, delta, & omicron","~53 weeks",NA,NA,"Italy","ITA",253,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-22,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-04-22
"2160",253,"Martellucci","Retrospective cohort","22Apr2022","AZD1222 (AstraZeneca)","excluded","2","final","14+","hospitalization","severe","Italy",">= 18 years","general pop",93,"92",95,NA,"alpha, delta, & omicron","~53 weeks",NA,NA,"Italy","ITA",253,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-22,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-04-22
"2161",253,"Martellucci","Retrospective cohort","22Apr2022","AZD1222 (AstraZeneca)","excluded","2","final","14+","death","death","Italy",">= 18 years","general pop",98,"96",99,NA,"alpha, delta, & omicron","~53 weeks",NA,NA,"Italy","ITA",253,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-22,"death","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-04-22
"2162",253,"Martellucci","Retrospective cohort","22Apr2022","Ad26.COV2.S (Janssen)","excluded","1","final","14+","infection","infection","Italy",">= 18 years","general pop",12,"7",17,NA,"alpha, delta, & omicron","~53 weeks",NA,NA,"Italy","ITA",253,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-22,"infection","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-04-22
"2163",253,"Martellucci","Retrospective cohort","22Apr2022","Ad26.COV2.S (Janssen)","excluded","1","final","14+","hospitalization","severe","Italy",">= 18 years","general pop",87,"73",94,NA,"alpha, delta, & omicron","~53 weeks",NA,NA,"Italy","ITA",253,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-22,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-04-22
"2164",254,"Braeye","Retrospective cohort","11May2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7-57","infection","infection","Belgium","contacts of index cases among women aged 45-64","contacts of index cases among women aged 45-64",72,"70",74,NA,"alpha","~28.5 weeks",NA,NA,"Belgium","BEL",254,"BEL",56280,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,22,190,243,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-05-11,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2022-05-11
"2165",254,"Braeye","Retrospective cohort","11May2022","mRNA-1273 (Moderna)","excluded","2","final","14-64","infection","infection","Belgium","contacts of index cases among women aged 45-64","contacts of index cases among women aged 45-64",82,"79",84,NA,"alpha","~28.5 weeks",NA,NA,"Belgium","BEL",254,"BEL",56280,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,22,190,243,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-05-11,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","alpha",NA,2022-05-11
"2166",254,"Braeye","Retrospective cohort","11May2022","Ad26.COV2.S (Janssen)","excluded","1","final","21-71","infection","infection","Belgium","contacts of index cases among women aged 45-64","contacts of index cases among women aged 45-64",38,"34",44,NA,"alpha","~28.5 weeks",NA,NA,"Belgium","BEL",254,"BEL",56280,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,22,190,243,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-05-11,"infection","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","alpha",NA,2022-05-11
"2167",254,"Braeye","Retrospective cohort","11May2022","AZD1222 (AstraZeneca)","excluded","2","final","14-64","infection","infection","Belgium","contacts of index cases among women aged 45-64","contacts of index cases among women aged 45-64",56,"51",59,NA,"alpha","~28.5 weeks",NA,NA,"Belgium","BEL",254,"BEL",56280,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,22,190,243,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-05-11,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2022-05-11
"2168",254,"Braeye","Retrospective cohort","11May2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7-57","infection","infection","Belgium","contacts of index cases among women aged 45-64","contacts of index cases among women aged 45-64",64,"63",66,NA,"delta","~28.5 weeks",NA,NA,"Belgium","BEL",254,"BEL",56280,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,22,190,243,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-05-11,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-05-11
"2169",254,"Braeye","Retrospective cohort","11May2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","157-207","infection","infection","Belgium","contacts of index cases among women aged 45-64","contacts of index cases among women aged 45-64",44,"43",44,NA,"delta","~28.5 weeks",NA,NA,"Belgium","BEL",254,"BEL",56280,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,22,190,243,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-05-11,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-05-11
"2170",254,"Braeye","Retrospective cohort","11May2022","mRNA-1273 (Moderna)","excluded","2","final","14-64","infection","infection","Belgium","contacts of index cases among women aged 45-64","contacts of index cases among women aged 45-64",75,"71",77,NA,"delta","~28.5 weeks",NA,NA,"Belgium","BEL",254,"BEL",56280,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,22,190,243,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-05-11,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta",NA,2022-05-11
"2171",254,"Braeye","Retrospective cohort","11May2022","mRNA-1273 (Moderna)","excluded","2","final","164-214","infection","infection","Belgium","contacts of index cases among women aged 45-64","contacts of index cases among women aged 45-64",56,"55",58,NA,"delta","~28.5 weeks",NA,NA,"Belgium","BEL",254,"BEL",56280,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,22,190,243,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-05-11,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta",NA,2022-05-11
"2172",254,"Braeye","Retrospective cohort","11May2022","Ad26.COV2.S (Janssen)","excluded","1","final","21-71","infection","infection","Belgium","contacts of index cases among women aged 45-64","contacts of index cases among women aged 45-64",33,"28",38,NA,"delta","~28.5 weeks",NA,NA,"Belgium","BEL",254,"BEL",56280,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,22,190,243,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-05-11,"infection","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta",NA,2022-05-11
"2173",254,"Braeye","Retrospective cohort","11May2022","Ad26.COV2.S (Janssen)","excluded","1","final","171-221","infection","infection","Belgium","contacts of index cases among women aged 45-64","contacts of index cases among women aged 45-64",22,"19",25,NA,"delta","~28.5 weeks",NA,NA,"Belgium","BEL",254,"BEL",56280,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,22,190,243,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-05-11,"infection","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta",NA,2022-05-11
"2174",254,"Braeye","Retrospective cohort","11May2022","AZD1222 (AstraZeneca)","excluded","2","final","14-64","infection","infection","Belgium","contacts of index cases among women aged 45-64","contacts of index cases among women aged 45-64",49,"45",52,NA,"delta","~28.5 weeks",NA,NA,"Belgium","BEL",254,"BEL",56280,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,22,190,243,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-05-11,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2022-05-11
"2175",254,"Braeye","Retrospective cohort","11May2022","AZD1222 (AstraZeneca)","excluded","2","final","164-214","infection","infection","Belgium","contacts of index cases among women aged 45-64","contacts of index cases among women aged 45-64",35,"33",37,NA,"delta","~28.5 weeks",NA,NA,"Belgium","BEL",254,"BEL",56280,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,22,190,243,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-05-11,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2022-05-11
"2176",254,"Braeye","Retrospective cohort","11May2022","BNT162b2 (Pfizer BioNTech)","previously infected only","2","final","7-57","infection","infection","Belgium","contacts of index cases among women aged 45-64","contacts of index cases among women aged 45-64",87,"84",88,NA,"delta","~28.5 weeks",NA,NA,"Belgium","BEL",254,"BEL",56280,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,22,190,243,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-05-11,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-05-11
"2177",254,"Braeye","Retrospective cohort","11May2022","BNT162b2 (Pfizer BioNTech)","previously infected only","2","final","157-207","infection","infection","Belgium","contacts of index cases among women aged 45-64","contacts of index cases among women aged 45-64",82,"81",83,NA,"delta","~28.5 weeks",NA,NA,"Belgium","BEL",254,"BEL",56280,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,22,190,243,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-05-11,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-05-11
"2178",254,"Braeye","Retrospective cohort","11May2022","mRNA-1273 (Moderna)","previously infected only","2","final","14-64","infection","infection","Belgium","contacts of index cases among women aged 45-64","contacts of index cases among women aged 45-64",87,"83",92,NA,"delta","~28.5 weeks",NA,NA,"Belgium","BEL",254,"BEL",56280,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,22,190,243,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-05-11,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta",NA,2022-05-11
"2179",254,"Braeye","Retrospective cohort","11May2022","mRNA-1273 (Moderna)","previously infected only","2","final","164-214","infection","infection","Belgium","contacts of index cases among women aged 45-64","contacts of index cases among women aged 45-64",85,"80",89,NA,"delta","~28.5 weeks",NA,NA,"Belgium","BEL",254,"BEL",56280,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,22,190,243,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-05-11,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta",NA,2022-05-11
"2180",254,"Braeye","Retrospective cohort","11May2022","Ad26.COV2.S (Janssen)","previously infected only","1","final","21-71","infection","infection","Belgium","contacts of index cases among women aged 45-64","contacts of index cases among women aged 45-64",88,"85",91,NA,"delta","~28.5 weeks",NA,NA,"Belgium","BEL",254,"BEL",56280,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,22,190,243,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-05-11,"infection","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta",NA,2022-05-11
"2181",254,"Braeye","Retrospective cohort","11May2022","Ad26.COV2.S (Janssen)","previously infected only","1","final","171-221","infection","infection","Belgium","contacts of index cases among women aged 45-64","contacts of index cases among women aged 45-64",87,"84",89,NA,"delta","~28.5 weeks",NA,NA,"Belgium","BEL",254,"BEL",56280,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,22,190,243,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-05-11,"infection","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta",NA,2022-05-11
"2182",254,"Braeye","Retrospective cohort","11May2022","AZD1222 (AstraZeneca)","previously infected only","2","final","14-64","infection","infection","Belgium","contacts of index cases among women aged 45-64","contacts of index cases among women aged 45-64",88,"84",94,NA,"delta","~28.5 weeks",NA,NA,"Belgium","BEL",254,"BEL",56280,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,22,190,243,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-05-11,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2022-05-11
"2183",254,"Braeye","Retrospective cohort","11May2022","AZD1222 (AstraZeneca)","previously infected only","2","final","164-214","infection","infection","Belgium","contacts of index cases among women aged 45-64","contacts of index cases among women aged 45-64",83,"81",85,NA,"delta","~28.5 weeks",NA,NA,"Belgium","BEL",254,"BEL",56280,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,22,190,243,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-05-11,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2022-05-11
"2184",255,"Lan","Retrospective cohort","12May2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","USA","HCW","HCW",82.3,"75.1",87.4,NA,"non-VOC, alpha, & delta","~36 weeks",NA,NA,"USA","USA",255,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-05-12,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-05-12
"2185",255,"Lan","Retrospective cohort","12May2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","USA","HCW","HCW",76.5,"40.9",90.6,NA,"non-VOC, alpha, & delta","~36 weeks",NA,NA,"USA","USA",255,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-05-12,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-05-12
"2186",256,"Tenforde","Case-control","17May2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14-179","hospitalization","severe","USA","hospitalized adults","hospitalized adults",88,"86",90,NA,"alpha & delta","~23.5 weeks",NA,NA,"USA","USA",256,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-05-17,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-05-17
"2187",256,"Tenforde","Case-control","17May2022","BNT162b2 (Pfizer BioNTech)","included","2","final","180+","hospitalization","severe","USA","hospitalized adults","hospitalized adults",79,"74",83,NA,"alpha & delta","~47 weeks",NA,NA,"USA","USA",256,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-05-17,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-05-17
"2188",256,"Tenforde","Case-control","17May2022","mRNA-1273 (Moderna)","included","2","final","14-179","hospitalization","severe","USA","hospitalized adults","hospitalized adults",93,"91",94,NA,"alpha & delta","~23.5 weeks",NA,NA,"USA","USA",256,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-05-17,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-05-17
"2189",256,"Tenforde","Case-control","17May2022","mRNA-1273 (Moderna)","included","2","final","180+","hospitalization","severe","USA","hospitalized adults","hospitalized adults",87,"83",90,NA,"alpha & delta","~47 weeks",NA,NA,"USA","USA",256,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-05-17,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-05-17
"2190",256,"Tenforde","Case-control","17May2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-179","hospitalization","severe","USA","immunocompetent adults","immunocompetent adults",90,"88",91,NA,"alpha & delta","~23.5 weeks",NA,NA,"USA","USA",256,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-05-17,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-05-17
"2191",256,"Tenforde","Case-control","17May2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","180+","hospitalization","severe","USA","immunocompetent adults","immunocompetent adults",82,"79",85,NA,"alpha & delta","~47 weeks",NA,NA,"USA","USA",256,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-05-17,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-05-17
"2192",256,"Tenforde","Case-control","17May2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","hospitalized immunocompromised adults","immunocompromised adults",63,"55",69,NA,"alpha & delta","~47 weeks",NA,NA,"USA","USA",256,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-05-17,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-05-17
"2193",256,"Tenforde","Case-control","17May2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-179","hospitalization","severe","USA","hospitalized immunocompromised adults","immunocompromised adults",65,"57",72,NA,"alpha & delta","~23.5 weeks",NA,NA,"USA","USA",256,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-05-17,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-05-17
"2194",256,"Tenforde","Case-control","17May2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","180+","hospitalization","severe","USA","hospitalized immunocompromised adults","immunocompromised adults",53,"38",65,NA,"alpha & delta","~47 weeks",NA,NA,"USA","USA",256,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-05-17,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-05-17
"2195",256,"Tenforde","Case-control","17May2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-179","hospitalization","severe","USA","hospitalized adults","hospitalized adults",90,"88",91,NA,"delta","~23.5 weeks",NA,NA,"USA","USA",256,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-05-17,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2022-05-17
"2196",256,"Tenforde","Case-control","17May2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","180+","hospitalization","severe","USA","hospitalized adults","hospitalized adults",83,"80",86,NA,"delta","~47 weeks",NA,NA,"USA","USA",256,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-05-17,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2022-05-17
"2197",257,"Fano","Retrospective cohort","18May2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","40-44","infection","infection","Italy",">= 12 years","general pop",70.9,"69.3",72.4,NA,"alpha & delta","~48 weeks",NA,NA,"Italy","ITA",257,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-05-18,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-05-18
"2198",257,"Fano","Retrospective cohort","18May2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","200+","infection","infection","Italy",">= 12 years","general pop",22.7,"18.5",26.8,NA,"alpha & delta","~48 weeks",NA,NA,"Italy","ITA",257,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-05-18,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-05-18
"2199",257,"Fano","Retrospective cohort","18May2022","AZD1222 (AstraZeneca)","excluded","2","final","40-44","infection","infection","Italy",">= 12 years","general pop",76.3,"71.9",80,NA,"alpha & delta","~48 weeks",NA,NA,"Italy","ITA",257,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-05-18,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-05-18
"2200",257,"Fano","Retrospective cohort","18May2022","AZD1222 (AstraZeneca)","excluded","2","final","125+","infection","infection","Italy",">= 12 years","general pop",3.8,"0",9.2,NA,"alpha & delta","~48 weeks",NA,NA,"Italy","ITA",257,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-05-18,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-05-18
"2201",257,"Fano","Retrospective cohort","18May2022","Ad26.COV2.S (Janssen)","excluded","1","final","40-44","infection","infection","Italy",">= 12 years","general pop",39.4,"28.3",48.8,NA,"alpha & delta","~48 weeks",NA,NA,"Italy","ITA",257,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-05-18,"infection","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-05-18
"2202",257,"Fano","Retrospective cohort","18May2022","Ad26.COV2.S (Janssen)","excluded","1","final","150+","infection","infection","Italy",">= 12 years","general pop",2.5,"0",9.1,NA,"alpha & delta","~48 weeks",NA,NA,"Italy","ITA",257,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-05-18,"infection","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-05-18
"2203",257,"Fano","Retrospective cohort","18May2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","40-44","infection","infection","Italy",">= 12 years","general pop",81.6,"75.3",86.3,NA,"alpha & delta","~48 weeks",NA,NA,"Italy","ITA",257,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-05-18,"infection","2022 (Jan-Jun)","Heterologous platforms","Multiple","other combinations",NA,2022-05-18
"2204",257,"Fano","Retrospective cohort","18May2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","125+","infection","infection","Italy",">= 12 years","general pop",3.1,"0",12,NA,"alpha & delta","~48 weeks",NA,NA,"Italy","ITA",257,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-05-18,"infection","2022 (Jan-Jun)","Heterologous platforms","Multiple","other combinations",NA,2022-05-18
"2205",258,"Paranthaman","Retrospective cohort","20May2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7-34","infection","infection","UK","LTCF residents","LTCF residents",62,"46",73,NA,"alpha & delta","~3 weeks",NA,NA,"UK","GBR",258,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-05-20,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-05-20
"2206",258,"Paranthaman","Retrospective cohort","20May2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","147+","infection","infection","UK","LTCF residents","LTCF residents",47,"32",58,NA,"alpha & delta","~37 weeks",NA,NA,"UK","GBR",258,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-05-20,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-05-20
"2207",258,"Paranthaman","Retrospective cohort","20May2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7-34","death","death","UK","LTCF residents","LTCF residents",86,"67",94,NA,"alpha & delta","~3 weeks",NA,NA,"UK","GBR",258,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-05-20,"death","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-05-20
"2208",258,"Paranthaman","Retrospective cohort","20May2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","147+","death","death","UK","LTCF residents","LTCF residents",69,"51",80,NA,"alpha & delta","~37 weeks",NA,NA,"UK","GBR",258,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-05-20,"death","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-05-20
"2209",258,"Paranthaman","Retrospective cohort","20May2022","AZD1222 (AstraZeneca)","excluded","2","final","7-34","infection","infection","UK","LTCF residents","LTCF residents",61,"40",74,NA,"alpha & delta","~3 weeks",NA,NA,"UK","GBR",258,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-05-20,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-05-20
"2210",258,"Paranthaman","Retrospective cohort","20May2022","AZD1222 (AstraZeneca)","excluded","2","final","147+","infection","infection","UK","LTCF residents","LTCF residents",29,"10",43,NA,"alpha & delta","~24.5 weeks",NA,NA,"UK","GBR",258,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-05-20,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-05-20
"2211",258,"Paranthaman","Retrospective cohort","20May2022","AZD1222 (AstraZeneca)","excluded","2","final","7-34","death","death","UK","LTCF residents","LTCF residents",83,"58",94,NA,"alpha & delta","~3 weeks",NA,NA,"UK","GBR",258,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-05-20,"death","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-05-20
"2212",258,"Paranthaman","Retrospective cohort","20May2022","AZD1222 (AstraZeneca)","excluded","2","final","147+","death","death","UK","LTCF residents","LTCF residents",56,"33",70,NA,"alpha & delta","~24.5 weeks",NA,NA,"UK","GBR",258,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-05-20,"death","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-05-20
"2213",258,"Paranthaman","Retrospective cohort","20May2022","BNT162b2 (Pfizer BioNTech)","previously infected only","2","final","7-34","infection","infection","UK","LTCF residents","LTCF residents",79,"15",95,NA,"alpha & delta","~3 weeks",NA,NA,"UK","GBR",258,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-05-20,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-05-20
"2214",258,"Paranthaman","Retrospective cohort","20May2022","BNT162b2 (Pfizer BioNTech)","previously infected only","2","final","147+","infection","infection","UK","LTCF residents","LTCF residents",80,"43",93,NA,"alpha & delta","~37 weeks",NA,NA,"UK","GBR",258,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-05-20,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-05-20
"2215",258,"Paranthaman","Retrospective cohort","20May2022","AZD1222 (AstraZeneca)","previously infected only","2","final","7-34","infection","infection","UK","LTCF residents","LTCF residents",37,"-50",73,NA,"alpha & delta","~3 weeks",NA,NA,"UK","GBR",258,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-05-20,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-05-20
"2216",258,"Paranthaman","Retrospective cohort","20May2022","AZD1222 (AstraZeneca)","previously infected only","2","final","147+","infection","infection","UK","LTCF residents","LTCF residents",65,"14",86,NA,"alpha & delta","~24.5 weeks",NA,NA,"UK","GBR",258,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-05-20,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-05-20
"2217",259,"Tsundue","Prospective cohort","24May2022","AZD1222 (Covishield)","included","2","final","14+","infection","infection","India","residents of congregate living facilities","general pop",98,"85",99.8,NA,"delta","13 weeks",NA,NA,"India","IND",259,"IND",6820,2019,"India","South Asia","Lower middle income",2,"Asia",2021-01-16,2021-12-24,NA,2021-01-16,2021-01-16,0,39,342,NA,"equal",39,"jan/2021","30-59","Dec/2021 +","270-359","yes","yes","no",2022-05-24,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2022-05-24
"2218",259,"Tsundue","Prospective cohort","24May2022","AZD1222 (Covishield)","included","2","final","14+","shortness of breath/use of supplemental oxygen, hospitalization or death","severe","India","residents of congregate living facilities","general pop",99,"90",99.8,NA,"delta","13 weeks",NA,NA,"India","IND",259,"IND",6820,2019,"India","South Asia","Lower middle income",2,"Asia",2021-01-16,2021-12-24,NA,2021-01-16,2021-01-16,0,39,342,NA,"equal",39,"jan/2021","30-59","Dec/2021 +","270-359","yes","yes","no",2022-05-24,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2022-05-24
"2219",260,"Amir","Retrospective cohort","09Sept2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14-35","infection","infection","Israel","5-10 years","5-10 years",58.3,"54.6",61.5,NA,"omicron","~2 weeks",NA,NA,"Israel","ISR",260,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-09,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","25/05/2022",2022-05-25
"2220",261,"Chin","Retrospective cohort","26Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","USA","prison residents >= 18 years","prison residents",18.6,"7.7",28.1,NA,"omicron","~65 weeks",NA,NA,"USA","USA",261,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-10-26,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","27/05/2022",2022-05-27
"2221",261,"Chin","Retrospective cohort","26Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","USA","prison staff >= 18 years","prison staff",40.1,"34",45.6,NA,"omicron","~65 weeks",NA,NA,"USA","USA",261,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-10-26,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","27/05/2022",2022-05-27
"2222",261,"Chin","Retrospective cohort","26Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","previously infected before July 1, 2021","2","final","14+","infection","infection","USA","prison residents >= 18 years","prison residents",51.2,"41.5",59.2,NA,"omicron","~65 weeks",NA,NA,"USA","USA",261,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-10-26,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","27/05/2022",2022-05-27
"2223",261,"Chin","Retrospective cohort","26Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","previously infected before July 1, 2021","2","final","14+","infection","infection","USA","prison staff >= 18 years","prison staff",55.8,"49.6",61.2,NA,"omicron","~65 weeks",NA,NA,"USA","USA",261,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-10-26,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","27/05/2022",2022-05-27
"2224",261,"Chin","Retrospective cohort","26Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","previously infected between July 1 and November 30, 2021","2","final","14+","infection","infection","USA","prison residents >= 18 years","prison residents",68.7,"38.5",84.1,NA,"omicron","~65 weeks",NA,NA,"USA","USA",261,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-10-26,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","27/05/2022",2022-05-27
"2225",261,"Chin","Retrospective cohort","26Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","previously infected between July 1 and November 30, 2021","2","final","14+","infection","infection","USA","prison staff >= 18 years","prison staff",83.2,"77.7",87.4,NA,"omicron","~65 weeks",NA,NA,"USA","USA",261,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-10-26,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","27/05/2022",2022-05-27
"2226",261,"Chin","Retrospective test-negative case control","26Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","USA","prison residents and staff >= 18 years","prison residents and staff",14.9,"12.3",19.7,NA,"omicron","~65 weeks",NA,NA,"USA","USA",261,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-10-26,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","27/05/2022",2022-05-27
"2227",261,"Chin","Retrospective test-negative case control","26Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","previously infected before July 1, 2021","2","final","14+","infection","infection","USA","prison residents and staff >= 18 years","prison residents and staff",47.8,"46.6",52.8,NA,"omicron","~65 weeks",NA,NA,"USA","USA",261,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-10-26,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","27/05/2022",2022-05-27
"2228",261,"Chin","Retrospective test-negative case control","26Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","previously infected between July 1 and November 30, 2021","2","final","14+","infection","infection","USA","prison residents and staff >= 18 years","prison residents and staff",73.1,"69.8",80.1,NA,"omicron","~65 weeks",NA,NA,"USA","USA",261,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-10-26,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","27/05/2022",2022-05-27
"2229",262,"Carlsen","Retrospective cohort","01Jun2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","infection during an infant's first 4 months of life (born to unvaccinated mothers and mothers vaccinated in 2nd or 3rd trimester)","infection during an infant's first 4 months of life","Norway","newborns","newborns",30,"17",41,NA,"omicron","~45 weeks",NA,NA,"Norway","NOR",262,"NOR",71400,2019,"Norway","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-08-12,2021-11-18,2020-12-23,2020-12-23,5,15,232,330,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-01,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-06-01
"2230",262,"Carlsen","Retrospective cohort","01Jun2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","infection during an infant's first 4 months of life (born to unvaccinated mothers and mothers vaccinated in 2nd or 3rd trimester)","infection during an infant's first 4 months of life","Norway","newborns","newborns",71,"56",81,NA,"delta","~45 weeks",NA,NA,"Norway","NOR",262,"NOR",71400,2019,"Norway","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-08-12,2021-11-18,2020-12-23,2020-12-23,5,15,232,330,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-01,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2022-06-01
"2231",263,"Grewal","Test-negative case-control","06Jul2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","0+","infection","infection","Canada","LTCF residents","LTCF residents",6,"-5",15,"omicron","omicron","~66 weeks",NA,NA,"Canada","CAN",263,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-07-06,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-07-06
"2232",263,"Grewal","Test-negative case-control","06Jul2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","0+","symptomatic disease","symptomatic","Canada","LTCF residents","LTCF residents",23,"1",40,"omicron","omicron","~66 weeks",NA,NA,"Canada","CAN",263,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-07-06,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-07-06
"2233",263,"Grewal","Test-negative case-control","06Jul2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","0+","hospitalization or death","severe","Canada","LTCF residents","LTCF residents",52,"33",65,"omicron","omicron","~66 weeks",NA,NA,"Canada","CAN",263,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-07-06,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-07-06
"2234",264,"Spicer","Test-negative case-control","26May2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","USA","12-17 years","12-17 years",81,"79.7",82.3,NA,"delta","~36.5 weeks",NA,NA,"USA","USA",264,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-05-26,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2022-05-26
"2235",264,"Spicer","Test-negative case-control","26May2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","previously infected only","2","final","14+","infection","infection","USA","12-17 years","12-17 years",78.3,"66.7",86.5,NA,"delta","~36.5 weeks",NA,NA,"USA","USA",264,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-05-26,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2022-05-26
"2236",265,"Richterman","Test-negative case-control","06Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease","symptomatic","USA","HCW","HCW",41,"-17",87,NA,"omicron","~63 weeks",NA,NA,"USA","USA",265,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-06,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-06-06
"2237",265,"Richterman","Test-negative case-control","06Jun2022","mRNA-1273 (Moderna)","excluded","2","final","14+","symptomatic disease","symptomatic","USA","HCW","HCW",5,"-69",47,NA,"omicron","~63 weeks",NA,NA,"USA","USA",265,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-06,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron",NA,2022-06-06
"2238",265,"Richterman","Test-negative case-control","06Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease","symptomatic","USA","HCW","HCW",75,"52",87,NA,"delta","~63 weeks",NA,NA,"USA","USA",265,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-06,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-06-06
"2239",265,"Richterman","Test-negative case-control","06Jun2022","mRNA-1273 (Moderna)","excluded","2","final","14+","symptomatic disease","symptomatic","USA","HCW","HCW",73,"56",84,NA,"delta","~63 weeks",NA,NA,"USA","USA",265,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-06,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta",NA,2022-06-06
"2240",266,"Lin","RCT crossover","08Jun2022","mRNA-1273 (Moderna)","excluded","2","final","12 days","symptomatic disease","symptomatic","USA",">= 18 years","general pop",92.6,"80.5",97.2,NA,"original & alpha","~0 weeks",NA,NA,"USA","USA",266,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-08,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-06-08
"2241",266,"Lin","RCT crossover","08Jun2022","mRNA-1273 (Moderna)","excluded","2","final","172 days","symptomatic disease","symptomatic","USA",">= 18 years","general pop",89.6,"41.7",98.2,NA,"original & alpha","~22.5 weeks",NA,NA,"USA","USA",266,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-08,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-06-08
"2242",267,"Lewis","Test-negative case-control","08Jun2022","Ad26.COV2.S (Janssen)","included","1","final","14+","hospitalization","severe","USA","hospitalized adults","general pop",70,"63",75,NA,"alpha & delta","~39.5 weeks",NA,NA,"USA","USA",267,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-08,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-06-08
"2243",267,"Lewis","Test-negative case-control","08Jun2022","Ad26.COV2.S (Janssen)","included","1","final","14-90","hospitalization","severe","USA","hospitalized adults","general pop",73,"60",82,NA,"alpha & delta","~39.5 weeks",NA,NA,"USA","USA",267,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-08,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-06-08
"2244",267,"Lewis","Test-negative case-control","08Jun2022","Ad26.COV2.S (Janssen)","included","1","final","180+","hospitalization","severe","USA","hospitalized adults","general pop",70,"54",81,NA,"alpha & delta","~39.5 weeks",NA,NA,"USA","USA",267,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-08,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-06-08
"2245",267,"Lewis","Test-negative case-control","08Jun2022","Ad26.COV2.S (Janssen)","included","1","final","14+","hospitalization","severe","USA","hospitalized immunocompromised adults","immunocompromised adults",55,"31",72,NA,"alpha & delta","~39.5 weeks",NA,NA,"USA","USA",267,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-08,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-06-08
"2246",267,"Lewis","Test-negative case-control","08Jun2022","Ad26.COV2.S (Janssen)","included","1","final","14+","hospitalization","severe","USA","hospitalized adults","general pop",68,"43",83,NA,"alpha","~39.5 weeks",NA,NA,"USA","USA",267,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-08,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","alpha",NA,2022-06-08
"2247",267,"Lewis","Test-negative case-control","08Jun2022","Ad26.COV2.S (Janssen)","included","1","final","14+","hospitalization","severe","USA","hospitalized adults","general pop",72,"64",78,NA,"delta","~39.5 weeks",NA,NA,"USA","USA",267,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-08,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta",NA,2022-06-08
"2248",270,"Al Kaabi","Retrospective cohort","09Jun2022","BBIBP-CorV (Beijing CNBG)","excluded","2","final","14+","hospitalization","severe","UAE",">= 18 years","general pop",97.3,"95.7",98.3,NA,"non-VOC","~39 weeks",NA,NA,"United Arab Emirates","ARE",270,"ARE",75180,2019,"United Arab Emirates","Middle East & North Africa","High income",4,"Asia",2021-01-05,2021-04-20,2021-07-15,NA,2021-01-05,NA,28,105,191,"owid",28,"jan/2021","<30","before Jun/2021","<180","yes","yes","yes",2022-06-09,"severe","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","original",NA,2022-06-09
"2249",270,"Al Kaabi","Retrospective cohort","09Jun2022","BBIBP-CorV (Beijing CNBG)","excluded","2","final","14+","critical care admission","severe","UAE",">= 18 years","general pop",98.8,"95.3",99.7,NA,"non-VOC","~39 weeks",NA,NA,"United Arab Emirates","ARE",270,"ARE",75180,2019,"United Arab Emirates","Middle East & North Africa","High income",4,"Asia",2021-01-05,2021-04-20,2021-07-15,NA,2021-01-05,NA,28,105,191,"owid",28,"jan/2021","<30","before Jun/2021","<180","yes","yes","yes",2022-06-09,"severe","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","original",NA,2022-06-09
"2250",270,"Al Kaabi","Retrospective cohort","09Jun2022","BBIBP-CorV (Beijing CNBG)","excluded","2","final","14+","death","death","UAE",">= 18 years","general pop",100,"100",100,NA,"non-VOC","~39 weeks",NA,NA,"United Arab Emirates","ARE",270,"ARE",75180,2019,"United Arab Emirates","Middle East & North Africa","High income",4,"Asia",2021-01-05,2021-04-20,2021-07-15,NA,2021-01-05,NA,28,105,191,"owid",28,"jan/2021","<30","before Jun/2021","<180","yes","yes","yes",2022-06-09,"death","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","original",NA,2022-06-09
"2251",270,"Al Kaabi","Retrospective cohort","09Jun2022","BBIBP-CorV (Beijing CNBG)","excluded","2","final","14+","hospitalization","severe","UAE",">= 18 years","general pop",73.3,"70.6",75.7,NA,"alpha","~39 weeks",NA,NA,"United Arab Emirates","ARE",270,"ARE",75180,2019,"United Arab Emirates","Middle East & North Africa","High income",4,"Asia",2021-01-05,2021-04-20,2021-07-15,NA,2021-01-05,NA,28,105,191,"owid",28,"jan/2021","<30","before Jun/2021","<180","yes","yes","yes",2022-06-09,"severe","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","alpha",NA,2022-06-09
"2252",270,"Al Kaabi","Retrospective cohort","09Jun2022","BBIBP-CorV (Beijing CNBG)","excluded","2","final","14+","critical care admission","severe","UAE",">= 18 years","general pop",79.1,"73.1",83.7,NA,"alpha","~39 weeks",NA,NA,"United Arab Emirates","ARE",270,"ARE",75180,2019,"United Arab Emirates","Middle East & North Africa","High income",4,"Asia",2021-01-05,2021-04-20,2021-07-15,NA,2021-01-05,NA,28,105,191,"owid",28,"jan/2021","<30","before Jun/2021","<180","yes","yes","yes",2022-06-09,"severe","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","alpha",NA,2022-06-09
"2253",270,"Al Kaabi","Retrospective cohort","09Jun2022","BBIBP-CorV (Beijing CNBG)","excluded","2","final","14+","death","death","UAE",">= 18 years","general pop",81.9,"66.9",90.1,NA,"alpha","~39 weeks",NA,NA,"United Arab Emirates","ARE",270,"ARE",75180,2019,"United Arab Emirates","Middle East & North Africa","High income",4,"Asia",2021-01-05,2021-04-20,2021-07-15,NA,2021-01-05,NA,28,105,191,"owid",28,"jan/2021","<30","before Jun/2021","<180","yes","yes","yes",2022-06-09,"death","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","alpha",NA,2022-06-09
"2254",270,"Al Kaabi","Retrospective cohort","09Jun2022","BBIBP-CorV (Beijing CNBG)","excluded","2","final","14+","hospitalization","severe","UAE",">= 18 years","general pop",34.6,"14.2",50.2,NA,"delta","~39 weeks",NA,NA,"United Arab Emirates","ARE",270,"ARE",75180,2019,"United Arab Emirates","Middle East & North Africa","High income",4,"Asia",2021-01-05,2021-04-20,2021-07-15,NA,2021-01-05,NA,28,105,191,"owid",28,"jan/2021","<30","before Jun/2021","<180","yes","yes","yes",2022-06-09,"severe","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta",NA,2022-06-09
"2255",270,"Al Kaabi","Retrospective cohort","09Jun2022","BBIBP-CorV (Beijing CNBG)","excluded","2","final","14+","critical care admission","severe","UAE",">= 18 years","general pop",49.6,"0",76.4,NA,"delta","~39 weeks",NA,NA,"United Arab Emirates","ARE",270,"ARE",75180,2019,"United Arab Emirates","Middle East & North Africa","High income",4,"Asia",2021-01-05,2021-04-20,2021-07-15,NA,2021-01-05,NA,28,105,191,"owid",28,"jan/2021","<30","before Jun/2021","<180","yes","yes","yes",2022-06-09,"severe","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta",NA,2022-06-09
"2256",270,"Al Kaabi","Retrospective cohort","09Jun2022","BBIBP-CorV (Beijing CNBG)","excluded","2","final","14+","death","death","UAE",">= 18 years","general pop",62.5,"31.4",79.5,NA,"delta","~39 weeks",NA,NA,"United Arab Emirates","ARE",270,"ARE",75180,2019,"United Arab Emirates","Middle East & North Africa","High income",4,"Asia",2021-01-05,2021-04-20,2021-07-15,NA,2021-01-05,NA,28,105,191,"owid",28,"jan/2021","<30","before Jun/2021","<180","yes","yes","yes",2022-06-09,"death","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta",NA,2022-06-09
"2257",271,"Gray","Test-negative case-control","09Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-27","hospitalization","severe","South Africa","HCW","HCW",88,"62",96,NA,"omicron","~30 weeks",NA,NA,"South Africa","ZAF",271,"ZAF",14080,2019,"South Africa","Sub-Saharan Africa","Upper middle income",2,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,71,NA,NA,"who",71,"feb/2021","60-89","not reached","not reached","yes","no","no",2022-06-09,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","29/12/2021",2021-12-29
"2258",271,"Gray","Test-negative case-control","09Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","148-207","hospitalization","severe","South Africa","HCW","HCW",67,"63",71,NA,"omicron","~30 weeks",NA,NA,"South Africa","ZAF",271,"ZAF",14080,2019,"South Africa","Sub-Saharan Africa","Upper middle income",2,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,71,NA,NA,"who",71,"feb/2021","60-89","not reached","not reached","yes","no","no",2022-06-09,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","29/12/2021",2021-12-29
"2259",271,"Gray","Test-negative case-control","09Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-27","ICU admission","severe","South Africa","HCW","HCW",69,"56",79,NA,"omicron","~30 weeks",NA,NA,"South Africa","ZAF",271,"ZAF",14080,2019,"South Africa","Sub-Saharan Africa","Upper middle income",2,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,71,NA,NA,"who",71,"feb/2021","60-89","not reached","not reached","yes","no","no",2022-06-09,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","29/12/2021",2021-12-29
"2260",271,"Gray","Test-negative case-control","09Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","148-207","ICU admission","severe","South Africa","HCW","HCW",71,"65",76,NA,"omicron","~30 weeks",NA,NA,"South Africa","ZAF",271,"ZAF",14080,2019,"South Africa","Sub-Saharan Africa","Upper middle income",2,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,71,NA,NA,"who",71,"feb/2021","60-89","not reached","not reached","yes","no","no",2022-06-09,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","29/12/2021",2021-12-29
"2261",272,"Adams","Prospective test-negative case control","11Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","hospitalization","severe","USA",">= 18 years","general pop",36,"21",48,"omicron BA.1, BA.2, BA.5","omicron BA.1, BA.2, BA.5","~72 weeks",NA,NA,"USA","USA",272,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-10-11,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","14/06/2022",2022-06-14
"2262",272,"Adams","Prospective test-negative case control","11Oct2022","mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA",">= 18 years","general pop",41,"25",54,"omicron BA.1, BA.2, BA.5","omicron BA.1, BA.2, BA.5","~72 weeks",NA,NA,"USA","USA",272,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-10-11,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron","14/06/2022",2022-06-14
"2263",272,"Adams","Prospective test-negative case control","11Oct2022","Ad26.COV2.S (Janssen)","included","2","final","14+","hospitalization","severe","USA",">= 18 years","general pop",32,"9",62,"omicron BA.1, BA.2, BA.5","omicron BA.1, BA.2, BA.5","~72 weeks",NA,NA,"USA","USA",272,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-10-11,"severe","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","omicron","14/06/2022",2022-06-14
"2264",273,"Magro","Matched case-control","22Jun2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","USA","SNF personnel 18+ years","SNF employees",1,"55.9",81.8,NA,"non-VOC & alpha","~10 weeks",NA,NA,"USA","USA",273,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-22,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-06-22
"2265",273,"Magro","Matched case-control","22Jun2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","USA","SNF personnel 18+ years","SNF employees",32,"1",54,NA,"non-VOC & alpha","~10 weeks",NA,NA,"USA","USA",273,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-22,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-06-22
"2266",274,"Moline","Outbreak investigation","27Jun2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","USA","SNF residents","SNF residents",65,"25",84,NA,"beta","~12 weeks",NA,NA,"USA","USA",274,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-27,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","beta",NA,2022-06-27
"2267",275,"Carazo","Test-negative case-control","21Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","Canada","HCW","HCW",35,"27",42,"omicron BA.2","omicron BA.2","~70 weeks",NA,NA,"Canada","CAN",275,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-21,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","27/06/2022",2022-06-27
"2268",275,"Carazo","Test-negative case-control","21Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","symptomatic disease","symptomatic","Canada","HCW","HCW",61,"52",69,"omicron BA.2","omicron BA.2","~70 weeks",NA,NA,"Canada","CAN",275,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-21,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","27/06/2022",2022-06-27
"2269",276,"Cohen-Stavi","Taget trial emulation study","29Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7-21","infection","infection","Israel","5-11 years","5-11 years",51,"39",61,NA,"omicron","1 week",NA,NA,"Israel","ISR",276,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-29,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-06-29
"2270",276,"Cohen-Stavi","Taget trial emulation study","29Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7-21","symptomatic disease","symptomatic","Israel","5-11 years","5-11 years",48,"29",63,NA,"omicron","1 week",NA,NA,"Israel","ISR",276,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-29,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-06-29
"2271",277,"Ionescu","Test-negative case-control","16Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","Canada (Quebec)","12-17 years","12-17 years",41.9,"37.7",45.8,NA,"omicron","~26 weeks",NA,NA,"Canada","CAN",277,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-01-16,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","28/06/2022",2022-06-28
"2272",277,"Ionescu","Test-negative case-control","16Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-27","infection","infection","Canada (Quebec)","12-17 years","12-17 years",75.6,"65.8",82.6,NA,"omicron","2 weeks",NA,NA,"Canada","CAN",277,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-01-16,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","28/06/2022",2022-06-28
"2273",277,"Ionescu","Test-negative case-control","16Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","168-195","infection","infection","Canada (Quebec)","12-17 years","12-17 years",33.9,"27.4",39.9,NA,"omicron","~26 weeks",NA,NA,"Canada","CAN",277,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-01-16,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","28/06/2022",2022-06-28
"2274",277,"Ionescu","Test-negative case-control","16Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease","symptomatic","Canada (Quebec)","12-17 years","12-17 years",55.2,"49.5",60.3,NA,"omicron","~26 weeks",NA,NA,"Canada","CAN",277,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-01-16,"symptomatic","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","28/06/2022",2022-06-28
"2275",277,"Ionescu","Test-negative case-control","16Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","Canada (Quebec)","12-17 years","12-17 years",82.8,"81",94.4,NA,"delta & omicron","~22 weeks",NA,NA,"Canada","CAN",277,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-01-16,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta/omicron","28/06/2022",2022-06-28
"2276",277,"Ionescu","Test-negative case-control","16Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-27","infection","infection","Canada (Quebec)","12-17 years","12-17 years",83.1,"68.9",90.8,NA,"delta & omicron","2 weeks",NA,NA,"Canada","CAN",277,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-01-16,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta/omicron","28/06/2022",2022-06-28
"2277",277,"Ionescu","Test-negative case-control","16Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","140-167","infection","infection","Canada (Quebec)","12-17 years","12-17 years",75.4,"72.1",78.4,NA,"delta & omicron","~22 weeks",NA,NA,"Canada","CAN",277,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-01-16,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta/omicron","28/06/2022",2022-06-28
"2278",277,"Ionescu","Test-negative case-control","16Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease","symptomatic","Canada (Quebec)","12-17 years","12-17 years",87.9,"86.1",89.5,NA,"delta & omicron","~22 weeks",NA,NA,"Canada","CAN",277,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-01-16,"symptomatic","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta/omicron","28/06/2022",2022-06-28
"2279",277,"Ionescu","Test-negative case-control","16Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","Canada (Quebec)","12-17 years","12-17 years",95.5,"95",96,NA,"delta","~18 weeks",NA,NA,"Canada","CAN",277,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-01-16,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","28/06/2022",2022-06-28
"2280",277,"Ionescu","Test-negative case-control","16Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-27","infection","infection","Canada (Quebec)","12-17 years","12-17 years",97.7,"96.2",98.6,NA,"delta","2 weeks",NA,NA,"Canada","CAN",277,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-01-16,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","28/06/2022",2022-06-28
"2281",277,"Ionescu","Test-negative case-control","16Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","112-139","infection","infection","Canada (Quebec)","12-17 years","12-17 years",92.4,"90.4",94,NA,"delta","~18 weeks",NA,NA,"Canada","CAN",277,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-01-16,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","28/06/2022",2022-06-28
"2282",277,"Ionescu","Test-negative case-control","16Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease","symptomatic","Canada (Quebec)","12-17 years","12-17 years",97.3,"96.8",97.7,NA,"delta","~18 weeks",NA,NA,"Canada","CAN",277,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-01-16,"symptomatic","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","28/06/2022",2022-06-28
"2283",277,"Ionescu","Test-negative case-control","16Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","Canada (British Colombia)","12-17 years","12-17 years",33.9,"25.7",41.1,NA,"omicron","~26 weeks",NA,NA,"Canada","CAN",277,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-01-16,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","28/06/2022",2022-06-28
"2284",277,"Ionescu","Test-negative case-control","16Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-27","infection","infection","Canada (British Colombia)","12-17 years","12-17 years",63.4,"21.4",83,NA,"omicron","2 weeks",NA,NA,"Canada","CAN",277,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-01-16,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","28/06/2022",2022-06-28
"2285",277,"Ionescu","Test-negative case-control","16Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","168-195","infection","infection","Canada (British Colombia)","12-17 years","12-17 years",22.2,"8.4",33.9,NA,"omicron","~26 weeks",NA,NA,"Canada","CAN",277,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-01-16,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","28/06/2022",2022-06-28
"2286",277,"Ionescu","Test-negative case-control","16Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","Canada (British Colombia)","12-17 years","12-17 years",88,"85.1",90.3,NA,"delta & omicron","~22 weeks",NA,NA,"Canada","CAN",277,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-01-16,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta/omicron","28/06/2022",2022-06-28
"2287",277,"Ionescu","Test-negative case-control","16Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","28-55","infection","infection","Canada (British Colombia)","12-17 years","12-17 years",94.8,"83.7",98.4,NA,"delta & omicron","2 weeks",NA,NA,"Canada","CAN",277,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-01-16,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta/omicron","28/06/2022",2022-06-28
"2288",277,"Ionescu","Test-negative case-control","16Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","140-167","infection","infection","Canada (British Colombia)","12-17 years","12-17 years",84.2,"77.8",88.8,NA,"delta & omicron","~22 weeks",NA,NA,"Canada","CAN",277,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-01-16,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta/omicron","28/06/2022",2022-06-28
"2289",277,"Ionescu","Test-negative case-control","16Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","Canada (British Colombia)","12-17 years","12-17 years",95.7,"95.1",96.2,NA,"delta","~18 weeks",NA,NA,"Canada","CAN",277,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-01-16,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","28/06/2022",2022-06-28
"2290",277,"Ionescu","Test-negative case-control","16Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-27","infection","infection","Canada (British Colombia)","12-17 years","12-17 years",96.8,"94.4",98.2,NA,"delta","2 weeks",NA,NA,"Canada","CAN",277,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-01-16,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","28/06/2022",2022-06-28
"2291",277,"Ionescu","Test-negative case-control","16Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","112-139","infection","infection","Canada (British Colombia)","12-17 years","12-17 years",90.9,"87.7",93.2,NA,"delta","~18 weeks",NA,NA,"Canada","CAN",277,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-01-16,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","28/06/2022",2022-06-28
"2292",278,"Tartof","Test-negative case-control","07Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final","<6 months","hospitalization","severe","USA",">= 18 years","general pop",54,"38",65,"omicron BA.1","omicron BA.1","~70 weeks",NA,NA,"USA","USA",278,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-10-07,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","30/06/2022",2022-06-30
"2293",278,"Tartof","Test-negative case-control","07Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final",">=6 months","hospitalization","severe","USA",">= 18 years","general pop",32,"16",45,"omicron BA.1","omicron BA.1","~70 weeks",NA,NA,"USA","USA",278,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-10-07,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","30/06/2022",2022-06-30
"2294",278,"Tartof","Test-negative case-control","07Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final","<6 months","ED admissions","symptomatic","USA",">= 18 years","general pop",42,"31",52,"omicron BA.1","omicron BA.1","~70 weeks",NA,NA,"USA","USA",278,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-10-07,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","30/06/2022",2022-06-30
"2295",278,"Tartof","Test-negative case-control","07Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final",">=6 months","ED admissions","symptomatic","USA",">= 18 years","general pop",19,"6",31,"omicron BA.1","omicron BA.1","~70 weeks",NA,NA,"USA","USA",278,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-10-07,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","30/06/2022",2022-06-30
"2296",278,"Tartof","Test-negative case-control","07Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final","<6 months","hospitalization","severe","USA",">= 18 years","general pop",56,"-2",81,"omicron BA.2","omicron BA.2","~70 weeks",NA,NA,"USA","USA",278,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-10-07,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","30/06/2022",2022-06-30
"2297",278,"Tartof","Test-negative case-control","07Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final",">=6 months","hospitalization","severe","USA",">= 18 years","general pop",56,"28",73,"omicron BA.2","omicron BA.2","~70 weeks",NA,NA,"USA","USA",278,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-10-07,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","30/06/2022",2022-06-30
"2298",278,"Tartof","Test-negative case-control","07Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final","<6 months","ED admissions","symptomatic","USA",">= 18 years","general pop",27,"-11",52,"omicron BA.2","omicron BA.2","~70 weeks",NA,NA,"USA","USA",278,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-10-07,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","30/06/2022",2022-06-30
"2299",278,"Tartof","Test-negative case-control","07Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final",">=6 months","ED admissions","symptomatic","USA",">= 18 years","general pop",12,"-10",31,"omicron BA.2","omicron BA.2","~70 weeks",NA,NA,"USA","USA",278,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-10-07,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","30/06/2022",2022-06-30
"2300",279,"Paternina-Caicedo","Retrospective cohort","01Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","symptomatic disease","symptomatic","Colombia",">= 40 years",">= 40 years",13,"5.3",20,NA,"mu","~25 weeks",NA,NA,"Colombia","COL",279,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2022-07-01,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","mu",NA,2022-07-01
"2301",279,"Paternina-Caicedo","Retrospective cohort","01Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","hospitalization","severe","Colombia",">= 40 years",">= 40 years",45.5,"29.4",58,NA,"mu","~25 weeks",NA,NA,"Colombia","COL",279,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2022-07-01,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","mu",NA,2022-07-01
"2302",279,"Paternina-Caicedo","Retrospective cohort","01Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","critical care admission","severe","Colombia",">= 40 years",">= 40 years",82.2,"60.1",92.1,NA,"mu","~25 weeks",NA,NA,"Colombia","COL",279,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2022-07-01,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","mu",NA,2022-07-01
"2303",279,"Paternina-Caicedo","Retrospective cohort","01Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","death","death","Colombia",">= 40 years",">= 40 years",94.1,"76.4",98.5,NA,"mu","~25 weeks",NA,NA,"Colombia","COL",279,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2022-07-01,"death","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","mu",NA,2022-07-01
"2304",279,"Paternina-Caicedo","Retrospective cohort","01Jul2022","CoronaVac (Sinovac)","included","2","final","14+","symptomatic disease","symptomatic","Colombia",">= 40 years",">= 40 years",-45.1,"-53.6",-37.1,NA,"mu","~25 weeks",NA,NA,"Colombia","COL",279,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2022-07-01,"symptomatic","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","mu",NA,2022-07-01
"2305",279,"Paternina-Caicedo","Retrospective cohort","01Jul2022","CoronaVac (Sinovac)","included","2","final","14+","hospitalization","severe","Colombia",">= 40 years",">= 40 years",-3,"-18",10.2,NA,"mu","~25 weeks",NA,NA,"Colombia","COL",279,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2022-07-01,"severe","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","mu",NA,2022-07-01
"2306",279,"Paternina-Caicedo","Retrospective cohort","01Jul2022","CoronaVac (Sinovac)","included","2","final","14+","critical care admission","severe","Colombia",">= 40 years",">= 40 years",13.6,"-13.2",34,NA,"mu","~25 weeks",NA,NA,"Colombia","COL",279,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2022-07-01,"severe","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","mu",NA,2022-07-01
"2307",279,"Paternina-Caicedo","Retrospective cohort","01Jul2022","CoronaVac (Sinovac)","included","2","final","14+","death","death","Colombia",">= 40 years",">= 40 years",20.6,"-0.5",37.3,NA,"mu","~25 weeks",NA,NA,"Colombia","COL",279,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2022-07-01,"death","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","mu",NA,2022-07-01
"2308",280,"Tonnara","Retrospective cohort","04Jul2022","Gam-COVID-Vac (Gamaleya)","excluded","2","final","7-59","infection","infection","Republic of San Marino",">= 18 years","general pop",91.8,"86.3",95.1,NA,"alpha & delta","~27 weeks",NA,NA,"Republic of San Marino","SMR",280,"SMR",57320,2019,"San Marino","Europe & Central Asia","High income",4,"Europe",2021-02-27,2021-05-23,2022-03-20,2021-02-24,2021-02-24,3,78,88,389,"who",78,"feb/2021","60-89","before Jun/2021","<180","yes","yes","yes",2022-07-04,"infection","2022 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","other combinations",NA,2022-07-04
"2309",280,"Tonnara","Retrospective cohort","04Jul2022","Gam-COVID-Vac (Gamaleya)","excluded","2","final","120+","infection","infection","Republic of San Marino",">= 18 years","general pop",57.8,"42.2",69.2,NA,"alpha & delta","~27 weeks",NA,NA,"Republic of San Marino","SMR",280,"SMR",57320,2019,"San Marino","Europe & Central Asia","High income",4,"Europe",2021-02-27,2021-05-23,2022-03-20,2021-02-24,2021-02-24,3,78,88,389,"who",78,"feb/2021","60-89","before Jun/2021","<180","yes","yes","yes",2022-07-04,"infection","2022 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","other combinations",NA,2022-07-04
"2310",280,"Tonnara","Retrospective cohort","04Jul2022","Gam-COVID-Vac (Gamaleya)","excluded","2","final","7-59","hospitalization","severe","Republic of San Marino",">= 18 years","general pop",95.2,"79.1",98.9,NA,"alpha & delta","~27 weeks",NA,NA,"Republic of San Marino","SMR",280,"SMR",57320,2019,"San Marino","Europe & Central Asia","High income",4,"Europe",2021-02-27,2021-05-23,2022-03-20,2021-02-24,2021-02-24,3,78,88,389,"who",78,"feb/2021","60-89","before Jun/2021","<180","yes","yes","yes",2022-07-04,"severe","2022 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","other combinations",NA,2022-07-04
"2311",280,"Tonnara","Retrospective cohort","04Jul2022","Gam-COVID-Vac (Gamaleya)","excluded","2","final","120+","hospitalization","severe","Republic of San Marino",">= 18 years","general pop",89.7,"52.7",97.7,NA,"alpha & delta","~27 weeks",NA,NA,"Republic of San Marino","SMR",280,"SMR",57320,2019,"San Marino","Europe & Central Asia","High income",4,"Europe",2021-02-27,2021-05-23,2022-03-20,2021-02-24,2021-02-24,3,78,88,389,"who",78,"feb/2021","60-89","before Jun/2021","<180","yes","yes","yes",2022-07-04,"severe","2022 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","other combinations",NA,2022-07-04
"2312",280,"Tonnara","Retrospective cohort","04Jul2022","Gam-COVID-Vac (Gamaleya)","excluded","2","final","7+","infection","infection","Republic of San Marino",">= 18 years","general pop",97.3,"94.2",98.7,NA,"alpha","~15 weeks",NA,NA,"Republic of San Marino","SMR",280,"SMR",57320,2019,"San Marino","Europe & Central Asia","High income",4,"Europe",2021-02-27,2021-05-23,2022-03-20,2021-02-24,2021-02-24,3,78,88,389,"who",78,"feb/2021","60-89","before Jun/2021","<180","yes","yes","yes",2022-07-04,"infection","2022 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","alpha",NA,2022-07-04
"2313",280,"Tonnara","Retrospective cohort","04Jul2022","Gam-COVID-Vac (Gamaleya)","excluded","2","final","7+","hospitalization","severe","Republic of San Marino",">= 18 years","general pop",96.9,"86.5",99.3,NA,"alpha","~15 weeks",NA,NA,"Republic of San Marino","SMR",280,"SMR",57320,2019,"San Marino","Europe & Central Asia","High income",4,"Europe",2021-02-27,2021-05-23,2022-03-20,2021-02-24,2021-02-24,3,78,88,389,"who",78,"feb/2021","60-89","before Jun/2021","<180","yes","yes","yes",2022-07-04,"severe","2022 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","alpha",NA,2022-07-04
"2314",281,"Kerr","Test-negative case-control","09Jul2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","symptomatic disease","symptomatic","Scotland",">= 18 years","general pop",78.7,"69.9",85,NA,"delta & delta plus (AY.4.2)","~38 weeks",NA,NA,"UK","GBR",281,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-07-09,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-07-09
"2315",281,"Kerr","Test-negative case-control","09Jul2022","mRNA-1273 (Moderna)","unknown","2","final","14+","symptomatic disease","symptomatic","Scotland",">= 18 years","general pop",93.7,"86.4",97.1,NA,"delta & delta plus (AY.4.2)","~38 weeks",NA,NA,"UK","GBR",281,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-07-09,"symptomatic","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2022-07-09
"2316",281,"Kerr","Test-negative case-control","09Jul2022","AZD1222 (AstraZeneca)","unknown","2","final","14+","symptomatic disease","symptomatic","Scotland",">= 18 years","general pop",54.5,"35.7",67.8,NA,"delta & delta plus (AY.4.2)","~38 weeks",NA,NA,"UK","GBR",281,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-07-09,"symptomatic","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2022-07-09
"2317",282,"Stephenson","Retrospective cohort","11Jul2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA",">= 18 years","general pop",85,"81",89,NA,"non-VOC & alpha","~18 weeks",NA,NA,"USA","USA",282,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-07-11,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-07-11
"2318",283,"Guedalia","Retrospective cohort","15Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","0+","hospitalization","severe","Israel","pregnant women aged 16+","pregnant persons",-12,"-36",8,NA,"omicron BA.1","~60 weeks",NA,NA,"Israel","ISR",283,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-11-15,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","11/07/2022",2022-07-11
"2319",283,"Guedalia","Retrospective cohort","15Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","0+","hospitalization with moderate disease","severe","Israel","pregnant women aged 16+","pregnant persons",51,"-47",84,NA,"omicron BA.1","~60 weeks",NA,NA,"Israel","ISR",283,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-11-15,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","11/07/2022",2022-07-11
"2320",283,"Guedalia","Retrospective cohort","15Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","0+","severe disease","severe","Israel","pregnant women aged 16+","pregnant persons",83,"-47",98,NA,"omicron BA.1","~60 weeks",NA,NA,"Israel","ISR",283,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-11-15,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","11/07/2022",2022-07-11
"2321",283,"Guedalia","Retrospective cohort","15Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","0+","hospitalization","severe","Israel","pregnant women aged 16+","pregnant persons",61,"51",69,NA,"delta","~44 weeks",NA,NA,"Israel","ISR",283,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-11-15,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","11/07/2022",2022-07-11
"2322",283,"Guedalia","Retrospective cohort","15Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","0+","hospitalization with moderate disease","severe","Israel","pregnant women aged 16+","pregnant persons",97,"92",99,NA,"delta","~44 weeks",NA,NA,"Israel","ISR",283,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-11-15,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","11/07/2022",2022-07-11
"2323",283,"Guedalia","Retrospective cohort","15Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","0+","severe disease","severe","Israel","pregnant women aged 16+","pregnant persons",96,"86",99,NA,"delta","~44 weeks",NA,NA,"Israel","ISR",283,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-11-15,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","11/07/2022",2022-07-11
"2324",284,"Link-Gelles","Test-negative case-control","15Jul2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-140","ED or UC visit","symptomatic","USA",">= 18 years","general pop",47,"44",50,NA,"omicron BA.1","~44 weeks",NA,NA,"USA","USA",284,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-07-15,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-07-15
"2325",284,"Link-Gelles","Test-negative case-control","15Jul2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","150+","ED or UC visit","symptomatic","USA",">= 18 years","general pop",39,"37",41,NA,"omicron BA.1","~44 weeks",NA,NA,"USA","USA",284,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-07-15,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-07-15
"2326",284,"Link-Gelles","Test-negative case-control","15Jul2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-140","hospitalization","severe","USA",">= 18 years","general pop",68,"63",73,NA,"omicron BA.1","~44 weeks",NA,NA,"USA","USA",284,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-07-15,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-07-15
"2327",284,"Link-Gelles","Test-negative case-control","15Jul2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","150+","hospitalization","severe","USA",">= 18 years","general pop",61,"58",63,NA,"omicron BA.1","~44 weeks",NA,NA,"USA","USA",284,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-07-15,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-07-15
"2328",284,"Link-Gelles","Test-negative case-control","15Jul2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-140","ED or UC visit","symptomatic","USA",">= 18 years","general pop",59,"40",71,NA,"omicron BA.2","~44 weeks",NA,NA,"USA","USA",284,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-07-15,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-07-15
"2329",284,"Link-Gelles","Test-negative case-control","15Jul2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","150+","ED or UC visit","symptomatic","USA",">= 18 years","general pop",18,"10",26,NA,"omicron BA.2","~44 weeks",NA,NA,"USA","USA",284,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-07-15,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-07-15
"2330",284,"Link-Gelles","Test-negative case-control","15Jul2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-140","hospitalization","severe","USA",">= 18 years","general pop",57,"19",77,NA,"omicron BA.2","~44 weeks",NA,NA,"USA","USA",284,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-07-15,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-07-15
"2331",284,"Link-Gelles","Test-negative case-control","15Jul2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","150+","hospitalization","severe","USA",">= 18 years","general pop",24,"12",35,NA,"omicron BA.2","~44 weeks",NA,NA,"USA","USA",284,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-07-15,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-07-15
"2332",285,"Cerqueira-Silva","Test-negative case-control","18Jul2022","CoronaVac (Sinovac)","included","2","final","14-180","infection","infection","Brazil",">= 18 years","general pop",-0.7,"-1.6",0.2,NA,"omicron","~59 weeks",NA,NA,"Brazil","BRA",285,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-18,"infection","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2022-07-18
"2333",285,"Cerqueira-Silva","Test-negative case-control","18Jul2022","CoronaVac (Sinovac)","included","2","final","180+","infection","infection","Brazil",">= 18 years","general pop",3.2,"2.1",4.2,NA,"omicron","~59 weeks",NA,NA,"Brazil","BRA",285,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-18,"infection","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2022-07-18
"2334",285,"Cerqueira-Silva","Test-negative case-control","18Jul2022","CoronaVac (Sinovac)","included","2","final","14-180","hospitalization or death","severe","Brazil",">= 18 years","general pop",64.5,"62.6",66.3,NA,"omicron","~59 weeks",NA,NA,"Brazil","BRA",285,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-18,"severe","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2022-07-18
"2335",285,"Cerqueira-Silva","Test-negative case-control","18Jul2022","CoronaVac (Sinovac)","included","2","final","180+","hospitalization or death","severe","Brazil",">= 18 years","general pop",61.8,"60.3",63.2,NA,"omicron","~59 weeks",NA,NA,"Brazil","BRA",285,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-18,"severe","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2022-07-18
"2336",285,"Cerqueira-Silva","Test-negative case-control","18Jul2022","CoronaVac (Sinovac)","included","2","final","14-180","death","death","Brazil",">= 18 years","general pop",67.8,"64",71.3,NA,"omicron","~59 weeks",NA,NA,"Brazil","BRA",285,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-18,"death","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2022-07-18
"2337",285,"Cerqueira-Silva","Test-negative case-control","18Jul2022","CoronaVac (Sinovac)","included","2","final","180+","death","death","Brazil",">= 18 years","general pop",63.1,"60.9",65.1,NA,"omicron","~59 weeks",NA,NA,"Brazil","BRA",285,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-18,"death","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2022-07-18
"2338",286,"Hatfield","Retrospective cohort","20Jul2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7-157","infection","infection","USA","nursing home residents","nursing home residents",67,"40",82,NA,"non-VOC & alpha","~44 weeks",NA,NA,"USA","USA",286,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-07-20,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-07-20
"2339",286,"Hatfield","Retrospective cohort","20Jul2022","mRNA-1273 (Moderna)","excluded","2","final","7-157","infection","infection","USA","nursing home residents","nursing home residents",75,"32",91,NA,"non-VOC & alpha","~44 weeks",NA,NA,"USA","USA",286,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-07-20,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-07-20
"2340",286,"Hatfield","Retrospective cohort","20Jul2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","157+","infection","infection","USA","nursing home residents","nursing home residents",33,"-2",56,NA,"delta","~44 weeks",NA,NA,"USA","USA",286,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-07-20,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-07-20
"2341",286,"Hatfield","Retrospective cohort","20Jul2022","mRNA-1273 (Moderna)","excluded","2","final","157+","infection","infection","USA","nursing home residents","nursing home residents",77,"48",91,NA,"delta","~44 weeks",NA,NA,"USA","USA",286,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-07-20,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2022-07-20
"2342",287,"Tan","Retrospective cohort","20Jul2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7-14","infection (PCR or antigen)","infection","Singapore","5-11 years","5-11 years",48.8,"46.9",50.8,NA,"omicron","~9 weeks",NA,NA,"Singapore","SGP",287,"SGP",89630,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,22,192,227,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-07-20,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-07-20
"2343",287,"Tan","Retrospective cohort","20Jul2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","60+","infection (PCR or antigen)","infection","Singapore","5-11 years","5-11 years",25.6,"19.3",31.5,NA,"omicron","~9 weeks",NA,NA,"Singapore","SGP",287,"SGP",89630,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,22,192,227,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-07-20,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-07-20
"2344",287,"Tan","Retrospective cohort","20Jul2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7-14","infection (PCR only)","infection","Singapore","5-11 years","5-11 years",70.6,"65.9",74.7,NA,"omicron","~9 weeks",NA,NA,"Singapore","SGP",287,"SGP",89630,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,22,192,227,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-07-20,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-07-20
"2345",287,"Tan","Retrospective cohort","20Jul2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","60+","infection (PCR only)","infection","Singapore","5-11 years","5-11 years",42.7,"12",62.7,NA,"omicron","~9 weeks",NA,NA,"Singapore","SGP",287,"SGP",89630,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,22,192,227,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-07-20,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-07-20
"2346",287,"Tan","Retrospective cohort","20Jul2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7-14","hospitalization","severe","Singapore","5-11 years","5-11 years",87.8,"72.2",94.7,NA,"omicron","~9 weeks",NA,NA,"Singapore","SGP",287,"SGP",89630,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,22,192,227,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-07-20,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-07-20
"2347",287,"Tan","Retrospective cohort","20Jul2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","30-59","hospitalization","severe","Singapore","5-11 years","5-11 years",80.4,"67",88.4,NA,"omicron","~9 weeks",NA,NA,"Singapore","SGP",287,"SGP",89630,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,22,192,227,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-07-20,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-07-20
"2348",288,"Mazagatos","Test-negative case-control","26Jul2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization with SARI","severe","Spain","20-59 years","20-59 years",92,"78",97,NA,"alpha & delta","~19 weeks",NA,NA,"Spain","ESP",288,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-07-26,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-07-26
"2349",288,"Mazagatos","Test-negative case-control","26Jul2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","<90","hospitalization with SARI","severe","Spain","20-59 years","20-59 years",95,"82",98,NA,"alpha & delta","~19 weeks",NA,NA,"Spain","ESP",288,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-07-26,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-07-26
"2350",288,"Mazagatos","Test-negative case-control","26Jul2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","152+","hospitalization with SARI","severe","Spain","20-59 years","20-59 years",91,"50",98,NA,"alpha & delta","~19 weeks",NA,NA,"Spain","ESP",288,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-07-26,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-07-26
"2351",288,"Mazagatos","Test-negative case-control","26Jul2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization with SARI","severe","Spain","60-69 years","60-69 years",97,"86",99,NA,"alpha & delta","~19 weeks",NA,NA,"Spain","ESP",288,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-07-26,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-07-26
"2352",288,"Mazagatos","Test-negative case-control","26Jul2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","<90","hospitalization with SARI","severe","Spain","60-69 years","60-69 years",97,"87",99,NA,"alpha & delta","~19 weeks",NA,NA,"Spain","ESP",288,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-07-26,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-07-26
"2353",288,"Mazagatos","Test-negative case-control","26Jul2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","152+","hospitalization with SARI","severe","Spain","60-69 years","60-69 years",96,"47",100,NA,"alpha & delta","~19 weeks",NA,NA,"Spain","ESP",288,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-07-26,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-07-26
"2354",288,"Mazagatos","Test-negative case-control","26Jul2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","<90","hospitalization with SARI","severe","Spain","70-79 years","70-79 years",98,"90",100,NA,"alpha & delta","~23 weeks",NA,NA,"Spain","ESP",288,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-07-26,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-07-26
"2355",288,"Mazagatos","Test-negative case-control","26Jul2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","152+","hospitalization with SARI","severe","Spain","70-79 years","70-79 years",91,"24",99,NA,"alpha & delta","~23 weeks",NA,NA,"Spain","ESP",288,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-07-26,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-07-26
"2356",288,"Mazagatos","Test-negative case-control","26Jul2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","<90","hospitalization with SARI","severe","Spain",">= 80 years",">= 80 years",86,"70",94,NA,"alpha & delta","~33 weeks",NA,NA,"Spain","ESP",288,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-07-26,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-07-26
"2357",288,"Mazagatos","Test-negative case-control","26Jul2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","152+","hospitalization with SARI","severe","Spain",">= 80 years",">= 80 years",48,"-51",82,NA,"alpha & delta","~33 weeks",NA,NA,"Spain","ESP",288,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-07-26,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-07-26
"2358",288,"Mazagatos","Test-negative case-control","26Jul2022","Ad26.COV2.S (Janssen)","included","1","final","14+","hospitalization with SARI","severe","Spain","20-59 years","20-59 years",71,"-3",92,NA,"alpha & delta","~19 weeks",NA,NA,"Spain","ESP",288,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-07-26,"severe","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-07-26
"2359",288,"Mazagatos","Test-negative case-control","26Jul2022","Ad26.COV2.S (Janssen)","included","1","final","14+","hospitalization with SARI","severe","Spain","60-69 years","60-69 years",82,"-78",98,NA,"alpha & delta","~19 weeks",NA,NA,"Spain","ESP",288,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-07-26,"severe","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-07-26
"2360",288,"Mazagatos","Test-negative case-control","26Jul2022","AZD1222 (AstraZeneca)","included","2","final","14+","hospitalization with SARI","severe","Spain","60-69 years","60-69 years",89,"25",98,NA,"alpha & delta","~19 weeks",NA,NA,"Spain","ESP",288,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-07-26,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-07-26
"2361",289,"Chemaitelly","Retrospective cohort","02Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","Qatar","12-17 years","12-17 years",51.3,"34.9",63.6,NA,"omicron","~68 weeks",NA,NA,"Qatar","QAT",289,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2022-11-02,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","26/07/2022",2022-07-26
"2362",289,"Chemaitelly","Retrospective cohort","02Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","172+","infection","infection","Qatar","12-17 years","12-17 years",-1.7,"-20",10,NA,"omicron","~68 weeks",NA,NA,"Qatar","QAT",289,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2022-11-02,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","26/07/2022",2022-07-26
"2363",289,"Chemaitelly","Retrospective cohort","02Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-30","infection","infection","Qatar","5-11 years","5-11 years",49.6,"28.5",64.5,NA,"omicron","~68 weeks",NA,NA,"Qatar","QAT",289,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2022-11-02,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","26/07/2022",2022-07-26
"2364",289,"Chemaitelly","Retrospective cohort","02Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","120+","infection","infection","Qatar","5-11 years","5-11 years",-9.5,"-30",35,NA,"omicron","~68 weeks",NA,NA,"Qatar","QAT",289,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2022-11-02,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","26/07/2022",2022-07-26
"2365",289,"Chemaitelly","Retrospective cohort","02Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-30","infection","infection","Qatar","12-17 years","12-17 years",95.3,"92",97.2,NA,"alpha & delta","~68 weeks",NA,NA,"Qatar","QAT",289,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2022-11-02,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","26/07/2022",2022-07-26
"2366",289,"Chemaitelly","Retrospective cohort","02Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","152+","infection","infection","Qatar","12-17 years","12-17 years",70.6,"18",92,NA,"alpha & delta","~68 weeks",NA,NA,"Qatar","QAT",289,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2022-11-02,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","26/07/2022",2022-07-26
"2367",290,"Mayr","Test-negative case-control","22Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14 days-1 month","symptomatic disease","symptomatic","USA","veterans","veterans",76.1,"71.1",80.2,NA,"non-VOC, alpha, & delta","2 weeks",NA,NA,"USA","USA",290,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-22,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-06-22
"2368",290,"Mayr","Test-negative case-control","22Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7 months","symptomatic disease","symptomatic","USA","veterans","veterans",0.1,"-10.9",10.1,NA,"non-VOC, alpha, & delta","~26 weeks",NA,NA,"USA","USA",290,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-22,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-06-22
"2369",290,"Mayr","Test-negative case-control","22Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14 days-1 month","symptomatic disease","symptomatic","USA","veterans < 65 years","veterans < 65 years",81.6,"75.9",85.9,NA,"non-VOC, alpha, & delta","2 weeks",NA,NA,"USA","USA",290,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-22,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-06-22
"2370",290,"Mayr","Test-negative case-control","22Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7 months","symptomatic disease","symptomatic","USA","veterans < 65 years","veterans < 65 years",22.5,"7.2",35.2,NA,"non-VOC, alpha, & delta","~26 weeks",NA,NA,"USA","USA",290,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-22,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-06-22
"2371",290,"Mayr","Test-negative case-control","22Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14 days-1 month","symptomatic disease","symptomatic","USA","veterans >= 65 years","veterans >= 65 years",66.3,"55.7",74.4,NA,"non-VOC, alpha, & delta","2 weeks",NA,NA,"USA","USA",290,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-22,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-06-22
"2372",290,"Mayr","Test-negative case-control","22Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7 months","symptomatic disease","symptomatic","USA","veterans >= 65 years","veterans >= 65 years",-23.3,"-40.5",-8.2,NA,"non-VOC, alpha, & delta","~26 weeks",NA,NA,"USA","USA",290,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-22,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-06-22
"2373",290,"Mayr","Test-negative case-control","22Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14 days-1 month","hospitalization","severe","USA","veterans","veterans",72.9,"61.7",80.7,NA,"non-VOC, alpha, & delta","2 weeks",NA,NA,"USA","USA",290,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-06-22
"2374",290,"Mayr","Test-negative case-control","22Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7 months","hospitalization","severe","USA","veterans","veterans",19.8,"2.5",34.1,NA,"non-VOC, alpha, & delta","~26 weeks",NA,NA,"USA","USA",290,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-06-22
"2375",290,"Mayr","Test-negative case-control","22Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14 days-1 month","hospitalization","severe","USA","veterans < 65 years","veterans < 65 years",85.6,"72.6",92.4,NA,"non-VOC, alpha, & delta","2 weeks",NA,NA,"USA","USA",290,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-06-22
"2376",290,"Mayr","Test-negative case-control","22Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7 months","hospitalization","severe","USA","veterans < 65 years","veterans < 65 years",57,"31.2",73.2,NA,"non-VOC, alpha, & delta","~26 weeks",NA,NA,"USA","USA",290,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-06-22
"2377",290,"Mayr","Test-negative case-control","22Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14 days-1 month","hospitalization","severe","USA","veterans >= 65 years","veterans >= 65 years",61,"41.3",74.2,NA,"non-VOC, alpha, & delta","2 weeks",NA,NA,"USA","USA",290,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-06-22
"2378",290,"Mayr","Test-negative case-control","22Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7 months","hospitalization","severe","USA","veterans >= 65 years","veterans >= 65 years",1.7,"-22",20.8,NA,"non-VOC, alpha, & delta","~26 weeks",NA,NA,"USA","USA",290,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-06-22
"2379",290,"Mayr","Test-negative case-control","22Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14 days-1 month","ICU admission or death","severe","USA","veterans","veterans",74.7,"54.2",86,NA,"non-VOC, alpha, & delta","2 weeks",NA,NA,"USA","USA",290,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-06-22
"2380",290,"Mayr","Test-negative case-control","22Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7 months","ICU admission or death","severe","USA","veterans","veterans",39.5,"17.6",55.6,NA,"non-VOC, alpha, & delta","~26 weeks",NA,NA,"USA","USA",290,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-06-22
"2381",290,"Mayr","Test-negative case-control","22Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14 days-1 month","ICU admission or death","severe","USA","veterans < 65 years","veterans < 65 years",87.6,"61",96.1,NA,"non-VOC, alpha, & delta","2 weeks",NA,NA,"USA","USA",290,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-06-22
"2382",290,"Mayr","Test-negative case-control","22Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7 months","ICU admission or death","severe","USA","veterans < 65 years","veterans < 65 years",66.4,"7.7",87.8,NA,"non-VOC, alpha, & delta","~26 weeks",NA,NA,"USA","USA",290,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-06-22
"2383",290,"Mayr","Test-negative case-control","22Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14 days-1 month","ICU admission or death","severe","USA","veterans >= 65 years","veterans >= 65 years",67.4,"32.6",84.3,NA,"non-VOC, alpha, & delta","2 weeks",NA,NA,"USA","USA",290,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-06-22
"2384",290,"Mayr","Test-negative case-control","22Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7 months","ICU admission or death","severe","USA","veterans >= 65 years","veterans >= 65 years",29.3,"2.3",48.9,NA,"non-VOC, alpha, & delta","~26 weeks",NA,NA,"USA","USA",290,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-06-22
"2385",290,"Mayr","Test-negative case-control","22Jun2022","mRNA-1273 (Moderna)","excluded","2","final","14 days-1 month","symptomatic disease","symptomatic","USA","veterans","veterans",84.6,"80.5",87.8,NA,"non-VOC, alpha, & delta","2 weeks",NA,NA,"USA","USA",290,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-22,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-06-22
"2386",290,"Mayr","Test-negative case-control","22Jun2022","mRNA-1273 (Moderna)","excluded","2","final","7 months","symptomatic disease","symptomatic","USA","veterans","veterans",46.6,"40.8",51.9,NA,"non-VOC, alpha, & delta","~26 weeks",NA,NA,"USA","USA",290,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-22,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-06-22
"2387",290,"Mayr","Test-negative case-control","22Jun2022","mRNA-1273 (Moderna)","excluded","2","final","14 days-1 month","symptomatic disease","symptomatic","USA","veterans < 65 years","veterans < 65 years",89.7,"84.8",93,NA,"non-VOC, alpha, & delta","2 weeks",NA,NA,"USA","USA",290,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-22,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-06-22
"2388",290,"Mayr","Test-negative case-control","22Jun2022","mRNA-1273 (Moderna)","excluded","2","final","7 months","symptomatic disease","symptomatic","USA","veterans < 65 years","veterans < 65 years",57.3,"48.4",64.7,NA,"non-VOC, alpha, & delta","~26 weeks",NA,NA,"USA","USA",290,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-22,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-06-22
"2389",290,"Mayr","Test-negative case-control","22Jun2022","mRNA-1273 (Moderna)","excluded","2","final","14 days-1 month","symptomatic disease","symptomatic","USA","veterans >= 65 years","veterans >= 65 years",78.4,"71.1",83.9,NA,"non-VOC, alpha, & delta","2 weeks",NA,NA,"USA","USA",290,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-22,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-06-22
"2390",290,"Mayr","Test-negative case-control","22Jun2022","mRNA-1273 (Moderna)","excluded","2","final","7 months","symptomatic disease","symptomatic","USA","veterans >= 65 years","veterans >= 65 years",36.2,"27.7",43.6,NA,"non-VOC, alpha, & delta","~26 weeks",NA,NA,"USA","USA",290,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-22,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-06-22
"2391",290,"Mayr","Test-negative case-control","22Jun2022","mRNA-1273 (Moderna)","excluded","2","final","14 days-1 month","hospitalization","severe","USA","veterans","veterans",76.6,"63.9",84.8,NA,"non-VOC, alpha, & delta","2 weeks",NA,NA,"USA","USA",290,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-06-22
"2392",290,"Mayr","Test-negative case-control","22Jun2022","mRNA-1273 (Moderna)","excluded","2","final","7 months","hospitalization","severe","USA","veterans","veterans",71.3,"64",77.1,NA,"non-VOC, alpha, & delta","~26 weeks",NA,NA,"USA","USA",290,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-06-22
"2393",290,"Mayr","Test-negative case-control","22Jun2022","mRNA-1273 (Moderna)","excluded","2","final","14 days-1 month","hospitalization","severe","USA","veterans < 65 years","veterans < 65 years",92,"76.1",97.3,NA,"non-VOC, alpha, & delta","2 weeks",NA,NA,"USA","USA",290,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-06-22
"2394",290,"Mayr","Test-negative case-control","22Jun2022","mRNA-1273 (Moderna)","excluded","2","final","7 months","hospitalization","severe","USA","veterans < 65 years","veterans < 65 years",83.1,"66.8",91.4,NA,"non-VOC, alpha, & delta","~26 weeks",NA,NA,"USA","USA",290,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-06-22
"2395",290,"Mayr","Test-negative case-control","22Jun2022","mRNA-1273 (Moderna)","excluded","2","final","14 days-1 month","hospitalization","severe","USA","veterans >= 65 years","veterans >= 65 years",66.1,"45.3",79,NA,"non-VOC, alpha, & delta","2 weeks",NA,NA,"USA","USA",290,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-06-22
"2396",290,"Mayr","Test-negative case-control","22Jun2022","mRNA-1273 (Moderna)","excluded","2","final","7 months","hospitalization","severe","USA","veterans >= 65 years","veterans >= 65 years",64.7,"55.2",72.3,NA,"non-VOC, alpha, & delta","~26 weeks",NA,NA,"USA","USA",290,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-06-22
"2397",290,"Mayr","Test-negative case-control","22Jun2022","mRNA-1273 (Moderna)","excluded","2","final","14 days-1 month","ICU admission or death","severe","USA","veterans","veterans",80.5,"64.1",89.4,NA,"non-VOC, alpha, & delta","2 weeks",NA,NA,"USA","USA",290,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-06-22
"2398",290,"Mayr","Test-negative case-control","22Jun2022","mRNA-1273 (Moderna)","excluded","2","final","7 months","ICU admission or death","severe","USA","veterans","veterans",77.2,"68.4",83.5,NA,"non-VOC, alpha, & delta","~26 weeks",NA,NA,"USA","USA",290,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-06-22
"2399",290,"Mayr","Test-negative case-control","22Jun2022","mRNA-1273 (Moderna)","excluded","2","final","14 days-1 month","ICU admission or death","severe","USA","veterans < 65 years","veterans < 65 years",89.2,"49.5",97.7,NA,"non-VOC, alpha, & delta","2 weeks",NA,NA,"USA","USA",290,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-06-22
"2400",290,"Mayr","Test-negative case-control","22Jun2022","mRNA-1273 (Moderna)","excluded","2","final","7 months","ICU admission or death","severe","USA","veterans < 65 years","veterans < 65 years",84.4,"59",94.1,NA,"non-VOC, alpha, & delta","~26 weeks",NA,NA,"USA","USA",290,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-06-22
"2401",290,"Mayr","Test-negative case-control","22Jun2022","mRNA-1273 (Moderna)","excluded","2","final","14 days-1 month","ICU admission or death","severe","USA","veterans >= 65 years","veterans >= 65 years",75.4,"51.7",87.5,NA,"non-VOC, alpha, & delta","2 weeks",NA,NA,"USA","USA",290,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-06-22
"2402",290,"Mayr","Test-negative case-control","22Jun2022","mRNA-1273 (Moderna)","excluded","2","final","7 months","ICU admission or death","severe","USA","veterans >= 65 years","veterans >= 65 years",73.8,"62.9",81.5,NA,"non-VOC, alpha, & delta","~26 weeks",NA,NA,"USA","USA",290,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-06-22
"2403",290,"Mayr","Test-negative case-control","22Jun2022","Ad26.COV2.S (Janssen)","excluded","1","final","14 days-1 month","symptomatic disease","symptomatic","USA","veterans","veterans",25.4,"2.9",42.6,NA,"non-VOC, alpha, & delta","2 weeks",NA,NA,"USA","USA",290,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-22,"symptomatic","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-06-22
"2404",290,"Mayr","Test-negative case-control","22Jun2022","Ad26.COV2.S (Janssen)","excluded","1","final","7 months","symptomatic disease","symptomatic","USA","veterans","veterans",25.5,"-2.2",45.6,NA,"non-VOC, alpha, & delta","~26 weeks",NA,NA,"USA","USA",290,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-22,"symptomatic","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-06-22
"2405",290,"Mayr","Test-negative case-control","22Jun2022","Ad26.COV2.S (Janssen)","excluded","1","final","14 days-1 month","hospitalization","severe","USA","veterans","veterans",55.8,"20.6",75.4,NA,"non-VOC, alpha, & delta","2 weeks",NA,NA,"USA","USA",290,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-06-22
"2406",290,"Mayr","Test-negative case-control","22Jun2022","Ad26.COV2.S (Janssen)","excluded","1","final","7 months","hospitalization","severe","USA","veterans","veterans",16.9,"-90.9",63.8,NA,"non-VOC, alpha, & delta","~26 weeks",NA,NA,"USA","USA",290,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-06-22
"2407",290,"Mayr","Test-negative case-control","22Jun2022","Ad26.COV2.S (Janssen)","excluded","1","final","14 days-1 month","ICU admission or death","severe","USA","veterans","veterans",61.1,"11.9",82.8,NA,"non-VOC, alpha, & delta","2 weeks",NA,NA,"USA","USA",290,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-06-22
"2408",290,"Mayr","Test-negative case-control","22Jun2022","Ad26.COV2.S (Janssen)","excluded","1","final","7 months","ICU admission or death","severe","USA","veterans","veterans",63.3,"-15.5",88.3,NA,"non-VOC, alpha, & delta","~26 weeks",NA,NA,"USA","USA",290,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-06-22
"2409",291,"Piche-Renaud","Test-negative case-control","03Mar2023","BNT162b2 (Pfizer BioNTech)","included","2","final","7+","symptomatic disease","symptomatic","Canada","5-11 years","5-11 years",49,"43",54,NA,"omicron BA.1, BA.2, BA.4, BA.5","~29 weeks",NA,NA,"Canada","CAN",291,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-03-03,"symptomatic","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","01/08/2022",2022-08-01
"2410",291,"Piche-Renaud","Test-negative case-control","03Mar2023","BNT162b2 (Pfizer BioNTech)","included","2","final","7-29","symptomatic disease","symptomatic","Canada","5-11 years","5-11 years",66,"60",71,NA,"omicron BA.1, BA.2, BA.4, BA.5","~29 weeks",NA,NA,"Canada","CAN",291,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-03-03,"symptomatic","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","01/08/2022",2022-08-01
"2411",291,"Piche-Renaud","Test-negative case-control","03Mar2023","BNT162b2 (Pfizer BioNTech)","included","2","final","120+","symptomatic disease","symptomatic","Canada","5-11 years","5-11 years",-4,"-30",46,NA,"omicron BA.1, BA.2, BA.4, BA.5","~29 weeks",NA,NA,"Canada","CAN",291,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-03-03,"symptomatic","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","01/08/2022",2022-08-01
"2412",291,"Piche-Renaud","Test-negative case-control","03Mar2023","BNT162b2 (Pfizer BioNTech)","included","2","final","7+","hospitalization or death","severe","Canada","5-11 years","5-11 years",79,"63",88,NA,"omicron BA.1, BA.2, BA.4, BA.5","~29 weeks",NA,NA,"Canada","CAN",291,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-03-03,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","01/08/2022",2022-08-01
"2413",291,"Piche-Renaud","Test-negative case-control","03Mar2023","BNT162b2 (Pfizer BioNTech)","included","2","final","7-29","hospitalization or death","severe","Canada","5-11 years","5-11 years",94,"57",99,NA,"omicron BA.1, BA.2, BA.4, BA.5","~29 weeks",NA,NA,"Canada","CAN",291,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-03-03,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","01/08/2022",2022-08-01
"2414",291,"Piche-Renaud","Test-negative case-control","03Mar2023","BNT162b2 (Pfizer BioNTech)","included","2","final","120+","hospitalization or death","severe","Canada","5-11 years","5-11 years",57,"-20",85,NA,"omicron BA.1, BA.2, BA.4, BA.5","~29 weeks",NA,NA,"Canada","CAN",291,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-03-03,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","01/08/2022",2022-08-01
"2415",292,"Arashiro","Case-control","03Aug2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-89","symptomatic disease","symptomatic","Japan",">= 20 years","general pop",55,"34",69,NA,"omicron","~54 weeks",NA,NA,"Japan","JPN",292,"JPN",43970,2019,"Japan","East Asia & Pacific","High income",4,"Asia",2021-02-22,2021-08-11,2021-10-16,2021-02-17,2021-02-17,5,71,175,241,"who",71,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2022-08-03,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-08-03
"2416",292,"Arashiro","Case-control","03Aug2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","180+","symptomatic disease","symptomatic","Japan",">= 20 years","general pop",52,"37",63,NA,"omicron","~54 weeks",NA,NA,"Japan","JPN",292,"JPN",43970,2019,"Japan","East Asia & Pacific","High income",4,"Asia",2021-02-22,2021-08-11,2021-10-16,2021-02-17,2021-02-17,5,71,175,241,"who",71,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2022-08-03,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-08-03
"2417",292,"Arashiro","Case-control","03Aug2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-89","symptomatic disease","symptomatic","Japan",">= 20 years","general pop",88,"80",92,NA,"delta","~54 weeks",NA,NA,"Japan","JPN",292,"JPN",43970,2019,"Japan","East Asia & Pacific","High income",4,"Asia",2021-02-22,2021-08-11,2021-10-16,2021-02-17,2021-02-17,5,71,175,241,"who",71,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2022-08-03,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2022-08-03
"2418",292,"Arashiro","Case-control","03Aug2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","90-179","symptomatic disease","symptomatic","Japan",">= 20 years","general pop",86,"35",97,NA,"delta","~54 weeks",NA,NA,"Japan","JPN",292,"JPN",43970,2019,"Japan","East Asia & Pacific","High income",4,"Asia",2021-02-22,2021-08-11,2021-10-16,2021-02-17,2021-02-17,5,71,175,241,"who",71,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2022-08-03,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2022-08-03
"2419",293,"Tartof","Test-negative case-control","03Aug2022","BNT162b2 (Pfizer BioNTech)","included","2","final","<60","ED or UC visit","symptomatic","USA","12-17 years","12-17 years",73,"54",84,"omicron","omicron","~44 weeks",NA,NA,"USA","USA",293,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-08-03,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-08-03
"2420",293,"Tartof","Test-negative case-control","03Aug2022","BNT162b2 (Pfizer BioNTech)","included","2","final","180+","ED or UC visit","symptomatic","USA","12-17 years","12-17 years",16,"-7",34,"omicron","omicron","~44 weeks",NA,NA,"USA","USA",293,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-08-03,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-08-03
"2421",293,"Tartof","Test-negative case-control","03Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","<60","ED or UC visit","symptomatic","USA","12-17 years","12-17 years",72,"52",84,"omicron","omicron","~44 weeks",NA,NA,"USA","USA",293,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-08-03,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-08-03
"2422",293,"Tartof","Test-negative case-control","03Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","180+","ED or UC visit","symptomatic","USA","12-17 years","12-17 years",18,"-6",36,"omicron","omicron","~44 weeks",NA,NA,"USA","USA",293,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-08-03,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-08-03
"2423",293,"Tartof","Test-negative case-control","03Aug2022","BNT162b2 (Pfizer BioNTech)","included","2","final","<60","ED or UC visit","symptomatic","USA","12-17 years","12-17 years",89,"69",96,NA,"delta","~44 weeks",NA,NA,"USA","USA",293,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-08-03,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-08-03
"2424",293,"Tartof","Test-negative case-control","03Aug2022","BNT162b2 (Pfizer BioNTech)","included","2","final","180+","ED or UC visit","symptomatic","USA","12-17 years","12-17 years",49,"27",65,NA,"delta","~44 weeks",NA,NA,"USA","USA",293,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-08-03,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-08-03
"2425",293,"Tartof","Test-negative case-control","03Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","<60","ED or UC visit","symptomatic","USA","12-17 years","12-17 years",88,"68",96,NA,"delta","~44 weeks",NA,NA,"USA","USA",293,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-08-03,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-08-03
"2426",293,"Tartof","Test-negative case-control","03Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","180+","ED or UC visit","symptomatic","USA","12-17 years","12-17 years",47,"23",63,NA,"delta","~44 weeks",NA,NA,"USA","USA",293,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-08-03,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-08-03
"2427",294,"Pinto-Alvarez","Nested cohort","13Oct2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","15+","infection","infection","Colombia",">= 16 years","general pop",73.4,"68.6",77.5,NA,"mu, delta, & omicron","~56 weeks",NA,NA,"Colombia","COL",294,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2022-10-13,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","06/08/2022",2022-08-06
"2428",294,"Pinto-Alvarez","Nested cohort","13Oct2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","15+","hospitalization","severe","Colombia",">= 16 years","general pop",85.4,"80.1",89.3,NA,"mu, delta, & omicron","~56 weeks",NA,NA,"Colombia","COL",294,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2022-10-13,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","06/08/2022",2022-08-06
"2429",294,"Pinto-Alvarez","Nested cohort","13Oct2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","15+","death","death","Colombia",">= 16 years","general pop",93.4,"89.8",95.7,NA,"mu, delta, & omicron","~56 weeks",NA,NA,"Colombia","COL",294,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2022-10-13,"death","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","06/08/2022",2022-08-06
"2430",294,"Pinto-Alvarez","Nested cohort","13Oct2022","mRNA-1273 (Moderna)","excluded","2","final","15+","infection","infection","Colombia",">= 16 years","general pop",28.1,"0",48.9,NA,"mu, delta, & omicron","~56 weeks",NA,NA,"Colombia","COL",294,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2022-10-13,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","06/08/2022",2022-08-06
"2431",294,"Pinto-Alvarez","Nested cohort","13Oct2022","mRNA-1273 (Moderna)","excluded","2","final","15+","hospitalization","severe","Colombia",">= 16 years","general pop",85.2,"64.6",93.8,NA,"mu, delta, & omicron","~56 weeks",NA,NA,"Colombia","COL",294,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2022-10-13,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","06/08/2022",2022-08-06
"2432",294,"Pinto-Alvarez","Nested cohort","13Oct2022","mRNA-1273 (Moderna)","excluded","2","final","15+","death","death","Colombia",">= 16 years","general pop",96.9,"76.5",99.6,NA,"mu, delta, & omicron","~56 weeks",NA,NA,"Colombia","COL",294,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2022-10-13,"death","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","06/08/2022",2022-08-06
"2433",294,"Pinto-Alvarez","Nested cohort","13Oct2022","AZD1222 (AstraZeneca)","excluded","2","final","15+","infection","infection","Colombia",">= 16 years","general pop",67.9,"57.9",75.5,NA,"mu, delta, & omicron","~56 weeks",NA,NA,"Colombia","COL",294,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2022-10-13,"infection","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","06/08/2022",2022-08-06
"2434",294,"Pinto-Alvarez","Nested cohort","13Oct2022","AZD1222 (AstraZeneca)","excluded","2","final","15+","hospitalization","severe","Colombia",">= 16 years","general pop",82.5,"70.9",89.5,NA,"mu, delta, & omicron","~56 weeks",NA,NA,"Colombia","COL",294,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2022-10-13,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","06/08/2022",2022-08-06
"2435",294,"Pinto-Alvarez","Nested cohort","13Oct2022","AZD1222 (AstraZeneca)","excluded","2","final","15+","death","death","Colombia",">= 16 years","general pop",93.8,"86.4",97.1,NA,"mu, delta, & omicron","~56 weeks",NA,NA,"Colombia","COL",294,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2022-10-13,"death","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","06/08/2022",2022-08-06
"2436",294,"Pinto-Alvarez","Nested cohort","13Oct2022","CoronaVac (Sinovac)","excluded","2","final","15+","infection","infection","Colombia",">= 16 years","general pop",74.2,"68.3",79.1,NA,"mu, delta, & omicron","~56 weeks",NA,NA,"Colombia","COL",294,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2022-10-13,"infection","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","other combinations","06/08/2022",2022-08-06
"2437",294,"Pinto-Alvarez","Nested cohort","13Oct2022","CoronaVac (Sinovac)","excluded","2","final","15+","hospitalization","severe","Colombia",">= 16 years","general pop",83.3,"75.3",88.7,NA,"mu, delta, & omicron","~56 weeks",NA,NA,"Colombia","COL",294,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2022-10-13,"severe","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","other combinations","06/08/2022",2022-08-06
"2438",294,"Pinto-Alvarez","Nested cohort","13Oct2022","CoronaVac (Sinovac)","excluded","2","final","15+","death","death","Colombia",">= 16 years","general pop",92.6,"87.5",95.6,NA,"mu, delta, & omicron","~56 weeks",NA,NA,"Colombia","COL",294,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2022-10-13,"death","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","other combinations","06/08/2022",2022-08-06
"2439",294,"Pinto-Alvarez","Nested cohort","13Oct2022","Ad26.COV2.S (Janssen)","excluded","1","final","15+","infection","infection","Colombia",">= 16 years","general pop",73.7,"65.2",80.1,NA,"mu, delta, & omicron","~56 weeks",NA,NA,"Colombia","COL",294,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2022-10-13,"infection","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations","06/08/2022",2022-08-06
"2440",294,"Pinto-Alvarez","Nested cohort","13Oct2022","Ad26.COV2.S (Janssen)","excluded","1","final","15+","hospitalization","severe","Colombia",">= 16 years","general pop",88.4,"77.4",94,NA,"mu, delta, & omicron","~56 weeks",NA,NA,"Colombia","COL",294,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2022-10-13,"severe","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations","06/08/2022",2022-08-06
"2441",294,"Pinto-Alvarez","Nested cohort","13Oct2022","Ad26.COV2.S (Janssen)","excluded","1","final","15+","death","death","Colombia",">= 16 years","general pop",97.1,"87.9",99.3,NA,"mu, delta, & omicron","~56 weeks",NA,NA,"Colombia","COL",294,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2022-10-13,"death","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations","06/08/2022",2022-08-06
"2442",295,"Zambrano","Test-negative case-control","04Aug2022","BNT162b2 (Pfizer BioNTech)","included","2","final","28+","hospitalization with MIS-C","hospitalization with MIS-C","USA","12-18 years","12-18 years",92,"71",98,NA,"omicron","~40 weeks",NA,NA,"USA","USA",295,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-08-04,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-08-04
"2443",295,"Zambrano","Test-negative case-control","04Aug2022","BNT162b2 (Pfizer BioNTech)","included","2","final","28+","hospitalization with MIS-C","hospitalization with MIS-C","USA","12-18 years","12-18 years",94,"83",98,NA,"delta","~40 weeks",NA,NA,"USA","USA",295,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-08-04,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-08-04
"2444",295,"Zambrano","Test-negative case-control","04Aug2022","BNT162b2 (Pfizer BioNTech)","included","2","final","28-120","hospitalization with MIS-C","hospitalization with MIS-C","USA","12-18 years","12-18 years",90,"75",96,NA,"delta & omicron","~40 weeks",NA,NA,"USA","USA",295,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-08-04,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta/omicron",NA,2022-08-04
"2445",295,"Zambrano","Test-negative case-control","04Aug2022","BNT162b2 (Pfizer BioNTech)","included","2","final","120+","hospitalization with MIS-C","hospitalization with MIS-C","USA","12-18 years","12-18 years",92,"78",97,NA,"delta & omicron","~40 weeks",NA,NA,"USA","USA",295,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-08-04,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta/omicron",NA,2022-08-04
"2446",295,"Zambrano","Test-negative case-control","04Aug2022","BNT162b2 (Pfizer BioNTech)","included","2","final","28+","hospitalization with MIS-C","hospitalization with MIS-C","USA","5-11 years","5-11 years",78,"48",90,NA,"delta & omicron","~16 weeks",NA,NA,"USA","USA",295,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-08-04,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta/omicron",NA,2022-08-04
"2447",296,"El Adam","Test-negative case-control","15Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","Canada (British Colombia)","HCW","HCW",89,"87",91,NA,"alpha, gamma, & delta","~34 weeks",NA,NA,"Canada","CAN",296,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-15,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-04-15
"2448",296,"El Adam","Test-negative case-control","15Apr2022","mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","Canada (British Colombia)","HCW","HCW",93,"90",95,NA,"alpha, gamma, & delta","~34 weeks",NA,NA,"Canada","CAN",296,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-15,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-04-15
"2449",296,"El Adam","Test-negative case-control","15Apr2022","Heterologous mRNA","excluded","2","final","14+","infection","infection","Canada (British Colombia)","HCW","HCW",92,"86",95,NA,"alpha, gamma, & delta","~34 weeks",NA,NA,"Canada","CAN",296,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-15,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-04-15
"2450",296,"El Adam","Test-negative case-control","15Apr2022","Any mRNA","excluded","2","final","14+","infection","infection","Canada (British Colombia)","HCW","HCW",90,"88",92,NA,"alpha, gamma, & delta","~34 weeks",NA,NA,"Canada","CAN",296,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-15,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-04-15
"2451",296,"El Adam","Test-negative case-control","15Apr2022","Any mRNA","excluded","2","final","14-20","infection","infection","Canada (British Colombia)","HCW","HCW",99,"90",100,NA,"alpha, gamma, & delta","~34 weeks",NA,NA,"Canada","CAN",296,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-15,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-04-15
"2452",296,"El Adam","Test-negative case-control","15Apr2022","Any mRNA","excluded","2","final","196+","infection","infection","Canada (British Colombia)","HCW","HCW",82,"75",87,NA,"alpha, gamma, & delta","~34 weeks",NA,NA,"Canada","CAN",296,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-15,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-04-15
"2453",297,"Lewis","Retrospective cohort","27Jul2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","previously infected only","2","final","14+","infection","infection","USA",">= 12 years",">= 12 years",64,"58",69,NA,"non-VOC, alpha, & delta","~46 weeks",NA,NA,"USA","USA",297,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-07-27,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-07-27
"2454",297,"Lewis","Retrospective cohort","27Jul2022","Ad26.COV2.S (Janssen)","previously infected only","1","final","14+","infection","infection","USA",">= 12 years",">= 12 years",48,"26",63,NA,"non-VOC, alpha, & delta","~46 weeks",NA,NA,"USA","USA",297,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-07-27,"infection","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-07-27
"2455",297,"Lewis","Retrospective cohort","27Jul2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","previously infected only","2","final","14+","infection","infection","USA","LTCF residents","LTCF residents",49,"26",65,NA,"non-VOC, alpha, & delta","~46 weeks",NA,NA,"USA","USA",297,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-07-27,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-07-27
"2456",297,"Lewis","Retrospective cohort","27Jul2022","Ad26.COV2.S (Janssen)","previously infected only","1","final","14+","infection","infection","USA","LTCF residents","LTCF residents",57,"-211",94,NA,"non-VOC, alpha, & delta","~46 weeks",NA,NA,"USA","USA",297,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-07-27,"infection","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-07-27
"2457",297,"Lewis","Retrospective cohort","27Jul2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","previously infected only","2","final","14+","infection","infection","USA","LTCF employees","LTCF employees",52,"26",68,NA,"non-VOC, alpha, & delta","~46 weeks",NA,NA,"USA","USA",297,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-07-27,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-07-27
"2458",297,"Lewis","Retrospective cohort","27Jul2022","Ad26.COV2.S (Janssen)","previously infected only","1","final","14+","infection","infection","USA","LTCF employees","LTCF employees",-68,"-415",45,NA,"non-VOC, alpha, & delta","~46 weeks",NA,NA,"USA","USA",297,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-07-27,"infection","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-07-27
"2459",298,"Cheng","Retrospective cohort","11Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","Hong Kong","patients with chronic kidney disease","patients with chronic kidney disease",38,"34",41,NA,"omicron","~51 weeks",NA,NA,"Hong Kong","HKG",298,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2022-08-11,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-08-11
"2460",298,"Cheng","Retrospective cohort","11Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization","severe","Hong Kong","patients with chronic kidney disease","patients with chronic kidney disease",64,"57",69,NA,"omicron","~51 weeks",NA,NA,"Hong Kong","HKG",298,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2022-08-11,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-08-11
"2461",298,"Cheng","Retrospective cohort","11Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","death","death","Hong Kong","patients with chronic kidney disease","patients with chronic kidney disease",86,"80",90,NA,"omicron","~51 weeks",NA,NA,"Hong Kong","HKG",298,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2022-08-11,"death","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-08-11
"2462",298,"Cheng","Retrospective cohort","11Aug2022","CoronaVac (Sinovac)","excluded","2","final","14+","infection","infection","Hong Kong","patients with chronic kidney disease","patients with chronic kidney disease",4,"0",8,NA,"omicron","~51 weeks",NA,NA,"Hong Kong","HKG",298,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2022-08-11,"infection","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2022-08-11
"2463",298,"Cheng","Retrospective cohort","11Aug2022","CoronaVac (Sinovac)","excluded","2","final","14+","hospitalization","severe","Hong Kong","patients with chronic kidney disease","patients with chronic kidney disease",44,"37",91,NA,"omicron","~51 weeks",NA,NA,"Hong Kong","HKG",298,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2022-08-11,"severe","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2022-08-11
"2464",298,"Cheng","Retrospective cohort","11Aug2022","CoronaVac (Sinovac)","excluded","2","final","14+","death","death","Hong Kong","patients with chronic kidney disease","patients with chronic kidney disease",70,"64",75,NA,"omicron","~51 weeks",NA,NA,"Hong Kong","HKG",298,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2022-08-11,"death","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2022-08-11
"2465",299,"Risk","Retrospective cohort","16Aug2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection","infection","USA","immunocompromised adults","immunocompromised adults",13,"-23",39,NA,"omicron","~56 weeks",NA,NA,"USA","USA",299,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-08-16,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-08-16
"2466",299,"Risk","Retrospective cohort","16Aug2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection","infection","USA","immunocompetent adults","immunocompetent adults",-6,"-16",4,NA,"omicron","~56 weeks",NA,NA,"USA","USA",299,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-08-16,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-08-16
"2467",299,"Risk","Retrospective cohort","16Aug2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","hospitalization","severe","USA",">= 18 years","general pop",67,"51",78,NA,"omicron","~56 weeks",NA,NA,"USA","USA",299,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-08-16,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-08-16
"2468",299,"Risk","Retrospective cohort","16Aug2022","mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","USA","immunocompromised adults","immunocompromised adults",57,"29",74,NA,"omicron","~56 weeks",NA,NA,"USA","USA",299,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-08-16,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron",NA,2022-08-16
"2469",299,"Risk","Retrospective cohort","16Aug2022","mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","USA","immunocompetent adults","immunocompetent adults",16,"5",26,NA,"omicron","~56 weeks",NA,NA,"USA","USA",299,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-08-16,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron",NA,2022-08-16
"2470",299,"Risk","Retrospective cohort","16Aug2022","mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA",">= 18 years","general pop",79,"63",88,NA,"omicron","~56 weeks",NA,NA,"USA","USA",299,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-08-16,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron",NA,2022-08-16
"2471",299,"Risk","Retrospective cohort","16Aug2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","immunocompromised adults","immunocompromised adults",85,"62",94,NA,"omicron","~56 weeks",NA,NA,"USA","USA",299,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-08-16,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-08-16
"2472",299,"Risk","Retrospective cohort","16Aug2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","immunocompetent adults","immunocompetent adults",68,"53",78,NA,"omicron","~56 weeks",NA,NA,"USA","USA",299,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-08-16,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-08-16
"2473",299,"Risk","Retrospective cohort","16Aug2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","ICU admission","severe","USA",">= 18 years","general pop",92,"66",98,NA,"omicron","~56 weeks",NA,NA,"USA","USA",299,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-08-16,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-08-16
"2474",300,"Kim","Retrospective cohort","17Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-29","infection","infection","South Korea","12-18 years","12-18 years",76.6,"74.3",78.6,NA,"delta & omicron","~6 weeks",NA,NA,"South Korea","KOR",300,"KOR",43780,2019,"Korea, Rep.","East Asia & Pacific","High income",4,"Asia",2021-02-26,2021-09-15,2021-10-25,2021-02-26,2021-02-26,0,80,201,241,"equal",80,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","yes",2022-08-17,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta/omicron",NA,2022-08-17
"2475",300,"Kim","Retrospective cohort","17Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","30-59","infection","infection","South Korea","12-18 years","12-18 years",49.6,"45.9",53.2,NA,"delta & omicron","~6 weeks",NA,NA,"South Korea","KOR",300,"KOR",43780,2019,"Korea, Rep.","East Asia & Pacific","High income",4,"Asia",2021-02-26,2021-09-15,2021-10-25,2021-02-26,2021-02-26,0,80,201,241,"equal",80,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","yes",2022-08-17,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta/omicron",NA,2022-08-17
"2476",300,"Kim","Retrospective cohort","17Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-29","infection","infection","South Korea","12-18 years","12-18 years",83.5,"81.3",85.4,NA,"delta & omicron","~11 weeks",NA,NA,"South Korea","KOR",300,"KOR",43780,2019,"Korea, Rep.","East Asia & Pacific","High income",4,"Asia",2021-02-26,2021-09-15,2021-10-25,2021-02-26,2021-02-26,0,80,201,241,"equal",80,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","yes",2022-08-17,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta/omicron",NA,2022-08-17
"2477",300,"Kim","Retrospective cohort","17Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","60-89","infection","infection","South Korea","12-18 years","12-18 years",41.8,"35.3",47.6,NA,"delta & omicron","~11 weeks",NA,NA,"South Korea","KOR",300,"KOR",43780,2019,"Korea, Rep.","East Asia & Pacific","High income",4,"Asia",2021-02-26,2021-09-15,2021-10-25,2021-02-26,2021-02-26,0,80,201,241,"equal",80,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","yes",2022-08-17,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta/omicron",NA,2022-08-17
"2478",300,"Kim","Retrospective cohort","17Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-29","infection","infection","South Korea","12-18 years","12-18 years",82.8,"75.1",88.1,NA,"delta & omicron","~22 weeks",NA,NA,"South Korea","KOR",300,"KOR",43780,2019,"Korea, Rep.","East Asia & Pacific","High income",4,"Asia",2021-02-26,2021-09-15,2021-10-25,2021-02-26,2021-02-26,0,80,201,241,"equal",80,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","yes",2022-08-17,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta/omicron",NA,2022-08-17
"2479",300,"Kim","Retrospective cohort","17Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","90+","infection","infection","South Korea","12-18 years","12-18 years",28.9,"20.6",36.4,NA,"delta & omicron","~22 weeks",NA,NA,"South Korea","KOR",300,"KOR",43780,2019,"Korea, Rep.","East Asia & Pacific","High income",4,"Asia",2021-02-26,2021-09-15,2021-10-25,2021-02-26,2021-02-26,0,80,201,241,"equal",80,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","yes",2022-08-17,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta/omicron",NA,2022-08-17
"2480",301,"Yan","Case-control","18Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","severe disease","severe","Hong Kong","18-50 years","18-50 years",73.7,"54.2",84.9,NA,"omicron BA.2","~52 weeks",NA,NA,"Hong Kong","HKG",301,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2022-08-18,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-08-18
"2481",301,"Yan","Case-control","18Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","severe disease","severe","Hong Kong","51-64 years","51-64 years",84.5,"72.2",91.4,NA,"omicron BA.2","~52 weeks",NA,NA,"Hong Kong","HKG",301,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2022-08-18,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-08-18
"2482",301,"Yan","Case-control","18Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","severe disease","severe","Hong Kong",">= 65 years",">= 65 years",81.9,"74.4",87.2,NA,"omicron BA.2","~52 weeks",NA,NA,"Hong Kong","HKG",301,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2022-08-18,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-08-18
"2483",301,"Yan","Case-control","18Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","death","death","Hong Kong","18-50 years","18-50 years",84.2,"67.3",92.4,NA,"omicron BA.2","~52 weeks",NA,NA,"Hong Kong","HKG",301,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2022-08-18,"death","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-08-18
"2484",301,"Yan","Case-control","18Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","death","death","Hong Kong","51-64 years","51-64 years",86.9,"80.3",91.3,NA,"omicron BA.2","~52 weeks",NA,NA,"Hong Kong","HKG",301,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2022-08-18,"death","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-08-18
"2485",301,"Yan","Case-control","18Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","death","death","Hong Kong",">= 65 years",">= 65 years",90.6,"88.5",92.4,NA,"omicron BA.2","~52 weeks",NA,NA,"Hong Kong","HKG",301,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2022-08-18,"death","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-08-18
"2486",301,"Yan","Case-control","18Aug2022","CoronaVac (Sinovac)","excluded","2","final","14+","severe disease","severe","Hong Kong","18-50 years","18-50 years",72.6,"40.1",87.5,NA,"omicron BA.2","~52 weeks",NA,NA,"Hong Kong","HKG",301,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2022-08-18,"severe","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2022-08-18
"2487",301,"Yan","Case-control","18Aug2022","CoronaVac (Sinovac)","excluded","2","final","14+","severe disease","severe","Hong Kong","51-64 years","51-64 years",67.8,"48.7",79.7,NA,"omicron BA.2","~52 weeks",NA,NA,"Hong Kong","HKG",301,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2022-08-18,"severe","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2022-08-18
"2488",301,"Yan","Case-control","18Aug2022","CoronaVac (Sinovac)","excluded","2","final","14+","severe disease","severe","Hong Kong",">= 65 years",">= 65 years",56.7,"47.4",64.4,NA,"omicron BA.2","~52 weeks",NA,NA,"Hong Kong","HKG",301,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2022-08-18,"severe","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2022-08-18
"2489",301,"Yan","Case-control","18Aug2022","CoronaVac (Sinovac)","excluded","2","final","14+","death","death","Hong Kong","18-50 years","18-50 years",83.7,"57.9",93.7,NA,"omicron BA.2","~52 weeks",NA,NA,"Hong Kong","HKG",301,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2022-08-18,"death","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2022-08-18
"2490",301,"Yan","Case-control","18Aug2022","CoronaVac (Sinovac)","excluded","2","final","14+","death","death","Hong Kong","51-64 years","51-64 years",78.1,"69.4",84.3,NA,"omicron BA.2","~52 weeks",NA,NA,"Hong Kong","HKG",301,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2022-08-18,"death","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2022-08-18
"2491",301,"Yan","Case-control","18Aug2022","CoronaVac (Sinovac)","excluded","2","final","14+","death","death","Hong Kong",">= 65 years",">= 65 years",72.5,"69.9",74.9,NA,"omicron BA.2","~52 weeks",NA,NA,"Hong Kong","HKG",301,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2022-08-18,"death","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2022-08-18
"2492",302,"Powell","Test-negative case-control","22Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-104","symptomatic disease","symptomatic","UK","11-17 years","11-17 years",64.5,"63.6",65.4,NA,"omicron","~38 weeks",NA,NA,"UK","GBR",302,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-08-22,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","22/08/2022",2022-08-22
"2493",302,"Powell","Test-negative case-control","22Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","280-286","symptomatic disease","symptomatic","UK","11-17 years","11-17 years",25.7,"-4.2",47,NA,"omicron","~38 weeks",NA,NA,"UK","GBR",302,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-08-22,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","22/08/2022",2022-08-22
"2494",302,"Powell","Test-negative case-control","22Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-104","symptomatic disease","symptomatic","UK","11-17 years","11-17 years",91.8,"91.2",92.3,NA,"delta","~38 weeks",NA,NA,"UK","GBR",302,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-08-22,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","22/08/2022",2022-08-22
"2495",302,"Powell","Test-negative case-control","22Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","175-279","symptomatic disease","symptomatic","UK","11-17 years","11-17 years",71.9,"67.9",75.4,NA,"delta","~38 weeks",NA,NA,"UK","GBR",302,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-08-22,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","22/08/2022",2022-08-22
"2496",303,"Wan","Case-control","17Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","Hong Kong",">=12 years with diabetes mellitus",">=12 years with diabetes mellitus",22.1,"20",24.2,NA,"omicron BA.2","~53 weeks",NA,NA,"Hong Kong","HKG",303,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2022-08-17,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-08-17
"2497",303,"Wan","Case-control","17Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization","severe","Hong Kong",">=12 years with diabetes mellitus",">=12 years with diabetes mellitus",74.2,"71.7",76.4,NA,"omicron BA.2","~53 weeks",NA,NA,"Hong Kong","HKG",303,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2022-08-17,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-08-17
"2498",303,"Wan","Case-control","17Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","ICU admission","severe","Hong Kong",">=12 years with diabetes mellitus",">=12 years with diabetes mellitus",82.3,"72.1",88.8,NA,"omicron BA.2","~53 weeks",NA,NA,"Hong Kong","HKG",303,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2022-08-17,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-08-17
"2499",303,"Wan","Case-control","17Aug2022","CoronaVac (Sinovac)","excluded","2","final","14+","infection","infection","Hong Kong",">=12 years with diabetes mellitus",">=12 years with diabetes mellitus",-0.3,"-2.7",2.1,NA,"omicron BA.2","~53 weeks",NA,NA,"Hong Kong","HKG",303,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2022-08-17,"infection","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2022-08-17
"2500",303,"Wan","Case-control","17Aug2022","CoronaVac (Sinovac)","excluded","2","final","14+","hospitalization","severe","Hong Kong",">=12 years with diabetes mellitus",">=12 years with diabetes mellitus",64.2,"61.8",66.4,NA,"omicron BA.2","~53 weeks",NA,NA,"Hong Kong","HKG",303,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2022-08-17,"severe","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2022-08-17
"2501",303,"Wan","Case-control","17Aug2022","CoronaVac (Sinovac)","excluded","2","final","14+","ICU admission","severe","Hong Kong",">=12 years with diabetes mellitus",">=12 years with diabetes mellitus",58.1,"45",68.1,NA,"omicron BA.2","~53 weeks",NA,NA,"Hong Kong","HKG",303,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2022-08-17,"severe","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2022-08-17
"2502",304,"Tsang","Prospective cohort","12Dec2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-89","infection","infection","Hong Kong",">=5 years","general pop",27.6,"-6.3",50.7,NA,"omicron BA.2","~55 weeks",NA,NA,"Hong Kong","HKG",304,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2022-12-12,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","25/08/2022",2022-08-25
"2503",304,"Tsang","Prospective cohort","12Dec2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","90+","infection","infection","Hong Kong",">=5 years","general pop",1.1,"-22.4",20.1,NA,"omicron BA.2","~55 weeks",NA,NA,"Hong Kong","HKG",304,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2022-12-12,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","25/08/2022",2022-08-25
"2504",304,"Tsang","Prospective cohort","12Dec2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-89","symptomatic disease","symptomatic","Hong Kong",">=5 years","general pop",31.6,"-9.3",57.2,NA,"omicron BA.2","~55 weeks",NA,NA,"Hong Kong","HKG",304,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2022-12-12,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","25/08/2022",2022-08-25
"2505",304,"Tsang","Prospective cohort","12Dec2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","90+","symptomatic disease","symptomatic","Hong Kong",">=5 years","general pop",4.7,"-23.5",26.6,NA,"omicron BA.2","~55 weeks",NA,NA,"Hong Kong","HKG",304,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2022-12-12,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","25/08/2022",2022-08-25
"2506",304,"Tsang","Prospective cohort","12Dec2022","CoronaVac (Sinovac)","excluded","2","final","14-89","infection","infection","Hong Kong",">=5 years","general pop",22.7,"-15.2",48.2,NA,"omicron BA.2","~55 weeks",NA,NA,"Hong Kong","HKG",304,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2022-12-12,"infection","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron","25/08/2022",2022-08-25
"2507",304,"Tsang","Prospective cohort","12Dec2022","CoronaVac (Sinovac)","excluded","2","final","90+","infection","infection","Hong Kong",">=5 years","general pop",5.4,"-25.6",28.8,NA,"omicron BA.2","~55 weeks",NA,NA,"Hong Kong","HKG",304,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2022-12-12,"infection","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron","25/08/2022",2022-08-25
"2508",304,"Tsang","Prospective cohort","12Dec2022","CoronaVac (Sinovac)","excluded","2","final","14-89","symptomatic disease","symptomatic","Hong Kong",">=5 years","general pop",12.2,"-40",44.9,NA,"omicron BA.2","~55 weeks",NA,NA,"Hong Kong","HKG",304,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2022-12-12,"symptomatic","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron","25/08/2022",2022-08-25
"2509",304,"Tsang","Prospective cohort","12Dec2022","CoronaVac (Sinovac)","excluded","2","final","90+","symptomatic disease","symptomatic","Hong Kong",">=5 years","general pop",6.4,"-32.1",33.7,NA,"omicron BA.2","~55 weeks",NA,NA,"Hong Kong","HKG",304,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2022-12-12,"symptomatic","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron","25/08/2022",2022-08-25
"2510",305,"Cocchio","Retrospective cohort","20Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-34","infection","infection","Italy","5-11 years","5-11 years",53,"51",55,NA,"omicron","~16 weeks",NA,NA,"Italy","ITA",305,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-08-20,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-08-20
"2511",305,"Cocchio","Retrospective cohort","20Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","70+","infection","infection","Italy","5-11 years","5-11 years",23,"20",26,NA,"omicron","~16 weeks",NA,NA,"Italy","ITA",305,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-08-20,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-08-20
"2512",305,"Cocchio","Retrospective cohort","20Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-34","infection","infection","Italy","12-17 years","12-17 years",59,"55",62,NA,"omicron","~53 weeks",NA,NA,"Italy","ITA",305,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-08-20,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-08-20
"2513",305,"Cocchio","Retrospective cohort","20Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","70+","infection","infection","Italy","12-17 years","12-17 years",8,"5",11,NA,"omicron","~53 weeks",NA,NA,"Italy","ITA",305,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-08-20,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-08-20
"2514",305,"Cocchio","Retrospective cohort","20Aug2022","mRNA-1273 (Moderna)","excluded","2","final","14-34","infection","infection","Italy","12-17 years","12-17 years",55,"49",61,NA,"omicron","~33 weeks",NA,NA,"Italy","ITA",305,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-08-20,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron",NA,2022-08-20
"2515",305,"Cocchio","Retrospective cohort","20Aug2022","mRNA-1273 (Moderna)","excluded","2","final","70+","infection","infection","Italy","12-17 years","12-17 years",20,"15",24,NA,"omicron","~33 weeks",NA,NA,"Italy","ITA",305,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-08-20,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron",NA,2022-08-20
"2516",305,"Cocchio","Retrospective cohort","20Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-34","infection","infection","Italy","12-17 years","12-17 years",88,"85",91,NA,"delta","~28 weeks",NA,NA,"Italy","ITA",305,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-08-20,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-08-20
"2517",305,"Cocchio","Retrospective cohort","20Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","70+","infection","infection","Italy","12-17 years","12-17 years",82,"74",88,NA,"delta","~28 weeks",NA,NA,"Italy","ITA",305,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-08-20,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-08-20
"2518",305,"Cocchio","Retrospective cohort","20Aug2022","mRNA-1273 (Moderna)","excluded","2","final","14-34","infection","infection","Italy","12-17 years","12-17 years",90,"68",97,NA,"delta","~7 weeks",NA,NA,"Italy","ITA",305,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-08-20,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2022-08-20
"2519",305,"Cocchio","Retrospective cohort","20Aug2022","mRNA-1273 (Moderna)","excluded","2","final","35-69","infection","infection","Italy","12-17 years","12-17 years",96,"86",99,NA,"delta","~7 weeks",NA,NA,"Italy","ITA",305,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-08-20,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2022-08-20
"2520",306,"Lim","Test-negative case-control","24Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-27","infection","infection","Malaysia",">=18 years","general pop",58.9,"40.7",71.9,NA,"alpha & delta","~28 weeks",NA,NA,"Malaysia","MYS",306,"MYS",28090,2019,"Malaysia","East Asia & Pacific","Upper middle income",3,"Asia",2021-02-26,2021-08-24,2021-10-21,2021-02-24,2021-02-24,2,78,181,239,"who",78,"feb/2021","60-89","Jun-Aug/2021","180-269","yes","yes","yes",2022-08-24,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-08-24
"2521",306,"Lim","Test-negative case-control","24Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","98-111","infection","infection","Malaysia",">=18 years","general pop",31.3,"10.8",47.2,NA,"alpha & delta","~28 weeks",NA,NA,"Malaysia","MYS",306,"MYS",28090,2019,"Malaysia","East Asia & Pacific","Upper middle income",3,"Asia",2021-02-26,2021-08-24,2021-10-21,2021-02-24,2021-02-24,2,78,181,239,"who",78,"feb/2021","60-89","Jun-Aug/2021","180-269","yes","yes","yes",2022-08-24,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-08-24
"2522",306,"Lim","Test-negative case-control","24Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","ICU admission","severe","Malaysia",">=18 years","general pop",92.5,"72.3",98.8,NA,"alpha & delta","~28 weeks",NA,NA,"Malaysia","MYS",306,"MYS",28090,2019,"Malaysia","East Asia & Pacific","Upper middle income",3,"Asia",2021-02-26,2021-08-24,2021-10-21,2021-02-24,2021-02-24,2,78,181,239,"who",78,"feb/2021","60-89","Jun-Aug/2021","180-269","yes","yes","yes",2022-08-24,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-08-24
"2523",306,"Lim","Test-negative case-control","24Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","death","death","Malaysia",">=18 years","general pop",96.5,"82.3",99.8,NA,"alpha & delta","~28 weeks",NA,NA,"Malaysia","MYS",306,"MYS",28090,2019,"Malaysia","East Asia & Pacific","Upper middle income",3,"Asia",2021-02-26,2021-08-24,2021-10-21,2021-02-24,2021-02-24,2,78,181,239,"who",78,"feb/2021","60-89","Jun-Aug/2021","180-269","yes","yes","yes",2022-08-24,"death","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-08-24
"2524",306,"Lim","Retrospective cohort","24Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","Malaysia",">=18 years","general pop",87.9,"86.3",89.4,NA,"alpha & delta","~28 weeks",NA,NA,"Malaysia","MYS",306,"MYS",28090,2019,"Malaysia","East Asia & Pacific","Upper middle income",3,"Asia",2021-02-26,2021-08-24,2021-10-21,2021-02-24,2021-02-24,2,78,181,239,"who",78,"feb/2021","60-89","Jun-Aug/2021","180-269","yes","yes","yes",2022-08-24,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-08-24
"2525",306,"Lim","Retrospective cohort","24Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","ICU admission","severe","Malaysia",">=18 years","general pop",97.5,"81.2",99.6,NA,"alpha & delta","~28 weeks",NA,NA,"Malaysia","MYS",306,"MYS",28090,2019,"Malaysia","East Asia & Pacific","Upper middle income",3,"Asia",2021-02-26,2021-08-24,2021-10-21,2021-02-24,2021-02-24,2,78,181,239,"who",78,"feb/2021","60-89","Jun-Aug/2021","180-269","yes","yes","yes",2022-08-24,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-08-24
"2526",306,"Lim","Retrospective cohort","24Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","death","death","Malaysia",">=18 years","general pop",99.3,"96.3",100,NA,"alpha & delta","~28 weeks",NA,NA,"Malaysia","MYS",306,"MYS",28090,2019,"Malaysia","East Asia & Pacific","Upper middle income",3,"Asia",2021-02-26,2021-08-24,2021-10-21,2021-02-24,2021-02-24,2,78,181,239,"who",78,"feb/2021","60-89","Jun-Aug/2021","180-269","yes","yes","yes",2022-08-24,"death","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-08-24
"2527",307,"Lind","Test-negative case-control","21Nov2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-89","infection","infection","USA",">=16 years","general pop",84.4,"75.5",90,NA,"alpha","~29 weeks",NA,NA,"USA","USA",307,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-11-21,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha","26/08/2022",2022-08-26
"2528",307,"Lind","Test-negative case-control","21Nov2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","90-149","infection","infection","USA",">=16 years","general pop",96.5,"75.1",99.5,NA,"alpha","~29 weeks",NA,NA,"USA","USA",307,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-11-21,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha","26/08/2022",2022-08-26
"2529",307,"Lind","Test-negative case-control","21Nov2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-89","symptomatic disease","symptomatic","USA",">=16 years","general pop",86.6,"75.5",92.7,NA,"alpha","~29 weeks",NA,NA,"USA","USA",307,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-11-21,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha","26/08/2022",2022-08-26
"2530",307,"Lind","Test-negative case-control","21Nov2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","90-149","symptomatic disease","symptomatic","USA",">=16 years","general pop",93.8,"55",99.1,NA,"alpha","~29 weeks",NA,NA,"USA","USA",307,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-11-21,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha","26/08/2022",2022-08-26
"2531",307,"Lind","Test-negative case-control","21Nov2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-89","hospitalization","severe","USA",">=16 years","general pop",85.5,"65.5",93.9,NA,"alpha","~29 weeks",NA,NA,"USA","USA",307,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-11-21,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha","26/08/2022",2022-08-26
"2532",307,"Lind","Test-negative case-control","21Nov2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","90-149","hospitalization","severe","USA",">=16 years","general pop",82.2,"-34.5",97.7,NA,"alpha","~29 weeks",NA,NA,"USA","USA",307,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-11-21,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha","26/08/2022",2022-08-26
"2533",307,"Lind","Test-negative case-control","21Nov2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-89","infection","infection","USA",">=16 years","general pop",68.9,"58",77.1,NA,"delta","~29 weeks",NA,NA,"USA","USA",307,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-11-21,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta","26/08/2022",2022-08-26
"2534",307,"Lind","Test-negative case-control","21Nov2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","150+","infection","infection","USA",">=16 years","general pop",37.1,"24",48.1,NA,"delta","~29 weeks",NA,NA,"USA","USA",307,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-11-21,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta","26/08/2022",2022-08-26
"2535",307,"Lind","Test-negative case-control","21Nov2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-89","symptomatic disease","symptomatic","USA",">=16 years","general pop",74.8,"62.9",82.9,NA,"delta","~29 weeks",NA,NA,"USA","USA",307,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-11-21,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta","26/08/2022",2022-08-26
"2536",307,"Lind","Test-negative case-control","21Nov2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","150+","symptomatic disease","symptomatic","USA",">=16 years","general pop",48.4,"32.8",60.4,NA,"delta","~29 weeks",NA,NA,"USA","USA",307,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-11-21,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta","26/08/2022",2022-08-26
"2537",307,"Lind","Test-negative case-control","21Nov2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-89","hospitalization","severe","USA",">=16 years","general pop",85.4,"60.2",94.6,NA,"delta","~29 weeks",NA,NA,"USA","USA",307,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-11-21,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta","26/08/2022",2022-08-26
"2538",307,"Lind","Test-negative case-control","21Nov2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","150+","hospitalization","severe","USA",">=16 years","general pop",66.2,"42.5",80.1,NA,"delta","~29 weeks",NA,NA,"USA","USA",307,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-11-21,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta","26/08/2022",2022-08-26
"2539",308,"Suphanchaimat","Test-negative case-control","05Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final","15-29","infection","infection","Thailand",">=18 years","general pop",74.2,"71.8",76.3,NA,"delta","~2 weeks",NA,NA,"Thailand","THA",308,"THA",18070,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,82,240,395,"who",82,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-05,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-07-05
"2540",308,"Suphanchaimat","Test-negative case-control","05Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final","90+","infection","infection","Thailand",">=18 years","general pop",57,"43.6",57.2,NA,"delta","~15 weeks",NA,NA,"Thailand","THA",308,"THA",18070,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,82,240,395,"who",82,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-05,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-07-05
"2541",308,"Suphanchaimat","Test-negative case-control","05Jul2022","AZD1222 (AstraZeneca)","included","2","final","15-29","infection","infection","Thailand",">=18 years","general pop",61.4,"59.6",63.2,NA,"delta","~2 weeks",NA,NA,"Thailand","THA",308,"THA",18070,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,82,240,395,"who",82,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-05,"infection","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2022-07-05
"2542",308,"Suphanchaimat","Test-negative case-control","05Jul2022","AZD1222 (AstraZeneca)","included","2","final","90+","infection","infection","Thailand",">=18 years","general pop",25.8,"19.1",31.9,NA,"delta","~31 weeks",NA,NA,"Thailand","THA",308,"THA",18070,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,82,240,395,"who",82,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-05,"infection","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2022-07-05
"2543",308,"Suphanchaimat","Test-negative case-control","05Jul2022","CoronaVac (Sinovac)","included","2","final","15-29","infection","infection","Thailand",">=18 years","general pop",27.9,"0.3",47.9,NA,"delta","~2 weeks",NA,NA,"Thailand","THA",308,"THA",18070,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,82,240,395,"who",82,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-05,"infection","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","delta",NA,2022-07-05
"2544",308,"Suphanchaimat","Test-negative case-control","05Jul2022","CoronaVac (Sinovac)","included","2","final","90+","infection","infection","Thailand",">=18 years","general pop",49.8,"47.8",51.6,NA,"delta","~40 weeks",NA,NA,"Thailand","THA",308,"THA",18070,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,82,240,395,"who",82,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-05,"infection","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","delta",NA,2022-07-05
"2545",308,"Suphanchaimat","Test-negative case-control","05Jul2022","AZD1222 (AstraZeneca) & BNT162b2 (Pfizer BioNTech) -heterologous","included","2","final","15-29","infection","infection","Thailand",">=18 years","general pop",79.9,"74",84.5,NA,"delta","~2 weeks",NA,NA,"Thailand","THA",308,"THA",18070,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,82,240,395,"who",82,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-05,"infection","2022 (Jul-Dec)","Heterologous platforms","Multiple","delta",NA,2022-07-05
"2546",308,"Suphanchaimat","Test-negative case-control","05Jul2022","AZD1222 (AstraZeneca) & BNT162b2 (Pfizer BioNTech) -heterologous","included","2","final","90+","infection","infection","Thailand",">=18 years","general pop",77.4,"68.2",84,NA,"delta","~19 weeks",NA,NA,"Thailand","THA",308,"THA",18070,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,82,240,395,"who",82,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-05,"infection","2022 (Jul-Dec)","Heterologous platforms","Multiple","delta",NA,2022-07-05
"2547",308,"Suphanchaimat","Test-negative case-control","05Jul2022","CoronaVac (Sinovac) & AZD1222 (AstraZeneca) - heterologous","included","2","final","15-29","infection","infection","Thailand",">=18 years","general pop",57.8,"56.3",59.2,NA,"delta","~2 weeks",NA,NA,"Thailand","THA",308,"THA",18070,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,82,240,395,"who",82,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-05,"infection","2022 (Jul-Dec)","Heterologous platforms","Multiple","delta",NA,2022-07-05
"2548",308,"Suphanchaimat","Test-negative case-control","05Jul2022","CoronaVac (Sinovac) & AZD1222 (AstraZeneca) - heterologous","included","2","final","90+","infection","infection","Thailand",">=18 years","general pop",36.6,"33.6",39.4,NA,"delta","~39 weeks",NA,NA,"Thailand","THA",308,"THA",18070,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,82,240,395,"who",82,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-05,"infection","2022 (Jul-Dec)","Heterologous platforms","Multiple","delta",NA,2022-07-05
"2549",308,"Suphanchaimat","Test-negative case-control","05Jul2022","CoronaVac (Sinovac) & BNT162b2 (Pfizer BioNTech) - heterologous","included","2","final","15-29","infection","infection","Thailand",">=18 years","general pop",74.7,"62.8",82.8,NA,"delta","~2 weeks",NA,NA,"Thailand","THA",308,"THA",18070,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,82,240,395,"who",82,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-05,"infection","2022 (Jul-Dec)","Heterologous platforms","Multiple","delta",NA,2022-07-05
"2550",308,"Suphanchaimat","Test-negative case-control","05Jul2022","CoronaVac (Sinovac) & BNT162b2 (Pfizer BioNTech) - heterologous","included","2","final","90+","infection","infection","Thailand",">=18 years","general pop",84.6,"64.9",89.3,NA,"delta","~19 weeks",NA,NA,"Thailand","THA",308,"THA",18070,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,82,240,395,"who",82,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-05,"infection","2022 (Jul-Dec)","Heterologous platforms","Multiple","delta",NA,2022-07-05
"2551",309,"Barraza","Retrospective cohort","05Aug2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","hospitalization with SARI","severe","Chile",">=18 years","general pop",80.3,"68.9",87.5,NA,"gamma, delta & omicron","~77 weeks",NA,NA,"Chile","CHL",309,"CHL",24650,2019,"Chile","Latin America & Caribbean","High income",3,"South America",2020-12-25,2021-05-25,2021-09-02,2020-12-21,2020-12-21,4,13,155,255,"who",13,"before jan/2021","<30","before Jun/2021","<180","yes","yes","yes",2022-08-05,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-08-05
"2552",309,"Barraza","Retrospective cohort","05Aug2022","AZD1222 (AstraZeneca)","included","2","final","14+","hospitalization with SARI","severe","Chile",">=18 years","general pop",72.4,"32.8",88.6,NA,"gamma, delta & omicron","~71 weeks",NA,NA,"Chile","CHL",309,"CHL",24650,2019,"Chile","Latin America & Caribbean","High income",3,"South America",2020-12-25,2021-05-25,2021-09-02,2020-12-21,2020-12-21,4,13,155,255,"who",13,"before jan/2021","<30","before Jun/2021","<180","yes","yes","yes",2022-08-05,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-08-05
"2553",309,"Barraza","Retrospective cohort","05Aug2022","CoronaVac (Sinovac)","included","2","final","14+","hospitalization with SARI","severe","Chile",">=18 years","general pop",54.5,"45.2",62.3,NA,"gamma, delta & omicron","~72 weeks",NA,NA,"Chile","CHL",309,"CHL",24650,2019,"Chile","Latin America & Caribbean","High income",3,"South America",2020-12-25,2021-05-25,2021-09-02,2020-12-21,2020-12-21,4,13,155,255,"who",13,"before jan/2021","<30","before Jun/2021","<180","yes","yes","yes",2022-08-05,"severe","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","other combinations",NA,2022-08-05
"2554",310,"Penayo","Test-negative case-control","01Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","hospitalization with SARI","severe","Paraguay",">=18 years","general pop",91.9,"72.2",97.6,NA,"delta","~38 weeks",NA,NA,"Paraguay","PRY",310,"PRY",13770,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,76,291,NA,"who",76,"feb/2021","60-89","Dec/2021 +","270-359","yes","yes","no",2022-06-01,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-06-01
"2555",310,"Penayo","Test-negative case-control","01Jun2022","mRNA-1273 (Moderna)","included","2","final","14+","hospitalization with SARI","severe","Paraguay",">=18 years","general pop",76.1,"-127.4",97.5,NA,"delta","~37 weeks",NA,NA,"Paraguay","PRY",310,"PRY",13770,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,76,291,NA,"who",76,"feb/2021","60-89","Dec/2021 +","270-359","yes","yes","no",2022-06-01,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta",NA,2022-06-01
"2556",310,"Penayo","Test-negative case-control","01Jun2022","AZD1222 (AstraZeneca)","included","2","final","14+","hospitalization with SARI","severe","Paraguay",">=18 years","general pop",83,"66.3",91.5,NA,"delta","~33 weeks",NA,NA,"Paraguay","PRY",310,"PRY",13770,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,76,291,NA,"who",76,"feb/2021","60-89","Dec/2021 +","270-359","yes","yes","no",2022-06-01,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2022-06-01
"2557",310,"Penayo","Test-negative case-control","01Jun2022","Gam-COVID-Vac (Gamaleya)","included","2","final","14+","hospitalization with SARI","severe","Paraguay",">=18 years","general pop",83.2,"48.9",94.5,NA,"delta","~38 weeks",NA,NA,"Paraguay","PRY",310,"PRY",13770,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,76,291,NA,"who",76,"feb/2021","60-89","Dec/2021 +","270-359","yes","yes","no",2022-06-01,"severe","2022 (Jan-Jun)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","delta",NA,2022-06-01
"2558",310,"Penayo","Test-negative case-control","01Jun2022","Hayat-Vax (Julphar)","included","2","final","14+","hospitalization with SARI","severe","Paraguay",">=18 years","general pop",31.8,"-41.2",67.1,NA,"delta","~39 weeks",NA,NA,"Paraguay","PRY",310,"PRY",13770,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,76,291,NA,"who",76,"feb/2021","60-89","Dec/2021 +","270-359","yes","yes","no",2022-06-01,"severe","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta",NA,2022-06-01
"2559",310,"Penayo","Test-negative case-control","01Jun2022","BBV152 (Bharat)","included","2","final","14+","hospitalization with SARI","severe","Paraguay",">=18 years","general pop",25.8,"-37.1",59.9,NA,"delta","~37 weeks",NA,NA,"Paraguay","PRY",310,"PRY",13770,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,76,291,NA,"who",76,"feb/2021","60-89","Dec/2021 +","270-359","yes","yes","no",2022-06-01,"severe","2022 (Jan-Jun)","Bharat Covaxin/BBV152","Inactivated","delta",NA,2022-06-01
"2560",310,"Penayo","Test-negative case-control","01Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","hospitalization with SARI","severe","Paraguay",">=18 years","general pop",49.5,"9.9",71.7,NA,"omicron","~53 weeks",NA,NA,"Paraguay","PRY",310,"PRY",13770,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,76,291,NA,"who",76,"feb/2021","60-89","Dec/2021 +","270-359","yes","yes","no",2022-06-01,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-06-01
"2561",310,"Penayo","Test-negative case-control","01Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14-89","hospitalization with SARI","severe","Paraguay",">=18 years","general pop",78,"-97",97.5,NA,"omicron","~11 weeks",NA,NA,"Paraguay","PRY",310,"PRY",13770,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,76,291,NA,"who",76,"feb/2021","60-89","Dec/2021 +","270-359","yes","yes","no",2022-06-01,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-06-01
"2562",310,"Penayo","Test-negative case-control","01Jun2022","mRNA-1273 (Moderna)","included","2","final","14+","hospitalization with SARI","severe","Paraguay",">=18 years","general pop",42.1,"-105.4",83.7,NA,"omicron","~52 weeks",NA,NA,"Paraguay","PRY",310,"PRY",13770,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,76,291,NA,"who",76,"feb/2021","60-89","Dec/2021 +","270-359","yes","yes","no",2022-06-01,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron",NA,2022-06-01
"2563",310,"Penayo","Test-negative case-control","01Jun2022","AZD1222 (AstraZeneca)","included","2","final","14+","hospitalization with SARI","severe","Paraguay",">=18 years","general pop",10.1,"-31",38.3,NA,"omicron","~48 weeks",NA,NA,"Paraguay","PRY",310,"PRY",13770,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,76,291,NA,"who",76,"feb/2021","60-89","Dec/2021 +","270-359","yes","yes","no",2022-06-01,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron",NA,2022-06-01
"2564",310,"Penayo","Test-negative case-control","01Jun2022","Gam-COVID-Vac (Gamaleya)","included","2","final","14+","hospitalization with SARI","severe","Paraguay",">=18 years","general pop",25.7,"-29.9",57.5,NA,"omicron","~53 weeks",NA,NA,"Paraguay","PRY",310,"PRY",13770,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,76,291,NA,"who",76,"feb/2021","60-89","Dec/2021 +","270-359","yes","yes","no",2022-06-01,"severe","2022 (Jan-Jun)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","omicron",NA,2022-06-01
"2565",310,"Penayo","Test-negative case-control","01Jun2022","Gam-COVID-Vac (Gamaleya)","included","2","final","14-89","hospitalization with SARI","severe","Paraguay",">=18 years","general pop",64.4,"-44.6",92.2,NA,"omicron","~11 weeks",NA,NA,"Paraguay","PRY",310,"PRY",13770,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,76,291,NA,"who",76,"feb/2021","60-89","Dec/2021 +","270-359","yes","yes","no",2022-06-01,"severe","2022 (Jan-Jun)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","omicron",NA,2022-06-01
"2566",310,"Penayo","Test-negative case-control","01Jun2022","Hayat-Vax (Julphar)","included","2","final","14+","hospitalization with SARI","severe","Paraguay",">=18 years","general pop",40.4,"-5.1",66.2,NA,"omicron","~54 weeks",NA,NA,"Paraguay","PRY",310,"PRY",13770,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,76,291,NA,"who",76,"feb/2021","60-89","Dec/2021 +","270-359","yes","yes","no",2022-06-01,"severe","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","omicron",NA,2022-06-01
"2567",310,"Penayo","Test-negative case-control","01Jun2022","BBV152 (Bharat)","included","2","final","14+","hospitalization with SARI","severe","Paraguay",">=18 years","general pop",13,"-45.8",48,NA,"omicron","~52 weeks",NA,NA,"Paraguay","PRY",310,"PRY",13770,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,76,291,NA,"who",76,"feb/2021","60-89","Dec/2021 +","270-359","yes","yes","no",2022-06-01,"severe","2022 (Jan-Jun)","Bharat Covaxin/BBV152","Inactivated","omicron",NA,2022-06-01
"2568",311,"Monge","Case cohort","02Sept2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection","infection","Spain","50-59 years","50-59 years",77,"76",77,NA,"delta","~21 weeks",NA,NA,"Spain","ESP",311,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-02,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-09-02
"2569",311,"Monge","Case cohort","02Sept2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","symptomatic disease","symptomatic","Spain","50-59 years","50-59 years",77,"76",78,NA,"delta","~21 weeks",NA,NA,"Spain","ESP",311,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-02,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-09-02
"2570",311,"Monge","Case cohort","02Sept2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","hospitalization","severe","Spain","50-59 years","50-59 years",97,"97",98,NA,"delta","~21 weeks",NA,NA,"Spain","ESP",311,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-02,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-09-02
"2571",311,"Monge","Case cohort","02Sept2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","death","death","Spain","50-59 years","50-59 years",97,"93",99,NA,"delta","~21 weeks",NA,NA,"Spain","ESP",311,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-02,"death","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-09-02
"2572",311,"Monge","Case cohort","02Sept2022","mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","Spain","50-59 years","50-59 years",87,"86",87,NA,"delta","~21 weeks",NA,NA,"Spain","ESP",311,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-02,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2022-09-02
"2573",311,"Monge","Case cohort","02Sept2022","mRNA-1273 (Moderna)","included","2","final","14+","symptomatic disease","symptomatic","Spain","50-59 years","50-59 years",89,"88",90,NA,"delta","~21 weeks",NA,NA,"Spain","ESP",311,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-02,"symptomatic","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2022-09-02
"2574",311,"Monge","Case cohort","02Sept2022","mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","Spain","50-59 years","50-59 years",98,"97",99,NA,"delta","~21 weeks",NA,NA,"Spain","ESP",311,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-02,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2022-09-02
"2575",311,"Monge","Case cohort","02Sept2022","mRNA-1273 (Moderna)","included","2","final","14+","death","death","Spain","50-59 years","50-59 years",94,"75",99,NA,"delta","~21 weeks",NA,NA,"Spain","ESP",311,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-02,"death","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2022-09-02
"2576",311,"Monge","Case cohort","02Sept2022","AZD1222 (AstraZeneca)","included","2","final","14+","infection","infection","Spain","50-59 years","50-59 years",59,"56",61,NA,"delta","~21 weeks",NA,NA,"Spain","ESP",311,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-02,"infection","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2022-09-02
"2577",311,"Monge","Case cohort","02Sept2022","AZD1222 (AstraZeneca)","included","2","final","14+","symptomatic disease","symptomatic","Spain","50-59 years","50-59 years",59,"55",62,NA,"delta","~21 weeks",NA,NA,"Spain","ESP",311,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-02,"symptomatic","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2022-09-02
"2578",311,"Monge","Case cohort","02Sept2022","AZD1222 (AstraZeneca)","included","2","final","14+","hospitalization","severe","Spain","50-59 years","50-59 years",96,"93",98,NA,"delta","~21 weeks",NA,NA,"Spain","ESP",311,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-02,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2022-09-02
"2579",311,"Monge","Case cohort","02Sept2022","Ad26.COV2.S (Janssen)","included","1","final","14+","infection","infection","Spain","50-59 years","50-59 years",64,"62",66,NA,"delta","~21 weeks",NA,NA,"Spain","ESP",311,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-02,"infection","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta",NA,2022-09-02
"2580",311,"Monge","Case cohort","02Sept2022","Ad26.COV2.S (Janssen)","included","1","final","14+","symptomatic disease","symptomatic","Spain","50-59 years","50-59 years",56,"53",59,NA,"delta","~21 weeks",NA,NA,"Spain","ESP",311,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-02,"symptomatic","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta",NA,2022-09-02
"2581",311,"Monge","Case cohort","02Sept2022","Ad26.COV2.S (Janssen)","included","1","final","14+","hospitalization","severe","Spain","50-59 years","50-59 years",86,"83",89,NA,"delta","~21 weeks",NA,NA,"Spain","ESP",311,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-02,"severe","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta",NA,2022-09-02
"2582",311,"Monge","Case cohort","02Sept2022","Ad26.COV2.S (Janssen)","included","1","final","14+","death","death","Spain","50-59 years","50-59 years",89,"64",97,NA,"delta","~21 weeks",NA,NA,"Spain","ESP",311,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-02,"death","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta",NA,2022-09-02
"2583",311,"Monge","Case cohort","02Sept2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","included","2","final","14+","infection","infection","Spain","50-59 years","50-59 years",88,"85",91,NA,"delta","~21 weeks",NA,NA,"Spain","ESP",311,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-02,"infection","2022 (Jul-Dec)","Heterologous platforms","Multiple","delta",NA,2022-09-02
"2584",311,"Monge","Case cohort","02Sept2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","included","2","final","14+","symptomatic disease","symptomatic","Spain","50-59 years","50-59 years",82,"75",87,NA,"delta","~21 weeks",NA,NA,"Spain","ESP",311,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-02,"symptomatic","2022 (Jul-Dec)","Heterologous platforms","Multiple","delta",NA,2022-09-02
"2585",311,"Monge","Case cohort","02Sept2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","included","2","final","14+","hospitalization","severe","Spain","50-59 years","50-59 years",98,"84",100,NA,"delta","~21 weeks",NA,NA,"Spain","ESP",311,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-02,"severe","2022 (Jul-Dec)","Heterologous platforms","Multiple","delta",NA,2022-09-02
"2586",312,"Huang","Matched case-control","20Oct2022","Ad5-nCOV (CanSino)","excluded","1","final","14+","infection","infection","China",">=3 years","general pop",13.2,"10.9",15.5,NA,"omicron","~62 weeks",NA,NA,"China","CHN",312,"CHN",16610,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,-139,386,420,"who",0,"before jan/2021","<30","Jun-Aug/2021","360+","yes","yes","yes",2022-10-20,"infection","2022 (Jul-Dec)","Cansino Ad5-nCoV","Vectored","omicron","09/09/2022",2022-09-09
"2587",312,"Huang","Matched case-control","20Oct2022","Ad5-nCOV (CanSino)","excluded","1","final","14+","severe/critical illness","severe","China",">=3 years","general pop",77.9,"15.6",94.2,NA,"omicron","~62 weeks",NA,NA,"China","CHN",312,"CHN",16610,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,-139,386,420,"who",0,"before jan/2021","<30","Jun-Aug/2021","360+","yes","yes","yes",2022-10-20,"severe","2022 (Jul-Dec)","Cansino Ad5-nCoV","Vectored","omicron","09/09/2022",2022-09-09
"2588",313,"Chico-Sanchez","Test-negative case-control","31Aug2022","BNT162b2 (Pfizer BioNTech)","included","2","final","12-120","infection","infection","Spain","HCW","HCW",91.6,"89.6",93.2,NA,"non-VOC & alpha","~22 weeks",NA,NA,"Spain","ESP",313,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-08-31,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-08-31
"2589",313,"Chico-Sanchez","Test-negative case-control","31Aug2022","BNT162b2 (Pfizer BioNTech)","included","2","final","120+","infection","infection","Spain","HCW","HCW",71.5,"67",75.5,NA,"non-VOC & alpha","~22 weeks",NA,NA,"Spain","ESP",313,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-08-31,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-08-31
"2590",313,"Chico-Sanchez","Test-negative case-control","31Aug2022","mRNA-1273 (Moderna)","included","2","final","12-120","infection","infection","Spain","HCW","HCW",95.2,"88.3",98.1,NA,"non-VOC & alpha","~22 weeks",NA,NA,"Spain","ESP",313,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-08-31,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-08-31
"2591",313,"Chico-Sanchez","Test-negative case-control","31Aug2022","mRNA-1273 (Moderna)","included","2","final","120+","infection","infection","Spain","HCW","HCW",88.3,"75.7",94.4,NA,"non-VOC & alpha","~22 weeks",NA,NA,"Spain","ESP",313,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-08-31,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-08-31
"2592",313,"Chico-Sanchez","Test-negative case-control","31Aug2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","12+","hospitalization","severe","Spain","HCW","HCW",96.8,"76.1",99.6,NA,"non-VOC & alpha","~22 weeks",NA,NA,"Spain","ESP",313,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-08-31,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-08-31
"2593",314,"Mallah","Test-negative case-control","10Sept2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","infection","infection","Spain",">=11 years","general pop",72,"71",73,NA,"alpha & delta","~42 weeks",NA,NA,"Spain","ESP",314,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-10,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-09-10
"2594",314,"Mallah","Test-negative case-control","10Sept2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","hospitalization","severe","Spain",">=11 years","general pop",74,"70",77,NA,"alpha & delta","~42 weeks",NA,NA,"Spain","ESP",314,"ESP",43160,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,22,186,244,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-10,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-09-10
"2595",315,"Chatzilena","Test-negative case-control","07Dec2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7+","hospitalization","severe","UK",">=18 years","general pop",82.5,"76.2",87.2,NA,"delta","~56 weeks",NA,NA,"UK","GBR",315,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-12-07,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","12/09/2022",2022-09-12
"2596",315,"Chatzilena","Test-negative case-control","07Dec2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">=3 months","hospitalization","severe","UK",">=18 years","general pop",91.5,"83.1",96.2,NA,"delta","~56 weeks",NA,NA,"UK","GBR",315,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-12-07,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","12/09/2022",2022-09-12
"2597",315,"Chatzilena","Test-negative case-control","07Dec2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">3 months","hospitalization","severe","UK",">=18 years","general pop",79.5,"71.5",85.3,NA,"delta","~56 weeks",NA,NA,"UK","GBR",315,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-12-07,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","12/09/2022",2022-09-12
"2598",316,"Collie","Test-negative case-control","14Sept2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14-27","hospitalization","severe","South Africa",">=18 years","general pop",80.3,"62.8",89.5,NA,"omicron BA.1 or BA.2","~36 weeks",NA,NA,"South Africa","ZAF",316,"ZAF",14080,2019,"South Africa","Sub-Saharan Africa","Upper middle income",2,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,71,NA,NA,"who",71,"feb/2021","60-89","not reached","not reached","yes","no","no",2022-09-14,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-09-14
"2599",316,"Collie","Test-negative case-control","14Sept2022","BNT162b2 (Pfizer BioNTech)","included","2","final","7-8 months","hospitalization","severe","South Africa",">=18 years","general pop",38.4,"16.9",54.4,NA,"omicron BA.1 or BA.2","~36 weeks",NA,NA,"South Africa","ZAF",316,"ZAF",14080,2019,"South Africa","Sub-Saharan Africa","Upper middle income",2,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,71,NA,NA,"who",71,"feb/2021","60-89","not reached","not reached","yes","no","no",2022-09-14,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-09-14
"2600",316,"Collie","Test-negative case-control","14Sept2022","BNT162b2 (Pfizer BioNTech)","included","2","final","3-4 months","hospitalization","severe","South Africa",">=18 years","general pop",47.4,"19.9",65.5,NA,"omicron BA.4 or BA.5","~53 weeks",NA,NA,"South Africa","ZAF",316,"ZAF",14080,2019,"South Africa","Sub-Saharan Africa","Upper middle income",2,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,71,NA,NA,"who",71,"feb/2021","60-89","not reached","not reached","yes","no","no",2022-09-14,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-09-14
"2601",316,"Collie","Test-negative case-control","14Sept2022","BNT162b2 (Pfizer BioNTech)","included","2","final","9+ months","hospitalization","severe","South Africa",">=18 years","general pop",19.3,"6.3",30.5,NA,"omicron BA.4 or BA.5","~53 weeks",NA,NA,"South Africa","ZAF",316,"ZAF",14080,2019,"South Africa","Sub-Saharan Africa","Upper middle income",2,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,71,NA,NA,"who",71,"feb/2021","60-89","not reached","not reached","yes","no","no",2022-09-14,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-09-14
"2602",317,"Martin","Prospective cohort","10Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection","infection","UK","patients with end-stage kidney disease undergoing hemodialysis","immunocompromised adults",62,"18",82,NA,"non-VOC, alpha, & delta","~46 weeks",NA,NA,"UK","GBR",317,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-09-10,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-09-10
"2603",317,"Martin","Prospective cohort","10Sep2022","AZD1222 (AstraZeneca)","included","2","final","14+","infection","infection","UK","patients with end-stage kidney disease undergoing hemodialysis","immunocompromised adults",42,"-22",70,NA,"non-VOC, alpha, & delta","~46 weeks",NA,NA,"UK","GBR",317,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-09-10,"infection","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-09-10
"2604",318,"Chung","Test-negative case-control","07Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7-59","infection","infection","Canada",">=16 years","general pop",89,"88",90,NA,"non-VOC & alpha","~6 weeks",NA,NA,"Canada","CAN",318,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-07,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-09-07
"2605",318,"Chung","Test-negative case-control","07Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","60-119","infection","infection","Canada",">=16 years","general pop",80,"75",85,NA,"non-VOC & alpha","~15 weeks",NA,NA,"Canada","CAN",318,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-07,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-09-07
"2606",318,"Chung","Test-negative case-control","07Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7-59","symptomatic disease","symptomatic","Canada",">=16 years","general pop",94,"91",96,NA,"non-VOC & alpha","~6 weeks",NA,NA,"Canada","CAN",318,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-07,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-09-07
"2607",318,"Chung","Test-negative case-control","07Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","60-119","symptomatic disease","symptomatic","Canada",">=16 years","general pop",93,"79",98,NA,"non-VOC & alpha","~15 weeks",NA,NA,"Canada","CAN",318,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-07,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-09-07
"2608",318,"Chung","Test-negative case-control","07Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7-59","severe disease","severe","Canada",">=16 years","general pop",95,"90",97,NA,"non-VOC & alpha","~6 weeks",NA,NA,"Canada","CAN",318,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-07,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-09-07
"2609",318,"Chung","Test-negative case-control","07Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7-59","infection","infection","Canada",">=16 years","general pop",92,"91",93,NA,"alpha","~6 weeks",NA,NA,"Canada","CAN",318,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-07,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha",NA,2022-09-07
"2610",318,"Chung","Test-negative case-control","07Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","120-179","infection","infection","Canada",">=16 years","general pop",82,"79",85,NA,"alpha","~24 weeks",NA,NA,"Canada","CAN",318,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-07,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha",NA,2022-09-07
"2611",318,"Chung","Test-negative case-control","07Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7-59","symptomatic disease","symptomatic","Canada",">=16 years","general pop",92,"91",94,NA,"alpha","~6 weeks",NA,NA,"Canada","CAN",318,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-07,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha",NA,2022-09-07
"2612",318,"Chung","Test-negative case-control","07Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","120-179","symptomatic disease","symptomatic","Canada",">=16 years","general pop",86,"78",91,NA,"alpha","~24 weeks",NA,NA,"Canada","CAN",318,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-07,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha",NA,2022-09-07
"2613",318,"Chung","Test-negative case-control","07Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7-59","severe disease","severe","Canada",">=16 years","general pop",94,"92",95,NA,"alpha","~6 weeks",NA,NA,"Canada","CAN",318,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-07,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha",NA,2022-09-07
"2614",318,"Chung","Test-negative case-control","07Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","120-179","severe disease","severe","Canada",">=16 years","general pop",97,"95",98,NA,"alpha","~24 weeks",NA,NA,"Canada","CAN",318,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-07,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha",NA,2022-09-07
"2615",318,"Chung","Test-negative case-control","07Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7-59","infection","infection","Canada",">=16 years","general pop",90,"90",90,NA,"delta","~6 weeks",NA,NA,"Canada","CAN",318,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-07,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2022-09-07
"2616",318,"Chung","Test-negative case-control","07Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","240+","infection","infection","Canada",">=16 years","general pop",78,"76",80,NA,"delta","~42 weeks",NA,NA,"Canada","CAN",318,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-07,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2022-09-07
"2617",318,"Chung","Test-negative case-control","07Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7-59","symptomatic disease","symptomatic","Canada",">=16 years","general pop",94,"94",95,NA,"delta","~6 weeks",NA,NA,"Canada","CAN",318,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-07,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2022-09-07
"2618",318,"Chung","Test-negative case-control","07Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","240+","symptomatic disease","symptomatic","Canada",">=16 years","general pop",88,"86",90,NA,"delta","~42 weeks",NA,NA,"Canada","CAN",318,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-07,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2022-09-07
"2619",318,"Chung","Test-negative case-control","07Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7-59","severe disease","severe","Canada",">=16 years","general pop",98,"98",99,NA,"delta","~6 weeks",NA,NA,"Canada","CAN",318,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-07,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2022-09-07
"2620",318,"Chung","Test-negative case-control","07Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","240+","severe disease","severe","Canada",">=16 years","general pop",98,"95",99,NA,"delta","~42 weeks",NA,NA,"Canada","CAN",318,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-07,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2022-09-07
"2621",319,"Xu","Retrospective cohort","05Dec2022","BNT162b2 (Pfizer BioNTech)","included","2","final","28+","infection","infection","Sweden",">=65 years",">=65 years",85.8,"83.8",88.2,NA,"non-VOC, alpha, delta, & omicron","~51 weeks",NA,NA,"Sweden","SWE",319,"SWE",58060,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,15,228,396,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-12-05,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","20/09/2022",2022-09-20
"2622",319,"Xu","Retrospective cohort","05Dec2022","BNT162b2 (Pfizer BioNTech)","included","2","final","350-371","infection","infection","Sweden",">=65 years",">=65 years",18.2,"2.2",31.6,NA,"non-VOC, alpha, delta, & omicron",NA,NA,NA,"Sweden","SWE",319,"SWE",58060,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,15,228,396,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-12-05,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","20/09/2022",2022-09-20
"2623",319,"Xu","Retrospective cohort","05Dec2022","BNT162b2 (Pfizer BioNTech)","included","2","final","28+","hospitalization","severe","Sweden",">=65 years",">=65 years",87.2,"83.6",90,NA,"non-VOC, alpha, delta, & omicron","~51 weeks",NA,NA,"Sweden","SWE",319,"SWE",58060,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,15,228,396,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-12-05,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","20/09/2022",2022-09-20
"2624",319,"Xu","Retrospective cohort","05Dec2022","BNT162b2 (Pfizer BioNTech)","included","2","final","350-371","hospitalization","severe","Sweden",">=65 years",">=65 years",68.5,"45.5",81.8,NA,"non-VOC, alpha, delta, & omicron",NA,NA,NA,"Sweden","SWE",319,"SWE",58060,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,15,228,396,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-12-05,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","20/09/2022",2022-09-20
"2625",319,"Xu","Retrospective cohort","05Dec2022","mRNA-1273 (Moderna)","included","2","final","28+","infection","infection","Sweden",">=65 years",">=65 years",94.6,"89.6",97.2,NA,"non-VOC, alpha, delta, & omicron","~51 weeks",NA,NA,"Sweden","SWE",319,"SWE",58060,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,15,228,396,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-12-05,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","20/09/2022",2022-09-20
"2626",319,"Xu","Retrospective cohort","05Dec2022","mRNA-1273 (Moderna)","included","2","final","350-371","infection","infection","Sweden",">=65 years",">=65 years",11.8,"-55.5",50,NA,"non-VOC, alpha, delta, & omicron",NA,NA,NA,"Sweden","SWE",319,"SWE",58060,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,15,228,396,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-12-05,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","20/09/2022",2022-09-20
"2627",319,"Xu","Retrospective cohort","05Dec2022","mRNA-1273 (Moderna)","included","2","final","28+","hospitalization","severe","Sweden",">=65 years",">=65 years",96,"89.5",98.5,NA,"non-VOC, alpha, delta, & omicron","~51 weeks",NA,NA,"Sweden","SWE",319,"SWE",58060,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,15,228,396,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-12-05,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","20/09/2022",2022-09-20
"2628",319,"Xu","Retrospective cohort","05Dec2022","mRNA-1273 (Moderna)","included","2","final","350-371","hospitalization","severe","Sweden",">=65 years",">=65 years",21.5,"-89.2",67.4,NA,"non-VOC, alpha, delta, & omicron",NA,NA,NA,"Sweden","SWE",319,"SWE",58060,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,15,228,396,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-12-05,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","20/09/2022",2022-09-20
"2629",319,"Xu","Retrospective cohort","05Dec2022","AZD1222 (AstraZeneca)","included","2","final","28+","infection","infection","Sweden",">=65 years",">=65 years",43.6,"1.9",67.6,NA,"non-VOC, alpha, delta, & omicron","~39 weeks",NA,NA,"Sweden","SWE",319,"SWE",58060,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,15,228,396,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-12-05,"infection","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","20/09/2022",2022-09-20
"2630",319,"Xu","Retrospective cohort","05Dec2022","AZD1222 (AstraZeneca)","included","2","final","266-287","infection","infection","Sweden",">=65 years",">=65 years",-2.3,"-627.9",85.6,NA,"non-VOC, alpha, delta, & omicron",NA,NA,NA,"Sweden","SWE",319,"SWE",58060,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,15,228,396,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-12-05,"infection","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","20/09/2022",2022-09-20
"2631",319,"Xu","Retrospective cohort","05Dec2022","AZD1222 (AstraZeneca)","included","2","final","28+","hospitalization","severe","Sweden",">=65 years",">=65 years",74.6,"-5",93.9,NA,"non-VOC, alpha, delta, & omicron","~39 weeks",NA,NA,"Sweden","SWE",319,"SWE",58060,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,15,228,396,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-12-05,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","20/09/2022",2022-09-20
"2632",319,"Xu","Retrospective cohort","05Dec2022","AZD1222 (AstraZeneca)","included","2","final","238-259","hospitalization","severe","Sweden",">=65 years",">=65 years",28.7,"-37.6",63,NA,"non-VOC, alpha, delta, & omicron",NA,NA,NA,"Sweden","SWE",319,"SWE",58060,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,15,228,396,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-12-05,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","20/09/2022",2022-09-20
"2633",321,"Copur","Retrospective cohort","28Sep2022","CoronaVac (Sinovac)","excluded","2","final","14+","infection","infection","Turkey","HCW","HCW",65,"50",75,NA,"alpha","~15 weeks",NA,NA,"Turkey","TUR",321,"TUR",27240,2019,"Türkiye","Europe & Central Asia","Upper middle income",3,"Asia",2021-01-14,2021-08-19,NA,NA,2021-01-14,NA,37,217,NA,"owid",37,"jan/2021","30-59","Jun-Aug/2021","180-269","yes","yes","no",2022-09-28,"infection","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","alpha",NA,2022-09-28
"2634",322,"Schrag","Test-negative case-control","26Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","ED or UC visit","symptomatic","USA","pregnant persons 18-49 years","pregnant persons",16,"-22",42,NA,"omicron","~55 weeks",NA,NA,"USA","USA",322,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-09-26
"2635",322,"Schrag","Test-negative case-control","26Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-149","ED or UC visit","symptomatic","USA","pregnant persons 18-49 years","pregnant persons",3,"-49",37,NA,"omicron",NA,NA,NA,"USA","USA",322,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-09-26
"2636",322,"Schrag","Test-negative case-control","26Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","150+","ED or UC visit","symptomatic","USA","pregnant persons 18-49 years","pregnant persons",42,"-16",72,NA,"omicron","~55 weeks",NA,NA,"USA","USA",322,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-09-26
"2637",322,"Schrag","Test-negative case-control","26Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","pregnant persons 18-49 years","pregnant persons",77,"28",93,NA,"omicron","~55 weeks",NA,NA,"USA","USA",322,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-09-26
"2638",322,"Schrag","Test-negative case-control","26Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-149","hospitalization","severe","USA","pregnant persons 18-49 years","pregnant persons",86,"41",97,NA,"omicron",NA,NA,NA,"USA","USA",322,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-09-26
"2639",322,"Schrag","Test-negative case-control","26Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","150+","hospitalization","severe","USA","pregnant persons 18-49 years","pregnant persons",64,"-102",93,NA,"omicron","~55 weeks",NA,NA,"USA","USA",322,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-09-26
"2640",322,"Schrag","Test-negative case-control","26Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","ED or UC visit","symptomatic","USA","pregnant persons 18-49 years","pregnant persons",83,"68",91,NA,"delta","~55 weeks",NA,NA,"USA","USA",322,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2022-09-26
"2641",322,"Schrag","Test-negative case-control","26Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-149","ED or UC visit","symptomatic","USA","pregnant persons 18-49 years","pregnant persons",84,"69",92,NA,"delta",NA,NA,NA,"USA","USA",322,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2022-09-26
"2642",322,"Schrag","Test-negative case-control","26Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","150+","ED or UC visit","symptomatic","USA","pregnant persons 18-49 years","pregnant persons",75,"5",93,NA,"delta","~55 weeks",NA,NA,"USA","USA",322,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2022-09-26
"2643",322,"Schrag","Test-negative case-control","26Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","pregnant persons 18-49 years","pregnant persons",98,"96",99,NA,"delta",NA,NA,NA,"USA","USA",322,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2022-09-26
"2644",322,"Schrag","Test-negative case-control","26Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-149","hospitalization","severe","USA","pregnant persons 18-49 years","pregnant persons",99,"96",100,NA,"delta",NA,NA,NA,"USA","USA",322,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2022-09-26
"2645",322,"Schrag","Test-negative case-control","26Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","150+","hospitalization","severe","USA","pregnant persons 18-49 years","pregnant persons",96,"86",99,NA,"delta","~55 weeks",NA,NA,"USA","USA",322,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2022-09-26
"2646",323,"Ferdinands","Test-negative case-control","03Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","<2 months","ED or UC visit","symptomatic","USA",">=18 years","general pop",63,"57",68,NA,"omicron",NA,NA,NA,"USA","USA",323,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-10-03,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-10-03
"2647",323,"Ferdinands","Test-negative case-control","03Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","16-<18 months","ED or UC visit","symptomatic","USA",">=18 years","general pop",22,"5",36,NA,"omicron",NA,NA,NA,"USA","USA",323,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-10-03,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-10-03
"2648",323,"Ferdinands","Test-negative case-control","03Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","<2 months","hospitalization","severe","USA",">=18 years","general pop",73,"63",80,NA,"omicron",NA,NA,NA,"USA","USA",323,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-10-03,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-10-03
"2649",323,"Ferdinands","Test-negative case-control","03Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+ months","hospitalization","severe","USA",">=18 years","general pop",19,"6",30,NA,"omicron","~67 weeks",NA,NA,"USA","USA",323,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-10-03,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-10-03
"2650",323,"Ferdinands","Test-negative case-control","03Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","<4 months","hospitalization","severe","USA","immunocompromised, >=18 years","immunocompromised adults",34,"13",51,NA,"omicron",NA,NA,NA,"USA","USA",323,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-10-03,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-10-03
"2651",323,"Ferdinands","Test-negative case-control","03Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","6+ months","hospitalization","severe","USA","immunocompromised, >=18 years","immunocompromised adults",20,"1",36,NA,"omicron","~67 weeks",NA,NA,"USA","USA",323,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-10-03,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-10-03
"2652",323,"Ferdinands","Test-negative case-control","03Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","<2 months","ED or UC visit","symptomatic","USA",">=18 years","general pop",93,"92",94,NA,"delta",NA,NA,NA,"USA","USA",323,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-10-03,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2022-10-03
"2653",323,"Ferdinands","Test-negative case-control","03Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","10-<12 months","ED or UC visit","symptomatic","USA",">=18 years","general pop",66,"60",72,NA,"delta",NA,NA,NA,"USA","USA",323,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-10-03,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2022-10-03
"2654",323,"Ferdinands","Test-negative case-control","03Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","<2 months","hospitalization","severe","USA",">=18 years","general pop",96,"95",97,NA,"delta",NA,NA,NA,"USA","USA",323,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-10-03,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2022-10-03
"2655",323,"Ferdinands","Test-negative case-control","03Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","10-<12 months","hospitalization","severe","USA",">=18 years","general pop",68,"59",75,NA,"delta",NA,NA,NA,"USA","USA",323,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-10-03,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2022-10-03
"2656",323,"Ferdinands","Test-negative case-control","03Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","<2 months","ED or UC visit","symptomatic","USA",">=18 years","general pop",95,"94",96,NA,"alpha","~19 weeks",NA,NA,"USA","USA",323,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-10-03,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha",NA,2022-10-03
"2657",323,"Ferdinands","Test-negative case-control","03Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","4-<6 months","ED or UC visit","symptomatic","USA",">=18 years","general pop",86,"78",91,NA,"alpha","~19 weeks",NA,NA,"USA","USA",323,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-10-03,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha",NA,2022-10-03
"2658",323,"Ferdinands","Test-negative case-control","03Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","<2 months","hospitalization","severe","USA",">=18 years","general pop",94,"93",95,NA,"alpha","~19 weeks",NA,NA,"USA","USA",323,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-10-03,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha",NA,2022-10-03
"2659",323,"Ferdinands","Test-negative case-control","03Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","4-<6 months","hospitalization","severe","USA",">=18 years","general pop",87,"77",93,NA,"alpha","~19 weeks",NA,NA,"USA","USA",323,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-10-03,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha",NA,2022-10-03
"2660",324,"Link-Gelles","Test-negative case-control","05Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14-159","ED or UC visit","symptomatic","USA",">=18 years","general pop",45,"27",59,NA,"omicron BA.4 or BA.5",NA,NA,NA,"USA","USA",324,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-10-05,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","05/10/2022",2022-10-05
"2661",324,"Link-Gelles","Test-negative case-control","05Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final","150+","ED or UC visit","symptomatic","USA",">=18 years","general pop",24,"19",27,NA,"omicron BA.4 or BA.5","~82 weeks",NA,NA,"USA","USA",324,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-10-05,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","05/10/2022",2022-10-05
"2662",324,"Link-Gelles","Test-negative case-control","05Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final","150+","hospitalization","severe","USA",">=18 years","general pop",17,"7",27,NA,"omicron BA.4 or BA.5","~82 weeks",NA,NA,"USA","USA",324,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-10-05,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","05/10/2022",2022-10-05
"2663",324,"Link-Gelles","Test-negative case-control","05Oct2022","mRNA-1273 (Moderna)","included","2","final","14-159","ED or UC visit","symptomatic","USA",">=18 years","general pop",51,"30",66,NA,"omicron BA.4 or BA.5",NA,NA,NA,"USA","USA",324,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-10-05,"symptomatic","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron","05/10/2022",2022-10-05
"2664",324,"Link-Gelles","Test-negative case-control","05Oct2022","mRNA-1273 (Moderna)","included","2","final","150+","ED or UC visit","symptomatic","USA",">=18 years","general pop",30,"25",34,NA,"omicron BA.4 or BA.5","~82 weeks",NA,NA,"USA","USA",324,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-10-05,"symptomatic","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron","05/10/2022",2022-10-05
"2665",324,"Link-Gelles","Test-negative case-control","05Oct2022","mRNA-1273 (Moderna)","included","2","final","150+","hospitalization","severe","USA",">=18 years","general pop",28,"17",38,NA,"omicron BA.4 or BA.5","~82 weeks",NA,NA,"USA","USA",324,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-10-05,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron","05/10/2022",2022-10-05
"2666",324,"Link-Gelles","Test-negative case-control","05Oct2022","Any mRNA - heterologous","included","2","final","14-159","ED or UC visit","symptomatic","USA",">=18 years","general pop",70,"52",81,NA,"omicron BA.4 or BA.5",NA,NA,NA,"USA","USA",324,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-10-05,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","05/10/2022",2022-10-05
"2667",324,"Link-Gelles","Test-negative case-control","05Oct2022","Any mRNA - heterologous","included","2","final","150+","ED or UC visit","symptomatic","USA",">=18 years","general pop",38,"29",46,NA,"omicron BA.4 or BA.5","~82 weeks",NA,NA,"USA","USA",324,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-10-05,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","05/10/2022",2022-10-05
"2668",325,"Grewal","Test-negative case-control","03Dec2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","0+","infection","infection","Canada","LTCF residents, >=60 years","LTCF residents",3,"-7",12,NA,"omicron BA.1 or BA.2 or BA.4 or BA.5","~80 weeks",NA,NA,"Canada","CAN",325,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-12-03,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","30/09/2022",2022-09-30
"2669",325,"Grewal","Test-negative case-control","03Dec2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","0+","symptomatic disease","symptomatic","Canada","LTCF residents, >=60 years","LTCF residents",21,"1",38,NA,"omicron BA.1 or BA.2 or BA.4 or BA.5","~80 weeks",NA,NA,"Canada","CAN",325,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-12-03,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","30/09/2022",2022-09-30
"2670",325,"Grewal","Test-negative case-control","03Dec2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","0+","severe disease","severe","Canada","LTCF residents, >=60 years","LTCF residents",43,"24",58,NA,"omicron BA.1 or BA.2 or BA.4 or BA.5","~80 weeks",NA,NA,"Canada","CAN",325,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-12-03,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","30/09/2022",2022-09-30
"2671",326,"Lin","Retrospective cohort","26Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","~47 weeks","infection ","infection ","USA",">=5 years","general pop",37.5,"36",39,NA,"omicron","~47 weeks",NA,"Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021","USA","USA",326,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-09-26
"2672",326,"Lin","Retrospective cohort","26Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","~60 weeks","infection ","infection ","USA",">=5 years","general pop",0.8,"-1.5",3,NA,"omicron","~60 weeks",NA,"Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021","USA","USA",326,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-09-26
"2673",326,"Lin","Retrospective cohort","26Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","~47 weeks","hospitalization","severe","USA",">=5 years","general pop",58.8,"49.3",66.5,NA,"omicron","~47 weeks",NA,"Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021","USA","USA",326,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-09-26
"2674",326,"Lin","Retrospective cohort","26Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","~60 weeks","hospitalization","severe","USA",">=5 years","general pop",29.4,"50.4",76.9,NA,"omicron","~60 weeks",NA,"Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021","USA","USA",326,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-09-26
"2675",326,"Lin","Retrospective cohort","26Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","~47 weeks","death ","death ","USA",">=5 years","general pop",75.2,"67.7",81,NA,"omicron","~47 weeks",NA,"Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021","USA","USA",326,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"death","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-09-26
"2676",326,"Lin","Retrospective cohort","26Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","~60 weeks","death ","death ","USA",">=5 years","general pop",59.1,"27.2",77,NA,"omicron","~60 weeks",NA,"Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021","USA","USA",326,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"death","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-09-26
"2677",326,"Lin","Retrospective cohort","26Sep2022","mRNA-1273 (Moderna)","included","2","final","~46 weeks","infection ","infection ","USA",">=5 years","general pop",47.2,"45.8",48.5,NA,"omicron","~46 weeks",NA,"Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021","USA","USA",326,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron",NA,2022-09-26
"2678",326,"Lin","Retrospective cohort","26Sep2022","mRNA-1273 (Moderna)","included","2","final","~59 weeks","infection ","infection ","USA",">=5 years","general pop",30.3,"28.9",32.9,NA,"omicron","~59 weeks",NA,"Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021","USA","USA",326,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron",NA,2022-09-26
"2679",326,"Lin","Retrospective cohort","26Sep2022","mRNA-1273 (Moderna)","included","2","final","~46 weeks","hospitalization","severe","USA",">=5 years","general pop",64.7,"57.2",70.9,NA,"omicron","~46 weeks",NA,"Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021","USA","USA",326,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron",NA,2022-09-26
"2680",326,"Lin","Retrospective cohort","26Sep2022","mRNA-1273 (Moderna)","included","2","final","~59 weeks","hospitalization","severe","USA",">=5 years","general pop",61.5,"49.6",70.6,NA,"omicron","~59 weeks",NA,"Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021","USA","USA",326,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron",NA,2022-09-26
"2681",326,"Lin","Retrospective cohort","26Sep2022","mRNA-1273 (Moderna)","included","2","final","~46 weeks","death ","death ","USA",">=5 years","general pop",69.6,"62.3",75.5,NA,"omicron","~46 weeks",NA,"Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021","USA","USA",326,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"death","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron",NA,2022-09-26
"2682",326,"Lin","Retrospective cohort","26Sep2022","mRNA-1273 (Moderna)","included","2","final","~59 weeks","death ","death ","USA",">=5 years","general pop",48.3,"22.6",65.4,NA,"omicron","~59 weeks",NA,"Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021","USA","USA",326,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"death","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron",NA,2022-09-26
"2683",326,"Lin","Retrospective cohort","26Sep2022","Ad26.COV2.S (Janssen)","included","2","final","~41 weeks","infection ","infection ","USA",">=5 years","general pop",48.8,"47.2",50.4,NA,"omicron","~41 weeks",NA,"Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021","USA","USA",326,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"infection","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","omicron",NA,2022-09-26
"2684",326,"Lin","Retrospective cohort","26Sep2022","Ad26.COV2.S (Janssen)","included","2","final","~54 weeks","infection ","infection ","USA",">=5 years","general pop",49,"46.4",51.4,NA,"omicron","~54 weeks",NA,"Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021","USA","USA",326,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"infection","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","omicron",NA,2022-09-26
"2685",326,"Lin","Retrospective cohort","26Sep2022","Ad26.COV2.S (Janssen)","included","2","final","~41 weeks","hospitalization","severe","USA",">=5 years","general pop",65.3,"58.3",71.1,NA,"omicron","~41 weeks",NA,"Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021","USA","USA",326,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"severe","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","omicron",NA,2022-09-26
"2686",326,"Lin","Retrospective cohort","26Sep2022","Ad26.COV2.S (Janssen)","included","2","final","~54 weeks","hospitalization","severe","USA",">=5 years","general pop",53.3,"26.7",70.2,NA,"omicron","~54 weeks",NA,"Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021","USA","USA",326,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"severe","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","omicron",NA,2022-09-26
"2687",326,"Lin","Retrospective cohort","26Sep2022","Ad26.COV2.S (Janssen)","included","2","final","~41 weeks","death ","death ","USA",">=5 years","general pop",76.1,"69.2",81.4,NA,"omicron","~41 weeks",NA,"Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021","USA","USA",326,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"death","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","omicron",NA,2022-09-26
"2688",326,"Lin","Retrospective cohort","26Sep2022","Ad26.COV2.S (Janssen)","included","2","final","~54 weeks","death ","death ","USA",">=5 years","general pop",77.5,"19.6",93.7,NA,"omicron","~54 weeks",NA,"Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021","USA","USA",326,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"death","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","omicron",NA,2022-09-26
"2689",326,"Lin","Retrospective cohort","26Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","~25 weeks","infection ","infection ","USA",">=5 years","general pop",54.3,"53.6",55,NA,"delta","~25 weeks",NA,"Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021","USA","USA",326,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-09-26
"2690",326,"Lin","Retrospective cohort","26Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","~38 weeks","infection ","infection ","USA",">=5 years","general pop",47.4,"46.6",48.2,NA,"delta","~38 weeks",NA,"Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021","USA","USA",326,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-09-26
"2691",326,"Lin","Retrospective cohort","26Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","~25 weeks","hospitalization","severe","USA",">=5 years","general pop",85.8,"83.4",87.8,NA,"delta","~25 weeks",NA,"Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021","USA","USA",326,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-09-26
"2692",326,"Lin","Retrospective cohort","26Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","~38 weeks","hospitalization","severe","USA",">=5 years","general pop",70.9,"65.3",75.6,NA,"delta","~38 weeks",NA,"Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021","USA","USA",326,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-09-26
"2693",326,"Lin","Retrospective cohort","26Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","~25 weeks","death ","death ","USA",">=5 years","general pop",89.6,"87",91.6,NA,"delta","~25 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods","USA","USA",326,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"death","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-09-26
"2694",326,"Lin","Retrospective cohort","26Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","~38 weeks","death ","death ","USA",">=5 years","general pop",77.4,"70.6",82.6,NA,"delta","~38 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods","USA","USA",326,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"death","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-09-26
"2695",326,"Lin","Retrospective cohort","26Sep2022","mRNA-1273 (Moderna)","included","2","final","~24 weeks","infection ","infection ","USA",">=5 years","general pop",69.2,"68.5",69.9,NA,"delta","~24 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods","USA","USA",326,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2022-09-26
"2696",326,"Lin","Retrospective cohort","26Sep2022","mRNA-1273 (Moderna)","included","2","final","~37 weeks","infection ","infection ","USA",">=5 years","general pop",48.4,"47.5",49.3,NA,"delta","~37 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods","USA","USA",326,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2022-09-26
"2697",326,"Lin","Retrospective cohort","26Sep2022","mRNA-1273 (Moderna)","included","2","final","~24 weeks","hospitalization","severe","USA",">=5 years","general pop",89.8,"88.1",91.3,NA,"delta","~24 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods","USA","USA",326,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2022-09-26
"2698",326,"Lin","Retrospective cohort","26Sep2022","mRNA-1273 (Moderna)","included","2","final","~37 weeks","hospitalization","severe","USA",">=5 years","general pop",72.7,"67.8",77,NA,"delta","~37 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods","USA","USA",326,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2022-09-26
"2699",326,"Lin","Retrospective cohort","26Sep2022","mRNA-1273 (Moderna)","included","2","final","~24 weeks","death ","death ","USA",">=5 years","general pop",93,"91.1",94.5,NA,"delta","~24 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods","USA","USA",326,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"death","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2022-09-26
"2700",326,"Lin","Retrospective cohort","26Sep2022","mRNA-1273 (Moderna)","included","2","final","~37 weeks","death ","death ","USA",">=5 years","general pop",85.1,"80.1",88.8,NA,"delta","~37 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods","USA","USA",326,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"death","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2022-09-26
"2701",326,"Lin","Retrospective cohort","26Sep2022","Ad26.COV2.S (Janssen)","included","2","final","~20 weeks","infection ","infection ","USA",">=5 years","general pop",59.2,"57.7",60.7,NA,"delta","~20 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods","USA","USA",326,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"infection","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta",NA,2022-09-26
"2702",326,"Lin","Retrospective cohort","26Sep2022","Ad26.COV2.S (Janssen)","included","2","final","~33 weeks","infection ","infection ","USA",">=5 years","general pop",60.5,"58.9",62.1,NA,"delta","~33 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods","USA","USA",326,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"infection","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta",NA,2022-09-26
"2703",326,"Lin","Retrospective cohort","26Sep2022","Ad26.COV2.S (Janssen)","included","2","final","~20 weeks","hospitalization","severe","USA",">=5 years","general pop",77.9,"72.2",82.4,NA,"delta","~20 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods","USA","USA",326,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"severe","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta",NA,2022-09-26
"2704",326,"Lin","Retrospective cohort","26Sep2022","Ad26.COV2.S (Janssen)","included","2","final","~33 weeks","hospitalization","severe","USA",">=5 years","general pop",70,"64.8",74.5,NA,"delta","~33 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods","USA","USA",326,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"severe","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta",NA,2022-09-26
"2705",326,"Lin","Retrospective cohort","26Sep2022","Ad26.COV2.S (Janssen)","included","2","final","~20 weeks","death ","death ","USA",">=5 years","general pop",83.8,"76.1",89,NA,"delta","~20 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods","USA","USA",326,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"death","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta",NA,2022-09-26
"2706",326,"Lin","Retrospective cohort","26Sep2022","Ad26.COV2.S (Janssen)","included","2","final","~33 weeks","death ","death ","USA",">=5 years","general pop",79.2,"73.1",84,NA,"delta","~33 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods","USA","USA",326,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"death","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta",NA,2022-09-26
"2707",326,"Lin","Retrospective cohort","26Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","~3 weeks","infection ","infection ","USA",">=5 years","general pop",67.6,"66.9",68.3,NA,"alpha","~3 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods","USA","USA",326,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2022-09-26
"2708",326,"Lin","Retrospective cohort","26Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","~21 weeks","infection ","infection ","USA",">=5 years","general pop",58.6,"58",59.2,NA,"alpha","~21 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods","USA","USA",326,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2022-09-26
"2709",326,"Lin","Retrospective cohort","26Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","~3 weeks","hospitalization","severe","USA",">=5 years","general pop",94.1,"92.2",95.5,NA,"alpha","~3 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods","USA","USA",326,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2022-09-26
"2710",326,"Lin","Retrospective cohort","26Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","~21 weeks","hospitalization","severe","USA",">=5 years","general pop",87.1,"85",88.9,NA,"alpha","~21 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods","USA","USA",326,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2022-09-26
"2711",326,"Lin","Retrospective cohort","26Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","~3 weeks","death ","death ","USA",">=5 years","general pop",97.1,"94.7",98.4,NA,"alpha","~3 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods","USA","USA",326,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"death","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2022-09-26
"2712",326,"Lin","Retrospective cohort","26Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","~21 weeks","death ","death ","USA",">=5 years","general pop",91.9,"89.4",93.8,NA,"alpha","~21 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods","USA","USA",326,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"death","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2022-09-26
"2713",326,"Lin","Retrospective cohort","26Sep2022","mRNA-1273 (Moderna)","included","2","final","~2 weeks","infection ","infection ","USA",">=5 years","general pop",90.1,"89.6",90.7,NA,"alpha","~2 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods","USA","USA",326,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","alpha",NA,2022-09-26
"2714",326,"Lin","Retrospective cohort","26Sep2022","mRNA-1273 (Moderna)","included","2","final","~20 weeks","infection ","infection ","USA",">=5 years","general pop",71.9,"71.3",72.6,NA,"alpha","~20 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods","USA","USA",326,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","alpha",NA,2022-09-26
"2715",326,"Lin","Retrospective cohort","26Sep2022","mRNA-1273 (Moderna)","included","2","final","~2 weeks","hospitalization","severe","USA",">=5 years","general pop",96.5,"95.1",97.6,NA,"alpha","~2 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods","USA","USA",326,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","alpha",NA,2022-09-26
"2716",326,"Lin","Retrospective cohort","26Sep2022","mRNA-1273 (Moderna)","included","2","final","~20 weeks","hospitalization","severe","USA",">=5 years","general pop",90.4,"88.6",91.9,NA,"alpha","~20 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods","USA","USA",326,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","alpha",NA,2022-09-26
"2717",326,"Lin","Retrospective cohort","26Sep2022","mRNA-1273 (Moderna)","included","2","final","~2 weeks","death ","death ","USA",">=5 years","general pop",97.2,"95.1",98.4,NA,"alpha","~2 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods","USA","USA",326,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"death","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","alpha",NA,2022-09-26
"2718",326,"Lin","Retrospective cohort","26Sep2022","mRNA-1273 (Moderna)","included","2","final","~20 weeks","death ","death ","USA",">=5 years","general pop",92.8,"90.3",94.6,NA,"alpha","~20 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods","USA","USA",326,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"death","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","alpha",NA,2022-09-26
"2719",326,"Lin","Retrospective cohort","26Sep2022","Ad26.COV2.S (Janssen)","included","2","final","~2 weeks","infection ","infection ","USA",">=5 years","general pop",70.6,"68.8",72.3,NA,"alpha","~2 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods","USA","USA",326,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"infection","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","alpha",NA,2022-09-26
"2720",326,"Lin","Retrospective cohort","26Sep2022","Ad26.COV2.S (Janssen)","included","2","final","~10 weeks","infection ","infection ","USA",">=5 years","general pop",63,"60.8",65,NA,"alpha","~10 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods","USA","USA",326,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"infection","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","alpha",NA,2022-09-26
"2721",326,"Lin","Retrospective cohort","26Sep2022","Ad26.COV2.S (Janssen)","included","2","final","~2 weeks","hospitalization","severe","USA",">=5 years","general pop",67.9,"56.5",76.3,NA,"alpha","~2 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods","USA","USA",326,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"severe","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","alpha",NA,2022-09-26
"2722",326,"Lin","Retrospective cohort","26Sep2022","Ad26.COV2.S (Janssen)","included","2","final","~10 weeks","hospitalization","severe","USA",">=5 years","general pop",79.3,"71.7",84.8,NA,"alpha","~10 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods","USA","USA",326,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"severe","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","alpha",NA,2022-09-26
"2723",326,"Lin","Retrospective cohort","26Sep2022","Ad26.COV2.S (Janssen)","included","2","final","~2 weeks","death ","death ","USA",">=5 years","general pop",85.7,"74.6",91.9,NA,"alpha","~2 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods","USA","USA",326,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"death","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","alpha",NA,2022-09-26
"2724",326,"Lin","Retrospective cohort","26Sep2022","Ad26.COV2.S (Janssen)","included","2","final","~10 weeks","death ","death ","USA",">=5 years","general pop",80.5,"75.7",84.4,NA,"alpha","~10 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods","USA","USA",326,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-26,"death","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","alpha",NA,2022-09-26
"2725",327,"Rudan","Test-negative case-control","28Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14-35","symptomatic disease","symptomatic","UK (Scotland)","12-15 years","12-15 years",81.2,"77.7",84.2,"omicron","omicron",NA,NA,NA,"UK","GBR",327,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-09-28,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-09-28
"2726",327,"Rudan","Test-negative case-control","28Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","98+","symptomatic disease","symptomatic","UK (Scotland)","12-15 years","12-15 years",48.7,"22",66.3,"omicron","omicron","~21 weeks",NA,NA,"UK","GBR",327,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-09-28,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-09-28
"2727",327,"Rudan","Test-negative case-control","28Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14-35","symptomatic disease","symptomatic","UK (Scotland)","12-15 years","12-15 years",100,"-∞",100,"delta","delta",NA,NA,NA,"UK","GBR",327,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-09-28,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-09-28
"2728",327,"Rudan","Test-negative case-control","28Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","42-63","symptomatic disease","symptomatic","UK (Scotland)","12-15 years","12-15 years",92.9,"42.5",99.1,"delta","delta","~10 weeks",NA,NA,"UK","GBR",327,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-09-28,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-09-28
"2729",327,"Rudan","Test-negative case-control","28Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14-35","symptomatic disease","symptomatic","UK (Scotland)","16-17 years","16-17 years",65.5,"56",73,"omicron","omicron",NA,NA,NA,"UK","GBR",327,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-09-28,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-09-28
"2730",327,"Rudan","Test-negative case-control","28Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","98+","symptomatic disease","symptomatic","UK (Scotland)","16-17 years","16-17 years",1.2,"-49.3",34.6,"omicron","omicron","~27 weeks",NA,NA,"UK","GBR",327,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-09-28,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-09-28
"2731",327,"Rudan","Test-negative case-control","28Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14-35","symptomatic disease","symptomatic","UK (Scotland)","16-17 years","16-17 years",95.6,"77",99.1,"delta","delta",NA,NA,NA,"UK","GBR",327,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-09-28,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-09-28
"2732",327,"Rudan","Test-negative case-control","28Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","42-63","symptomatic disease","symptomatic","UK (Scotland)","16-17 years","16-17 years",96.7,"51.3",99.8,"delta","delta","~17 weeks",NA,NA,"UK","GBR",327,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2022-09-28,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-09-28
"2733",328,"Lewis","Outbreak investigation","28Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","unknown","2","final","14+","infection","infection","USA",">=60 years",">=60 years",80,"46.4",92.6,"gamma","gamma","~14 weeks",NA,NA,"USA","USA",328,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-09-28,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","gamma",NA,2022-09-28
"2734",329,"Buchan","Test-negative case-control","22Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","7-59 ","symptomatic disease","symptomatic","Canada",">=18 years","general pop",36,"24",45,"omicron","omicron",NA,NA,NA,"Canada","CAN",329,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-22,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-09-22
"2735",329,"Buchan","Test-negative case-control","22Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","240+ ","symptomatic disease","symptomatic","Canada",">=18 years","general pop",2,"-17",17,"omicron","omicron","~49 weeks",NA,NA,"Canada","CAN",329,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-22,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-09-22
"2736",329,"Buchan","Test-negative case-control","22Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","120-179 ","severe disease","severe","Canada",">=18 years","general pop",75,"51",87,"omicron","omicron",NA,NA,NA,"Canada","CAN",329,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-22,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-09-22
"2737",329,"Buchan","Test-negative case-control","22Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","180-239 ","severe disease","severe","Canada",">=18 years","general pop",82,"62",91,"omicron","omicron","~32 weeks",NA,NA,"Canada","CAN",329,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-22,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-09-22
"2738",329,"Buchan","Test-negative case-control","22Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","7-59 ","symptomatic disease","symptomatic","Canada",">=18 years","general pop",89,"86",92,"delta","delta",NA,NA,NA,"Canada","CAN",329,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-22,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2022-09-22
"2739",329,"Buchan","Test-negative case-control","22Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","240+ ","symptomatic disease","symptomatic","Canada",">=18 years","general pop",80,"74",84,"delta","delta","~49 weeks",NA,NA,"Canada","CAN",329,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-22,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2022-09-22
"2740",329,"Buchan","Test-negative case-control","22Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","7-59 ","severe disease","severe","Canada",">=18 years","general pop",94,"84",98,"delta","delta",NA,NA,NA,"Canada","CAN",329,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-22,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2022-09-22
"2741",329,"Buchan","Test-negative case-control","22Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","240+","severe disease","severe","Canada",">=18 years","general pop",95,"85",99,"delta","delta","~49 weeks",NA,NA,"Canada","CAN",329,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-22,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2022-09-22
"2742",330,"Risk","Test-negative case-control","08Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final","0-3 months","infection","infection","USA","12-17 years","12-17 years",54.5,"17.8",76.9,"omicron","omicron",NA,NA,"This study does not adjust for calendar time","USA","USA",330,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-10-08,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-10-08
"2743",330,"Risk","Test-negative case-control","08Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final",">=6 months","infection","infection","USA","12-17 years","12-17 years",4.2,"-20.2",23.6,"omicron","omicron","~58 weeks",NA,"This study does not adjust for calendar time","USA","USA",330,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-10-08,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-10-08
"2744",330,"Risk","Test-negative case-control","08Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final","0-3 months","infection","infection","USA","12-17 years","12-17 years",81.9,"67.9",90.8,"delta","delta",NA,NA,"This study does not adjust for calendar time","USA","USA",330,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-10-08,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-10-08
"2745",330,"Risk","Test-negative case-control","08Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final",">=6 months","infection","infection","USA","12-17 years","12-17 years",65.3,"34.6",83.8,"delta","delta","~44 weeks",NA,"This study does not adjust for calendar time","USA","USA",330,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-10-08,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-10-08
"2746",331,"Mimura","Retrospective cohort","08Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+ (includes up to 13 days post booster dose)","infection","infection","Japan","16-64 years","16-64 years",15.8,"7.9",23.1,"omicron","omicron","~43 weeks",NA,NA,"Japan","JPN",331,"JPN",43970,2019,"Japan","East Asia & Pacific","High income",4,"Asia",2021-02-22,2021-08-11,2021-10-16,2021-02-17,2021-02-17,5,71,175,241,"who",71,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2022-10-08,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-10-08
"2747",331,"Mimura","Retrospective cohort","08Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+ (includes up to 13 days post booster dose)","symptomatic disease","symptomatic","Japan","16-64 years","16-64 years",21.2,"11",30.3,"omicron","omicron","~43 weeks",NA,NA,"Japan","JPN",331,"JPN",43970,2019,"Japan","East Asia & Pacific","High income",4,"Asia",2021-02-22,2021-08-11,2021-10-16,2021-02-17,2021-02-17,5,71,175,241,"who",71,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2022-10-08,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-10-08
"2748",331,"Mimura","Retrospective cohort","08Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+ (includes up to 13 days post booster dose)","infection","infection","Japan","16-64 years","16-64 years",82.9,"69.4",90.4,"delta","delta","~31 weeks",NA,NA,"Japan","JPN",331,"JPN",43970,2019,"Japan","East Asia & Pacific","High income",4,"Asia",2021-02-22,2021-08-11,2021-10-16,2021-02-17,2021-02-17,5,71,175,241,"who",71,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2022-10-08,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2022-10-08
"2749",331,"Mimura","Retrospective cohort","08Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+ (includes up to 13 days post booster dose)","symptomatic disease","symptomatic","Japan","16-64 years","16-64 years",95.7,"82.5",98.9,"delta","delta","~31 weeks",NA,NA,"Japan","JPN",331,"JPN",43970,2019,"Japan","East Asia & Pacific","High income",4,"Asia",2021-02-22,2021-08-11,2021-10-16,2021-02-17,2021-02-17,5,71,175,241,"who",71,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2022-10-08,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2022-10-08
"2750",332,"Wan","Case-control","17Oct2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-180","infection","infection","Hong Kong","60-79 years","60-79 years",17.3,"15.2",19.3,NA,"omicron BA.2","~24 weeks",NA,NA,"Hong Kong","HKG",332,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2022-10-17,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-10-17
"2751",332,"Wan","Case-control","17Oct2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-180","hospitalization","severe","Hong Kong","60-79 years","60-79 years",74.6,"72.1",76.8,NA,"omicron BA.2","~24 weeks",NA,NA,"Hong Kong","HKG",332,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2022-10-17,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-10-17
"2752",332,"Wan","Case-control","17Oct2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-180","severe disease","severe","Hong Kong","60-79 years","60-79 years",77.5,"65.7",85.2,NA,"omicron BA.2","~24 weeks",NA,NA,"Hong Kong","HKG",332,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2022-10-17,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-10-17
"2753",332,"Wan","Case-control","17Oct2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-180","death","death","Hong Kong","60-79 years","60-79 years",92.1,"88.7",94.5,NA,"omicron BA.2","~24 weeks",NA,NA,"Hong Kong","HKG",332,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2022-10-17,"death","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-10-17
"2754",332,"Wan","Case-control","17Oct2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-180","infection","infection","Hong Kong",">=80 years",">=80 years",54.2,"51.4",56.9,NA,"omicron BA.2","~24 weeks",NA,NA,"Hong Kong","HKG",332,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2022-10-17,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-10-17
"2755",332,"Wan","Case-control","17Oct2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-180","hospitalization","severe","Hong Kong",">=80 years",">=80 years",81,"78.2",83.5,NA,"omicron BA.2","~24 weeks",NA,NA,"Hong Kong","HKG",332,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2022-10-17,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-10-17
"2756",332,"Wan","Case-control","17Oct2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-180","severe disease","severe","Hong Kong",">=80 years",">=80 years",82.7,"62.7",92,NA,"omicron BA.2","~24 weeks",NA,NA,"Hong Kong","HKG",332,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2022-10-17,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-10-17
"2757",332,"Wan","Case-control","17Oct2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-180","death","death","Hong Kong",">=80 years",">=80 years",92.5,"89.3",94.8,NA,"omicron BA.2","~24 weeks",NA,NA,"Hong Kong","HKG",332,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2022-10-17,"death","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-10-17
"2758",332,"Wan","Case-control","17Oct2022","CoronaVac (Sinovac)","excluded","2","final","14-180","infection","infection","Hong Kong","60-79 years","60-79 years",-23.1,"-25.8",-20.5,NA,"omicron BA.2","~24 weeks",NA,NA,"Hong Kong","HKG",332,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2022-10-17,"infection","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2022-10-17
"2759",332,"Wan","Case-control","17Oct2022","CoronaVac (Sinovac)","excluded","2","final","14-180","hospitalization","severe","Hong Kong","60-79 years","60-79 years",59.4,"56.6",62,NA,"omicron BA.2","~24 weeks",NA,NA,"Hong Kong","HKG",332,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2022-10-17,"severe","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2022-10-17
"2760",332,"Wan","Case-control","17Oct2022","CoronaVac (Sinovac)","excluded","2","final","14-180","severe disease","severe","Hong Kong","60-79 years","60-79 years",57.7,"43.8",68.2,NA,"omicron BA.2","~24 weeks",NA,NA,"Hong Kong","HKG",332,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2022-10-17,"severe","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2022-10-17
"2761",332,"Wan","Case-control","17Oct2022","CoronaVac (Sinovac)","excluded","2","final","14-180","death","death","Hong Kong","60-79 years","60-79 years",79.6,"75",83.3,NA,"omicron BA.2","~24 weeks",NA,NA,"Hong Kong","HKG",332,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2022-10-17,"death","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2022-10-17
"2762",332,"Wan","Case-control","17Oct2022","CoronaVac (Sinovac)","excluded","2","final","14-180","infection","infection","Hong Kong",">=80 years",">=80 years",31.2,"28.7",33.6,NA,"omicron BA.2","~24 weeks",NA,NA,"Hong Kong","HKG",332,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2022-10-17,"infection","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2022-10-17
"2763",332,"Wan","Case-control","17Oct2022","CoronaVac (Sinovac)","excluded","2","final","14-180","hospitalization","severe","Hong Kong",">=80 years",">=80 years",58.4,"55.8",60.9,NA,"omicron BA.2","~24 weeks",NA,NA,"Hong Kong","HKG",332,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2022-10-17,"severe","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2022-10-17
"2764",332,"Wan","Case-control","17Oct2022","CoronaVac (Sinovac)","excluded","2","final","14-180","severe disease","severe","Hong Kong",">=80 years",">=80 years",55,"38.6",67,NA,"omicron BA.2","~24 weeks",NA,NA,"Hong Kong","HKG",332,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2022-10-17,"severe","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2022-10-17
"2765",332,"Wan","Case-control","17Oct2022","CoronaVac (Sinovac)","excluded","2","final","14-180","death","death","Hong Kong",">=80 years",">=80 years",69.4,"65.6",72.8,NA,"omicron BA.2","~24 weeks",NA,NA,"Hong Kong","HKG",332,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2022-10-17,"death","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2022-10-17
"2766",333,"Chambers","Test-negative case-control","19Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","infection","infection","Canada",">=19 years","general pop",82,"74",88,NA,"alpha & delta","~44 weeks",NA,NA,"Canada","CAN",333,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-10-19,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-10-19
"2767",333,"Chambers","Test-negative case-control","19Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","symptomatic disease","symptomatic","Canada",">=19 years","general pop",93,"79",98,NA,"alpha & delta","~44 weeks",NA,NA,"Canada","CAN",333,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-10-19,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-10-19
"2768",333,"Chambers","Test-negative case-control","19Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","severe disease","severe","Canada",">=19 years","general pop",97,"80",99,NA,"alpha & delta","~44 weeks",NA,NA,"Canada","CAN",333,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-10-19,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-10-19
"2769",333,"Chambers","Test-negative case-control","19Oct2022","AZD1222 (AstraZeneca)","excluded","2","final","7+","infection","infection","Canada",">=19 years","general pop",77,"34",92,NA,"alpha & delta","~44 weeks",NA,NA,"Canada","CAN",333,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-10-19,"infection","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-10-19
"2770",333,"Chambers","Test-negative case-control","19Oct2022","AZD1222 (AstraZeneca) + any mRNA - heterologous","excluded","2","final","7+","infection","infection","Canada",">=19 years","general pop",80,"49",92,NA,"alpha & delta","~44 weeks",NA,NA,"Canada","CAN",333,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-10-19,"infection","2022 (Jul-Dec)","Heterologous platforms","Multiple","other combinations",NA,2022-10-19
"2771",334,"Consonni","Retrospective cohort","19Oct2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7-119","infection","infection","Italy","HCW","HCW",70,"54",80,NA,"omicron","~67 weeks",NA,"88.3% of cases were during the Omicron period; 8.2% and 3.5% of cases were during Alpha, and Delta periods, respectively","Italy","ITA",334,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-10-19,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-10-19
"2772",334,"Consonni","Retrospective cohort","19Oct2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","120+","infection","infection","Italy","HCW","HCW",16,"0",43,NA,"omicron","~67 weeks",NA,"88.3% of cases were during the Omicron period; 8.2% and 3.5% of cases were during Alpha, and Delta periods, respectively","Italy","ITA",334,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-10-19,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-10-19
"2773",334,"Consonni","Retrospective cohort","19Oct2022","BNT162b2 (Pfizer BioNTech)","previously infected only","2","final","7-119","infection","infection","Italy","HCW","HCW",25,"0",69,NA,"omicron","~67 weeks",NA,"88.3% of cases were during the Omicron period; 8.2% and 3.5% of cases were during Alpha, and Delta periods, respectively","Italy","ITA",334,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-10-19,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-10-19
"2774",334,"Consonni","Retrospective cohort","19Oct2022","BNT162b2 (Pfizer BioNTech)","previously infected only","2","final","120+","infection","infection","Italy","HCW","HCW",88,"66",96,NA,"omicron","~67 weeks",NA,"88.3% of cases were during the Omicron period; 8.2% and 3.5% of cases were during Alpha, and Delta periods, respectively","Italy","ITA",334,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-10-19,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-10-19
"2775",335,"Zerbo","Cohort study","28Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna) received in first trimester","excluded","2","final","7+","infection in the first 2 months of life","infection in the first 2 months of life","USA","infants born to mothers 16-50 years of age","infants",26,"-22",56,NA,"omicron","~11 months",NA,NA,"USA","USA",335,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-02-28,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","18/10/2022",2022-10-18
"2776",335,"Zerbo","Cohort study","28Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna) received in first trimester","excluded","2","final","7+","infection in the first 4 months of life","infection in the first 4 months of life","USA","infants born to mothers 16-50 years of age","infants",23,"-6",44,NA,"omicron","~13 months",NA,NA,"USA","USA",335,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-02-28,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","18/10/2022",2022-10-18
"2777",335,"Zerbo","Cohort study","28Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna) received in first trimester","excluded","2","final","7+","infection in the first 6 months of life","infection in the first 6 months of life","USA","infants born to mothers 16-50 years of age","infants",19,"-3",37,NA,"omicron","~15 months",NA,NA,"USA","USA",335,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-02-28,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","18/10/2022",2022-10-18
"2778",335,"Zerbo","Cohort study","28Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna) received in second trimester","excluded","2","final","7+","infection in the first 2 months of life","infection in the first 2 months of life","USA","infants born to mothers 16-50 years of age","infants",37,"-21",67,NA,"omicron","~8 months",NA,NA,"USA","USA",335,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-02-28,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","18/10/2022",2022-10-18
"2779",335,"Zerbo","Cohort study","28Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna) received in second trimester","excluded","2","final","7+","infection in the first 4 months of life","infection in the first 4 months of life","USA","infants born to mothers 16-50 years of age","infants",5,"-28",29,NA,"omicron","~10 months",NA,NA,"USA","USA",335,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-02-28,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","18/10/2022",2022-10-18
"2780",335,"Zerbo","Cohort study","28Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna) received in second trimester","excluded","2","final","7+","infection in the first 6 months of life","infection in the first 6 months of life","USA","infants born to mothers 16-50 years of age","infants",3,"-19",21,NA,"omicron","~12 months",NA,NA,"USA","USA",335,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-02-28,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","18/10/2022",2022-10-18
"2781",335,"Zerbo","Cohort study","28Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna) received in third trimester","excluded","2","final","7+","infection in the first 2 months of life","infection in the first 2 months of life","USA","infants born to mothers 16-50 years of age","infants",-4,"-84",41,NA,"omicron","~5 months",NA,NA,"USA","USA",335,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-02-28,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","18/10/2022",2022-10-18
"2782",335,"Zerbo","Cohort study","28Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna) received in third trimester","excluded","2","final","7+","infection in the first 4 months of life","infection in the first 4 months of life","USA","infants born to mothers 16-50 years of age","infants",12,"-23",37,NA,"omicron","~7 months",NA,NA,"USA","USA",335,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-02-28,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","18/10/2022",2022-10-18
"2783",335,"Zerbo","Cohort study","28Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna) received in third trimester","excluded","2","final","7+","infection in the first 6 months of life","infection in the first 6 months of life","USA","infants born to mothers 16-50 years of age","infants",18,"-4",36,NA,"omicron","~9 months",NA,NA,"USA","USA",335,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-02-28,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","18/10/2022",2022-10-18
"2784",335,"Zerbo","Cohort study","28Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna) received in first trimester","excluded","2","final","7+","infection in the first 2 months of life","infection in the first 2 months of life","USA","infants born to mothers 16-50 years of age","infants",61,"-31",89,NA,"delta","~11 months",NA,NA,"USA","USA",335,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-02-28,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta","18/10/2022",2022-10-18
"2785",335,"Zerbo","Cohort study","28Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna) received in first trimester","excluded","2","final","7+","infection in the first 4 months of life","infection in the first 4 months of life","USA","infants born to mothers 16-50 years of age","infants",48,"-54",82,NA,"delta","~13 months",NA,NA,"USA","USA",335,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-02-28,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta","18/10/2022",2022-10-18
"2786",335,"Zerbo","Cohort study","28Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna) received in first trimester","excluded","2","final","7+","infection in the first 6 months of life","infection in the first 6 months of life","USA","infants born to mothers 16-50 years of age","infants",49,"-46",82,NA,"delta","~15 months",NA,NA,"USA","USA",335,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-02-28,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta","18/10/2022",2022-10-18
"2787",335,"Zerbo","Cohort study","28Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna) received in second trimester","excluded","2","final","7+","infection in the first 2 months of life","infection in the first 2 months of life","USA","infants born to mothers 16-50 years of age","infants",91,"63",98,NA,"delta","~8 months",NA,NA,"USA","USA",335,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-02-28,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta","18/10/2022",2022-10-18
"2788",335,"Zerbo","Cohort study","28Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna) received in second trimester","excluded","2","final","7+","infection in the first 4 months of life","infection in the first 4 months of life","USA","infants born to mothers 16-50 years of age","infants",60,"23",79,NA,"delta","~10 months",NA,NA,"USA","USA",335,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-02-28,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta","18/10/2022",2022-10-18
"2789",335,"Zerbo","Cohort study","28Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna) received in second trimester","excluded","2","final","7+","infection in the first 6 months of life","infection in the first 6 months of life","USA","infants born to mothers 16-50 years of age","infants",65,"33",81,NA,"delta","~12 months",NA,NA,"USA","USA",335,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-02-28,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta","18/10/2022",2022-10-18
"2790",335,"Zerbo","Cohort study","28Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna) received in third trimester","excluded","2","final","7+","infection in the first 2 months of life","infection in the first 2 months of life","USA","infants born to mothers 16-50 years of age","infants",87,"55",96,NA,"delta","~5 months",NA,NA,"USA","USA",335,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-02-28,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta","18/10/2022",2022-10-18
"2791",335,"Zerbo","Cohort study","28Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna) received in third trimester","excluded","2","final","7+","infection in the first 4 months of life","infection in the first 4 months of life","USA","infants born to mothers 16-50 years of age","infants",70,"43",84,NA,"delta","~7 months",NA,NA,"USA","USA",335,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-02-28,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta","18/10/2022",2022-10-18
"2792",335,"Zerbo","Cohort study","28Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna) received in third trimester","excluded","2","final","7+","infection in the first 6 months of life","infection in the first 6 months of life","USA","infants born to mothers 16-50 years of age","infants",54,"27",71,NA,"delta","~9 months",NA,NA,"USA","USA",335,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-02-28,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta","18/10/2022",2022-10-18
"2793",336,"Embi","Test-negative case-control","22May2023","mRNA-1273 (Moderna)","included","2","final","14-149","ED or UC visits with COVID-like illness","symptomatic","USA","immunocompetent adults >=18 years","immunocompetent adults",90,"89",91,NA,"delta","~46 weeks",NA,NA,"USA","USA",336,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-05-22,"symptomatic","2023 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","21/10/2022",2022-10-21
"2794",336,"Embi","Test-negative case-control","22May2023","mRNA-1273 (Moderna)","included","2","final","150+","ED or UC visits with COVID-like illness","symptomatic","USA","immunocompetent adults >=18 years","immunocompetent adults",84,"83",85,NA,"delta","~46 weeks",NA,NA,"USA","USA",336,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-05-22,"symptomatic","2023 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","21/10/2022",2022-10-21
"2795",336,"Embi","Test-negative case-control","22May2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14-149","ED or UC visits with COVID-like illness","symptomatic","USA","immunocompetent adults >=18 years","immunocompetent adults",85,"84",86,NA,"delta","~46 weeks",NA,NA,"USA","USA",336,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-05-22,"symptomatic","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","21/10/2022",2022-10-21
"2796",336,"Embi","Test-negative case-control","22May2023","BNT162b2 (Pfizer BioNTech)","included","2","final","150+","ED or UC visits with COVID-like illness","symptomatic","USA","immunocompetent adults >=18 years","immunocompetent adults",73,"72",74,NA,"delta","~46 weeks",NA,NA,"USA","USA",336,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-05-22,"symptomatic","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","21/10/2022",2022-10-21
"2797",336,"Embi","Test-negative case-control","22May2023","mRNA-1273 (Moderna)","included","2","final","14-149","hospitalization with COVID-like illness","severe","USA","immunocompetent adults >=18 years","immunocompetent adults",95,"92",95,NA,"delta","~46 weeks",NA,NA,"USA","USA",336,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-05-22,"severe","2023 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","21/10/2022",2022-10-21
"2798",336,"Embi","Test-negative case-control","22May2023","mRNA-1273 (Moderna)","included","2","final","150+","hospitalization with COVID-like illness","severe","USA","immunocompetent adults >=18 years","immunocompetent adults",89,"88",90,NA,"delta","~46 weeks",NA,NA,"USA","USA",336,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-05-22,"severe","2023 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","21/10/2022",2022-10-21
"2799",336,"Embi","Test-negative case-control","22May2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14-149","hospitalization with COVID-like illness","severe","USA","immunocompetent adults >=18 years","immunocompetent adults",90,"88",91,NA,"delta","~46 weeks",NA,NA,"USA","USA",336,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-05-22,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","21/10/2022",2022-10-21
"2800",336,"Embi","Test-negative case-control","22May2023","BNT162b2 (Pfizer BioNTech)","included","2","final","150+","hospitalization with COVID-like illness","severe","USA","immunocompetent adults >=18 years","immunocompetent adults",80,"79",82,NA,"delta","~46 weeks",NA,NA,"USA","USA",336,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-05-22,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","21/10/2022",2022-10-21
"2801",336,"Embi","Test-negative case-control","22May2023","mRNA-1273 (Moderna)","included","2","final","14-149","ED or UC visits with COVID-like illness","symptomatic","USA","immunocompromised adults >=18 years","immunocompromised adults",79,"64",88,NA,"delta","~46 weeks",NA,NA,"USA","USA",336,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-05-22,"symptomatic","2023 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","21/10/2022",2022-10-21
"2802",336,"Embi","Test-negative case-control","22May2023","mRNA-1273 (Moderna)","included","2","final","150+","ED or UC visits with COVID-like illness","symptomatic","USA","immunocompromised adults >=18 years","immunocompromised adults",64,"54",72,NA,"delta","~46 weeks",NA,NA,"USA","USA",336,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-05-22,"symptomatic","2023 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","21/10/2022",2022-10-21
"2803",336,"Embi","Test-negative case-control","22May2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14-149","ED or UC visits with COVID-like illness","symptomatic","USA","immunocompromised adults >=18 years","immunocompromised adults",62,"45",73,NA,"delta","~46 weeks",NA,NA,"USA","USA",336,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-05-22,"symptomatic","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","21/10/2022",2022-10-21
"2804",336,"Embi","Test-negative case-control","22May2023","BNT162b2 (Pfizer BioNTech)","included","2","final","150+","ED or UC visits with COVID-like illness","symptomatic","USA","immunocompromised adults >=18 years","immunocompromised adults",56,"46",64,NA,"delta","~46 weeks",NA,NA,"USA","USA",336,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-05-22,"symptomatic","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","21/10/2022",2022-10-21
"2805",336,"Embi","Test-negative case-control","22May2023","mRNA-1273 (Moderna)","included","2","final","14-149","hospitalization with COVID-like illness","severe","USA","immunocompromised adults >=18 years","immunocompromised adults",81,"69",88,NA,"delta","~46 weeks",NA,NA,"USA","USA",336,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-05-22,"severe","2023 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","21/10/2022",2022-10-21
"2806",336,"Embi","Test-negative case-control","22May2023","mRNA-1273 (Moderna)","included","2","final","150+","hospitalization with COVID-like illness","severe","USA","immunocompromised adults >=18 years","immunocompromised adults",73,"68",77,NA,"delta","~46 weeks",NA,NA,"USA","USA",336,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-05-22,"severe","2023 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","21/10/2022",2022-10-21
"2807",336,"Embi","Test-negative case-control","22May2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14-149","hospitalization with COVID-like illness","severe","USA","immunocompromised adults >=18 years","immunocompromised adults",68,"58",75,NA,"delta","~46 weeks",NA,NA,"USA","USA",336,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-05-22,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","21/10/2022",2022-10-21
"2808",336,"Embi","Test-negative case-control","22May2023","BNT162b2 (Pfizer BioNTech)","included","2","final","150+","hospitalization with COVID-like illness","severe","USA","immunocompromised adults >=18 years","immunocompromised adults",64,"58",69,NA,"delta","~46 weeks",NA,NA,"USA","USA",336,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-05-22,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","21/10/2022",2022-10-21
"2809",336,"Embi","Test-negative case-control","22May2023","Ad26.COV2.S (Janssen)","included","1","final","14-149","ED or UC visits with COVID-like illness","symptomatic","USA","immunocompetent adults >=18 years","immunocompetent adults",67,"63",71,NA,"delta","~46 weeks",NA,NA,"USA","USA",336,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-05-22,"symptomatic","2023 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta","21/10/2022",2022-10-21
"2810",336,"Embi","Test-negative case-control","22May2023","Ad26.COV2.S (Janssen)","included","1","final","150+","ED or UC visits with COVID-like illness","symptomatic","USA","immunocompetent adults >=18 years","immunocompetent adults",62,"58",65,NA,"delta","~46 weeks",NA,NA,"USA","USA",336,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-05-22,"symptomatic","2023 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta","21/10/2022",2022-10-21
"2811",336,"Embi","Test-negative case-control","22May2023","Ad26.COV2.S (Janssen)","included","1","final","14-149","hospitalization with COVID-like illness","severe","USA","immunocompetent adults >=18 years","immunocompetent adults",77,"71",82,NA,"delta","~46 weeks",NA,NA,"USA","USA",336,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-05-22,"severe","2023 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta","21/10/2022",2022-10-21
"2812",336,"Embi","Test-negative case-control","22May2023","Ad26.COV2.S (Janssen)","included","1","final","150+","hospitalization with COVID-like illness","severe","USA","immunocompetent adults >=18 years","immunocompetent adults",69,"65",73,NA,"delta","~46 weeks",NA,NA,"USA","USA",336,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-05-22,"severe","2023 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta","21/10/2022",2022-10-21
"2813",336,"Embi","Test-negative case-control","22May2023","Ad26.COV2.S (Janssen)","included","1","final","14-149","ED or UC visits with COVID-like illness","symptomatic","USA","immunocompromised adults >=18 years","immunocompromised adults",9,"-66",50,NA,"delta","~46 weeks",NA,NA,"USA","USA",336,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-05-22,"symptomatic","2023 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta","21/10/2022",2022-10-21
"2814",336,"Embi","Test-negative case-control","22May2023","Ad26.COV2.S (Janssen)","included","1","final","150+","ED or UC visits with COVID-like illness","symptomatic","USA","immunocompromised adults >=18 years","immunocompromised adults",-6,"-49",25,NA,"delta","~46 weeks",NA,NA,"USA","USA",336,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-05-22,"symptomatic","2023 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta","21/10/2022",2022-10-21
"2815",336,"Embi","Test-negative case-control","22May2023","Ad26.COV2.S (Janssen)","included","1","final","14-149","hospitalization with COVID-like illness","severe","USA","immunocompromised adults >=18 years","immunocompromised adults",35,"-3",60,NA,"delta","~46 weeks",NA,NA,"USA","USA",336,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-05-22,"severe","2023 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta","21/10/2022",2022-10-21
"2816",336,"Embi","Test-negative case-control","22May2023","Ad26.COV2.S (Janssen)","included","1","final","150+","hospitalization with COVID-like illness","severe","USA","immunocompromised adults >=18 years","immunocompromised adults",43,"23",58,NA,"delta","~46 weeks",NA,NA,"USA","USA",336,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-05-22,"severe","2023 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta","21/10/2022",2022-10-21
"2817",337,"Britton","Test-negative case-control","21Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization with COVID-like illness","severe","USA","immunocompromised adults >=18 years","immunocompromised adults",40,"34",46,NA,"omicron BA.1","~56 weeks",NA,NA,"USA","USA",337,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-10-21,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-10-21
"2818",337,"Britton","Test-negative case-control","21Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization with COVID-like illness","severe","USA","immunocompromised adults >=18 years","immunocompromised adults",7,"-16",25,NA,"omicron BA.2/BA.2.12.1","~69 weeks",NA,NA,"USA","USA",337,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-10-21,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-10-21
"2819",337,"Britton","Test-negative case-control","21Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization with COVID-like illness","severe","USA","immunocompromised adults >=18 years","immunocompromised adults",38,"23",50,NA,"omicron BA.4/BA.5","~77 weeks",NA,NA,"USA","USA",337,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-10-21,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-10-21
"2820",337,"Britton","Test-negative case-control","21Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization with COVID-like illness","severe","USA","immunocompromised adults >=18 years","immunocompromised adults",22,"10",33,NA,"omicron BA.2/BA.2.12.1/BA.4/BA.5","~77 weeks",NA,NA,"USA","USA",337,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-10-21,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-10-21
"2821",338,"Surie","Test-negative case-control","21Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-150","hospitalization with COVID-like illness","severe","USA",">=18 years","general pop",63,"46",75,NA,"omicron BA.1/BA.2","~74 weeks",NA,NA,"USA","USA",338,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-10-21,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-10-21
"2822",338,"Surie","Test-negative case-control","21Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","150+","hospitalization with COVID-like illness","severe","USA",">=18 years","general pop",34,"20",46,NA,"omicron BA.1/BA.2","~74 weeks",NA,NA,"USA","USA",338,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-10-21,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-10-21
"2823",338,"Surie","Test-negative case-control","21Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-150","hospitalization with COVID-like illness","severe","USA",">=18 years","general pop",83,"35",96,NA,"omicron BA.4/BA.5","~82 weeks",NA,NA,"USA","USA",338,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-10-21,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-10-21
"2824",338,"Surie","Test-negative case-control","21Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","150+","hospitalization with COVID-like illness","severe","USA",">=18 years","general pop",37,"12",55,NA,"omicron BA.4/BA.5","~82 weeks",NA,NA,"USA","USA",338,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-10-21,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-10-21
"2825",339,"Collie","Test-negative case-control","24Oct2022","Ad26.COV2.S (Janssen)","included","1","final","14-20","infection","infection","South Africa","HCW >=18 years with low physical activity","HCW with low physical activity",48,"9.7",70.1,NA,"beta & delta","~34 weeks",NA,NA,"South Africa","ZAF",339,"ZAF",14080,2019,"South Africa","Sub-Saharan Africa","Upper middle income",2,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,71,NA,NA,"who",71,"feb/2021","60-89","not reached","not reached","yes","no","no",2022-10-24,"infection","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-10-24
"2826",339,"Collie","Test-negative case-control","24Oct2022","Ad26.COV2.S (Janssen)","included","1","final","28+","infection","infection","South Africa","HCW >=18 years with low physical activity","HCW with low physical activity",39.8,"34",45.1,NA,"beta & delta","~34 weeks",NA,NA,"South Africa","ZAF",339,"ZAF",14080,2019,"South Africa","Sub-Saharan Africa","Upper middle income",2,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,71,NA,NA,"who",71,"feb/2021","60-89","not reached","not reached","yes","no","no",2022-10-24,"infection","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-10-24
"2827",339,"Collie","Test-negative case-control","24Oct2022","Ad26.COV2.S (Janssen)","included","1","final","28+","hospitalization","severe","South Africa","HCW >=18 years with low physical activity","HCW with low physical activity",60,"39",73.8,NA,"beta & delta","~34 weeks",NA,NA,"South Africa","ZAF",339,"ZAF",14080,2019,"South Africa","Sub-Saharan Africa","Upper middle income",2,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,71,NA,NA,"who",71,"feb/2021","60-89","not reached","not reached","yes","no","no",2022-10-24,"severe","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-10-24
"2828",339,"Collie","Test-negative case-control","24Oct2022","Ad26.COV2.S (Janssen)","included","1","final","14-20","infection","infection","South Africa","HCW >=18 years with moderate physical activity","HCW years with moderate physical activity",39,"-4.9",64.5,NA,"beta & delta","~34 weeks",NA,NA,"South Africa","ZAF",339,"ZAF",14080,2019,"South Africa","Sub-Saharan Africa","Upper middle income",2,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,71,NA,NA,"who",71,"feb/2021","60-89","not reached","not reached","yes","no","no",2022-10-24,"infection","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-10-24
"2829",339,"Collie","Test-negative case-control","24Oct2022","Ad26.COV2.S (Janssen)","included","1","final","28+","infection","infection","South Africa","HCW >=18 years with moderate physical activity","HCW years with moderate physical activity",36.3,"31.3",41,NA,"beta & delta","~34 weeks",NA,NA,"South Africa","ZAF",339,"ZAF",14080,2019,"South Africa","Sub-Saharan Africa","Upper middle income",2,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,71,NA,NA,"who",71,"feb/2021","60-89","not reached","not reached","yes","no","no",2022-10-24,"infection","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-10-24
"2830",339,"Collie","Test-negative case-control","24Oct2022","Ad26.COV2.S (Janssen)","included","1","final","28+","hospitalization","severe","South Africa","HCW >=18 years with moderate physical activity","HCW years with moderate physical activity",72.1,"55.2",82.6,NA,"beta & delta","~34 weeks",NA,NA,"South Africa","ZAF",339,"ZAF",14080,2019,"South Africa","Sub-Saharan Africa","Upper middle income",2,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,71,NA,NA,"who",71,"feb/2021","60-89","not reached","not reached","yes","no","no",2022-10-24,"severe","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-10-24
"2831",339,"Collie","Test-negative case-control","24Oct2022","Ad26.COV2.S (Janssen)","included","1","final","14-20","infection","infection","South Africa","HCW >=18 years with high physical activity","HCW years with high physical activity",51,"16.8",71.1,NA,"beta & delta","~34 weeks",NA,NA,"South Africa","ZAF",339,"ZAF",14080,2019,"South Africa","Sub-Saharan Africa","Upper middle income",2,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,71,NA,NA,"who",71,"feb/2021","60-89","not reached","not reached","yes","no","no",2022-10-24,"infection","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-10-24
"2832",339,"Collie","Test-negative case-control","24Oct2022","Ad26.COV2.S (Janssen)","included","1","final","28+","infection","infection","South Africa","HCW >=18 years with high physical activity","HCW years with high physical activity",41.2,"37.5",44.7,NA,"beta & delta","~34 weeks",NA,NA,"South Africa","ZAF",339,"ZAF",14080,2019,"South Africa","Sub-Saharan Africa","Upper middle income",2,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,71,NA,NA,"who",71,"feb/2021","60-89","not reached","not reached","yes","no","no",2022-10-24,"infection","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-10-24
"2833",339,"Collie","Test-negative case-control","24Oct2022","Ad26.COV2.S (Janssen)","included","1","final","28+","hospitalization","severe","South Africa","HCW >=18 years with high physical activity","HCW years with high physical activity",85.8,"74.1",92.2,NA,"beta & delta","~34 weeks",NA,NA,"South Africa","ZAF",339,"ZAF",14080,2019,"South Africa","Sub-Saharan Africa","Upper middle income",2,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,71,NA,NA,"who",71,"feb/2021","60-89","not reached","not reached","yes","no","no",2022-10-24,"severe","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-10-24
"2834",340,"Nordstrom","Case-control","21Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","7+","infection","infection","Sweden","adolescents vaccinated on or after January 1, 2022","adolescents",51,"48",55,NA,"omicron","~6 weeks",NA,NA,"Sweden","SWE",340,"SWE",58060,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,15,228,396,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-02-21,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","24/10/2022",2022-10-24
"2835",340,"Nordstrom","Case-control","21Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","7+","infection","infection","Sweden","adolescents vaccinated on or after September 1, 2021","adolescents",12,"10",13,NA,"omicron BA.1/BA.2","~24 weeks",NA,NA,"Sweden","SWE",340,"SWE",58060,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,15,228,396,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-02-21,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","24/10/2022",2022-10-24
"2836",340,"Nordstrom","Case-control","21Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","7+","hospitalization with COVID-19 as the main diagnosis","severe","Sweden","adolescents vaccinated on or after November 15, 2021","adolescents",87,"66",95,NA,"omicron BA.1/BA.2","~27 weeks",NA,NA,"Sweden","SWE",340,"SWE",58060,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,15,228,396,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-02-21,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","24/10/2022",2022-10-24
"2837",340,"Nordstrom","Case-control","21Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","48+","hospitalization with COVID-19 as the main diagnosis","severe","Sweden","adolescents vaccinated before November 15, 2021","adolescents",69,"29",87,NA,"omicron BA.1/BA.2","~45 weeks",NA,NA,"Sweden","SWE",340,"SWE",58060,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,15,228,396,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-02-21,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","24/10/2022",2022-10-24
"2838",341,"Tartof","Test-negative case-control","25Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final","<6 months","ED visit for ARI","symptomatic","USA",">=18 years","general pop",30,"-86",74,"omicron BA.4/BA.5","omicron BA.4/BA.5","~84 weeks",NA,NA,"USA","USA",341,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-10-25,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-10-25
"2839",341,"Tartof","Test-negative case-control","25Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final",">=6 months","ED visit for ARI","symptomatic","USA",">=18 years","general pop",44,"20",61,"omicron BA.4/BA.5","omicron BA.4/BA.5","~84 weeks",NA,NA,"USA","USA",341,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-10-25,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-10-25
"2840",341,"Tartof","Test-negative case-control","25Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final","<6 months","UC visit for ARI","symptomatic","USA",">=18 years","general pop",50,"10",72,"omicron BA.4/BA.5","omicron BA.4/BA.5","~84 weeks",NA,NA,"USA","USA",341,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-10-25,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-10-25
"2841",341,"Tartof","Test-negative case-control","25Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final",">=6 months","UC visit for ARI","symptomatic","USA",">=18 years","general pop",7,"-11",22,"omicron BA.4/BA.5","omicron BA.4/BA.5","~84 weeks",NA,NA,"USA","USA",341,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-10-25,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-10-25
"2842",341,"Tartof","Test-negative case-control","25Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final","<6 months","outpatient care visit for ARI","symptomatic","USA",">=18 years","general pop",30,"4",49,"omicron BA.4/BA.5","omicron BA.4/BA.5","~84 weeks",NA,NA,"USA","USA",341,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-10-25,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-10-25
"2843",341,"Tartof","Test-negative case-control","25Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final",">=6 months","outpatient care visit for ARI","symptomatic","USA",">=18 years","general pop",19,"9",29,"omicron BA.4/BA.5","omicron BA.4/BA.5","~84 weeks",NA,NA,"USA","USA",341,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-10-25,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-10-25
"2844",341,"Tartof","Test-negative case-control","25Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final",">=6 months","hospitalization for ARI","severe","USA",">=18 years","general pop",-4,"-118",50,"omicron BA.4/BA.5","omicron BA.4/BA.5","~84 weeks",NA,NA,"USA","USA",341,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-10-25,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-10-25
"2845",342,"Moghnieh","Retrospective cohort","22Sept2022","Gam-COVID-Vac (Gamaleya)","included","2","final","3-5 months","infection","infection","Lebanon",">=18 years","general pop",52.3,"-27.4",78.7,"delta","delta","~30 weeks",NA,NA,"Lebanon","LBN",342,"LBN",17420,2019,"Lebanon","Middle East & North Africa","Lower middle income",3,"Asia",2021-02-15,2022-03-24,NA,2021-02-14,2021-02-14,1,68,403,NA,"who",68,"feb/2021","60-89","Dec/2021 +","360+","yes","no","no",2022-09-22,"infection","2022 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","delta",NA,2022-09-22
"2846",342,"Moghnieh","Retrospective cohort","22Sept2022","Gam-COVID-Vac (Gamaleya)","included","2","final","7-9 months","infection","infection","Lebanon",">=18 years","general pop",23.7,"-84.7",62.8,"delta","delta","~30 weeks",NA,NA,"Lebanon","LBN",342,"LBN",17420,2019,"Lebanon","Middle East & North Africa","Lower middle income",3,"Asia",2021-02-15,2022-03-24,NA,2021-02-14,2021-02-14,1,68,403,NA,"who",68,"feb/2021","60-89","Dec/2021 +","360+","yes","no","no",2022-09-22,"infection","2022 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","delta",NA,2022-09-22
"2847",342,"Moghnieh","Retrospective cohort","22Sept2022","Gam-COVID-Vac (Gamaleya)","excluded","2","final","7-9 months","infection","infection","Lebanon",">=18 years","general pop",20.1,"-94.7",61.6,"delta","delta","~30 weeks",NA,NA,"Lebanon","LBN",342,"LBN",17420,2019,"Lebanon","Middle East & North Africa","Lower middle income",3,"Asia",2021-02-15,2022-03-24,NA,2021-02-14,2021-02-14,1,68,403,NA,"who",68,"feb/2021","60-89","Dec/2021 +","360+","yes","no","no",2022-09-22,"infection","2022 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","delta",NA,2022-09-22
"2848",342,"Moghnieh","Retrospective cohort","22Sept2022","BNT162b2 (Pfizer BioNTech)","included","2","final","<3 months","infection","infection","Lebanon",">=18 years","general pop",95.1,"78.4",99.3,"delta","delta","~30 weeks",NA,NA,"Lebanon","LBN",342,"LBN",17420,2019,"Lebanon","Middle East & North Africa","Lower middle income",3,"Asia",2021-02-15,2022-03-24,NA,2021-02-14,2021-02-14,1,68,403,NA,"who",68,"feb/2021","60-89","Dec/2021 +","360+","yes","no","no",2022-09-22,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-09-22
"2849",342,"Moghnieh","Retrospective cohort","22Sept2022","BNT162b2 (Pfizer BioNTech)","included","2","final","<7 months","infection","infection","Lebanon",">=18 years","general pop",67.5,"12.8",87.2,"delta","delta","~30 weeks",NA,NA,"Lebanon","LBN",342,"LBN",17420,2019,"Lebanon","Middle East & North Africa","Lower middle income",3,"Asia",2021-02-15,2022-03-24,NA,2021-02-14,2021-02-14,1,68,403,NA,"who",68,"feb/2021","60-89","Dec/2021 +","360+","yes","no","no",2022-09-22,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-09-22
"2850",342,"Moghnieh","Retrospective cohort","22Sept2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","<7 months","infection","infection","Lebanon",">=18 years","general pop",71.8,"22.3",89.1,"delta","delta","~30 weeks",NA,NA,"Lebanon","LBN",342,"LBN",17420,2019,"Lebanon","Middle East & North Africa","Lower middle income",3,"Asia",2021-02-15,2022-03-24,NA,2021-02-14,2021-02-14,1,68,403,NA,"who",68,"feb/2021","60-89","Dec/2021 +","360+","yes","no","no",2022-09-22,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-09-22
"2851",342,"Moghnieh","Retrospective cohort","22Sept2022","Gam-COVID-Vac (Gamaleya)","included","2","final",">6 months","infection","infection","Lebanon",">=18 years","general pop",-54.1,"-151",0.84,"omicron","omicron","~43 weeks",NA,NA,"Lebanon","LBN",342,"LBN",17420,2019,"Lebanon","Middle East & North Africa","Lower middle income",3,"Asia",2021-02-15,2022-03-24,NA,2021-02-14,2021-02-14,1,68,403,NA,"who",68,"feb/2021","60-89","Dec/2021 +","360+","yes","no","no",2022-09-22,"infection","2022 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","omicron",NA,2022-09-22
"2852",342,"Moghnieh","Retrospective cohort","22Sept2022","Gam-COVID-Vac (Gamaleya)","excluded","2","final",">6 months","infection","infection","Lebanon",">=18 years","general pop",-46,"-149.7",10.1,"omicron","omicron","~43 weeks",NA,NA,"Lebanon","LBN",342,"LBN",17420,2019,"Lebanon","Middle East & North Africa","Lower middle income",3,"Asia",2021-02-15,2022-03-24,NA,2021-02-14,2021-02-14,1,68,403,NA,"who",68,"feb/2021","60-89","Dec/2021 +","360+","yes","no","no",2022-09-22,"infection","2022 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","omicron",NA,2022-09-22
"2853",342,"Moghnieh","Retrospective cohort","22Sept2022","BNT162b2 (Pfizer BioNTech)","included","2","final","3-5 months","infection","infection","Lebanon",">=18 years","general pop",23.1,"-28.7",52.1,"omicron","omicron","~43 weeks",NA,NA,"Lebanon","LBN",342,"LBN",17420,2019,"Lebanon","Middle East & North Africa","Lower middle income",3,"Asia",2021-02-15,2022-03-24,NA,2021-02-14,2021-02-14,1,68,403,NA,"who",68,"feb/2021","60-89","Dec/2021 +","360+","yes","no","no",2022-09-22,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-09-22
"2854",342,"Moghnieh","Retrospective cohort","22Sept2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","3-5 months","infection","infection","Lebanon",">=18 years","general pop",21.9,"-38.9",54.1,"omicron","omicron","~43 weeks",NA,NA,"Lebanon","LBN",342,"LBN",17420,2019,"Lebanon","Middle East & North Africa","Lower middle income",3,"Asia",2021-02-15,2022-03-24,NA,2021-02-14,2021-02-14,1,68,403,NA,"who",68,"feb/2021","60-89","Dec/2021 +","360+","yes","no","no",2022-09-22,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-09-22
"2855",343,"Grewal","Test-negative case-control","07Mar2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","240-299","severe disease","severe","Canada","50-59 years","50-59 years",83,"76",88,"omicron BA.1/BA.2","omicron BA.1/BA.2","~74 weeks",NA,NA,"Canada","CAN",343,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-03-07,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","01/11/2022",2022-11-01
"2856",343,"Grewal","Test-negative case-control","07Mar2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","300+","severe disease","severe","Canada","50-59 years","50-59 years",83,"74",89,"omicron BA.1/BA.2","omicron BA.1/BA.2","~74 weeks",NA,NA,"Canada","CAN",343,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-03-07,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","01/11/2022",2022-11-01
"2857",343,"Grewal","Test-negative case-control","07Mar2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","300+","severe disease","severe","Canada","60-69 years","60-69 years",79,"71",86,"omicron BA.1/BA.2","omicron BA.1/BA.2","~74 weeks",NA,NA,"Canada","CAN",343,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-03-07,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","01/11/2022",2022-11-01
"2858",343,"Grewal","Test-negative case-control","07Mar2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","300+","severe disease","severe","Canada","70-79 years","70-79 years",80,"72",86,"omicron BA.1/BA.2","omicron BA.1/BA.2","~74 weeks",NA,NA,"Canada","CAN",343,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-03-07,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","01/11/2022",2022-11-01
"2859",343,"Grewal","Test-negative case-control","07Mar2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","300+","severe disease","severe","Canada",">=80 years",">=80 years",72,"62",79,"omicron BA.1/BA.2","omicron BA.1/BA.2","~74 weeks",NA,NA,"Canada","CAN",343,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-03-07,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","01/11/2022",2022-11-01
"2860",343,"Grewal","Test-negative case-control","07Mar2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","240-299","severe disease","severe","Canada","50-59 years","50-59 years",87,"43",97,"omicron BA.4/BA.5","omicron BA.4/BA.5","~86 weeks",NA,NA,"Canada","CAN",343,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-03-07,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","01/11/2022",2022-11-01
"2861",343,"Grewal","Test-negative case-control","07Mar2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","300+","severe disease","severe","Canada","50-59 years","50-59 years",56,"30",72,"omicron BA.4/BA.5","omicron BA.4/BA.5","~86 weeks",NA,NA,"Canada","CAN",343,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-03-07,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","01/11/2022",2022-11-01
"2862",343,"Grewal","Test-negative case-control","07Mar2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","300+","severe disease","severe","Canada","60-69 years","60-69 years",43,"16",61,"omicron BA.4/BA.5","omicron BA.4/BA.5","~86 weeks",NA,NA,"Canada","CAN",343,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-03-07,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","01/11/2022",2022-11-01
"2863",343,"Grewal","Test-negative case-control","07Mar2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","300+","severe disease","severe","Canada","70-79 years","70-79 years",48,"25",64,"omicron BA.4/BA.5","omicron BA.4/BA.5","~86 weeks",NA,NA,"Canada","CAN",343,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-03-07,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","01/11/2022",2022-11-01
"2864",343,"Grewal","Test-negative case-control","07Mar2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","300+","severe disease","severe","Canada",">=80 years",">=80 years",40,"18",56,"omicron BA.4/BA.5","omicron BA.4/BA.5","~86 weeks",NA,NA,"Canada","CAN",343,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-03-07,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","01/11/2022",2022-11-01
"2865",344,"Chemaitelly","Retrospective cohort","07Mar2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","previously infected only","2","final","91+ (90+ days post primary Omicron infection)","reinfection","reinfection","Qatar",">=18 years with prior breakthrough Omicron infection",">=18 years with prior breakthrough Omicron infection",57,"52",62,NA,"omicron","~85 weeks",NA,NA,"Qatar","QAT",344,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2023-03-07,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-03-07
"2866",345,"Clemens","Test-negative case-control","13Oct2022","AZD1222 (AstraZeneca)","included","2","final","14+","infection","infection","Brazil","18-60 years","18-60 years",76,"49.5",87.8,"delta","delta","~12.5 weeks",NA,NA,"Brazil","BRA",345,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-10-13,"infection","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2022-10-13
"2867",345,"Clemens","Test-negative case-control","13Oct2022","AZD1222 (AstraZeneca)","included","2","final","14+","severe disease","severe","Brazil","18-60 years","18-60 years",100,"44.3",100,NA,"delta","~12.5 weeks",NA,NA,"Brazil","BRA",345,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-10-13,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2022-10-13
"2868",345,"Clemens","Test-negative case-control","13Oct2022","AZD1222 (AstraZeneca)","included","2","final","14+","infection","infection","Brazil","18-60 years","18-60 years",81.3,"-298",97.9,"gamma","gamma","~12.5 weeks",NA,NA,"Brazil","BRA",345,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2022-10-13,"infection","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","gamma",NA,2022-10-13
"2869",346,"Jorgensen","Test-negative case-control","08Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","Canada","infants < 6 months","mothers of infants < 6 months",45,"37",53,NA,"omicron","~66 weeks",NA,NA,"Canada","CAN",346,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-02-08,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","08/11/2022",2022-11-08
"2870",346,"Jorgensen","Test-negative case-control","08Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","Canada","infants < 6 months of mothers receiving second dose in first trimester","infants < 6 months of mothers receiving second dose in first trimester",47,"31",59,NA,"omicron","~66 weeks",NA,NA,"Canada","CAN",346,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-02-08,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","08/11/2022",2022-11-08
"2871",346,"Jorgensen","Test-negative case-control","08Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","Canada","infants < 6 months of mothers receiving second dose in second trimester","infants < 6 months of mothers receiving second dose in second trimester",37,"24",47,NA,"omicron","~66 weeks",NA,NA,"Canada","CAN",346,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-02-08,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","08/11/2022",2022-11-08
"2872",346,"Jorgensen","Test-negative case-control","08Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","Canada","infants < 6 months of mothers receiving second dose in third trimester","infants < 6 months of mothers receiving second dose in third trimester",53,"42",62,NA,"omicron","~66 weeks",NA,NA,"Canada","CAN",346,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-02-08,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","08/11/2022",2022-11-08
"2873",346,"Jorgensen","Test-negative case-control","08Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","Canada","infants 0-8 weeks","infants 0-8 weeks",57,"44",66,NA,"omicron","~66 weeks",NA,NA,"Canada","CAN",346,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-02-08,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","08/11/2022",2022-11-08
"2874",346,"Jorgensen","Test-negative case-control","08Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","Canada","infants 9-16 weeks","infants 9-16 weeks",47,"31",60,NA,"omicron","~66 weeks",NA,NA,"Canada","CAN",346,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-02-08,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","08/11/2022",2022-11-08
"2875",346,"Jorgensen","Test-negative case-control","08Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","Canada","infants >16 weeks and < 6 months","infants >16 weeks and < 6 months",40,"21",54,NA,"omicron","~66 weeks",NA,NA,"Canada","CAN",346,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-02-08,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","08/11/2022",2022-11-08
"2876",346,"Jorgensen","Test-negative case-control","08Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","Canada","infants < 6 months","infants < 6 months",58,"44",69,NA,"omicron","~66 weeks",NA,NA,"Canada","CAN",346,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-02-08,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","08/11/2022",2022-11-08
"2877",346,"Jorgensen","Test-negative case-control","08Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","Canada","infants < 6 months","infants < 6 months",95,"88",98,NA,"delta","~28 weeks",NA,NA,"Canada","CAN",346,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-02-08,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta","08/11/2022",2022-11-08
"2878",346,"Jorgensen","Test-negative case-control","08Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization","severe","Canada","infants < 6 months","infants < 6 months",97,"74",100,NA,"delta","~28 weeks",NA,NA,"Canada","CAN",346,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-02-08,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta","08/11/2022",2022-11-08
"2879",347,"Van Ewijk","Test-negative case-control","10Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","Netherlands",">=18 years","general pop",64,"51",74,NA,"delta","~41 weeks",NA,NA,"Netherlands","NLD",347,"NLD",60460,2019,"Netherlands","Europe & Central Asia","High income",4,"Europe",2021-01-08,2021-07-16,NA,2020-12-30,2020-12-30,9,22,198,NA,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-11-10,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-11-10
"2880",347,"Van Ewijk","Test-negative case-control","10Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease","symptomatic","Netherlands",">=18 years","general pop",64,"49",75,NA,"delta","~41 weeks",NA,NA,"Netherlands","NLD",347,"NLD",60460,2019,"Netherlands","Europe & Central Asia","High income",4,"Europe",2021-01-08,2021-07-16,NA,2020-12-30,2020-12-30,9,22,198,NA,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-11-10,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-11-10
"2881",347,"Van Ewijk","Test-negative case-control","10Nov2022","mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","Netherlands",">=18 years","general pop",76,"62",85,NA,"delta","~41 weeks",NA,NA,"Netherlands","NLD",347,"NLD",60460,2019,"Netherlands","Europe & Central Asia","High income",4,"Europe",2021-01-08,2021-07-16,NA,2020-12-30,2020-12-30,9,22,198,NA,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-11-10,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2022-11-10
"2882",347,"Van Ewijk","Test-negative case-control","10Nov2022","mRNA-1273 (Moderna)","excluded","2","final","14+","symptomatic disease","symptomatic","Netherlands",">=18 years","general pop",75,"58",85,NA,"delta","~41 weeks",NA,NA,"Netherlands","NLD",347,"NLD",60460,2019,"Netherlands","Europe & Central Asia","High income",4,"Europe",2021-01-08,2021-07-16,NA,2020-12-30,2020-12-30,9,22,198,NA,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-11-10,"symptomatic","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2022-11-10
"2883",347,"Van Ewijk","Test-negative case-control","10Nov2022","AZD1222 (AstraZeneca)","excluded","2","final","14+","infection","infection","Netherlands",">=18 years","general pop",53,"37",68,NA,"delta","~41 weeks",NA,NA,"Netherlands","NLD",347,"NLD",60460,2019,"Netherlands","Europe & Central Asia","High income",4,"Europe",2021-01-08,2021-07-16,NA,2020-12-30,2020-12-30,9,22,198,NA,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-11-10,"infection","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2022-11-10
"2884",347,"Van Ewijk","Test-negative case-control","10Nov2022","AZD1222 (AstraZeneca)","excluded","2","final","14+","symptomatic disease","symptomatic","Netherlands",">=18 years","general pop",52,"26",69,NA,"delta","~41 weeks",NA,NA,"Netherlands","NLD",347,"NLD",60460,2019,"Netherlands","Europe & Central Asia","High income",4,"Europe",2021-01-08,2021-07-16,NA,2020-12-30,2020-12-30,9,22,198,NA,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-11-10,"symptomatic","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2022-11-10
"2885",347,"Van Ewijk","Test-negative case-control","10Nov2022","Ad26.COV2.S (Janssen)","excluded","1","final","28+","infection","infection","Netherlands",">=18 years","general pop",55,"32",70,NA,"delta","~36 weeks",NA,NA,"Netherlands","NLD",347,"NLD",60460,2019,"Netherlands","Europe & Central Asia","High income",4,"Europe",2021-01-08,2021-07-16,NA,2020-12-30,2020-12-30,9,22,198,NA,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-11-10,"infection","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta",NA,2022-11-10
"2886",347,"Van Ewijk","Test-negative case-control","10Nov2022","Ad26.COV2.S (Janssen)","excluded","1","final","28+","symptomatic disease","symptomatic","Netherlands",">=18 years","general pop",59,"35",74,NA,"delta","~36 weeks",NA,NA,"Netherlands","NLD",347,"NLD",60460,2019,"Netherlands","Europe & Central Asia","High income",4,"Europe",2021-01-08,2021-07-16,NA,2020-12-30,2020-12-30,9,22,198,NA,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-11-10,"symptomatic","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta",NA,2022-11-10
"2887",347,"Van Ewijk","Test-negative case-control","10Nov2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","<120","infection","infection","Netherlands",">=18 years","general pop",74,"63",81,NA,"delta",NA,NA,NA,"Netherlands","NLD",347,"NLD",60460,2019,"Netherlands","Europe & Central Asia","High income",4,"Europe",2021-01-08,2021-07-16,NA,2020-12-30,2020-12-30,9,22,198,NA,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-11-10,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2022-11-10
"2888",347,"Van Ewijk","Test-negative case-control","10Nov2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final",">120","infection","infection","Netherlands",">=18 years","general pop",56,"36",69,NA,"delta","~41 weeks",NA,NA,"Netherlands","NLD",347,"NLD",60460,2019,"Netherlands","Europe & Central Asia","High income",4,"Europe",2021-01-08,2021-07-16,NA,2020-12-30,2020-12-30,9,22,198,NA,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-11-10,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2022-11-10
"2889",347,"Van Ewijk","Test-negative case-control","10Nov2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection","infection","Netherlands",">=18 years","general pop",59,"25",70,NA,"delta","~41 weeks",NA,NA,"Netherlands","NLD",347,"NLD",60460,2019,"Netherlands","Europe & Central Asia","High income",4,"Europe",2021-01-08,2021-07-16,NA,2020-12-30,2020-12-30,9,22,198,NA,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-11-10,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-11-10
"2890",347,"Van Ewijk","Test-negative case-control","10Nov2022","mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","Netherlands",">=18 years","general pop",73,"59",83,NA,"delta","~41 weeks",NA,NA,"Netherlands","NLD",347,"NLD",60460,2019,"Netherlands","Europe & Central Asia","High income",4,"Europe",2021-01-08,2021-07-16,NA,2020-12-30,2020-12-30,9,22,198,NA,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-11-10,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2022-11-10
"2891",347,"Van Ewijk","Test-negative case-control","10Nov2022","AZD1222 (AstraZeneca)","included","2","final","14+","infection","infection","Netherlands",">=18 years","general pop",48,"25",64,NA,"delta","~36 weeks",NA,NA,"Netherlands","NLD",347,"NLD",60460,2019,"Netherlands","Europe & Central Asia","High income",4,"Europe",2021-01-08,2021-07-16,NA,2020-12-30,2020-12-30,9,22,198,NA,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-11-10,"infection","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2022-11-10
"2892",347,"Van Ewijk","Test-negative case-control","10Nov2022","Ad26.COV2.S (Janssen)","included","1","final","14+","infection","infection","Netherlands",">=18 years","general pop",50,"24",66,NA,"delta","~36 weeks",NA,NA,"Netherlands","NLD",347,"NLD",60460,2019,"Netherlands","Europe & Central Asia","High income",4,"Europe",2021-01-08,2021-07-16,NA,2020-12-30,2020-12-30,9,22,198,NA,"who",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","no",2022-11-10,"infection","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta",NA,2022-11-10
"2893",348,"Turbyfill","Test-negative case-control","15Nov2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","immunocompetent adults >=18 years","immunocompetent adults",91,"88",93,NA,"alpha & delta","~30 weeks",NA,NA,"USA","USA",348,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-11-15,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-11-15
"2894",348,"Turbyfill","Test-negative case-control","15Nov2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","immunocompetent adults >=18 years","immunocompetent adults",84,"80",88,NA,"alpha & delta","~30 weeks",NA,NA,"USA","USA",348,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-11-15,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-11-15
"2895",348,"Turbyfill","Test-negative case-control","15Nov2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","immunocompromised, >=18 years","immunocompromised adults",64,"48",75,NA,"alpha & delta","~30 weeks",NA,NA,"USA","USA",348,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-11-15,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-11-15
"2896",348,"Turbyfill","Test-negative case-control","15Nov2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","immunocompromised, >=18 years","immunocompromised adults",53,"22",72,NA,"alpha & delta","~30 weeks",NA,NA,"USA","USA",348,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-11-15,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-11-15
"2897",349,"Castelli","Test-negative case-control","30Nov2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection","infection","Argentina","12-17 years","12-17 years",28.1,"25.2",30.8,NA,"omicron","~32.5 weeks",NA,NA,"Argentina","ARG",349,"ARG",22100,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,21,263,381,"equal",21,"before jan/2021","<30","Sep-Nov/2021","180-269","yes","yes","yes",2022-11-30,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-11-30
"2898",349,"Castelli","Test-negative case-control","30Nov2022","mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","Argentina","12-17 years","12-17 years",17.9,"14",21.5,NA,"omicron","~32.5 weeks",NA,NA,"Argentina","ARG",349,"ARG",22100,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,21,263,381,"equal",21,"before jan/2021","<30","Sep-Nov/2021","180-269","yes","yes","yes",2022-11-30,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron",NA,2022-11-30
"2899",349,"Castelli","Test-negative case-control","30Nov2022","BNT162b2 (Pfizer BioNTech) & mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","Argentina","12-17 years","12-17 years",40.6,"29.4",50,NA,"omicron","~32.5 weeks",NA,NA,"Argentina","ARG",349,"ARG",22100,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,21,263,381,"equal",21,"before jan/2021","<30","Sep-Nov/2021","180-269","yes","yes","yes",2022-11-30,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-11-30
"2900",349,"Castelli","Test-negative case-control","30Nov2022","BNT162b2 (Pfizer BioNTech) & mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","Argentina","12-17 years","12-17 years",31.5,"26.3",36.4,NA,"omicron","~32.5 weeks",NA,NA,"Argentina","ARG",349,"ARG",22100,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,21,263,381,"equal",21,"before jan/2021","<30","Sep-Nov/2021","180-269","yes","yes","yes",2022-11-30,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-11-30
"2901",349,"Castelli","Test-negative case-control","30Nov2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","15-30","infection","infection","Argentina","12-17 years","12-17 years",55.8,"52.4",59,NA,"omicron","~32.5 weeks",NA,NA,"Argentina","ARG",349,"ARG",22100,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,21,263,381,"equal",21,"before jan/2021","<30","Sep-Nov/2021","180-269","yes","yes","yes",2022-11-30,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-11-30
"2902",349,"Castelli","Test-negative case-control","30Nov2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","61+","infection","infection","Argentina","12-17 years","12-17 years",12.4,"8.6",16.1,NA,"omicron","~32.5 weeks",NA,NA,"Argentina","ARG",349,"ARG",22100,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,21,263,381,"equal",21,"before jan/2021","<30","Sep-Nov/2021","180-269","yes","yes","yes",2022-11-30,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-11-30
"2903",349,"Castelli","Test-negative case-control","30Nov2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","death","death","Argentina","12-17 years","12-17 years",97.6,"81",99.7,NA,"omicron","~32.5 weeks",NA,NA,"Argentina","ARG",349,"ARG",22100,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,21,263,381,"equal",21,"before jan/2021","<30","Sep-Nov/2021","180-269","yes","yes","yes",2022-11-30,"death","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-11-30
"2904",349,"Castelli","Test-negative case-control","30Nov2022","BBIBP-CorV (Beijing CNBG)","included","2","final","14+","infection","infection","Argentina","3-11 years","3-11 years",26,"23.2",28.8,NA,"omicron","~22.5 weeks",NA,NA,"Argentina","ARG",349,"ARG",22100,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,21,263,381,"equal",21,"before jan/2021","<30","Sep-Nov/2021","180-269","yes","yes","yes",2022-11-30,"infection","2022 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","omicron",NA,2022-11-30
"2905",349,"Castelli","Test-negative case-control","30Nov2022","BBIBP-CorV (Beijing CNBG)","included","2","final","15-30","infection","infection","Argentina","3-11 years","3-11 years",37.6,"34.2",40.8,NA,"omicron","~22.5 weeks",NA,NA,"Argentina","ARG",349,"ARG",22100,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,21,263,381,"equal",21,"before jan/2021","<30","Sep-Nov/2021","180-269","yes","yes","yes",2022-11-30,"infection","2022 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","omicron",NA,2022-11-30
"2906",349,"Castelli","Test-negative case-control","30Nov2022","BBIBP-CorV (Beijing CNBG)","included","2","final","61+","infection","infection","Argentina","3-11 years","3-11 years",2,"1.8",5.6,NA,"omicron","~22.5 weeks",NA,NA,"Argentina","ARG",349,"ARG",22100,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,21,263,381,"equal",21,"before jan/2021","<30","Sep-Nov/2021","180-269","yes","yes","yes",2022-11-30,"infection","2022 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","omicron",NA,2022-11-30
"2907",349,"Castelli","Test-negative case-control","30Nov2022","BBIBP-CorV (Beijing CNBG)","included","2","final","14+","death","death","Argentina","3-11 years","3-11 years",66.9,"6.4",89.8,NA,"omicron","~22.5 weeks",NA,NA,"Argentina","ARG",349,"ARG",22100,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,21,263,381,"equal",21,"before jan/2021","<30","Sep-Nov/2021","180-269","yes","yes","yes",2022-11-30,"death","2022 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","omicron",NA,2022-11-30
"2908",349,"Castelli","Test-negative case-control","30Nov2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection","infection","Argentina","12-17 years","12-17 years",64.1,"60.5",67.3,NA,"delta","~15.5 weeks",NA,NA,"Argentina","ARG",349,"ARG",22100,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,21,263,381,"equal",21,"before jan/2021","<30","Sep-Nov/2021","180-269","yes","yes","yes",2022-11-30,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-11-30
"2909",349,"Castelli","Test-negative case-control","30Nov2022","mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","Argentina","12-17 years","12-17 years",70.2,"66.8",73.1,NA,"delta","~15.5 weeks",NA,NA,"Argentina","ARG",349,"ARG",22100,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,21,263,381,"equal",21,"before jan/2021","<30","Sep-Nov/2021","180-269","yes","yes","yes",2022-11-30,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2022-11-30
"2910",349,"Castelli","Test-negative case-control","30Nov2022","BNT162b2 (Pfizer BioNTech) & mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","Argentina","12-17 years","12-17 years",88.9,"66.1",96.4,NA,"delta","~15.5 weeks",NA,NA,"Argentina","ARG",349,"ARG",22100,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,21,263,381,"equal",21,"before jan/2021","<30","Sep-Nov/2021","180-269","yes","yes","yes",2022-11-30,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2022-11-30
"2911",349,"Castelli","Test-negative case-control","30Nov2022","BNT162b2 (Pfizer BioNTech) & mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","Argentina","12-17 years","12-17 years",66.3,"54",75.4,NA,"delta","~15.5 weeks",NA,NA,"Argentina","ARG",349,"ARG",22100,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,21,263,381,"equal",21,"before jan/2021","<30","Sep-Nov/2021","180-269","yes","yes","yes",2022-11-30,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2022-11-30
"2912",349,"Castelli","Test-negative case-control","30Nov2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","15-30","infection","infection","Argentina","12-17 years","12-17 years",74.8,"71.3",77.9,NA,"delta","~15.5 weeks",NA,NA,"Argentina","ARG",349,"ARG",22100,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,21,263,381,"equal",21,"before jan/2021","<30","Sep-Nov/2021","180-269","yes","yes","yes",2022-11-30,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2022-11-30
"2913",349,"Castelli","Test-negative case-control","30Nov2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","61+","infection","infection","Argentina","12-17 years","12-17 years",56.3,"50.2",61.7,NA,"delta","~15.5 weeks",NA,NA,"Argentina","ARG",349,"ARG",22100,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,21,263,381,"equal",21,"before jan/2021","<30","Sep-Nov/2021","180-269","yes","yes","yes",2022-11-30,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2022-11-30
"2914",349,"Castelli","Test-negative case-control","30Nov2022","BBIBP-CorV (Beijing CNBG)","included","2","final","14+","infection","infection","Argentina","3-11 years","3-11 years",61.2,"56.4",65.5,NA,"delta","~5.5 weeks",NA,NA,"Argentina","ARG",349,"ARG",22100,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,21,263,381,"equal",21,"before jan/2021","<30","Sep-Nov/2021","180-269","yes","yes","yes",2022-11-30,"infection","2022 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta",NA,2022-11-30
"2915",349,"Castelli","Test-negative case-control","30Nov2022","BBIBP-CorV (Beijing CNBG)","included","2","final","15-30","infection","infection","Argentina","3-11 years","3-11 years",68.4,"64.1",72.2,NA,"delta","~5.5 weeks",NA,NA,"Argentina","ARG",349,"ARG",22100,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,21,263,381,"equal",21,"before jan/2021","<30","Sep-Nov/2021","180-269","yes","yes","yes",2022-11-30,"infection","2022 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta",NA,2022-11-30
"2916",349,"Castelli","Test-negative case-control","30Nov2022","BBIBP-CorV (Beijing CNBG)","included","2","final","61+","infection","infection","Argentina","3-11 years","3-11 years",65.2,"44",78.4,NA,"delta","~5.5 weeks",NA,NA,"Argentina","ARG",349,"ARG",22100,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,21,263,381,"equal",21,"before jan/2021","<30","Sep-Nov/2021","180-269","yes","yes","yes",2022-11-30,"infection","2022 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta",NA,2022-11-30
"2917",350,"Fu","Retrospective cohort","22Sep2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection","infection","USA",">=18 years","general pop",-122.3,"-124.2",120.3,NA,"omicron BA.1, BA.2","~75.5 weeks",NA,NA,"USA","USA",350,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-09-22,"infection","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","10/12/2022",2022-12-10
"2918",350,"Fu","Retrospective cohort","22Sep2023","mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","USA",">=18 years","general pop",-163.5,"-166.6",-160.5,NA,"omicron BA.1, BA.2","~73.5 weeks",NA,NA,"USA","USA",350,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-09-22,"infection","2023 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron","10/12/2022",2022-12-10
"2919",350,"Fu","Retrospective cohort","22Sep2023","mRNA (heterologous)","included","2","final","14+","infection","infection","USA",">=18 years","general pop",-19,"-27.4",-11,NA,"omicron BA.1, BA.2","~75.5 weeks",NA,NA,"USA","USA",350,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-09-22,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","10/12/2022",2022-12-10
"2920",350,"Fu","Retrospective cohort","22Sep2023","Ad26.COV2.S (Janssen)","included","1","final","14+","infection","infection","USA",">=18 years","general pop",-38.1,"-44.2",32.2,NA,"omicron BA.1, BA.2","~69.5 weeks",NA,NA,"USA","USA",350,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-09-22,"infection","2023 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","omicron","10/12/2022",2022-12-10
"2921",350,"Fu","Retrospective cohort","22Sep2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection","infection","USA",">=18 years","general pop",-25,"-26.2",-23.8,NA,"delta","~48.5 weeks",NA,NA,"USA","USA",350,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-09-22,"infection","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","10/12/2022",2022-12-10
"2922",350,"Fu","Retrospective cohort","22Sep2023","mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","USA",">=18 years","general pop",-11.3,"-12.9",-9.8,NA,"delta","~46.5 weeks",NA,NA,"USA","USA",350,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-09-22,"infection","2023 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","10/12/2022",2022-12-10
"2923",350,"Fu","Retrospective cohort","22Sep2023","mRNA (heterologous)","included","2","final","14+","infection","infection","USA",">=18 years","general pop",-13.6,"-22.7",-5.2,NA,"delta","~48.5 weeks",NA,NA,"USA","USA",350,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-09-22,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta","10/12/2022",2022-12-10
"2924",350,"Fu","Retrospective cohort","22Sep2023","Ad26.COV2.S (Janssen)","included","1","final","14+","infection","infection","USA",">=18 years","general pop",33,"29.2",36.5,NA,"delta","~42.5 weeks",NA,NA,"USA","USA",350,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-09-22,"infection","2023 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta","10/12/2022",2022-12-10
"2925",350,"Fu","Retrospective cohort","22Sep2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection","infection","USA",">=18 years","general pop",77.9,"77.2",78.5,NA,"pre-delta (non-VOC, alpha)","~23 weeks",NA,NA,"USA","USA",350,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-09-22,"infection","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","10/12/2022",2022-12-10
"2926",350,"Fu","Retrospective cohort","22Sep2023","mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","USA",">=18 years","general pop",85.9,"85.1",86.5,NA,"pre-delta (non-VOC, alpha)","~21 weeks",NA,NA,"USA","USA",350,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-09-22,"infection","2023 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","10/12/2022",2022-12-10
"2927",350,"Fu","Retrospective cohort","22Sep2023","mRNA (heterologous)","included","2","final","14+","infection","infection","USA",">=18 years","general pop",78.9,"66.6",87.7,NA,"pre-delta (non-VOC, alpha)","~23 weeks",NA,NA,"USA","USA",350,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-09-22,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","10/12/2022",2022-12-10
"2928",350,"Fu","Retrospective cohort","22Sep2023","Ad26.COV2.S (Janssen)","included","1","final","14+","infection","infection","USA",">=18 years","general pop",81.4,"78.4",84.2,NA,"pre-delta (non-VOC, alpha)","~17 weeks",NA,NA,"USA","USA",350,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-09-22,"infection","2023 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations","10/12/2022",2022-12-10
"2929",350,"Fu","Retrospective cohort","22Sep2023","BNT162b2 (Pfizer BioNTech)","included","2","final","1st month","infection","infection","USA",">=18 years","general pop",47.3,"46",48.5,NA,"pre-delta & delta & omicron BA.1, BA.2",NA,NA,NA,"USA","USA",350,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-09-22,"infection","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","10/12/2022",2022-12-10
"2930",350,"Fu","Retrospective cohort","22Sep2023","BNT162b2 (Pfizer BioNTech)","included","2","final","6th month","infection","infection","USA",">=18 years","general pop",-77,"-80.6",-73.5,NA,"pre-delta & delta & omicron BA.1, BA.2","~50 weeks",NA,NA,"USA","USA",350,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-09-22,"infection","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","10/12/2022",2022-12-10
"2931",350,"Fu","Retrospective cohort","22Sep2023","mRNA-1273 (Moderna)","included","2","final","1st month","infection","infection","USA",">=18 years","general pop",64.7,"63.3",66,NA,"pre-delta & delta & omicron BA.1, BA.2",NA,NA,NA,"USA","USA",350,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-09-22,"infection","2023 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","10/12/2022",2022-12-10
"2932",350,"Fu","Retrospective cohort","22Sep2023","mRNA-1273 (Moderna)","included","2","final","6th month","infection","infection","USA",">=18 years","general pop",-62.6,"-67.2",-58.1,NA,"pre-delta & delta & omicron BA.1, BA.2","~50 weeks",NA,NA,"USA","USA",350,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-09-22,"infection","2023 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","10/12/2022",2022-12-10
"2933",350,"Fu","Retrospective cohort","22Sep2023","mRNA (heterologous)","included","2","final","1st month","infection","infection","USA",">=18 years","general pop",-35.5,"-48.6",-23.6,NA,"pre-delta & delta & omicron BA.1, BA.2",NA,NA,NA,"USA","USA",350,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-09-22,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","10/12/2022",2022-12-10
"2934",350,"Fu","Retrospective cohort","22Sep2023","mRNA (heterologous)","included","2","final","6th month","infection","infection","USA",">=18 years","general pop",-4.2,"-27.4",14.8,NA,"pre-delta & delta & omicron BA.1, BA.2","~34 weeks",NA,NA,"USA","USA",350,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-09-22,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","10/12/2022",2022-12-10
"2935",350,"Fu","Retrospective cohort","22Sep2023","Ad26.COV2.S (Janssen)","included","1","final","1st month","infection","infection","USA",">=18 years","general pop",30.8,"23.5",37.4,NA,"pre-delta & delta & omicron BA.1, BA.2",NA,NA,NA,"USA","USA",350,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-09-22,"infection","2023 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations","10/12/2022",2022-12-10
"2936",350,"Fu","Retrospective cohort","22Sep2023","Ad26.COV2.S (Janssen)","included","1","final","6th month","infection","infection","USA",">=18 years","general pop",-1.2,"-13.2",9.5,NA,"pre-delta & delta & omicron BA.1, BA.2","~50 weeks",NA,NA,"USA","USA",350,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-09-22,"infection","2023 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations","10/12/2022",2022-12-10
"2937",351,"Cegolon","Retrospective cohort","30Nov2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","infection","infection","Italy","HCW","HCW",41,"-49",77,NA,"omicron BA.1, BA.2, BA.4/BA.5","~69 weeks",NA,NA,"Italy","ITA",351,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-30,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-11-30
"2938",351,"Cegolon","Retrospective cohort","30Nov2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","previously infected only","2","final","7+","infection","infection","Italy","HCW","HCW",-4,"-43",24,NA,"omicron BA.1, BA.2, BA.4/BA.5","~69 weeks",NA,NA,"Italy","ITA",351,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-30,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-11-30
"2939",352,"Khanam","Test-negative case-control","02Dec2022","AZD1222 (AstraZeneca)","excluded","2","final","14+","symptomatic disease","symptomatic","Bangladesh",">=18 years","general pop",-45,"-119",4,NA,"delta","~36 weeks",NA,NA,"Bangladesh","BGD",352,"BGD",5930,2019,"Bangladesh","South Asia","Lower middle income",2,"Asia",2021-02-07,2022-02-18,2022-07-16,2021-01-27,2021-01-27,11,50,387,535,"who",50,"jan/2021","30-59","Dec/2021 +","360+","yes","no","no",2022-12-02,"symptomatic","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2022-12-02
"2940",352,"Khanam","Test-negative case-control","02Dec2022","AZD1222 (AstraZeneca)","excluded","2","final","<19 weeks","symptomatic disease","symptomatic","Bangladesh",">=18 years","general pop",3,"-129",59,NA,"delta","~36 weeks",NA,NA,"Bangladesh","BGD",352,"BGD",5930,2019,"Bangladesh","South Asia","Lower middle income",2,"Asia",2021-02-07,2022-02-18,2022-07-16,2021-01-27,2021-01-27,11,50,387,535,"who",50,"jan/2021","30-59","Dec/2021 +","360+","yes","no","no",2022-12-02,"symptomatic","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2022-12-02
"2941",352,"Khanam","Test-negative case-control","02Dec2022","AZD1222 (AstraZeneca)","excluded","2","final",">19 weeks","symptomatic disease","symptomatic","Bangladesh",">=18 years","general pop",-35,"-112",14,NA,"delta","~36 weeks",NA,NA,"Bangladesh","BGD",352,"BGD",5930,2019,"Bangladesh","South Asia","Lower middle income",2,"Asia",2021-02-07,2022-02-18,2022-07-16,2021-01-27,2021-01-27,11,50,387,535,"who",50,"jan/2021","30-59","Dec/2021 +","360+","yes","no","no",2022-12-02,"symptomatic","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2022-12-02
"2942",352,"Khanam","Test-negative case-control","02Dec2022","AZD1222 (AstraZeneca)","excluded","2","final","14+","death","death","Bangladesh",">=18 years","general pop",86,"-23",98,NA,"delta","~36 weeks",NA,NA,"Bangladesh","BGD",352,"BGD",5930,2019,"Bangladesh","South Asia","Lower middle income",2,"Asia",2021-02-07,2022-02-18,2022-07-16,2021-01-27,2021-01-27,11,50,387,535,"who",50,"jan/2021","30-59","Dec/2021 +","360+","yes","no","no",2022-12-02,"death","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2022-12-02
"2943",352,"Khanam","Test-negative case-control","02Dec2022","BBIBP-CorV (Beijing CNBG)","excluded","2","final","14+","symptomatic disease","symptomatic","Bangladesh",">=18 years","general pop",29,"-22",58,NA,"delta","~36 weeks",NA,NA,"Bangladesh","BGD",352,"BGD",5930,2019,"Bangladesh","South Asia","Lower middle income",2,"Asia",2021-02-07,2022-02-18,2022-07-16,2021-01-27,2021-01-27,11,50,387,535,"who",50,"jan/2021","30-59","Dec/2021 +","360+","yes","no","no",2022-12-02,"symptomatic","2022 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta",NA,2022-12-02
"2944",352,"Khanam","Test-negative case-control","02Dec2022","BBIBP-CorV (Beijing CNBG)","excluded","2","final","<19 weeks","symptomatic disease","symptomatic","Bangladesh",">=18 years","general pop",34,"-16",62,NA,"delta","~36 weeks",NA,NA,"Bangladesh","BGD",352,"BGD",5930,2019,"Bangladesh","South Asia","Lower middle income",2,"Asia",2021-02-07,2022-02-18,2022-07-16,2021-01-27,2021-01-27,11,50,387,535,"who",50,"jan/2021","30-59","Dec/2021 +","360+","yes","no","no",2022-12-02,"symptomatic","2022 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta",NA,2022-12-02
"2945",352,"Khanam","Test-negative case-control","02Dec2022","BBIBP-CorV (Beijing CNBG)","excluded","2","final",">19 weeks","symptomatic disease","symptomatic","Bangladesh",">=18 years","general pop",-36,"-886",81,NA,"delta","~36 weeks",NA,NA,"Bangladesh","BGD",352,"BGD",5930,2019,"Bangladesh","South Asia","Lower middle income",2,"Asia",2021-02-07,2022-02-18,2022-07-16,2021-01-27,2021-01-27,11,50,387,535,"who",50,"jan/2021","30-59","Dec/2021 +","360+","yes","no","no",2022-12-02,"symptomatic","2022 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta",NA,2022-12-02
"2946",352,"Khanam","Test-negative case-control","02Dec2022","BBIBP-CorV (Beijing CNBG)","excluded","2","final","14+","death","death","Bangladesh",">=18 years","general pop",75,"-124",97,NA,"delta","~36 weeks",NA,NA,"Bangladesh","BGD",352,"BGD",5930,2019,"Bangladesh","South Asia","Lower middle income",2,"Asia",2021-02-07,2022-02-18,2022-07-16,2021-01-27,2021-01-27,11,50,387,535,"who",50,"jan/2021","30-59","Dec/2021 +","360+","yes","no","no",2022-12-02,"death","2022 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta",NA,2022-12-02
"2947",352,"Khanam","Test-negative case-control","02Dec2022","mRNA-1273 (Moderna)","excluded","2","final","14+","symptomatic disease","symptomatic","Bangladesh",">=18 years","general pop",64,"10",86,NA,"delta","~36 weeks",NA,NA,"Bangladesh","BGD",352,"BGD",5930,2019,"Bangladesh","South Asia","Lower middle income",2,"Asia",2021-02-07,2022-02-18,2022-07-16,2021-01-27,2021-01-27,11,50,387,535,"who",50,"jan/2021","30-59","Dec/2021 +","360+","yes","no","no",2022-12-02,"symptomatic","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2022-12-02
"2948",353,"Nittayasoot","Test-negative case-control","12Dec2022","BBIBP-CorV (Beijing CNBG)","included","2","final","14+","pneumonia requiring invasive ventilation","severe","Thailand",">=18 years","general pop",65.8,"39.4",80.7,NA,"delta & omicron BA.1, BA.2","~54 weeks",NA,NA,"Thailand","THA",353,"THA",18070,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,82,240,395,"who",82,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","yes",2022-12-12,"severe","2022 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta/omicron",NA,2022-12-12
"2949",353,"Nittayasoot","Test-negative case-control","12Dec2022","AZD1222 (AstraZeneca)","included","2","final","14+","pneumonia requiring invasive ventilation","severe","Thailand",">=18 years","general pop",58.4,"39.9",71.2,NA,"delta & omicron BA.1, BA.3","~54 weeks",NA,NA,"Thailand","THA",353,"THA",18070,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,82,240,395,"who",82,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","yes",2022-12-12,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta/omicron",NA,2022-12-12
"2950",353,"Nittayasoot","Test-negative case-control","12Dec2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","pneumonia requiring invasive ventilation","severe","Thailand",">=18 years","general pop",71.7,"49.7",84.1,NA,"delta & omicron BA.1, BA.4","~54 weeks",NA,NA,"Thailand","THA",353,"THA",18070,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,82,240,395,"who",82,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","yes",2022-12-12,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta/omicron",NA,2022-12-12
"2951",353,"Nittayasoot","Test-negative case-control","12Dec2022","CoronaVac (Sinovac) & AZD1222 (AstraZeneca) - heterologous","included","2","final","14+","pneumonia requiring invasive ventilation","severe","Thailand",">=18 years","general pop",71.7,"63.2",78.2,NA,"delta & omicron BA.1, BA.5","~54 weeks",NA,NA,"Thailand","THA",353,"THA",18070,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,82,240,395,"who",82,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","yes",2022-12-12,"severe","2022 (Jul-Dec)","Heterologous platforms","Multiple","delta/omicron",NA,2022-12-12
"2952",353,"Nittayasoot","Test-negative case-control","12Dec2022","CoronaVac (Sinovac) & BNT162b2 (Pfizer BioNTech) - heterologous","included","2","final","14+","pneumonia requiring invasive ventilation","severe","Thailand",">=18 years","general pop",79.7,"7.3",95.6,NA,"delta & omicron BA.1, BA.6","~54 weeks",NA,NA,"Thailand","THA",353,"THA",18070,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,82,240,395,"who",82,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","yes",2022-12-12,"severe","2022 (Jul-Dec)","Heterologous platforms","Multiple","delta/omicron",NA,2022-12-12
"2953",353,"Nittayasoot","Test-negative case-control","12Dec2022","AZD1222 (AstraZeneca) & BNT162b2 (Pfizer BioNTech) - heterologous","included","2","final","14+","pneumonia requiring invasive ventilation","severe","Thailand",">=18 years","general pop",83.1,"62.3",92.4,NA,"delta & omicron BA.1, BA.7","~54 weeks",NA,NA,"Thailand","THA",353,"THA",18070,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,82,240,395,"who",82,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","yes",2022-12-12,"severe","2022 (Jul-Dec)","Heterologous platforms","Multiple","delta/omicron",NA,2022-12-12
"2954",354,"Carazo","Test-negative case-control","14Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","hospitalization","severe","Canada",">=60 years",">=60 years",78,"75",80,NA,"omicron BA.1","~60 weeks",NA,NA,"Canada","CAN",354,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-07-14,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","27/12/2022",2022-12-27
"2955",354,"Carazo","Test-negative case-control","14Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7-90","hospitalization","severe","Canada",">=60 years",">=60 years",86,"78",91,NA,"omicron BA.1","~60 weeks",NA,NA,"Canada","CAN",354,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-07-14,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","27/12/2022",2022-12-27
"2956",354,"Carazo","Test-negative case-control","14Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","270-359","hospitalization","severe","Canada",">=60 years",">=60 years",68,"37",84,NA,"omicron BA.1","~60 weeks",NA,NA,"Canada","CAN",354,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-07-14,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","27/12/2022",2022-12-27
"2957",354,"Carazo","Test-negative case-control","14Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","hospitalization","severe","Canada",">=60 years",">=60 years",60,"50",67,NA,"omicron BA.2","~73 weeks",NA,NA,"Canada","CAN",354,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-07-14,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","27/12/2022",2022-12-27
"2958",354,"Carazo","Test-negative case-control","14Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7-90","hospitalization","severe","Canada",">=60 years",">=60 years",66,"28",84,NA,"omicron BA.2","~73 weeks",NA,NA,"Canada","CAN",354,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-07-14,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","27/12/2022",2022-12-27
"2959",354,"Carazo","Test-negative case-control","14Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","360-449","hospitalization","severe","Canada",">=60 years",">=60 years",73,"-13",94,NA,"omicron BA.2","~73 weeks",NA,NA,"Canada","CAN",354,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-07-14,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","27/12/2022",2022-12-27
"2960",354,"Carazo","Test-negative case-control","14Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","hospitalization","severe","Canada",">=60 years",">=60 years",40,"30",49,NA,"omicron BA.4/BA.5","~94 weeks",NA,NA,"Canada","CAN",354,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-07-14,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","27/12/2022",2022-12-27
"2961",354,"Carazo","Test-negative case-control","14Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7-90","hospitalization","severe","Canada",">=60 years",">=60 years",55,"-95",89,NA,"omicron BA.4/BA.5","~94 weeks",NA,NA,"Canada","CAN",354,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-07-14,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","27/12/2022",2022-12-27
"2962",354,"Carazo","Test-negative case-control","14Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","360-449","hospitalization","severe","Canada",">=60 years",">=60 years",47,"35",57,NA,"omicron BA.4/BA.5","~94 weeks",NA,NA,"Canada","CAN",354,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-07-14,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","27/12/2022",2022-12-27
"2963",354,"Carazo","Test-negative case-control","14Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","pre-Omicron prior infection","2","final","7+","hospitalization","severe","Canada",">=60 years",">=60 years",97,"96",99,NA,"omicron BA.1","~60 weeks",NA,NA,"Canada","CAN",354,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-07-14,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","27/12/2022",2022-12-27
"2964",354,"Carazo","Test-negative case-control","14Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","pre-Omicron prior infection","2","final","7+","hospitalization","severe","Canada",">=60 years",">=60 years",92,"86",96,NA,"omicron BA.2","~73 weeks",NA,NA,"Canada","CAN",354,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-07-14,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","27/12/2022",2022-12-27
"2965",354,"Carazo","Test-negative case-control","14Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","Omicron prior infection","2","final","7+","hospitalization","severe","Canada",">=60 years",">=60 years",99,"94",100,NA,"omicron BA.2","~73 weeks",NA,NA,"Canada","CAN",354,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-07-14,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","27/12/2022",2022-12-27
"2966",354,"Carazo","Test-negative case-control","14Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","pre-Omicron prior infection","2","final","7+","hospitalization","severe","Canada",">=60 years",">=60 years",92,"80",97,NA,"omicron BA.4/BA.5","~94 weeks",NA,NA,"Canada","CAN",354,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-07-14,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","27/12/2022",2022-12-27
"2967",354,"Carazo","Test-negative case-control","14Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","Omicron prior infection","2","final","7+","hospitalization","severe","Canada",">=60 years",">=60 years",91,"85",95,NA,"omicron BA.4/BA.5","~94 weeks",NA,NA,"Canada","CAN",354,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-07-14,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","27/12/2022",2022-12-27
"2968",356,"Horne","Retrospective cohort","05Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","21-48","infection","infection","UK","18-39 years","18-39 years",75,"74",76,NA,"alpha, delta, & omicron","~45 weeks",NA,NA,"UK","GBR",356,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-01-05
"2969",356,"Horne","Retrospective cohort","05Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","245-272","infection","infection","UK","18-39 years","18-39 years",-83,"-294",15,NA,"alpha, delta, & omicron","~45 weeks",NA,NA,"UK","GBR",356,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-01-05
"2970",356,"Horne","Retrospective cohort","05Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","21-48","hospitalization","severe","UK","18-39 years","18-39 years",96,"93",97,NA,"alpha, delta, & omicron","~45 weeks",NA,NA,"UK","GBR",356,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-01-05
"2971",356,"Horne","Retrospective cohort","05Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","245-272","hospitalization","severe","UK","18-39 years","18-39 years",-48,"-217",31,NA,"alpha, delta, & omicron","~45 weeks",NA,NA,"UK","GBR",356,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-01-05
"2972",356,"Horne","Retrospective cohort","05Jan2023","AZD1222 (AstraZeneca)","excluded","2","final","21-48","infection","infection","UK","40-64 years","40-64 years",22,"19",25,NA,"alpha, delta, & omicron","~36 weeks",NA,NA,"UK","GBR",356,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"infection","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2023-01-05
"2973",356,"Horne","Retrospective cohort","05Jan2023","AZD1222 (AstraZeneca)","excluded","2","final","301-328","infection","infection","UK","40-64 years","40-64 years",41,"-47",77,NA,"alpha, delta, & omicron","~36 weeks",NA,NA,"UK","GBR",356,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"infection","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2023-01-05
"2974",356,"Horne","Retrospective cohort","05Jan2023","AZD1222 (AstraZeneca)","excluded","2","final","21-48","hospitalization","severe","UK","40-64 years","40-64 years",95,"93",96,NA,"alpha, delta, & omicron","~36 weeks",NA,NA,"UK","GBR",356,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"severe","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2023-01-05
"2975",356,"Horne","Retrospective cohort","05Jan2023","AZD1222 (AstraZeneca)","excluded","2","final","301-328","hospitalization","severe","UK","40-64 years","40-64 years",44,"-41",78,NA,"alpha, delta, & omicron","~36 weeks",NA,NA,"UK","GBR",356,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"severe","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2023-01-05
"2976",356,"Horne","Retrospective cohort","05Jan2023","AZD1222 (AstraZeneca)","excluded","2","final","77-104","death","death","UK","40-64 years","40-64 years",99,"96",100,NA,"alpha, delta, & omicron","~36 weeks",NA,NA,"UK","GBR",356,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"death","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2023-01-05
"2977",356,"Horne","Retrospective cohort","05Jan2023","AZD1222 (AstraZeneca)","excluded","2","final","217-244","death","death","UK","40-64 years","40-64 years",74,"36",89,NA,"alpha, delta, & omicron","~36 weeks",NA,NA,"UK","GBR",356,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"death","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2023-01-05
"2978",356,"Horne","Retrospective cohort","05Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","21-48","infection","infection","UK","18-64 years clinically vulnerable","18-64 years clinically vulnerable",78,"73",82,NA,"alpha, delta, & omicron","~48 weeks",NA,NA,"UK","GBR",356,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-01-05
"2979",356,"Horne","Retrospective cohort","05Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","329-356","infection","infection","UK","18-64 years clinically vulnerable","18-64 years clinically vulnerable",28,"-41",63,NA,"alpha, delta, & omicron","~48 weeks",NA,NA,"UK","GBR",356,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-01-05
"2980",356,"Horne","Retrospective cohort","05Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","21-48","hospitalization","severe","UK","18-64 years clinically vulnerable","18-64 years clinically vulnerable",97,"92",99,NA,"alpha, delta, & omicron","~48 weeks",NA,NA,"UK","GBR",356,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-01-05
"2981",356,"Horne","Retrospective cohort","05Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","329-356","hospitalization","severe","UK","18-64 years clinically vulnerable","18-64 years clinically vulnerable",28,"-38",62,NA,"alpha, delta, & omicron","~48 weeks",NA,NA,"UK","GBR",356,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-01-05
"2982",356,"Horne","Retrospective cohort","05Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","105-132","death","death","UK","18-64 years clinically vulnerable","18-64 years clinically vulnerable",96,"92",98,NA,"alpha, delta, & omicron","~48 weeks",NA,NA,"UK","GBR",356,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"death","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-01-05
"2983",356,"Horne","Retrospective cohort","05Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","245-272","death","death","UK","18-64 years clinically vulnerable","18-64 years clinically vulnerable",37,"-36",70,NA,"alpha, delta, & omicron","~48 weeks",NA,NA,"UK","GBR",356,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"death","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-01-05
"2984",356,"Horne","Retrospective cohort","05Jan2023","AZD1222 (AstraZeneca)","excluded","2","final","21-48","infection","infection","UK","18-64 years clinically vulnerable","18-64 years clinically vulnerable",26,"20",33,NA,"alpha, delta, & omicron","~48 weeks",NA,NA,"UK","GBR",356,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"infection","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2023-01-05
"2985",356,"Horne","Retrospective cohort","05Jan2023","AZD1222 (AstraZeneca)","excluded","2","final","329-356","infection","infection","UK","18-64 years clinically vulnerable","18-64 years clinically vulnerable",14,"-42",48,NA,"alpha, delta, & omicron","~48 weeks",NA,NA,"UK","GBR",356,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"infection","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2023-01-05
"2986",356,"Horne","Retrospective cohort","05Jan2023","AZD1222 (AstraZeneca)","excluded","2","final","21-48","hospitalization","severe","UK","18-64 years clinically vulnerable","18-64 years clinically vulnerable",93,"89",96,NA,"alpha, delta, & omicron","~48 weeks",NA,NA,"UK","GBR",356,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"severe","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2023-01-05
"2987",356,"Horne","Retrospective cohort","05Jan2023","AZD1222 (AstraZeneca)","excluded","2","final","329-356","hospitalization","severe","UK","18-64 years clinically vulnerable","18-64 years clinically vulnerable",21,"-30",52,NA,"alpha, delta, & omicron","~48 weeks",NA,NA,"UK","GBR",356,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"severe","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2023-01-05
"2988",356,"Horne","Retrospective cohort","05Jan2023","AZD1222 (AstraZeneca)","excluded","2","final","49-76","death","death","UK","18-64 years clinically vulnerable","18-64 years clinically vulnerable",96,"87",99,NA,"alpha, delta, & omicron","~48 weeks",NA,NA,"UK","GBR",356,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"death","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2023-01-05
"2989",356,"Horne","Retrospective cohort","05Jan2023","AZD1222 (AstraZeneca)","excluded","2","final","301-328","death","death","UK","18-64 years clinically vulnerable","18-64 years clinically vulnerable",50,"-125",89,NA,"alpha, delta, & omicron","~48 weeks",NA,NA,"UK","GBR",356,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"death","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2023-01-05
"2990",356,"Horne","Retrospective cohort","05Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","21-48","infection","infection","UK",">=65 years",">=65 years",77,"67",84,NA,"alpha, delta, & omicron","~48 weeks",NA,NA,"UK","GBR",356,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-01-05
"2991",356,"Horne","Retrospective cohort","05Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","329-356","infection","infection","UK",">=65 years",">=65 years",4,"-30",29,NA,"alpha, delta, & omicron","~48 weeks",NA,NA,"UK","GBR",356,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-01-05
"2992",356,"Horne","Retrospective cohort","05Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","21-48","hospitalization","severe","UK",">=65 years",">=65 years",92,"86",95,NA,"alpha, delta, & omicron","~48 weeks",NA,NA,"UK","GBR",356,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-01-05
"2993",356,"Horne","Retrospective cohort","05Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","329-356","hospitalization","severe","UK",">=65 years",">=65 years",2,"-34",27,NA,"alpha, delta, & omicron","~48 weeks",NA,NA,"UK","GBR",356,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-01-05
"2994",356,"Horne","Retrospective cohort","05Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","21-48","death","death","UK",">=65 years",">=65 years",97,"92",99,NA,"alpha, delta, & omicron","~48 weeks",NA,NA,"UK","GBR",356,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"death","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-01-05
"2995",356,"Horne","Retrospective cohort","05Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","329-356","death","death","UK",">=65 years",">=65 years",33,"-49",70,NA,"alpha, delta, & omicron","~48 weeks",NA,NA,"UK","GBR",356,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"death","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-01-05
"2996",356,"Horne","Retrospective cohort","05Jan2023","AZD1222 (AstraZeneca)","excluded","2","final","21-48","infection","infection","UK",">=65 years",">=65 years",47,"29",61,NA,"alpha, delta, & omicron","~48 weeks",NA,NA,"UK","GBR",356,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"infection","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2023-01-05
"2997",356,"Horne","Retrospective cohort","05Jan2023","AZD1222 (AstraZeneca)","excluded","2","final","329-356","infection","infection","UK",">=65 years",">=65 years",-12,"-54",18,NA,"alpha, delta, & omicron","~48 weeks",NA,NA,"UK","GBR",356,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"infection","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2023-01-05
"2998",356,"Horne","Retrospective cohort","05Jan2023","AZD1222 (AstraZeneca)","excluded","2","final","21-48","hospitalization","severe","UK",">=65 years",">=65 years",86,"75",92,NA,"alpha, delta, & omicron","~48 weeks",NA,NA,"UK","GBR",356,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"severe","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2023-01-05
"2999",356,"Horne","Retrospective cohort","05Jan2023","AZD1222 (AstraZeneca)","excluded","2","final","329-356","hospitalization","severe","UK",">=65 years",">=65 years",-12,"-53",18,NA,"alpha, delta, & omicron","~48 weeks",NA,NA,"UK","GBR",356,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"severe","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2023-01-05
"3000",356,"Horne","Retrospective cohort","05Jan2023","AZD1222 (AstraZeneca)","excluded","2","final","49-76","death","death","UK",">=65 years",">=65 years",93,"84",97,NA,"alpha, delta, & omicron","~48 weeks",NA,NA,"UK","GBR",356,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"death","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2023-01-05
"3001",356,"Horne","Retrospective cohort","05Jan2023","AZD1222 (AstraZeneca)","excluded","2","final","329-356","death","death","UK",">=65 years",">=65 years",23,"-82",68,NA,"alpha, delta, & omicron","~48 weeks",NA,NA,"UK","GBR",356,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"death","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2023-01-05
"3002",357,"Lewis","Test-negative case-control","31Dec2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","150+","hospitalization","severe","USA",">=18 years","general pop",46,"30",58,NA,"omicron BA.1/BA.2","~63 weeks",NA,NA,"USA","USA",357,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-12-31,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-12-31
"3003",357,"Lewis","Test-negative case-control","31Dec2022","Ad26.COV2.S (Janssen)","included","1","final","60+","hospitalization","severe","USA",">=18 years","general pop",36,"-4",60,NA,"omicron BA.1/BA.2","~55 weeks",NA,NA,"USA","USA",357,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-12-31,"severe","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","omicron",NA,2022-12-31
"3004",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-149","ED or UC visit","symptomatic","USA",">=18 years, Social Vulnerability Index Quartile 1",">=18 years, Social Vulnerability Index Quartile 1",47,"40",53,NA,"omicron BA.1","~62 weeks",NA,NA,"USA","USA",358,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-01-06,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-01-06
"3005",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","150+","ED or UC visit","symptomatic","USA",">=18 years, Social Vulnerability Index Quartile 1",">=18 years, Social Vulnerability Index Quartile 1",35,"31",40,NA,"omicron BA.1","~62 weeks",NA,NA,"USA","USA",358,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-01-06,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-01-06
"3006",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-149","hospitalization","severe","USA",">=18 years, Social Vulnerability Index Quartile 1",">=18 years, Social Vulnerability Index Quartile 1",59,"39",72,NA,"omicron BA.1","~62 weeks",NA,NA,"USA","USA",358,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-01-06,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-01-06
"3007",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","150+","hospitalization","severe","USA",">=18 years, Social Vulnerability Index Quartile 1",">=18 years, Social Vulnerability Index Quartile 1",58,"51",65,NA,"omicron BA.1","~62 weeks",NA,NA,"USA","USA",358,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-01-06,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-01-06
"3008",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-149","ED or UC visit","symptomatic","USA",">=18 years, Social Vulnerability Index Quartile 2",">=18 years, Social Vulnerability Index Quartile 2",42,"33",49,NA,"omicron BA.1","~62 weeks",NA,NA,"USA","USA",358,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-01-06,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-01-06
"3009",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","150+","ED or UC visit","symptomatic","USA",">=18 years, Social Vulnerability Index Quartile 2",">=18 years, Social Vulnerability Index Quartile 2",37,"32",41,NA,"omicron BA.1","~62 weeks",NA,NA,"USA","USA",358,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-01-06,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-01-06
"3010",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-149","hospitalization","severe","USA",">=18 years, Social Vulnerability Index Quartile 2",">=18 years, Social Vulnerability Index Quartile 2",65,"48",76,NA,"omicron BA.1","~62 weeks",NA,NA,"USA","USA",358,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-01-06,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-01-06
"3011",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","150+","hospitalization","severe","USA",">=18 years, Social Vulnerability Index Quartile 2",">=18 years, Social Vulnerability Index Quartile 2",57,"49",64,NA,"omicron BA.1","~62 weeks",NA,NA,"USA","USA",358,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-01-06,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-01-06
"3012",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-149","ED or UC visit","symptomatic","USA",">=18 years, Social Vulnerability Index Quartile 3",">=18 years, Social Vulnerability Index Quartile 3",54,"47",61,NA,"omicron BA.1","~62 weeks",NA,NA,"USA","USA",358,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-01-06,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-01-06
"3013",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","150+","ED or UC visit","symptomatic","USA",">=18 years, Social Vulnerability Index Quartile 3",">=18 years, Social Vulnerability Index Quartile 3",31,"25",36,NA,"omicron BA.1","~62 weeks",NA,NA,"USA","USA",358,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-01-06,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-01-06
"3014",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-149","hospitalization","severe","USA",">=18 years, Social Vulnerability Index Quartile 3",">=18 years, Social Vulnerability Index Quartile 3",62,"45",74,NA,"omicron BA.1","~62 weeks",NA,NA,"USA","USA",358,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-01-06,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-01-06
"3015",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","150+","hospitalization","severe","USA",">=18 years, Social Vulnerability Index Quartile 3",">=18 years, Social Vulnerability Index Quartile 3",55,"47",63,NA,"omicron BA.1","~62 weeks",NA,NA,"USA","USA",358,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-01-06,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-01-06
"3016",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-149","ED or UC visit","symptomatic","USA",">=18 years, Social Vulnerability Index Quartile 4",">=18 years, Social Vulnerability Index Quartile 4",51,"43",58,NA,"omicron BA.1","~62 weeks",NA,NA,"USA","USA",358,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-01-06,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-01-06
"3017",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","150+","ED or UC visit","symptomatic","USA",">=18 years, Social Vulnerability Index Quartile 4",">=18 years, Social Vulnerability Index Quartile 4",27,"20",33,NA,"omicron BA.1","~62 weeks",NA,NA,"USA","USA",358,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-01-06,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-01-06
"3018",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-149","hospitalization","severe","USA",">=18 years, Social Vulnerability Index Quartile 4",">=18 years, Social Vulnerability Index Quartile 4",63,"43",75,NA,"omicron BA.1","~62 weeks",NA,NA,"USA","USA",358,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-01-06,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-01-06
"3019",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","150+","hospitalization","severe","USA",">=18 years, Social Vulnerability Index Quartile 4",">=18 years, Social Vulnerability Index Quartile 4",43,"32",52,NA,"omicron BA.1","~62 weeks",NA,NA,"USA","USA",358,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-01-06,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-01-06
"3020",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-149","ED or UC visit","symptomatic","USA",">=18 years, Social Vulnerability Index Quartile 1",">=18 years, Social Vulnerability Index Quartile 1",87,"84",89,NA,"delta","~48.5 weeks",NA,NA,"USA","USA",358,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-01-06,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2023-01-06
"3021",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","150+","ED or UC visit","symptomatic","USA",">=18 years, Social Vulnerability Index Quartile 1",">=18 years, Social Vulnerability Index Quartile 1",81,"79",82,NA,"delta","~48.5 weeks",NA,NA,"USA","USA",358,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-01-06,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2023-01-06
"3022",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-149","hospitalization","severe","USA",">=18 years, Social Vulnerability Index Quartile 1",">=18 years, Social Vulnerability Index Quartile 1",90,"84",94,NA,"delta","~48.5 weeks",NA,NA,"USA","USA",358,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-01-06,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2023-01-06
"3023",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","150+","hospitalization","severe","USA",">=18 years, Social Vulnerability Index Quartile 1",">=18 years, Social Vulnerability Index Quartile 1",85,"82",87,NA,"delta","~48.5 weeks",NA,NA,"USA","USA",358,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-01-06,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2023-01-06
"3024",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-149","ED or UC visit","symptomatic","USA",">=18 years, Social Vulnerability Index Quartile 2",">=18 years, Social Vulnerability Index Quartile 2",85,"81",88,NA,"delta","~48.5 weeks",NA,NA,"USA","USA",358,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-01-06,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2023-01-06
"3025",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","150+","ED or UC visit","symptomatic","USA",">=18 years, Social Vulnerability Index Quartile 2",">=18 years, Social Vulnerability Index Quartile 2",80,"77",81,NA,"delta","~48.5 weeks",NA,NA,"USA","USA",358,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-01-06,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2023-01-06
"3026",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-149","hospitalization","severe","USA",">=18 years, Social Vulnerability Index Quartile 2",">=18 years, Social Vulnerability Index Quartile 2",91,"85",95,NA,"delta","~48.5 weeks",NA,NA,"USA","USA",358,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-01-06,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2023-01-06
"3027",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","150+","hospitalization","severe","USA",">=18 years, Social Vulnerability Index Quartile 2",">=18 years, Social Vulnerability Index Quartile 2",86,"83",88,NA,"delta","~48.5 weeks",NA,NA,"USA","USA",358,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-01-06,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2023-01-06
"3028",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-149","ED or UC visit","symptomatic","USA",">=18 years, Social Vulnerability Index Quartile 3",">=18 years, Social Vulnerability Index Quartile 3",89,"85",91,NA,"delta","~48.5 weeks",NA,NA,"USA","USA",358,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-01-06,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2023-01-06
"3029",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","150+","ED or UC visit","symptomatic","USA",">=18 years, Social Vulnerability Index Quartile 3",">=18 years, Social Vulnerability Index Quartile 3",74,"71",77,NA,"delta","~48.5 weeks",NA,NA,"USA","USA",358,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-01-06,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2023-01-06
"3030",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-149","hospitalization","severe","USA",">=18 years, Social Vulnerability Index Quartile 3",">=18 years, Social Vulnerability Index Quartile 3",94,"88",97,NA,"delta","~48.5 weeks",NA,NA,"USA","USA",358,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-01-06,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2023-01-06
"3031",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","150+","hospitalization","severe","USA",">=18 years, Social Vulnerability Index Quartile 3",">=18 years, Social Vulnerability Index Quartile 3",82,"78",85,NA,"delta","~48.5 weeks",NA,NA,"USA","USA",358,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-01-06,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2023-01-06
"3032",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-149","ED or UC visit","symptomatic","USA",">=18 years, Social Vulnerability Index Quartile 4",">=18 years, Social Vulnerability Index Quartile 4",84,"79",87,NA,"delta","~48.5 weeks",NA,NA,"USA","USA",358,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-01-06,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2023-01-06
"3033",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","150+","ED or UC visit","symptomatic","USA",">=18 years, Social Vulnerability Index Quartile 4",">=18 years, Social Vulnerability Index Quartile 4",75,"72",78,NA,"delta","~48.5 weeks",NA,NA,"USA","USA",358,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-01-06,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2023-01-06
"3034",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-149","hospitalization","severe","USA",">=18 years, Social Vulnerability Index Quartile 4",">=18 years, Social Vulnerability Index Quartile 4",90,"83",94,NA,"delta","~48.5 weeks",NA,NA,"USA","USA",358,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-01-06,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2023-01-06
"3035",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","150+","hospitalization","severe","USA",">=18 years, Social Vulnerability Index Quartile 4",">=18 years, Social Vulnerability Index Quartile 4",84,"80",87,NA,"delta","~48.5 weeks",NA,NA,"USA","USA",358,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-01-06,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2023-01-06
"3036",359,"Jang","Retrospective cohort","09Jan2023","BNT162b2 (Pfizer BioNTech)","unknown","2","final","15-30","infection","infection","South Korea","5-11 years","5-11 years",57.6,"51.6",62.8,NA,"omicron","~11 weeks",NA,NA,"South Korea","KOR",359,"KOR",43780,2019,"Korea, Rep.","East Asia & Pacific","High income",4,"Asia",2021-02-26,2021-09-15,2021-10-25,2021-02-26,2021-02-26,0,80,201,241,"equal",80,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","yes",2023-01-09,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-01-09
"3037",359,"Jang","Retrospective cohort","09Jan2023","BNT162b2 (Pfizer BioNTech)","unknown","2","final","31-60","infection","infection","South Korea","5-11 years","5-11 years",46.9,"43.7",49.9,NA,"omicron","~11 weeks",NA,NA,"South Korea","KOR",359,"KOR",43780,2019,"Korea, Rep.","East Asia & Pacific","High income",4,"Asia",2021-02-26,2021-09-15,2021-10-25,2021-02-26,2021-02-26,0,80,201,241,"equal",80,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","yes",2023-01-09,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-01-09
"3038",359,"Jang","Retrospective cohort","09Jan2023","BNT162b2 (Pfizer BioNTech)","unknown","2","final","61-90","infection","infection","South Korea","5-11 years","5-11 years",41.2,"34.3",47.4,NA,"omicron","~11 weeks",NA,NA,"South Korea","KOR",359,"KOR",43780,2019,"Korea, Rep.","East Asia & Pacific","High income",4,"Asia",2021-02-26,2021-09-15,2021-10-25,2021-02-26,2021-02-26,0,80,201,241,"equal",80,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","yes",2023-01-09,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-01-09
"3039",359,"Jang","Retrospective cohort","09Jan2023","BNT162b2 (Pfizer BioNTech)","unknown","2","final","15-30","ICU admission or death","severe","South Korea","5-11 years","5-11 years",100,"100",100,NA,"omicron","~11 weeks",NA,NA,"South Korea","KOR",359,"KOR",43780,2019,"Korea, Rep.","East Asia & Pacific","High income",4,"Asia",2021-02-26,2021-09-15,2021-10-25,2021-02-26,2021-02-26,0,80,201,241,"equal",80,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","yes",2023-01-09,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-01-09
"3040",359,"Jang","Retrospective cohort","09Jan2023","BNT162b2 (Pfizer BioNTech)","unknown","2","final","31-60","ICU admission or death","severe","South Korea","5-11 years","5-11 years",100,"100",100,NA,"omicron","~11 weeks",NA,NA,"South Korea","KOR",359,"KOR",43780,2019,"Korea, Rep.","East Asia & Pacific","High income",4,"Asia",2021-02-26,2021-09-15,2021-10-25,2021-02-26,2021-02-26,0,80,201,241,"equal",80,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","yes",2023-01-09,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-01-09
"3041",359,"Jang","Retrospective cohort","09Jan2023","BNT162b2 (Pfizer BioNTech)","unknown","2","final","61-90","ICU admission or death","severe","South Korea","5-11 years","5-11 years",100,"100",100,NA,"omicron","~11 weeks",NA,NA,"South Korea","KOR",359,"KOR",43780,2019,"Korea, Rep.","East Asia & Pacific","High income",4,"Asia",2021-02-26,2021-09-15,2021-10-25,2021-02-26,2021-02-26,0,80,201,241,"equal",80,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","yes",2023-01-09,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-01-09
"3042",360,"Peebles","Retrospective cohort","10Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","USA","LTCF staff <65 years","LTCF staff <65 years",80,"67.6",87.7,NA,"non-VOC & alpha","~17 weeks",NA,NA,"USA","USA",360,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-01-10,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-01-10
"3043",360,"Peebles","Retrospective cohort","10Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease","symptomatic","USA","LTCF staff <65 years","LTCF staff <65 years",87.5,"69.4",94.9,NA,"non-VOC & alpha","~17 weeks",NA,NA,"USA","USA",360,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-01-10,"symptomatic","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-01-10
"3044",360,"Peebles","Retrospective cohort","10Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","asymptomatic infection","asymptomatic","USA","LTCF staff <65 years","LTCF staff <65 years",68.9,"36",84.9,NA,"non-VOC & alpha","~17 weeks",NA,NA,"USA","USA",360,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-01-10,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-01-10
"3045",361,"Tartof","Test-negative case-control","11Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","symptomatic disease","symptomatic","USA",">=18 years","general pop",-53,"-205",23,NA,"omicron","~64.5 weeks",NA,NA,"USA","USA",361,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-01-11,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-01-11
"3046",361,"Tartof","Test-negative case-control","11Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","prior infection only","2","final","14+","symptomatic disease","symptomatic","USA",">=18 years","general pop",45,"-4",70,NA,"omicron","~64.5 weeks",NA,NA,"USA","USA",361,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-01-11,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-01-11
"3047",361,"Tartof","Test-negative case-control","11Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","symptomatic disease","symptomatic","USA",">=18 years","general pop",70,"11",90,NA,"delta","~46.5 weeks",NA,NA,"USA","USA",361,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-01-11,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2023-01-11
"3048",361,"Tartof","Test-negative case-control","11Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","prior infection only","2","final","14+","symptomatic disease","symptomatic","USA",">=18 years","general pop",23,"-225",82,NA,"delta","~46.5 weeks",NA,NA,"USA","USA",361,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-01-11,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2023-01-11
"3049",361,"Tartof","Test-negative case-control","11Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","symptomatic disease","symptomatic","USA",">=18 years","general pop",17,"-40",51,NA,"omicron or delta","~64.5 weeks",NA,NA,"USA","USA",361,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-01-11,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta/omicron",NA,2023-01-11
"3050",361,"Tartof","Test-negative case-control","11Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","prior infection only","2","final","14+","symptomatic disease","symptomatic","USA",">=18 years","general pop",42,"-1",66,NA,"omicron or delta","~64.5 weeks",NA,NA,"USA","USA",361,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-01-11,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta/omicron",NA,2023-01-11
"3051",363,"Alkadi","Test-negative case-control","26Dec2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","infection","infection","Qatar",">=18 years on chronic hemodialysis",">=18 years on chronic hemodialysis",94.3,"89",97,NA,"non-VOC, alpha, & delta","~48 weeks",NA,NA,"Qatar","QAT",363,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2022-12-26,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-12-26
"3052",363,"Alkadi","Test-negative case-control","26Dec2022","mRNA-1273 (Moderna)","unknown","2","final","14+","infection","infection","Qatar",">=18 years on chronic hemodialysis",">=18 years on chronic hemodialysis",98.2,"88.6",99.9,NA,"non-VOC, alpha, & delta","~40 weeks",NA,NA,"Qatar","QAT",363,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2022-12-26,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-12-26
"3053",364,"Heidarzadeh","Test-negative case-control","23Dec2022","AZD1222 (AstraZeneca)","included","2","final","31-60","hospitalization (moderate)","severe","Iran",">=5 years","general pop",97,"75",99.5,NA,"alpha & delta","~23 weeks",NA,NA,"Iran","IRN",364,"IRN",14710,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",3,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,63,266,NA,"who",63,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-12-23
"3054",364,"Heidarzadeh","Test-negative case-control","23Dec2022","AZD1222 (AstraZeneca)","included","2","final","91-120","hospitalization (moderate)","severe","Iran",">=5 years","general pop",93,"69",99,NA,"alpha & delta","~23 weeks",NA,NA,"Iran","IRN",364,"IRN",14710,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",3,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,63,266,NA,"who",63,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-12-23
"3055",364,"Heidarzadeh","Test-negative case-control","23Dec2022","AZD1222 (AstraZeneca)","included","2","final","31-60","hospitalization (severe)","severe","Iran",">=5 years","general pop",87,"80",92,NA,"alpha & delta","~23 weeks",NA,NA,"Iran","IRN",364,"IRN",14710,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",3,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,63,266,NA,"who",63,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-12-23
"3056",364,"Heidarzadeh","Test-negative case-control","23Dec2022","AZD1222 (AstraZeneca)","included","2","final","151+","hospitalization (severe)","severe","Iran",">=5 years","general pop",90,"51",98,NA,"alpha & delta","~23 weeks",NA,NA,"Iran","IRN",364,"IRN",14710,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",3,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,63,266,NA,"who",63,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-12-23
"3057",364,"Heidarzadeh","Test-negative case-control","23Dec2022","AZD1222 (AstraZeneca)","included","2","final","31-60","ICU admission","severe","Iran",">=5 years","general pop",57,"-41",87,NA,"alpha & delta","~23 weeks",NA,NA,"Iran","IRN",364,"IRN",14710,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",3,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,63,266,NA,"who",63,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-12-23
"3058",364,"Heidarzadeh","Test-negative case-control","23Dec2022","AZD1222 (AstraZeneca)","included","2","final","91-120","ICU admission","severe","Iran",">=5 years","general pop",12,"-113",63,NA,"alpha & delta","~23 weeks",NA,NA,"Iran","IRN",364,"IRN",14710,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",3,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,63,266,NA,"who",63,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-12-23
"3059",364,"Heidarzadeh","Test-negative case-control","23Dec2022","AZD1222 (AstraZeneca)","included","2","final","31-60","death","death","Iran",">=5 years","general pop",80,"48",92,NA,"alpha & delta","~23 weeks",NA,NA,"Iran","IRN",364,"IRN",14710,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",3,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,63,266,NA,"who",63,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"death","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-12-23
"3060",364,"Heidarzadeh","Test-negative case-control","23Dec2022","AZD1222 (AstraZeneca)","included","2","final","121-150","death","death","Iran",">=5 years","general pop",92,"48",99,NA,"alpha & delta","~23 weeks",NA,NA,"Iran","IRN",364,"IRN",14710,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",3,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,63,266,NA,"who",63,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"death","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-12-23
"3061",364,"Heidarzadeh","Test-negative case-control","23Dec2022","BBIBP-CorV (Beijing CNBG)","included","2","final","31-60","hospitalization (moderate)","severe","Iran",">=5 years","general pop",78,"69",84,NA,"alpha & delta","~36 weeks",NA,NA,"Iran","IRN",364,"IRN",14710,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",3,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,63,266,NA,"who",63,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"severe","2022 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","other combinations",NA,2022-12-23
"3062",364,"Heidarzadeh","Test-negative case-control","23Dec2022","BBIBP-CorV (Beijing CNBG)","included","2","final","151+","hospitalization (moderate)","severe","Iran",">=5 years","general pop",95,"67",99.4,NA,"alpha & delta","~36 weeks",NA,NA,"Iran","IRN",364,"IRN",14710,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",3,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,63,266,NA,"who",63,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"severe","2022 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","other combinations",NA,2022-12-23
"3063",364,"Heidarzadeh","Test-negative case-control","23Dec2022","BBIBP-CorV (Beijing CNBG)","included","2","final","31-60","hospitalization (severe)","severe","Iran",">=5 years","general pop",71,"68",75,NA,"alpha & delta","~36 weeks",NA,NA,"Iran","IRN",364,"IRN",14710,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",3,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,63,266,NA,"who",63,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"severe","2022 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","other combinations",NA,2022-12-23
"3064",364,"Heidarzadeh","Test-negative case-control","23Dec2022","BBIBP-CorV (Beijing CNBG)","included","2","final","151+","hospitalization (severe)","severe","Iran",">=5 years","general pop",85,"77",91,NA,"alpha & delta","~36 weeks",NA,NA,"Iran","IRN",364,"IRN",14710,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",3,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,63,266,NA,"who",63,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"severe","2022 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","other combinations",NA,2022-12-23
"3065",364,"Heidarzadeh","Test-negative case-control","23Dec2022","BBIBP-CorV (Beijing CNBG)","included","2","final","31-60","ICU admission","severe","Iran",">=5 years","general pop",25,"-9",48,NA,"alpha & delta","~36 weeks",NA,NA,"Iran","IRN",364,"IRN",14710,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",3,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,63,266,NA,"who",63,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"severe","2022 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","other combinations",NA,2022-12-23
"3066",364,"Heidarzadeh","Test-negative case-control","23Dec2022","BBIBP-CorV (Beijing CNBG)","included","2","final","151+","ICU admission","severe","Iran",">=5 years","general pop",26,"-77",69,NA,"alpha & delta","~36 weeks",NA,NA,"Iran","IRN",364,"IRN",14710,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",3,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,63,266,NA,"who",63,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"severe","2022 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","other combinations",NA,2022-12-23
"3067",364,"Heidarzadeh","Test-negative case-control","23Dec2022","BBIBP-CorV (Beijing CNBG)","included","2","final","31-60","death","death","Iran",">=5 years","general pop",41,"23",55,NA,"alpha & delta","~36 weeks",NA,NA,"Iran","IRN",364,"IRN",14710,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",3,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,63,266,NA,"who",63,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"death","2022 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","other combinations",NA,2022-12-23
"3068",364,"Heidarzadeh","Test-negative case-control","23Dec2022","BBIBP-CorV (Beijing CNBG)","included","2","final","151+","death","death","Iran",">=5 years","general pop",33,"-40",69,NA,"alpha & delta","~36 weeks",NA,NA,"Iran","IRN",364,"IRN",14710,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",3,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,63,266,NA,"who",63,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"death","2022 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","other combinations",NA,2022-12-23
"3069",364,"Heidarzadeh","Test-negative case-control","23Dec2022","BIV1-CovIran","included","2","final","31-60","hospitalization (moderate)","severe","Iran",">=5 years","general pop",96,"68",99.4,NA,"alpha & delta","~21 weeks",NA,NA,"Iran","IRN",364,"IRN",14710,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",3,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,63,266,NA,"who",63,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"severe","2022 (Jul-Dec)","Shifa Pharmed COVIran","Inactivated","other combinations",NA,2022-12-23
"3070",364,"Heidarzadeh","Test-negative case-control","23Dec2022","BIV1-CovIran","included","2","final","61-90","hospitalization (moderate)","severe","Iran",">=5 years","general pop",97,"76",99.6,NA,"alpha & delta","~21 weeks",NA,NA,"Iran","IRN",364,"IRN",14710,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",3,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,63,266,NA,"who",63,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"severe","2022 (Jul-Dec)","Shifa Pharmed COVIran","Inactivated","other combinations",NA,2022-12-23
"3071",364,"Heidarzadeh","Test-negative case-control","23Dec2022","BIV1-CovIran","included","2","final","31-60","hospitalization (severe)","severe","Iran",">=5 years","general pop",82,"73",88,NA,"alpha & delta","~21 weeks",NA,NA,"Iran","IRN",364,"IRN",14710,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",3,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,63,266,NA,"who",63,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"severe","2022 (Jul-Dec)","Shifa Pharmed COVIran","Inactivated","other combinations",NA,2022-12-23
"3072",364,"Heidarzadeh","Test-negative case-control","23Dec2022","BIV1-CovIran","included","2","final","91-120","hospitalization (severe)","severe","Iran",">=5 years","general pop",92,"86",96,NA,"alpha & delta","~21 weeks",NA,NA,"Iran","IRN",364,"IRN",14710,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",3,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,63,266,NA,"who",63,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"severe","2022 (Jul-Dec)","Shifa Pharmed COVIran","Inactivated","other combinations",NA,2022-12-23
"3073",364,"Heidarzadeh","Test-negative case-control","23Dec2022","BIV1-CovIran","included","2","final","31-60","ICU admission","severe","Iran",">=5 years","general pop",61,"-61",91,NA,"alpha & delta","~21 weeks",NA,NA,"Iran","IRN",364,"IRN",14710,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",3,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,63,266,NA,"who",63,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"severe","2022 (Jul-Dec)","Shifa Pharmed COVIran","Inactivated","other combinations",NA,2022-12-23
"3074",364,"Heidarzadeh","Test-negative case-control","23Dec2022","BIV1-CovIran","included","2","final","91-120","ICU admission","severe","Iran",">=5 years","general pop",35,"-116",80,NA,"alpha & delta","~21 weeks",NA,NA,"Iran","IRN",364,"IRN",14710,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",3,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,63,266,NA,"who",63,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"severe","2022 (Jul-Dec)","Shifa Pharmed COVIran","Inactivated","other combinations",NA,2022-12-23
"3075",364,"Heidarzadeh","Test-negative case-control","23Dec2022","BIV1-CovIran","included","2","final","31-60","death","death","Iran",">=5 years","general pop",88,"48",97,NA,"alpha & delta","~21 weeks",NA,NA,"Iran","IRN",364,"IRN",14710,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",3,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,63,266,NA,"who",63,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"death","2022 (Jul-Dec)","Shifa Pharmed COVIran","Inactivated","other combinations",NA,2022-12-23
"3076",364,"Heidarzadeh","Test-negative case-control","23Dec2022","BIV1-CovIran","included","2","final","91-120","death","death","Iran",">=5 years","general pop",93,"46",99,NA,"alpha & delta","~21 weeks",NA,NA,"Iran","IRN",364,"IRN",14710,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",3,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,63,266,NA,"who",63,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"death","2022 (Jul-Dec)","Shifa Pharmed COVIran","Inactivated","other combinations",NA,2022-12-23
"3077",364,"Heidarzadeh","Test-negative case-control","23Dec2022","BBV152 (Bharat)","included","2","final","61-90","hospitalization (severe)","severe","Iran",">=5 years","general pop",55,"-33",85,NA,"alpha & delta","~35 weeks",NA,NA,"Iran","IRN",364,"IRN",14710,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",3,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,63,266,NA,"who",63,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"severe","2022 (Jul-Dec)","Bharat Covaxin/BBV152","Inactivated","other combinations",NA,2022-12-23
"3078",364,"Heidarzadeh","Test-negative case-control","23Dec2022","BBV152 (Bharat)","included","2","final","151+","hospitalization (severe)","severe","Iran",">=5 years","general pop",96,"68",99.5,NA,"alpha & delta","~35 weeks",NA,NA,"Iran","IRN",364,"IRN",14710,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",3,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,63,266,NA,"who",63,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"severe","2022 (Jul-Dec)","Bharat Covaxin/BBV152","Inactivated","other combinations",NA,2022-12-23
"3079",364,"Heidarzadeh","Test-negative case-control","23Dec2022","BBV152 (Bharat)","included","2","final","91-120","death","death","Iran",">=5 years","general pop",4,"-671",79,NA,"alpha & delta","~35 weeks",NA,NA,"Iran","IRN",364,"IRN",14710,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",3,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,63,266,NA,"who",63,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"death","2022 (Jul-Dec)","Bharat Covaxin/BBV152","Inactivated","other combinations",NA,2022-12-23
"3080",364,"Heidarzadeh","Test-negative case-control","23Dec2022","Gam-COVID-Vac (Gamaleya)","included","2","final","31-60","hospitalization (moderate)","severe","Iran",">=5 years","general pop",74,"-9",94,NA,"alpha & delta","~40 weeks",NA,NA,"Iran","IRN",364,"IRN",14710,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",3,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,63,266,NA,"who",63,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"severe","2022 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","other combinations",NA,2022-12-23
"3081",364,"Heidarzadeh","Test-negative case-control","23Dec2022","Gam-COVID-Vac (Gamaleya)","included","2","final","151+","hospitalization (moderate)","severe","Iran",">=5 years","general pop",95,"79",99,NA,"alpha & delta","~40 weeks",NA,NA,"Iran","IRN",364,"IRN",14710,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",3,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,63,266,NA,"who",63,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"severe","2022 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","other combinations",NA,2022-12-23
"3082",364,"Heidarzadeh","Test-negative case-control","23Dec2022","Gam-COVID-Vac (Gamaleya)","included","2","final","31-60","hospitalization (severe)","severe","Iran",">=5 years","general pop",62,"32",78,NA,"alpha & delta","~40 weeks",NA,NA,"Iran","IRN",364,"IRN",14710,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",3,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,63,266,NA,"who",63,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"severe","2022 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","other combinations",NA,2022-12-23
"3083",364,"Heidarzadeh","Test-negative case-control","23Dec2022","Gam-COVID-Vac (Gamaleya)","included","2","final","151+","hospitalization (severe)","severe","Iran",">=5 years","general pop",93,"88",96,NA,"alpha & delta","~40 weeks",NA,NA,"Iran","IRN",364,"IRN",14710,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",3,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,63,266,NA,"who",63,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"severe","2022 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","other combinations",NA,2022-12-23
"3084",364,"Heidarzadeh","Test-negative case-control","23Dec2022","Gam-COVID-Vac (Gamaleya)","included","2","final","91-120","ICU admission","severe","Iran",">=5 years","general pop",51,"-258",94,NA,"alpha & delta","~40 weeks",NA,NA,"Iran","IRN",364,"IRN",14710,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",3,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,63,266,NA,"who",63,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"severe","2022 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","other combinations",NA,2022-12-23
"3085",364,"Heidarzadeh","Test-negative case-control","23Dec2022","Gam-COVID-Vac (Gamaleya)","included","2","final","151+","ICU admission","severe","Iran",">=5 years","general pop",18,"-136",71,NA,"alpha & delta","~40 weeks",NA,NA,"Iran","IRN",364,"IRN",14710,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",3,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,63,266,NA,"who",63,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"severe","2022 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","other combinations",NA,2022-12-23
"3086",364,"Heidarzadeh","Test-negative case-control","23Dec2022","Gam-COVID-Vac (Gamaleya)","included","2","final","31-60","death","death","Iran",">=5 years","general pop",25,"-149",78,NA,"alpha & delta","~40 weeks",NA,NA,"Iran","IRN",364,"IRN",14710,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",3,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,63,266,NA,"who",63,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"death","2022 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","other combinations",NA,2022-12-23
"3087",364,"Heidarzadeh","Test-negative case-control","23Dec2022","Gam-COVID-Vac (Gamaleya)","included","2","final","151+","death","death","Iran",">=5 years","general pop",93,"47",99.1,NA,"alpha & delta","~40 weeks",NA,NA,"Iran","IRN",364,"IRN",14710,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",3,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,63,266,NA,"who",63,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"death","2022 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","other combinations",NA,2022-12-23
"3088",365,"Lin","Retrospective cohort","16Jun2023","mRNA-1273 (Moderna)","included","2","final","0 to ~4 weeks","infection","infection","USA","0-4 years","0-4 years",58,"47.5",66.5,NA,"omicron (all lineages)","~23 weeks",NA,NA,"USA","USA",365,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-06-16,"infection","2023 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","19/01/2023",2023-01-19
"3089",365,"Lin","Retrospective cohort","16Jun2023","mRNA-1273 (Moderna)","included","2","final","~16-21 weeks","infection","infection","USA","0-4 years","0-4 years",47.6,"27.7",62,NA,"omicron (all lineages)","~23 weeks",NA,NA,"USA","USA",365,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-06-16,"infection","2023 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","19/01/2023",2023-01-19
"3090",365,"Lin","Retrospective cohort","16Jun2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","0 to ~5 weeks","hospitalization or death","severe","USA","5-11 years","5-11 years",73.3,"8.3",92.3,NA,"omicron (all lineages)","~57 weeks",NA,NA,"USA","USA",365,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-06-16,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","19/01/2023",2023-01-19
"3091",365,"Lin","Retrospective cohort","16Jun2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","~20-25 weeks","hospitalization or death","severe","USA","5-11 years","5-11 years",2.9,"-50.8",37.4,NA,"omicron (all lineages)","~57 weeks",NA,NA,"USA","USA",365,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-06-16,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","19/01/2023",2023-01-19
"3092",365,"Lin","Retrospective cohort","16Jun2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","prior infection only","2","final","0 to ~5 weeks","infection","infection","USA","0-4 years","0-4 years",37.5,"21.2",50.4,NA,"omicron (all lineages)","~24 weeks",NA,NA,"USA","USA",365,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-06-16,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","19/01/2023",2023-01-19
"3093",365,"Lin","Retrospective cohort","16Jun2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","prior infection only","2","final","~16-21 weeks","infection","infection","USA","0-4 years","0-4 years",46.8,"-0.3",71.8,NA,"omicron (all lineages)","~24 weeks",NA,NA,"USA","USA",365,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-06-16,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","19/01/2023",2023-01-19
"3094",365,"Lin","Retrospective cohort","16Jun2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","prior infection only","2","final","0 to ~5 weeks","infection","infection","USA","5-11 years","5-11 years",65.3,"58.1",71.2,NA,"omicron (all lineages)","~57 weeks",NA,NA,"USA","USA",365,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-06-16,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","19/01/2023",2023-01-19
"3095",365,"Lin","Retrospective cohort","16Jun2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","prior infection only","2","final","~24-29 weeks","infection","infection","USA","5-11 years","5-11 years",4.6,"-2.1",10.9,NA,"omicron (all lineages)","~57 weeks",NA,NA,"USA","USA",365,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-06-16,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","19/01/2023",2023-01-19
"3096",365,"Lin","Retrospective cohort","16Jun2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","0 to ~5 weeks","infection","infection","USA","0-4 years","0-4 years",55.7,"49.1",61.5,NA,"omicron (all lineages)","~24 weeks",NA,NA,"USA","USA",365,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-06-16,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","19/01/2023",2023-01-19
"3097",365,"Lin","Retrospective cohort","16Jun2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","~16-21 weeks","infection","infection","USA","0-4 years","0-4 years",58.6,"48.3",66.9,NA,"omicron (all lineages)","~24 weeks",NA,NA,"USA","USA",365,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-06-16,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","19/01/2023",2023-01-19
"3098",365,"Lin","Retrospective cohort","16Jun2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","0 to ~5 weeks","infection","infection","USA","5-11 years","5-11 years",59.7,"58.3",61,NA,"omicron (all lineages)","~57 weeks",NA,NA,"USA","USA",365,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-06-16,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","19/01/2023",2023-01-19
"3099",365,"Lin","Retrospective cohort","16Jun2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","~36-41 weeks","infection","infection","USA","5-11 years","5-11 years",16,"13.1",18.7,NA,"omicron (all lineages)","~57 weeks",NA,NA,"USA","USA",365,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-06-16,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","19/01/2023",2023-01-19
"3100",366,"Battacharya","Test-negative case-control","06Jan2023","BBV152 (Bharat)","included","2","final","7+","hospitalization with symptoms of pulmonary disease","severe","India",">=18 years","general pop",74,"50.5",86,NA,"delta","~22 weeks",NA,NA,"India","IND",366,"IND",6820,2019,"India","South Asia","Lower middle income",2,"Asia",2021-01-16,2021-12-24,NA,2021-01-16,2021-01-16,0,39,342,NA,"equal",39,"jan/2021","30-59","Dec/2021 +","270-359","yes","yes","no",2023-01-06,"severe","2023 (Jan-Jun)","Bharat Covaxin/BBV152","Inactivated","delta",NA,2023-01-06
"3101",366,"Battacharya","Test-negative case-control","06Jan2023","AZD1222 (Covishield)","included","2","final","7+","hospitalization with symptoms of pulmonary disease","severe","India",">=18 years","general pop",79,"53.1",81,NA,"delta","~22 weeks",NA,NA,"India","IND",366,"IND",6820,2019,"India","South Asia","Lower middle income",2,"Asia",2021-01-16,2021-12-24,NA,2021-01-16,2021-01-16,0,39,342,NA,"equal",39,"jan/2021","30-59","Dec/2021 +","270-359","yes","yes","no",2023-01-06,"severe","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2023-01-06
"3102",367,"Ellingson","Prospective cohort","26Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","prior infection only","2","final","14+","infection","infection","USA","frontline workers","general pop",43,"35",57,NA,"omicron","~63 weeks",NA,NA,"USA","USA",367,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-01-26,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-01-26
"3103",368,"Niesen","Test-negative case-control","28Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-73","symptomatic disease","symptomatic","USA",">=18 years","general pop",80.6,"76.9",83.7,NA,"delta","~54 weeks",NA,NA,"USA","USA",368,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-28,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-04-28
"3104",368,"Niesen","Test-negative case-control","28Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","314-355","symptomatic disease","symptomatic","USA",">=18 years","general pop",43.3,"28.8",54.7,NA,"delta","~54 weeks",NA,NA,"USA","USA",368,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-28,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-04-28
"3105",368,"Niesen","Test-negative case-control","28Apr2022","mRNA-1273 (Moderna)","excluded","2","final","7-13","symptomatic disease","symptomatic","USA",">=18 years","general pop",94.8,"88",97.8,NA,"delta","~54 weeks",NA,NA,"USA","USA",368,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-28,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta",NA,2022-04-28
"3106",368,"Niesen","Test-negative case-control","28Apr2022","mRNA-1273 (Moderna)","excluded","2","final","254-313","symptomatic disease","symptomatic","USA",">=18 years","general pop",63.2,"53.7",70.7,NA,"delta","~54 weeks",NA,NA,"USA","USA",368,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2022-04-28,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta",NA,2022-04-28
"3107",369,"Toh","Test-negative case-control","27Jan2023","CoronaVac (Sinovac)","included","2","final","15+","hospitalization","severe","Malaysia",">=18 years","general pop",76.5,"45.6",89.8,NA,"non-VOC & delta","~24 weeks",NA,NA,"Malaysia","MYS",369,"MYS",28090,2019,"Malaysia","East Asia & Pacific","Upper middle income",3,"Asia",2021-02-26,2021-08-24,2021-10-21,2021-02-24,2021-02-24,2,78,181,239,"who",78,"feb/2021","60-89","Jun-Aug/2021","180-269","yes","yes","yes",2023-01-27,"severe","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations",NA,2023-01-27
"3108",370,"Tartof","Test-negative case-control","28Jan2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14-89","ED or UC visit","symptomatic","USA","5-11 years","5-11 years",60,"47",69,NA,"omicron BA.1, BA.2, BA.4/BA.5","~39 weeks",NA,NA,"USA","USA",370,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-01-28,"symptomatic","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-01-28
"3109",370,"Tartof","Test-negative case-control","28Jan2023","BNT162b2 (Pfizer BioNTech)","included","2","final","90+","ED or UC visit","symptomatic","USA","5-11 years","5-11 years",28,"8",43,NA,"omicron BA.1, BA.2, BA.4/BA.5","~39 weeks",NA,NA,"USA","USA",370,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-01-28,"symptomatic","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-01-28
"3110",370,"Tartof","Test-negative case-control","28Jan2023","BNT162b2 (Pfizer BioNTech)","included","2","final","90+","ED or UC visit","symptomatic","USA","5-11 years","5-11 years",85,"59",95,NA,"delta","~5 weeks",NA,NA,"USA","USA",370,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-01-28,"symptomatic","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-01-28
"3111",371,"Sritipsukho","Test-negative case-control","30Jan2023","CoronaVac (Sinovac)","excluded","2","final","14+","infection","infection","Thailand",">=18 years","general pop",26,"-9",50,NA,"omicron BA.1/BA.2","~67 weeks",NA,NA,"Thailand","THA",371,"THA",18070,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,82,240,395,"who",82,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","yes",2023-01-30,"infection","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","omicron",NA,2023-01-30
"3112",371,"Sritipsukho","Test-negative case-control","30Jan2023","CoronaVac (Sinovac)","excluded","2","final","<90 days","infection","infection","Thailand",">=18 years","general pop",47,"7",70,NA,"omicron BA.1/BA.2","~67 weeks",NA,NA,"Thailand","THA",371,"THA",18070,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,82,240,395,"who",82,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","yes",2023-01-30,"infection","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","omicron",NA,2023-01-30
"3113",371,"Sritipsukho","Test-negative case-control","30Jan2023","CoronaVac (Sinovac)","excluded","2","final",">90 days","infection","infection","Thailand",">=18 years","general pop",21,"-15",47,NA,"omicron BA.1/BA.2","~67 weeks",NA,NA,"Thailand","THA",371,"THA",18070,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,82,240,395,"who",82,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","yes",2023-01-30,"infection","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","omicron",NA,2023-01-30
"3114",371,"Sritipsukho","Test-negative case-control","30Jan2023","CoronaVac (Sinovac)","excluded","2","final","14+","moderate to critical disease","symptomatic","Thailand",">=18 years","general pop",-4,"-50",45,NA,"omicron BA.1/BA.2","~67 weeks",NA,NA,"Thailand","THA",371,"THA",18070,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,82,240,395,"who",82,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","yes",2023-01-30,"symptomatic","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","omicron",NA,2023-01-30
"3115",371,"Sritipsukho","Test-negative case-control","30Jan2023","AZD1222 (AstraZeneca)","excluded","2","final","14+","infection","infection","Thailand",">=18 years","general pop",38,"13",56,NA,"omicron BA.1/BA.2","~67 weeks",NA,NA,"Thailand","THA",371,"THA",18070,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,82,240,395,"who",82,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","yes",2023-01-30,"infection","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron",NA,2023-01-30
"3116",371,"Sritipsukho","Test-negative case-control","30Jan2023","AZD1222 (AstraZeneca)","excluded","2","final","<90 days","infection","infection","Thailand",">=18 years","general pop",61,"41",74,NA,"omicron BA.1/BA.2","~67 weeks",NA,NA,"Thailand","THA",371,"THA",18070,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,82,240,395,"who",82,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","yes",2023-01-30,"infection","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron",NA,2023-01-30
"3117",371,"Sritipsukho","Test-negative case-control","30Jan2023","AZD1222 (AstraZeneca)","excluded","2","final",">90 days","infection","infection","Thailand",">=18 years","general pop",30,"0",51,NA,"omicron BA.1/BA.2","~67 weeks",NA,NA,"Thailand","THA",371,"THA",18070,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,82,240,395,"who",82,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","yes",2023-01-30,"infection","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron",NA,2023-01-30
"3118",371,"Sritipsukho","Test-negative case-control","30Jan2023","AZD1222 (AstraZeneca)","excluded","2","final","14+","moderate to critical disease","symptomatic","Thailand",">=18 years","general pop",56,"25",74,NA,"omicron BA.1/BA.2","~67 weeks",NA,NA,"Thailand","THA",371,"THA",18070,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,82,240,395,"who",82,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","yes",2023-01-30,"symptomatic","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron",NA,2023-01-30
"3119",371,"Sritipsukho","Test-negative case-control","30Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","Thailand",">=18 years","general pop",23,"-13",49,NA,"omicron BA.1/BA.2","~67 weeks",NA,NA,"Thailand","THA",371,"THA",18070,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,82,240,395,"who",82,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","yes",2023-01-30,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-01-30
"3120",371,"Sritipsukho","Test-negative case-control","30Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","<90 days","infection","infection","Thailand",">=18 years","general pop",38,"4",60,NA,"omicron BA.1/BA.2","~67 weeks",NA,NA,"Thailand","THA",371,"THA",18070,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,82,240,395,"who",82,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","yes",2023-01-30,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-01-30
"3121",371,"Sritipsukho","Test-negative case-control","30Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">90 days","infection","infection","Thailand",">=18 years","general pop",-38,"-60",24,NA,"omicron BA.1/BA.2","~67 weeks",NA,NA,"Thailand","THA",371,"THA",18070,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,82,240,395,"who",82,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","yes",2023-01-30,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-01-30
"3122",371,"Sritipsukho","Test-negative case-control","30Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","moderate to critical disease","infection","Thailand",">=18 years","general pop",30,"-37",69,NA,"omicron BA.1/BA.2","~67 weeks",NA,NA,"Thailand","THA",371,"THA",18070,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,82,240,395,"who",82,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","yes",2023-01-30,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-01-30
"3123",372,"Weng","Retrospective cohort","01Feb2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection","infection","USA",">=12 years","general pop",94.6,"83.4",98.3,NA,"alpha","~48 weeks",NA,NA,"USA","USA",372,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-02-01,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2023-02-01
"3124",372,"Weng","Retrospective cohort","01Feb2023","mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","USA",">=12 years","general pop",97.5,"82.5",99.7,NA,"alpha","~48 weeks",NA,NA,"USA","USA",372,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-02-01,"infection","2023 (Jan-Jun)","Moderna mRNA-1273","mRNA","alpha",NA,2023-02-01
"3125",372,"Weng","Retrospective cohort","01Feb2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection","infection","USA",">=12 years","general pop",64.8,"54.2",73,NA,"delta","~48 weeks",NA,NA,"USA","USA",372,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-02-01,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-02-01
"3126",372,"Weng","Retrospective cohort","01Feb2023","mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","USA",">=12 years","general pop",65,"52.9",74.1,NA,"delta","~48 weeks",NA,NA,"USA","USA",372,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-02-01,"infection","2023 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta",NA,2023-02-01
"3127",372,"Weng","Retrospective cohort","01Feb2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection","infection","USA",">=12 years","general pop",31.6,"19.6",42.5,NA,"omicron BA.1","~48 weeks",NA,NA,"USA","USA",372,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-02-01,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-02-01
"3128",372,"Weng","Retrospective cohort","01Feb2023","mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","USA",">=12 years","general pop",25.6,"10.7",39,NA,"omicron BA.1","~48 weeks",NA,NA,"USA","USA",372,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-02-01,"infection","2023 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron",NA,2023-02-01
"3129",374,"Bello Chavolla","Test-negative case-control","02Feb2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","Mexico",">=18 years","general pop",80.3,"80.1",80.6,NA,"alpha & delta","~35 weeks",NA,NA,"Mexico","MEX",374,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2023-02-02,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","02/02/2023",2023-02-02
"3130",374,"Bello Chavolla","Test-negative case-control","02Feb2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization","severe","Mexico",">=18 years","general pop",84.3,"83.6",84.9,NA,"alpha & delta","~35 weeks",NA,NA,"Mexico","MEX",374,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2023-02-02,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","02/02/2023",2023-02-02
"3131",374,"Bello Chavolla","Test-negative case-control","02Feb2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","death","death","Mexico",">=18 years","general pop",89.8,"89.1",90.4,NA,"alpha & delta","~35 weeks",NA,NA,"Mexico","MEX",374,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2023-02-02,"death","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","02/02/2023",2023-02-02
"3132",374,"Bello Chavolla","Test-negative case-control","02Feb2023","mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","Mexico",">=18 years","general pop",91.5,"90.3",92.4,NA,"alpha & delta","~1 week",NA,NA,"Mexico","MEX",374,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2023-02-02,"infection","2023 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","02/02/2023",2023-02-02
"3133",374,"Bello Chavolla","Test-negative case-control","02Feb2023","mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization","severe","Mexico",">=18 years","general pop",78,"69",84.4,NA,"alpha & delta","~1 week",NA,NA,"Mexico","MEX",374,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2023-02-02,"severe","2023 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","02/02/2023",2023-02-02
"3134",374,"Bello Chavolla","Test-negative case-control","02Feb2023","mRNA-1273 (Moderna)","excluded","2","final","14+","death","death","Mexico",">=18 years","general pop",93.5,"85.9",96.9,NA,"alpha & delta","~1 week",NA,NA,"Mexico","MEX",374,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2023-02-02,"death","2023 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","02/02/2023",2023-02-02
"3135",374,"Bello Chavolla","Test-negative case-control","02Feb2023","AZD1222 (AstraZeneca)","excluded","2","final","14+","infection","infection","Mexico",">=18 years","general pop",80.8,"80.4",81.1,NA,"alpha & delta","~32 weeks",NA,NA,"Mexico","MEX",374,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2023-02-02,"infection","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","02/02/2023",2023-02-02
"3136",374,"Bello Chavolla","Test-negative case-control","02Feb2023","AZD1222 (AstraZeneca)","excluded","2","final","14+","hospitalization","severe","Mexico",">=18 years","general pop",80.2,"79.3",81.1,NA,"alpha & delta","~32 weeks",NA,NA,"Mexico","MEX",374,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2023-02-02,"severe","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","02/02/2023",2023-02-02
"3137",374,"Bello Chavolla","Test-negative case-control","02Feb2023","AZD1222 (AstraZeneca)","excluded","2","final","14+","death","death","Mexico",">=18 years","general pop",86.8,"85.9",87.7,NA,"alpha & delta","~32 weeks",NA,NA,"Mexico","MEX",374,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2023-02-02,"death","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","02/02/2023",2023-02-02
"3138",374,"Bello Chavolla","Test-negative case-control","02Feb2023","Ad26.COV2.S (Janssen)","excluded","1","final","14+","infection","infection","Mexico",">=18 years","general pop",82.2,"81.4",82.9,NA,"alpha & delta","~11 weeks",NA,NA,"Mexico","MEX",374,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2023-02-02,"infection","2023 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations","02/02/2023",2023-02-02
"3139",374,"Bello Chavolla","Test-negative case-control","02Feb2023","Ad26.COV2.S (Janssen)","excluded","1","final","14+","hospitalization","severe","Mexico",">=18 years","general pop",77.3,"72.9",81,NA,"alpha & delta","~11 weeks",NA,NA,"Mexico","MEX",374,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2023-02-02,"severe","2023 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations","02/02/2023",2023-02-02
"3140",374,"Bello Chavolla","Test-negative case-control","02Feb2023","Ad26.COV2.S (Janssen)","excluded","1","final","14+","death","death","Mexico",">=18 years","general pop",85.8,"80.1",89.9,NA,"alpha & delta","~11 weeks",NA,NA,"Mexico","MEX",374,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2023-02-02,"death","2023 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations","02/02/2023",2023-02-02
"3141",374,"Bello Chavolla","Test-negative case-control","02Feb2023","Ad5-nCOV (CanSino)","excluded","1","final","14+","infection","infection","Mexico",">=18 years","general pop",70.5,"70.1",70.9,NA,"alpha & delta","~27 weeks",NA,NA,"Mexico","MEX",374,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2023-02-02,"infection","2023 (Jan-Jun)","Cansino Ad5-nCoV","Vectored","other combinations","02/02/2023",2023-02-02
"3142",374,"Bello Chavolla","Test-negative case-control","02Feb2023","Ad5-nCOV (CanSino)","excluded","1","final","14+","hospitalization","severe","Mexico",">=18 years","general pop",72.3,"71.1",73.5,NA,"alpha & delta","~27 weeks",NA,NA,"Mexico","MEX",374,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2023-02-02,"severe","2023 (Jan-Jun)","Cansino Ad5-nCoV","Vectored","other combinations","02/02/2023",2023-02-02
"3143",374,"Bello Chavolla","Test-negative case-control","02Feb2023","Ad5-nCOV (CanSino)","excluded","1","final","14+","death","death","Mexico",">=18 years","general pop",79.9,"78.5",81.2,NA,"alpha & delta","~27 weeks",NA,NA,"Mexico","MEX",374,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2023-02-02,"death","2023 (Jan-Jun)","Cansino Ad5-nCoV","Vectored","other combinations","02/02/2023",2023-02-02
"3144",374,"Bello Chavolla","Test-negative case-control","02Feb2023","CoronaVac (Sinovac)","excluded","2","final","14+","infection","infection","Mexico",">=18 years","general pop",71.9,"71.4",72.5,NA,"alpha & delta","~27 weeks",NA,NA,"Mexico","MEX",374,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2023-02-02,"infection","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations","02/02/2023",2023-02-02
"3145",374,"Bello Chavolla","Test-negative case-control","02Feb2023","CoronaVac (Sinovac)","excluded","2","final","14+","hospitalization","severe","Mexico",">=18 years","general pop",73.8,"72.5",75,NA,"alpha & delta","~27 weeks",NA,NA,"Mexico","MEX",374,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2023-02-02,"severe","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations","02/02/2023",2023-02-02
"3146",374,"Bello Chavolla","Test-negative case-control","02Feb2023","CoronaVac (Sinovac)","excluded","2","final","14+","death","death","Mexico",">=18 years","general pop",80.4,"79",81.6,NA,"alpha & delta","~27 weeks",NA,NA,"Mexico","MEX",374,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2023-02-02,"death","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations","02/02/2023",2023-02-02
"3147",374,"Bello Chavolla","Test-negative case-control","02Feb2023","Gam-COVID-Vac (Gamaleya)","excluded","2","final","14+","infection","infection","Mexico",">=18 years","general pop",78.8,"78.2",79.3,NA,"alpha & delta","~26 weeks",NA,NA,"Mexico","MEX",374,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2023-02-02,"infection","2023 (Jan-Jun)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","other combinations","02/02/2023",2023-02-02
"3148",374,"Bello Chavolla","Test-negative case-control","02Feb2023","Gam-COVID-Vac (Gamaleya)","excluded","2","final","14+","hospitalization","severe","Mexico",">=18 years","general pop",81.4,"79.5",83.1,NA,"alpha & delta","~26 weeks",NA,NA,"Mexico","MEX",374,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2023-02-02,"severe","2023 (Jan-Jun)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","other combinations","02/02/2023",2023-02-02
"3149",374,"Bello Chavolla","Test-negative case-control","02Feb2023","Gam-COVID-Vac (Gamaleya)","excluded","2","final","14+","death","death","Mexico",">=18 years","general pop",87.7,"85.8",89.3,NA,"alpha & delta","~26 weeks",NA,NA,"Mexico","MEX",374,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2023-02-02,"death","2023 (Jan-Jun)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","other combinations","02/02/2023",2023-02-02
"3150",375,"Jorgensen","Test-negative case-control","27Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","Canada","infants of mothers vaccinated post-partum","infants of mothers vaccinated post-partum",13,"-14",33,NA,"omicron BA.5","~66 weeks",NA,NA,"Canada","CAN",375,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-02-27,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-02-27
"3151",375,"Jorgensen","Test-negative case-control","27Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","Canada","infants of mothers vaccinated post-partum","infants of mothers vaccinated post-partum",36,"-21",66,NA,"omicron BA.5","~66 weeks",NA,NA,"Canada","CAN",375,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-02-27,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-02-27
"3152",375,"Jorgensen","Test-negative case-control","27Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","Canada","infants of mothers vaccinated post-partum","infants of mothers vaccinated post-partum",73,"72",87,NA,"omicron BA.5","~66 weeks",NA,NA,"Canada","CAN",375,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-02-27,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-02-27
"3153",376,"Yan","Case-control","28Feb2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-60","infection","infection","Hong Kong","3-17 years","3-17 years",39.7,"29",48.7,NA,"omicron BA.1, BA.2, BA.4, BA.5","~68 weeks",NA,NA,"Hong Kong","HKG",376,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-02-28,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-02-28
"3154",376,"Yan","Case-control","28Feb2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","180+","infection","infection","Hong Kong","3-17 years","3-17 years",16.5,"8.7",23.6,NA,"omicron BA.1, BA.2, BA.4, BA.5","~68 weeks",NA,NA,"Hong Kong","HKG",376,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-02-28,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-02-28
"3155",376,"Yan","Case-control","28Feb2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-60","hospitalization","severe","Hong Kong","3-17 years","3-17 years",45.5,"-0.2",70.3,NA,"omicron BA.1, BA.2, BA.4, BA.5","~68 weeks",NA,NA,"Hong Kong","HKG",376,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-02-28,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-02-28
"3156",376,"Yan","Case-control","28Feb2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","180+","hospitalization","severe","Hong Kong","3-17 years","3-17 years",33.6,"5.5",53.3,NA,"omicron BA.1, BA.2, BA.4, BA.5","~68 weeks",NA,NA,"Hong Kong","HKG",376,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-02-28,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-02-28
"3157",376,"Yan","Case-control","28Feb2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-60","severe disease","severe","Hong Kong","3-17 years","3-17 years",67.3,"34.1",83.8,NA,"omicron BA.1, BA.2, BA.4, BA.5","~68 weeks",NA,NA,"Hong Kong","HKG",376,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-02-28,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-02-28
"3158",376,"Yan","Case-control","28Feb2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","180+","severe disease","severe","Hong Kong","3-17 years","3-17 years",29.2,"-4.9",52.2,NA,"omicron BA.1, BA.2, BA.4, BA.5","~68 weeks",NA,NA,"Hong Kong","HKG",376,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-02-28,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-02-28
"3159",376,"Yan","Case-control","28Feb2023","CoronaVac (Sinovac)","excluded","2","final","14-60","infection","infection","Hong Kong","3-17 years","3-17 years",29.5,"20.1",37.7,NA,"omicron BA.1, BA.2, BA.4, BA.5","~68 weeks",NA,NA,"Hong Kong","HKG",376,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-02-28,"infection","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","omicron",NA,2023-02-28
"3160",376,"Yan","Case-control","28Feb2023","CoronaVac (Sinovac)","excluded","2","final","121-179","infection","infection","Hong Kong","3-17 years","3-17 years",-35.2,"-63.3",-12,NA,"omicron BA.1, BA.2, BA.4, BA.5","~68 weeks",NA,NA,"Hong Kong","HKG",376,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-02-28,"infection","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","omicron",NA,2023-02-28
"3161",376,"Yan","Case-control","28Feb2023","CoronaVac (Sinovac)","excluded","2","final","14-60","hospitalization","severe","Hong Kong","3-17 years","3-17 years",55.8,"34.9",70,NA,"omicron BA.1, BA.2, BA.4, BA.5","~68 weeks",NA,NA,"Hong Kong","HKG",376,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-02-28,"severe","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","omicron",NA,2023-02-28
"3162",376,"Yan","Case-control","28Feb2023","CoronaVac (Sinovac)","excluded","2","final","121-179","hospitalization","severe","Hong Kong","3-17 years","3-17 years",-66.9,"-137.3",17.3,NA,"omicron BA.1, BA.2, BA.4, BA.5","~68 weeks",NA,NA,"Hong Kong","HKG",376,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-02-28,"severe","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","omicron",NA,2023-02-28
"3163",376,"Yan","Case-control","28Feb2023","CoronaVac (Sinovac)","excluded","2","final","14-60","severe disease","severe","Hong Kong","3-17 years","3-17 years",57.6,"32.8",73.2,NA,"omicron BA.1, BA.2, BA.4, BA.5","~68 weeks",NA,NA,"Hong Kong","HKG",376,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-02-28,"severe","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","omicron",NA,2023-02-28
"3164",376,"Yan","Case-control","28Feb2023","CoronaVac (Sinovac)","excluded","2","final","121-179","severe disease","severe","Hong Kong","3-17 years","3-17 years",-48.8,"-120",0.7,NA,"omicron BA.1, BA.2, BA.4, BA.5","~68 weeks",NA,NA,"Hong Kong","HKG",376,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-02-28,"severe","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","omicron",NA,2023-02-28
"3165",378,"Glatman-Freedman","Test-negative case-control","02Mar2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","8-14","infection","infection","Israel","5-11 years","5-11 years",58.1,"55.5",60.6,NA,"omicron BA.1","4 weeks",NA,NA,"Israel","ISR",378,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-03-02,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-03-02
"3166",378,"Glatman-Freedman","Test-negative case-control","02Mar2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","36-42","infection","infection","Israel","5-11 years","5-11 years",39.5,"36.1",42.8,NA,"omicron BA.1","4 weeks",NA,NA,"Israel","ISR",378,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-03-02,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-03-02
"3167",380,"Tamandjou Tchuem","Test-negative case-control","27Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","8-30","symptomatic disease","symptomatic","France",">=50 years",">=50 years",69.8,"58.3",79.3,NA,"omicron BA.1","~54 weeks",NA,NA,"France","FRA",380,"FRA",51580,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,15,204,345,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-02-27,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-02-27
"3168",380,"Tamandjou Tchuem","Test-negative case-control","27Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final",">120","symptomatic disease","symptomatic","France",">=50 years",">=50 years",19.9,"16.3",24.1,NA,"omicron BA.1","~54 weeks",NA,NA,"France","FRA",380,"FRA",51580,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,15,204,345,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-02-27,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-02-27
"3169",380,"Tamandjou Tchuem","Test-negative case-control","27Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","8-30","symptomatic disease","symptomatic","France",">=50 years",">=50 years",85.9,"75.2",92.4,NA,"delta","~45 weeks",NA,NA,"France","FRA",380,"FRA",51580,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,15,204,345,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-02-27,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2023-02-27
"3170",380,"Tamandjou Tchuem","Test-negative case-control","27Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final",">120","symptomatic disease","symptomatic","France",">=50 years",">=50 years",60.1,"57.2",63,NA,"delta","~45 weeks",NA,NA,"France","FRA",380,"FRA",51580,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,15,204,345,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-02-27,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2023-02-27
"3171",381,"Rojas-Botero","Retrospective cohort","08Sep2023","BNT162b2 (Pfizer BioNTech)","included","2","final","15+","hospitalization","severe","Colombia",">=18 years","general pop",90.5,"89.8",91.2,NA,"mu, delta, & omicron","~64 weeks",NA,NA,"Colombia","COL",381,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2023-09-08,"severe","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","22/03/2023",2023-03-22
"3172",381,"Rojas-Botero","Retrospective cohort","08Sep2023","BNT162b2 (Pfizer BioNTech)","included","2","final","15+","death","death","Colombia",">=18 years","general pop",93.5,"92.8",94.2,NA,"mu, delta, & omicron","~64 weeks",NA,NA,"Colombia","COL",381,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2023-09-08,"death","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","22/03/2023",2023-03-22
"3173",381,"Rojas-Botero","Retrospective cohort","08Sep2023","mRNA-1273 (Moderna)","included","2","final","15+","hospitalization","severe","Colombia",">=18 years","general pop",93.7,"91.8",95.2,NA,"mu, delta, & omicron","~41 weeks",NA,NA,"Colombia","COL",381,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2023-09-08,"severe","2023 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","22/03/2023",2023-03-22
"3174",381,"Rojas-Botero","Retrospective cohort","08Sep2023","mRNA-1273 (Moderna)","included","2","final","15+","death","death","Colombia",">=18 years","general pop",95.7,"93.5",97.2,NA,"mu, delta, & omicron","~41 weeks",NA,NA,"Colombia","COL",381,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2023-09-08,"death","2023 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","22/03/2023",2023-03-22
"3175",381,"Rojas-Botero","Retrospective cohort","08Sep2023","AZD1222 (AstraZeneca)","included","2","final","15+","hospitalization","severe","Colombia",">=18 years","general pop",88,"86.8",89.1,NA,"mu, delta, & omicron","~57 weeks",NA,NA,"Colombia","COL",381,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2023-09-08,"severe","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","22/03/2023",2023-03-22
"3176",381,"Rojas-Botero","Retrospective cohort","08Sep2023","AZD1222 (AstraZeneca)","included","2","final","15+","death","death","Colombia",">=18 years","general pop",92.6,"91.5",93.6,NA,"mu, delta, & omicron","~57 weeks",NA,NA,"Colombia","COL",381,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2023-09-08,"death","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","22/03/2023",2023-03-22
"3177",381,"Rojas-Botero","Retrospective cohort","08Sep2023","CoronaVac (Sinovac)","included","2","final","15+","hospitalization","severe","Colombia",">=18 years","general pop",77.4,"76.5",78.2,NA,"mu, delta, & omicron","~64 weeks",NA,NA,"Colombia","COL",381,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2023-09-08,"severe","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","other combinations","22/03/2023",2023-03-22
"3178",381,"Rojas-Botero","Retrospective cohort","08Sep2023","CoronaVac (Sinovac)","included","2","final","15+","death","death","Colombia",">=18 years","general pop",81.9,"81.2",82.7,NA,"mu, delta, & omicron","~64 weeks",NA,NA,"Colombia","COL",381,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2023-09-08,"death","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","other combinations","22/03/2023",2023-03-22
"3179",381,"Rojas-Botero","Retrospective cohort","08Sep2023","Ad26.COV2.S (Janssen)","included","1","final","15+","hospitalization","severe","Colombia",">=18 years","general pop",85.4,"83.8",86.9,NA,"mu, delta, & omicron","~51 weeks",NA,NA,"Colombia","COL",381,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2023-09-08,"severe","2023 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations","22/03/2023",2023-03-22
"3180",381,"Rojas-Botero","Retrospective cohort","08Sep2023","Ad26.COV2.S (Janssen)","included","1","final","15+","death","death","Colombia",">=18 years","general pop",90.5,"88.8",91.9,NA,"mu, delta, & omicron","~51 weeks",NA,NA,"Colombia","COL",381,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2023-09-08,"death","2023 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations","22/03/2023",2023-03-22
"3181",382,"Bouillon","Retrospective cohort","13Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14-30","hospitalization","severe","France",">=50 years",">=50 years",90,"88",91,NA,"alpha & delta","~28 weeks",NA,NA,"France","FRA",382,"FRA",51580,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,15,204,345,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-13,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-06-13
"3182",382,"Bouillon","Retrospective cohort","13Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final","152-180","hospitalization","severe","France",">=50 years",">=50 years",94,"92",94,NA,"alpha & delta","~28 weeks",NA,NA,"France","FRA",382,"FRA",51580,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,15,204,345,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-13,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-06-13
"3183",382,"Bouillon","Retrospective cohort","13Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","death","death","France",">=50 years",">=50 years",91,"90",93,NA,"alpha & delta","~28 weeks",NA,NA,"France","FRA",382,"FRA",51580,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,15,204,345,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-13,"death","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-06-13
"3184",382,"Bouillon","Retrospective cohort","13Jun2022","mRNA-1273 (Moderna)","included","2","final","14-30","hospitalization","severe","France",">=50 years",">=50 years",92,"85",95,NA,"alpha & delta","~28 weeks",NA,NA,"France","FRA",382,"FRA",51580,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,15,204,345,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-13,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-06-13
"3185",382,"Bouillon","Retrospective cohort","13Jun2022","mRNA-1273 (Moderna)","included","2","final","152-180","hospitalization","severe","France",">=50 years",">=50 years",98,"93",100,NA,"alpha & delta","~28 weeks",NA,NA,"France","FRA",382,"FRA",51580,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,15,204,345,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-13,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-06-13
"3186",382,"Bouillon","Retrospective cohort","13Jun2022","mRNA-1273 (Moderna)","included","2","final","14+","death","death","France",">=50 years",">=50 years",96,"92",98,NA,"alpha & delta","~28 weeks",NA,NA,"France","FRA",382,"FRA",51580,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,15,204,345,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-13,"death","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-06-13
"3187",382,"Bouillon","Retrospective cohort","13Jun2022","AZD1222 (AstraZeneca)","included","2","final","14-30","hospitalization","severe","France",">=50 years",">=50 years",94,"88",97,NA,"alpha & delta","~23 weeks",NA,NA,"France","FRA",382,"FRA",51580,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,15,204,345,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-13,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-06-13
"3188",382,"Bouillon","Retrospective cohort","13Jun2022","AZD1222 (AstraZeneca)","included","2","final","90-120","hospitalization","severe","France",">=50 years",">=50 years",90,"63",97,NA,"alpha & delta","~23 weeks",NA,NA,"France","FRA",382,"FRA",51580,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,15,204,345,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-13,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-06-13
"3189",382,"Bouillon","Retrospective cohort","13Jun2022","AZD1222 (AstraZeneca)","included","2","final","14+","death","death","France",">=50 years",">=50 years",88,"68",95,NA,"alpha & delta","~23 weeks",NA,NA,"France","FRA",382,"FRA",51580,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,15,204,345,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-13,"death","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-06-13
"3190",383,"Lipshuetz","Retrospective cohort","23Mar2023","BNT162b2 (Pfizer BioNTech) in mothers during pregnancy","excluded","2","final","120 days after birth","hospitalization up to 120 days after birth","severe","Israel","infants 0-120 days of unvaccinated mothers and mothers vaccinated during pregnancy at least 5 months prior","infants",-16,"-56",14,NA,"delta & omicron BA.1","~59 weeks",NA,NA,"Israel","ISR",383,"ISR",40250,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,8,81,NA,"who",8,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-03-23,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta/omicron",NA,2023-03-23
"3191",384,"Lutz","Test-negative case-control","27Mar2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","hospitalization","severe","USA",">=12 years","general pop",93.9,"85.7",97.4,NA,"alpha & delta","~45 weeks",NA,NA,"USA","USA",384,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-03-27,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-03-27
"3192",384,"Lutz","Test-negative case-control","27Mar2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","outpatient clinic and emergency visits","symptomatic","USA",">=12 years","general pop",85.9,"60",95,NA,"alpha & delta","~45 weeks",NA,NA,"USA","USA",384,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-03-27,"symptomatic","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-03-27
"3193",384,"Lutz","Test-negative case-control","27Mar2023","mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA",">=12 years","general pop",97.3,"88.3",99.4,NA,"alpha & delta","~45 weeks",NA,NA,"USA","USA",384,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-03-27,"severe","2023 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2023-03-27
"3194",384,"Lutz","Test-negative case-control","27Mar2023","mRNA-1273 (Moderna)","included","2","final","14+","outpatient clinic and emergency visits","symptomatic","USA",">=12 years","general pop",85.4,"39.3",96.5,NA,"alpha & delta","~45 weeks",NA,NA,"USA","USA",384,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-03-27,"symptomatic","2023 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2023-03-27
"3195",384,"Lutz","Test-negative case-control","27Mar2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-149","hospitalization","severe","USA",">=12 years","general pop",96.2,"94",99.4,NA,"alpha & delta","~45 weeks",NA,NA,"USA","USA",384,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-03-27,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2023-03-27
"3196",384,"Lutz","Test-negative case-control","27Mar2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","150+","hospitalization","severe","USA",">=12 years","general pop",87.7,"69.4",95,NA,"alpha & delta","~45 weeks",NA,NA,"USA","USA",384,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-03-27,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2023-03-27
"3197",384,"Lutz","Test-negative case-control","27Mar2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-149","outpatient clinic and emergency visits","symptomatic","USA",">=12 years","general pop",87.7,"60.5",96.2,NA,"alpha & delta","~45 weeks",NA,NA,"USA","USA",384,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-03-27,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2023-03-27
"3198",384,"Lutz","Test-negative case-control","27Mar2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","150+","outpatient clinic and emergency visits","symptomatic","USA",">=12 years","general pop",87,"55.6",96.2,NA,"alpha & delta","~45 weeks",NA,NA,"USA","USA",384,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-03-27,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2023-03-27
"3199",385,"Klein","Test-negative case-control","07Apr2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14-59","ED or UC visit","symptomatic","USA","5-11 years","5-11 years",49,"33",61,NA,"omicron BA.1, BA.2, BA.4/BA.5","~6 weeks",NA,NA,"USA","USA",385,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-04-07,"symptomatic","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-04-07
"3200",385,"Klein","Test-negative case-control","07Apr2023","BNT162b2 (Pfizer BioNTech)","included","2","final","150+","ED or UC visit","symptomatic","USA","5-11 years","5-11 years",41,"29",51,NA,"omicron BA.1, BA.2, BA.4/BA.5","~31 weeks",NA,NA,"USA","USA",385,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-04-07,"symptomatic","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-04-07
"3201",385,"Klein","Test-negative case-control","07Apr2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14-59","ED or UC visit","symptomatic","USA","12-15 years","12-15 years",64,"44",77,NA,"omicron BA.1, BA.2, BA.4/BA.5","~6 weeks",NA,NA,"USA","USA",385,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-04-07,"symptomatic","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-04-07
"3202",385,"Klein","Test-negative case-control","07Apr2023","BNT162b2 (Pfizer BioNTech)","included","2","final","150+","ED or UC visit","symptomatic","USA","12-15 years","12-15 years",13,"3",23,NA,"omicron BA.1, BA.2, BA.4/BA.5","~62 weeks",NA,NA,"USA","USA",385,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-04-07,"symptomatic","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-04-07
"3203",385,"Klein","Test-negative case-control","07Apr2023","BNT162b2 (Pfizer BioNTech)","included","2","final","60-149","ED or UC visit","symptomatic","USA","16-17 years","16-17 years",31,"10",47,NA,"omicron BA.1, BA.2, BA.4/BA.5","~19 weeks",NA,NA,"USA","USA",385,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-04-07,"symptomatic","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-04-07
"3204",385,"Klein","Test-negative case-control","07Apr2023","BNT162b2 (Pfizer BioNTech)","included","2","final","150+","ED or UC visit","symptomatic","USA","16-17 years","16-17 years",7,"-8",20,NA,"omicron BA.1, BA.2, BA.4/BA.5","~72 weeks",NA,NA,"USA","USA",385,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-04-07,"symptomatic","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-04-07
"3205",385,"Klein","Test-negative case-control","07Apr2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14-59","ED or UC visit","symptomatic","USA","12-15 years","12-15 years",93,"89",95,NA,"delta","~6 weeks",NA,NA,"USA","USA",385,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-04-07,"symptomatic","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-04-07
"3206",385,"Klein","Test-negative case-control","07Apr2023","BNT162b2 (Pfizer BioNTech)","included","2","final","150+","ED or UC visit","symptomatic","USA","12-15 years","12-15 years",77,"69",84,NA,"delta","~22 weeks",NA,NA,"USA","USA",385,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-04-07,"symptomatic","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-04-07
"3207",385,"Klein","Test-negative case-control","07Apr2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14-59","ED or UC visit","symptomatic","USA","16-17 years","16-17 years",93,"86",97,NA,"delta","~ 6 weeks",NA,NA,"USA","USA",385,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-04-07,"symptomatic","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-04-07
"3208",385,"Klein","Test-negative case-control","07Apr2023","BNT162b2 (Pfizer BioNTech)","included","2","final","150+","ED or UC visit","symptomatic","USA","16-17 years","16-17 years",72,"63",79,NA,"delta","~32 weeks",NA,NA,"USA","USA",385,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-04-07,"symptomatic","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-04-07
"3209",385,"Klein","Test-negative case-control","07Apr2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14-59","hospitalization","severe","USA","12-15 years","12-15 years",98,"21",100,NA,"delta","~6 weeks",NA,NA,"USA","USA",385,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-04-07,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-04-07
"3210",385,"Klein","Test-negative case-control","07Apr2023","BNT162b2 (Pfizer BioNTech)","included","2","final","60-149","hospitalization","severe","USA","12-15 years","12-15 years",97,"74",100,NA,"delta","~19 weeks",NA,NA,"USA","USA",385,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-04-07,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-04-07
"3211",385,"Klein","Test-negative case-control","07Apr2023","BNT162b2 (Pfizer BioNTech)","included","2","final","60-149","hospitalization","severe","USA","16-17 years","16-17 years",99,"90",100,NA,"delta","~19 weeks",NA,NA,"USA","USA",385,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-04-07,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-04-07
"3212",385,"Klein","Test-negative case-control","07Apr2023","BNT162b2 (Pfizer BioNTech)","included","2","final","150+","hospitalization","severe","USA","16-17 years","16-17 years",98,"73",100,NA,"delta","~32 weeks",NA,NA,"USA","USA",385,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-04-07,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-04-07
"3213",386,"Huang","Retrospective cohort","12Apr2023","CoronaVac (Sinovac)","Partially excluded (excluded if prior infection prior to study start)","2","final","8+","severe disease","severe","China",">=60 years",">=60 years",65.5,"50.9",75.7,NA,"alpha & delta & omicron BA.1, BA.2","~66 weeks",NA,NA,"China","CHN",386,"CHN",16610,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,-139,386,420,"who",0,"before jan/2021","<30","Jun-Aug/2021","360+","yes","yes","yes",2023-04-12,"severe","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations",NA,2023-04-12
"3214",386,"Huang","Retrospective cohort","12Apr2023","CoronaVac (Sinovac)","Partially excluded (excluded if prior infection prior to study start)","2","final","8+","death","death","China",">=60 years",">=60 years",80.4,"55.8",91.3,NA,"alpha & delta & omicron BA.1, BA.2","~66 weeks",NA,NA,"China","CHN",386,"CHN",16610,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,-139,386,420,"who",0,"before jan/2021","<30","Jun-Aug/2021","360+","yes","yes","yes",2023-04-12,"death","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations",NA,2023-04-12
"3215",386,"Huang","Retrospective cohort","12Apr2023","BBIBP-CorV (Beijing CNBG)","Partially excluded (excluded if prior infection prior to study start)","2","final","8+","severe disease","severe","China",">=60 years",">=60 years",76.4,"61.8",85.4,NA,"alpha & delta & omicron BA.1, BA.2","~66 weeks",NA,NA,"China","CHN",386,"CHN",16610,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,-139,386,420,"who",0,"before jan/2021","<30","Jun-Aug/2021","360+","yes","yes","yes",2023-04-12,"severe","2023 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","other combinations",NA,2023-04-12
"3216",386,"Huang","Retrospective cohort","12Apr2023","BBIBP-CorV (Beijing CNBG)","Partially excluded (excluded if prior infection prior to study start)","2","final","8+","death","death","China",">=60 years",">=60 years",82.7,"53.4",93.6,NA,"alpha & delta & omicron BA.1, BA.2","~66 weeks",NA,NA,"China","CHN",386,"CHN",16610,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,-139,386,420,"who",0,"before jan/2021","<30","Jun-Aug/2021","360+","yes","yes","yes",2023-04-12,"death","2023 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","other combinations",NA,2023-04-12
"3217",387,"Altarawneh","Test-negative case-control","27Jul2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease","symptomatic","Qatar","all ages","general pop",90.5,"83.9",94.4,NA,"alpha","~8 weeks",NA,NA,"Qatar","QAT",387,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2023-07-27,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","22/04/2023",2023-04-22
"3218",387,"Altarawneh","Test-negative case-control","27Jul2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","severe, critical or fatal disease","severe","Qatar","all ages","general pop",96.1,"71.2",99.5,NA,"alpha","~8 weeks",NA,NA,"Qatar","QAT",387,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2023-07-27,"severe","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","22/04/2023",2023-04-22
"3219",387,"Altarawneh","Test-negative case-control","27Jul2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease","symptomatic","Qatar","all ages","general pop",80.5,"79",82,NA,"beta","~17 weeks",NA,NA,"Qatar","QAT",387,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2023-07-27,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","beta","22/04/2023",2023-04-22
"3220",387,"Altarawneh","Test-negative case-control","27Jul2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","severe, critical or fatal disease","severe","Qatar","all ages","general pop",97.4,"95.8",98.4,NA,"beta","~17 weeks",NA,NA,"Qatar","QAT",387,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2023-07-27,"severe","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","beta","22/04/2023",2023-04-22
"3221",387,"Altarawneh","Test-negative case-control","27Jul2023","mRNA-1273 (Moderna)","excluded","2","final","14+","symptomatic disease","symptomatic","Qatar","all ages","general pop",96,"91.6",98.1,NA,"beta","~17 weeks",NA,NA,"Qatar","QAT",387,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2023-07-27,"symptomatic","2023 (Jul-Dec)","Moderna mRNA-1273","mRNA","beta","22/04/2023",2023-04-22
"3222",387,"Altarawneh","Test-negative case-control","27Jul2023","mRNA-1273 (Moderna)","excluded","2","final","14+","severe, critical or fatal disease","severe","Qatar","all ages","general pop",100,"92.2",100,NA,"beta","~17 weeks",NA,NA,"Qatar","QAT",387,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2023-07-27,"severe","2023 (Jul-Dec)","Moderna mRNA-1273","mRNA","beta","22/04/2023",2023-04-22
"3223",387,"Altarawneh","Test-negative case-control","27Jul2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease","symptomatic","Qatar","all ages","general pop",58.1,"54.6",61.3,NA,"delta","~48 weeks",NA,NA,"Qatar","QAT",387,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2023-07-27,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","22/04/2023",2023-04-22
"3224",387,"Altarawneh","Test-negative case-control","27Jul2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","severe, critical or fatal disease","severe","Qatar","all ages","general pop",91.1,"86.3",94.2,NA,"delta","~48 weeks",NA,NA,"Qatar","QAT",387,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2023-07-27,"severe","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","22/04/2023",2023-04-22
"3225",387,"Altarawneh","Test-negative case-control","27Jul2023","mRNA-1273 (Moderna)","excluded","2","final","14+","symptomatic disease","symptomatic","Qatar","all ages","general pop",71,"66.4",74.9,NA,"delta","~48 weeks",NA,NA,"Qatar","QAT",387,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2023-07-27,"symptomatic","2023 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","22/04/2023",2023-04-22
"3226",387,"Altarawneh","Test-negative case-control","27Jul2023","mRNA-1273 (Moderna)","excluded","2","final","14+","severe, critical or fatal disease","severe","Qatar","all ages","general pop",97.9,"91.2",99.5,NA,"delta","~48 weeks",NA,NA,"Qatar","QAT",387,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2023-07-27,"severe","2023 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","22/04/2023",2023-04-22
"3227",388,"Braeye","Retrospective cohort","05Apr2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7-57","infection","infection","Belgium","close contacts of unvaccinated index cases, females 45-64 years","close contacts of unvaccinated index cases, females 45-64 years",3,"1",5,NA,"omicron BA.1","~28.5 weeks",NA,NA,"Belgium","BEL",388,"BEL",56280,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,22,190,243,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-04-05,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-04-05
"3228",388,"Braeye","Retrospective cohort","05Apr2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","157-207","infection","infection","Belgium","close contacts of unvaccinated index cases, females 45-64 years","close contacts of unvaccinated index cases, females 45-64 years",2,"0",3,NA,"omicron BA.1","~28.5 weeks",NA,NA,"Belgium","BEL",388,"BEL",56280,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,22,190,243,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-04-05,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-04-05
"3229",388,"Braeye","Retrospective cohort","05Apr2023","mRNA-1273 (Moderna)","excluded","2","final","14-64","infection","infection","Belgium","close contacts of unvaccinated index cases, females 45-64 years","close contacts of unvaccinated index cases, females 45-64 years",4,"1",7,NA,"omicron BA.1","~28.5 weeks",NA,NA,"Belgium","BEL",388,"BEL",56280,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,22,190,243,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-04-05,"infection","2023 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron",NA,2023-04-05
"3230",388,"Braeye","Retrospective cohort","05Apr2023","mRNA-1273 (Moderna)","excluded","2","final","164-214","infection","infection","Belgium","close contacts of unvaccinated index cases, females 45-64 years","close contacts of unvaccinated index cases, females 45-64 years",3,"0",4,NA,"omicron BA.1","~28.5 weeks",NA,NA,"Belgium","BEL",388,"BEL",56280,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,22,190,243,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-04-05,"infection","2023 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron",NA,2023-04-05
"3231",388,"Braeye","Retrospective cohort","05Apr2023","AZD1222 (AstraZeneca)","excluded","2","final","14-64","infection","infection","Belgium","close contacts of unvaccinated index cases, females 45-64 years","close contacts of unvaccinated index cases, females 45-64 years",2,"0",4,NA,"omicron BA.1","~28.5 weeks",NA,NA,"Belgium","BEL",388,"BEL",56280,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,22,190,243,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-04-05,"infection","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron",NA,2023-04-05
"3232",388,"Braeye","Retrospective cohort","05Apr2023","AZD1222 (AstraZeneca)","excluded","2","final","164-214","infection","infection","Belgium","close contacts of unvaccinated index cases, females 45-64 years","close contacts of unvaccinated index cases, females 45-64 years",1,"0",2,NA,"omicron BA.1","~28.5 weeks",NA,NA,"Belgium","BEL",388,"BEL",56280,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,22,190,243,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-04-05,"infection","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron",NA,2023-04-05
"3233",388,"Braeye","Retrospective cohort","05Apr2023","Ad26.COV2.S (Janssen)","excluded","1","final","21-71","infection","infection","Belgium","close contacts of unvaccinated index cases, females 45-64 years","close contacts of unvaccinated index cases, females 45-64 years",1,"0",2,NA,"omicron BA.1","~28.5 weeks",NA,NA,"Belgium","BEL",388,"BEL",56280,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,22,190,243,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-04-05,"infection","2023 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","omicron",NA,2023-04-05
"3234",388,"Braeye","Retrospective cohort","05Apr2023","Ad26.COV2.S (Janssen)","excluded","1","final","171-221","infection","infection","Belgium","close contacts of unvaccinated index cases, females 45-64 years","close contacts of unvaccinated index cases, females 45-64 years",1,"0",2,NA,"omicron BA.1","~28.5 weeks",NA,NA,"Belgium","BEL",388,"BEL",56280,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,22,190,243,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-04-05,"infection","2023 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","omicron",NA,2023-04-05
"3235",388,"Braeye","Retrospective cohort","05Apr2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7-57","infection","infection","Belgium","close contacts of unvaccinated index cases, females 45-64 years","close contacts of unvaccinated index cases, females 45-64 years",62,"56",66,NA,"delta","~28.5 weeks",NA,NA,"Belgium","BEL",388,"BEL",56280,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,22,190,243,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-04-05,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-04-05
"3236",388,"Braeye","Retrospective cohort","05Apr2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","157-207","infection","infection","Belgium","close contacts of unvaccinated index cases, females 45-64 years","close contacts of unvaccinated index cases, females 45-64 years",43,"41",45,NA,"delta","~28.5 weeks",NA,NA,"Belgium","BEL",388,"BEL",56280,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,22,190,243,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-04-05,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-04-05
"3237",388,"Braeye","Retrospective cohort","05Apr2023","mRNA-1273 (Moderna)","excluded","2","final","14-64","infection","infection","Belgium","close contacts of unvaccinated index cases, females 45-64 years","close contacts of unvaccinated index cases, females 45-64 years",75,"70",77,NA,"delta","~28.5 weeks",NA,NA,"Belgium","BEL",388,"BEL",56280,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,22,190,243,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-04-05,"infection","2023 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta",NA,2023-04-05
"3238",388,"Braeye","Retrospective cohort","05Apr2023","mRNA-1273 (Moderna)","excluded","2","final","164-214","infection","infection","Belgium","close contacts of unvaccinated index cases, females 45-64 years","close contacts of unvaccinated index cases, females 45-64 years",56,"54",58,NA,"delta","~28.5 weeks",NA,NA,"Belgium","BEL",388,"BEL",56280,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,22,190,243,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-04-05,"infection","2023 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta",NA,2023-04-05
"3239",388,"Braeye","Retrospective cohort","05Apr2023","AZD1222 (AstraZeneca)","excluded","2","final","14-64","infection","infection","Belgium","close contacts of unvaccinated index cases, females 45-64 years","close contacts of unvaccinated index cases, females 45-64 years",48,"43",55,NA,"delta","~28.5 weeks",NA,NA,"Belgium","BEL",388,"BEL",56280,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,22,190,243,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-04-05,"infection","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2023-04-05
"3240",388,"Braeye","Retrospective cohort","05Apr2023","AZD1222 (AstraZeneca)","excluded","2","final","164-214","infection","infection","Belgium","close contacts of unvaccinated index cases, females 45-64 years","close contacts of unvaccinated index cases, females 45-64 years",35,"34",38,NA,"delta","~28.5 weeks",NA,NA,"Belgium","BEL",388,"BEL",56280,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,22,190,243,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-04-05,"infection","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2023-04-05
"3241",388,"Braeye","Retrospective cohort","05Apr2023","Ad26.COV2.S (Janssen)","excluded","1","final","21-71","infection","infection","Belgium","close contacts of unvaccinated index cases, females 45-64 years","close contacts of unvaccinated index cases, females 45-64 years",28,"26",31,NA,"delta","~28.5 weeks",NA,NA,"Belgium","BEL",388,"BEL",56280,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,22,190,243,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-04-05,"infection","2023 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta",NA,2023-04-05
"3242",388,"Braeye","Retrospective cohort","05Apr2023","Ad26.COV2.S (Janssen)","excluded","1","final","171-221","infection","infection","Belgium","close contacts of unvaccinated index cases, females 45-64 years","close contacts of unvaccinated index cases, females 45-64 years",27,"23",30,NA,"delta","~28.5 weeks",NA,NA,"Belgium","BEL",388,"BEL",56280,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,22,190,243,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-04-05,"infection","2023 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta",NA,2023-04-05
"3243",389,"DeCuir","Test-negative case-control","28Apr2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","7+","invasive mechanical ventilation or death","severe","USA",">=18 years","general pop",53,"37",65,NA,"omicron BA.1, BA.2, BA.4/BA.5, BQ.1","62 weeks",NA,NA,"USA","USA",389,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-04-28,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-04-28
"3244",389,"DeCuir","Test-negative case-control","28Apr2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","180+","invasive mechanical ventilation or death","severe","USA",">=18 years","general pop",50,"32",64,NA,"omicron BA.1, BA.2, BA.4/BA.5, BQ.1","62 weeks",NA,NA,"USA","USA",389,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-04-28,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-04-28
"3245",390,"Qassim","Test-negative case-control","19Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+ (median 459)","infection, September 2022","infection","Qatar","all ages","general pop",-5.8,"-11.1",-0.3,NA,"omicron BA.2.75, XBB","~87 weeks",NA,NA,"Qatar","QAT",390,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2023-07-19,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","29/04/2023",2023-04-29
"3246",390,"Qassim","Test-negative case-control","19Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+ (median 541)","infection, November 2022","infection","Qatar","all ages","general pop",-2.1,"-10.5",6.7,NA,"omicron BA.2.75, XBB","~96 weeks",NA,NA,"Qatar","QAT",390,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2023-07-19,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","29/04/2023",2023-04-29
"3247",390,"Qassim","Test-negative case-control","19Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+ (median 453)","severe critical, or fatal disease, August-November 2022","severe","Qatar","all ages","general pop",53.1,"-41.3",87.1,NA,"omicron BA.4/BA.5, BA.2.75, XBB","~96 weeks",NA,NA,"Qatar","QAT",390,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2023-07-19,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","29/04/2023",2023-04-29
"3248",390,"Qassim","Test-negative case-control","19Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+ (median 389)","infection, June 2022","infection","Qatar","all ages","general pop",-20.7,"-26.7",-14.2,NA,"omicron BA.4/BA.5","~74 weeks",NA,NA,"Qatar","QAT",390,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2023-07-19,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","29/04/2023",2023-04-29
"3249",390,"Qassim","Test-negative case-control","19Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+ (median 432)","infection, August 2022","infection","Qatar","all ages","general pop",-1.1,"-7.1",5.1,NA,"omicron BA.4/BA.5","~83 weeks",NA,NA,"Qatar","QAT",390,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2023-07-19,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","29/04/2023",2023-04-29
"3250",390,"Qassim","Test-negative case-control","19Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+ (median 425)","severe critical, or fatal disease, May-July 2022","severe","Qatar","all ages","general pop",83.8,"14.1",96.9,NA,"omicron BA.1, BA.2, BA.4/BA.5","~78.5 weeks",NA,NA,"Qatar","QAT",390,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2023-07-19,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","29/04/2023",2023-04-29
"3251",390,"Qassim","Test-negative case-control","19Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+ (median 228)","infection, December 2021","infection","Qatar","all ages","general pop",-3.9,"-7.8",0,NA,"omicron BA.1, BA.2","~48 weeks",NA,NA,"Qatar","QAT",390,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2023-07-19,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","29/04/2023",2023-04-29
"3252",390,"Qassim","Test-negative case-control","19Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+ (median 364)","infection, May 2022","infection","Qatar","all ages","general pop",-1.6,"-14.7",11.9,NA,"omicron BA.1, BA.2","~70 weeks",NA,NA,"Qatar","QAT",390,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2023-07-19,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","29/04/2023",2023-04-29
"3253",390,"Qassim","Test-negative case-control","19Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+ (median 254)","severe critical, or fatal disease, February-April 2022","severe","Qatar","all ages","general pop",81.4,"48.5",93.3,NA,"omicron BA.1, BA.2","~65 weeks",NA,NA,"Qatar","QAT",390,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2023-07-19,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","29/04/2023",2023-04-29
"3254",390,"Qassim","Test-negative case-control","19Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+ (median 64)","infection, June 2021","infection","Qatar","all ages","general pop",80.7,"77.2",83.7,NA,"delta","~22 weeks",NA,NA,"Qatar","QAT",390,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2023-07-19,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta","29/04/2023",2023-04-29
"3255",390,"Qassim","Test-negative case-control","19Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+ (median 209)","infection, November 2021","infection","Qatar","all ages","general pop",52.7,"46.5",58.2,NA,"delta","~44 weeks",NA,NA,"Qatar","QAT",390,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2023-07-19,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta","29/04/2023",2023-04-29
"3256",390,"Qassim","Test-negative case-control","19Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+ (median 189)","severe critical, or fatal disease, August-October 2021","severe","Qatar","all ages","general pop",91.4,"86.6",94.5,NA,"delta","~39.5 weeks",NA,NA,"Qatar","QAT",390,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2023-07-19,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta","29/04/2023",2023-04-29
"3257",390,"Qassim","Test-negative case-control","19Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+ (median 34)","infection, March 2021","infection","Qatar","all ages","general pop",81.8,"79.8",83.6,NA,"beta","~9 weeks",NA,NA,"Qatar","QAT",390,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2023-07-19,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","beta","29/04/2023",2023-04-29
"3258",390,"Qassim","Test-negative case-control","19Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+ (median 48)","infection, May 2021","infection","Qatar","all ages","general pop",80.9,"78.4",83.1,NA,"beta","~17.5 weeks",NA,NA,"Qatar","QAT",390,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2023-07-19,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","beta","29/04/2023",2023-04-29
"3259",390,"Qassim","Test-negative case-control","19Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+ (median 50)","severe critical, or fatal disease, February-April 2021","severe","Qatar","all ages","general pop",95.4,"93.6",96.7,NA,"alpha & beta","~13 weeks",NA,NA,"Qatar","QAT",390,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2023-07-19,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","29/04/2023",2023-04-29
"3260",390,"Qassim","Test-negative case-control","19Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+ (median 24)","infection, February 2021","infection","Qatar","all ages","general pop",84.5,"77.8",89.2,NA,"alpha","~4.5 weeks",NA,NA,"Qatar","QAT",390,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2023-07-19,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha","29/04/2023",2023-04-29
"3261",391,"Huang","Case-control","01May2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-180","infection","infection","Hong Kong",">=18 years with substance abuse disorders",">=18 years with substance abuse disorders",20.7,"14",27,NA,"omicron BA.1, BA.2","~24 weeks",NA,NA,"Hong Kong","HKG",391,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-05-01,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-05-01
"3262",391,"Huang","Case-control","01May2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization","severe","Hong Kong",">=18 years with substance abuse disorders",">=18 years with substance abuse disorders",73.3,"64.3",80,NA,"omicron BA.1, BA.2","~60.5 weeks",NA,NA,"Hong Kong","HKG",391,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-05-01,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-05-01
"3263",391,"Huang","Case-control","01May2023","CoronaVac (Sinovac)","excluded","2","final","14-180","infection","infection","Hong Kong",">=18 years with substance abuse disorders",">=18 years with substance abuse disorders",6.1,"-0.5",12.3,NA,"omicron BA.1, BA.2","~24 weeks",NA,NA,"Hong Kong","HKG",391,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-05-01,"infection","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","omicron",NA,2023-05-01
"3264",391,"Huang","Case-control","01May2023","CoronaVac (Sinovac)","excluded","2","final","14+","hospitalization","severe","Hong Kong",">=18 years with substance abuse disorders",">=18 years with substance abuse disorders",59.9,"50.2",67.7,NA,"omicron BA.1, BA.2","~59.5 weeks",NA,NA,"Hong Kong","HKG",391,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-05-01,"severe","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","omicron",NA,2023-05-01
"3265",392,"Yan","Case-control","03May2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-30","hospitalization","severe","Hong Kong",">=18 years","general pop",73,"69.2",76.3,NA,"omicron BA.2","~32 weeks",NA,NA,"Hong Kong","HKG",392,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-05-03,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-05-03
"3266",392,"Yan","Case-control","03May2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","211-240","hospitalization","severe","Hong Kong",">=18 years","general pop",46.6,"40.7",51.8,NA,"omicron BA.2","~32 weeks",NA,NA,"Hong Kong","HKG",392,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-05-03,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-05-03
"3267",392,"Yan","Case-control","03May2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-30","severe disease","severe","Hong Kong",">=18 years","general pop",69.7,"50",81.6,NA,"omicron BA.2","~32 weeks",NA,NA,"Hong Kong","HKG",392,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-05-03,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-05-03
"3268",392,"Yan","Case-control","03May2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","211-240","severe disease","severe","Hong Kong",">=18 years","general pop",71.8,"47.2",84.9,NA,"omicron BA.2","~32 weeks",NA,NA,"Hong Kong","HKG",392,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-05-03,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-05-03
"3269",392,"Yan","Case-control","03May2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-30","death","death","Hong Kong",">=18 years","general pop",89.8,"83.7",93.6,NA,"omicron BA.2","~32 weeks",NA,NA,"Hong Kong","HKG",392,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-05-03,"death","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-05-03
"3270",392,"Yan","Case-control","03May2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","211-240","death","death","Hong Kong",">=18 years","general pop",73.8,"55.9",84.4,NA,"omicron BA.2","~32 weeks",NA,NA,"Hong Kong","HKG",392,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-05-03,"death","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-05-03
"3271",392,"Yan","Case-control","03May2023","CoronaVac (Sinovac)","excluded","2","final","14-30","hospitalization","severe","Hong Kong",">=18 years","general pop",66,"63.5",68.3,NA,"omicron BA.2","~32 weeks",NA,NA,"Hong Kong","HKG",392,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-05-03,"severe","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","omicron",NA,2023-05-03
"3272",392,"Yan","Case-control","03May2023","CoronaVac (Sinovac)","excluded","2","final","211-240","hospitalization","severe","Hong Kong",">=18 years","general pop",36.2,"28",43.4,NA,"omicron BA.2","~32 weeks",NA,NA,"Hong Kong","HKG",392,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-05-03,"severe","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","omicron",NA,2023-05-03
"3273",392,"Yan","Case-control","03May2023","CoronaVac (Sinovac)","excluded","2","final","14-30","severe disease","severe","Hong Kong",">=18 years","general pop",54.5,"40.6",65.1,NA,"omicron BA.2","~32 weeks",NA,NA,"Hong Kong","HKG",392,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-05-03,"severe","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","omicron",NA,2023-05-03
"3274",392,"Yan","Case-control","03May2023","CoronaVac (Sinovac)","excluded","2","final","211-240","severe disease","severe","Hong Kong",">=18 years","general pop",67.1,"34",83.6,NA,"omicron BA.2","~32 weeks",NA,NA,"Hong Kong","HKG",392,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-05-03,"severe","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","omicron",NA,2023-05-03
"3275",392,"Yan","Case-control","03May2023","CoronaVac (Sinovac)","excluded","2","final","14-30","death","death","Hong Kong",">=18 years","general pop",81.1,"77.4",84.2,NA,"omicron BA.2","~32 weeks",NA,NA,"Hong Kong","HKG",392,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-05-03,"death","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","omicron",NA,2023-05-03
"3276",392,"Yan","Case-control","03May2023","CoronaVac (Sinovac)","excluded","2","final","211-240","death","death","Hong Kong",">=18 years","general pop",76.6,"60.8",86,NA,"omicron BA.2","~32 weeks",NA,NA,"Hong Kong","HKG",392,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-05-03,"death","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","omicron",NA,2023-05-03
"3277",393,"Finci","Test-negative case-control","12Oct2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection","infection","Albania","HCW >=20 years","HCW",17,"-38",50,NA,"omicron BA.1, BA.2","~65 weeks",NA,NA,"Albania","ALB",393,"ALB",14220,2019,"Albania","Europe & Central Asia","Upper middle income",2,"Europe",2021-01-13,2022-02-01,NA,2021-01-13,2021-01-13,0,36,384,NA,"equal",36,"jan/2021","30-59","Dec/2021 +","360+","yes","no","no",2023-10-12,"infection","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","05/05/2023",2023-05-05
"3278",393,"Finci","Test-negative case-control","12Oct2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","symptomatic disease (PCR only)","symptomatic","Albania","HCW >=20 years","HCW",26,"-53",64,NA,"omicron BA.1, BA.2","~65 weeks",NA,NA,"Albania","ALB",393,"ALB",14220,2019,"Albania","Europe & Central Asia","Upper middle income",2,"Europe",2021-01-13,2022-02-01,NA,2021-01-13,2021-01-13,0,36,384,NA,"equal",36,"jan/2021","30-59","Dec/2021 +","360+","yes","no","no",2023-10-12,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","05/05/2023",2023-05-05
"3279",393,"Finci","Test-negative case-control","12Oct2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","symptomatic disease (PCR or RAT)","symptomatic","Albania","HCW >=20 years","HCW",33,"-32",66,NA,"omicron BA.1, BA.2","~65 weeks",NA,NA,"Albania","ALB",393,"ALB",14220,2019,"Albania","Europe & Central Asia","Upper middle income",2,"Europe",2021-01-13,2022-02-01,NA,2021-01-13,2021-01-13,0,36,384,NA,"equal",36,"jan/2021","30-59","Dec/2021 +","360+","yes","no","no",2023-10-12,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","05/05/2023",2023-05-05
"3280",394,"Surie","Test-negative case-control","29Jun2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna) (ascertained by electronic medical records)","included","2","final","14+","hospitalization","severe","USA",">=18 years","general pop",20,"3",34,NA,"omicron BA.1, BA.2, BA.4/BA.5","~82 weeks",NA,NA,"USA","USA",394,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-06-29,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","05/05/2023",2023-05-05
"3281",394,"Surie","Test-negative case-control","29Jun2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna) (ascertained by immunization information system)","included","2","final","14+","hospitalization","severe","USA",">=18 years","general pop",32,"16",45,NA,"omicron BA.1, BA.2, BA.4/BA.5","~82 weeks",NA,NA,"USA","USA",394,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-06-29,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","05/05/2023",2023-05-05
"3282",395,"Langlete","Retrospective cohort","10May2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","7-112","infection","infection","Norway","HCW 18-66 years","HCW",73.3,"70.6",75.8,NA,"delta","~43 weeks",NA,NA,"Norway","NOR",395,"NOR",71400,2019,"Norway","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-08-12,2021-11-18,2020-12-23,2020-12-23,5,15,232,330,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-05-10,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2023-05-10
"3283",395,"Langlete","Retrospective cohort","10May2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","225-336","infection","infection","Norway","HCW 18-66 years","HCW",8.9,"-2.1",18.7,NA,"delta","~43 weeks",NA,NA,"Norway","NOR",395,"NOR",71400,2019,"Norway","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-08-12,2021-11-18,2020-12-23,2020-12-23,5,15,232,330,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-05-10,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2023-05-10
"3284",395,"Langlete","Retrospective cohort","10May2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","7-112","infection","infection","Norway","18-66 years","18-66 years",68.7,"67.7",69.7,NA,"delta","~43 weeks",NA,NA,"Norway","NOR",395,"NOR",71400,2019,"Norway","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-08-12,2021-11-18,2020-12-23,2020-12-23,5,15,232,330,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-05-10,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2023-05-10
"3285",395,"Langlete","Retrospective cohort","10May2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","225-336","infection","infection","Norway","18-66 years","18-66 years",10.6,"-15.4",30.8,NA,"delta","~43 weeks",NA,NA,"Norway","NOR",395,"NOR",71400,2019,"Norway","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-08-12,2021-11-18,2020-12-23,2020-12-23,5,15,232,330,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-05-10,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2023-05-10
"3286",395,"Langlete","Retrospective cohort","10May2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","7-112","infection","infection","Norway","HCW 18-66 years","HCW",16.7,"10.5",22.4,NA,"omicron BA.1","~54 weeks",NA,NA,"Norway","NOR",395,"NOR",71400,2019,"Norway","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-08-12,2021-11-18,2020-12-23,2020-12-23,5,15,232,330,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-05-10,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-05-10
"3287",395,"Langlete","Retrospective cohort","10May2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","225-336","infection","infection","Norway","HCW 18-66 years","HCW",9.7,"2.3",16.6,NA,"omicron BA.1","~54 weeks",NA,NA,"Norway","NOR",395,"NOR",71400,2019,"Norway","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-08-12,2021-11-18,2020-12-23,2020-12-23,5,15,232,330,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-05-10,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-05-10
"3288",395,"Langlete","Retrospective cohort","10May2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","7-112","infection","infection","Norway","18-66 years","18-66 years",-32.6,"-35.6",-29.7,NA,"omicron BA.1","~54 weeks",NA,NA,"Norway","NOR",395,"NOR",71400,2019,"Norway","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-08-12,2021-11-18,2020-12-23,2020-12-23,5,15,232,330,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-05-10,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-05-10
"3289",395,"Langlete","Retrospective cohort","10May2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","225-336","infection","infection","Norway","18-66 years","18-66 years",-29.8,"-37.9",-22.2,NA,"omicron BA.1","~54 weeks",NA,NA,"Norway","NOR",395,"NOR",71400,2019,"Norway","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-08-12,2021-11-18,2020-12-23,2020-12-23,5,15,232,330,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-05-10,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-05-10
"3290",396,"Park","Retrospective cohort","15May2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","death","death","South Korea",">=60 years",">=60 years",72,"70",74,NA,"omicron BA.1, BA.2, BA.4/BA.5","~80 weeks",NA,NA,"South Korea","KOR",396,"KOR",43780,2019,"Korea, Rep.","East Asia & Pacific","High income",4,"Asia",2021-02-26,2021-09-15,2021-10-25,2021-02-26,2021-02-26,0,80,201,241,"equal",80,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","yes",2023-05-15,"death","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-05-15
"3291",396,"Park","Retrospective cohort","15May2023","AZD1222 (AstraZeneca)","included","2","final","14+","death","death","South Korea",">=60 years",">=60 years",65,"62",68,NA,"omicron BA.1, BA.2, BA.4/BA.5","~80 weeks",NA,NA,"South Korea","KOR",396,"KOR",43780,2019,"Korea, Rep.","East Asia & Pacific","High income",4,"Asia",2021-02-26,2021-09-15,2021-10-25,2021-02-26,2021-02-26,0,80,201,241,"equal",80,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","yes",2023-05-15,"death","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron",NA,2023-05-15
"3292",396,"Park","Retrospective cohort","15May2023","AZD1222 (AstraZeneca) + any mRNA - heterologous","included","2","final","14+","death","death","South Korea",">=60 years",">=60 years",55,"44",60,NA,"omicron BA.1, BA.2, BA.4/BA.5","~80 weeks",NA,NA,"South Korea","KOR",396,"KOR",43780,2019,"Korea, Rep.","East Asia & Pacific","High income",4,"Asia",2021-02-26,2021-09-15,2021-10-25,2021-02-26,2021-02-26,0,80,201,241,"equal",80,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","yes",2023-05-15,"death","2023 (Jan-Jun)","Heterologous platforms","Multiple","omicron",NA,2023-05-15
"3293",396,"Park","Retrospective cohort","15May2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","critical infection","severe","South Korea",">=60 years",">=60 years",68,"67",69,NA,"omicron BA.1, BA.2, BA.4/BA.5","~80 weeks",NA,NA,"South Korea","KOR",396,"KOR",43780,2019,"Korea, Rep.","East Asia & Pacific","High income",4,"Asia",2021-02-26,2021-09-15,2021-10-25,2021-02-26,2021-02-26,0,80,201,241,"equal",80,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","yes",2023-05-15,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-05-15
"3294",396,"Park","Retrospective cohort","15May2023","AZD1222 (AstraZeneca)","included","2","final","14+","critical infection","severe","South Korea",">=60 years",">=60 years",72,"70",74,NA,"omicron BA.1, BA.2, BA.4/BA.5","~80 weeks",NA,NA,"South Korea","KOR",396,"KOR",43780,2019,"Korea, Rep.","East Asia & Pacific","High income",4,"Asia",2021-02-26,2021-09-15,2021-10-25,2021-02-26,2021-02-26,0,80,201,241,"equal",80,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","yes",2023-05-15,"severe","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron",NA,2023-05-15
"3295",396,"Park","Retrospective cohort","15May2023","AZD1222 (AstraZeneca) + any mRNA - heterologous","included","2","final","14+","critical infection","severe","South Korea",">=60 years",">=60 years",61,"55",67,NA,"omicron BA.1, BA.2, BA.4/BA.5","~80 weeks",NA,NA,"South Korea","KOR",396,"KOR",43780,2019,"Korea, Rep.","East Asia & Pacific","High income",4,"Asia",2021-02-26,2021-09-15,2021-10-25,2021-02-26,2021-02-26,0,80,201,241,"equal",80,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","yes",2023-05-15,"severe","2023 (Jan-Jun)","Heterologous platforms","Multiple","omicron",NA,2023-05-15
"3296",397,"Yung","Retrospective cohort","15May2023","BNT162b2 (Pfizer BioNTech)","previously infected only","2","final","14+","infection","infection","Singapore","5-11 years","5-11 years",74,"67.7",79.1,NA,"omicron BA.4/BA.5","~34 weeks",NA,NA,"Singapore","SGP",397,"SGP",89630,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,22,192,227,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-05-15,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-05-15
"3297",397,"Yung","Retrospective cohort","15May2023","BNT162b2 (Pfizer BioNTech)","previously infected only","2","final","14-119","infection","infection","Singapore","5-11 years","5-11 years",67.9,"58.5",75.2,NA,"omicron BA.4/BA.5","~34 weeks",NA,NA,"Singapore","SGP",397,"SGP",89630,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,22,192,227,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-05-15,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-05-15
"3298",397,"Yung","Retrospective cohort","15May2023","BNT162b2 (Pfizer BioNTech)","previously infected only","2","final","180+","infection","infection","Singapore","5-11 years","5-11 years",78.7,"70.4",84.7,NA,"omicron BA.4/BA.5","~34 weeks",NA,NA,"Singapore","SGP",397,"SGP",89630,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,22,192,227,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-05-15,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-05-15
"3299",397,"Yung","Retrospective cohort","15May2023","BNT162b2 (Pfizer BioNTech)","previously infected only","2","final","14+","infection","infection","Singapore","12-17 years","12-17 years",84.9,"77",90.1,NA,"omicron BA.4/BA.5","~68 weeks",NA,NA,"Singapore","SGP",397,"SGP",89630,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,22,192,227,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-05-15,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-05-15
"3300",397,"Yung","Retrospective cohort","15May2023","BNT162b2 (Pfizer BioNTech)","previously infected only","2","final","14+","infection","infection","Singapore","5-11 years","5-11 years",62.8,"42.3",76,NA,"omicron XBB","~47 weeks",NA,NA,"Singapore","SGP",397,"SGP",89630,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,22,192,227,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-05-15,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-05-15
"3301",397,"Yung","Retrospective cohort","15May2023","BNT162b2 (Pfizer BioNTech)","previously infected only","2","final","14+","infection","infection","Singapore","12-17 years","12-17 years",57.9,"33.6",73.3,NA,"omicron XBB","~82 weeks",NA,NA,"Singapore","SGP",397,"SGP",89630,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,22,192,227,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-05-15,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-05-15
"3302",398,"Ng","Test-negative case-control","26May2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","<180","infection","infection","Hong Kong","3-105 years","general pop",27,"4.2",44.5,NA,"omicron BA.2","~63 weeks",NA,NA,"Hong Kong","HKG",398,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-05-26,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-05-26
"3303",398,"Ng","Test-negative case-control","26May2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","180+","infection","infection","Hong Kong","3-105 years","general pop",20.9,"-4.3",39.9,NA,"omicron BA.2","~63 weeks",NA,NA,"Hong Kong","HKG",398,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-05-26,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-05-26
"3304",398,"Ng","Test-negative case-control","26May2023","CoronaVac (Sinovac)","excluded","2","final","<180","infection","infection","Hong Kong","3-105 years","general pop",22.9,"1.3",39.7,NA,"omicron BA.2","~63 weeks",NA,NA,"Hong Kong","HKG",398,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-05-26,"infection","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","omicron",NA,2023-05-26
"3305",398,"Ng","Test-negative case-control","26May2023","CoronaVac (Sinovac)","excluded","2","final","180+","infection","infection","Hong Kong","3-105 years","general pop",16.8,"-15.4",39.9,NA,"omicron BA.2","~63 weeks",NA,NA,"Hong Kong","HKG",398,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-05-26,"infection","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","omicron",NA,2023-05-26
"3306",399,"Monteiro","Target trial emulation","10Aug2023","CoronaVac (Sinovac)","excluded","2","final","14+","hospitalization","severe","Brazil",">=60 years",">=60 years",55.8,"42.7",68.3,NA,"gamma","~30 weeks",NA,NA,"Brazil","BRA",399,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2023-08-10,"severe","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","gamma","07/06/2023",2023-06-07
"3307",399,"Monteiro","Target trial emulation","10Aug2023","CoronaVac (Sinovac)","excluded","2","final","14+","ICU admission","severe","Brazil",">=60 years",">=60 years",68.4,"425.3",86.4,NA,"gamma","~30 weeks",NA,NA,"Brazil","BRA",399,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2023-08-10,"severe","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","gamma","07/06/2023",2023-06-07
"3308",399,"Monteiro","Target trial emulation","10Aug2023","CoronaVac (Sinovac)","excluded","2","final","14+","death","death","Brazil",">=60 years",">=60 years",82.3,"66.3",93.9,NA,"gamma","~30 weeks",NA,NA,"Brazil","BRA",399,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2023-08-10,"death","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","gamma","07/06/2023",2023-06-07
"3309",401,"Bozio","Retrospective cohort","18Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","ED or UC visit","symptomatic","USA",">=18 years","general pop",18,"14",22,NA,"omicron BA.1, BA.2","~73 weeks",NA,NA,"USA","USA",401,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-02-18,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-02-18
"3310",401,"Bozio","Retrospective cohort","18Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-149","ED or UC visit","symptomatic","USA",">=18 years","general pop",21,"12",28,NA,"omicron BA.1, BA.2","~73 weeks",NA,NA,"USA","USA",401,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-02-18,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-02-18
"3311",401,"Bozio","Retrospective cohort","18Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","150+","ED or UC visit","symptomatic","USA",">=18 years","general pop",18,"14",22,NA,"omicron BA.1, BA.2","~73 weeks",NA,NA,"USA","USA",401,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-02-18,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-02-18
"3312",401,"Bozio","Retrospective cohort","18Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization","severe","USA",">=18 years","general pop",39,"33",44,NA,"omicron BA.1, BA.2","~73 weeks",NA,NA,"USA","USA",401,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-02-18,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-02-18
"3313",401,"Bozio","Retrospective cohort","18Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-149","hospitalization","severe","USA",">=18 years","general pop",39,"24",51,NA,"omicron BA.1, BA.2","~73 weeks",NA,NA,"USA","USA",401,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-02-18,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-02-18
"3314",401,"Bozio","Retrospective cohort","18Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","150+","hospitalization","severe","USA",">=18 years","general pop",39,"33",44,NA,"omicron BA.1, BA.2","~73 weeks",NA,NA,"USA","USA",401,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-02-18,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-02-18
"3315",401,"Bozio","Retrospective cohort","18Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","ED or UC visit","symptomatic","USA",">=18 years","general pop",72,"70",74,NA,"delta","~49 weeks",NA,NA,"USA","USA",401,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-02-18,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2023-02-18
"3316",401,"Bozio","Retrospective cohort","18Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-149","ED or UC visit","symptomatic","USA",">=18 years","general pop",82,"79",84,NA,"delta","~49 weeks",NA,NA,"USA","USA",401,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-02-18,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2023-02-18
"3317",401,"Bozio","Retrospective cohort","18Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","150+","ED or UC visit","symptomatic","USA",">=18 years","general pop",68,"65",70,NA,"delta","~49 weeks",NA,NA,"USA","USA",401,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-02-18,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2023-02-18
"3318",401,"Bozio","Retrospective cohort","18Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization","severe","USA",">=18 years","general pop",73,"70",75,NA,"delta","~49 weeks",NA,NA,"USA","USA",401,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-02-18,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2023-02-18
"3319",401,"Bozio","Retrospective cohort","18Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-149","hospitalization","severe","USA",">=18 years","general pop",85,"81",88,NA,"delta","~49 weeks",NA,NA,"USA","USA",401,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-02-18,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2023-02-18
"3320",401,"Bozio","Retrospective cohort","18Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","150+","hospitalization","severe","USA",">=18 years","general pop",69,"65",72,NA,"delta","~49 weeks",NA,NA,"USA","USA",401,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-02-18,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2023-02-18
"3321",403,"Wu","Target trial emulation","09Jan2024","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","USA","5-11 years","5-11 years",74.3,"72.2",76.2,NA,"omicron BA.1, BA.2, BA.2.12.1, BA.5","~48 weeks",NA,NA,"USA","USA",403,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2024-01-09,"infection","2024 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","01/06/2023",2023-06-01
"3322",403,"Wu","Target trial emulation","09Jan2024","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","mild disease","symptomatic","USA","5-11 years","5-11 years",73.5,"69.2",77.1,NA,"omicron BA.1, BA.2, BA.2.12.1, BA.5","~48 weeks",NA,NA,"USA","USA",403,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2024-01-09,"symptomatic","2024 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","01/06/2023",2023-06-01
"3323",403,"Wu","Target trial emulation","09Jan2024","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","moderate or severe disease","symptomatic","USA","5-11 years","5-11 years",75.5,"69",81,NA,"omicron BA.1, BA.2, BA.2.12.1, BA.5","~48 weeks",NA,NA,"USA","USA",403,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2024-01-09,"symptomatic","2024 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","01/06/2023",2023-06-01
"3324",403,"Wu","Target trial emulation","09Jan2024","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","ICU admission","severe","USA","5-11 years","5-11 years",84.9,"64.8",93.5,NA,"omicron BA.1, BA.2, BA.2.12.1, BA.5","~48 weeks",NA,NA,"USA","USA",403,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2024-01-09,"severe","2024 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","01/06/2023",2023-06-01
"3325",403,"Wu","Target trial emulation","09Jan2024","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","USA","12-20 years","12-20 years",85.5,"83.8",87.1,NA,"omicron BA.1, BA.2, BA.2.12.1, BA.5","~52 weeks",NA,NA,"USA","USA",403,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2024-01-09,"infection","2024 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","01/06/2023",2023-06-01
"3326",403,"Wu","Target trial emulation","09Jan2024","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","mild disease","symptomatic","USA","12-20 years","12-20 years",87,"83.5",89.8,NA,"omicron BA.1, BA.2, BA.2.12.1, BA.5","~52 weeks",NA,NA,"USA","USA",403,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2024-01-09,"symptomatic","2024 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","01/06/2023",2023-06-01
"3327",403,"Wu","Target trial emulation","09Jan2024","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","moderate or severe disease","symptomatic","USA","12-20 years","12-20 years",84.8,"77.3",89.9,NA,"omicron BA.1, BA.2, BA.2.12.1, BA.5","~52 weeks",NA,NA,"USA","USA",403,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2024-01-09,"symptomatic","2024 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","01/06/2023",2023-06-01
"3328",403,"Wu","Target trial emulation","09Jan2024","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","ICU admission","severe","USA","12-20 years","12-20 years",91.5,"69.5",97.6,NA,"omicron BA.1, BA.2, BA.2.12.1, BA.5","~52 weeks",NA,NA,"USA","USA",403,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2024-01-09,"severe","2024 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","01/06/2023",2023-06-01
"3329",403,"Wu","Target trial emulation","09Jan2024","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","USA","12-20 years","12-20 years",98.4,"98.1",98.7,NA,"delta","~22 weeks",NA,NA,"USA","USA",403,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2024-01-09,"infection","2024 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","01/06/2023",2023-06-01
"3330",403,"Wu","Target trial emulation","09Jan2024","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","mild disease","symptomatic","USA","12-20 years","12-20 years",99,"98.5",99.3,NA,"delta","~22 weeks",NA,NA,"USA","USA",403,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2024-01-09,"symptomatic","2024 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","01/06/2023",2023-06-01
"3331",403,"Wu","Target trial emulation","09Jan2024","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","moderate or severe disease","symptomatic","USA","12-20 years","12-20 years",98.7,"97.4",99.3,NA,"delta","~22 weeks",NA,NA,"USA","USA",403,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2024-01-09,"symptomatic","2024 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","01/06/2023",2023-06-01
"3332",403,"Wu","Target trial emulation","09Jan2024","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","ICU admission","severe","USA","12-20 years","12-20 years",99,"92.5",99.9,NA,"delta","~22 weeks",NA,NA,"USA","USA",403,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2024-01-09,"severe","2024 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","01/06/2023",2023-06-01
"3333",404,"Spicer","Retrospective cohort","12May2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-90","infection","infection","USA","12-17 years","12-17 years",31.5,"24.6",37.7,NA,"omicron BA.1","~35 weeks",NA,NA,"USA","USA",404,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-05-12,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-05-12
"3334",404,"Spicer","Retrospective cohort","12May2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","151+","infection","infection","USA","12-17 years","12-17 years",1.3,"-2.4",4.9,NA,"omicron BA.1","~35 weeks",NA,NA,"USA","USA",404,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-05-12,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-05-12
"3335",405,"Lowthian","Retrospective cohort","22Jun2023","BNT162b2 (Pfizer BioNTech)","included","2","final","0+","infection","infection","UK","4-11 years","4-11 years",87,"83",90,NA,"omicron BA.1, BA.2","~13 weeks",NA,NA,"UK","GBR",405,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-06-22,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-06-22
"3336",405,"Lowthian","Retrospective cohort","22Jun2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","0+","infection","infection","UK","11-16 years","11-16 years",64,"62",65,NA,"delta & omicron BA.1, BA.2","~35 weeks",NA,NA,"UK","GBR",405,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-06-22,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta/omicron",NA,2023-06-22
"3337",406,"Aglipay","Test-negative case-control","28Jun2023","mRNA-1273 (Moderna)","included","2","final","7+","symptomatic disease","symptomatic","Canada","6m-5 years","6m-5 years",90,"53",99,NA,"omicron BA.5, BQ.1","~12 weeks",NA,NA,"Canada","CAN",406,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-06-28,"symptomatic","2023 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron",NA,2023-06-28
"3338",406,"Aglipay","Test-negative case-control","28Jun2023","mRNA-1273 (Moderna)","included","2","final","7+","hospitalization","severe","Canada","6m-5 years","6m-5 years",82,"4",99,NA,"omicron BA.5, BQ.1","~12 weeks",NA,NA,"Canada","CAN",406,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-06-28,"severe","2023 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron",NA,2023-06-28
"3339",408,"Cegolon","Retrospective cohort","14Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","previously infected only","2","final","8+","infection","infection","Italy","HCW","HCW",51,"37",62,NA,"omicron BA.1, BA.2, BA.5, BQ.1","~104 weeks",NA,NA,"Italy","ITA",408,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-07-14,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-07-14
"3340",409,"Tamada","Test-negative case-control","22Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-34","infection","infection","Japan",">=20 years","general pop",89.1,"80.5",93.9,NA,"delta","~27 weeks",NA,NA,"Japan","JPN",409,"JPN",43970,2019,"Japan","East Asia & Pacific","High income",4,"Asia",2021-02-22,2021-08-11,2021-10-16,2021-02-17,2021-02-17,5,71,175,241,"who",71,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-07-22,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2023-07-22
"3341",409,"Tamada","Test-negative case-control","22Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","56+","infection","infection","Japan",">=20 years","general pop",73.1,"59.7",82,NA,"delta","~27 weeks",NA,NA,"Japan","JPN",409,"JPN",43970,2019,"Japan","East Asia & Pacific","High income",4,"Asia",2021-02-22,2021-08-11,2021-10-16,2021-02-17,2021-02-17,5,71,175,241,"who",71,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-07-22,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2023-07-22
"3342",409,"Tamada","Test-negative case-control","22Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization","severe","Japan",">=20 years","general pop",81.8,"58.2",92.1,NA,"delta","~27 weeks",NA,NA,"Japan","JPN",409,"JPN",43970,2019,"Japan","East Asia & Pacific","High income",4,"Asia",2021-02-22,2021-08-11,2021-10-16,2021-02-17,2021-02-17,5,71,175,241,"who",71,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-07-22,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2023-07-22
"3343",409,"Tamada","Test-negative case-control","22Jul2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","Japan",">=20 years","general pop",78.2,"70.5",83.8,NA,"delta","~27 weeks",NA,NA,"Japan","JPN",409,"JPN",43970,2019,"Japan","East Asia & Pacific","High income",4,"Asia",2021-02-22,2021-08-11,2021-10-16,2021-02-17,2021-02-17,5,71,175,241,"who",71,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-07-22,"infection","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-07-22
"3344",410,"Liu","Retrospective cohort","29Jul2023","mRNA-1273 (Moderna) vs. BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-63","infection","infection","Australia",">=18 years","general pop",-3,"-30",18,NA,"omicron BA.1, BA.2","~7 weeks",NA,"Note this estimate is comparative VE (reference group = receipt of BNT162b2 primary series 14-63 days prior rather than unvaccinated persons)","Australia","AUS",410,"AUS",50180,2019,"Australia","East Asia & Pacific","High income",4,"Oceania",2021-02-22,2021-09-24,2021-11-21,2021-02-21,2021-02-21,1,75,215,273,"who",75,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","yes",2023-07-29,"infection","2023 (Jul-Dec)","Comparative","mRNA","omicron",NA,2023-07-29
"3345",410,"Liu","Retrospective cohort","29Jul2023","AZD1222 (AstraZeneca) vs. BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-63","infection","infection","Australia",">=18 years","general pop",-19,"-49",5,NA,"omicron BA.1, BA.2","~7 weeks",NA,"Note this estimate is comparative VE (reference group = receipt of BNT162b2 primary series 14-63 days prior rather than unvaccinated persons)","Australia","AUS",410,"AUS",50180,2019,"Australia","East Asia & Pacific","High income",4,"Oceania",2021-02-22,2021-09-24,2021-11-21,2021-02-21,2021-02-21,1,75,215,273,"who",75,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","yes",2023-07-29,"infection","2023 (Jul-Dec)","Comparative","Multiple","omicron",NA,2023-07-29
"3346",410,"Liu","Retrospective cohort","29Jul2023","NVX-CoV2373 (Novavax) vs. BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-63","infection","infection","Australia",">=18 years","general pop",-70,"-97",-46,NA,"omicron BA.1, BA.2","~7 weeks",NA,"Note this estimate is comparative VE (reference group = receipt of BNT162b2 primary series 14-63 days prior rather than unvaccinated persons)","Australia","AUS",410,"AUS",50180,2019,"Australia","East Asia & Pacific","High income",4,"Oceania",2021-02-22,2021-09-24,2021-11-21,2021-02-21,2021-02-21,1,75,215,273,"who",75,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","yes",2023-07-29,"infection","2023 (Jul-Dec)","Comparative","Multiple","omicron",NA,2023-07-29
"3347",410,"Liu","Retrospective cohort","29Jul2023","mRNA-1273 (Moderna) vs. BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-63","infection","infection","Australia",">=18 years","general pop",-15,"-62",18,NA,"omicron BA.2","~7 weeks",NA,"Note this estimate is comparative VE (reference group = receipt of BNT162b2 primary series 14-63 days prior rather than unvaccinated persons)","Australia","AUS",410,"AUS",50180,2019,"Australia","East Asia & Pacific","High income",4,"Oceania",2021-02-22,2021-09-24,2021-11-21,2021-02-21,2021-02-21,1,75,215,273,"who",75,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","yes",2023-07-29,"infection","2023 (Jul-Dec)","Comparative","mRNA","omicron",NA,2023-07-29
"3348",410,"Liu","Retrospective cohort","29Jul2023","AZD1222 (AstraZeneca) vs. BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-63","infection","infection","Australia",">=18 years","general pop",1,"-51",35,NA,"omicron BA.2","~7 weeks",NA,"Note this estimate is comparative VE (reference group = receipt of BNT162b2 primary series 14-63 days prior rather than unvaccinated persons)","Australia","AUS",410,"AUS",50180,2019,"Australia","East Asia & Pacific","High income",4,"Oceania",2021-02-22,2021-09-24,2021-11-21,2021-02-21,2021-02-21,1,75,215,273,"who",75,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","yes",2023-07-29,"infection","2023 (Jul-Dec)","Comparative","Multiple","omicron",NA,2023-07-29
"3349",410,"Liu","Retrospective cohort","29Jul2023","NVX-CoV2373 (Novavax) vs. BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-63","infection","infection","Australia",">=18 years","general pop",-71,"-105",-43,NA,"omicron BA.2","~7 weeks",NA,"Note this estimate is comparative VE (reference group = receipt of BNT162b2 primary series 14-63 days prior rather than unvaccinated persons)","Australia","AUS",410,"AUS",50180,2019,"Australia","East Asia & Pacific","High income",4,"Oceania",2021-02-22,2021-09-24,2021-11-21,2021-02-21,2021-02-21,1,75,215,273,"who",75,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","yes",2023-07-29,"infection","2023 (Jul-Dec)","Comparative","Multiple","omicron",NA,2023-07-29
"3350",411,"Rosa","Test-negative case-control","26Jul2023","BNT162b2 (Pfizer BioNTech)","included","2","final","7+","symptomatic disease","symptomatic","Brazil",">=12 years","general pop",46.7,"19.9",64.6,NA,"omicron BA.1, BA.2","~70 weeks",NA,NA,"Brazil","BRA",411,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2023-07-26,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-07-26
"3351",411,"Rosa","Test-negative case-control","26Jul2023","BNT162b2 (Pfizer BioNTech)","included","2","final","7-29","symptomatic disease","symptomatic","Brazil",">=12 years","general pop",77.7,"54.8",89.4,NA,"omicron BA.1, BA.2","~70 weeks",NA,NA,"Brazil","BRA",411,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2023-07-26,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-07-26
"3352",411,"Rosa","Test-negative case-control","26Jul2023","BNT162b2 (Pfizer BioNTech)","included","2","final","180+","symptomatic disease","symptomatic","Brazil",">=12 years","general pop",22.5,"-55.2",61.3,NA,"omicron BA.1, BA.2","~70 weeks",NA,NA,"Brazil","BRA",411,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2023-07-26,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-07-26
"3353",411,"Rosa","Test-negative case-control","26Jul2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","symptomatic disease","symptomatic","Brazil",">=12 years","general pop",58.2,"27.7",76,NA,"omicron BA.1","~70 weeks",NA,NA,"Brazil","BRA",411,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2023-07-26,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-07-26
"3354",411,"Rosa","Test-negative case-control","26Jul2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","symptomatic disease","symptomatic","Brazil",">=12 years","general pop",51.5,"-82.5",69.4,NA,"omicron BA.2","~70 weeks",NA,NA,"Brazil","BRA",411,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2023-07-26,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-07-26
"3355",411,"Rosa","Test-negative case-control","26Jul2023","BNT162b2 (Pfizer BioNTech) vs. AZD1222 (AstraZeneca)","included","2","final","14+","symptomatic disease","symptomatic","Brazil",">=12 years","general pop",25,"5",41,NA,"omicron BA.1, BA.2","~70 weeks",NA,"Note this estimate is comparative VE (reference group = receipt of BNT162b2 primary series rather than unvaccinated persons)","Brazil","BRA",411,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2023-07-26,"symptomatic","2023 (Jul-Dec)","Comparative","Multiple","omicron",NA,2023-07-26
"3356",411,"Rosa","Test-negative case-control","26Jul2023","BNT162b2 (Pfizer BioNTech) vs. CoronaVac (Sinovac)","included","2","final","14+","symptomatic disease","symptomatic","Brazil",">=12 years","general pop",33,"8",51,NA,"omicron BA.1, BA.2","~70 weeks",NA,"Note this estimate is comparative VE (reference group = receipt of BNT162b2 primary series rather than unvaccinated persons)","Brazil","BRA",411,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2023-07-26,"symptomatic","2023 (Jul-Dec)","Comparative","Multiple","omicron",NA,2023-07-26
"3357",411,"Rosa","Test-negative case-control","26Jul2023","BNT162b2 (Pfizer BioNTech) vs. Ad26.COV2.S (Janssen)","included","2","final","14+","symptomatic disease","symptomatic","Brazil",">=12 years","general pop",14,"-52",51,NA,"omicron BA.1, BA.2","~70 weeks",NA,"Note this estimate is comparative VE (reference group = receipt of BNT162b2 primary series rather than unvaccinated persons)","Brazil","BRA",411,"BRA",14890,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,40,250,384,"who",40,"jan/2021","30-59","Sep-Nov/2021","180-269","yes","yes","yes",2023-07-26,"symptomatic","2023 (Jul-Dec)","Comparative","Multiple","omicron",NA,2023-07-26
"3358",412,"Franchi","Nested case-control","01Aug2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","Italy",">=12 years","general pop",18,"13",23,NA,"omicron BA.1, BA.2","~72 weeks",NA,NA,"Italy","ITA",412,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-08-01,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-08-01
"3359",412,"Franchi","Nested case-control","01Aug2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","Italy",">=12 years","general pop",81,"65",89,NA,"delta","~43 weeks",NA,NA,"Italy","ITA",412,"ITA",46190,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,15,201,285,"who",15,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-08-01,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2023-08-01
"3360",413,"Whitaker","Retrospective cohort","12Aug2023","AZD1222 (AstraZeneca)","included","2","final","14-69","death","death","UK","general pop with overrepsentation of clinical risk groups (30%)","general pop with overrepsentation of clinical risk groups (30%)",89.9,"86.1",92.6,NA,"delta","~44 weeks",NA,NA,"UK","GBR",413,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-08-12,"death","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2023-08-12
"3361",413,"Whitaker","Retrospective cohort","12Aug2023","AZD1222 (AstraZeneca)","included","2","final","182+","death","death","UK","general pop with overrepsentation of clinical risk groups (30%)","general pop with overrepsentation of clinical risk groups (30%)",72.3,"67.6",76.4,NA,"delta","~44 weeks",NA,NA,"UK","GBR",413,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-08-12,"death","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2023-08-12
"3362",413,"Whitaker","Retrospective cohort","12Aug2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14-69","death","death","UK","general pop with overrepsentation of clinical risk groups (30%)","general pop with overrepsentation of clinical risk groups (30%)",95.5,"91.8",97.5,NA,"delta","~47 weeks",NA,NA,"UK","GBR",413,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-08-12,"death","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-08-12
"3363",413,"Whitaker","Retrospective cohort","12Aug2023","BNT162b2 (Pfizer BioNTech)","included","2","final","182+","death","death","UK","general pop with overrepsentation of clinical risk groups (30%)","general pop with overrepsentation of clinical risk groups (30%)",81.7,"78.7",84.3,NA,"delta","~47 weeks",NA,NA,"UK","GBR",413,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-08-12,"death","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-08-12
"3364",413,"Whitaker","Retrospective cohort","12Aug2023","AZD1222 (AstraZeneca)","included","2","final","14-69","hospitalization","hospitalization","UK","general pop with overrepsentation of clinical risk groups (30%)","general pop with overrepsentation of clinical risk groups (30%)",92.5,"91.7",93.2,NA,"delta","~44 weeks",NA,NA,"UK","GBR",413,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-08-12,"severe","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2023-08-12
"3365",413,"Whitaker","Retrospective cohort","12Aug2023","AZD1222 (AstraZeneca)","included","2","final","182+","hospitalization","hospitalization","UK","general pop with overrepsentation of clinical risk groups (30%)","general pop with overrepsentation of clinical risk groups (30%)",68.7,"66.3",71,NA,"delta","~44 weeks",NA,NA,"UK","GBR",413,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-08-12,"severe","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2023-08-12
"3366",413,"Whitaker","Retrospective cohort","12Aug2023","AZD1222 (AstraZeneca)","included","2","final","14-69","hospitalization","hospitalization","UK","Immunocompromised","Immunocompromised",76.6,"66.9",83.4,NA,"delta","~44 weeks",NA,NA,"UK","GBR",413,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-08-12,"severe","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2023-08-12
"3367",413,"Whitaker","Retrospective cohort","12Aug2023","AZD1222 (AstraZeneca)","included","2","final","182+","hospitalization","hospitalization","UK","Immunocompromised","Immunocompromised",62.1,"51.4",70.5,NA,"delta","~44 weeks",NA,NA,"UK","GBR",413,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-08-12,"severe","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2023-08-12
"3368",413,"Whitaker","Retrospective cohort","12Aug2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14-69","hospitalization","hospitalization","UK","general pop with overrepsentation of clinical risk groups (30%)","general pop with overrepsentation of clinical risk groups (30%)",96,"95.1",96.7,NA,"delta","~47 weeks",NA,NA,"UK","GBR",413,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-08-12,"severe","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-08-12
"3369",413,"Whitaker","Retrospective cohort","12Aug2023","BNT162b2 (Pfizer BioNTech)","included","2","final","182+","hospitalization","hospitalization","UK","general pop with overrepsentation of clinical risk groups (30%)","general pop with overrepsentation of clinical risk groups (30%)",82.9,"81.4",84.2,NA,"delta","~47 weeks",NA,NA,"UK","GBR",413,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-08-12,"severe","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-08-12
"3370",413,"Whitaker","Retrospective cohort","12Aug2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14-69","hospitalization","hospitalization","UK","Immunocompromised","Immunocompromised",86.7,"76.8",92.4,NA,"delta","~47 weeks",NA,NA,"UK","GBR",413,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-08-12,"severe","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-08-12
"3371",413,"Whitaker","Retrospective cohort","12Aug2023","BNT162b2 (Pfizer BioNTech)","included","2","final","182+","hospitalization","hospitalization","UK","Immunocompromised","Immunocompromised",72.1,"64.1",78.3,NA,"delta","~47 weeks",NA,NA,"UK","GBR",413,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-08-12,"severe","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-08-12
"3372",414,"Link-Gelles","Test-negative case-control","17Aug2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","ED or UC visit","symptomatic","USA","6 months - 5 years","6 months - 5 years",37,"19",51,NA,"omicron BA.4, BA.5","~44 weeks",NA,NA,"USA","USA",414,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-08-17,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-08-17
"3373",414,"Link-Gelles","Test-negative case-control","17Aug2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14-59","ED or UC visit","symptomatic","USA","6 months - 5 years","6 months - 5 years",46,"22",62,NA,"omicron BA.4, BA.5","~44 weeks",NA,NA,"USA","USA",414,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-08-17,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-08-17
"3374",414,"Link-Gelles","Test-negative case-control","17Aug2023","BNT162b2 (Pfizer BioNTech)","included","2","final","60+","ED or UC visit","symptomatic","USA","6 months - 5 years","6 months - 5 years",27,"-2",47,NA,"omicron BA.4, BA.5","~44 weeks",NA,NA,"USA","USA",414,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-08-17,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-08-17
"3375",414,"Link-Gelles","Test-negative case-control","17Aug2023","mRNA-1273 (Moderna)","included","2","final","14+","ED or UC visit","symptomatic","USA","6 months - 4 years","6 months - 4 years",29,"12",42,NA,"omicron BA.4, BA.5","~44 weeks",NA,NA,"USA","USA",414,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-08-17,"symptomatic","2023 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron",NA,2023-08-17
"3376",414,"Link-Gelles","Test-negative case-control","17Aug2023","mRNA-1273 (Moderna)","included","2","final","14-59","ED or UC visit","symptomatic","USA","6 months - 4 years","6 months - 4 years",46,"17",64,NA,"omicron BA.4, BA.5","~44 weeks",NA,NA,"USA","USA",414,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-08-17,"symptomatic","2023 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron",NA,2023-08-17
"3377",414,"Link-Gelles","Test-negative case-control","17Aug2023","mRNA-1273 (Moderna)","included","2","final","60+","ED or UC visit","symptomatic","USA","6 months - 4 years","6 months - 4 years",21,"-1",38,NA,"omicron BA.4, BA.5","~44 weeks",NA,NA,"USA","USA",414,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-08-17,"symptomatic","2023 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron",NA,2023-08-17
"3378",415,"Zerbo","Test-negative case-control","25Aug2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","<150","infection","infection","USA","16-49 years","16-49 years",22,"-7",44,NA,"omicron BA.1","~80 weeks",NA,NA,"USA","USA",415,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-08-25,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-08-25
"3379",415,"Zerbo","Test-negative case-control","25Aug2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","150+","infection","infection","USA","16-49 years","16-49 years",19,"-2",50,NA,"omicron BA.1","~80 weeks",NA,NA,"USA","USA",415,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-08-25,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-08-25
"3380",415,"Zerbo","Test-negative case-control","25Aug2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","<150","infection","infection","USA","16-49 years","16-49 years",12,"-48",59,NA,"omicron BA.2, BA.4/BA.5","~55 weeks",NA,NA,"USA","USA",415,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-08-25,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-08-25
"3381",415,"Zerbo","Test-negative case-control","25Aug2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","150+","infection","infection","USA","16-49 years","16-49 years",-55,"-79",-6,NA,"omicron BA.2, BA.4/BA.5","~55 weeks",NA,NA,"USA","USA",415,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-08-25,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-08-25
"3382",415,"Zerbo","Test-negative case-control","25Aug2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","<150","infection","infection","USA","16-49 years","16-49 years",77,"69",82,NA,"delta","~42 weeks",NA,NA,"USA","USA",415,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-08-25,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2023-08-25
"3383",415,"Zerbo","Test-negative case-control","25Aug2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","150+","infection","infection","USA","16-49 years","16-49 years",66,"49",77,NA,"delta","~42 weeks",NA,NA,"USA","USA",415,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-08-25,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2023-08-25
"3384",415,"Zerbo","Retrospective cohort","25Aug2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","<150","infection","infection","USA","16-49 years","16-49 years",14,"-5",30,NA,"omicron BA.1","~80 weeks",NA,NA,"USA","USA",415,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-08-25,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-08-25
"3385",415,"Zerbo","Retrospective cohort","25Aug2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","150+","infection","infection","USA","16-49 years","16-49 years",10,"-17",33,NA,"omicron BA.1","~80 weeks",NA,NA,"USA","USA",415,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-08-25,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-08-25
"3386",415,"Zerbo","Retrospective cohort","25Aug2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","<150","infection","infection","USA","16-49 years","16-49 years",-16,"-60",43,NA,"omicron BA.2, BA.4/BA.5","~55 weeks",NA,NA,"USA","USA",415,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-08-25,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-08-25
"3387",415,"Zerbo","Retrospective cohort","25Aug2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","150+","infection","infection","USA","16-49 years","16-49 years",-33,"-65",24,NA,"omicron BA.2, BA.4/BA.5","~55 weeks",NA,NA,"USA","USA",415,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-08-25,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-08-25
"3388",415,"Zerbo","Retrospective cohort","25Aug2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","<150","infection","infection","USA","16-49 years","16-49 years",78,"72",83,NA,"delta","~42 weeks",NA,NA,"USA","USA",415,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-08-25,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2023-08-25
"3389",415,"Zerbo","Retrospective cohort","25Aug2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","150+","infection","infection","USA","16-49 years","16-49 years",68,"52",78,NA,"delta","~42 weeks",NA,NA,"USA","USA",415,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-08-25,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2023-08-25
"3390",416,"Ogilvie","Retrospective cohort","08Sep2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection","infection","USA","5-17 years","5-17 years",9,"-1",19,NA,"omicron BA.1, BA.2","~69 weeks",NA,NA,"USA","USA",416,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-09-08,"infection","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-09-08
"3391",416,"Ogilvie","Retrospective cohort","08Sep2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","hospitalization or ED visit","symptomatic or severe","USA","5-17 years","5-17 years",13,"-39",46,NA,"omicron BA.1, BA.2","~69 weeks",NA,NA,"USA","USA",416,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-09-08,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-09-08
"3392",416,"Ogilvie","Retrospective cohort","08Sep2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection","infection","USA","5-17 years","5-17 years",61,"59",64,NA,"delta","~47 weeks",NA,NA,"USA","USA",416,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-09-08,"infection","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-09-08
"3393",416,"Ogilvie","Retrospective cohort","08Sep2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","hospitalization or ED visit","symptomatic or severe","USA","5-17 years","5-17 years",78,"71",83,NA,"delta","~47 weeks",NA,NA,"USA","USA",416,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-09-08,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-09-08
"3394",416,"Ogilvie","Retrospective cohort","08Sep2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection","infection","USA","5-17 years","5-17 years",61,"52",68,NA,"non-VOC & alpha","~17 weeks",NA,NA,"USA","USA",416,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-09-08,"infection","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-09-08
"3395",416,"Ogilvie","Retrospective cohort","08Sep2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","hospitalization or ED visit","symptomatic or severe","USA","5-17 years","5-17 years",65,"4",87,NA,"non-VOC & alpha","~17 weeks",NA,NA,"USA","USA",416,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-09-08,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-09-08
"3396",417,"Copland","Nested case-control","07Sep2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14-41","hospitalization","severe","UK",">=12 years with blood cancer",">=12 years with blood cancer",72,"18",89,NA,"alpha, delta, & omicron BA.1","~65 weeks",NA,NA,"UK","GBR",417,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-09-07,"severe","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-09-07
"3397",417,"Copland","Nested case-control","07Sep2023","BNT162b2 (Pfizer BioNTech)","included","2","final","182+","hospitalization","severe","UK",">=12 years with blood cancer",">=12 years with blood cancer",-46,"-130",7,NA,"alpha, delta, & omicron BA.1","~65 weeks",NA,NA,"UK","GBR",417,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-09-07,"severe","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-09-07
"3398",417,"Copland","Nested case-control","07Sep2023","BNT162b2 (Pfizer BioNTech)","included","2","final","42-97","death","death","UK",">=12 years with blood cancer",">=12 years with blood cancer",64,"-3",87,NA,"alpha, delta, & omicron BA.1","~65 weeks",NA,NA,"UK","GBR",417,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-09-07,"death","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-09-07
"3399",417,"Copland","Nested case-control","07Sep2023","BNT162b2 (Pfizer BioNTech)","included","2","final","182+","death","death","UK",">=12 years with blood cancer",">=12 years with blood cancer",-52,"-176",17,NA,"alpha, delta, & omicron BA.1","~65 weeks",NA,NA,"UK","GBR",417,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-09-07,"death","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-09-07
"3400",417,"Copland","Nested case-control","07Sep2023","AZD1222 (AstraZeneca)","included","2","final","14-41","hospitalization","severe","UK",">=12 years with blood cancer",">=12 years with blood cancer",15,"-77",59,NA,"alpha, delta, & omicron BA.1","~56 weeks",NA,NA,"UK","GBR",417,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-09-07,"severe","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2023-09-07
"3401",417,"Copland","Nested case-control","07Sep2023","AZD1222 (AstraZeneca)","included","2","final","182+","hospitalization","severe","UK",">=12 years with blood cancer",">=12 years with blood cancer",6,"-47",39,NA,"alpha, delta, & omicron BA.1","~56 weeks",NA,NA,"UK","GBR",417,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-09-07,"severe","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2023-09-07
"3402",417,"Copland","Nested case-control","07Sep2023","AZD1222 (AstraZeneca)","included","2","final","42-97","death","death","UK",">=12 years with blood cancer",">=12 years with blood cancer",-13,"-188",55,NA,"alpha, delta, & omicron BA.1","~56 weeks",NA,NA,"UK","GBR",417,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-09-07,"death","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2023-09-07
"3403",417,"Copland","Nested case-control","07Sep2023","AZD1222 (AstraZeneca)","included","2","final","182+","death","death","UK",">=12 years with blood cancer",">=12 years with blood cancer",-100,"-283",-4,NA,"alpha, delta, & omicron BA.1","~56 weeks",NA,NA,"UK","GBR",417,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-09-07,"death","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2023-09-07
"3404",417,"Copland","Nested case-control","07Sep2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14-41","hospitalization","severe","UK",">=12 years","general pop",61,"56",66,NA,"alpha, delta, & omicron BA.1","~65 weeks",NA,NA,"UK","GBR",417,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-09-07,"severe","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-09-07
"3405",417,"Copland","Nested case-control","07Sep2023","BNT162b2 (Pfizer BioNTech)","included","2","final","182+","hospitalization","severe","UK",">=12 years","general pop",-38,"-48",-29,NA,"alpha, delta, & omicron BA.1","~65 weeks",NA,NA,"UK","GBR",417,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-09-07,"severe","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-09-07
"3406",417,"Copland","Nested case-control","07Sep2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14-41","death","death","UK",">=12 years","general pop",80,"73",85,NA,"alpha, delta, & omicron BA.1","~65 weeks",NA,NA,"UK","GBR",417,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-09-07,"death","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-09-07
"3407",417,"Copland","Nested case-control","07Sep2023","BNT162b2 (Pfizer BioNTech)","included","2","final","182+","death","death","UK",">=12 years","general pop",-97,"-127",-72,NA,"alpha, delta, & omicron BA.1","~65 weeks",NA,NA,"UK","GBR",417,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-09-07,"death","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-09-07
"3408",417,"Copland","Nested case-control","07Sep2023","AZD1222 (AstraZeneca)","included","2","final","14-41","hospitalization","severe","UK",">=12 years","general pop",66,"61",70,NA,"alpha, delta, & omicron BA.1","~56 weeks",NA,NA,"UK","GBR",417,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-09-07,"severe","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2023-09-07
"3409",417,"Copland","Nested case-control","07Sep2023","AZD1222 (AstraZeneca)","included","2","final","182+","hospitalization","severe","UK",">=12 years","general pop",-22,"-31",-13,NA,"alpha, delta, & omicron BA.1","~56 weeks",NA,NA,"UK","GBR",417,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-09-07,"severe","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2023-09-07
"3410",417,"Copland","Nested case-control","07Sep2023","AZD1222 (AstraZeneca)","included","2","final","14-41","death","death","UK",">=12 years","general pop",62,"43",75,NA,"alpha, delta, & omicron BA.1","~56 weeks",NA,NA,"UK","GBR",417,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-09-07,"death","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2023-09-07
"3411",417,"Copland","Nested case-control","07Sep2023","AZD1222 (AstraZeneca)","included","2","final","182+","death","death","UK",">=12 years","general pop",-74,"-101",-50,NA,"alpha, delta, & omicron BA.1","~56 weeks",NA,NA,"UK","GBR",417,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-09-07,"death","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2023-09-07
"3412",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","AZD1222 (AstraZeneca)","excluded","2","final","14-44","symptomatic disease","symptomatic","Colombia",">=5 years","general pop",36,"24",47,NA,"omicron BA.1","~43 weeks",NA,NA,"Colombia","COL",418,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"symptomatic","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron",NA,2023-09-09
"3413",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","AZD1222 (AstraZeneca)","excluded","2","final","165+","symptomatic disease","symptomatic","Colombia",">=5 years","general pop",-8,"-34",13,NA,"omicron BA.1","~43 weeks",NA,NA,"Colombia","COL",418,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"symptomatic","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron",NA,2023-09-09
"3414",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","AZD1222 (AstraZeneca)","excluded","2","final","14+","hospitalization","severe","Colombia",">=5 years","general pop",10,"-78",55,NA,"omicron BA.1","~43 weeks",NA,NA,"Colombia","COL",418,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"severe","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron",NA,2023-09-09
"3415",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","CoronaVac (Sinovac)","excluded","2","final","14-44","symptomatic disease","symptomatic","Colombia",">=5 years","general pop",37,"8",56,NA,"omicron BA.1","~46 weeks",NA,NA,"Colombia","COL",418,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"symptomatic","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2023-09-09
"3416",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","CoronaVac (Sinovac)","excluded","2","final","165+","symptomatic disease","symptomatic","Colombia",">=5 years","general pop",-36,"-48",24,NA,"omicron BA.1","~46 weeks",NA,NA,"Colombia","COL",418,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"symptomatic","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2023-09-09
"3417",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","CoronaVac (Sinovac)","excluded","2","final","14+","hospitalization","severe","Colombia",">=5 years","general pop",7,"-41",38,NA,"omicron BA.1","~46 weeks",NA,NA,"Colombia","COL",418,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"severe","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2023-09-09
"3418",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-44","symptomatic disease","symptomatic","Colombia",">=5 years","general pop",59,"45",70,NA,"omicron BA.1","~47 weeks",NA,NA,"Colombia","COL",418,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-09-09
"3419",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","165+","symptomatic disease","symptomatic","Colombia",">=5 years","general pop",4,"-2",11,NA,"omicron BA.1","~47 weeks",NA,NA,"Colombia","COL",418,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-09-09
"3420",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization","severe","Colombia",">=5 years","general pop",45,"1",70,NA,"omicron BA.1","~47 weeks",NA,NA,"Colombia","COL",418,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"severe","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-09-09
"3421",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","mRNA-1273 (Moderna)","excluded","2","final","14-44","symptomatic disease","symptomatic","Colombia",">=5 years","general pop",65,"54",74,NA,"omicron BA.1","~25 weeks",NA,NA,"Colombia","COL",418,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"symptomatic","2023 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron",NA,2023-09-09
"3422",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","mRNA-1273 (Moderna)","excluded","2","final","165+","symptomatic disease","symptomatic","Colombia",">=5 years","general pop",-22,"-639",80,NA,"omicron BA.1","~25 weeks",NA,NA,"Colombia","COL",418,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"symptomatic","2023 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron",NA,2023-09-09
"3423",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization","severe","Colombia",">=5 years","general pop",95,"54",99,NA,"omicron BA.1","~25 weeks",NA,NA,"Colombia","COL",418,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"severe","2023 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron",NA,2023-09-09
"3424",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","Ad26.COV2.S (Janssen)","excluded","1","final","14-44","symptomatic disease","symptomatic","Colombia",">=5 years","general pop",34,"11",51,NA,"omicron BA.1","~33 weeks",NA,NA,"Colombia","COL",418,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"symptomatic","2023 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","omicron",NA,2023-09-09
"3425",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","Ad26.COV2.S (Janssen)","excluded","1","final","165+","symptomatic disease","symptomatic","Colombia",">=5 years","general pop",-29,"-43",17,NA,"omicron BA.1","~33 weeks",NA,NA,"Colombia","COL",418,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"symptomatic","2023 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","omicron",NA,2023-09-09
"3426",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","Ad26.COV2.S (Janssen)","excluded","1","final","14+","hospitalization","severe","Colombia",">=5 years","general pop",-5,"-158",57,NA,"omicron BA.1","~33 weeks",NA,NA,"Colombia","COL",418,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"severe","2023 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","omicron",NA,2023-09-09
"3427",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","AZD1222 (AstraZeneca)","excluded","2","final","14-44","symptomatic disease","symptomatic","Colombia",">=5 years","general pop",-2,"-32",21,NA,"delta","~32 weeks",NA,NA,"Colombia","COL",418,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"symptomatic","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2023-09-09
"3428",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","AZD1222 (AstraZeneca)","excluded","2","final","165+","symptomatic disease","symptomatic","Colombia",">=5 years","general pop",54,"-177",92,NA,"delta","~32 weeks",NA,NA,"Colombia","COL",418,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"symptomatic","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2023-09-09
"3429",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","AZD1222 (AstraZeneca)","excluded","2","final","14+","hospitalization","severe","Colombia",">=5 years","general pop",71,"27",89,NA,"delta","~32 weeks",NA,NA,"Colombia","COL",418,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"severe","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2023-09-09
"3430",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","CoronaVac (Sinovac)","excluded","2","final","14-44","symptomatic disease","symptomatic","Colombia",">=5 years","general pop",31,"10",47,NA,"delta","~35 weeks",NA,NA,"Colombia","COL",418,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"symptomatic","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","delta",NA,2023-09-09
"3431",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","CoronaVac (Sinovac)","excluded","2","final","165+","symptomatic disease","symptomatic","Colombia",">=5 years","general pop",34,"18",47,NA,"delta","~35 weeks",NA,NA,"Colombia","COL",418,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"symptomatic","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","delta",NA,2023-09-09
"3432",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","CoronaVac (Sinovac)","excluded","2","final","14+","hospitalization","severe","Colombia",">=5 years","general pop",63,"35",79,NA,"delta","~35 weeks",NA,NA,"Colombia","COL",418,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"severe","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","delta",NA,2023-09-09
"3433",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-44","symptomatic disease","symptomatic","Colombia",">=5 years","general pop",10,"-20",33,NA,"delta","~36 weeks",NA,NA,"Colombia","COL",418,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-09-09
"3434",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","165+","symptomatic disease","symptomatic","Colombia",">=5 years","general pop",62,"57",67,NA,"delta","~36 weeks",NA,NA,"Colombia","COL",418,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-09-09
"3435",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization","severe","Colombia",">=5 years","general pop",91,"79",96,NA,"delta","~36 weeks",NA,NA,"Colombia","COL",418,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"severe","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-09-09
"3436",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","mRNA-1273 (Moderna)","excluded","2","final","14-44","symptomatic disease","symptomatic","Colombia",">=5 years","general pop",52,"41",61,NA,"delta","~14 weeks",NA,NA,"Colombia","COL",418,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"symptomatic","2023 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2023-09-09
"3437",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","mRNA-1273 (Moderna)","excluded","2","final","105-134","symptomatic disease","symptomatic","Colombia",">=5 years","general pop",89,"-8",99,NA,"delta","~14 weeks",NA,NA,"Colombia","COL",418,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"symptomatic","2023 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2023-09-09
"3438",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","Ad26.COV2.S (Janssen)","excluded","1","final","14-44","symptomatic disease","symptomatic","Colombia",">=5 years","general pop",7,"-19",27,NA,"delta","~22 weeks",NA,NA,"Colombia","COL",418,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"symptomatic","2023 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta",NA,2023-09-09
"3439",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","Ad26.COV2.S (Janssen)","excluded","1","final","165+","symptomatic disease","symptomatic","Colombia",">=5 years","general pop",70,"-5",92,NA,"delta","~22 weeks",NA,NA,"Colombia","COL",418,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"symptomatic","2023 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta",NA,2023-09-09
"3440",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","Ad26.COV2.S (Janssen)","excluded","1","final","14+","hospitalization","severe","Colombia",">=5 years","general pop",73,"23",91,NA,"delta","~22 weeks",NA,NA,"Colombia","COL",418,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"severe","2023 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta",NA,2023-09-09
"3441",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","AZD1222 (AstraZeneca)","excluded","2","final","14-44","symptomatic disease","symptomatic","Colombia",">=5 years","general pop",62,"26",81,NA,"mu","~14 weeks",NA,NA,"Colombia","COL",418,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"symptomatic","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","mu",NA,2023-09-09
"3442",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","AZD1222 (AstraZeneca)","excluded","2","final","14+","hospitalization","severe","Colombia",">=5 years","general pop",-57,"-1646",86,NA,"mu","~14 weeks",NA,NA,"Colombia","COL",418,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"severe","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","mu",NA,2023-09-09
"3443",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","CoronaVac (Sinovac)","excluded","2","final","14-44","symptomatic disease","symptomatic","Colombia",">=5 years","general pop",56,"46",65,NA,"mu","~18 weeks",NA,NA,"Colombia","COL",418,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"symptomatic","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","mu",NA,2023-09-09
"3444",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","CoronaVac (Sinovac)","excluded","2","final","165+","symptomatic disease","symptomatic","Colombia",">=5 years","general pop",59,"-385",97,NA,"mu","~18 weeks",NA,NA,"Colombia","COL",418,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"symptomatic","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","mu",NA,2023-09-09
"3445",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","CoronaVac (Sinovac)","excluded","2","final","14+","hospitalization","severe","Colombia",">=5 years","general pop",68,"24",86,NA,"mu","~18 weeks",NA,NA,"Colombia","COL",418,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"severe","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","mu",NA,2023-09-09
"3446",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-44","symptomatic disease","symptomatic","Colombia",">=5 years","general pop",67,"61",72,NA,"mu","~19 weeks",NA,NA,"Colombia","COL",418,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","mu",NA,2023-09-09
"3447",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","165+","symptomatic disease","symptomatic","Colombia",">=5 years","general pop",77,"53",89,NA,"mu","~19 weeks",NA,NA,"Colombia","COL",418,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","mu",NA,2023-09-09
"3448",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization","severe","Colombia",">=5 years","general pop",88,"59",96,NA,"mu","~19 weeks",NA,NA,"Colombia","COL",418,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"severe","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","mu",NA,2023-09-09
"3449",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","Ad26.COV2.S (Janssen)","excluded","1","final","14-44","symptomatic disease","symptomatic","Colombia",">=5 years","general pop",50,"33",63,NA,"mu","~5 weeks",NA,NA,"Colombia","COL",418,"COL",15530,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,71,251,527,"who",71,"feb/2021","60-89","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"symptomatic","2023 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","mu",NA,2023-09-09
"3450",419,"Chen","Nested test-negative case-control","14Sep2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14-41","hospitalization","severe","UK","Immunocompromised","immunocompromised",77,"63",86,NA,"alpha, delta, & omicron BA.1","~50 weeks",NA,NA,"UK","GBR",419,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-09-14,"severe","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-09-14
"3451",419,"Chen","Nested test-negative case-control","14Sep2023","BNT162b2 (Pfizer BioNTech)","included","2","final","182-272","hospitalization","severe","UK","Immunocompromised","immunocompromised",49,"13",70,NA,"alpha, delta, & omicron BA.1","~50 weeks",NA,NA,"UK","GBR",419,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-09-14,"severe","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-09-14
"3452",419,"Chen","Nested test-negative case-control","14Sep2023","AZD1222 (AstraZeneca)","included","2","final","14-41","hospitalization","severe","UK","Immunocompromised","immunocompromised",43,"-9",70,NA,"alpha, delta, & omicron BA.1","~50 weeks",NA,NA,"UK","GBR",419,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-09-14,"severe","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2023-09-14
"3453",419,"Chen","Nested test-negative case-control","14Sep2023","AZD1222 (AstraZeneca)","included","2","final","42-97","hospitalization","severe","UK","Immunocompromised","immunocompromised",31,"-33",64,NA,"alpha, delta, & omicron BA.1","~50 weeks",NA,NA,"UK","GBR",419,"GBR",49370,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,13,165,367,"who",13,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","yes",2023-09-14,"severe","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2023-09-14
"3454",420,"Irala","Test-negative case-control","15Sep2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization due to SARI","severe","Paraguay",">=5 years","general pop",45.3,"5.8",68.7,NA,"omicron BA.1","~52 weeks",NA,NA,"Paraguay","PRY",420,"PRY",13770,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,76,291,NA,"who",76,"feb/2021","60-89","Dec/2021 +","270-359","yes","yes","no",2023-09-15,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-09-15
"3455",420,"Irala","Test-negative case-control","15Sep2023","AZD1222 (AstraZeneca)","included","2","final","14+","hospitalization due to SARI","severe","Paraguay",">=5 years","general pop",10,"-31.3",38.2,NA,"omicron BA.1","~52 weeks",NA,NA,"Paraguay","PRY",420,"PRY",13770,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,76,291,NA,"who",76,"feb/2021","60-89","Dec/2021 +","270-359","yes","yes","no",2023-09-15,"severe","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron",NA,2023-09-15
"3456",420,"Irala","Test-negative case-control","15Sep2023","Gam-COVID-Vac (Gamaleya)","included","2","final","14+","hospitalization due to SARI","severe","Paraguay",">=5 years","general pop",25.4,"-30.2",57.5,NA,"omicron BA.1","~52 weeks",NA,NA,"Paraguay","PRY",420,"PRY",13770,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,76,291,NA,"who",76,"feb/2021","60-89","Dec/2021 +","270-359","yes","yes","no",2023-09-15,"severe","2023 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","omicron",NA,2023-09-15
"3457",420,"Irala","Test-negative case-control","15Sep2023","BBIBP-CorV (Beijing CNBG)","included","2","final","14+","hospitalization due to SARI","severe","Paraguay",">=5 years","general pop",42.3,"-2",67.6,NA,"omicron BA.1","~52 weeks",NA,NA,"Paraguay","PRY",420,"PRY",13770,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,76,291,NA,"who",76,"feb/2021","60-89","Dec/2021 +","270-359","yes","yes","no",2023-09-15,"severe","2023 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","omicron",NA,2023-09-15
"3458",420,"Irala","Test-negative case-control","15Sep2023","BBV152 (Bharat)","included","2","final","14+","hospitalization due to SARI","severe","Paraguay",">=5 years","general pop",13,"-46.1",48,NA,"omicron BA.1","~52 weeks",NA,NA,"Paraguay","PRY",420,"PRY",13770,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,76,291,NA,"who",76,"feb/2021","60-89","Dec/2021 +","270-359","yes","yes","no",2023-09-15,"severe","2023 (Jul-Dec)","Bharat Covaxin/BBV152","Inactivated","omicron",NA,2023-09-15
"3459",420,"Irala","Test-negative case-control","15Sep2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization due to SARI","severe","Paraguay",">=5 years","general pop",90.4,"74.3",97.3,NA,"delta","~37 weeks",NA,NA,"Paraguay","PRY",420,"PRY",13770,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,76,291,NA,"who",76,"feb/2021","60-89","Dec/2021 +","270-359","yes","yes","no",2023-09-15,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2023-09-15
"3460",420,"Irala","Test-negative case-control","15Sep2023","AZD1222 (AstraZeneca)","included","2","final","14+","hospitalization due to SARI","severe","Paraguay",">=5 years","general pop",83.2,"67.8",91.9,NA,"delta","~37 weeks",NA,NA,"Paraguay","PRY",420,"PRY",13770,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,76,291,NA,"who",76,"feb/2021","60-89","Dec/2021 +","270-359","yes","yes","no",2023-09-15,"severe","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2023-09-15
"3461",420,"Irala","Test-negative case-control","15Sep2023","Gam-COVID-Vac (Gamaleya)","included","2","final","14+","hospitalization due to SARI","severe","Paraguay",">=5 years","general pop",82.9,"53",95.2,NA,"delta","~37 weeks",NA,NA,"Paraguay","PRY",420,"PRY",13770,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,76,291,NA,"who",76,"feb/2021","60-89","Dec/2021 +","270-359","yes","yes","no",2023-09-15,"severe","2023 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","delta",NA,2023-09-15
"3462",420,"Irala","Test-negative case-control","15Sep2023","BBIBP-CorV (Beijing CNBG)","included","2","final","14+","hospitalization due to SARI","severe","Paraguay",">=5 years","general pop",29.7,"-42.6",67.3,NA,"delta","~37 weeks",NA,NA,"Paraguay","PRY",420,"PRY",13770,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,76,291,NA,"who",76,"feb/2021","60-89","Dec/2021 +","270-359","yes","yes","no",2023-09-15,"severe","2023 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta",NA,2023-09-15
"3463",420,"Irala","Test-negative case-control","15Sep2023","BBV152 (Bharat)","included","2","final","14+","hospitalization due to SARI","severe","Paraguay",">=5 years","general pop",24.9,"-36.9",59.8,NA,"delta","~37 weeks",NA,NA,"Paraguay","PRY",420,"PRY",13770,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,76,291,NA,"who",76,"feb/2021","60-89","Dec/2021 +","270-359","yes","yes","no",2023-09-15,"severe","2023 (Jul-Dec)","Bharat Covaxin/BBV152","Inactivated","delta",NA,2023-09-15
"3464",421,"Tartof","Test-negative case-control","15Sep2023","BNT162b2 (Pfizer BioNTech)","included","3 (pediatric dose)","final","14+","ED or UC visit due to ARI","symptomatic","USA","6 months - 4 years","6 months - 4 years",10,"-40",42,NA,"omicron BA.4/BA.5, BQ.1, XBB","~35 weeks",NA,NA,"USA","USA",421,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-09-15,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-09-15
"3465",421,"Tartof","Test-negative case-control","15Sep2023","BNT162b2 (Pfizer BioNTech)","included","3 (pediatric dose)","final","14+","other outpatient encounter due to ARI","symptomatic","USA","6 months - 4 years","6 months - 4 years",21,"-41",56,NA,"omicron BA.4/BA.5, BQ.1, XBB","~35 weeks",NA,NA,"USA","USA",421,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-09-15,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-09-15
"3466",422,"Mimura","Retrospective cohort","23Sep2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7+","infection","infection","Japan",">=65 years",">=65 years",78.1,"65.2",87.8,NA,"delta","~22 weeks",NA,NA,"Japan","JPN",422,"JPN",43970,2019,"Japan","East Asia & Pacific","High income",4,"Asia",2021-02-22,2021-08-11,2021-10-16,2021-02-17,2021-02-17,5,71,175,241,"who",71,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-09-23,"infection","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-09-23
"3467",422,"Mimura","Retrospective cohort","23Sep2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7+","symptomatic disease","symptomatic","Japan",">=65 years",">=65 years",79.1,"64.6",88.9,NA,"delta","~22 weeks",NA,NA,"Japan","JPN",422,"JPN",43970,2019,"Japan","East Asia & Pacific","High income",4,"Asia",2021-02-22,2021-08-11,2021-10-16,2021-02-17,2021-02-17,5,71,175,241,"who",71,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-09-23,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-09-23
"3468",422,"Mimura","Retrospective cohort","23Sep2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7+","hospitalization","severe","Japan",">=65 years",">=65 years",93.5,"83.7",100,NA,"delta","~22 weeks",NA,NA,"Japan","JPN",422,"JPN",43970,2019,"Japan","East Asia & Pacific","High income",4,"Asia",2021-02-22,2021-08-11,2021-10-16,2021-02-17,2021-02-17,5,71,175,241,"who",71,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-09-23,"severe","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-09-23
"3469",423,"Patel","Test-negative case-control","29Sep2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","ED/UC visit","symptomatic","USA",">=18 years with any disability",">=18 years with any disability",45,"36",52,NA,"omicron BA.1, BA.2, BA.5","~82 weeks",NA,NA,"USA","USA",423,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-09-29,"symptomatic","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-09-29
"3470",423,"Patel","Test-negative case-control","29Sep2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA",">=18 years with any disability",">=18 years with any disability",45,"38",52,NA,"omicron BA.1, BA.2, BA.5","~82 weeks",NA,NA,"USA","USA",423,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-09-29,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-09-29
"3471",423,"Patel","Test-negative case-control","29Sep2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","ED/UC visit","symptomatic","USA",">=18 years with no disability",">=18 years with no disability",31,"29",32,NA,"omicron BA.1, BA.2, BA.5","~82 weeks",NA,NA,"USA","USA",423,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-09-29,"symptomatic","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-09-29
"3472",423,"Patel","Test-negative case-control","29Sep2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA",">=18 years with no disability",">=18 years with no disability",45,"43",48,NA,"omicron BA.1, BA.2, BA.5","~82 weeks",NA,NA,"USA","USA",423,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-09-29,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-09-29
"3473",423,"Patel","Test-negative case-control","29Sep2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","ED/UC visit","symptomatic","USA",">=18 years with any disability",">=18 years with any disability",79,"75",83,NA,"delta","~42 weeks",NA,NA,"USA","USA",423,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-09-29,"symptomatic","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2023-09-29
"3474",423,"Patel","Test-negative case-control","29Sep2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA",">=18 years with any disability",">=18 years with any disability",79,"76",83,NA,"delta","~42 weeks",NA,NA,"USA","USA",423,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-09-29,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2023-09-29
"3475",423,"Patel","Test-negative case-control","29Sep2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","ED/UC visit","symptomatic","USA",">=18 years with no disability",">=18 years with no disability",82,"82",83,NA,"delta","~42 weeks",NA,NA,"USA","USA",423,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-09-29,"symptomatic","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2023-09-29
"3476",423,"Patel","Test-negative case-control","29Sep2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA",">=18 years with no disability",">=18 years with no disability",87,"86",87,NA,"delta","~42 weeks",NA,NA,"USA","USA",423,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-09-29,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2023-09-29
"3477",424,"Chemaitelly","Retrospective cohort","04Oct2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","previously infected with Omicron only","2","final","90+","infection","infection","Qatar","all ages","all ages",57,"51",61,NA,"omicron BA.2, BA.2.75, BA.4/BA.5","~85 weeks",NA,NA,"Qatar","QAT",424,"QAT",92300,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,51,123,200,"owid",51,"jan/2021","30-59","before Jun/2021","<180","yes","yes","yes",2023-10-04,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-10-04
"3478",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","<91","symptomatic disease","symptomatic","Mexico",">=65 years",">=65 years",74.3,"70.5",77.6,NA,"delta","~33 weeks",NA,NA,"Mexico","MEX",426,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-10-19
"3479",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","141+","symptomatic disease","symptomatic","Mexico",">=65 years",">=65 years",66.9,"62.7",70.7,NA,"delta","~33 weeks",NA,NA,"Mexico","MEX",426,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-10-19
"3480",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","<91","hospitalization with ARI","severe","Mexico",">=65 years",">=65 years",87.5,"84.9",89.7,NA,"delta","~33 weeks",NA,NA,"Mexico","MEX",426,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"severe","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-10-19
"3481",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","141+","hospitalization with ARI","severe","Mexico",">=65 years",">=65 years",80.5,"77.4",83.2,NA,"delta","~33 weeks",NA,NA,"Mexico","MEX",426,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"severe","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-10-19
"3482",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","<91","severe disease","severe","Mexico",">=65 years",">=65 years",90.4,"87.8",92.4,NA,"delta","~33 weeks",NA,NA,"Mexico","MEX",426,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"severe","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-10-19
"3483",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","141+","severe disease","severe","Mexico",">=65 years",">=65 years",85.3,"82.3",87.8,NA,"delta","~33 weeks",NA,NA,"Mexico","MEX",426,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"severe","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-10-19
"3484",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","<91","death","death","Mexico",">=65 years",">=65 years",90.3,"87.7",92.4,NA,"delta","~33 weeks",NA,NA,"Mexico","MEX",426,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"death","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-10-19
"3485",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","141+","death","death","Mexico",">=65 years",">=65 years",85.7,"82.8",88.2,NA,"delta","~33 weeks",NA,NA,"Mexico","MEX",426,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"death","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-10-19
"3486",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","AZD1222 (AstraZeneca)","excluded","2","final","<91","symptomatic disease","symptomatic","Mexico",">=65 years",">=65 years",61.2,"56.9",65.1,NA,"delta","~33 weeks",NA,NA,"Mexico","MEX",426,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"symptomatic","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2023-10-19
"3487",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","AZD1222 (AstraZeneca)","excluded","2","final","141+","symptomatic disease","symptomatic","Mexico",">=65 years",">=65 years",51.8,"43.5",58.8,NA,"delta","~33 weeks",NA,NA,"Mexico","MEX",426,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"symptomatic","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2023-10-19
"3488",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","AZD1222 (AstraZeneca)","excluded","2","final","<91","hospitalization with ARI","severe","Mexico",">=65 years",">=65 years",81.1,"78.4",83.5,NA,"delta","~33 weeks",NA,NA,"Mexico","MEX",426,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"severe","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2023-10-19
"3489",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","AZD1222 (AstraZeneca)","excluded","2","final","141+","hospitalization with ARI","severe","Mexico",">=65 years",">=65 years",70.5,"64.2",75.8,NA,"delta","~33 weeks",NA,NA,"Mexico","MEX",426,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"severe","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2023-10-19
"3490",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","AZD1222 (AstraZeneca)","excluded","2","final","<91","severe disease","severe","Mexico",">=65 years",">=65 years",85.3,"82.8",87.5,NA,"delta","~33 weeks",NA,NA,"Mexico","MEX",426,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"severe","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2023-10-19
"3491",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","AZD1222 (AstraZeneca)","excluded","2","final","141+","severe disease","severe","Mexico",">=65 years",">=65 years",73.5,"66.5",79.1,NA,"delta","~33 weeks",NA,NA,"Mexico","MEX",426,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"severe","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2023-10-19
"3492",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","AZD1222 (AstraZeneca)","excluded","2","final","<91","death","death","Mexico",">=65 years",">=65 years",85.4,"82.9",87.6,NA,"delta","~33 weeks",NA,NA,"Mexico","MEX",426,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"death","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2023-10-19
"3493",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","AZD1222 (AstraZeneca)","excluded","2","final","141+","death","death","Mexico",">=65 years",">=65 years",73.6,"66.6",79.2,NA,"delta","~33 weeks",NA,NA,"Mexico","MEX",426,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"death","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2023-10-19
"3494",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","CoronaVac (Sinovac)","excluded","2","final","<91","symptomatic disease","symptomatic","Mexico",">=65 years",">=65 years",47,"39.6",53.5,NA,"delta","~33 weeks",NA,NA,"Mexico","MEX",426,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"symptomatic","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","delta",NA,2023-10-19
"3495",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","CoronaVac (Sinovac)","excluded","2","final","141+","symptomatic disease","symptomatic","Mexico",">=65 years",">=65 years",34.9,"26.2",42.6,NA,"delta","~33 weeks",NA,NA,"Mexico","MEX",426,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"symptomatic","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","delta",NA,2023-10-19
"3496",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","CoronaVac (Sinovac)","excluded","2","final","<91","hospitalization with ARI","severe","Mexico",">=65 years",">=65 years",69.8,"64.5",74.2,NA,"delta","~33 weeks",NA,NA,"Mexico","MEX",426,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"severe","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","delta",NA,2023-10-19
"3497",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","CoronaVac (Sinovac)","excluded","2","final","141+","hospitalization with ARI","severe","Mexico",">=65 years",">=65 years",57.8,"51",63.6,NA,"delta","~33 weeks",NA,NA,"Mexico","MEX",426,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"severe","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","delta",NA,2023-10-19
"3498",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","CoronaVac (Sinovac)","excluded","2","final","<91","severe disease","severe","Mexico",">=65 years",">=65 years",75.4,"70.3",79.7,NA,"delta","~33 weeks",NA,NA,"Mexico","MEX",426,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"severe","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","delta",NA,2023-10-19
"3499",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","CoronaVac (Sinovac)","excluded","2","final","141+","severe disease","severe","Mexico",">=65 years",">=65 years",59.2,"51.6",65.5,NA,"delta","~33 weeks",NA,NA,"Mexico","MEX",426,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"severe","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","delta",NA,2023-10-19
"3500",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","CoronaVac (Sinovac)","excluded","2","final","<91","death","death","Mexico",">=65 years",">=65 years",75.6,"70.5",79.8,NA,"delta","~33 weeks",NA,NA,"Mexico","MEX",426,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"death","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","delta",NA,2023-10-19
"3501",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","CoronaVac (Sinovac)","excluded","2","final","141+","death","death","Mexico",">=65 years",">=65 years",59.2,"51.6",65.5,NA,"delta","~33 weeks",NA,NA,"Mexico","MEX",426,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"death","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","delta",NA,2023-10-19
"3502",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","Ad5-nCOV (CanSino)","excluded","1","final","<91","symptomatic disease","symptomatic","Mexico",">=65 years",">=65 years",29,"5.3",46.7,NA,"delta","~33 weeks",NA,NA,"Mexico","MEX",426,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"symptomatic","2023 (Jul-Dec)","Cansino Ad5-nCoV","Vectored","delta",NA,2023-10-19
"3503",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","Ad5-nCOV (CanSino)","excluded","1","final","141+","symptomatic disease","symptomatic","Mexico",">=65 years",">=65 years",43.6,"32.1",53.1,NA,"delta","~33 weeks",NA,NA,"Mexico","MEX",426,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"symptomatic","2023 (Jul-Dec)","Cansino Ad5-nCoV","Vectored","delta",NA,2023-10-19
"3504",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","Ad5-nCOV (CanSino)","excluded","1","final","<91","hospitalization with ARI","severe","Mexico",">=65 years",">=65 years",58.2,"39",71.3,NA,"delta","~33 weeks",NA,NA,"Mexico","MEX",426,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"severe","2023 (Jul-Dec)","Cansino Ad5-nCoV","Vectored","delta",NA,2023-10-19
"3505",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","Ad5-nCOV (CanSino)","excluded","1","final","141+","hospitalization with ARI","severe","Mexico",">=65 years",">=65 years",58.8,"48.7",66.9,NA,"delta","~33 weeks",NA,NA,"Mexico","MEX",426,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"severe","2023 (Jul-Dec)","Cansino Ad5-nCoV","Vectored","delta",NA,2023-10-19
"3506",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","Ad5-nCOV (CanSino)","excluded","1","final","<91","severe disease","severe","Mexico",">=65 years",">=65 years",69.4,"50.6",81,NA,"delta","~33 weeks",NA,NA,"Mexico","MEX",426,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"severe","2023 (Jul-Dec)","Cansino Ad5-nCoV","Vectored","delta",NA,2023-10-19
"3507",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","Ad5-nCOV (CanSino)","excluded","1","final","141+","severe disease","severe","Mexico",">=65 years",">=65 years",63.8,"53.2",72,NA,"delta","~33 weeks",NA,NA,"Mexico","MEX",426,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"severe","2023 (Jul-Dec)","Cansino Ad5-nCoV","Vectored","delta",NA,2023-10-19
"3508",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","Ad5-nCOV (CanSino)","excluded","1","final","<91","death","death","Mexico",">=65 years",">=65 years",69.1,"50",80.8,NA,"delta","~33 weeks",NA,NA,"Mexico","MEX",426,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"death","2023 (Jul-Dec)","Cansino Ad5-nCoV","Vectored","delta",NA,2023-10-19
"3509",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","Ad5-nCOV (CanSino)","excluded","1","final","141+","death","death","Mexico",">=65 years",">=65 years",64.1,"53.6",72.3,NA,"delta","~33 weeks",NA,NA,"Mexico","MEX",426,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"death","2023 (Jul-Dec)","Cansino Ad5-nCoV","Vectored","delta",NA,2023-10-19
"3510",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","Gam-COVID-Vac (Gamaleya)","excluded","2","final","<91","symptomatic disease","symptomatic","Mexico",">=65 years",">=65 years",68.5,"59.5",75.5,NA,"delta","~33 weeks",NA,NA,"Mexico","MEX",426,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"symptomatic","2023 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","delta",NA,2023-10-19
"3511",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","Gam-COVID-Vac (Gamaleya)","excluded","2","final","141+","symptomatic disease","symptomatic","Mexico",">=65 years",">=65 years",75.5,"69.1",80.6,NA,"delta","~33 weeks",NA,NA,"Mexico","MEX",426,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"symptomatic","2023 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","delta",NA,2023-10-19
"3512",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","Gam-COVID-Vac (Gamaleya)","excluded","2","final","<91","hospitalization with ARI","severe","Mexico",">=65 years",">=65 years",90.4,"85.5",93.7,NA,"delta","~33 weeks",NA,NA,"Mexico","MEX",426,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"severe","2023 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","delta",NA,2023-10-19
"3513",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","Gam-COVID-Vac (Gamaleya)","excluded","2","final","141+","hospitalization with ARI","severe","Mexico",">=65 years",">=65 years",87.1,"82.2",90.6,NA,"delta","~33 weeks",NA,NA,"Mexico","MEX",426,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"severe","2023 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","delta",NA,2023-10-19
"3514",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","Gam-COVID-Vac (Gamaleya)","excluded","2","final","<91","severe disease","severe","Mexico",">=65 years",">=65 years",94.8,"90.5",97.2,NA,"delta","~33 weeks",NA,NA,"Mexico","MEX",426,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"severe","2023 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","delta",NA,2023-10-19
"3515",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","Gam-COVID-Vac (Gamaleya)","excluded","2","final","141+","severe disease","severe","Mexico",">=65 years",">=65 years",91.8,"87.3",94.7,NA,"delta","~33 weeks",NA,NA,"Mexico","MEX",426,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"severe","2023 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","delta",NA,2023-10-19
"3516",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","Gam-COVID-Vac (Gamaleya)","excluded","2","final","<91","death","death","Mexico",">=65 years",">=65 years",95.2,"91",94.7,NA,"delta","~33 weeks",NA,NA,"Mexico","MEX",426,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"death","2023 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","delta",NA,2023-10-19
"3517",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","Gam-COVID-Vac (Gamaleya)","excluded","2","final","141+","death","death","Mexico",">=65 years",">=65 years",91.8,"87.3",94.7,NA,"delta","~33 weeks",NA,NA,"Mexico","MEX",426,"MEX",19630,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,16,298,NA,"who",16,"before jan/2021","<30","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"death","2023 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","delta",NA,2023-10-19
"3518",427,"Lee","Test-negative case-control","24Nov2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","3 months","severe disease","severe","Canada",">=50 years",">=50 years",80,"78",83,NA,"omicron BA.1, BA.2","~63 weeks",NA,"Note 3.2% of participants received AZ+mRNA as their primary series  ","Canada","CAN",427,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-11-24,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","25/08/2023",2023-08-25
"3519",427,"Lee","Test-negative case-control","24Nov2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","15 months","severe disease","severe","Canada",">=50 years",">=50 years",80,"77",82,NA,"omicron BA.1, BA.2","~63 weeks",NA,"Note 3.2% of participants received AZ+mRNA as their primary series  ","Canada","CAN",427,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-11-24,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","25/08/2023",2023-08-25
"3520",427,"Lee","Test-negative case-control","24Nov2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","3 months","severe disease","severe","Canada",">=50 years",">=50 years",43,"19",60,NA,"omicron BA.4, BA.5","~63 weeks",NA,"Note 3.2% of participants received AZ+mRNA as their primary series  ","Canada","CAN",427,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-11-24,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","25/08/2023",2023-08-25
"3521",427,"Lee","Test-negative case-control","24Nov2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","15 months","severe disease","severe","Canada",">=50 years",">=50 years",49,"41",56,NA,"omicron BA.4, BA.5","~63 weeks",NA,"Note 3.2% of participants received AZ+mRNA as their primary series  ","Canada","CAN",427,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-11-24,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","25/08/2023",2023-08-25
"3522",427,"Lee","Test-negative case-control","24Nov2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","3 months","severe disease","severe","Canada",">=50 years",">=50 years",25,"-61",65,NA,"omicron BQ, XBB","~63 weeks",NA,"Note 3.2% of participants received AZ+mRNA as their primary series  ","Canada","CAN",427,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-11-24,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","25/08/2023",2023-08-25
"3523",427,"Lee","Test-negative case-control","24Nov2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","15 months","severe disease","severe","Canada",">=50 years",">=50 years",31,"17",43,NA,"omicron BQ, XBB","~63 weeks",NA,"Note 3.2% of participants received AZ+mRNA as their primary series  ","Canada","CAN",427,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-11-24,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","25/08/2023",2023-08-25
"3524",428,"Yiu","Case-control","10Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization due to COVID-19","severe","Hong Kong",">=18 years with a mental disorder",">=18 years with a mental disorder",71.1,"68",73.9,NA,"omicron BA.2","~70 weeks",NA,NA,"Hong Kong","HKG",428,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-10-10,"severe","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-10-10
"3525",428,"Yiu","Case-control","10Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","death","death","Hong Kong",">=18 years with a mental disorder",">=18 years with a mental disorder",86.1,"80.5",90.1,NA,"omicron BA.2","~70 weeks",NA,NA,"Hong Kong","HKG",428,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-10-10,"death","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-10-10
"3526",428,"Yiu","Case-control","10Oct2023","CoronaVac (Sinovac)","excluded","2","final","14+","hospitalization due to COVID-19","severe","Hong Kong",">=18 years with a mental disorder",">=18 years with a mental disorder",46.1,"42.7",49.3,NA,"omicron BA.2","~71 weeks",NA,NA,"Hong Kong","HKG",428,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-10-10,"severe","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2023-10-10
"3527",428,"Yiu","Case-control","10Oct2023","CoronaVac (Sinovac)","excluded","2","final","14+","death","death","Hong Kong",">=18 years with a mental disorder",">=18 years with a mental disorder",59.5,"53.7",64.6,NA,"omicron BA.2","~71 weeks",NA,NA,"Hong Kong","HKG",428,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-10-10,"death","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2023-10-10
"3528",429,"Tartof","Test-negative case-control","25Oct2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","severe disease","severe","USA",">=18 years","general pop",29,"-7",53,NA,"omicron BA.4, BA.5, XBB, XBB.1.5, XBB.1.16","~116 weeks",NA,NA,"USA","USA",429,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-10-25,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-10-25
"3529",429,"Tartof","Test-negative case-control","25Oct2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA",">=18 years","general pop",27,"13",39,NA,"omicron BA.4, BA.5, XBB, XBB.1.5, XBB.1.16","~116 weeks",NA,NA,"USA","USA",429,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-10-25,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-10-25
"3530",429,"Tartof","Test-negative case-control","25Oct2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","ED/UC visit","symptomatic","USA",">=18 years","general pop",18,"12",24,NA,"omicron BA.4, BA.5, XBB, XBB.1.5, XBB.1.16","~116 weeks",NA,NA,"USA","USA",429,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-10-25,"symptomatic","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-10-25
"3531",429,"Tartof","Test-negative case-control","25Oct2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","outpatient visit","symptomatic","USA",">=18 years","general pop",14,"6",21,NA,"omicron BA.4, BA.5, XBB, XBB.1.5, XBB.1.16","~116 weeks",NA,NA,"USA","USA",429,"USA",66120,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,5,152,NA,"owid",5,"before jan/2021","<30","before Jun/2021","<180","yes","yes","no",2023-10-25,"symptomatic","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-10-25
"3532",430,"Razafimandimby","Test-negative case-control","30Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","Canada","5-11 years","5-11 years",20,"13",26,NA,"omicron BA.1, BA.2, BA.4/BA.5","~54 weeks",NA,NA,"Canada","CAN",430,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-10-30,"infection","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-10-30
"3533",430,"Razafimandimby","Test-negative case-control","30Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-55","infection","infection","Canada","5-11 years","5-11 years",42,"35",49,NA,"omicron BA.1, BA.2, BA.4/BA.5","~54 weeks",NA,NA,"Canada","CAN",430,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-10-30,"infection","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-10-30
"3534",430,"Razafimandimby","Test-negative case-control","30Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","56-385","infection","infection","Canada","5-11 years","5-11 years",2,"-7",11,NA,"omicron BA.1, BA.2, BA.4/BA.5","~54 weeks",NA,NA,"Canada","CAN",430,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-10-30,"infection","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-10-30
"3535",430,"Razafimandimby","Test-negative case-control","30Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","Canada","5-11 years","5-11 years",10,"-2",21,NA,"omicron BA.1, BA.2, BA.4/BA.5","~54 weeks","21-55 days",NA,"Canada","CAN",430,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-10-30,"infection","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-10-30
"3536",430,"Razafimandimby","Test-negative case-control","30Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","Canada","5-11 years","5-11 years",39,"20",55,NA,"omicron BA.1, BA.2, BA.4/BA.5","~54 weeks","84-362 days",NA,"Canada","CAN",430,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-10-30,"infection","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-10-30
"3537",430,"Razafimandimby","Test-negative case-control","30Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease (ambulatory centers)","symptomatic","Canada","5-11 years","5-11 years",47,"40",54,NA,"omicron BA.1, BA.2, BA.4/BA.5","~54 weeks",NA,NA,"Canada","CAN",430,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-10-30,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-10-30
"3538",430,"Razafimandimby","Test-negative case-control","30Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-55","symptomatic disease (ambulatory centers)","symptomatic","Canada","5-11 years","5-11 years",68,"62",74,NA,"omicron BA.1, BA.2, BA.4/BA.5","~54 weeks",NA,NA,"Canada","CAN",430,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-10-30,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-10-30
"3539",430,"Razafimandimby","Test-negative case-control","30Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","56-385","symptomatic disease (ambulatory centers)","symptomatic","Canada","5-11 years","5-11 years",25,"11",36,NA,"omicron BA.1, BA.2, BA.4/BA.5","~54 weeks",NA,NA,"Canada","CAN",430,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-10-30,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-10-30
"3540",430,"Razafimandimby","Test-negative case-control","30Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease (ambulatory centers)","symptomatic","Canada","5-11 years","5-11 years",48,"36",57,NA,"omicron BA.1, BA.2, BA.4/BA.5","~54 weeks","21-55 days",NA,"Canada","CAN",430,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-10-30,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-10-30
"3541",430,"Razafimandimby","Test-negative case-control","30Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease (ambulatory centers)","symptomatic","Canada","5-11 years","5-11 years",45,"10",68,NA,"omicron BA.1, BA.2, BA.4/BA.5","~54 weeks","84-362 days",NA,"Canada","CAN",430,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-10-30,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-10-30
"3542",430,"Razafimandimby","Test-negative case-control","30Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease (acute care hospital)","symptomatic","Canada","5-11 years","5-11 years",42,"30",52,NA,"omicron BA.1, BA.2, BA.4/BA.5","~54 weeks",NA,NA,"Canada","CAN",430,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-10-30,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-10-30
"3543",430,"Razafimandimby","Test-negative case-control","30Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-55","symptomatic disease (acute care hospital)","symptomatic","Canada","5-11 years","5-11 years",41,"17",59,NA,"omicron BA.1, BA.2, BA.4/BA.5","~54 weeks",NA,NA,"Canada","CAN",430,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-10-30,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-10-30
"3544",430,"Razafimandimby","Test-negative case-control","30Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","56-385","symptomatic disease (acute care hospital)","symptomatic","Canada","5-11 years","5-11 years",42,"29",53,NA,"omicron BA.1, BA.2, BA.4/BA.5","~54 weeks",NA,NA,"Canada","CAN",430,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-10-30,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-10-30
"3545",430,"Razafimandimby","Test-negative case-control","30Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease (acute care hospital)","symptomatic","Canada","5-11 years","5-11 years",18,"-17",44,NA,"omicron BA.1, BA.2, BA.4/BA.5","~54 weeks","21-55 days",NA,"Canada","CAN",430,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-10-30,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-10-30
"3546",430,"Razafimandimby","Test-negative case-control","30Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease (acute care hospital)","symptomatic","Canada","5-11 years","5-11 years",69,"43",86,NA,"omicron BA.1, BA.2, BA.4/BA.5","~54 weeks","84-362 days",NA,"Canada","CAN",430,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-10-30,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-10-30
"3547",430,"Razafimandimby","Test-negative case-control","30Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","Canada","5-11 years","5-11 years",40,"31",47,NA,"omicron BA.1","~13 weeks",NA,NA,"Canada","CAN",430,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-10-30,"infection","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-10-30
"3548",430,"Razafimandimby","Test-negative case-control","30Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease (ambulatory centers)","symptomatic","Canada","5-11 years","5-11 years",70,"63",76,NA,"omicron BA.1","~13 weeks",NA,NA,"Canada","CAN",430,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-10-30,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-10-30
"3549",430,"Razafimandimby","Test-negative case-control","30Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease (acute care hospital)","symptomatic","Canada","5-11 years","5-11 years",27,"-13",53,NA,"omicron BA.1","~13 weeks",NA,NA,"Canada","CAN",430,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-10-30,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-10-30
"3550",430,"Razafimandimby","Test-negative case-control","30Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","Canada","5-11 years","5-11 years",14,"0",26,NA,"omicron BA.2","~25 weeks",NA,NA,"Canada","CAN",430,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-10-30,"infection","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-10-30
"3551",430,"Razafimandimby","Test-negative case-control","30Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease (ambulatory centers)","symptomatic","Canada","5-11 years","5-11 years",32,"13",47,NA,"omicron BA.2","~25 weeks",NA,NA,"Canada","CAN",430,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-10-30,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-10-30
"3552",430,"Razafimandimby","Test-negative case-control","30Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease (acute care hospital)","symptomatic","Canada","5-11 years","5-11 years",47,"26",62,NA,"omicron BA.2","~25 weeks",NA,NA,"Canada","CAN",430,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-10-30,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-10-30
"3553",430,"Razafimandimby","Test-negative case-control","30Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","Canada","5-11 years","5-11 years",-5,"-22",9,NA,"omicron BA.4/BA.5","~54 weeks",NA,NA,"Canada","CAN",430,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-10-30,"infection","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-10-30
"3554",430,"Razafimandimby","Test-negative case-control","30Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease (ambulatory centers)","symptomatic","Canada","5-11 years","5-11 years",-15,"-55",14,NA,"omicron BA.4/BA.5","~54 weeks",NA,NA,"Canada","CAN",430,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-10-30,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-10-30
"3555",430,"Razafimandimby","Test-negative case-control","30Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease (acute care hospital)","symptomatic","Canada","5-11 years","5-11 years",38,"18",54,NA,"omicron BA.4/BA.5","~54 weeks",NA,NA,"Canada","CAN",430,"CAN",49140,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,6,207,288,"who",6,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-10-30,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-10-30
"3556",431,"Goh","Retrospective cohort","10Nov2023","any mRNA in mothers before pregnancy","included (refers to mothers)","2","final","14+","infection","infection","Singapore","infants 0-6 months","infants 0-6 months",60.7,"-56.6",90.1,NA,"omicron XBB, XBB.1.5","~126 weeks",NA,NA,"Singapore","SGP",431,"SGP",89630,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,22,192,227,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-11-10,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-11-10
"3557",431,"Goh","Retrospective cohort","10Nov2023","any mRNA in mothers during pregnancy","included (refers to mothers)","2","final","14+","infection","infection","Singapore","infants 0-6 months","infants 0-6 months",73,"-30.6",94.4,NA,"omicron XBB, XBB.1.5","~63 weeks",NA,NA,"Singapore","SGP",431,"SGP",89630,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,22,192,227,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-11-10,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-11-10
"3558",431,"Goh","Retrospective cohort","10Nov2023","any mRNA in mothers before pregnancy","included (refers to mothers)","2","final","14+","infection","infection","Singapore","infants 0-6 months","infants 0-6 months",18.3,"-14.6",41.8,NA,"omicron BA.2, BA.5, XBB, XBB.1.5","~126 weeks",NA,NA,"Singapore","SGP",431,"SGP",89630,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,22,192,227,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-11-10,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-11-10
"3559",431,"Goh","Retrospective cohort","10Nov2023","any mRNA in mothers during pregnancy","included (refers to mothers)","2","final","14+","infection","infection","Singapore","infants 0-6 months","infants 0-6 months",37.6,"17.2",53.1,NA,"omicron BA.2, BA.5, XBB, XBB.1.5","~63 weeks",NA,NA,"Singapore","SGP",431,"SGP",89630,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,22,192,227,"equal",22,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-11-10,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-11-10
"3560",432,"Culpan","Retrospective cohort","15Nov2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","Turkey","HCW","HCW",82.3,"68",90.2,NA,"delta","~30 weeks",NA,NA,"Turkey","TUR",432,"TUR",27240,2019,"Türkiye","Europe & Central Asia","Upper middle income",3,"Asia",2021-01-14,2021-08-19,NA,NA,2021-01-14,NA,37,217,NA,"owid",37,"jan/2021","30-59","Jun-Aug/2021","180-269","yes","yes","no",2023-11-15,"infection","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-11-15
"3561",432,"Culpan","Retrospective cohort","15Nov2023","CoronaVac (Sinovac)","excluded","2","final","14+","infection","infection","Turkey","HCW","HCW",21,"-20.7",48.3,NA,"delta","~42 weeks",NA,NA,"Turkey","TUR",432,"TUR",27240,2019,"Türkiye","Europe & Central Asia","Upper middle income",3,"Asia",2021-01-14,2021-08-19,NA,NA,2021-01-14,NA,37,217,NA,"owid",37,"jan/2021","30-59","Jun-Aug/2021","180-269","yes","yes","no",2023-11-15,"infection","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","delta",NA,2023-11-15
"3562",433,"Szekanecz","Retrospective cohort","02Nov2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-120","infection","infection","Hungary","immunocompromised adults 18-84 years","immunocompromised",73,"68.8",76.7,NA,"delta","~32 weeks",NA,NA,"Hungary","HUN",433,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2023-11-02,"infection","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-11-02
"3563",433,"Szekanecz","Retrospective cohort","02Nov2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","181-240","infection","infection","Hungary","immunocompromised adults 18-84 years","immunocompromised",38.7,"35.1",42.1,NA,"delta","~32 weeks",NA,NA,"Hungary","HUN",433,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2023-11-02,"infection","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-11-02
"3564",433,"Szekanecz","Retrospective cohort","02Nov2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14-120","death","death","Hungary","immunocompromised adults 18-84 years","immunocompromised",53,"7.7",76.1,NA,"delta","~32 weeks",NA,NA,"Hungary","HUN",433,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2023-11-02,"death","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-11-02
"3565",433,"Szekanecz","Retrospective cohort","02Nov2023","BNT162b2 (Pfizer BioNTech)","included","2","final","181-240","death","death","Hungary","immunocompromised adults 18-84 years","immunocompromised",51.1,"33.3",64.1,NA,"delta","~32 weeks",NA,NA,"Hungary","HUN",433,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2023-11-02,"death","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-11-02
"3566",433,"Szekanecz","Retrospective cohort","02Nov2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-120","infection","infection","Hungary","non-immunocompromised adults 18-84 years","immunocompetent adults",68.1,"66.8",69.3,NA,"delta","~32 weeks",NA,NA,"Hungary","HUN",433,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2023-11-02,"infection","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-11-02
"3567",433,"Szekanecz","Retrospective cohort","02Nov2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","181-240","infection","infection","Hungary","non-immunocompromised adults 18-84 years","immunocompetent adults",16.1,"14.2",17.9,NA,"delta","~32 weeks",NA,NA,"Hungary","HUN",433,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2023-11-02,"infection","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-11-02
"3568",433,"Szekanecz","Retrospective cohort","02Nov2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14-120","death","death","Hungary","non-immunocompromised adults 18-84 years","immunocompetent adults",74.9,"64.6",82.2,NA,"delta","~32 weeks",NA,NA,"Hungary","HUN",433,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2023-11-02,"death","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-11-02
"3569",433,"Szekanecz","Retrospective cohort","02Nov2023","BNT162b2 (Pfizer BioNTech)","included","2","final","181-240","death","death","Hungary","non-immunocompromised adults 18-84 years","immunocompetent adults",80.8,"76.6",84.2,NA,"delta","~32 weeks",NA,NA,"Hungary","HUN",433,"HUN",33630,2019,"Hungary","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,15,164,NA,"who",15,"before jan/2021","<30","Jun-Aug/2021","<180","yes","yes","no",2023-11-02,"death","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-11-02
"3570",436,"Qin","Retrospective cohort","12Dec2023","CoronaVac (Sinovac)","excluded","2","final","0+","hospitalization","severe","Hong Kong",">=18 years","general pop",18,"6",23,NA,"delta & omicron BA.2, BA.5","~88 weeks",NA,NA,"Hong Kong","HKG",436,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-12-12,"severe","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","delta/omicron",NA,2023-12-12
"3571",436,"Qin","Retrospective cohort","12Dec2023","CoronaVac (Sinovac)","excluded","2","final","0+","severe disease","severe","Hong Kong",">=18 years","general pop",29,"12",43,NA,"delta & omicron BA.2, BA.5","~88 weeks",NA,NA,"Hong Kong","HKG",436,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-12-12,"severe","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","delta/omicron",NA,2023-12-12
"3572",436,"Qin","Retrospective cohort","12Dec2023","CoronaVac (Sinovac)","excluded","2","final","0+","death","death","Hong Kong",">=18 years","general pop",77,"74",80,NA,"delta & omicron BA.2, BA.5","~88 weeks",NA,NA,"Hong Kong","HKG",436,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-12-12,"death","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","delta/omicron",NA,2023-12-12
"3573",436,"Qin","Retrospective cohort","12Dec2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","0+","hospitalization","severe","Hong Kong",">=18 years","general pop",33,"30",37,NA,"delta & omicron BA.2, BA.5","~87 weeks",NA,NA,"Hong Kong","HKG",436,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-12-12,"severe","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta/omicron",NA,2023-12-12
"3574",436,"Qin","Retrospective cohort","12Dec2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","0+","severe disease","severe","Hong Kong",">=18 years","general pop",57,"45",66,NA,"delta & omicron BA.2, BA.5","~87 weeks",NA,NA,"Hong Kong","HKG",436,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-12-12,"severe","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta/omicron",NA,2023-12-12
"3575",436,"Qin","Retrospective cohort","12Dec2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","0+","death","death","Hong Kong",">=18 years","general pop",92,"91",94,NA,"delta & omicron BA.2, BA.5","~87 weeks",NA,NA,"Hong Kong","HKG",436,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-12-12,"death","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta/omicron",NA,2023-12-12
"3576",437,"Arashiro","Retrospective cohort","19Dec2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-180 (median 76)","severe disease requiring oxygen therapy","severe","Japan",">=16 years","general pop",95.2,"88.7",98,NA,"delta","24 weeks",NA,NA,"Japan","JPN",437,"JPN",43970,2019,"Japan","East Asia & Pacific","High income",4,"Asia",2021-02-22,2021-08-11,2021-10-16,2021-02-17,2021-02-17,5,71,175,241,"who",71,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-12-19,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2023-12-19
"3577",437,"Arashiro","Retrospective cohort","19Dec2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-180 (median 83)","severe disease requiring mechanical ventilation","severe","Japan",">=16 years","general pop",99.6,"97.3",99.9,NA,"delta","24 weeks",NA,NA,"Japan","JPN",437,"JPN",43970,2019,"Japan","East Asia & Pacific","High income",4,"Asia",2021-02-22,2021-08-11,2021-10-16,2021-02-17,2021-02-17,5,71,175,241,"who",71,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-12-19,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2023-12-19
"3578",437,"Arashiro","Retrospective cohort","19Dec2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-180 (median 83)","death","death","Japan",">=16 years","general pop",98.6,"92.3",99.7,NA,"delta","24 weeks",NA,NA,"Japan","JPN",437,"JPN",43970,2019,"Japan","East Asia & Pacific","High income",4,"Asia",2021-02-22,2021-08-11,2021-10-16,2021-02-17,2021-02-17,5,71,175,241,"who",71,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-12-19,"death","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2023-12-19
"3579",437,"Arashiro","Retrospective cohort","19Dec2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-180 (median 79)","severe disease requiring oxygen therapy with respiratory failure","severe","Japan",">=16 years","general pop",65.5,"89.3",98.1,NA,"delta","24 weeks",NA,NA,"Japan","JPN",437,"JPN",43970,2019,"Japan","East Asia & Pacific","High income",4,"Asia",2021-02-22,2021-08-11,2021-10-16,2021-02-17,2021-02-17,5,71,175,241,"who",71,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-12-19,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2023-12-19
"3580",437,"Arashiro","Retrospective cohort","19Dec2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-180 (median 155)","severe disease requiring oxygen therapy","severe","Japan",">=16 years","general pop",37,"-50.9",73.7,NA,"omicron BA.1, BA.2","~65 weeks",NA,NA,"Japan","JPN",437,"JPN",43970,2019,"Japan","East Asia & Pacific","High income",4,"Asia",2021-02-22,2021-08-11,2021-10-16,2021-02-17,2021-02-17,5,71,175,241,"who",71,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-12-19,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-12-19
"3581",437,"Arashiro","Retrospective cohort","19Dec2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","180+ (median 218)","severe disease requiring oxygen therapy","severe","Japan",">=16 years","general pop",47.9,"-2.1",73.4,NA,"omicron BA.1, BA.2","~65 weeks",NA,NA,"Japan","JPN",437,"JPN",43970,2019,"Japan","East Asia & Pacific","High income",4,"Asia",2021-02-22,2021-08-11,2021-10-16,2021-02-17,2021-02-17,5,71,175,241,"who",71,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-12-19,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-12-19
"3582",437,"Arashiro","Retrospective cohort","19Dec2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-180 (median 149)","severe disease requiring mechanical ventilation","severe","Japan",">=16 years","general pop",73.7,"-30.6",94.7,NA,"omicron BA.1, BA.2","~65 weeks",NA,NA,"Japan","JPN",437,"JPN",43970,2019,"Japan","East Asia & Pacific","High income",4,"Asia",2021-02-22,2021-08-11,2021-10-16,2021-02-17,2021-02-17,5,71,175,241,"who",71,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-12-19,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-12-19
"3583",437,"Arashiro","Retrospective cohort","19Dec2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","180+ (median 215)","severe disease requiring mechanical ventilation","severe","Japan",">=16 years","general pop",82.7,"37.1",95.3,NA,"omicron BA.1, BA.2","~65 weeks",NA,NA,"Japan","JPN",437,"JPN",43970,2019,"Japan","East Asia & Pacific","High income",4,"Asia",2021-02-22,2021-08-11,2021-10-16,2021-02-17,2021-02-17,5,71,175,241,"who",71,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-12-19,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-12-19
"3584",437,"Arashiro","Retrospective cohort","19Dec2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-180 (median 139)","death","death","Japan",">=16 years","general pop",43.1,"-213.4",89.7,NA,"omicron BA.1, BA.2","~65 weeks",NA,NA,"Japan","JPN",437,"JPN",43970,2019,"Japan","East Asia & Pacific","High income",4,"Asia",2021-02-22,2021-08-11,2021-10-16,2021-02-17,2021-02-17,5,71,175,241,"who",71,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-12-19,"death","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-12-19
"3585",437,"Arashiro","Retrospective cohort","19Dec2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","180+ (median 216)","death","death","Japan",">=16 years","general pop",59.5,"-41.9",216,NA,"omicron BA.1, BA.2","~65 weeks",NA,NA,"Japan","JPN",437,"JPN",43970,2019,"Japan","East Asia & Pacific","High income",4,"Asia",2021-02-22,2021-08-11,2021-10-16,2021-02-17,2021-02-17,5,71,175,241,"who",71,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-12-19,"death","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-12-19
"3586",437,"Arashiro","Retrospective cohort","19Dec2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-180 (median 155)","severe disease requiring oxygen therapy with respiratory failure","severe","Japan",">=16 years","general pop",41.1,"-43.9",155,NA,"omicron BA.1, BA.2","~65 weeks",NA,NA,"Japan","JPN",437,"JPN",43970,2019,"Japan","East Asia & Pacific","High income",4,"Asia",2021-02-22,2021-08-11,2021-10-16,2021-02-17,2021-02-17,5,71,175,241,"who",71,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-12-19,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-12-19
"3587",437,"Arashiro","Retrospective cohort","19Dec2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","180+ (median 218)","severe disease requiring oxygen therapy with respiratory failure","severe","Japan",">=16 years","general pop",50.2,"1.1",218,NA,"omicron BA.1, BA.2","~65 weeks",NA,NA,"Japan","JPN",437,"JPN",43970,2019,"Japan","East Asia & Pacific","High income",4,"Asia",2021-02-22,2021-08-11,2021-10-16,2021-02-17,2021-02-17,5,71,175,241,"who",71,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-12-19,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-12-19
"3588",438,"Cheng","Retrospective cohort","26Dec2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","Hong Kong",">=18 years with chronic kidney disease",">=18 years with chronic kidney disease",35,"31",39,NA,"omicron BA.2","~51 weeks",NA,NA,"Hong Kong","HKG",438,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-12-26,"infection","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-12-26
"3589",438,"Cheng","Retrospective cohort","26Dec2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization","severe","Hong Kong",">=18 years with chronic kidney disease",">=18 years with chronic kidney disease",66,"62",80,NA,"omicron BA.2","~51 weeks",NA,NA,"Hong Kong","HKG",438,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-12-26,"severe","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-12-26
"3590",438,"Cheng","Retrospective cohort","26Dec2023","CoronaVac (Sinovac)","excluded","2","final","14+","infection","infection","Hong Kong",">=18 years with chronic kidney disease",">=18 years with chronic kidney disease",29,"26",32,NA,"omicron BA.2","~51 weeks",NA,NA,"Hong Kong","HKG",438,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-12-26,"infection","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2023-12-26
"3591",438,"Cheng","Retrospective cohort","26Dec2023","CoronaVac (Sinovac)","excluded","2","final","14+","hospitalization","severe","Hong Kong",">=18 years with chronic kidney disease",">=18 years with chronic kidney disease",63,"60",66,NA,"omicron BA.2","~51 weeks",NA,NA,"Hong Kong","HKG",438,"HKG",65240,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,77,177,374,"owid",77,"feb/2021","60-89","Jun-Aug/2021","<180","yes","yes","yes",2023-12-26,"severe","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2023-12-26
"3592",439,"Birk","Retrospective cohort","29Dec2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","0-56","infection","infection","Denmark","12-15 years","12-15 years",96.2,"95.4",96.9,NA,"delta & omicron BA.1","~24 weeks",NA,NA,"Denmark","DNK",439,"DNK",61830,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,8,212,261,"who",8,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-12-29,"infection","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta/omicron",NA,2023-12-29
"3593",439,"Birk","Retrospective cohort","29Dec2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","57-182","infection","infection","Denmark","12-15 years","12-15 years",5.8,"4.6",7,NA,"delta & omicron BA.1","~24 weeks",NA,NA,"Denmark","DNK",439,"DNK",61830,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,8,212,261,"who",8,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-12-29,"infection","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta/omicron",NA,2023-12-29
"3594",439,"Birk","Retrospective cohort","29Dec2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","0-56","infection","infection","Denmark","16-18 years","16-18 years",95.5,"94.8",96.1,NA,"delta & omicron BA.1","~24 weeks",NA,NA,"Denmark","DNK",439,"DNK",61830,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,8,212,261,"who",8,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-12-29,"infection","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta/omicron",NA,2023-12-29
"3595",439,"Birk","Retrospective cohort","29Dec2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","57-182","infection","infection","Denmark","16-18 years","16-18 years",9.2,"7.7",10.6,NA,"delta & omicron BA.1","~24 weeks",NA,NA,"Denmark","DNK",439,"DNK",61830,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,8,212,261,"who",8,"before jan/2021","<30","Jun-Aug/2021","180-269","yes","yes","yes",2023-12-29,"infection","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta/omicron",NA,2023-12-29
"3596",440,"Ye","Test-negative case-control","14Dec2023","CoronaVac (Sinovac)","included","2","final","28+","symptomatic disease","symptomatic","China",">=3 years",">=3 years",14,"-11",33,NA,"omicron BA.2","~61 weeks",NA,"Note: this study was conucted in an outbreak setting.","China","CHN",440,"CHN",16610,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,-139,386,420,"who",0,"before jan/2021","<30","Jun-Aug/2021","360+","yes","yes","yes",2023-12-14,"symptomatic","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2023-12-14
"3597",440,"Ye","Test-negative case-control","14Dec2023","BBIBP-CorV (Beijing CNBG)","included","2","final","28+","symptomatic disease","symptomatic","China",">=3 years",">=3 years",20,"-10",43,NA,"omicron BA.2","~66 weeks",NA,"Note: this study was conucted in an outbreak setting.","China","CHN",440,"CHN",16610,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,-139,386,420,"who",0,"before jan/2021","<30","Jun-Aug/2021","360+","yes","yes","yes",2023-12-14,"symptomatic","2023 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","omicron",NA,2023-12-14
